[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "Specific outcomes upon activation of the c-Jun N-terminal kinase (JNK) pathway critically depend on the intensity and duration of signal transmission. Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK. It has been shown that M3/6 itself is phosphorylated by JNK upon stimulation with arsenite, but the role of this phosphorylation has not been investigated. In this study, we mapped JNK-induced phosphorylation sites on M3/6 using mass spectrometry. Phosphorylated residues Ser 515, Thr 518 and Ser 520 were identified and site-directed mutagenesis was employed to investigate their role. Upon arsenite stimulation, M3/6 mutated at these sites exhibited decreased phosphorylation compared to the wild-type protein. No difference was observed in terms of the enzyme's in vitro phosphatase activity, its substrate specificity towards JNK isoforms, its interactions with JNK and the scaffold family of JNK-interacting proteins (JIPs), its stability or its subcellular localization. Interestingly, expression of M3/6 phosphorylation mutants delayed the time-course of JNK phosphorylation and activation by arsenite. We propose that phosphorylation of the M3/6 phosphatase by JNK in response to stress stimuli results in attenuation of phosphatase activity and acceleration of JNK activation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "a351b22b820341a499b92892e91315d8", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [112, 112], [77, 77], [192, 192], [186, 186], [198, 198], [226, 226], [89, 89], [242, 242], [14, 14], [257, 257]], "char_spans": [[260, 262], [630, 632], [444, 446], [1115, 1117], [1079, 1081], [1146, 1148], [1311, 1313], [505, 507], [1418, 1420], [66, 68], [1519, 1521]]}]}], "context_tokens": [["Specific", 0], ["outcomes", 9], ["upon", 18], ["activation", 23], ["of", 34], ["the", 37], ["c", 41], ["-", 42], ["Jun", 43], ["N", 47], ["-", 48], ["terminal", 49], ["kinase", 58], ["(", 65], ["JNK", 66], [")", 69], ["pathway", 71], ["critically", 79], ["depend", 90], ["on", 97], ["the", 100], ["intensity", 104], ["and", 114], ["duration", 118], ["of", 127], ["signal", 130], ["transmission", 137], [".", 149], ["Dual", 151], ["-", 155], ["specificity", 156], ["phosphatases", 168], ["(", 181], ["DUSPs", 182], [")", 187], ["play", 189], ["a", 194], ["very", 196], ["important", 201], ["role", 211], ["in", 216], ["these", 219], ["events", 225], ["by", 232], ["modulating", 235], ["the", 246], ["extent", 250], ["of", 257], ["JNK", 260], ["phosphorylation", 264], ["and", 280], ["activation", 284], ["and", 295], ["thus", 299], ["regulating", 304], ["cellular", 315], ["responses", 324], ["to", 334], ["stress", 337], [".", 343], ["M3/6", 345], ["(", 350], ["DUSP8", 351], [")", 356], ["is", 358], ["one", 361], ["of", 365], ["the", 368], ["dual", 372], ["-", 376], ["specificity", 377], ["protein", 389], ["phosphatases", 397], ["with", 410], ["distinct", 415], ["specificity", 424], ["towards", 436], ["JNK", 444], [".", 447], ["It", 449], ["has", 452], ["been", 456], ["shown", 461], ["that", 467], ["M3/6", 472], ["itself", 477], ["is", 484], ["phosphorylated", 487], ["by", 502], ["JNK", 505], ["upon", 509], ["stimulation", 514], ["with", 526], ["arsenite", 531], [",", 539], ["but", 541], ["the", 545], ["role", 549], ["of", 554], ["this", 557], ["phosphorylation", 562], ["has", 578], ["not", 582], ["been", 586], ["investigated", 591], [".", 603], ["In", 605], ["this", 608], ["study", 613], [",", 618], ["we", 620], ["mapped", 623], ["JNK", 630], ["-", 633], ["induced", 634], ["phosphorylation", 642], ["sites", 658], ["on", 664], ["M3/6", 667], ["using", 672], ["mass", 678], ["spectrometry", 683], [".", 695], ["Phosphorylated", 697], ["residues", 712], ["Ser", 721], ["515", 725], [",", 728], ["Thr", 730], ["518", 734], ["and", 738], ["Ser", 742], ["520", 746], ["were", 750], ["identified", 755], ["and", 766], ["site", 770], ["-", 774], ["directed", 775], ["mutagenesis", 784], ["was", 796], ["employed", 800], ["to", 809], ["investigate", 812], ["their", 824], ["role", 830], [".", 834], ["Upon", 836], ["arsenite", 841], ["stimulation", 850], [",", 861], ["M3/6", 863], ["mutated", 868], ["at", 876], ["these", 879], ["sites", 885], ["exhibited", 891], ["decreased", 901], ["phosphorylation", 911], ["compared", 927], ["to", 936], ["the", 939], ["wild", 943], ["-", 947], ["type", 948], ["protein", 953], [".", 960], ["No", 962], ["difference", 965], ["was", 976], ["observed", 980], ["in", 989], ["terms", 992], ["of", 998], ["the", 1001], ["enzyme", 1005], ["'s", 1011], ["in", 1014], ["vitro", 1017], ["phosphatase", 1023], ["activity", 1035], [",", 1043], ["its", 1045], ["substrate", 1049], ["specificity", 1059], ["towards", 1071], ["JNK", 1079], ["isoforms", 1083], [",", 1091], ["its", 1093], ["interactions", 1097], ["with", 1110], ["JNK", 1115], ["and", 1119], ["the", 1123], ["scaffold", 1127], ["family", 1136], ["of", 1143], ["JNK", 1146], ["-", 1149], ["interacting", 1150], ["proteins", 1162], ["(", 1171], ["JIPs", 1172], [")", 1176], [",", 1177], ["its", 1179], ["stability", 1183], ["or", 1193], ["its", 1196], ["subcellular", 1200], ["localization", 1212], [".", 1224], ["Interestingly", 1226], [",", 1239], ["expression", 1241], ["of", 1252], ["M3/6", 1255], ["phosphorylation", 1260], ["mutants", 1276], ["delayed", 1284], ["the", 1292], ["time", 1296], ["-", 1300], ["course", 1301], ["of", 1308], ["JNK", 1311], ["phosphorylation", 1315], ["and", 1331], ["activation", 1335], ["by", 1346], ["arsenite", 1349], [".", 1357], ["We", 1359], ["propose", 1362], ["that", 1370], ["phosphorylation", 1375], ["of", 1391], ["the", 1394], ["M3/6", 1398], ["phosphatase", 1403], ["by", 1415], ["JNK", 1418], ["in", 1422], ["response", 1425], ["to", 1434], ["stress", 1437], ["stimuli", 1444], ["results", 1452], ["in", 1460], ["attenuation", 1463], ["of", 1475], ["phosphatase", 1478], ["activity", 1490], ["and", 1499], ["acceleration", 1503], ["of", 1516], ["JNK", 1519], ["activation", 1523], [".", 1533]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disease with characteristics and symptoms that are well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies inside neurons. \u03b1-Synuclein (\u03b1-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence suggests that \u03b1-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy bodies localized in the dopaminergic neurons of PD patients. In the present study, we investigated the influence of wild type (WT) and A30P \u03b1-syn overexpression on neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged with lipopolysaccharide (LPS) from Escherichia coli. We observed that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show evidence of cell death, which is not reverted by NF-\u03baB inhibition by sodium salicylate or by blockage of P50 (NF-\u03baB subunit). Furthermore, the expression of A30P \u03b1-syn in neuroblastoma SH-SY5Y decreases the cell death triggered by the CM of activated glia versus WT \u03b1-syn or control group. This effect of A30P \u03b1-syn may be due to the low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release by CM in SH-SY5Y cells. Our results suggest that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show cell death, which is not reverted by NF-\u03baB blockage. Additionally, the expression of A30P \u03b1-syn on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT \u03b1-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present data suggest that MAPK42/44 phosphorylation plays an important role in this process. CRD42015020829.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "770cdf4bff11453d9e85c2d6c5857367", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[38, 40]], "char_spans": [[225, 235]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disease", 48], ["with", 56], ["characteristics", 61], ["and", 77], ["symptoms", 81], ["that", 90], ["are", 95], ["well", 99], ["defined", 104], [".", 111], ["Nevertheless", 113], [",", 125], ["its", 127], ["aetiology", 131], ["remains", 141], ["unknown", 149], [".", 156], ["PD", 158], ["is", 161], ["characterized", 164], ["by", 178], ["the", 181], ["presence", 185], ["of", 194], ["Lewy", 197], ["bodies", 202], ["inside", 209], ["neurons", 216], [".", 223], ["\u03b1", 225], ["-", 226], ["Synuclein", 227], ["(", 237], ["\u03b1", 238], ["-", 239], ["syn", 240], [")", 243], ["is", 245], ["a", 248], ["soluble", 250], ["protein", 258], ["present", 266], ["in", 274], ["the", 277], ["pre", 281], ["-", 284], ["synaptic", 285], ["terminal", 294], ["of", 303], ["neurons", 306], [".", 313], ["Evidence", 315], ["suggests", 324], ["that", 333], ["\u03b1", 338], ["-", 339], ["syn", 340], ["has", 344], ["a", 348], ["fundamental", 350], ["role", 362], ["in", 367], ["PD", 370], ["pathogenesis", 373], [",", 385], ["given", 387], ["that", 393], ["it", 398], ["is", 401], ["an", 404], ["important", 407], ["component", 417], ["of", 427], ["Lewy", 430], ["bodies", 435], ["localized", 442], ["in", 452], ["the", 455], ["dopaminergic", 459], ["neurons", 472], ["of", 480], ["PD", 483], ["patients", 486], [".", 494], ["In", 496], ["the", 499], ["present", 503], ["study", 511], [",", 516], ["we", 518], ["investigated", 521], ["the", 534], ["influence", 538], ["of", 548], ["wild", 551], ["type", 556], ["(", 561], ["WT", 562], [")", 564], ["and", 566], ["A30P", 570], ["\u03b1", 575], ["-", 576], ["syn", 577], ["overexpression", 581], ["on", 596], ["neuroblastoma", 599], ["SH", 613], ["-", 615], ["SY5Y", 616], ["toxicity", 621], ["induced", 630], ["by", 638], ["the", 641], ["conditioned", 645], ["medium", 657], ["(", 664], ["CM", 665], [")", 667], ["from", 669], ["primary", 674], ["cultures", 682], ["of", 691], ["glia", 694], ["challenged", 699], ["with", 710], ["lipopolysaccharide", 715], ["(", 734], ["LPS", 735], [")", 738], ["from", 740], ["Escherichia", 745], ["coli", 757], [".", 761], ["We", 763], ["observed", 766], ["that", 775], ["SH", 780], ["-", 782], ["SY5Y", 783], ["cells", 788], ["transduced", 794], ["with", 805], ["\u03b1", 810], ["-", 811], ["syn", 812], ["(", 816], ["WT", 817], ["or", 820], ["A30P", 823], [")", 827], ["and", 829], ["treated", 833], ["with", 841], ["CM", 846], ["from", 849], ["LPS", 854], ["-", 857], ["activated", 858], ["glia", 868], ["cells", 873], ["show", 879], ["evidence", 884], ["of", 893], ["cell", 896], ["death", 901], [",", 906], ["which", 908], ["is", 914], ["not", 917], ["reverted", 921], ["by", 930], ["NF", 933], ["-", 935], ["\u03baB", 936], ["inhibition", 939], ["by", 950], ["sodium", 953], ["salicylate", 960], ["or", 971], ["by", 974], ["blockage", 977], ["of", 986], ["P50", 989], ["(", 993], ["NF", 994], ["-", 996], ["\u03baB", 997], ["subunit", 1000], [")", 1007], [".", 1008], ["Furthermore", 1010], [",", 1021], ["the", 1023], ["expression", 1027], ["of", 1038], ["A30P", 1041], ["\u03b1", 1046], ["-", 1047], ["syn", 1048], ["in", 1052], ["neuroblastoma", 1055], ["SH", 1069], ["-", 1071], ["SY5Y", 1072], ["decreases", 1077], ["the", 1087], ["cell", 1091], ["death", 1096], ["triggered", 1102], ["by", 1112], ["the", 1115], ["CM", 1119], ["of", 1122], ["activated", 1125], ["glia", 1135], ["versus", 1140], ["WT", 1147], ["\u03b1", 1150], ["-", 1151], ["syn", 1152], ["or", 1156], ["control", 1159], ["group", 1167], [".", 1172], ["This", 1174], ["effect", 1179], ["of", 1186], ["A30P", 1189], ["\u03b1", 1194], ["-", 1195], ["syn", 1196], ["may", 1200], ["be", 1204], ["due", 1207], ["to", 1211], ["the", 1214], ["low", 1218], ["MAPK42/44", 1222], ["phosphorylation", 1232], [".", 1247], ["This", 1249], ["finding", 1254], ["is", 1262], ["substantiated", 1265], ["by", 1279], ["MEK1", 1282], ["inhibition", 1287], ["by", 1298], ["PD98059", 1301], [",", 1308], ["decreasing", 1310], ["LDH", 1321], ["release", 1325], ["by", 1333], ["CM", 1336], ["in", 1339], ["SH", 1342], ["-", 1344], ["SY5Y", 1345], ["cells", 1350], [".", 1355], ["Our", 1357], ["results", 1361], ["suggest", 1369], ["that", 1377], ["SH", 1382], ["-", 1384], ["SY5Y", 1385], ["cells", 1390], ["transduced", 1396], ["with", 1407], ["\u03b1", 1412], ["-", 1413], ["syn", 1414], ["(", 1418], ["WT", 1419], ["or", 1422], ["A30P", 1425], [")", 1429], ["and", 1431], ["treated", 1435], ["with", 1443], ["CM", 1448], ["from", 1451], ["LPS", 1456], ["-", 1459], ["activated", 1460], ["glia", 1470], ["cells", 1475], ["show", 1481], ["cell", 1486], ["death", 1491], [",", 1496], ["which", 1498], ["is", 1504], ["not", 1507], ["reverted", 1511], ["by", 1520], ["NF", 1523], ["-", 1525], ["\u03baB", 1526], ["blockage", 1529], [".", 1537], ["Additionally", 1539], [",", 1551], ["the", 1553], ["expression", 1557], ["of", 1568], ["A30P", 1571], ["\u03b1", 1576], ["-", 1577], ["syn", 1578], ["on", 1582], ["neuroblastoma", 1585], ["SH", 1599], ["-", 1601], ["SY5Y", 1602], ["leads", 1607], ["to", 1613], ["decreased", 1616], ["cell", 1626], ["death", 1631], ["triggered", 1637], ["by", 1647], ["the", 1650], ["CM", 1654], ["of", 1657], ["activated", 1660], ["glia", 1670], [",", 1674], ["when", 1676], ["compared", 1681], ["to", 1690], ["WT", 1693], ["\u03b1", 1696], ["-", 1697], ["syn", 1698], ["or", 1702], ["control", 1705], ["group", 1713], [".", 1718], ["The", 1720], ["mechanism", 1724], ["underlying", 1734], ["this", 1745], ["process", 1750], ["remains", 1758], ["to", 1766], ["be", 1769], ["completely", 1772], ["elucidated", 1783], [",", 1793], ["but", 1795], ["the", 1799], ["present", 1803], ["data", 1811], ["suggest", 1816], ["that", 1824], ["MAPK42/44", 1829], ["phosphorylation", 1839], ["plays", 1855], ["an", 1861], ["important", 1864], ["role", 1874], ["in", 1879], ["this", 1882], ["process", 1887], [".", 1894], ["CRD42015020829", 1896], [".", 1910]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "631900f5ead84eacaf274c45701f595a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[27, 29]], "char_spans": [[172, 178]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI", 19], ["571", 23], [";", 26], ["Gleevec", 28], [";", 35], ["Novartis", 37], ["Pharmaceuticals", 46], [",", 61], ["Basel", 63], [",", 68], ["Switzerland", 70], [")", 81], ["is", 83], ["an", 86], ["orally", 89], ["available", 96], ["tyrosine", 106], ["kinase", 115], ["inhibitor", 122], ["that", 132], ["targets", 137], ["a", 145], ["constitutively", 147], ["activated", 162], ["BCR", 172], ["-", 175], ["ABL", 176], ["tyrosine", 180], ["kinase", 189], ["with", 196], ["additional", 201], ["inhibitory", 212], ["effects", 223], ["on", 231], ["platelet", 234], ["derived", 243], ["growth", 251], ["factor", 258], ["(", 265], ["PDGF", 266], [")", 270], ["receptors", 272], ["alpha", 282], ["and", 288], ["beta", 292], [",", 296], ["and", 298], ["KIT", 302], [".", 305], ["It", 307], ["has", 310], ["revolutionized", 314], ["the", 329], ["treatment", 333], ["of", 343], ["adult", 346], ["and", 352], ["pediatric", 356], ["patients", 366], ["with", 375], ["Philadelphia", 380], ["chromosome", 393], ["positive", 404], ["chronic", 413], ["myelogenous", 421], ["leukemia", 433], ["(", 442], ["CML", 443], [")", 446], ["and", 448], ["is", 452], ["also", 455], ["FDA", 460], ["-", 463], ["approved", 464], ["for", 473], ["KIT", 477], ["-", 480], ["positive", 481], ["advanced", 490], ["gastrointestinal", 499], ["tumor", 516], ["(", 522], ["GIST", 523], [")", 527], ["and", 529], ["dermatofibrosarcoma", 533], ["protuberans", 553], [".", 564], ["A", 566], ["wide", 568], ["spectrum", 573], ["of", 582], ["dermatologic", 585], ["toxicities", 598], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["this", 634], ["agent", 639], [",", 644], ["among", 646], ["which", 652], ["a", 658], ["maculopapular", 660], ["rash", 674], ["is", 679], ["the", 682], ["most", 686], ["common", 691], ["event", 698], [".", 703], ["In", 705], ["addition", 708], [",", 716], ["a", 718], ["variety", 720], ["of", 728], ["pigmentary", 731], ["abnormalities", 742], ["of", 756], ["the", 759], ["skin", 763], ["and", 768], ["mucosal", 772], ["surfaces", 780], ["have", 789], ["been", 794], ["reported", 799], [".", 807], ["Hypopigmentation", 809], ["is", 826], ["a", 829], ["well", 831], ["-", 835], ["recognized", 836], ["adverse", 847], ["effect", 855], [".", 861], ["In", 863], ["contrast", 866], [",", 874], ["paradoxical", 876], ["hyperpigmentation", 888], ["has", 906], ["only", 910], ["rarely", 915], ["been", 922], ["documented", 927], [".", 937], ["In", 939], ["this", 942], ["case", 947], ["report", 952], ["we", 959], ["describe", 962], ["imatinib", 971], ["-", 979], ["induced", 980], ["cutaneous", 988], ["hyperpigmentation", 998], ["and", 1016], ["graying", 1020], ["of", 1028], ["hair", 1031], ["occurring", 1036], ["in", 1046], ["the", 1049], ["same", 1053], ["patient", 1058], ["with", 1066], ["dermatofibrosarcoma", 1071], ["protuberans", 1091], ["treated", 1103], ["with", 1111], ["imatinib", 1116], [".", 1124]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteristics similar to patients receiving anticoagulant therapy. In this randomized, double-blind, crossover study, 46 subjects (12 middle-aged, 45-64\u00a0years; 16 elderly, 65-80\u00a0years; and 18 with mild or moderate renal impairment) received dabigatran etexilate (DE; 220 or 150\u00a0mg twice daily) for 4\u00a0days. Idarucizumab doses of 1, 2.5 and 5\u00a0g or 2\u00a0\u00d7\u00a02.5\u00a0g 1\u00a0h apart, or placebo, were administered as a rapid (5\u00a0min) infusion ~2\u00a0h after DE at steady state. Dabigatran-prolonged diluted thrombin time, ecarin clotting time and activated partial thromboplastin time were reversed to baseline immediately after idarucizumab infusion in all groups. Reversal was sustained with doses \u22652.5\u00a0g. Idarucizumab was well tolerated under all conditions. No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84\u00a0%), decreased clearance and prolonged (by up to 49\u00a0%) initial half-life of idarucizumab compared with healthy middle-aged subjects. Impaired renal function was associated with increased exposure and decreased clearance of idarucizumab. Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. The results support the clinical use of a 5\u00a0g dose of idarucizumab. http://www.clinicaltrials.gov . Unique identifier: NCT01955720.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "1617e42426ba4b0483170d68366da72d", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[262, 262], [87, 87], [23, 23], [8, 8], [142, 142]], "char_spans": [[1474, 1483], [505, 514], [184, 193], [64, 73], [720, 729]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antibody", 19], ["fragment", 28], ["that", 37], ["specifically", 42], ["reverses", 55], ["dabigatran", 64], ["-", 74], ["mediated", 75], ["anticoagulation", 84], [".", 99], ["Safety", 101], [",", 107], ["pharmacokinetics", 109], ["and", 126], ["pharmacodynamics", 130], ["of", 147], ["idarucizumab", 150], ["were", 163], ["investigated", 168], ["in", 181], ["dabigatran", 184], ["-", 194], ["treated", 195], [",", 202], ["middle", 204], ["-", 210], ["aged", 211], [",", 215], ["elderly", 217], ["and", 225], ["renally", 229], ["impaired", 237], ["volunteers", 246], ["with", 257], ["characteristics", 262], ["similar", 278], ["to", 286], ["patients", 289], ["receiving", 298], ["anticoagulant", 308], ["therapy", 322], [".", 329], ["In", 331], ["this", 334], ["randomized", 339], [",", 349], ["double", 351], ["-", 357], ["blind", 358], [",", 363], ["crossover", 365], ["study", 375], [",", 380], ["46", 382], ["subjects", 385], ["(", 394], ["12", 395], ["middle", 398], ["-", 404], ["aged", 405], [",", 409], ["45", 411], ["-", 413], ["64", 414], ["years", 417], [";", 422], ["16", 424], ["elderly", 427], [",", 434], ["65", 436], ["-", 438], ["80", 439], ["years", 442], [";", 447], ["and", 449], ["18", 453], ["with", 456], ["mild", 461], ["or", 466], ["moderate", 469], ["renal", 478], ["impairment", 484], [")", 494], ["received", 496], ["dabigatran", 505], ["etexilate", 516], ["(", 526], ["DE", 527], [";", 529], ["220", 531], ["or", 535], ["150", 538], ["mg", 542], ["twice", 545], ["daily", 551], [")", 556], ["for", 558], ["4", 562], ["days", 564], [".", 568], ["Idarucizumab", 570], ["doses", 583], ["of", 589], ["1", 592], [",", 593], ["2.5", 595], ["and", 599], ["5", 603], ["g", 605], ["or", 607], ["2", 610], ["\u00d7", 612], ["2.5", 614], ["g", 618], ["1", 620], ["h", 622], ["apart", 624], [",", 629], ["or", 631], ["placebo", 634], [",", 641], ["were", 643], ["administered", 648], ["as", 661], ["a", 664], ["rapid", 666], ["(", 672], ["5", 673], ["min", 675], [")", 678], ["infusion", 680], ["~2", 689], ["h", 692], ["after", 694], ["DE", 700], ["at", 703], ["steady", 706], ["state", 713], [".", 718], ["Dabigatran", 720], ["-", 730], ["prolonged", 731], ["diluted", 741], ["thrombin", 749], ["time", 758], [",", 762], ["ecarin", 764], ["clotting", 771], ["time", 780], ["and", 785], ["activated", 789], ["partial", 799], ["thromboplastin", 807], ["time", 822], ["were", 827], ["reversed", 832], ["to", 841], ["baseline", 844], ["immediately", 853], ["after", 865], ["idarucizumab", 871], ["infusion", 884], ["in", 893], ["all", 896], ["groups", 900], [".", 906], ["Reversal", 908], ["was", 917], ["sustained", 921], ["with", 931], ["doses", 936], ["\u22652.5", 942], ["g.", 947], ["Idarucizumab", 950], ["was", 963], ["well", 967], ["tolerated", 972], ["under", 982], ["all", 988], ["conditions", 992], [".", 1002], ["No", 1004], ["impact", 1007], ["of", 1014], ["age", 1017], ["on", 1021], ["idarucizumab", 1024], ["pharmacokinetics", 1037], ["was", 1054], ["observed", 1058], [";", 1066], ["however", 1068], [",", 1075], ["subjects", 1077], ["with", 1086], ["mild", 1091], ["or", 1096], ["moderate", 1099], ["renal", 1108], ["impairment", 1114], ["demonstrated", 1125], ["increased", 1138], ["exposure", 1148], ["(", 1157], ["up", 1158], ["to", 1161], ["84", 1164], ["%", 1167], [")", 1168], [",", 1169], ["decreased", 1171], ["clearance", 1181], ["and", 1191], ["prolonged", 1195], ["(", 1205], ["by", 1206], ["up", 1209], ["to", 1212], ["49", 1215], ["%", 1218], [")", 1219], ["initial", 1221], ["half", 1229], ["-", 1233], ["life", 1234], ["of", 1239], ["idarucizumab", 1242], ["compared", 1255], ["with", 1264], ["healthy", 1269], ["middle", 1277], ["-", 1283], ["aged", 1284], ["subjects", 1289], [".", 1297], ["Impaired", 1299], ["renal", 1308], ["function", 1314], ["was", 1323], ["associated", 1327], ["with", 1338], ["increased", 1343], ["exposure", 1353], ["and", 1362], ["decreased", 1366], ["clearance", 1376], ["of", 1386], ["idarucizumab", 1389], [".", 1401], ["Idarucizumab", 1403], ["resulted", 1416], ["in", 1425], ["immediate", 1428], [",", 1437], ["complete", 1439], ["and", 1448], ["sustained", 1452], ["reversal", 1462], ["of", 1471], ["dabigatran", 1474], ["anticoagulant", 1485], ["activity", 1499], [",", 1507], ["and", 1509], ["was", 1513], ["safe", 1517], ["and", 1522], ["well", 1526], ["tolerated", 1531], ["in", 1541], ["middle", 1544], ["-", 1550], ["aged", 1551], [",", 1555], ["elderly", 1557], ["and", 1565], ["renally", 1569], ["impaired", 1577], ["volunteers", 1586], [".", 1596], ["The", 1598], ["results", 1602], ["support", 1610], ["the", 1618], ["clinical", 1622], ["use", 1631], ["of", 1635], ["a", 1638], ["5", 1640], ["g", 1642], ["dose", 1644], ["of", 1649], ["idarucizumab", 1652], [".", 1664], ["http://www.clinicaltrials.gov", 1666], [".", 1696], ["Unique", 1698], ["identifier", 1705], [":", 1715], ["NCT01955720", 1717], [".", 1728]]}
{"context": "The Ehlers-Danlos syndrome (EDS), inherited disorder of connective tissue, frequently leads to impairment of various functional areas, including employment. In 35 subjects with classic type EDS, 14 hypermobile, 3 vascular was administered 7 visual analogical scales (pain, stiffness, activities of daily living, instrumental activities of daily living, work, social relations). An impairment of particular significance in total score and in individual areas emerges is in the hypermobile group, followed by classic, less for the vasculature. Overall there is a significant alteration of the quality of life that deserves proper evaluation to facilitate the definition of fitness and the improvement of job insertion in patients with EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "82da9c6e605c480c956b7f95c0e9d90b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[12, 13]], "char_spans": [[56, 72]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], [",", 32], ["inherited", 34], ["disorder", 44], ["of", 53], ["connective", 56], ["tissue", 67], [",", 73], ["frequently", 75], ["leads", 86], ["to", 92], ["impairment", 95], ["of", 106], ["various", 109], ["functional", 117], ["areas", 128], [",", 133], ["including", 135], ["employment", 145], [".", 155], ["In", 157], ["35", 160], ["subjects", 163], ["with", 172], ["classic", 177], ["type", 185], ["EDS", 190], [",", 193], ["14", 195], ["hypermobile", 198], [",", 209], ["3", 211], ["vascular", 213], ["was", 222], ["administered", 226], ["7", 239], ["visual", 241], ["analogical", 248], ["scales", 259], ["(", 266], ["pain", 267], [",", 271], ["stiffness", 273], [",", 282], ["activities", 284], ["of", 295], ["daily", 298], ["living", 304], [",", 310], ["instrumental", 312], ["activities", 325], ["of", 336], ["daily", 339], ["living", 345], [",", 351], ["work", 353], [",", 357], ["social", 359], ["relations", 366], [")", 375], [".", 376], ["An", 378], ["impairment", 381], ["of", 392], ["particular", 395], ["significance", 406], ["in", 419], ["total", 422], ["score", 428], ["and", 434], ["in", 438], ["individual", 441], ["areas", 452], ["emerges", 458], ["is", 466], ["in", 469], ["the", 472], ["hypermobile", 476], ["group", 488], [",", 493], ["followed", 495], ["by", 504], ["classic", 507], [",", 514], ["less", 516], ["for", 521], ["the", 525], ["vasculature", 529], [".", 540], ["Overall", 542], ["there", 550], ["is", 556], ["a", 559], ["significant", 561], ["alteration", 573], ["of", 584], ["the", 587], ["quality", 591], ["of", 599], ["life", 602], ["that", 607], ["deserves", 612], ["proper", 621], ["evaluation", 628], ["to", 639], ["facilitate", 642], ["the", 653], ["definition", 657], ["of", 668], ["fitness", 671], ["and", 679], ["the", 683], ["improvement", 687], ["of", 699], ["job", 702], ["insertion", 706], ["in", 716], ["patients", 719], ["with", 728], ["EDS", 733], [".", 736]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard-dose imatinib therapy (400 mg daily), imatinib dose escalation (600-800 mg daily) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "9f71ac936fe846a99b99d2e030c881b0", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[218, 220], [77, 79], [244, 246], [48, 50]], "char_spans": [[1195, 1201], [441, 447], [1366, 1372], [286, 292]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["progressive", 36], ["and", 48], ["often", 52], ["fatal", 58], ["myeloproliferative", 64], ["neoplasm", 83], [".", 91], ["The", 93], ["hallmark", 97], ["of", 106], ["CML", 109], ["is", 113], ["an", 116], ["acquired", 119], ["chromosomal", 128], ["translocation", 140], ["known", 154], ["as", 160], ["the", 163], ["Philadelphia", 167], ["chromosome", 180], ["(", 191], ["Ph", 192], [")", 194], [",", 195], ["which", 197], ["results", 203], ["in", 211], ["the", 214], ["synthesis", 218], ["of", 228], ["the", 231], ["breakpoint", 235], ["cluster", 246], ["region", 254], ["-", 260], ["Abelson", 261], ["murine", 269], ["leukemia", 276], ["(", 285], ["BCR", 286], ["-", 289], ["ABL", 290], [")", 293], ["fusion", 295], ["oncoprotein", 302], [",", 313], ["a", 315], ["constitutively", 317], ["active", 332], ["tyrosine", 339], ["kinase", 348], [".", 354], ["The", 356], ["introduction", 360], ["of", 373], ["imatinib", 376], [",", 384], ["a", 386], ["tyrosine", 388], ["kinase", 397], ["inhibitor", 404], ["(", 414], ["TKI", 415], [")", 418], ["that", 420], ["is", 425], ["specific", 428], ["for", 437], ["BCR", 441], ["-", 444], ["ABL", 445], [",", 448], ["was", 450], ["a", 454], ["major", 456], ["breakthrough", 462], ["in", 475], ["CML", 478], ["therapy", 482], [".", 489], ["Although", 491], ["most", 500], ["patients", 505], ["respond", 514], ["to", 522], ["first", 525], ["-", 530], ["line", 531], ["imatinib", 536], ["therapy", 545], [",", 552], ["some", 554], ["experience", 559], ["loss", 570], ["of", 575], ["response", 578], ["(", 587], ["resistance", 588], [")", 598], ["or", 600], ["require", 603], ["treatment", 611], ["discontinuation", 621], ["because", 637], ["of", 645], ["toxicity", 648], ["(", 657], ["intolerance", 658], [")", 669], [".", 670], ["For", 672], ["patients", 676], ["with", 685], ["CML", 690], [",", 693], ["failure", 695], ["on", 703], ["standard", 706], ["-", 714], ["dose", 715], ["imatinib", 720], ["therapy", 729], ["(", 737], ["400", 738], ["mg", 742], ["daily", 745], [")", 750], [",", 751], ["imatinib", 753], ["dose", 762], ["escalation", 767], ["(", 778], ["600", 779], ["-", 782], ["800", 783], ["mg", 787], ["daily", 790], [")", 795], ["is", 797], ["a", 800], ["second", 802], ["-", 808], ["line", 809], ["option", 814], [".", 820], ["However", 822], [",", 829], ["high", 831], ["-", 835], ["dose", 836], ["imatinib", 841], ["is", 850], ["not", 853], ["an", 857], ["appropriate", 860], ["approach", 872], ["for", 881], ["patients", 885], ["who", 894], ["experience", 898], ["drug", 909], ["toxicity", 914], [",", 922], ["and", 924], ["there", 928], ["remain", 934], ["questions", 941], ["over", 951], ["the", 956], ["durability", 960], ["of", 971], ["responses", 974], ["achieved", 984], ["with", 993], ["this", 998], ["strategy", 1003], [".", 1011], ["Alternative", 1013], ["second", 1025], ["-", 1031], ["line", 1032], ["options", 1037], ["include", 1045], ["the", 1053], ["TKIs", 1057], ["dasatinib", 1062], ["and", 1072], ["nilotinib", 1076], [".", 1085], ["A", 1087], ["substantial", 1089], ["amount", 1101], ["of", 1108], ["long", 1111], ["-", 1115], ["term", 1116], ["data", 1121], ["for", 1126], ["these", 1130], ["agents", 1136], ["is", 1143], ["available", 1146], [".", 1155], ["Although", 1157], ["both", 1166], ["are", 1171], ["potent", 1175], ["and", 1182], ["specific", 1186], ["BCR", 1195], ["-", 1198], ["ABL", 1199], ["TKIs", 1203], [",", 1207], ["dasatinib", 1209], ["and", 1219], ["nilotinib", 1223], ["exhibit", 1233], ["unique", 1241], ["pharmacologic", 1248], ["profiles", 1262], ["and", 1271], ["response", 1275], ["patterns", 1284], ["relative", 1293], ["to", 1302], ["different", 1305], ["patient", 1315], ["characteristics", 1323], [",", 1338], ["such", 1340], ["as", 1345], ["disease", 1348], ["stage", 1356], ["and", 1362], ["BCR", 1366], ["-", 1369], ["ABL", 1370], ["mutation", 1374], ["status", 1383], [".", 1389], ["To", 1391], ["optimize", 1394], ["therapeutic", 1403], ["benefit", 1415], [",", 1422], ["clinicians", 1424], ["should", 1435], ["select", 1442], ["treatment", 1449], ["based", 1459], ["on", 1465], ["each", 1468], ["patient", 1473], ["'s", 1480], ["historic", 1483], ["response", 1492], [",", 1500], ["adverse", 1502], ["-", 1509], ["event", 1510], ["tolerance", 1516], [",", 1525], ["and", 1527], ["risk", 1531], ["factors", 1536], [".", 1543]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-Lep<ob>/WiscJ (BTBR ob/ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ob mice received 1 \u03bcg\u00b7kg body wt(-1)\u00b7day(-1) ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetes-related glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ob mice with and without hypertension.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "eee52f339cdf4af89a3273019a0da1ab", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[27, 27], [66, 66]], "char_spans": [[156, 160], [408, 412]]}]}], "context_tokens": [["Diabetic", 0], ["nephropathy", 9], ["is", 21], ["the", 24], ["leading", 28], ["cause", 36], ["of", 42], ["end", 45], ["-", 48], ["stage", 49], ["renal", 55], ["disease", 61], ["in", 69], ["humans", 72], ["in", 79], ["the", 82], ["Western", 86], ["world", 94], [".", 99], ["The", 101], ["recent", 105], ["development", 112], ["of", 124], ["Na+-glucose", 127], ["cotransporter", 139], ["2", 153], ["(", 155], ["SGLT2", 156], [")", 161], ["inhibitors", 163], ["offers", 174], ["a", 181], ["new", 183], ["antidiabetic", 187], ["therapy", 200], ["via", 208], ["enhanced", 212], ["glucose", 221], ["excretion", 229], [".", 238], ["Whether", 240], ["this", 248], ["strategy", 253], ["exerts", 262], ["beneficial", 269], ["effects", 280], ["on", 288], ["the", 291], ["development", 295], ["of", 307], ["type", 310], ["2", 315], ["diabetic", 317], ["nephropathy", 326], ["is", 338], ["still", 341], ["largely", 347], ["unclear", 355], [".", 362], ["We", 364], ["investigated", 367], ["the", 380], ["effects", 384], ["of", 392], ["the", 395], ["specific", 399], ["SGLT2", 408], ["inhibitor", 414], ["empagliflozin", 424], ["in", 438], ["BTBR.Cg", 441], ["-", 448], ["Lep", 449], ["<", 452], ["ob>/WiscJ", 453], ["(", 463], ["BTBR", 464], ["ob", 469], ["/", 471], ["ob", 472], [")", 474], ["mice", 476], [",", 480], ["which", 482], ["spontaneously", 488], ["develop", 502], ["type", 510], ["2", 515], ["diabetic", 517], ["nephropathy", 526], [".", 537], ["In", 539], ["the", 542], ["first", 546], ["experiment", 552], [",", 562], ["BTBR", 564], ["ob", 569], ["/", 571], ["ob", 572], ["mice", 575], ["received", 580], ["either", 589], ["a", 596], ["diet", 598], ["containing", 603], ["300", 614], ["ppm", 618], ["empagliflozin", 622], ["or", 636], ["equicaloric", 639], ["placebo", 651], ["chow", 659], ["for", 664], ["12", 668], ["wk", 671], [".", 673], ["In", 675], ["the", 678], ["second", 682], ["experiment", 689], [",", 699], ["BTBR", 701], ["ob", 706], ["/", 708], ["ob", 709], ["mice", 712], ["received", 717], ["1", 726], ["\u03bcg\u00b7kg", 728], ["body", 734], ["wt(-1)\u00b7day(-1", 739], [")", 752], ["ANG", 754], ["II", 758], ["to", 761], ["induce", 764], ["arterial", 771], ["hypertension", 780], ["and", 793], ["were", 797], ["separated", 802], ["into", 812], ["the", 817], ["same", 821], ["two", 826], ["diet", 830], ["groups", 835], ["for", 842], ["6", 846], ["wk", 848], [".", 850], ["In", 852], ["both", 855], ["experiments", 860], [",", 871], ["empagliflozin", 873], ["treatment", 887], ["enhanced", 897], ["glucosuria", 906], [",", 916], ["thereby", 918], ["lowering", 926], ["blood", 935], ["glucose", 941], [".", 948], ["Independently", 950], ["of", 964], ["hypertension", 967], [",", 979], ["empagliflozin", 981], ["reduced", 995], ["albuminuria", 1003], ["in", 1015], ["diabetic", 1018], ["mice", 1027], [".", 1031], ["However", 1033], [",", 1040], ["empagliflozin", 1042], ["treatment", 1056], ["affected", 1066], ["diabetes", 1075], ["-", 1083], ["related", 1084], ["glomerular", 1092], ["hypertrophy", 1103], [",", 1114], ["markers", 1116], ["of", 1124], ["renal", 1127], ["inflammation", 1133], [",", 1145], ["and", 1147], ["mesangial", 1151], ["matrix", 1161], ["expansion", 1168], ["only", 1178], ["in", 1183], ["BTBR", 1186], ["ob", 1191], ["/", 1193], ["ob", 1194], ["mice", 1197], ["without", 1202], ["hypertension", 1210], [".", 1222], ["In", 1224], ["summary", 1227], [",", 1234], ["empagliflozin", 1236], ["demonstrated", 1250], ["significant", 1263], ["antihyperglycemic", 1275], ["effects", 1293], [",", 1300], ["differentially", 1302], ["ameliorating", 1317], ["early", 1330], ["features", 1336], ["of", 1345], ["diabetic", 1348], ["nephropathy", 1357], ["in", 1369], ["BTBR", 1372], ["ob", 1377], ["/", 1379], ["ob", 1380], ["mice", 1383], ["with", 1388], ["and", 1393], ["without", 1397], ["hypertension", 1405], [".", 1417]]}
{"context": "Postoperative methicillin-resistant Staphylococcus aureus (MRSA) infections are occasionally fatal. We hypothesized that nasal MRSA screening might predict the risk of postoperative MRSA infections. The aim of the current study was to elucidate the relationship between the positivity of nasal MRSA screening and postoperative MRSA infections. Six hundred and fourteen surgical patients who were admitted to the intensive care unit and underwent nasal MRSA screening between April 2006 and March 2011 were divided into MRSA-positive and -negative groups. The incidence of postoperative MRSA infections in the MRSA-positive and MRSA-negative groups were compared, and various risk factors for MRSA infections were evaluated. The incidence of postoperative MRSA infections, such as pneumonia and enteritis, in the MRSA-positive group was significantly higher than that in the MRSA-negative group (41.9 vs. 3.1 %). The significant independent risk factors for postoperative MRSA infections were a positive MRSA screening, an operation lasting more than 300 min and an emergency operation. A positive MRSA screening was the most statistically significant risk factor for postoperative MRSA pneumonia and enteritis, but was not a risk factor for MRSA surgical site infections. Nasal MRSA screening can help to identify patients who have an increased risk of developing postoperative MRSA infections, and would enable physicians to take a prompt action if these complications occur.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a9817a6931814cc1929eed39d878021d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[80, 80], [160, 160], [45, 45], [205, 205], [211, 211], [7, 7], [111, 111], [120, 120], [69, 69], [131, 131], [142, 142], [226, 226], [193, 193], [49, 49], [26, 26], [91, 91], [99, 99], [165, 165], [182, 182], [18, 18], [95, 95]], "char_spans": [[519, 522], [971, 974], [294, 297], [1241, 1244], [1278, 1281], [59, 62], [692, 695], [755, 758], [452, 455], [812, 815], [874, 877], [1378, 1381], [1181, 1184], [327, 330], [182, 185], [586, 589], [627, 630], [1003, 1006], [1097, 1100], [127, 130], [609, 612]]}]}], "context_tokens": [["Postoperative", 0], ["methicillin", 14], ["-", 25], ["resistant", 26], ["Staphylococcus", 36], ["aureus", 51], ["(", 58], ["MRSA", 59], [")", 63], ["infections", 65], ["are", 76], ["occasionally", 80], ["fatal", 93], [".", 98], ["We", 100], ["hypothesized", 103], ["that", 116], ["nasal", 121], ["MRSA", 127], ["screening", 132], ["might", 142], ["predict", 148], ["the", 156], ["risk", 160], ["of", 165], ["postoperative", 168], ["MRSA", 182], ["infections", 187], [".", 197], ["The", 199], ["aim", 203], ["of", 207], ["the", 210], ["current", 214], ["study", 222], ["was", 228], ["to", 232], ["elucidate", 235], ["the", 245], ["relationship", 249], ["between", 262], ["the", 270], ["positivity", 274], ["of", 285], ["nasal", 288], ["MRSA", 294], ["screening", 299], ["and", 309], ["postoperative", 313], ["MRSA", 327], ["infections", 332], [".", 342], ["Six", 344], ["hundred", 348], ["and", 356], ["fourteen", 360], ["surgical", 369], ["patients", 378], ["who", 387], ["were", 391], ["admitted", 396], ["to", 405], ["the", 408], ["intensive", 412], ["care", 422], ["unit", 427], ["and", 432], ["underwent", 436], ["nasal", 446], ["MRSA", 452], ["screening", 457], ["between", 467], ["April", 475], ["2006", 481], ["and", 486], ["March", 490], ["2011", 496], ["were", 501], ["divided", 506], ["into", 514], ["MRSA", 519], ["-", 523], ["positive", 524], ["and", 533], ["-negative", 537], ["groups", 547], [".", 553], ["The", 555], ["incidence", 559], ["of", 569], ["postoperative", 572], ["MRSA", 586], ["infections", 591], ["in", 602], ["the", 605], ["MRSA", 609], ["-", 613], ["positive", 614], ["and", 623], ["MRSA", 627], ["-", 631], ["negative", 632], ["groups", 641], ["were", 648], ["compared", 653], [",", 661], ["and", 663], ["various", 667], ["risk", 675], ["factors", 680], ["for", 688], ["MRSA", 692], ["infections", 697], ["were", 708], ["evaluated", 713], [".", 722], ["The", 724], ["incidence", 728], ["of", 738], ["postoperative", 741], ["MRSA", 755], ["infections", 760], [",", 770], ["such", 772], ["as", 777], ["pneumonia", 780], ["and", 790], ["enteritis", 794], [",", 803], ["in", 805], ["the", 808], ["MRSA", 812], ["-", 816], ["positive", 817], ["group", 826], ["was", 832], ["significantly", 836], ["higher", 850], ["than", 857], ["that", 862], ["in", 867], ["the", 870], ["MRSA", 874], ["-", 878], ["negative", 879], ["group", 888], ["(", 894], ["41.9", 895], ["vs.", 900], ["3.1", 904], ["%", 908], [")", 909], [".", 910], ["The", 912], ["significant", 916], ["independent", 928], ["risk", 940], ["factors", 945], ["for", 953], ["postoperative", 957], ["MRSA", 971], ["infections", 976], ["were", 987], ["a", 992], ["positive", 994], ["MRSA", 1003], ["screening", 1008], [",", 1017], ["an", 1019], ["operation", 1022], ["lasting", 1032], ["more", 1040], ["than", 1045], ["300", 1050], ["min", 1054], ["and", 1058], ["an", 1062], ["emergency", 1065], ["operation", 1075], [".", 1084], ["A", 1086], ["positive", 1088], ["MRSA", 1097], ["screening", 1102], ["was", 1112], ["the", 1116], ["most", 1120], ["statistically", 1125], ["significant", 1139], ["risk", 1151], ["factor", 1156], ["for", 1163], ["postoperative", 1167], ["MRSA", 1181], ["pneumonia", 1186], ["and", 1196], ["enteritis", 1200], [",", 1209], ["but", 1211], ["was", 1215], ["not", 1219], ["a", 1223], ["risk", 1225], ["factor", 1230], ["for", 1237], ["MRSA", 1241], ["surgical", 1246], ["site", 1255], ["infections", 1260], [".", 1270], ["Nasal", 1272], ["MRSA", 1278], ["screening", 1283], ["can", 1293], ["help", 1297], ["to", 1302], ["identify", 1305], ["patients", 1314], ["who", 1323], ["have", 1327], ["an", 1332], ["increased", 1335], ["risk", 1345], ["of", 1350], ["developing", 1353], ["postoperative", 1364], ["MRSA", 1378], ["infections", 1383], [",", 1393], ["and", 1395], ["would", 1399], ["enable", 1405], ["physicians", 1412], ["to", 1423], ["take", 1426], ["a", 1431], ["prompt", 1433], ["action", 1440], ["if", 1447], ["these", 1450], ["complications", 1456], ["occur", 1470], [".", 1475]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "Individuals with Mowat-Wilson syndrome (MWS; OMIM#235730) have characteristic facial features, a variety of congenital anomalies such as Hirschsprung disease, and intellectual disabilities caused by mutation or deletion of ZEB2 gene. This deletion or cytogenetic abnormality has been reported primarily from Europe, Australia and the United States, but not in Korea. Here we report a patient with characteristic facial features of MWS, developmental delay and spasticity. High resolution microarray analysis revealed 0.9 Mb deletion of 2q22.3 involving two genes: ZEB2 and GTDC1. This case shows the important role of high resolution microarray in patients with unexplained psychomotor retardation and/or facial dysmorphism. Knowledge about the most striking clinical signs and implementation of effective molecular tests like microarray could significantly increase the detection rate of new cases of MWS in Korea. This is the first reported case of MWS in Korea.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "65d32f6d9c06430c970f8b3020a54497", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[92, 92], [35, 35]], "char_spans": [[564, 567], [223, 226]]}]}], "context_tokens": [["Individuals", 0], ["with", 12], ["Mowat", 17], ["-", 22], ["Wilson", 23], ["syndrome", 30], ["(", 39], ["MWS", 40], [";", 43], ["OMIM#235730", 45], [")", 56], ["have", 58], ["characteristic", 63], ["facial", 78], ["features", 85], [",", 93], ["a", 95], ["variety", 97], ["of", 105], ["congenital", 108], ["anomalies", 119], ["such", 129], ["as", 134], ["Hirschsprung", 137], ["disease", 150], [",", 157], ["and", 159], ["intellectual", 163], ["disabilities", 176], ["caused", 189], ["by", 196], ["mutation", 199], ["or", 208], ["deletion", 211], ["of", 220], ["ZEB2", 223], ["gene", 228], [".", 232], ["This", 234], ["deletion", 239], ["or", 248], ["cytogenetic", 251], ["abnormality", 263], ["has", 275], ["been", 279], ["reported", 284], ["primarily", 293], ["from", 303], ["Europe", 308], [",", 314], ["Australia", 316], ["and", 326], ["the", 330], ["United", 334], ["States", 341], [",", 347], ["but", 349], ["not", 353], ["in", 357], ["Korea", 360], [".", 365], ["Here", 367], ["we", 372], ["report", 375], ["a", 382], ["patient", 384], ["with", 392], ["characteristic", 397], ["facial", 412], ["features", 419], ["of", 428], ["MWS", 431], [",", 434], ["developmental", 436], ["delay", 450], ["and", 456], ["spasticity", 460], [".", 470], ["High", 472], ["resolution", 477], ["microarray", 488], ["analysis", 499], ["revealed", 508], ["0.9", 517], ["Mb", 521], ["deletion", 524], ["of", 533], ["2q22.3", 536], ["involving", 543], ["two", 553], ["genes", 557], [":", 562], ["ZEB2", 564], ["and", 569], ["GTDC1", 573], [".", 578], ["This", 580], ["case", 585], ["shows", 590], ["the", 596], ["important", 600], ["role", 610], ["of", 615], ["high", 618], ["resolution", 623], ["microarray", 634], ["in", 645], ["patients", 648], ["with", 657], ["unexplained", 662], ["psychomotor", 674], ["retardation", 686], ["and/or", 698], ["facial", 705], ["dysmorphism", 712], [".", 723], ["Knowledge", 725], ["about", 735], ["the", 741], ["most", 745], ["striking", 750], ["clinical", 759], ["signs", 768], ["and", 774], ["implementation", 778], ["of", 793], ["effective", 796], ["molecular", 806], ["tests", 816], ["like", 822], ["microarray", 827], ["could", 838], ["significantly", 844], ["increase", 858], ["the", 867], ["detection", 871], ["rate", 881], ["of", 886], ["new", 889], ["cases", 893], ["of", 899], ["MWS", 902], ["in", 906], ["Korea", 909], [".", 914], ["This", 916], ["is", 921], ["the", 924], ["first", 928], ["reported", 934], ["case", 943], ["of", 948], ["MWS", 951], ["in", 955], ["Korea", 958], [".", 963]]}
{"context": "Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "549c82a2fcb04e38a84c3f7661eeeaf0", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[7, 30]], "char_spans": [[50, 153]]}]}], "context_tokens": [["Biallelic", 0], ["mutations", 10], ["of", 20], ["the", 23], ["DNA", 27], ["annealing", 31], ["helicase", 41], ["SMARCAL1", 50], ["(", 59], ["SWI", 60], ["/", 63], ["SNF", 64], ["-", 67], ["related", 68], [",", 75], ["matrix", 77], ["-", 83], ["associated", 84], [",", 94], ["actin", 96], ["-", 101], ["dependent", 102], ["regulator", 112], ["of", 122], ["chromatin", 125], [",", 134], ["subfamily", 136], ["a", 146], ["-", 147], ["like", 148], ["1", 153], [")", 154], ["cause", 156], ["Schimke", 162], ["immuno", 170], ["-", 176], ["osseous", 177], ["dysplasia", 185], ["(", 195], ["SIOD", 196], [",", 200], ["MIM", 202], ["242900", 206], [")", 212], [",", 213], ["an", 215], ["incompletely", 218], ["penetrant", 231], ["autosomal", 241], ["recessive", 251], ["disorder", 261], [".", 269], ["Using", 271], ["human", 277], [",", 282], ["Drosophila", 284], ["and", 295], ["mouse", 299], ["models", 305], [",", 311], ["we", 313], ["show", 316], ["that", 321], ["the", 326], ["proteins", 330], ["encoded", 339], ["by", 347], ["SMARCAL1", 350], ["orthologs", 359], ["localize", 369], ["to", 378], ["transcriptionally", 381], ["active", 399], ["chromatin", 406], ["and", 416], ["modulate", 420], ["gene", 429], ["expression", 434], [".", 444], ["We", 446], ["also", 449], ["show", 454], ["that", 459], [",", 463], ["as", 465], ["found", 468], ["in", 474], ["SIOD", 477], ["patients", 482], [",", 490], ["deficiency", 492], ["of", 503], ["the", 506], ["SMARCAL1", 510], ["orthologs", 519], ["alone", 529], ["is", 535], ["insufficient", 538], ["to", 551], ["cause", 554], ["disease", 560], ["in", 568], ["fruit", 571], ["flies", 577], ["and", 583], ["mice", 587], [",", 591], ["although", 593], ["such", 602], ["deficiency", 607], ["causes", 618], ["modest", 625], ["diffuse", 632], ["alterations", 640], ["in", 652], ["gene", 655], ["expression", 660], [".", 670], ["Rather", 672], [",", 678], ["disease", 680], ["manifests", 688], ["when", 698], ["SMARCAL1", 703], ["deficiency", 712], ["interacts", 723], ["with", 733], ["genetic", 738], ["and", 746], ["environmental", 750], ["factors", 764], ["that", 772], ["further", 777], ["alter", 785], ["gene", 791], ["expression", 796], [".", 806], ["We", 808], ["conclude", 811], ["that", 820], ["the", 825], ["SMARCAL1", 829], ["annealing", 838], ["helicase", 848], ["buffers", 857], ["fluctuations", 865], ["in", 878], ["gene", 881], ["expression", 886], ["and", 897], ["that", 901], ["alterations", 906], ["in", 918], ["gene", 921], ["expression", 926], ["contribute", 937], ["to", 948], ["the", 951], ["penetrance", 955], ["of", 966], ["SIOD", 969], [".", 973]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2ff9e79323fb48ad9fe911c391aecaa8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[81, 81], [53, 53], [255, 255], [5, 5]], "char_spans": [[479, 481], [296, 298], [1516, 1518], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["inherited", 40], ["bone", 50], ["marrow", 55], ["failure", 62], ["syndrome", 70], ["that", 79], ["is", 84], ["characterized", 87], ["by", 101], ["pure", 104], ["red", 109], ["-", 112], ["cell", 113], ["aplasia", 118], ["and", 126], ["associated", 130], ["physical", 141], ["deformities", 150], [".", 161], ["It", 163], ["has", 166], ["been", 170], ["proven", 175], ["that", 182], ["defects", 187], ["of", 195], ["ribosomal", 198], ["proteins", 208], ["can", 217], ["lead", 221], ["to", 226], ["this", 229], ["disease", 234], ["and", 242], ["that", 246], ["RPS19", 251], ["is", 257], ["the", 260], ["most", 264], ["frequently", 269], ["mutated", 280], ["gene", 288], ["in", 293], ["DBA", 296], ["patients", 300], [".", 308], ["Previous", 310], ["studies", 319], ["suggest", 327], ["that", 335], ["p53-dependent", 340], ["genes", 354], ["and", 360], ["pathways", 364], ["play", 373], ["important", 378], ["roles", 388], ["in", 394], ["RPS19-deficient", 397], ["embryos", 413], [".", 420], ["However", 422], [",", 429], ["whether", 431], ["there", 439], ["are", 445], ["other", 449], ["vital", 455], ["factors", 461], ["linked", 469], ["to", 476], ["DBA", 479], ["has", 483], ["not", 487], ["been", 491], ["fully", 496], ["clarified", 502], [".", 511], ["In", 513], ["this", 516], ["study", 521], [",", 526], ["we", 528], ["compared", 531], ["the", 540], ["whole", 544], ["genome", 550], ["RNA", 557], ["-", 560], ["Seq", 561], ["data", 565], ["of", 570], ["zebrafish", 573], ["embryos", 583], ["injected", 591], ["with", 600], ["RPS19", 605], ["morpholino", 611], ["(", 622], ["RPS19", 623], ["MO", 629], [")", 631], [",", 632], ["RPS19", 634], ["and", 640], ["p53", 644], ["morpholino", 648], ["simultaneously", 659], ["(", 674], ["RPS19+p53", 675], ["MO", 685], [")", 687], ["and", 689], ["control", 693], ["morpholino", 701], ["(", 712], ["control", 713], [")", 720], [".", 721], ["We", 723], ["found", 726], ["that", 732], ["genes", 737], ["enriched", 743], ["in", 752], ["the", 755], ["functions", 759], ["of", 769], ["hematological", 772], ["systems", 786], [",", 793], ["nervous", 795], ["system", 803], ["development", 810], ["and", 822], ["skeletal", 826], ["and", 835], ["muscular", 839], ["disorders", 848], ["had", 858], ["significant", 862], ["differential", 874], ["expression", 887], ["in", 898], ["RPS19", 901], ["MO", 907], ["embryos", 910], ["compared", 918], ["with", 927], ["controls", 932], [".", 940], ["Co", 942], ["-", 944], ["inhibition", 945], ["of", 956], ["p53", 959], ["partially", 963], ["alleviates", 973], ["the", 984], ["abnormalities", 988], ["for", 1002], ["RPS19-deficient", 1006], ["embryos", 1022], [".", 1029], ["However", 1031], [",", 1038], ["the", 1040], ["hematopoietic", 1044], ["genes", 1058], [",", 1063], ["which", 1065], ["were", 1071], ["down", 1076], ["-", 1080], ["regulated", 1081], ["significantly", 1091], ["in", 1105], ["RPS19", 1108], ["MO", 1114], ["embryos", 1117], [",", 1124], ["were", 1126], ["not", 1131], ["completely", 1135], ["recovered", 1146], ["by", 1156], ["the", 1159], ["co", 1163], ["-", 1165], ["inhibition", 1166], ["of", 1177], ["p53", 1180], [".", 1183], ["Furthermore", 1185], [",", 1196], ["we", 1198], ["identified", 1201], ["the", 1212], ["genome", 1216], ["-", 1222], ["wide", 1223], ["p53-dependent", 1228], ["and", 1242], ["-independent", 1246], ["genes", 1259], ["and", 1265], ["pathways", 1269], [".", 1277], ["These", 1279], ["results", 1285], ["indicate", 1293], ["that", 1302], ["not", 1307], ["only", 1311], ["p53", 1316], ["family", 1320], ["members", 1327], ["but", 1335], ["also", 1339], ["other", 1344], ["factors", 1350], ["have", 1358], ["important", 1363], ["impacts", 1373], ["on", 1381], ["RPS19-deficient", 1384], ["embryos", 1400], [".", 1407], ["The", 1409], ["detection", 1413], ["of", 1423], ["potential", 1426], ["pathogenic", 1436], ["genes", 1447], ["and", 1453], ["pathways", 1457], ["provides", 1466], ["us", 1475], ["a", 1478], ["new", 1480], ["paradigm", 1484], ["for", 1493], ["future", 1497], ["research", 1504], ["on", 1513], ["DBA", 1516], [",", 1519], ["which", 1521], ["is", 1527], ["a", 1530], ["systematic", 1532], ["and", 1543], ["complex", 1547], ["hereditary", 1555], ["disease", 1566], [".", 1573]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2'-O-methyl phosphorothioate has demonstrated the capability to induce dystrophin expression in Duchenne muscular dystrophy (DMD) patients in phase II-III clinical trials with benefit in muscle functions. However, potential of the therapy for DMD at different stages of the disease progression is not understood. In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis. Biweekly intravenous (i.v.) administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. This was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. However, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started. The PPMO treatment alleviated the disease pathology and significantly prolonged the life span of the mice receiving treatment at younger age with mild phenotype. However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage. The results could be critical for design of clinical trials with antisense therapy to DMD.", "qas": [{"question": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "answers": ["100%"], "qid": "d6fb14e3be8245baaf66693d4b546e8f", "question_tokens": [["In", 0], ["what", 3], ["percentage", 8], ["of", 19], ["skeletal", 22], ["muscle", 31], ["fibers", 38], ["is", 45], ["dystrophin", 48], ["expression", 59], ["restored", 70], ["after", 79], ["PPMO-", 85], ["mediated", 91], ["exon", 100], ["skipping", 105], ["?", 113]], "detected_answers": [{"text": "100%", "token_spans": [[145, 145]], "char_spans": [[802, 804]]}]}], "context_tokens": [["Antisense", 0], ["therapy", 10], ["with", 18], ["both", 23], ["chemistries", 28], ["of", 40], ["phosphorodiamidate", 43], ["morpholino", 62], ["oligomers", 73], ["(", 83], ["PMOs", 84], [")", 88], ["and", 90], ["2'-O", 94], ["-", 98], ["methyl", 99], ["phosphorothioate", 106], ["has", 123], ["demonstrated", 127], ["the", 140], ["capability", 144], ["to", 155], ["induce", 158], ["dystrophin", 165], ["expression", 176], ["in", 187], ["Duchenne", 190], ["muscular", 199], ["dystrophy", 208], ["(", 218], ["DMD", 219], [")", 222], ["patients", 224], ["in", 233], ["phase", 236], ["II", 242], ["-", 244], ["III", 245], ["clinical", 249], ["trials", 258], ["with", 265], ["benefit", 270], ["in", 278], ["muscle", 281], ["functions", 288], [".", 297], ["However", 299], [",", 306], ["potential", 308], ["of", 318], ["the", 321], ["therapy", 325], ["for", 333], ["DMD", 337], ["at", 341], ["different", 344], ["stages", 354], ["of", 361], ["the", 364], ["disease", 368], ["progression", 376], ["is", 388], ["not", 391], ["understood", 395], [".", 405], ["In", 407], ["this", 410], ["study", 415], [",", 420], ["we", 422], ["examined", 425], ["the", 434], ["effect", 438], ["of", 445], ["peptide", 448], ["-", 455], ["conjugated", 456], ["PMO", 467], ["(", 471], ["PPMO)-mediated", 472], ["exon", 487], ["skipping", 492], ["on", 501], ["disease", 504], ["progression", 512], ["of", 524], ["utrophin", 527], ["-", 535], ["dystrophin", 536], ["-", 546], ["deficient", 547], ["mice", 557], ["(", 562], ["dko", 563], [")", 566], ["of", 568], ["four", 571], ["age", 576], ["groups", 580], ["(", 587], ["21", 588], ["-", 590], ["29", 591], [",", 593], ["30", 595], ["-", 597], ["39", 598], [",", 600], ["40", 602], ["-", 604], ["49", 605], ["and", 608], ["50", 612], ["+", 614], ["days", 616], [")", 620], [",", 621], ["representing", 623], ["diseases", 636], ["from", 645], ["early", 650], ["stage", 656], ["to", 662], ["advanced", 665], ["stage", 674], ["with", 680], ["severe", 685], ["kyphosis", 692], [".", 700], ["Biweekly", 702], ["intravenous", 711], ["(", 723], ["i.v", 724], [".", 727], [")", 728], ["administration", 730], ["of", 745], ["the", 748], ["PPMO", 752], ["restored", 757], ["the", 766], ["dystrophin", 770], ["expression", 781], ["in", 792], ["nearly", 795], ["100", 802], ["%", 805], ["skeletal", 807], ["muscle", 816], ["fibers", 823], ["in", 830], ["all", 833], ["age", 837], ["groups", 841], [".", 847], ["This", 849], ["was", 854], ["associated", 858], ["with", 869], ["the", 874], ["restoration", 878], ["of", 890], ["dystrophin", 893], ["-", 903], ["associated", 904], ["proteins", 915], ["including", 924], ["functional", 934], ["glycosylated", 945], ["dystroglycan", 958], ["and", 971], ["neuronal", 975], ["nitric", 984], ["synthase", 991], [".", 999], ["However", 1001], [",", 1008], ["therapeutic", 1010], ["outcomes", 1022], ["clearly", 1031], ["depended", 1039], ["on", 1048], ["severity", 1051], ["of", 1060], ["the", 1063], ["disease", 1067], ["at", 1075], ["the", 1078], ["time", 1082], ["the", 1087], ["treatment", 1091], ["started", 1101], [".", 1108], ["The", 1110], ["PPMO", 1114], ["treatment", 1119], ["alleviated", 1129], ["the", 1140], ["disease", 1144], ["pathology", 1152], ["and", 1162], ["significantly", 1166], ["prolonged", 1180], ["the", 1190], ["life", 1194], ["span", 1199], ["of", 1204], ["the", 1207], ["mice", 1211], ["receiving", 1216], ["treatment", 1226], ["at", 1236], ["younger", 1239], ["age", 1247], ["with", 1251], ["mild", 1256], ["phenotype", 1261], [".", 1270], ["However", 1272], [",", 1279], ["restoration", 1281], ["of", 1293], ["high", 1296], ["levels", 1301], ["of", 1308], ["dystrophin", 1311], ["expression", 1322], ["failed", 1333], ["to", 1340], ["prevent", 1343], ["disease", 1351], ["progression", 1359], ["to", 1371], ["the", 1374], ["mice", 1378], ["receiving", 1383], ["treatment", 1393], ["when", 1403], ["disease", 1408], ["was", 1416], ["already", 1420], ["at", 1428], ["advanced", 1431], ["stage", 1440], [".", 1445], ["The", 1447], ["results", 1451], ["could", 1459], ["be", 1465], ["critical", 1468], ["for", 1477], ["design", 1481], ["of", 1488], ["clinical", 1491], ["trials", 1500], ["with", 1507], ["antisense", 1512], ["therapy", 1522], ["to", 1530], ["DMD", 1533], [".", 1536]]}
{"context": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within LB-bearing neurons were performed by immunogold electron microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. In contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-terminal antibody, it diminished the N-terminal NACP/alpha-synuclein immunoreactivity. Furthermore, formic acid enhanced LB and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites. These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "d3600ecb55744469b54fde10d8d1c38e", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[247, 249], [100, 102], [20, 22], [228, 230], [109, 111], [153, 155], [351, 353], [315, 317], [75, 77]], "char_spans": [[1302, 1316], [489, 503], [94, 108], [1205, 1219], [543, 557], [787, 801], [1925, 1939], [1700, 1714], [372, 386]]}]}], "context_tokens": [["The", 0], ["precursor", 4], ["of", 14], ["the", 17], ["non", 21], ["-", 24], ["Abeta", 25], ["component", 31], ["of", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["amyloid", 64], ["(", 72], ["NACP", 73], [")", 77], ["(", 79], ["also", 80], ["known", 85], ["as", 91], ["alpha", 94], ["-", 99], ["synuclein", 100], [")", 109], ["is", 111], ["a", 114], ["presynaptic", 116], ["terminal", 128], ["molecule", 137], ["that", 146], ["abnormally", 151], ["accumulates", 162], ["in", 174], ["the", 177], ["plaques", 181], ["of", 189], ["Alzheimer", 192], ["'s", 201], ["disease", 204], ["(", 212], ["AD", 213], [")", 215], ["and", 217], ["in", 221], ["the", 224], ["Lewy", 228], ["bodies", 233], ["(", 240], ["LBs", 241], [")", 244], ["of", 246], ["Lewy", 249], ["body", 254], ["variant", 259], ["of", 267], ["AD", 270], [",", 272], ["diffuse", 274], ["Lewy", 282], ["body", 287], ["disease", 292], [",", 299], ["and", 301], ["Parkinson", 305], ["'s", 314], ["disease", 317], [".", 324], ["To", 326], ["better", 329], ["understand", 336], ["the", 347], ["distribution", 351], ["of", 364], ["NACP", 367], ["/", 371], ["alpha", 372], ["-", 377], ["synuclein", 378], ["and", 388], ["its", 392], ["fragments", 396], ["in", 406], ["the", 409], ["LB", 413], ["-", 415], ["bearing", 416], ["neurons", 424], ["and", 432], ["neurites", 436], [",", 444], ["as", 446], ["well", 449], ["as", 454], ["to", 457], ["clarify", 460], ["the", 468], ["patterns", 472], ["of", 481], ["NACP", 484], ["/", 488], ["alpha", 489], ["-", 494], ["synuclein", 495], ["compartmentalization", 505], [",", 525], ["we", 527], ["studied", 530], ["NACP", 538], ["/", 542], ["alpha", 543], ["-", 548], ["synuclein", 549], ["immunoreactivity", 559], ["using", 576], ["antibodies", 582], ["against", 593], ["the", 601], ["C", 605], ["-", 606], ["terminal", 607], [",", 615], ["N", 617], ["-", 618], ["terminal", 619], [",", 627], ["and", 629], ["NAC", 633], ["regions", 637], ["after", 645], ["Proteinase", 651], ["K", 662], ["and", 664], ["formic", 668], ["acid", 675], ["treatment", 680], ["in", 690], ["the", 693], ["cortex", 697], ["of", 704], ["patients", 707], ["with", 716], ["LBs", 721], [".", 724], ["Furthermore", 726], [",", 737], ["studies", 739], ["of", 747], ["the", 750], ["subcellular", 754], ["localization", 766], ["of", 779], ["NACP", 782], ["/", 786], ["alpha", 787], ["-", 792], ["synuclein", 793], ["within", 803], ["LB", 810], ["-", 812], ["bearing", 813], ["neurons", 821], ["were", 829], ["performed", 834], ["by", 844], ["immunogold", 847], ["electron", 858], ["microscopy", 867], [".", 877], ["These", 879], ["studies", 885], ["showed", 893], ["that", 900], ["the", 905], ["N", 909], ["-", 910], ["terminal", 911], ["antibody", 920], ["immunolabeled", 929], ["the", 943], ["LBs", 947], ["and", 951], ["dystrophic", 955], ["neurites", 966], ["with", 975], ["great", 980], ["intensity", 986], ["and", 996], [",", 999], ["to", 1001], ["a", 1004], ["lesser", 1006], ["extent", 1013], [",", 1019], ["the", 1021], ["synapses", 1025], [".", 1033], ["In", 1035], ["contrast", 1038], [",", 1046], ["the", 1048], ["C", 1052], ["-", 1053], ["terminal", 1054], ["antibody", 1063], ["strongly", 1072], ["labeled", 1081], ["the", 1089], ["synapses", 1093], ["and", 1102], [",", 1105], ["to", 1107], ["a", 1110], ["lesser", 1112], ["extent", 1119], [",", 1125], ["the", 1127], ["LBs", 1131], ["and", 1135], ["dystrophic", 1139], ["neurites", 1150], [".", 1158], ["Whereas", 1160], ["Proteinase", 1168], ["K", 1179], ["treatment", 1181], ["enhanced", 1191], ["NACP", 1200], ["/", 1204], ["alpha", 1205], ["-", 1210], ["synuclein", 1211], ["immunoreactivity", 1221], ["with", 1238], ["the", 1243], ["C", 1247], ["-", 1248], ["terminal", 1249], ["antibody", 1258], [",", 1266], ["it", 1268], ["diminished", 1271], ["the", 1282], ["N", 1286], ["-", 1287], ["terminal", 1288], ["NACP", 1297], ["/", 1301], ["alpha", 1302], ["-", 1307], ["synuclein", 1308], ["immunoreactivity", 1318], [".", 1334], ["Furthermore", 1336], [",", 1347], ["formic", 1349], ["acid", 1356], ["enhanced", 1361], ["LB", 1370], ["and", 1373], ["dystrophic", 1377], ["neurite", 1388], ["labeling", 1396], ["with", 1405], ["both", 1410], ["the", 1415], ["C-", 1419], ["and", 1422], ["N", 1426], ["-", 1427], ["terminal", 1428], ["antibodies", 1437], [".", 1447], ["In", 1449], ["addition", 1452], [",", 1460], ["whereas", 1462], ["without", 1470], ["pretreatment", 1478], ["only", 1491], ["slight", 1496], ["anti", 1503], ["-", 1507], ["NAC", 1508], ["immunoreactivity", 1512], ["was", 1529], ["found", 1533], ["in", 1539], ["the", 1542], ["LBs", 1546], [",", 1549], ["formic", 1551], ["acid", 1558], ["pretreatment", 1563], ["revealed", 1576], ["an", 1585], ["extensive", 1588], ["anti", 1598], ["-", 1602], ["NAC", 1603], ["immunostaining", 1607], ["of", 1622], ["LBs", 1625], [",", 1628], ["plaques", 1630], [",", 1637], ["and", 1639], ["glial", 1643], ["cells", 1649], [".", 1654], ["Ultrastructural", 1656], ["analysis", 1672], ["revealed", 1681], ["that", 1690], ["NACP", 1695], ["/", 1699], ["alpha", 1700], ["-", 1705], ["synuclein", 1706], ["immunoreactivity", 1716], ["was", 1733], ["diffusely", 1737], ["distributed", 1747], ["within", 1759], ["the", 1766], ["amorphous", 1770], ["electrodense", 1780], ["material", 1793], ["in", 1802], ["the", 1805], ["LBs", 1809], ["and", 1813], ["as", 1817], ["small", 1820], ["clusters", 1826], ["in", 1835], ["the", 1838], ["filaments", 1842], ["of", 1852], ["LBs", 1855], ["and", 1859], ["neurites", 1863], [".", 1871], ["These", 1873], ["results", 1879], ["support", 1887], ["the", 1895], ["view", 1899], ["that", 1904], ["aggregated", 1909], ["NACP", 1920], ["/", 1924], ["alpha", 1925], ["-", 1930], ["synuclein", 1931], ["might", 1941], ["play", 1947], ["an", 1952], ["important", 1955], ["role", 1965], ["in", 1970], ["the", 1973], ["pathogenesis", 1977], ["of", 1990], ["disorders", 1993], ["associated", 2003], ["with", 2014], ["LBs", 2019], [".", 2022]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "Two missense mutations (Ala-30 --> Pro and Ala-53 --> Thr) in the gene encoding alpha-synuclein are associated with rare autosomal dominant forms of familial Parkinson's disease. In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease. However, the normal conformation of alpha-synuclein, its cellular localization in neurons, and the effects of the mutations remain to be determined. In the present study, we examine these questions using sensitive fluorescence resonance energy transfer techniques. Transient transfection of alpha-synuclein expression constructs into primary cortical neurons and counterstaining with the lipophilic fluorescent marker, DiI, demonstrates a close association between alpha-synuclein and cellular membranes. Both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes. A weak interaction also occurs between the N and C termini themselves. The Parkinson's disease-associated mutations have no effect on membrane interaction; however, the Ala-30 --> Pro mutation alters the three-dimensional conformation of alpha-synuclein, as measured by significantly increased fluorescence resonance energy transfer between the N and C termini.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "9cf91c000cf144009e50440635f148d1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[129, 131], [145, 147], [196, 198], [37, 39], [105, 107], [64, 66], [18, 20]], "char_spans": [[776, 790], [854, 868], [1147, 1161], [192, 206], [602, 616], [347, 361], [80, 94]]}]}], "context_tokens": [["Two", 0], ["missense", 4], ["mutations", 13], ["(", 23], ["Ala-30", 24], ["--", 31], [">", 33], ["Pro", 35], ["and", 39], ["Ala-53", 43], ["--", 50], [">", 52], ["Thr", 54], [")", 57], ["in", 59], ["the", 62], ["gene", 66], ["encoding", 71], ["alpha", 80], ["-", 85], ["synuclein", 86], ["are", 96], ["associated", 100], ["with", 111], ["rare", 116], ["autosomal", 121], ["dominant", 131], ["forms", 140], ["of", 146], ["familial", 149], ["Parkinson", 158], ["'s", 167], ["disease", 170], [".", 177], ["In", 179], ["addition", 182], [",", 190], ["alpha", 192], ["-", 197], ["synuclein", 198], ["is", 208], ["an", 211], ["abundant", 214], ["component", 223], ["of", 233], ["Lewy", 236], ["bodies", 241], ["in", 248], ["sporadic", 251], ["Parkinson", 260], ["'s", 269], ["disease", 272], ["and", 280], ["diffuse", 284], ["Lewy", 292], ["body", 297], ["disease", 302], [".", 309], ["However", 311], [",", 318], ["the", 320], ["normal", 324], ["conformation", 331], ["of", 344], ["alpha", 347], ["-", 352], ["synuclein", 353], [",", 362], ["its", 364], ["cellular", 368], ["localization", 377], ["in", 390], ["neurons", 393], [",", 400], ["and", 402], ["the", 406], ["effects", 410], ["of", 418], ["the", 421], ["mutations", 425], ["remain", 435], ["to", 442], ["be", 445], ["determined", 448], [".", 458], ["In", 460], ["the", 463], ["present", 467], ["study", 475], [",", 480], ["we", 482], ["examine", 485], ["these", 493], ["questions", 499], ["using", 509], ["sensitive", 515], ["fluorescence", 525], ["resonance", 538], ["energy", 548], ["transfer", 555], ["techniques", 564], [".", 574], ["Transient", 576], ["transfection", 586], ["of", 599], ["alpha", 602], ["-", 607], ["synuclein", 608], ["expression", 618], ["constructs", 629], ["into", 640], ["primary", 645], ["cortical", 653], ["neurons", 662], ["and", 670], ["counterstaining", 674], ["with", 690], ["the", 695], ["lipophilic", 699], ["fluorescent", 710], ["marker", 722], [",", 728], ["DiI", 730], [",", 733], ["demonstrates", 735], ["a", 748], ["close", 750], ["association", 756], ["between", 768], ["alpha", 776], ["-", 781], ["synuclein", 782], ["and", 792], ["cellular", 796], ["membranes", 805], [".", 814], ["Both", 816], ["the", 821], ["N-", 825], ["and", 828], ["C", 832], ["-", 833], ["terminal", 834], ["regions", 843], ["of", 851], ["alpha", 854], ["-", 859], ["synuclein", 860], ["are", 870], ["tightly", 874], ["associated", 882], ["with", 893], ["membranes", 898], [".", 907], ["A", 909], ["weak", 911], ["interaction", 916], ["also", 928], ["occurs", 933], ["between", 940], ["the", 948], ["N", 952], ["and", 954], ["C", 958], ["termini", 960], ["themselves", 968], [".", 978], ["The", 980], ["Parkinson", 984], ["'s", 993], ["disease", 996], ["-", 1003], ["associated", 1004], ["mutations", 1015], ["have", 1025], ["no", 1030], ["effect", 1033], ["on", 1040], ["membrane", 1043], ["interaction", 1052], [";", 1063], ["however", 1065], [",", 1072], ["the", 1074], ["Ala-30", 1078], ["--", 1085], [">", 1087], ["Pro", 1089], ["mutation", 1093], ["alters", 1102], ["the", 1109], ["three", 1113], ["-", 1118], ["dimensional", 1119], ["conformation", 1131], ["of", 1144], ["alpha", 1147], ["-", 1152], ["synuclein", 1153], [",", 1162], ["as", 1164], ["measured", 1167], ["by", 1176], ["significantly", 1179], ["increased", 1193], ["fluorescence", 1203], ["resonance", 1216], ["energy", 1226], ["transfer", 1233], ["between", 1242], ["the", 1250], ["N", 1254], ["and", 1256], ["C", 1260], ["termini", 1262], [".", 1269]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "1e975a42f37e4673a2b441a56ec1c446", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[3, 3]], "char_spans": [[31, 34]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran. Dabigatran reversal with idarucizumab before administration of IV-tPA might reduce the risk of sICH. We report a case of a 69-year-old stroke patient on dabigatran for paroxysmal atrial fibrillation who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 12. There was no early evidence of ischemic stroke or hemorrhage on head computed tomography, and coagulation studies implied therapeutic dabigatran levels. After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197\u2009minutes after he was last seen at his baseline. Subsequent brain magnetic resonance imaging showed 2 punctate infarcts in the left temporal lobe and occipital lobe with no evidence of hemorrhage. The patient was discharged with an NIHSS of 1. Telephone follow-up 2 months later indicated that he was at his prestroke baseline, except for a complaint of worsened short-term memory. Idarucizumab reversal of dabigatran may reduce the risk of sICH and should be considered for acute stroke patients arriving in the IV-tPA time window.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "f9c27593e5f743369c33b2e1ea8791ae", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[0, 0], [176, 176], [97, 97], [29, 29], [71, 71], [263, 263], [168, 168], [126, 126], [95, 95]], "char_spans": [[0, 9], [1049, 1058], [575, 584], [180, 189], [408, 417], [1541, 1550], [996, 1005], [728, 737], [563, 572]]}]}], "context_tokens": [["Dabigatran", 0], ["is", 11], ["a", 14], ["direct", 16], ["thrombin", 23], ["inhibitor", 32], ["used", 42], ["to", 47], ["reduce", 50], ["the", 57], ["risk", 61], ["of", 66], ["stroke", 69], ["in", 76], ["patients", 79], ["with", 88], ["nonvalvular", 93], ["atrial", 105], ["fibrillation", 112], [".", 124], ["For", 126], ["patients", 130], ["who", 139], ["present", 143], ["with", 151], ["an", 156], ["acute", 159], ["stroke", 165], ["despite", 172], ["dabigatran", 180], ["therapy", 191], [",", 198], ["clinical", 200], ["data", 209], ["on", 214], ["the", 217], ["use", 221], ["of", 225], ["intravenous", 228], ["tissue", 240], ["plasminogen", 247], ["activator", 259], ["(", 269], ["IV", 270], ["-", 272], ["tPA", 273], [")", 276], ["is", 278], ["limited", 281], [".", 288], ["There", 290], ["is", 296], ["an", 299], ["anticipated", 302], ["increased", 314], ["risk", 324], ["of", 329], ["symptomatic", 332], ["intracranial", 344], ["hemorrhage", 357], ["(", 368], ["sICH", 369], [")", 373], ["when", 375], ["using", 380], ["IV", 386], ["-", 388], ["tPA", 389], ["in", 393], ["patients", 396], ["on", 405], ["dabigatran", 408], ["therapy", 419], [".", 426], ["In", 428], ["2015", 431], [",", 435], ["the", 437], ["humanized", 441], ["monoclonal", 451], ["antibody", 462], ["fragment", 471], ["idarucizumab", 480], ["was", 493], ["approved", 497], ["for", 506], ["rapid", 510], ["(", 516], ["minutes", 517], [")", 524], ["reversal", 526], ["of", 535], ["anticoagulant", 538], ["effects", 552], ["of", 560], ["dabigatran", 563], [".", 573], ["Dabigatran", 575], ["reversal", 586], ["with", 595], ["idarucizumab", 600], ["before", 613], ["administration", 620], ["of", 635], ["IV", 638], ["-", 640], ["tPA", 641], ["might", 645], ["reduce", 651], ["the", 658], ["risk", 662], ["of", 667], ["sICH", 670], [".", 674], ["We", 676], ["report", 679], ["a", 686], ["case", 688], ["of", 693], ["a", 696], ["69-year", 698], ["-", 705], ["old", 706], ["stroke", 710], ["patient", 717], ["on", 725], ["dabigatran", 728], ["for", 739], ["paroxysmal", 743], ["atrial", 754], ["fibrillation", 761], ["who", 774], ["presented", 778], ["with", 788], ["an", 793], ["initial", 796], ["National", 804], ["Institutes", 813], ["of", 824], ["Health", 827], ["Stroke", 834], ["Scale", 841], ["(", 847], ["NIHSS", 848], [")", 853], ["of", 855], ["12", 858], [".", 860], ["There", 862], ["was", 868], ["no", 872], ["early", 875], ["evidence", 881], ["of", 890], ["ischemic", 893], ["stroke", 902], ["or", 909], ["hemorrhage", 912], ["on", 923], ["head", 926], ["computed", 931], ["tomography", 940], [",", 950], ["and", 952], ["coagulation", 956], ["studies", 968], ["implied", 976], ["therapeutic", 984], ["dabigatran", 996], ["levels", 1007], [".", 1013], ["After", 1015], ["controlling", 1021], ["blood", 1033], ["pressure", 1039], [",", 1047], ["dabigatran", 1049], ["was", 1060], ["reversed", 1064], ["with", 1073], ["idarucizumab", 1078], [",", 1090], ["and", 1092], ["IV", 1096], ["-", 1098], ["tPA", 1099], ["was", 1103], ["administrated", 1107], ["beginning", 1121], ["197", 1131], ["minutes", 1135], ["after", 1143], ["he", 1149], ["was", 1152], ["last", 1156], ["seen", 1161], ["at", 1166], ["his", 1169], ["baseline", 1173], [".", 1181], ["Subsequent", 1183], ["brain", 1194], ["magnetic", 1200], ["resonance", 1209], ["imaging", 1219], ["showed", 1227], ["2", 1234], ["punctate", 1236], ["infarcts", 1245], ["in", 1254], ["the", 1257], ["left", 1261], ["temporal", 1266], ["lobe", 1275], ["and", 1280], ["occipital", 1284], ["lobe", 1294], ["with", 1299], ["no", 1304], ["evidence", 1307], ["of", 1316], ["hemorrhage", 1319], [".", 1329], ["The", 1331], ["patient", 1335], ["was", 1343], ["discharged", 1347], ["with", 1358], ["an", 1363], ["NIHSS", 1366], ["of", 1372], ["1", 1375], [".", 1376], ["Telephone", 1378], ["follow", 1388], ["-", 1394], ["up", 1395], ["2", 1398], ["months", 1400], ["later", 1407], ["indicated", 1413], ["that", 1423], ["he", 1428], ["was", 1431], ["at", 1435], ["his", 1438], ["prestroke", 1442], ["baseline", 1452], [",", 1460], ["except", 1462], ["for", 1469], ["a", 1473], ["complaint", 1475], ["of", 1485], ["worsened", 1488], ["short", 1497], ["-", 1502], ["term", 1503], ["memory", 1508], [".", 1514], ["Idarucizumab", 1516], ["reversal", 1529], ["of", 1538], ["dabigatran", 1541], ["may", 1552], ["reduce", 1556], ["the", 1563], ["risk", 1567], ["of", 1572], ["sICH", 1575], ["and", 1580], ["should", 1584], ["be", 1591], ["considered", 1594], ["for", 1605], ["acute", 1609], ["stroke", 1615], ["patients", 1622], ["arriving", 1631], ["in", 1640], ["the", 1643], ["IV", 1647], ["-", 1649], ["tPA", 1650], ["time", 1654], ["window", 1659], [".", 1665]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6cdfaee03ce4412b9875775aca7ac48e", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[14, 16]], "char_spans": [[91, 112]]}]}], "context_tokens": [["In", 0], ["patients", 3], ["with", 12], ["active", 17], ["rheumatoid", 24], ["arthritis", 35], ["despite", 45], ["therapy", 53], ["with", 61], ["DMARDS", 66], [",", 72], ["treatment", 74], ["with", 84], ["a", 89], ["spleen", 91], ["tyrosine", 98], ["kinase", 107], ["inhibitor", 114], ["has", 124], ["achieved", 128], ["similar", 137], ["response", 145], ["rates", 154], ["to", 160], ["those", 163], ["achieved", 169], ["in", 178], ["clinical", 181], ["trials", 190], ["of", 197], ["other", 200], ["drugs", 206], [",", 211], ["including", 213], ["biologic", 223], ["agents", 232], [".", 238], ["Where", 240], ["might", 246], ["these", 252], ["agents", 258], ["fit", 265], ["in", 269], ["the", 272], ["current", 276], ["armamentarium", 284], ["against", 298], ["this", 306], ["disease", 311], ["?", 318]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus. The clinical findings of SGS include neurological, cardiovascular, connective tissue, and skeletal abnormalities. Among these skeletal findings, developmental scoliosis is recognized in half of all patients with SGS. However, no earlier reports have described the surgical treatment of scoliosis associated with SGS. Four patients (2 boys and 2 girls; mean age at the time of surgery, 7.3\u00b14.4 y) with SGS who underwent surgical treatment for progressive scoliosis were reviewed. The radiologic findings, operative findings, and perioperative complications were evaluated. The mean preoperative Cobb angle was 102.8\u00b116.9 degrees. The curve patterns were a double curve in 2 cases and a triple curve in 2 cases. Local kyphosis at the thoracolumbar area was recognized in all the cases with a mean kyphosis angle of 49\u00b116 degrees. Growing rod procedures were performed in 2 patients, and posterior correction and fusion were performed in 2 patients. The mean correction rate was 45% in the patients who underwent the growing rod procedures at the time of growing rod placement and 51% in the patients who underwent posterior correction and fusion. Dislodgement of the proximal anchors occurred in 3 of the 4 patients. One patient developed pseudoarthrosis. Two patients developed deep wound infections, and implant removal was necessary in 1 patient. Surgical treatment for scoliosis in patients with SGS was associated with a high incidence of perioperative and postoperative complications including implant dislodgements and deep wound infections attributable to poor bone quality and a thin body habitus, which are characteristic clinical features of this syndrome. Careful preoperative surgical planning and postoperative care are critical for the surgical treatment of scoliosis associated with SGS, especially in infants requiring multiple surgeries. Level IV.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "07d30350f8434b48815eaa39fc6cedd9", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[10, 10]], "char_spans": [[55, 70]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["craniosynostosis", 55], ["and", 72], ["marfanoid", 76], ["habitus", 86], [".", 93], ["The", 95], ["clinical", 99], ["findings", 108], ["of", 117], ["SGS", 120], ["include", 124], ["neurological", 132], [",", 144], ["cardiovascular", 146], [",", 160], ["connective", 162], ["tissue", 173], [",", 179], ["and", 181], ["skeletal", 185], ["abnormalities", 194], [".", 207], ["Among", 209], ["these", 215], ["skeletal", 221], ["findings", 230], [",", 238], ["developmental", 240], ["scoliosis", 254], ["is", 264], ["recognized", 267], ["in", 278], ["half", 281], ["of", 286], ["all", 289], ["patients", 293], ["with", 302], ["SGS", 307], [".", 310], ["However", 312], [",", 319], ["no", 321], ["earlier", 324], ["reports", 332], ["have", 340], ["described", 345], ["the", 355], ["surgical", 359], ["treatment", 368], ["of", 378], ["scoliosis", 381], ["associated", 391], ["with", 402], ["SGS", 407], [".", 410], ["Four", 412], ["patients", 417], ["(", 426], ["2", 427], ["boys", 429], ["and", 434], ["2", 438], ["girls", 440], [";", 445], ["mean", 447], ["age", 452], ["at", 456], ["the", 459], ["time", 463], ["of", 468], ["surgery", 471], [",", 478], ["7.3\u00b14.4", 480], ["y", 488], [")", 489], ["with", 491], ["SGS", 496], ["who", 500], ["underwent", 504], ["surgical", 514], ["treatment", 523], ["for", 533], ["progressive", 537], ["scoliosis", 549], ["were", 559], ["reviewed", 564], [".", 572], ["The", 574], ["radiologic", 578], ["findings", 589], [",", 597], ["operative", 599], ["findings", 609], [",", 617], ["and", 619], ["perioperative", 623], ["complications", 637], ["were", 651], ["evaluated", 656], [".", 665], ["The", 667], ["mean", 671], ["preoperative", 676], ["Cobb", 689], ["angle", 694], ["was", 700], ["102.8\u00b116.9", 704], ["degrees", 715], [".", 722], ["The", 724], ["curve", 728], ["patterns", 734], ["were", 743], ["a", 748], ["double", 750], ["curve", 757], ["in", 763], ["2", 766], ["cases", 768], ["and", 774], ["a", 778], ["triple", 780], ["curve", 787], ["in", 793], ["2", 796], ["cases", 798], [".", 803], ["Local", 805], ["kyphosis", 811], ["at", 820], ["the", 823], ["thoracolumbar", 827], ["area", 841], ["was", 846], ["recognized", 850], ["in", 861], ["all", 864], ["the", 868], ["cases", 872], ["with", 878], ["a", 883], ["mean", 885], ["kyphosis", 890], ["angle", 899], ["of", 905], ["49\u00b116", 908], ["degrees", 914], [".", 921], ["Growing", 923], ["rod", 931], ["procedures", 935], ["were", 946], ["performed", 951], ["in", 961], ["2", 964], ["patients", 966], [",", 974], ["and", 976], ["posterior", 980], ["correction", 990], ["and", 1001], ["fusion", 1005], ["were", 1012], ["performed", 1017], ["in", 1027], ["2", 1030], ["patients", 1032], [".", 1040], ["The", 1042], ["mean", 1046], ["correction", 1051], ["rate", 1062], ["was", 1067], ["45", 1071], ["%", 1073], ["in", 1075], ["the", 1078], ["patients", 1082], ["who", 1091], ["underwent", 1095], ["the", 1105], ["growing", 1109], ["rod", 1117], ["procedures", 1121], ["at", 1132], ["the", 1135], ["time", 1139], ["of", 1144], ["growing", 1147], ["rod", 1155], ["placement", 1159], ["and", 1169], ["51", 1173], ["%", 1175], ["in", 1177], ["the", 1180], ["patients", 1184], ["who", 1193], ["underwent", 1197], ["posterior", 1207], ["correction", 1217], ["and", 1228], ["fusion", 1232], [".", 1238], ["Dislodgement", 1240], ["of", 1253], ["the", 1256], ["proximal", 1260], ["anchors", 1269], ["occurred", 1277], ["in", 1286], ["3", 1289], ["of", 1291], ["the", 1294], ["4", 1298], ["patients", 1300], [".", 1308], ["One", 1310], ["patient", 1314], ["developed", 1322], ["pseudoarthrosis", 1332], [".", 1347], ["Two", 1349], ["patients", 1353], ["developed", 1362], ["deep", 1372], ["wound", 1377], ["infections", 1383], [",", 1393], ["and", 1395], ["implant", 1399], ["removal", 1407], ["was", 1415], ["necessary", 1419], ["in", 1429], ["1", 1432], ["patient", 1434], [".", 1441], ["Surgical", 1443], ["treatment", 1452], ["for", 1462], ["scoliosis", 1466], ["in", 1476], ["patients", 1479], ["with", 1488], ["SGS", 1493], ["was", 1497], ["associated", 1501], ["with", 1512], ["a", 1517], ["high", 1519], ["incidence", 1524], ["of", 1534], ["perioperative", 1537], ["and", 1551], ["postoperative", 1555], ["complications", 1569], ["including", 1583], ["implant", 1593], ["dislodgements", 1601], ["and", 1615], ["deep", 1619], ["wound", 1624], ["infections", 1630], ["attributable", 1641], ["to", 1654], ["poor", 1657], ["bone", 1662], ["quality", 1667], ["and", 1675], ["a", 1679], ["thin", 1681], ["body", 1686], ["habitus", 1691], [",", 1698], ["which", 1700], ["are", 1706], ["characteristic", 1710], ["clinical", 1725], ["features", 1734], ["of", 1743], ["this", 1746], ["syndrome", 1751], [".", 1759], ["Careful", 1761], ["preoperative", 1769], ["surgical", 1782], ["planning", 1791], ["and", 1800], ["postoperative", 1804], ["care", 1818], ["are", 1823], ["critical", 1827], ["for", 1836], ["the", 1840], ["surgical", 1844], ["treatment", 1853], ["of", 1863], ["scoliosis", 1866], ["associated", 1876], ["with", 1887], ["SGS", 1892], [",", 1895], ["especially", 1897], ["in", 1908], ["infants", 1911], ["requiring", 1919], ["multiple", 1929], ["surgeries", 1938], [".", 1947], ["Level", 1949], ["IV", 1955], [".", 1957]]}
{"context": "The precise regulation of microRNA (miRNA) transcription and processing is important for eukaryotic development. Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1). We identified a cycling DOF transcription factor, CDF2, which interacts with DCL1 and regulates the accumulation of a population of miRNAs. CDF2 binds directly to the promoters of some miRNAs and works as a transcription activator or repressor for these miRNA genes. CDF2 binds preferentially to the pri-miRNAs regulated by itself and affects DCL1-mediated processing of these pri-miRNAs. Genetically, CDF2 works in the same pathway as miR156 or miR172 to control flowering. We conclude that CDF2 regulates a group of pri-miRNAs at both the transcriptional and posttranscriptional levels to maintain proper levels of their mature miRNAs to control plant development.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "0d62867611e34119b3f038886614e0ab", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[34, 36]], "char_spans": [[192, 208]]}]}], "context_tokens": [["The", 0], ["precise", 4], ["regulation", 12], ["of", 23], ["microRNA", 26], ["(", 35], ["miRNA", 36], [")", 41], ["transcription", 43], ["and", 57], ["processing", 61], ["is", 72], ["important", 75], ["for", 85], ["eukaryotic", 89], ["development", 100], [".", 111], ["Plant", 113], ["miRNAs", 119], ["are", 126], ["first", 130], ["transcribed", 136], ["as", 148], ["stem", 151], ["-", 155], ["loop", 156], ["primary", 161], ["miRNAs", 169], ["(", 176], ["pri", 177], ["-", 180], ["miRNAs", 181], [")", 187], ["by", 189], ["RNA", 192], ["polymerase", 196], ["II", 207], [",", 209], ["then", 210], ["cleaved", 215], ["in", 223], ["the", 226], ["nucleus", 230], ["into", 238], ["mature", 243], ["miRNAs", 250], ["by", 257], ["Dicer", 260], ["-", 265], ["like", 266], ["1", 271], ["(", 273], ["DCL1", 274], [")", 278], [".", 279], ["We", 281], ["identified", 284], ["a", 295], ["cycling", 297], ["DOF", 305], ["transcription", 309], ["factor", 323], [",", 329], ["CDF2", 331], [",", 335], ["which", 337], ["interacts", 343], ["with", 353], ["DCL1", 358], ["and", 363], ["regulates", 367], ["the", 377], ["accumulation", 381], ["of", 394], ["a", 397], ["population", 399], ["of", 410], ["miRNAs", 413], [".", 419], ["CDF2", 421], ["binds", 426], ["directly", 432], ["to", 441], ["the", 444], ["promoters", 448], ["of", 458], ["some", 461], ["miRNAs", 466], ["and", 473], ["works", 477], ["as", 483], ["a", 486], ["transcription", 488], ["activator", 502], ["or", 512], ["repressor", 515], ["for", 525], ["these", 529], ["miRNA", 535], ["genes", 541], [".", 546], ["CDF2", 548], ["binds", 553], ["preferentially", 559], ["to", 574], ["the", 577], ["pri", 581], ["-", 584], ["miRNAs", 585], ["regulated", 592], ["by", 602], ["itself", 605], ["and", 612], ["affects", 616], ["DCL1-mediated", 624], ["processing", 638], ["of", 649], ["these", 652], ["pri", 658], ["-", 661], ["miRNAs", 662], [".", 668], ["Genetically", 670], [",", 681], ["CDF2", 683], ["works", 688], ["in", 694], ["the", 697], ["same", 701], ["pathway", 706], ["as", 714], ["miR156", 717], ["or", 724], ["miR172", 727], ["to", 734], ["control", 737], ["flowering", 745], [".", 754], ["We", 756], ["conclude", 759], ["that", 768], ["CDF2", 773], ["regulates", 778], ["a", 788], ["group", 790], ["of", 796], ["pri", 799], ["-", 802], ["miRNAs", 803], ["at", 810], ["both", 813], ["the", 818], ["transcriptional", 822], ["and", 838], ["posttranscriptional", 842], ["levels", 862], ["to", 869], ["maintain", 872], ["proper", 881], ["levels", 888], ["of", 895], ["their", 898], ["mature", 904], ["miRNAs", 911], ["to", 918], ["control", 921], ["plant", 929], ["development", 935], [".", 946]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births. According to the majority of specific reports, intelligence in TS is generally found to be normal and the prevalence of mental retardation does not seem to be increased in TS except for those patients with a small ring X-chromosome. We evaluated 33 girls with TS with chronological age from 6-18 years. Intellectual assessment included the WISC III and the WAIS-R scales. Our results showed: 1) mean full scale intelligence quotient (FSIQ) was significantly lower than expected based on normative data (p < 0.0005); 2) no correlation was present between height and general intellectual ability; 3) mean performance intelligence quotient (PIQ) was significantly lower than both mean verbal intelligence quotient (VIQ) and FSIQ (p < 0.0025 and p < 0.01, respectively), and most patients had a VIQ-PIQ discrepancy; 4) the frequency of mental retardation in our study group was significantly higher than that observed in the general population (15.1% vs 2.3%, p < 0.025); 5) a significant association was found between karyotype and VIQ, and the best score was achieved in the subgroup of patients with structural abnormalities of the X-chromosome. In the light of these findings we conclude that the clinical picture in TS may encompass a slightly reduced FSIQ, VIQ and especially an inadequate PIQ, but this neurocognitive profile is not significantly affected by statural impairment. Since these neurocognitive defects can be responsible for misdiagnosed school difficulties, we suggest that girls with TS should receive specialized educational support and multidisciplinary care.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "12fa90a3c056479a92f47b23fd5275bf", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[252, 252], [72, 72], [23, 23]], "char_spans": [[1288, 1288], [376, 376], [107, 107]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["disorder", 40], ["that", 49], ["results", 54], ["from", 62], ["the", 67], ["loss", 71], ["of", 76], ["the", 79], ["entire", 83], ["or", 90], ["a", 93], ["part", 95], ["of", 100], ["the", 103], ["X", 107], ["-", 108], ["chromosome", 109], ["and", 120], ["occurs", 124], ["in", 131], ["1/2,500", 134], ["female", 142], ["births", 149], [".", 155], ["According", 157], ["to", 167], ["the", 170], ["majority", 174], ["of", 183], ["specific", 186], ["reports", 195], [",", 202], ["intelligence", 204], ["in", 217], ["TS", 220], ["is", 223], ["generally", 226], ["found", 236], ["to", 242], ["be", 245], ["normal", 248], ["and", 255], ["the", 259], ["prevalence", 263], ["of", 274], ["mental", 277], ["retardation", 284], ["does", 296], ["not", 301], ["seem", 305], ["to", 310], ["be", 313], ["increased", 316], ["in", 326], ["TS", 329], ["except", 332], ["for", 339], ["those", 343], ["patients", 349], ["with", 358], ["a", 363], ["small", 365], ["ring", 371], ["X", 376], ["-", 377], ["chromosome", 378], [".", 388], ["We", 390], ["evaluated", 393], ["33", 403], ["girls", 406], ["with", 412], ["TS", 417], ["with", 420], ["chronological", 425], ["age", 439], ["from", 443], ["6", 448], ["-", 449], ["18", 450], ["years", 453], [".", 458], ["Intellectual", 460], ["assessment", 473], ["included", 484], ["the", 493], ["WISC", 497], ["III", 502], ["and", 506], ["the", 510], ["WAIS", 514], ["-", 518], ["R", 519], ["scales", 521], [".", 527], ["Our", 529], ["results", 533], ["showed", 541], [":", 547], ["1", 549], [")", 550], ["mean", 552], ["full", 557], ["scale", 562], ["intelligence", 568], ["quotient", 581], ["(", 590], ["FSIQ", 591], [")", 595], ["was", 597], ["significantly", 601], ["lower", 615], ["than", 621], ["expected", 626], ["based", 635], ["on", 641], ["normative", 644], ["data", 654], ["(", 659], ["p", 660], ["<", 662], ["0.0005", 664], [")", 670], [";", 671], ["2", 673], [")", 674], ["no", 676], ["correlation", 679], ["was", 691], ["present", 695], ["between", 703], ["height", 711], ["and", 718], ["general", 722], ["intellectual", 730], ["ability", 743], [";", 750], ["3", 752], [")", 753], ["mean", 755], ["performance", 760], ["intelligence", 772], ["quotient", 785], ["(", 794], ["PIQ", 795], [")", 798], ["was", 800], ["significantly", 804], ["lower", 818], ["than", 824], ["both", 829], ["mean", 834], ["verbal", 839], ["intelligence", 846], ["quotient", 859], ["(", 868], ["VIQ", 869], [")", 872], ["and", 874], ["FSIQ", 878], ["(", 883], ["p", 884], ["<", 886], ["0.0025", 888], ["and", 895], ["p", 899], ["<", 901], ["0.01", 903], [",", 907], ["respectively", 909], [")", 921], [",", 922], ["and", 924], ["most", 928], ["patients", 933], ["had", 942], ["a", 946], ["VIQ", 948], ["-", 951], ["PIQ", 952], ["discrepancy", 956], [";", 967], ["4", 969], [")", 970], ["the", 972], ["frequency", 976], ["of", 986], ["mental", 989], ["retardation", 996], ["in", 1008], ["our", 1011], ["study", 1015], ["group", 1021], ["was", 1027], ["significantly", 1031], ["higher", 1045], ["than", 1052], ["that", 1057], ["observed", 1062], ["in", 1071], ["the", 1074], ["general", 1078], ["population", 1086], ["(", 1097], ["15.1", 1098], ["%", 1102], ["vs", 1104], ["2.3", 1107], ["%", 1110], [",", 1111], ["p", 1113], ["<", 1115], ["0.025", 1117], [")", 1122], [";", 1123], ["5", 1125], [")", 1126], ["a", 1128], ["significant", 1130], ["association", 1142], ["was", 1154], ["found", 1158], ["between", 1164], ["karyotype", 1172], ["and", 1182], ["VIQ", 1186], [",", 1189], ["and", 1191], ["the", 1195], ["best", 1199], ["score", 1204], ["was", 1210], ["achieved", 1214], ["in", 1223], ["the", 1226], ["subgroup", 1230], ["of", 1239], ["patients", 1242], ["with", 1251], ["structural", 1256], ["abnormalities", 1267], ["of", 1281], ["the", 1284], ["X", 1288], ["-", 1289], ["chromosome", 1290], [".", 1300], ["In", 1302], ["the", 1305], ["light", 1309], ["of", 1315], ["these", 1318], ["findings", 1324], ["we", 1333], ["conclude", 1336], ["that", 1345], ["the", 1350], ["clinical", 1354], ["picture", 1363], ["in", 1371], ["TS", 1374], ["may", 1377], ["encompass", 1381], ["a", 1391], ["slightly", 1393], ["reduced", 1402], ["FSIQ", 1410], [",", 1414], ["VIQ", 1416], ["and", 1420], ["especially", 1424], ["an", 1435], ["inadequate", 1438], ["PIQ", 1449], [",", 1452], ["but", 1454], ["this", 1458], ["neurocognitive", 1463], ["profile", 1478], ["is", 1486], ["not", 1489], ["significantly", 1493], ["affected", 1507], ["by", 1516], ["statural", 1519], ["impairment", 1528], [".", 1538], ["Since", 1540], ["these", 1546], ["neurocognitive", 1552], ["defects", 1567], ["can", 1575], ["be", 1579], ["responsible", 1582], ["for", 1594], ["misdiagnosed", 1598], ["school", 1611], ["difficulties", 1618], [",", 1630], ["we", 1632], ["suggest", 1635], ["that", 1643], ["girls", 1648], ["with", 1654], ["TS", 1659], ["should", 1662], ["receive", 1669], ["specialized", 1677], ["educational", 1689], ["support", 1701], ["and", 1709], ["multidisciplinary", 1713], ["care", 1731], [".", 1735]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. Our objective is to report our experience in Greece with patients suffering from TS and trying to conceive; therefore, we present four patients with TS, who underwent In vitro fertilization (ICSI) with donor oocytes in order to get pregnant. Three out of four patients managed to conceive and bring pregnancy to completion. It was shown that patients diagnosed in childhood or adolescence with TS have the possibility to undergo hormone replacement therapy (HRT) and thus, secondary sexual characteristics as well as uterus of almost normal size can develop. Assisted reproduction techniques (ART), predominantly with donated oocytes, could give these patients the possibility to have children.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "80b1b799ab8b4a54ad19e73ff5640506", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[17, 17]], "char_spans": [[84, 84]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["defect", 40], ["with", 47], ["partial", 52], ["or", 60], ["total", 63], ["absence", 69], ["of", 77], ["the", 80], ["X", 84], ["chromosome", 86], [".", 96], ["Our", 98], ["objective", 102], ["is", 112], ["to", 115], ["report", 118], ["our", 125], ["experience", 129], ["in", 140], ["Greece", 143], ["with", 150], ["patients", 155], ["suffering", 164], ["from", 174], ["TS", 179], ["and", 182], ["trying", 186], ["to", 193], ["conceive", 196], [";", 204], ["therefore", 206], [",", 215], ["we", 217], ["present", 220], ["four", 228], ["patients", 233], ["with", 242], ["TS", 247], [",", 249], ["who", 251], ["underwent", 255], ["In", 265], ["vitro", 268], ["fertilization", 274], ["(", 288], ["ICSI", 289], [")", 293], ["with", 295], ["donor", 300], ["oocytes", 306], ["in", 314], ["order", 317], ["to", 323], ["get", 326], ["pregnant", 330], [".", 338], ["Three", 340], ["out", 346], ["of", 350], ["four", 353], ["patients", 358], ["managed", 367], ["to", 375], ["conceive", 378], ["and", 387], ["bring", 391], ["pregnancy", 397], ["to", 407], ["completion", 410], [".", 420], ["It", 422], ["was", 425], ["shown", 429], ["that", 435], ["patients", 440], ["diagnosed", 449], ["in", 459], ["childhood", 462], ["or", 472], ["adolescence", 475], ["with", 487], ["TS", 492], ["have", 495], ["the", 500], ["possibility", 504], ["to", 516], ["undergo", 519], ["hormone", 527], ["replacement", 535], ["therapy", 547], ["(", 555], ["HRT", 556], [")", 559], ["and", 561], ["thus", 565], [",", 569], ["secondary", 571], ["sexual", 581], ["characteristics", 588], ["as", 604], ["well", 607], ["as", 612], ["uterus", 615], ["of", 622], ["almost", 625], ["normal", 632], ["size", 639], ["can", 644], ["develop", 648], [".", 655], ["Assisted", 657], ["reproduction", 666], ["techniques", 679], ["(", 690], ["ART", 691], [")", 694], [",", 695], ["predominantly", 697], ["with", 711], ["donated", 716], ["oocytes", 724], [",", 731], ["could", 733], ["give", 739], ["these", 744], ["patients", 750], ["the", 759], ["possibility", 763], ["to", 775], ["have", 778], ["children", 783], [".", 791]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "The mature central nervous system contains precursor cells in the subventricular zone of the lateral ventricle. In this study we examined the possibility to affect fate of precursor cells through exogenous manipulations. The results indicate that administration of thyroid hormone and retinoic acid increases the expression of Ki67, a nuclear antigen associated with cell proliferation, and of nestin, a marker protein for precursor cells in the subventricular zone of adult male rats. Moreover, retinoic acid increases polysialated-neural cell adhesion molecules (PSA-NCAM)-immunoreactivity. These data suggest that nuclear receptor ligands are potential candidates for fate determination of precursor cells in the subventricular zone also in the adult brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2a963d7335cb4cfa9452f4ded58a357f", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[61, 61]], "char_spans": [[394, 399]]}]}], "context_tokens": [["The", 0], ["mature", 4], ["central", 11], ["nervous", 19], ["system", 27], ["contains", 34], ["precursor", 43], ["cells", 53], ["in", 59], ["the", 62], ["subventricular", 66], ["zone", 81], ["of", 86], ["the", 89], ["lateral", 93], ["ventricle", 101], [".", 110], ["In", 112], ["this", 115], ["study", 120], ["we", 126], ["examined", 129], ["the", 138], ["possibility", 142], ["to", 154], ["affect", 157], ["fate", 164], ["of", 169], ["precursor", 172], ["cells", 182], ["through", 188], ["exogenous", 196], ["manipulations", 206], [".", 219], ["The", 221], ["results", 225], ["indicate", 233], ["that", 242], ["administration", 247], ["of", 262], ["thyroid", 265], ["hormone", 273], ["and", 281], ["retinoic", 285], ["acid", 294], ["increases", 299], ["the", 309], ["expression", 313], ["of", 324], ["Ki67", 327], [",", 331], ["a", 333], ["nuclear", 335], ["antigen", 343], ["associated", 351], ["with", 362], ["cell", 367], ["proliferation", 372], [",", 385], ["and", 387], ["of", 391], ["nestin", 394], [",", 400], ["a", 402], ["marker", 404], ["protein", 411], ["for", 419], ["precursor", 423], ["cells", 433], ["in", 439], ["the", 442], ["subventricular", 446], ["zone", 461], ["of", 466], ["adult", 469], ["male", 475], ["rats", 480], [".", 484], ["Moreover", 486], [",", 494], ["retinoic", 496], ["acid", 505], ["increases", 510], ["polysialated", 520], ["-", 532], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecules", 554], ["(", 564], ["PSA", 565], ["-", 568], ["NCAM)-immunoreactivity", 569], [".", 591], ["These", 593], ["data", 599], ["suggest", 604], ["that", 612], ["nuclear", 617], ["receptor", 625], ["ligands", 634], ["are", 642], ["potential", 646], ["candidates", 656], ["for", 667], ["fate", 671], ["determination", 676], ["of", 690], ["precursor", 693], ["cells", 703], ["in", 709], ["the", 712], ["subventricular", 716], ["zone", 731], ["also", 736], ["in", 741], ["the", 744], ["adult", 748], ["brain", 754], [".", 759]]}
{"context": "Methylation of lysine 9 (K9) in the N-terminus tail of histone H3 (H3) in chromatin is associated with transcriptionally silenced genes and is mediated by histone methyltransferases. Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and ANK repeats. In this paper, we have used a series of green fluorescent protein-tagged deletion constructs to identify two nuclear localization signals (NLS), the first NLS embedded between amino acids 24 and 109 and the second between amino acids 394 and 401 of murine G9a. Our data show that both long and short G9a isoforms were capable of entering the nucleus to methylate chromatin. Full-length or N-terminus-deleted G9a isoforms were also catalytically active enzymes that methylated recombinant H3 or synthetic peptides representing the N-terminus tail of H3. In vitro methylation reactions using N-terminus tail peptides resulted in tri-methylation of K9 that remained processive, even in G9a enzymes that lacked an N-terminus region by deletion. Co-expression of G9a and H3 resulted in di- and tri-methylation of H3-K9, while siRNA-mediated knockdown of G9a in HeLa cells resulted in reduction of global H3-K9 di- and tri-methylation. A recombinant deletion mutant enzyme fused with maltose-binding protein (MBP-G9aDelta634) was used for steady-state kinetic analysis with various substrates and was compared with full-length G9a (G9aFL). Turnover numbers of MBP-G9aDelta634 for various substrates was approximately 3-fold less compared with G9aFL, while their Michaelis constants (K(m)) for recombinant H3 were similar. The K(AdoMet)m for MBP-G9aDelta634 was approximately 2.3-2.65 microM with various substrates. Catalytic efficiencies (kcat/K(m)) for both MBP-G9aDelta634 and G9aFL were similar, suggesting that the N-terminus is not essential for catalysis. Furthermore, mutation of conserved amino acids R1097A, W1103A, Y1120A, Y1138A and R1162A, or the metal binding C1168A in the catalytic region, resulted in catalytically impaired enzymes, thereby confirming the involvement of the C-terminus of G9a in catalysis. Thus, distinct domains modulate nuclear targeting and catalytic functions of G9a.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e57c68a8293d462f9fdab7bb2767c729", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[46, 47]], "char_spans": [[269, 278]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["9", 22], ["(", 24], ["K9", 25], [")", 27], ["in", 29], ["the", 32], ["N", 36], ["-", 37], ["terminus", 38], ["tail", 47], ["of", 52], ["histone", 55], ["H3", 63], ["(", 66], ["H3", 67], [")", 69], ["in", 71], ["chromatin", 74], ["is", 84], ["associated", 87], ["with", 98], ["transcriptionally", 103], ["silenced", 121], ["genes", 130], ["and", 136], ["is", 140], ["mediated", 143], ["by", 152], ["histone", 155], ["methyltransferases", 163], [".", 181], ["Murine", 183], ["G9a", 190], ["is", 194], ["a", 197], ["1263", 199], ["amino", 204], ["acid", 210], ["H3-K9", 215], ["methyltransferase", 221], ["that", 239], ["possesses", 244], ["characteristic", 254], ["SET", 269], ["domain", 273], ["and", 280], ["ANK", 284], ["repeats", 288], [".", 295], ["In", 297], ["this", 300], ["paper", 305], [",", 310], ["we", 312], ["have", 315], ["used", 320], ["a", 325], ["series", 327], ["of", 334], ["green", 337], ["fluorescent", 343], ["protein", 355], ["-", 362], ["tagged", 363], ["deletion", 370], ["constructs", 379], ["to", 390], ["identify", 393], ["two", 402], ["nuclear", 406], ["localization", 414], ["signals", 427], ["(", 435], ["NLS", 436], [")", 439], [",", 440], ["the", 442], ["first", 446], ["NLS", 452], ["embedded", 456], ["between", 465], ["amino", 473], ["acids", 479], ["24", 485], ["and", 488], ["109", 492], ["and", 496], ["the", 500], ["second", 504], ["between", 511], ["amino", 519], ["acids", 525], ["394", 531], ["and", 535], ["401", 539], ["of", 543], ["murine", 546], ["G9a", 553], [".", 556], ["Our", 558], ["data", 562], ["show", 567], ["that", 572], ["both", 577], ["long", 582], ["and", 587], ["short", 591], ["G9a", 597], ["isoforms", 601], ["were", 610], ["capable", 615], ["of", 623], ["entering", 626], ["the", 635], ["nucleus", 639], ["to", 647], ["methylate", 650], ["chromatin", 660], [".", 669], ["Full", 671], ["-", 675], ["length", 676], ["or", 683], ["N", 686], ["-", 687], ["terminus", 688], ["-", 696], ["deleted", 697], ["G9a", 705], ["isoforms", 709], ["were", 718], ["also", 723], ["catalytically", 728], ["active", 742], ["enzymes", 749], ["that", 757], ["methylated", 762], ["recombinant", 773], ["H3", 785], ["or", 788], ["synthetic", 791], ["peptides", 801], ["representing", 810], ["the", 823], ["N", 827], ["-", 828], ["terminus", 829], ["tail", 838], ["of", 843], ["H3", 846], [".", 848], ["In", 850], ["vitro", 853], ["methylation", 859], ["reactions", 871], ["using", 881], ["N", 887], ["-", 888], ["terminus", 889], ["tail", 898], ["peptides", 903], ["resulted", 912], ["in", 921], ["tri", 924], ["-", 927], ["methylation", 928], ["of", 940], ["K9", 943], ["that", 946], ["remained", 951], ["processive", 960], [",", 970], ["even", 972], ["in", 977], ["G9a", 980], ["enzymes", 984], ["that", 992], ["lacked", 997], ["an", 1004], ["N", 1007], ["-", 1008], ["terminus", 1009], ["region", 1018], ["by", 1025], ["deletion", 1028], [".", 1036], ["Co", 1038], ["-", 1040], ["expression", 1041], ["of", 1052], ["G9a", 1055], ["and", 1059], ["H3", 1063], ["resulted", 1066], ["in", 1075], ["di-", 1078], ["and", 1082], ["tri", 1086], ["-", 1089], ["methylation", 1090], ["of", 1102], ["H3-K9", 1105], [",", 1110], ["while", 1112], ["siRNA", 1118], ["-", 1123], ["mediated", 1124], ["knockdown", 1133], ["of", 1143], ["G9a", 1146], ["in", 1150], ["HeLa", 1153], ["cells", 1158], ["resulted", 1164], ["in", 1173], ["reduction", 1176], ["of", 1186], ["global", 1189], ["H3-K9", 1196], ["di-", 1202], ["and", 1206], ["tri", 1210], ["-", 1213], ["methylation", 1214], [".", 1225], ["A", 1227], ["recombinant", 1229], ["deletion", 1241], ["mutant", 1250], ["enzyme", 1257], ["fused", 1264], ["with", 1270], ["maltose", 1275], ["-", 1282], ["binding", 1283], ["protein", 1291], ["(", 1299], ["MBP", 1300], ["-", 1303], ["G9aDelta634", 1304], [")", 1315], ["was", 1317], ["used", 1321], ["for", 1326], ["steady", 1330], ["-", 1336], ["state", 1337], ["kinetic", 1343], ["analysis", 1351], ["with", 1360], ["various", 1365], ["substrates", 1373], ["and", 1384], ["was", 1388], ["compared", 1392], ["with", 1401], ["full", 1406], ["-", 1410], ["length", 1411], ["G9a", 1418], ["(", 1422], ["G9aFL", 1423], [")", 1428], [".", 1429], ["Turnover", 1431], ["numbers", 1440], ["of", 1448], ["MBP", 1451], ["-", 1454], ["G9aDelta634", 1455], ["for", 1467], ["various", 1471], ["substrates", 1479], ["was", 1490], ["approximately", 1494], ["3-fold", 1508], ["less", 1515], ["compared", 1520], ["with", 1529], ["G9aFL", 1534], [",", 1539], ["while", 1541], ["their", 1547], ["Michaelis", 1553], ["constants", 1563], ["(", 1573], ["K(m", 1574], [")", 1577], [")", 1578], ["for", 1580], ["recombinant", 1584], ["H3", 1596], ["were", 1599], ["similar", 1604], [".", 1611], ["The", 1613], ["K(AdoMet)m", 1617], ["for", 1628], ["MBP", 1632], ["-", 1635], ["G9aDelta634", 1636], ["was", 1648], ["approximately", 1652], ["2.3", 1666], ["-", 1669], ["2.65", 1670], ["microM", 1675], ["with", 1682], ["various", 1687], ["substrates", 1695], [".", 1705], ["Catalytic", 1707], ["efficiencies", 1717], ["(", 1730], ["kcat", 1731], ["/", 1735], ["K(m", 1736], [")", 1739], [")", 1740], ["for", 1742], ["both", 1746], ["MBP", 1751], ["-", 1754], ["G9aDelta634", 1755], ["and", 1767], ["G9aFL", 1771], ["were", 1777], ["similar", 1782], [",", 1789], ["suggesting", 1791], ["that", 1802], ["the", 1807], ["N", 1811], ["-", 1812], ["terminus", 1813], ["is", 1822], ["not", 1825], ["essential", 1829], ["for", 1839], ["catalysis", 1843], [".", 1852], ["Furthermore", 1854], [",", 1865], ["mutation", 1867], ["of", 1876], ["conserved", 1879], ["amino", 1889], ["acids", 1895], ["R1097A", 1901], [",", 1907], ["W1103A", 1909], [",", 1915], ["Y1120A", 1917], [",", 1923], ["Y1138A", 1925], ["and", 1932], ["R1162A", 1936], [",", 1942], ["or", 1944], ["the", 1947], ["metal", 1951], ["binding", 1957], ["C1168A", 1965], ["in", 1972], ["the", 1975], ["catalytic", 1979], ["region", 1989], [",", 1995], ["resulted", 1997], ["in", 2006], ["catalytically", 2009], ["impaired", 2023], ["enzymes", 2032], [",", 2039], ["thereby", 2041], ["confirming", 2049], ["the", 2060], ["involvement", 2064], ["of", 2076], ["the", 2079], ["C", 2083], ["-", 2084], ["terminus", 2085], ["of", 2094], ["G9a", 2097], ["in", 2101], ["catalysis", 2104], [".", 2113], ["Thus", 2115], [",", 2119], ["distinct", 2121], ["domains", 2130], ["modulate", 2138], ["nuclear", 2147], ["targeting", 2155], ["and", 2165], ["catalytic", 2169], ["functions", 2179], ["of", 2189], ["G9a", 2192], [".", 2195]]}
{"context": "In yeast, the macromolecular complex Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4, forming human COMPASS-like complexes. We have shown that Wdr82, which associates with chromatin in a histone H2B ubiquitination-dependent manner, is a specific component of Set1 complexes but not that of MLL1-4 complexes. RNA interference-mediated knockdown of Wdr82 results in a reduction in the H3K4 trimethylation levels, although these cells still possess active MLL complexes. Comprehensive in vitro enzymatic studies with Set1 and MLL complexes demonstrated that the Set1 complex is a more robust H3K4 trimethylase in vitro than the MLL complexes. Given our in vivo and in vitro observations, it appears that the human Set1 complex plays a more widespread role in H3K4 trimethylation than do the MLL complexes in mammalian cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "66e99ba7d17c47c9b3445238952287b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[37, 37], [173, 173], [11, 11], [142, 142], [110, 110]], "char_spans": [[234, 237], [985, 988], [76, 79], [818, 821], [612, 615]]}]}], "context_tokens": [["In", 0], ["yeast", 3], [",", 8], ["the", 10], ["macromolecular", 14], ["complex", 29], ["Set1/COMPASS", 37], ["is", 50], ["capable", 53], ["of", 61], ["methylating", 64], ["H3K4", 76], [",", 80], ["a", 82], ["posttranslational", 84], ["modification", 102], ["associated", 115], ["with", 126], ["actively", 131], ["transcribed", 140], ["genes", 152], [".", 157], ["There", 159], ["is", 165], ["only", 168], ["one", 173], ["Set1", 177], ["in", 182], ["yeast", 185], [";", 190], ["yet", 192], ["in", 196], ["mammalian", 199], ["cells", 209], ["there", 215], ["are", 221], ["multiple", 225], ["H3K4", 234], ["methylases", 239], [",", 249], ["including", 251], ["Set1A", 261], ["/", 266], ["B", 267], [",", 268], ["forming", 270], ["human", 278], ["COMPASS", 284], ["complexes", 292], [",", 301], ["and", 303], ["MLL1", 307], ["-", 311], ["4", 312], [",", 313], ["forming", 315], ["human", 323], ["COMPASS", 329], ["-", 336], ["like", 337], ["complexes", 342], [".", 351], ["We", 353], ["have", 356], ["shown", 361], ["that", 367], ["Wdr82", 372], [",", 377], ["which", 379], ["associates", 385], ["with", 396], ["chromatin", 401], ["in", 411], ["a", 414], ["histone", 416], ["H2B", 424], ["ubiquitination", 428], ["-", 442], ["dependent", 443], ["manner", 453], [",", 459], ["is", 461], ["a", 464], ["specific", 466], ["component", 475], ["of", 485], ["Set1", 488], ["complexes", 493], ["but", 503], ["not", 507], ["that", 511], ["of", 516], ["MLL1", 519], ["-", 523], ["4", 524], ["complexes", 526], [".", 535], ["RNA", 537], ["interference", 541], ["-", 553], ["mediated", 554], ["knockdown", 563], ["of", 573], ["Wdr82", 576], ["results", 582], ["in", 590], ["a", 593], ["reduction", 595], ["in", 605], ["the", 608], ["H3K4", 612], ["trimethylation", 617], ["levels", 632], [",", 638], ["although", 640], ["these", 649], ["cells", 655], ["still", 661], ["possess", 667], ["active", 675], ["MLL", 682], ["complexes", 686], [".", 695], ["Comprehensive", 697], ["in", 711], ["vitro", 714], ["enzymatic", 720], ["studies", 730], ["with", 738], ["Set1", 743], ["and", 748], ["MLL", 752], ["complexes", 756], ["demonstrated", 766], ["that", 779], ["the", 784], ["Set1", 788], ["complex", 793], ["is", 801], ["a", 804], ["more", 806], ["robust", 811], ["H3K4", 818], ["trimethylase", 823], ["in", 836], ["vitro", 839], ["than", 845], ["the", 850], ["MLL", 854], ["complexes", 858], [".", 867], ["Given", 869], ["our", 875], ["in", 879], ["vivo", 882], ["and", 887], ["in", 891], ["vitro", 894], ["observations", 900], [",", 912], ["it", 914], ["appears", 917], ["that", 925], ["the", 930], ["human", 934], ["Set1", 940], ["complex", 945], ["plays", 953], ["a", 959], ["more", 961], ["widespread", 966], ["role", 977], ["in", 982], ["H3K4", 985], ["trimethylation", 990], ["than", 1005], ["do", 1010], ["the", 1013], ["MLL", 1017], ["complexes", 1021], ["in", 1031], ["mammalian", 1034], ["cells", 1044], [".", 1049]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common condition characterized by an irresistible urge to move the legs, concomitant with an unpleasant sensation in the lower limbs, which is typically relieved by movement. Symptoms occur predominantly at rest and prevail in the afternoon or evening. Treatment of patients with RLS/WED is indicated for those patients who suffer from clinically relevant symptoms. The management of mild forms of RLS/WED is mainly based on dopamine agonists (DA) therapy (including pramipexole and ropinirole) and \u03b1-2-\u03b4 calcium-channel ligand. Nevertheless, with passing of time, symptoms tend to become more severe and the patient can eventually develop pharmacoresistance. Furthermore, long-term treatment with dopaminergic agents may be complicated by the development of augmentation, which is defined by an increase in the severity and frequency of RLS/WED symptoms despite adequate treatment. Here, we discuss which are the best therapeutic options when RLS/WED becomes intractable, with a focus on advantages and side effects of the available medications. Prevention strategies include managing lifestyle changes and a good sleep hygiene. Different drug options are available. Switching to longer-acting dopaminergic agents may be a possibility if the patient is well-tolerating DA treatment. An association with \u03b1-2-\u03b4 calcium-channel ligand is another first-line approach. In refractory RLS/WED, opioids such as oxycodone-naloxone have demonstrated good efficacy. Other pharmacological approaches include IV iron, benzodiazepines such as clonazepam, and antiepileptic drugs, with different level of evidence of efficacy. Therefore, the final decision regarding the agent to use in treating severe RLS/WED symptoms should be tailored to the patient, taking into account the symptomatology, comorbidities, the availability of treatment and the history of the disease.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "57c7f4ca7dcc421f8be58691a3878467", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["Disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["a", 57], ["common", 59], ["condition", 66], ["characterized", 76], ["by", 90], ["an", 93], ["irresistible", 96], ["urge", 109], ["to", 114], ["move", 117], ["the", 122], ["legs", 126], [",", 130], ["concomitant", 132], ["with", 144], ["an", 149], ["unpleasant", 152], ["sensation", 163], ["in", 173], ["the", 176], ["lower", 180], ["limbs", 186], [",", 191], ["which", 193], ["is", 199], ["typically", 202], ["relieved", 212], ["by", 221], ["movement", 224], [".", 232], ["Symptoms", 234], ["occur", 243], ["predominantly", 249], ["at", 263], ["rest", 266], ["and", 271], ["prevail", 275], ["in", 283], ["the", 286], ["afternoon", 290], ["or", 300], ["evening", 303], [".", 310], ["Treatment", 312], ["of", 322], ["patients", 325], ["with", 334], ["RLS", 339], ["/", 342], ["WED", 343], ["is", 347], ["indicated", 350], ["for", 360], ["those", 364], ["patients", 370], ["who", 379], ["suffer", 383], ["from", 390], ["clinically", 395], ["relevant", 406], ["symptoms", 415], [".", 423], ["The", 425], ["management", 429], ["of", 440], ["mild", 443], ["forms", 448], ["of", 454], ["RLS", 457], ["/", 460], ["WED", 461], ["is", 465], ["mainly", 468], ["based", 475], ["on", 481], ["dopamine", 484], ["agonists", 493], ["(", 502], ["DA", 503], [")", 505], ["therapy", 507], ["(", 515], ["including", 516], ["pramipexole", 526], ["and", 538], ["ropinirole", 542], [")", 552], ["and", 554], ["\u03b1-2-\u03b4", 558], ["calcium", 564], ["-", 571], ["channel", 572], ["ligand", 580], [".", 586], ["Nevertheless", 588], [",", 600], ["with", 602], ["passing", 607], ["of", 615], ["time", 618], [",", 622], ["symptoms", 624], ["tend", 633], ["to", 638], ["become", 641], ["more", 648], ["severe", 653], ["and", 660], ["the", 664], ["patient", 668], ["can", 676], ["eventually", 680], ["develop", 691], ["pharmacoresistance", 699], [".", 717], ["Furthermore", 719], [",", 730], ["long", 732], ["-", 736], ["term", 737], ["treatment", 742], ["with", 752], ["dopaminergic", 757], ["agents", 770], ["may", 777], ["be", 781], ["complicated", 784], ["by", 796], ["the", 799], ["development", 803], ["of", 815], ["augmentation", 818], [",", 830], ["which", 832], ["is", 838], ["defined", 841], ["by", 849], ["an", 852], ["increase", 855], ["in", 864], ["the", 867], ["severity", 871], ["and", 880], ["frequency", 884], ["of", 894], ["RLS", 897], ["/", 900], ["WED", 901], ["symptoms", 905], ["despite", 914], ["adequate", 922], ["treatment", 931], [".", 940], ["Here", 942], [",", 946], ["we", 948], ["discuss", 951], ["which", 959], ["are", 965], ["the", 969], ["best", 973], ["therapeutic", 978], ["options", 990], ["when", 998], ["RLS", 1003], ["/", 1006], ["WED", 1007], ["becomes", 1011], ["intractable", 1019], [",", 1030], ["with", 1032], ["a", 1037], ["focus", 1039], ["on", 1045], ["advantages", 1048], ["and", 1059], ["side", 1063], ["effects", 1068], ["of", 1076], ["the", 1079], ["available", 1083], ["medications", 1093], [".", 1104], ["Prevention", 1106], ["strategies", 1117], ["include", 1128], ["managing", 1136], ["lifestyle", 1145], ["changes", 1155], ["and", 1163], ["a", 1167], ["good", 1169], ["sleep", 1174], ["hygiene", 1180], [".", 1187], ["Different", 1189], ["drug", 1199], ["options", 1204], ["are", 1212], ["available", 1216], [".", 1225], ["Switching", 1227], ["to", 1237], ["longer", 1240], ["-", 1246], ["acting", 1247], ["dopaminergic", 1254], ["agents", 1267], ["may", 1274], ["be", 1278], ["a", 1281], ["possibility", 1283], ["if", 1295], ["the", 1298], ["patient", 1302], ["is", 1310], ["well", 1313], ["-", 1317], ["tolerating", 1318], ["DA", 1329], ["treatment", 1332], [".", 1341], ["An", 1343], ["association", 1346], ["with", 1358], ["\u03b1-2-\u03b4", 1363], ["calcium", 1369], ["-", 1376], ["channel", 1377], ["ligand", 1385], ["is", 1392], ["another", 1395], ["first", 1403], ["-", 1408], ["line", 1409], ["approach", 1414], [".", 1422], ["In", 1424], ["refractory", 1427], ["RLS", 1438], ["/", 1441], ["WED", 1442], [",", 1445], ["opioids", 1447], ["such", 1455], ["as", 1460], ["oxycodone", 1463], ["-", 1472], ["naloxone", 1473], ["have", 1482], ["demonstrated", 1487], ["good", 1500], ["efficacy", 1505], [".", 1513], ["Other", 1515], ["pharmacological", 1521], ["approaches", 1537], ["include", 1548], ["IV", 1556], ["iron", 1559], [",", 1563], ["benzodiazepines", 1565], ["such", 1581], ["as", 1586], ["clonazepam", 1589], [",", 1599], ["and", 1601], ["antiepileptic", 1605], ["drugs", 1619], [",", 1624], ["with", 1626], ["different", 1631], ["level", 1641], ["of", 1647], ["evidence", 1650], ["of", 1659], ["efficacy", 1662], [".", 1670], ["Therefore", 1672], [",", 1681], ["the", 1683], ["final", 1687], ["decision", 1693], ["regarding", 1702], ["the", 1712], ["agent", 1716], ["to", 1722], ["use", 1725], ["in", 1729], ["treating", 1732], ["severe", 1741], ["RLS", 1748], ["/", 1751], ["WED", 1752], ["symptoms", 1756], ["should", 1765], ["be", 1772], ["tailored", 1775], ["to", 1784], ["the", 1787], ["patient", 1791], [",", 1798], ["taking", 1800], ["into", 1807], ["account", 1812], ["the", 1820], ["symptomatology", 1824], [",", 1838], ["comorbidities", 1840], [",", 1853], ["the", 1855], ["availability", 1859], ["of", 1872], ["treatment", 1875], ["and", 1885], ["the", 1889], ["history", 1893], ["of", 1901], ["the", 1904], ["disease", 1908], [".", 1915]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a9464ddc76874f33bc3080db5c5c07b9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[34, 35]], "char_spans": [[214, 231]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "The X-linked McLeod neuroacanthocytosis syndrome is a multisystem disorder with hematologic, neuromuscular, and central nervous system (CNS) manifestations. All carriers of the McLeod blood group phenotype examined so far had at least subclinical signs of systemic involvement. Evaluation of two brothers carrying the McLeod phenotype with neurologic examination, immunohematology, RBC membrane protein Western blotting, analysis of XK DNA sequence and RNA levels, muscle histology including XK/Kell immunohistochemistry, cerebral magnetic resonance imaging (MRI), and quantified positron emission tomography (PET). Immunohematology and Western blotting confirmed presence of the McLeod blood group phenotype. No acanthocytosis or other hematologic anomalies were found. XK gene sequence analysis revealed a missense mutation in exon 3 (E327K). WBC XK RNA levels were not decreased. There were no neuromuscular and CNS signs or symptoms. In addition, no subclinical involvement was discovered on the basis of normal muscle histology with a physiologic pattern of XK and Kell immunohistochemistry, normal cerebral MRI, and quantified PET. Known disease-causing XK gene mutations comprised deletions, nonsense, or splice-site mutations predicting absent or truncated XK protein devoid of the Kell-protein binding site. Although the E327K missense mutation was associated with the immunohematologic characteristics of McLeod syndrome, the mutated XK protein seemed to be largely functional. These findings contribute to the understanding of the physiology of XK and Kell proteins, and the pathogenetic mechanisms of acanthocytosis, myopathy, and striatal neurodegeneration in McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "9019bb534c7b4632b5c84114049ce836", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [256, 256], [67, 67], [77, 77], [138, 138], [121, 121], [209, 209], [238, 238], [175, 175]], "char_spans": [[1160, 1161], [1556, 1557], [433, 434], [492, 493], [849, 850], [771, 772], [1265, 1266], [1444, 1445], [1063, 1064]]}]}], "context_tokens": [["The", 0], ["X", 4], ["-", 5], ["linked", 6], ["McLeod", 13], ["neuroacanthocytosis", 20], ["syndrome", 40], ["is", 49], ["a", 52], ["multisystem", 54], ["disorder", 66], ["with", 75], ["hematologic", 80], [",", 91], ["neuromuscular", 93], [",", 106], ["and", 108], ["central", 112], ["nervous", 120], ["system", 128], ["(", 135], ["CNS", 136], [")", 139], ["manifestations", 141], [".", 155], ["All", 157], ["carriers", 161], ["of", 170], ["the", 173], ["McLeod", 177], ["blood", 184], ["group", 190], ["phenotype", 196], ["examined", 206], ["so", 215], ["far", 218], ["had", 222], ["at", 226], ["least", 229], ["subclinical", 235], ["signs", 247], ["of", 253], ["systemic", 256], ["involvement", 265], [".", 276], ["Evaluation", 278], ["of", 289], ["two", 292], ["brothers", 296], ["carrying", 305], ["the", 314], ["McLeod", 318], ["phenotype", 325], ["with", 335], ["neurologic", 340], ["examination", 351], [",", 362], ["immunohematology", 364], [",", 380], ["RBC", 382], ["membrane", 386], ["protein", 395], ["Western", 403], ["blotting", 411], [",", 419], ["analysis", 421], ["of", 430], ["XK", 433], ["DNA", 436], ["sequence", 440], ["and", 449], ["RNA", 453], ["levels", 457], [",", 463], ["muscle", 465], ["histology", 472], ["including", 482], ["XK", 492], ["/", 494], ["Kell", 495], ["immunohistochemistry", 500], [",", 520], ["cerebral", 522], ["magnetic", 531], ["resonance", 540], ["imaging", 550], ["(", 558], ["MRI", 559], [")", 562], [",", 563], ["and", 565], ["quantified", 569], ["positron", 580], ["emission", 589], ["tomography", 598], ["(", 609], ["PET", 610], [")", 613], [".", 614], ["Immunohematology", 616], ["and", 633], ["Western", 637], ["blotting", 645], ["confirmed", 654], ["presence", 664], ["of", 673], ["the", 676], ["McLeod", 680], ["blood", 687], ["group", 693], ["phenotype", 699], [".", 708], ["No", 710], ["acanthocytosis", 713], ["or", 728], ["other", 731], ["hematologic", 737], ["anomalies", 749], ["were", 759], ["found", 764], [".", 769], ["XK", 771], ["gene", 774], ["sequence", 779], ["analysis", 788], ["revealed", 797], ["a", 806], ["missense", 808], ["mutation", 817], ["in", 826], ["exon", 829], ["3", 834], ["(", 836], ["E327", 837], ["K", 841], [")", 842], [".", 843], ["WBC", 845], ["XK", 849], ["RNA", 852], ["levels", 856], ["were", 863], ["not", 868], ["decreased", 872], [".", 881], ["There", 883], ["were", 889], ["no", 894], ["neuromuscular", 897], ["and", 911], ["CNS", 915], ["signs", 919], ["or", 925], ["symptoms", 928], [".", 936], ["In", 938], ["addition", 941], [",", 949], ["no", 951], ["subclinical", 954], ["involvement", 966], ["was", 978], ["discovered", 982], ["on", 993], ["the", 996], ["basis", 1000], ["of", 1006], ["normal", 1009], ["muscle", 1016], ["histology", 1023], ["with", 1033], ["a", 1038], ["physiologic", 1040], ["pattern", 1052], ["of", 1060], ["XK", 1063], ["and", 1066], ["Kell", 1070], ["immunohistochemistry", 1075], [",", 1095], ["normal", 1097], ["cerebral", 1104], ["MRI", 1113], [",", 1116], ["and", 1118], ["quantified", 1122], ["PET", 1133], [".", 1136], ["Known", 1138], ["disease", 1144], ["-", 1151], ["causing", 1152], ["XK", 1160], ["gene", 1163], ["mutations", 1168], ["comprised", 1178], ["deletions", 1188], [",", 1197], ["nonsense", 1199], [",", 1207], ["or", 1209], ["splice", 1212], ["-", 1218], ["site", 1219], ["mutations", 1224], ["predicting", 1234], ["absent", 1245], ["or", 1252], ["truncated", 1255], ["XK", 1265], ["protein", 1268], ["devoid", 1276], ["of", 1283], ["the", 1286], ["Kell", 1290], ["-", 1294], ["protein", 1295], ["binding", 1303], ["site", 1311], [".", 1315], ["Although", 1317], ["the", 1326], ["E327", 1330], ["K", 1334], ["missense", 1336], ["mutation", 1345], ["was", 1354], ["associated", 1358], ["with", 1369], ["the", 1374], ["immunohematologic", 1378], ["characteristics", 1396], ["of", 1412], ["McLeod", 1415], ["syndrome", 1422], [",", 1430], ["the", 1432], ["mutated", 1436], ["XK", 1444], ["protein", 1447], ["seemed", 1455], ["to", 1462], ["be", 1465], ["largely", 1468], ["functional", 1476], [".", 1486], ["These", 1488], ["findings", 1494], ["contribute", 1503], ["to", 1514], ["the", 1517], ["understanding", 1521], ["of", 1535], ["the", 1538], ["physiology", 1542], ["of", 1553], ["XK", 1556], ["and", 1559], ["Kell", 1563], ["proteins", 1568], [",", 1576], ["and", 1578], ["the", 1582], ["pathogenetic", 1586], ["mechanisms", 1599], ["of", 1610], ["acanthocytosis", 1613], [",", 1627], ["myopathy", 1629], [",", 1637], ["and", 1639], ["striatal", 1643], ["neurodegeneration", 1652], ["in", 1670], ["McLeod", 1673], ["syndrome", 1680], [".", 1688]]}
{"context": "Viroids, satellite RNAs, satellites viruses and the human hepatitis delta virus form the 'brotherhood' of the smallest known infectious RNA agents, known as the subviral RNAs. For most of these species, it is generally accepted that characteristics such as cell movement, replication, host specificity and pathogenicity are encoded in their RNA sequences and their resulting RNA structures. Although many sequences are indexed in publicly available databases, these sequence annotation databases do not provide the advanced searches and data manipulation capability for identifying and characterizing subviral RNA motifs. The Subviral RNA database is a web-based environment that facilitates the research and analysis of viroids, satellite RNAs, satellites viruses, the human hepatitis delta virus, and related RNA sequences. It integrates a large number of Subviral RNA sequences, their respective RNA motifs, analysis tools, related publication links and additional pertinent information (ex. links, conferences, announcements), allowing users to efficiently retrieve and analyze relevant information about these small RNA agents. With its design, the Subviral RNA Database could be considered as a fundamental building block for the study of these related RNAs. It is freely available via a web browser at the URL: http://subviral.med.uottawa.ca.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2617acecfbd24533a69a8513130d6dde", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[116, 116], [0, 0]], "char_spans": [[721, 727], [0, 6]]}]}], "context_tokens": [["Viroids", 0], [",", 7], ["satellite", 9], ["RNAs", 19], [",", 23], ["satellites", 25], ["viruses", 36], ["and", 44], ["the", 48], ["human", 52], ["hepatitis", 58], ["delta", 68], ["virus", 74], ["form", 80], ["the", 85], ["'", 89], ["brotherhood", 90], ["'", 101], ["of", 103], ["the", 106], ["smallest", 110], ["known", 119], ["infectious", 125], ["RNA", 136], ["agents", 140], [",", 146], ["known", 148], ["as", 154], ["the", 157], ["subviral", 161], ["RNAs", 170], [".", 174], ["For", 176], ["most", 180], ["of", 185], ["these", 188], ["species", 194], [",", 201], ["it", 203], ["is", 206], ["generally", 209], ["accepted", 219], ["that", 228], ["characteristics", 233], ["such", 249], ["as", 254], ["cell", 257], ["movement", 262], [",", 270], ["replication", 272], [",", 283], ["host", 285], ["specificity", 290], ["and", 302], ["pathogenicity", 306], ["are", 320], ["encoded", 324], ["in", 332], ["their", 335], ["RNA", 341], ["sequences", 345], ["and", 355], ["their", 359], ["resulting", 365], ["RNA", 375], ["structures", 379], [".", 389], ["Although", 391], ["many", 400], ["sequences", 405], ["are", 415], ["indexed", 419], ["in", 427], ["publicly", 430], ["available", 439], ["databases", 449], [",", 458], ["these", 460], ["sequence", 466], ["annotation", 475], ["databases", 486], ["do", 496], ["not", 499], ["provide", 503], ["the", 511], ["advanced", 515], ["searches", 524], ["and", 533], ["data", 537], ["manipulation", 542], ["capability", 555], ["for", 566], ["identifying", 570], ["and", 582], ["characterizing", 586], ["subviral", 601], ["RNA", 610], ["motifs", 614], [".", 620], ["The", 622], ["Subviral", 626], ["RNA", 635], ["database", 639], ["is", 648], ["a", 651], ["web", 653], ["-", 656], ["based", 657], ["environment", 663], ["that", 675], ["facilitates", 680], ["the", 692], ["research", 696], ["and", 705], ["analysis", 709], ["of", 718], ["viroids", 721], [",", 728], ["satellite", 730], ["RNAs", 740], [",", 744], ["satellites", 746], ["viruses", 757], [",", 764], ["the", 766], ["human", 770], ["hepatitis", 776], ["delta", 786], ["virus", 792], [",", 797], ["and", 799], ["related", 803], ["RNA", 811], ["sequences", 815], [".", 824], ["It", 826], ["integrates", 829], ["a", 840], ["large", 842], ["number", 848], ["of", 855], ["Subviral", 858], ["RNA", 867], ["sequences", 871], [",", 880], ["their", 882], ["respective", 888], ["RNA", 899], ["motifs", 903], [",", 909], ["analysis", 911], ["tools", 920], [",", 925], ["related", 927], ["publication", 935], ["links", 947], ["and", 953], ["additional", 957], ["pertinent", 968], ["information", 978], ["(", 990], ["ex", 991], [".", 993], ["links", 995], [",", 1000], ["conferences", 1002], [",", 1013], ["announcements", 1015], [")", 1028], [",", 1029], ["allowing", 1031], ["users", 1040], ["to", 1046], ["efficiently", 1049], ["retrieve", 1061], ["and", 1070], ["analyze", 1074], ["relevant", 1082], ["information", 1091], ["about", 1103], ["these", 1109], ["small", 1115], ["RNA", 1121], ["agents", 1125], [".", 1131], ["With", 1133], ["its", 1138], ["design", 1142], [",", 1148], ["the", 1150], ["Subviral", 1154], ["RNA", 1163], ["Database", 1167], ["could", 1176], ["be", 1182], ["considered", 1185], ["as", 1196], ["a", 1199], ["fundamental", 1201], ["building", 1213], ["block", 1222], ["for", 1228], ["the", 1232], ["study", 1236], ["of", 1242], ["these", 1245], ["related", 1251], ["RNAs", 1259], [".", 1263], ["It", 1265], ["is", 1268], ["freely", 1271], ["available", 1278], ["via", 1288], ["a", 1292], ["web", 1294], ["browser", 1298], ["at", 1306], ["the", 1309], ["URL", 1313], [":", 1316], ["http://subviral.med.uottawa.ca", 1318], [".", 1348]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1\u03b2 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. Because IL-1\u03b2 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1\u03b2 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1\u03b2 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1\u03b2 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1\u03b2 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1\u03b2 to its receptor by altering the electrostatic surface potential of IL-1\u03b2, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "5389373ddbe048119c1dbeb0494dd528", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[128, 128], [51, 51], [227, 227], [150, 150], [266, 266], [2, 2], [277, 277], [36, 36], [76, 76], [84, 84], [185, 185], [238, 238], [104, 104], [62, 62]], "char_spans": [[794, 798], [309, 313], [1407, 1411], [946, 950], [1649, 1653], [16, 20], [1720, 1724], [217, 221], [484, 488], [541, 545], [1127, 1131], [1480, 1484], [664, 668], [377, 381]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["proinflammatory", 28], ["cytokine", 44], ["that", 53], ["is", 58], ["implicated", 61], ["in", 72], ["many", 75], ["autoinflammatory", 80], ["disorders", 97], [",", 106], ["but", 108], ["is", 112], ["also", 115], ["important", 120], ["in", 130], ["defense", 133], ["against", 141], ["pathogens", 149], [".", 158], ["Thus", 160], [",", 164], ["there", 166], ["is", 172], ["a", 175], ["need", 177], ["to", 182], ["safely", 185], ["and", 192], ["effectively", 196], ["modulate", 208], ["IL-1\u03b2", 217], ["activity", 223], ["to", 232], ["reduce", 235], ["pathology", 242], ["while", 252], ["maintaining", 258], ["function", 270], [".", 278], ["Gevokizumab", 280], ["is", 292], ["a", 295], ["potent", 297], ["anti", 304], ["-", 308], ["IL-1\u03b2", 309], ["antibody", 315], ["being", 324], ["developed", 330], ["as", 340], ["a", 343], ["treatment", 345], ["for", 355], ["diseases", 359], ["in", 368], ["which", 371], ["IL-1\u03b2", 377], ["has", 383], ["been", 387], ["associated", 392], ["with", 403], ["pathogenesis", 408], [".", 420], ["Previous", 422], ["data", 431], ["indicated", 436], ["that", 446], ["gevokizumab", 451], ["negatively", 463], ["modulates", 474], ["IL-1\u03b2", 484], ["signaling", 490], ["through", 500], ["an", 508], ["allosteric", 511], ["mechanism", 522], [".", 531], ["Because", 533], ["IL-1\u03b2", 541], ["signaling", 547], ["is", 557], ["a", 560], ["complex", 562], [",", 569], ["dynamic", 571], ["process", 579], ["involving", 587], ["multiple", 597], ["components", 606], [",", 616], ["it", 618], ["is", 621], ["important", 624], ["to", 634], ["understand", 637], ["the", 648], ["kinetics", 652], ["of", 661], ["IL-1\u03b2", 664], ["signaling", 670], ["and", 680], ["the", 684], ["impact", 688], ["of", 695], ["gevokizumab", 698], ["on", 710], ["this", 713], ["process", 718], [".", 725], ["In", 727], ["the", 730], ["present", 734], ["study", 742], [",", 747], ["we", 749], ["measured", 752], ["the", 761], ["impact", 765], ["of", 772], ["gevokizumab", 775], ["on", 787], ["the", 790], ["IL-1\u03b2", 794], ["system", 800], ["using", 807], ["Schild", 813], ["analysis", 820], ["and", 829], ["surface", 833], ["plasmon", 841], ["resonance", 849], ["studies", 859], [",", 866], ["both", 868], ["of", 873], ["which", 876], ["demonstrated", 882], ["that", 895], ["gevokizumab", 900], ["decreases", 912], ["the", 922], ["binding", 926], ["affinity", 934], ["of", 943], ["IL-1\u03b2", 946], ["for", 952], ["the", 956], ["IL-1", 960], ["receptor", 965], ["type", 974], ["I", 979], ["(", 981], ["IL-1RI", 982], [")", 988], ["signaling", 990], ["receptor", 1000], [",", 1008], ["but", 1010], ["not", 1014], ["the", 1018], ["IL-1", 1022], ["counter", 1027], ["-", 1034], ["regulatory", 1035], ["decoy", 1046], ["receptor", 1052], ["(", 1061], ["IL-1", 1062], ["receptor", 1067], ["type", 1076], ["II", 1081], [")", 1083], [".", 1084], ["Gevokizumab", 1086], ["inhibits", 1098], ["both", 1107], ["the", 1112], ["binding", 1116], ["of", 1124], ["IL-1\u03b2", 1127], ["to", 1133], ["IL-1RI", 1136], ["and", 1143], ["the", 1147], ["subsequent", 1151], ["recruitment", 1162], ["of", 1174], ["IL-1", 1177], ["accessory", 1182], ["protein", 1192], ["primarily", 1200], ["by", 1210], ["reducing", 1213], ["the", 1222], ["association", 1226], ["rates", 1238], ["of", 1244], ["these", 1247], ["interactions", 1253], [".", 1265], ["Based", 1267], ["on", 1273], ["this", 1276], ["information", 1281], ["and", 1293], ["recently", 1297], ["published", 1306], ["structural", 1316], ["data", 1327], [",", 1331], ["we", 1333], ["propose", 1336], ["that", 1344], ["gevokizumab", 1349], ["decreases", 1361], ["the", 1371], ["association", 1375], ["rate", 1387], ["for", 1392], ["binding", 1396], ["of", 1404], ["IL-1\u03b2", 1407], ["to", 1413], ["its", 1416], ["receptor", 1420], ["by", 1429], ["altering", 1432], ["the", 1441], ["electrostatic", 1445], ["surface", 1459], ["potential", 1467], ["of", 1477], ["IL-1\u03b2", 1480], [",", 1485], ["thus", 1487], ["reducing", 1492], ["the", 1501], ["contribution", 1505], ["of", 1518], ["electrostatic", 1521], ["steering", 1535], ["to", 1544], ["the", 1547], ["rapid", 1551], ["association", 1557], ["rate", 1569], [".", 1573], ["These", 1575], ["data", 1581], ["indicate", 1586], [",", 1594], ["therefore", 1596], [",", 1605], ["that", 1607], ["gevokizumab", 1612], ["is", 1624], ["a", 1627], ["unique", 1629], ["inhibitor", 1636], ["of", 1646], ["IL-1\u03b2", 1649], ["signaling", 1655], ["that", 1665], ["may", 1670], ["offer", 1674], ["an", 1680], ["alternative", 1683], ["to", 1695], ["current", 1698], ["therapies", 1706], ["for", 1716], ["IL-1\u03b2", 1720], ["-", 1725], ["associated", 1726], ["autoinflammatory", 1737], ["diseases", 1754], [".", 1762]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes. A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n\u2009=\u20092572) or placebo (n\u2009=\u20092573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P\u2009=\u2009.08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P\u2009=\u2009.005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P\u2009=\u2009.04). In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. clinicaltrials.gov Identifier: NCT01130246.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9b9bcd725a354906b933c55de76f23a8", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], ["generates", 35], ["bioactive", 45], ["phospholipid", 55], ["products", 68], ["implicated", 77], ["in", 88], ["atherosclerosis", 91], [".", 106], ["The", 108], ["sPLA2", 112], ["inhibitor", 118], ["varespladib", 128], ["has", 140], ["favorable", 144], ["effects", 154], ["on", 162], ["lipid", 165], ["and", 171], ["inflammatory", 175], ["markers", 188], [";", 195], ["however", 197], [",", 204], ["its", 206], ["effect", 210], ["on", 217], ["cardiovascular", 220], ["outcomes", 235], ["is", 244], ["unknown", 247], [".", 254], ["To", 256], ["determine", 259], ["the", 269], ["effects", 273], ["of", 281], ["sPLA2", 284], ["inhibition", 290], ["with", 301], ["varespladib", 306], ["on", 318], ["cardiovascular", 321], ["outcomes", 336], [".", 344], ["A", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["randomized", 362], [",", 372], ["multicenter", 374], ["trial", 386], ["at", 392], ["362", 395], ["academic", 399], ["and", 408], ["community", 412], ["hospitals", 422], ["in", 432], ["Europe", 435], [",", 441], ["Australia", 443], [",", 452], ["New", 454], ["Zealand", 458], [",", 465], ["India", 467], [",", 472], ["and", 474], ["North", 478], ["America", 484], ["of", 492], ["5145", 495], ["patients", 500], ["randomized", 509], ["within", 520], ["96", 527], ["hours", 530], ["of", 536], ["presentation", 539], ["of", 552], ["an", 555], ["acute", 558], ["coronary", 564], ["syndrome", 573], ["(", 582], ["ACS", 583], [")", 586], ["to", 588], ["either", 591], ["varespladib", 598], ["(", 610], ["n", 611], ["=", 613], ["2572", 615], [")", 619], ["or", 621], ["placebo", 624], ["(", 632], ["n", 633], ["=", 635], ["2573", 637], [")", 641], ["with", 643], ["enrollment", 648], ["between", 659], ["June", 667], ["1", 672], [",", 673], ["2010", 675], [",", 679], ["and", 681], ["March", 685], ["7", 691], [",", 692], ["2012", 694], ["(", 699], ["study", 700], ["termination", 706], ["on", 718], ["March", 721], ["9", 727], [",", 728], ["2012", 730], [")", 734], [".", 735], ["Participants", 737], ["were", 750], ["randomized", 755], ["to", 766], ["receive", 769], ["varespladib", 777], ["(", 789], ["500", 790], ["mg", 794], [")", 796], ["or", 798], ["placebo", 801], ["daily", 809], ["for", 815], ["16", 819], ["weeks", 822], [",", 827], ["in", 829], ["addition", 832], ["to", 841], ["atorvastatin", 844], ["and", 857], ["other", 861], ["established", 867], ["therapies", 879], [".", 888], ["The", 890], ["primary", 894], ["efficacy", 902], ["measure", 911], ["was", 919], ["a", 923], ["composite", 925], ["of", 935], ["cardiovascular", 938], ["mortality", 953], [",", 962], ["nonfatal", 964], ["myocardial", 973], ["infarction", 984], ["(", 995], ["MI", 996], [")", 998], [",", 999], ["nonfatal", 1001], ["stroke", 1010], [",", 1016], ["or", 1018], ["unstable", 1021], ["angina", 1030], ["with", 1037], ["evidence", 1042], ["of", 1051], ["ischemia", 1054], ["requiring", 1063], ["hospitalization", 1073], ["at", 1089], ["16", 1092], ["weeks", 1095], [".", 1100], ["Six", 1102], ["-", 1105], ["month", 1106], ["survival", 1112], ["status", 1121], ["was", 1128], ["also", 1132], ["evaluated", 1137], [".", 1146], ["At", 1148], ["a", 1151], ["prespecified", 1153], ["interim", 1166], ["analysis", 1174], [",", 1182], ["including", 1184], ["212", 1194], ["primary", 1198], ["end", 1206], ["point", 1210], ["events", 1216], [",", 1222], ["the", 1224], ["independent", 1228], ["data", 1240], ["and", 1245], ["safety", 1249], ["monitoring", 1256], ["board", 1267], ["recommended", 1273], ["termination", 1285], ["of", 1297], ["the", 1300], ["trial", 1304], ["for", 1310], ["futility", 1314], ["and", 1323], ["possible", 1327], ["harm", 1336], [".", 1340], ["The", 1342], ["primary", 1346], ["end", 1354], ["point", 1358], ["occurred", 1364], ["in", 1373], ["136", 1376], ["patients", 1380], ["(", 1389], ["6.1", 1390], ["%", 1393], [")", 1394], ["treated", 1396], ["with", 1404], ["varespladib", 1409], ["compared", 1421], ["with", 1430], ["109", 1435], ["patients", 1439], ["(", 1448], ["5.1", 1449], ["%", 1452], [")", 1453], ["treated", 1455], ["with", 1463], ["placebo", 1468], ["(", 1476], ["hazard", 1477], ["ratio", 1484], ["[", 1490], ["HR", 1491], ["]", 1493], [",", 1494], ["1.25", 1496], [";", 1500], ["95", 1502], ["%", 1504], ["CI", 1506], [",", 1508], ["0.97", 1510], ["-", 1514], ["1.61", 1515], [";", 1519], ["log", 1521], ["-", 1524], ["rank", 1525], ["P", 1530], ["=", 1532], [".08", 1534], [")", 1537], [".", 1538], ["Varespladib", 1540], ["was", 1552], ["associated", 1556], ["with", 1567], ["a", 1572], ["greater", 1574], ["risk", 1582], ["of", 1587], ["MI", 1590], ["(", 1593], ["78", 1594], ["[", 1597], ["3.4", 1598], ["%", 1601], ["]", 1602], ["vs", 1604], ["47", 1607], ["[", 1610], ["2.2", 1611], ["%", 1614], ["]", 1615], [";", 1616], ["HR", 1618], [",", 1620], ["1.66", 1622], [";", 1626], ["95", 1628], ["%", 1630], ["CI", 1632], [",", 1634], ["1.16", 1636], ["-", 1640], ["2.39", 1641], [";", 1645], ["log", 1647], ["-", 1650], ["rank", 1651], ["P", 1656], ["=", 1658], [".005", 1660], [")", 1664], [".", 1665], ["The", 1667], ["composite", 1671], ["secondary", 1681], ["end", 1691], ["point", 1695], ["of", 1701], ["cardiovascular", 1704], ["mortality", 1719], [",", 1728], ["MI", 1730], [",", 1732], ["and", 1734], ["stroke", 1738], ["was", 1745], ["observed", 1749], ["in", 1758], ["107", 1761], ["patients", 1765], ["(", 1774], ["4.6", 1775], ["%", 1778], [")", 1779], ["in", 1781], ["the", 1784], ["varespladib", 1788], ["group", 1800], ["and", 1806], ["79", 1810], ["patients", 1813], ["(", 1822], ["3.8", 1823], ["%", 1826], [")", 1827], ["in", 1829], ["the", 1832], ["placebo", 1836], ["group", 1844], ["(", 1850], ["HR", 1851], [",", 1853], ["1.36", 1855], [";", 1859], ["95", 1861], ["%", 1863], ["CI", 1865], [",", 1867], ["1.02", 1869], ["-", 1873], ["1.82", 1874], [";", 1878], ["P", 1880], ["=", 1882], [".04", 1884], [")", 1887], [".", 1888], ["In", 1890], ["patients", 1893], ["with", 1902], ["recent", 1907], ["ACS", 1914], [",", 1917], ["varespladib", 1919], ["did", 1931], ["not", 1935], ["reduce", 1939], ["the", 1946], ["risk", 1950], ["of", 1955], ["recurrent", 1958], ["cardiovascular", 1968], ["events", 1983], ["and", 1990], ["significantly", 1994], ["increased", 2008], ["the", 2018], ["risk", 2022], ["of", 2027], ["MI", 2030], [".", 2032], ["The", 2034], ["sPLA2", 2038], ["inhibition", 2044], ["with", 2055], ["varespladib", 2060], ["may", 2072], ["be", 2076], ["harmful", 2079], ["and", 2087], ["is", 2091], ["not", 2094], ["a", 2098], ["useful", 2100], ["strategy", 2107], ["to", 2116], ["reduce", 2119], ["adverse", 2126], ["cardiovascular", 2134], ["outcomes", 2149], ["after", 2158], ["ACS", 2164], [".", 2167], ["clinicaltrials.gov", 2169], ["Identifier", 2188], [":", 2198], ["NCT01130246", 2200], [".", 2211]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "This report describes the reliability, validity, treatment sensitivity, diagnostic performance and normative values for the Short Post-Traumatic Stress Disorder (PTSD) Rating Interview (SPRINT), a brief, global assessment for PTSD. The SPRINT was administered to subjects participating in a clinical trial of PTSD and in a population survey assessing PTSD prevalence. The 8-item SPRINT includes questions assessing the core symptoms of PTSD, as well as related aspects of somatic malaise, stress vulnerability and functional impairment. Validity was assessed against the MINI structured interview, the Davidson Trauma Scale, Treatment Outcome for PTSD Scale, Connor-Davidson Resilience Scale, Sheehan Stress Vulnerability Scale, Sheehan Disability Scale and Clinical Global Impressions of Severity and Improvement Scales. Good test-retest reliability, internal consistency, convergent and divergent validity were obtained. The SPRINT was responsive to symptom change over time and correlated with comparable PTSD symptom measures. In victims of trauma, a score of 14-17 was associated with 96% diagnostic accuracy, whereas in those with PTSD, highest efficiency corresponded to a range of 11-13. The SPRINT demonstrates solid psychometric properties and can serve as a reliable, valid and homogeneous measure of PTSD illness severity and of global improvement.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "4426d2042a6d4887bdddfa6bb9150c20", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[19, 23]], "char_spans": [[130, 159]]}, {"text": "PTSD", "token_spans": [[53, 53], [107, 107], [163, 163], [221, 221], [60, 60], [39, 39], [25, 25], [73, 73], [190, 190]], "char_spans": [[309, 312], [647, 650], [1008, 1011], [1312, 1315], [351, 354], [226, 229], [162, 165], [436, 439], [1137, 1140]]}]}], "context_tokens": [["This", 0], ["report", 5], ["describes", 12], ["the", 22], ["reliability", 26], [",", 37], ["validity", 39], [",", 47], ["treatment", 49], ["sensitivity", 59], [",", 70], ["diagnostic", 72], ["performance", 83], ["and", 95], ["normative", 99], ["values", 109], ["for", 116], ["the", 120], ["Short", 124], ["Post", 130], ["-", 134], ["Traumatic", 135], ["Stress", 145], ["Disorder", 152], ["(", 161], ["PTSD", 162], [")", 166], ["Rating", 168], ["Interview", 175], ["(", 185], ["SPRINT", 186], [")", 192], [",", 193], ["a", 195], ["brief", 197], [",", 202], ["global", 204], ["assessment", 211], ["for", 222], ["PTSD", 226], [".", 230], ["The", 232], ["SPRINT", 236], ["was", 243], ["administered", 247], ["to", 260], ["subjects", 263], ["participating", 272], ["in", 286], ["a", 289], ["clinical", 291], ["trial", 300], ["of", 306], ["PTSD", 309], ["and", 314], ["in", 318], ["a", 321], ["population", 323], ["survey", 334], ["assessing", 341], ["PTSD", 351], ["prevalence", 356], [".", 366], ["The", 368], ["8-item", 372], ["SPRINT", 379], ["includes", 386], ["questions", 395], ["assessing", 405], ["the", 415], ["core", 419], ["symptoms", 424], ["of", 433], ["PTSD", 436], [",", 440], ["as", 442], ["well", 445], ["as", 450], ["related", 453], ["aspects", 461], ["of", 469], ["somatic", 472], ["malaise", 480], [",", 487], ["stress", 489], ["vulnerability", 496], ["and", 510], ["functional", 514], ["impairment", 525], [".", 535], ["Validity", 537], ["was", 546], ["assessed", 550], ["against", 559], ["the", 567], ["MINI", 571], ["structured", 576], ["interview", 587], [",", 596], ["the", 598], ["Davidson", 602], ["Trauma", 611], ["Scale", 618], [",", 623], ["Treatment", 625], ["Outcome", 635], ["for", 643], ["PTSD", 647], ["Scale", 652], [",", 657], ["Connor", 659], ["-", 665], ["Davidson", 666], ["Resilience", 675], ["Scale", 686], [",", 691], ["Sheehan", 693], ["Stress", 701], ["Vulnerability", 708], ["Scale", 722], [",", 727], ["Sheehan", 729], ["Disability", 737], ["Scale", 748], ["and", 754], ["Clinical", 758], ["Global", 767], ["Impressions", 774], ["of", 786], ["Severity", 789], ["and", 798], ["Improvement", 802], ["Scales", 814], [".", 820], ["Good", 822], ["test", 827], ["-", 831], ["retest", 832], ["reliability", 839], [",", 850], ["internal", 852], ["consistency", 861], [",", 872], ["convergent", 874], ["and", 885], ["divergent", 889], ["validity", 899], ["were", 908], ["obtained", 913], [".", 921], ["The", 923], ["SPRINT", 927], ["was", 934], ["responsive", 938], ["to", 949], ["symptom", 952], ["change", 960], ["over", 967], ["time", 972], ["and", 977], ["correlated", 981], ["with", 992], ["comparable", 997], ["PTSD", 1008], ["symptom", 1013], ["measures", 1021], [".", 1029], ["In", 1031], ["victims", 1034], ["of", 1042], ["trauma", 1045], [",", 1051], ["a", 1053], ["score", 1055], ["of", 1061], ["14", 1064], ["-", 1066], ["17", 1067], ["was", 1070], ["associated", 1074], ["with", 1085], ["96", 1090], ["%", 1092], ["diagnostic", 1094], ["accuracy", 1105], [",", 1113], ["whereas", 1115], ["in", 1123], ["those", 1126], ["with", 1132], ["PTSD", 1137], [",", 1141], ["highest", 1143], ["efficiency", 1151], ["corresponded", 1162], ["to", 1175], ["a", 1178], ["range", 1180], ["of", 1186], ["11", 1189], ["-", 1191], ["13", 1192], [".", 1194], ["The", 1196], ["SPRINT", 1200], ["demonstrates", 1207], ["solid", 1220], ["psychometric", 1226], ["properties", 1239], ["and", 1250], ["can", 1254], ["serve", 1258], ["as", 1264], ["a", 1267], ["reliable", 1269], [",", 1277], ["valid", 1279], ["and", 1285], ["homogeneous", 1289], ["measure", 1301], ["of", 1309], ["PTSD", 1312], ["illness", 1317], ["severity", 1325], ["and", 1334], ["of", 1338], ["global", 1341], ["improvement", 1348], [".", 1359]]}
{"context": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue. Affected patients are at risk of arterial, bowel and uterine rupture during pregnancy. Generally, this syndrome remains undiagnosed until a sudden, acute presentation with organ rupture, and results in premature death, even if the patients survive the first and second major complications. An early diagnosis with genetic assays can help to plan the best treatment, which is often challenging due to the frailty of the arterial tissue. We report on a 28-year-old lady who presented with spontaneous rupture of a pseudoaneurysm of the posterior tibial artery.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "1a2e7aaf9e9148c98bfc8b68db1ea274", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[22, 23]], "char_spans": [[104, 120]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["type", 23], ["4", 28], [",", 29], ["the", 31], ["vascular", 35], ["type", 44], [",", 48], ["is", 50], ["a", 53], ["rare", 55], [",", 59], ["life", 61], ["-", 65], ["threatening", 66], ["inherited", 78], ["disorder", 88], ["of", 97], ["the", 100], ["connective", 104], ["tissue", 115], [".", 121], ["Affected", 123], ["patients", 132], ["are", 141], ["at", 145], ["risk", 148], ["of", 153], ["arterial", 156], [",", 164], ["bowel", 166], ["and", 172], ["uterine", 176], ["rupture", 184], ["during", 192], ["pregnancy", 199], [".", 208], ["Generally", 210], [",", 219], ["this", 221], ["syndrome", 226], ["remains", 235], ["undiagnosed", 243], ["until", 255], ["a", 261], ["sudden", 263], [",", 269], ["acute", 271], ["presentation", 277], ["with", 290], ["organ", 295], ["rupture", 301], [",", 308], ["and", 310], ["results", 314], ["in", 322], ["premature", 325], ["death", 335], [",", 340], ["even", 342], ["if", 347], ["the", 350], ["patients", 354], ["survive", 363], ["the", 371], ["first", 375], ["and", 381], ["second", 385], ["major", 392], ["complications", 398], [".", 411], ["An", 413], ["early", 416], ["diagnosis", 422], ["with", 432], ["genetic", 437], ["assays", 445], ["can", 452], ["help", 456], ["to", 461], ["plan", 464], ["the", 469], ["best", 473], ["treatment", 478], [",", 487], ["which", 489], ["is", 495], ["often", 498], ["challenging", 504], ["due", 516], ["to", 520], ["the", 523], ["frailty", 527], ["of", 535], ["the", 538], ["arterial", 542], ["tissue", 551], [".", 557], ["We", 559], ["report", 562], ["on", 569], ["a", 572], ["28-year", 574], ["-", 581], ["old", 582], ["lady", 586], ["who", 591], ["presented", 595], ["with", 605], ["spontaneous", 610], ["rupture", 622], ["of", 630], ["a", 633], ["pseudoaneurysm", 635], ["of", 650], ["the", 653], ["posterior", 657], ["tibial", 667], ["artery", 674], [".", 680]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients. In order to investigate a possible phenotype-genotype correlation and to further define the predictive value of NSD1 mutations, we performed mutational analysis of the NSD1 gene in 20 patients and one familial case with Sotos syndrome, five patients with Weaver syndrome, six patients with unclassified overgrowth/mental retardation, and six patients with macrocephaly/mental retardation. We were able to identify mutations within the NSD1 gene in 18 patients and the familial case with Sotos syndrome (90%). The mutations (six nonsense, eight frame shifts, three splice site, one missense, one in-frame deletion) are expected to result in an impairment of NSD1 function. The best correlation between clinical assessment and molecular results was obtained for the Sotos facial gestalt in conjunction with overgrowth, macrocephaly, and developmental delay. In contrast to the high mutation detection rate in Sotos syndrome, none of the patients with Weaver syndrome, unclassified overgrowth/mental retardation and macrocephaly/mental retardation, harbored NSD1 mutations. We tested for large deletions by FISH analysis but were not able to identify any deletion cases. The results indicate that the great majority of patients with Sotos syndrome are caused by mutations in NSD1. Deletions covering the NSD1 locus were not found in the patients analyzed here.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "c0eee31746d343f19dcd03ff0c8496b2", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[73, 74], [13, 15], [118, 119]], "char_spans": [[438, 446], [76, 85], [705, 713]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["deletions", 10], ["encompassing", 20], ["the", 33], ["nuclear", 37], ["receptor", 45], ["binding", 54], ["SET", 62], ["-", 65], ["Domain", 66], ["1", 73], ["(", 75], ["NSD1", 76], [")", 80], ["gene", 82], ["have", 87], ["been", 92], ["described", 97], ["as", 107], ["the", 110], ["major", 114], ["cause", 120], ["of", 126], ["Japanese", 129], ["patients", 138], ["with", 147], ["the", 152], ["Sotos", 156], ["syndrome", 162], [",", 170], ["whereas", 172], ["point", 180], ["mutations", 186], ["have", 196], ["been", 201], ["identified", 206], ["in", 217], ["the", 220], ["majority", 224], ["of", 233], ["European", 236], ["Sotos", 245], ["syndrome", 251], ["patients", 260], [".", 268], ["In", 270], ["order", 273], ["to", 279], ["investigate", 282], ["a", 294], ["possible", 296], ["phenotype", 305], ["-", 314], ["genotype", 315], ["correlation", 324], ["and", 336], ["to", 340], ["further", 343], ["define", 351], ["the", 358], ["predictive", 362], ["value", 373], ["of", 379], ["NSD1", 382], ["mutations", 387], [",", 396], ["we", 398], ["performed", 401], ["mutational", 411], ["analysis", 422], ["of", 431], ["the", 434], ["NSD1", 438], ["gene", 443], ["in", 448], ["20", 451], ["patients", 454], ["and", 463], ["one", 467], ["familial", 471], ["case", 480], ["with", 485], ["Sotos", 490], ["syndrome", 496], [",", 504], ["five", 506], ["patients", 511], ["with", 520], ["Weaver", 525], ["syndrome", 532], [",", 540], ["six", 542], ["patients", 546], ["with", 555], ["unclassified", 560], ["overgrowth", 573], ["/", 583], ["mental", 584], ["retardation", 591], [",", 602], ["and", 604], ["six", 608], ["patients", 612], ["with", 621], ["macrocephaly", 626], ["/", 638], ["mental", 639], ["retardation", 646], [".", 657], ["We", 659], ["were", 662], ["able", 667], ["to", 672], ["identify", 675], ["mutations", 684], ["within", 694], ["the", 701], ["NSD1", 705], ["gene", 710], ["in", 715], ["18", 718], ["patients", 721], ["and", 730], ["the", 734], ["familial", 738], ["case", 747], ["with", 752], ["Sotos", 757], ["syndrome", 763], ["(", 772], ["90", 773], ["%", 775], [")", 776], [".", 777], ["The", 779], ["mutations", 783], ["(", 793], ["six", 794], ["nonsense", 798], [",", 806], ["eight", 808], ["frame", 814], ["shifts", 820], [",", 826], ["three", 828], ["splice", 834], ["site", 841], [",", 845], ["one", 847], ["missense", 851], [",", 859], ["one", 861], ["in", 865], ["-", 867], ["frame", 868], ["deletion", 874], [")", 882], ["are", 884], ["expected", 888], ["to", 897], ["result", 900], ["in", 907], ["an", 910], ["impairment", 913], ["of", 924], ["NSD1", 927], ["function", 932], [".", 940], ["The", 942], ["best", 946], ["correlation", 951], ["between", 963], ["clinical", 971], ["assessment", 980], ["and", 991], ["molecular", 995], ["results", 1005], ["was", 1013], ["obtained", 1017], ["for", 1026], ["the", 1030], ["Sotos", 1034], ["facial", 1040], ["gestalt", 1047], ["in", 1055], ["conjunction", 1058], ["with", 1070], ["overgrowth", 1075], [",", 1085], ["macrocephaly", 1087], [",", 1099], ["and", 1101], ["developmental", 1105], ["delay", 1119], [".", 1124], ["In", 1126], ["contrast", 1129], ["to", 1138], ["the", 1141], ["high", 1145], ["mutation", 1150], ["detection", 1159], ["rate", 1169], ["in", 1174], ["Sotos", 1177], ["syndrome", 1183], [",", 1191], ["none", 1193], ["of", 1198], ["the", 1201], ["patients", 1205], ["with", 1214], ["Weaver", 1219], ["syndrome", 1226], [",", 1234], ["unclassified", 1236], ["overgrowth", 1249], ["/", 1259], ["mental", 1260], ["retardation", 1267], ["and", 1279], ["macrocephaly", 1283], ["/", 1295], ["mental", 1296], ["retardation", 1303], [",", 1314], ["harbored", 1316], ["NSD1", 1325], ["mutations", 1330], [".", 1339], ["We", 1341], ["tested", 1344], ["for", 1351], ["large", 1355], ["deletions", 1361], ["by", 1371], ["FISH", 1374], ["analysis", 1379], ["but", 1388], ["were", 1392], ["not", 1397], ["able", 1401], ["to", 1406], ["identify", 1409], ["any", 1418], ["deletion", 1422], ["cases", 1431], [".", 1436], ["The", 1438], ["results", 1442], ["indicate", 1450], ["that", 1459], ["the", 1464], ["great", 1468], ["majority", 1474], ["of", 1483], ["patients", 1486], ["with", 1495], ["Sotos", 1500], ["syndrome", 1506], ["are", 1515], ["caused", 1519], ["by", 1526], ["mutations", 1529], ["in", 1539], ["NSD1", 1542], [".", 1546], ["Deletions", 1548], ["covering", 1558], ["the", 1567], ["NSD1", 1571], ["locus", 1576], ["were", 1582], ["not", 1587], ["found", 1591], ["in", 1597], ["the", 1600], ["patients", 1604], ["analyzed", 1613], ["here", 1622], [".", 1626]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "Na\u00efve and primed pluripotent states retain distinct molecular properties, yet limited knowledge exists on how their state transitions are regulated. Here, we identify Mettl3, an N(6)-methyladenosine (m(6)A) transferase, as a regulator for terminating murine na\u00efve pluripotency. Mettl3 knockout preimplantation epiblasts and na\u00efve embryonic stem cells are depleted for m(6)A in mRNAs, yet are viable. However, they fail to adequately terminate their na\u00efve state and, subsequently, undergo aberrant and restricted lineage priming at the postimplantation stage, which leads to early embryonic lethality. m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. This study highlights a critical role for an mRNA epigenetic modification in vivo and identifies regulatory modules that functionally influence na\u00efve and primed pluripotency in an opposing manner.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "e2dccc6fa3a84b67a72cd87b03a0db2e", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[101, 102]], "char_spans": [[642, 655]]}]}], "context_tokens": [["Na\u00efve", 0], ["and", 6], ["primed", 10], ["pluripotent", 17], ["states", 29], ["retain", 36], ["distinct", 43], ["molecular", 52], ["properties", 62], [",", 72], ["yet", 74], ["limited", 78], ["knowledge", 86], ["exists", 96], ["on", 103], ["how", 106], ["their", 110], ["state", 116], ["transitions", 122], ["are", 134], ["regulated", 138], [".", 147], ["Here", 149], [",", 153], ["we", 155], ["identify", 158], ["Mettl3", 167], [",", 173], ["an", 175], ["N(6)-methyladenosine", 178], ["(", 199], ["m(6)A", 200], [")", 205], ["transferase", 207], [",", 218], ["as", 220], ["a", 223], ["regulator", 225], ["for", 235], ["terminating", 239], ["murine", 251], ["na\u00efve", 258], ["pluripotency", 264], [".", 276], ["Mettl3", 278], ["knockout", 285], ["preimplantation", 294], ["epiblasts", 310], ["and", 320], ["na\u00efve", 324], ["embryonic", 330], ["stem", 340], ["cells", 345], ["are", 351], ["depleted", 355], ["for", 364], ["m(6)A", 368], ["in", 374], ["mRNAs", 377], [",", 382], ["yet", 384], ["are", 388], ["viable", 392], [".", 398], ["However", 400], [",", 407], ["they", 409], ["fail", 414], ["to", 419], ["adequately", 422], ["terminate", 433], ["their", 443], ["na\u00efve", 449], ["state", 455], ["and", 461], [",", 464], ["subsequently", 466], [",", 478], ["undergo", 480], ["aberrant", 488], ["and", 497], ["restricted", 501], ["lineage", 512], ["priming", 520], ["at", 528], ["the", 531], ["postimplantation", 535], ["stage", 552], [",", 557], ["which", 559], ["leads", 565], ["to", 571], ["early", 574], ["embryonic", 580], ["lethality", 590], [".", 599], ["m(6)A", 601], ["predominantly", 607], ["and", 621], ["directly", 625], ["reduces", 634], ["mRNA", 642], ["stability", 647], [",", 656], ["including", 658], ["that", 668], ["of", 673], ["key", 676], ["na\u00efve", 680], ["pluripotency", 686], ["-", 698], ["promoting", 699], ["transcripts", 709], [".", 720], ["This", 722], ["study", 727], ["highlights", 733], ["a", 744], ["critical", 746], ["role", 755], ["for", 760], ["an", 764], ["mRNA", 767], ["epigenetic", 772], ["modification", 783], ["in", 796], ["vivo", 799], ["and", 804], ["identifies", 808], ["regulatory", 819], ["modules", 830], ["that", 838], ["functionally", 843], ["influence", 856], ["na\u00efve", 866], ["and", 872], ["primed", 876], ["pluripotency", 883], ["in", 896], ["an", 899], ["opposing", 902], ["manner", 911], [".", 917]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). This study was undertaken to investigate the effect of food on the pharmacokinetics of 25 mg empagliflozin and to assess dose proportionality between 10 mg and 25 mg empagliflozin under fasted conditions. In this open-label, 3-way, cross-over study, 18 healthy volunteers received 3 single doses of empagliflozin in a randomized sequence (25 mg empagliflozin under fasted conditions, 25 mg empagliflozin after a high-fat, high-calorie breakfast and 10 mg empagliflozin under fasted conditions), each separated by a washout period of at least 7 days. Serial plasma samples were collected at selected time points over a period of 72 hours. Administration with food had no clinically relevant effect on the area under the plasma concentration-time curve (AUC0-\u221e) of empagliflozin (geometric mean ratio (GMR): 84.04, 90% confidence interval (CI): 80.86 - 87.34). The decrease observed in the maximum plasma concentrations (Cmax) of empagliflozin (GMR: 63.22, 90% CI: 56.74 - 70.44) when administered with food was not considered clinically meaningful. The increases in AUC0-\u221e and Cmax for 10 mg vs. 25 mg empagliflozin administered under fasting conditions were roughly dose-proportional, as demonstrated by the slope \u03b2 of the regression lines being slightly less than 1 (slope \u03b2 for AUC0-\u221e: 0.94, 95% CI: 0.90 - 0.97; slope \u03b2 for Cmax: 0.91, 95% CI: 0.80 - 1.01). Empagliflozin was well tolerated under fed and fasting conditions. The results support administration of empagliflozin tablets independently of food. Increases in empagliflozin exposure under fasting conditions were roughly dose-proportional between 10 mg and 25 mg empagliflozin.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "1ac6a774b34748d0b2f90a6dd51379eb", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[18, 18]], "char_spans": [[115, 119]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["an", 17], ["orally", 20], ["available", 27], [",", 36], ["potent", 38], ["and", 45], ["highly", 49], ["selective", 56], ["inhibitor", 66], ["of", 76], ["the", 79], ["sodium", 83], ["glucose", 90], ["cotransporter", 98], ["2", 112], ["(", 114], ["SGLT2", 115], [")", 120], [".", 121], ["This", 123], ["study", 128], ["was", 134], ["undertaken", 138], ["to", 149], ["investigate", 152], ["the", 164], ["effect", 168], ["of", 175], ["food", 178], ["on", 183], ["the", 186], ["pharmacokinetics", 190], ["of", 207], ["25", 210], ["mg", 213], ["empagliflozin", 216], ["and", 230], ["to", 234], ["assess", 237], ["dose", 244], ["proportionality", 249], ["between", 265], ["10", 273], ["mg", 276], ["and", 279], ["25", 283], ["mg", 286], ["empagliflozin", 289], ["under", 303], ["fasted", 309], ["conditions", 316], [".", 326], ["In", 328], ["this", 331], ["open", 336], ["-", 340], ["label", 341], [",", 346], ["3-way", 348], [",", 353], ["cross", 355], ["-", 360], ["over", 361], ["study", 366], [",", 371], ["18", 373], ["healthy", 376], ["volunteers", 384], ["received", 395], ["3", 404], ["single", 406], ["doses", 413], ["of", 419], ["empagliflozin", 422], ["in", 436], ["a", 439], ["randomized", 441], ["sequence", 452], ["(", 461], ["25", 462], ["mg", 465], ["empagliflozin", 468], ["under", 482], ["fasted", 488], ["conditions", 495], [",", 505], ["25", 507], ["mg", 510], ["empagliflozin", 513], ["after", 527], ["a", 533], ["high", 535], ["-", 539], ["fat", 540], [",", 543], ["high", 545], ["-", 549], ["calorie", 550], ["breakfast", 558], ["and", 568], ["10", 572], ["mg", 575], ["empagliflozin", 578], ["under", 592], ["fasted", 598], ["conditions", 605], [")", 615], [",", 616], ["each", 618], ["separated", 623], ["by", 633], ["a", 636], ["washout", 638], ["period", 646], ["of", 653], ["at", 656], ["least", 659], ["7", 665], ["days", 667], [".", 671], ["Serial", 673], ["plasma", 680], ["samples", 687], ["were", 695], ["collected", 700], ["at", 710], ["selected", 713], ["time", 722], ["points", 727], ["over", 734], ["a", 739], ["period", 741], ["of", 748], ["72", 751], ["hours", 754], [".", 759], ["Administration", 761], ["with", 776], ["food", 781], ["had", 786], ["no", 790], ["clinically", 793], ["relevant", 804], ["effect", 813], ["on", 820], ["the", 823], ["area", 827], ["under", 832], ["the", 838], ["plasma", 842], ["concentration", 849], ["-", 862], ["time", 863], ["curve", 868], ["(", 874], ["AUC0-\u221e", 875], [")", 881], ["of", 883], ["empagliflozin", 886], ["(", 900], ["geometric", 901], ["mean", 911], ["ratio", 916], ["(", 922], ["GMR", 923], [")", 926], [":", 927], ["84.04", 929], [",", 934], ["90", 936], ["%", 938], ["confidence", 940], ["interval", 951], ["(", 960], ["CI", 961], [")", 963], [":", 964], ["80.86", 966], ["-", 972], ["87.34", 974], [")", 979], [".", 980], ["The", 982], ["decrease", 986], ["observed", 995], ["in", 1004], ["the", 1007], ["maximum", 1011], ["plasma", 1019], ["concentrations", 1026], ["(", 1041], ["Cmax", 1042], [")", 1046], ["of", 1048], ["empagliflozin", 1051], ["(", 1065], ["GMR", 1066], [":", 1069], ["63.22", 1071], [",", 1076], ["90", 1078], ["%", 1080], ["CI", 1082], [":", 1084], ["56.74", 1086], ["-", 1092], ["70.44", 1094], [")", 1099], ["when", 1101], ["administered", 1106], ["with", 1119], ["food", 1124], ["was", 1129], ["not", 1133], ["considered", 1137], ["clinically", 1148], ["meaningful", 1159], [".", 1169], ["The", 1171], ["increases", 1175], ["in", 1185], ["AUC0-\u221e", 1188], ["and", 1195], ["Cmax", 1199], ["for", 1204], ["10", 1208], ["mg", 1211], ["vs.", 1214], ["25", 1218], ["mg", 1221], ["empagliflozin", 1224], ["administered", 1238], ["under", 1251], ["fasting", 1257], ["conditions", 1265], ["were", 1276], ["roughly", 1281], ["dose", 1289], ["-", 1293], ["proportional", 1294], [",", 1306], ["as", 1308], ["demonstrated", 1311], ["by", 1324], ["the", 1327], ["slope", 1331], ["\u03b2", 1337], ["of", 1339], ["the", 1342], ["regression", 1346], ["lines", 1357], ["being", 1363], ["slightly", 1369], ["less", 1378], ["than", 1383], ["1", 1388], ["(", 1390], ["slope", 1391], ["\u03b2", 1397], ["for", 1399], ["AUC0-\u221e", 1403], [":", 1409], ["0.94", 1411], [",", 1415], ["95", 1417], ["%", 1419], ["CI", 1421], [":", 1423], ["0.90", 1425], ["-", 1430], ["0.97", 1432], [";", 1436], ["slope", 1438], ["\u03b2", 1444], ["for", 1446], ["Cmax", 1450], [":", 1454], ["0.91", 1456], [",", 1460], ["95", 1462], ["%", 1464], ["CI", 1466], [":", 1468], ["0.80", 1470], ["-", 1475], ["1.01", 1477], [")", 1481], [".", 1482], ["Empagliflozin", 1484], ["was", 1498], ["well", 1502], ["tolerated", 1507], ["under", 1517], ["fed", 1523], ["and", 1527], ["fasting", 1531], ["conditions", 1539], [".", 1549], ["The", 1551], ["results", 1555], ["support", 1563], ["administration", 1571], ["of", 1586], ["empagliflozin", 1589], ["tablets", 1603], ["independently", 1611], ["of", 1625], ["food", 1628], [".", 1632], ["Increases", 1634], ["in", 1644], ["empagliflozin", 1647], ["exposure", 1661], ["under", 1670], ["fasting", 1676], ["conditions", 1684], ["were", 1695], ["roughly", 1700], ["dose", 1708], ["-", 1712], ["proportional", 1713], ["between", 1726], ["10", 1734], ["mg", 1737], ["and", 1740], ["25", 1744], ["mg", 1747], ["empagliflozin", 1750], [".", 1763]]}
{"context": "Most previously reported mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) result in an odd number of cysteine residues within the epidermal growth factor (EGF)-like repeats in Notch3. We report here R75P mutation in two Japanese CADASIL families not directly involving cysteine residues located within the first EGF-like repeats. Probands in both families had repeated episodes of stroke, depression, dementia as well as T2 high-intensity lesions in the basal ganglia and periventricular white matter, but fewer white matter lesions in the temporal pole on MRI. These families provide new insights into the diagnosis and pathomechanisms of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "bcde6357432f432684078b4f2374b9d8", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[23, 23], [49, 49]], "char_spans": [[166, 173], [334, 341]]}]}], "context_tokens": [["Most", 0], ["previously", 5], ["reported", 16], ["mutations", 25], ["in", 35], ["cerebral", 38], ["autosomal", 47], ["dominant", 57], ["arteriopathy", 66], ["with", 79], ["subcortical", 84], ["infarcts", 96], ["and", 105], ["leukoencephalopathy", 109], ["(", 129], ["CADASIL", 130], [")", 137], ["result", 139], ["in", 146], ["an", 149], ["odd", 152], ["number", 156], ["of", 163], ["cysteine", 166], ["residues", 175], ["within", 184], ["the", 191], ["epidermal", 195], ["growth", 205], ["factor", 212], ["(", 219], ["EGF)-like", 220], ["repeats", 230], ["in", 238], ["Notch3", 241], [".", 247], ["We", 249], ["report", 252], ["here", 259], ["R75P", 264], ["mutation", 269], ["in", 278], ["two", 281], ["Japanese", 285], ["CADASIL", 294], ["families", 302], ["not", 311], ["directly", 315], ["involving", 324], ["cysteine", 334], ["residues", 343], ["located", 352], ["within", 360], ["the", 367], ["first", 371], ["EGF", 377], ["-", 380], ["like", 381], ["repeats", 386], [".", 393], ["Probands", 395], ["in", 404], ["both", 407], ["families", 412], ["had", 421], ["repeated", 425], ["episodes", 434], ["of", 443], ["stroke", 446], [",", 452], ["depression", 454], [",", 464], ["dementia", 466], ["as", 475], ["well", 478], ["as", 483], ["T2", 486], ["high", 489], ["-", 493], ["intensity", 494], ["lesions", 504], ["in", 512], ["the", 515], ["basal", 519], ["ganglia", 525], ["and", 533], ["periventricular", 537], ["white", 553], ["matter", 559], [",", 565], ["but", 567], ["fewer", 571], ["white", 577], ["matter", 583], ["lesions", 590], ["in", 598], ["the", 601], ["temporal", 605], ["pole", 614], ["on", 619], ["MRI", 622], [".", 625], ["These", 627], ["families", 633], ["provide", 642], ["new", 650], ["insights", 654], ["into", 663], ["the", 668], ["diagnosis", 672], ["and", 682], ["pathomechanisms", 686], ["of", 702], ["CADASIL", 705], [".", 712]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare genetic condition where variable and multiple congenital anomalies including Hirschsprung's disease, intellectual disability, and prominent facial features are present. At molecular level, MWS is characterized by many different described mutations in the zinc finger E-box protein 2 (ZEB2) gene, ultimately leading to loss of gene function. This report is the first to describe the association of MWS with two different asynchronous malignant brain tumors (medulloblastoma and glioblastoma) occurring in a child.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "1d067f852f5b46409f02c83de355022e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[55, 55]], "char_spans": [[322, 325]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["genetic", 38], ["condition", 46], ["where", 56], ["variable", 62], ["and", 71], ["multiple", 75], ["congenital", 84], ["anomalies", 95], ["including", 105], ["Hirschsprung", 115], ["'s", 127], ["disease", 130], [",", 137], ["intellectual", 139], ["disability", 152], [",", 162], ["and", 164], ["prominent", 168], ["facial", 178], ["features", 185], ["are", 194], ["present", 198], [".", 205], ["At", 207], ["molecular", 210], ["level", 220], [",", 225], ["MWS", 227], ["is", 231], ["characterized", 234], ["by", 248], ["many", 251], ["different", 256], ["described", 266], ["mutations", 276], ["in", 286], ["the", 289], ["zinc", 293], ["finger", 298], ["E", 305], ["-", 306], ["box", 307], ["protein", 311], ["2", 319], ["(", 321], ["ZEB2", 322], [")", 326], ["gene", 328], [",", 332], ["ultimately", 334], ["leading", 345], ["to", 353], ["loss", 356], ["of", 361], ["gene", 364], ["function", 369], [".", 377], ["This", 379], ["report", 384], ["is", 391], ["the", 394], ["first", 398], ["to", 404], ["describe", 407], ["the", 416], ["association", 420], ["of", 432], ["MWS", 435], ["with", 439], ["two", 444], ["different", 448], ["asynchronous", 458], ["malignant", 471], ["brain", 481], ["tumors", 487], ["(", 494], ["medulloblastoma", 495], ["and", 511], ["glioblastoma", 515], [")", 527], ["occurring", 529], ["in", 539], ["a", 542], ["child", 544], [".", 549]]}
{"context": "Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR. An understanding of the downstream cellular targets of gefitinib will allow the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies and provide information for key targets for therapeutic intervention. In this study, we investigated the role of FOXO3a in gefitinib action and resistance. Using two gefitinib-sensitive (i.e., BT474 and SKBR3) as well as three other resistant breast carcinoma cell lines (i.e., MCF-7, MDA-MB-231, and MDA-MB-453), we showed that gefitinib targets the transcription factor FOXO3a to mediate cell cycle arrest and cell death in sensitive breast cancer cells. In the sensitive cells, gefitinib treatment causes cell cycle arrest predominantly at the G(0)-G(1) phase and apoptosis, which is associated with FOXO3a dephosphorylation at Akt sites and nuclear translocation, whereas in the resistant cells, FOXO3a stays phosphorylated and remains in the cytoplasm. The nuclear accumulation of FOXO3a in response to gefitinib was confirmed in tumor tissue sections from breast cancer patients presurgically treated with gefitinib as monotherapy. We also showed that knockdown of FOXO3a expression using small interfering RNA (siRNA) can rescue sensitive BT474 cells from gefitinib-induced cell-proliferative arrest, whereas reintroduction of active FOXO3a in resistant MDA-MB-231 cells can at least partially restore cell-proliferative arrest and sensitivity to gefitinib. These results suggest that the FOXO3a dephosphorylation and nuclear localization have a direct role in mediating the gefitinib-induced proliferative arrest and in determining sensitivity to gefitinib.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "5ad5edb13de04cb2b3191b68d0eab76d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], ["is", 10], ["a", 13], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], ["that", 81], ["causes", 86], ["growth", 93], ["delay", 100], ["in", 106], ["cancer", 109], ["cell", 116], ["lines", 121], ["and", 127], ["human", 131], ["tumor", 137], ["xenografts", 143], ["expressing", 154], ["high", 165], ["levels", 170], ["of", 177], ["EGFR", 180], [".", 184], ["An", 186], ["understanding", 189], ["of", 203], ["the", 206], ["downstream", 210], ["cellular", 221], ["targets", 230], ["of", 238], ["gefitinib", 241], ["will", 251], ["allow", 256], ["the", 262], ["discovery", 266], ["of", 276], ["biomarkers", 279], ["for", 290], ["predicting", 294], ["outcomes", 305], ["and", 314], ["monitoring", 318], ["anti", 329], ["-", 333], ["EGFR", 334], ["therapies", 339], ["and", 349], ["provide", 353], ["information", 361], ["for", 373], ["key", 377], ["targets", 381], ["for", 389], ["therapeutic", 393], ["intervention", 405], [".", 417], ["In", 419], ["this", 422], ["study", 427], [",", 432], ["we", 434], ["investigated", 437], ["the", 450], ["role", 454], ["of", 459], ["FOXO3a", 462], ["in", 469], ["gefitinib", 472], ["action", 482], ["and", 489], ["resistance", 493], [".", 503], ["Using", 505], ["two", 511], ["gefitinib", 515], ["-", 524], ["sensitive", 525], ["(", 535], ["i.e.", 536], [",", 540], ["BT474", 542], ["and", 548], ["SKBR3", 552], [")", 557], ["as", 559], ["well", 562], ["as", 567], ["three", 570], ["other", 576], ["resistant", 582], ["breast", 592], ["carcinoma", 599], ["cell", 609], ["lines", 614], ["(", 620], ["i.e.", 621], [",", 625], ["MCF-7", 627], [",", 632], ["MDA", 634], ["-", 637], ["MB-231", 638], [",", 644], ["and", 646], ["MDA", 650], ["-", 653], ["MB-453", 654], [")", 660], [",", 661], ["we", 663], ["showed", 666], ["that", 673], ["gefitinib", 678], ["targets", 688], ["the", 696], ["transcription", 700], ["factor", 714], ["FOXO3a", 721], ["to", 728], ["mediate", 731], ["cell", 739], ["cycle", 744], ["arrest", 750], ["and", 757], ["cell", 761], ["death", 766], ["in", 772], ["sensitive", 775], ["breast", 785], ["cancer", 792], ["cells", 799], [".", 804], ["In", 806], ["the", 809], ["sensitive", 813], ["cells", 823], [",", 828], ["gefitinib", 830], ["treatment", 840], ["causes", 850], ["cell", 857], ["cycle", 862], ["arrest", 868], ["predominantly", 875], ["at", 889], ["the", 892], ["G(0)-G(1", 896], [")", 904], ["phase", 906], ["and", 912], ["apoptosis", 916], [",", 925], ["which", 927], ["is", 933], ["associated", 936], ["with", 947], ["FOXO3a", 952], ["dephosphorylation", 959], ["at", 977], ["Akt", 980], ["sites", 984], ["and", 990], ["nuclear", 994], ["translocation", 1002], [",", 1015], ["whereas", 1017], ["in", 1025], ["the", 1028], ["resistant", 1032], ["cells", 1042], [",", 1047], ["FOXO3a", 1049], ["stays", 1056], ["phosphorylated", 1062], ["and", 1077], ["remains", 1081], ["in", 1089], ["the", 1092], ["cytoplasm", 1096], [".", 1105], ["The", 1107], ["nuclear", 1111], ["accumulation", 1119], ["of", 1132], ["FOXO3a", 1135], ["in", 1142], ["response", 1145], ["to", 1154], ["gefitinib", 1157], ["was", 1167], ["confirmed", 1171], ["in", 1181], ["tumor", 1184], ["tissue", 1190], ["sections", 1197], ["from", 1206], ["breast", 1211], ["cancer", 1218], ["patients", 1225], ["presurgically", 1234], ["treated", 1248], ["with", 1256], ["gefitinib", 1261], ["as", 1271], ["monotherapy", 1274], [".", 1285], ["We", 1287], ["also", 1290], ["showed", 1295], ["that", 1302], ["knockdown", 1307], ["of", 1317], ["FOXO3a", 1320], ["expression", 1327], ["using", 1338], ["small", 1344], ["interfering", 1350], ["RNA", 1362], ["(", 1366], ["siRNA", 1367], [")", 1372], ["can", 1374], ["rescue", 1378], ["sensitive", 1385], ["BT474", 1395], ["cells", 1401], ["from", 1407], ["gefitinib", 1412], ["-", 1421], ["induced", 1422], ["cell", 1430], ["-", 1434], ["proliferative", 1435], ["arrest", 1449], [",", 1455], ["whereas", 1457], ["reintroduction", 1465], ["of", 1480], ["active", 1483], ["FOXO3a", 1490], ["in", 1497], ["resistant", 1500], ["MDA", 1510], ["-", 1513], ["MB-231", 1514], ["cells", 1521], ["can", 1527], ["at", 1531], ["least", 1534], ["partially", 1540], ["restore", 1550], ["cell", 1558], ["-", 1562], ["proliferative", 1563], ["arrest", 1577], ["and", 1584], ["sensitivity", 1588], ["to", 1600], ["gefitinib", 1603], [".", 1612], ["These", 1614], ["results", 1620], ["suggest", 1628], ["that", 1636], ["the", 1641], ["FOXO3a", 1645], ["dephosphorylation", 1652], ["and", 1670], ["nuclear", 1674], ["localization", 1682], ["have", 1695], ["a", 1700], ["direct", 1702], ["role", 1709], ["in", 1714], ["mediating", 1717], ["the", 1727], ["gefitinib", 1731], ["-", 1740], ["induced", 1741], ["proliferative", 1749], ["arrest", 1763], ["and", 1770], ["in", 1774], ["determining", 1777], ["sensitivity", 1789], ["to", 1801], ["gefitinib", 1804], [".", 1813]]}
{"context": "Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th century was use of arsenic in one or other form, which did undoubtedly reduce the leukocyte count but probably did little or nothing to prolong life. These early cases were probably examples of chronic myeloid leukemia (CML) (then called chronic granulocytic leukemia). In the 20th century important steps in unraveling the pathogenesis of CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CML in 1985. In the first half of the 20th century patients were treated predominantly with radiotherapy, and later on with busulfan, hydroxycarbamide, or interferon-alfa (IFN-\u03b1). From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7a34cd7025714d5fa78883088d8a1b82", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[130, 132]], "char_spans": [[735, 741]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["splenomegaly", 14], ["and", 27], ["abnormally", 31], ["high", 42], ["leukocyte", 47], ["counts", 57], ["were", 64], ["first", 69], ["recognized", 75], ["in", 86], ["France", 89], [",", 95], ["Germany", 97], [",", 104], ["and", 106], ["Scotland", 110], ["in", 119], ["the", 122], ["1840s", 126], [".", 131], ["The", 133], ["only", 137], ["well", 142], ["-", 146], ["documented", 147], ["therapy", 158], ["in", 166], ["the", 169], ["19th", 173], ["century", 178], ["was", 186], ["use", 190], ["of", 194], ["arsenic", 197], ["in", 205], ["one", 208], ["or", 212], ["other", 215], ["form", 221], [",", 225], ["which", 227], ["did", 233], ["undoubtedly", 237], ["reduce", 249], ["the", 256], ["leukocyte", 260], ["count", 270], ["but", 276], ["probably", 280], ["did", 289], ["little", 293], ["or", 300], ["nothing", 303], ["to", 311], ["prolong", 314], ["life", 322], [".", 326], ["These", 328], ["early", 334], ["cases", 340], ["were", 346], ["probably", 351], ["examples", 360], ["of", 369], ["chronic", 372], ["myeloid", 380], ["leukemia", 388], ["(", 397], ["CML", 398], [")", 401], ["(", 403], ["then", 404], ["called", 409], ["chronic", 416], ["granulocytic", 424], ["leukemia", 437], [")", 445], [".", 446], ["In", 448], ["the", 451], ["20th", 455], ["century", 460], ["important", 468], ["steps", 478], ["in", 484], ["unraveling", 487], ["the", 498], ["pathogenesis", 502], ["of", 515], ["CML", 518], ["were", 522], ["the", 527], ["discovery", 531], ["of", 541], ["the", 544], ["Philadelphia", 548], ["chromosome", 561], ["in", 572], ["1960", 575], [",", 579], ["and", 581], ["of", 585], ["the", 588], ["(", 592], ["9;22", 593], [")", 597], ["translocation", 599], ["in", 613], ["1973", 616], [".", 620], ["There", 622], ["followed", 628], ["definition", 637], ["of", 648], ["the", 651], ["breakpoint", 655], ["cluster", 666], ["region", 674], ["on", 681], ["chromosome", 684], ["22", 695], ["in", 698], ["1984", 701], ["and", 706], ["the", 710], ["demonstration", 714], ["of", 728], ["the", 731], ["BCR", 735], ["-", 738], ["ABL", 739], ["transcript", 743], ["in", 754], ["CML", 757], ["in", 761], ["1985", 764], [".", 768], ["In", 770], ["the", 773], ["first", 777], ["half", 783], ["of", 788], ["the", 791], ["20th", 795], ["century", 800], ["patients", 808], ["were", 817], ["treated", 822], ["predominantly", 830], ["with", 844], ["radiotherapy", 849], [",", 861], ["and", 863], ["later", 867], ["on", 873], ["with", 876], ["busulfan", 881], [",", 889], ["hydroxycarbamide", 891], [",", 907], ["or", 909], ["interferon", 912], ["-", 922], ["alfa", 923], ["(", 928], ["IFN", 929], ["-", 932], ["\u03b1", 933], [")", 934], [".", 935], ["From", 937], ["1980", 942], ["onwards", 947], ["allogeneic", 955], ["stem", 966], ["cell", 971], ["transplantation", 976], ["(", 992], ["SCT", 993], [")", 996], ["became", 998], ["the", 1005], ["treatment", 1009], ["of", 1019], ["choice", 1022], ["for", 1029], ["eligible", 1033], ["patients", 1042], [".", 1050], ["The", 1052], ["era", 1056], ["of", 1060], ["tyrosine", 1063], ["kinase", 1072], ["inhibitors", 1079], ["(", 1090], ["TKI", 1091], [")", 1094], ["began", 1096], ["in", 1102], ["1998", 1105], ["and", 1110], ["today", 1114], ["the", 1120], ["use", 1124], ["of", 1128], ["the", 1131], ["original", 1135], ["TKI", 1144], [",", 1147], ["imatinib", 1149], [",", 1157], ["has", 1159], ["replaced", 1163], ["SCT", 1172], ["as", 1176], ["initial", 1179], ["therapy", 1187], ["for", 1195], ["patients", 1199], ["who", 1208], ["present", 1212], ["with", 1220], ["CML", 1225], ["in", 1229], ["chronic", 1232], ["phase", 1240], [".", 1245]]}
{"context": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor that directly interacts with the histone deacetylase Rpd3. Although previous studies suggest that this interaction is required for repression of Gro-responsive reporters in cultured cells, the in vivo significance of this interaction and the mechanism by which it leads to repression remain largely unexplored. In this study, we show that Gro is partially dependent on Rpd3 for repression, supporting the idea that Rpd3-mediated repression is one mode of Gro-mediated repression. We demonstrate that Gro colocalizes with Rpd3 to the chromatin of a target gene and that this is accompanied by the deacetylation of specific lysines within the N-terminal tails of histones H3 and H4. Gro overexpression leads to wing patterning defects and ectopic repression in the wing disc of transcription directed by the vestigial quadrant enhancer. These effects are reversed by the histone deacetylase inhibitors TSA and HC-Toxin and by the reduction of Rpd3 gene dosage. Furthermore, repression of the vestigial quadrant enhancer is accompanied by a Gro-mediated increase in nucleosome density, an effect that is reversed by histone deacetylase inhibitors. We propose a model in which Gro-mediated histone deacetylation results in increased nucleosome density leading to transcriptional repression.", "qas": [{"question": "What is the Drosophila melanogaster Groucho protein?", "answers": ["Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor"], "qid": "cb1860ac490e4c2cb4db0aaf636faa83", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["Drosophila", 12], ["melanogaster", 23], ["Groucho", 36], ["protein", 44], ["?", 51]], "detected_answers": [{"text": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor", "token_spans": [[0, 9]], "char_spans": [[0, 69]]}]}], "context_tokens": [["Groucho", 0], ["(", 8], ["Gro", 9], [")", 12], ["is", 14], ["a", 17], ["Drosophila", 19], ["melanogaster", 30], ["transcriptional", 43], ["corepressor", 59], ["that", 71], ["directly", 76], ["interacts", 85], ["with", 95], ["the", 100], ["histone", 104], ["deacetylase", 112], ["Rpd3", 124], [".", 128], ["Although", 130], ["previous", 139], ["studies", 148], ["suggest", 156], ["that", 164], ["this", 169], ["interaction", 174], ["is", 186], ["required", 189], ["for", 198], ["repression", 202], ["of", 213], ["Gro", 216], ["-", 219], ["responsive", 220], ["reporters", 231], ["in", 241], ["cultured", 244], ["cells", 253], [",", 258], ["the", 260], ["in", 264], ["vivo", 267], ["significance", 272], ["of", 285], ["this", 288], ["interaction", 293], ["and", 305], ["the", 309], ["mechanism", 313], ["by", 323], ["which", 326], ["it", 332], ["leads", 335], ["to", 341], ["repression", 344], ["remain", 355], ["largely", 362], ["unexplored", 370], [".", 380], ["In", 382], ["this", 385], ["study", 390], [",", 395], ["we", 397], ["show", 400], ["that", 405], ["Gro", 410], ["is", 414], ["partially", 417], ["dependent", 427], ["on", 437], ["Rpd3", 440], ["for", 445], ["repression", 449], [",", 459], ["supporting", 461], ["the", 472], ["idea", 476], ["that", 481], ["Rpd3-mediated", 486], ["repression", 500], ["is", 511], ["one", 514], ["mode", 518], ["of", 523], ["Gro", 526], ["-", 529], ["mediated", 530], ["repression", 539], [".", 549], ["We", 551], ["demonstrate", 554], ["that", 566], ["Gro", 571], ["colocalizes", 575], ["with", 587], ["Rpd3", 592], ["to", 597], ["the", 600], ["chromatin", 604], ["of", 614], ["a", 617], ["target", 619], ["gene", 626], ["and", 631], ["that", 635], ["this", 640], ["is", 645], ["accompanied", 648], ["by", 660], ["the", 663], ["deacetylation", 667], ["of", 681], ["specific", 684], ["lysines", 693], ["within", 701], ["the", 708], ["N", 712], ["-", 713], ["terminal", 714], ["tails", 723], ["of", 729], ["histones", 732], ["H3", 741], ["and", 744], ["H4", 748], [".", 750], ["Gro", 752], ["overexpression", 756], ["leads", 771], ["to", 777], ["wing", 780], ["patterning", 785], ["defects", 796], ["and", 804], ["ectopic", 808], ["repression", 816], ["in", 827], ["the", 830], ["wing", 834], ["disc", 839], ["of", 844], ["transcription", 847], ["directed", 861], ["by", 870], ["the", 873], ["vestigial", 877], ["quadrant", 887], ["enhancer", 896], [".", 904], ["These", 906], ["effects", 912], ["are", 920], ["reversed", 924], ["by", 933], ["the", 936], ["histone", 940], ["deacetylase", 948], ["inhibitors", 960], ["TSA", 971], ["and", 975], ["HC", 979], ["-", 981], ["Toxin", 982], ["and", 988], ["by", 992], ["the", 995], ["reduction", 999], ["of", 1009], ["Rpd3", 1012], ["gene", 1017], ["dosage", 1022], [".", 1028], ["Furthermore", 1030], [",", 1041], ["repression", 1043], ["of", 1054], ["the", 1057], ["vestigial", 1061], ["quadrant", 1071], ["enhancer", 1080], ["is", 1089], ["accompanied", 1092], ["by", 1104], ["a", 1107], ["Gro", 1109], ["-", 1112], ["mediated", 1113], ["increase", 1122], ["in", 1131], ["nucleosome", 1134], ["density", 1145], [",", 1152], ["an", 1154], ["effect", 1157], ["that", 1164], ["is", 1169], ["reversed", 1172], ["by", 1181], ["histone", 1184], ["deacetylase", 1192], ["inhibitors", 1204], [".", 1214], ["We", 1216], ["propose", 1219], ["a", 1227], ["model", 1229], ["in", 1235], ["which", 1238], ["Gro", 1244], ["-", 1247], ["mediated", 1248], ["histone", 1257], ["deacetylation", 1265], ["results", 1279], ["in", 1287], ["increased", 1290], ["nucleosome", 1300], ["density", 1311], ["leading", 1319], ["to", 1327], ["transcriptional", 1330], ["repression", 1346], [".", 1356]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available. We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology. In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets. Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "bf0da804130241878073b33d36565f05", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[229, 229], [21, 21], [201, 201], [82, 82], [65, 65]], "char_spans": [[1255, 1257], [145, 147], [1119, 1121], [481, 483], [382, 384]]}]}], "context_tokens": [["Research", 0], ["is", 9], ["ongoing", 12], ["to", 20], ["develop", 23], ["multipurpose", 31], ["vaginal", 44], ["rings", 52], ["to", 58], ["be", 61], ["used", 64], ["continuously", 69], ["for", 82], ["contraception", 86], ["and", 100], ["to", 104], ["prevent", 107], ["Human", 115], ["Immunodeficiency", 121], ["Virus", 138], ["(", 144], ["HIV", 145], [")", 148], ["infection", 150], [".", 159], ["Contraceptive", 161], ["vaginal", 175], ["rings", 183], ["(", 189], ["CVRs", 190], [")", 194], ["are", 196], ["available", 200], ["in", 210], ["a", 213], ["number", 215], ["of", 222], ["countries", 225], ["and", 235], ["are", 239], ["most", 243], ["of", 248], ["the", 251], ["time", 255], ["used", 260], ["intermittently", 265], ["i.e.", 280], ["three", 285], ["weeks", 291], ["out", 297], ["of", 301], ["a", 304], ["4-week", 306], ["cycle", 313], [".", 318], ["Efficacy", 320], ["trials", 329], ["with", 336], ["a", 341], ["dapivirine", 343], ["-", 353], ["containing", 354], ["vaginal", 365], ["ring", 373], ["for", 378], ["HIV", 382], ["prevention", 386], ["are", 397], ["ongoing", 401], ["and", 409], ["plans", 413], ["to", 419], ["develop", 422], ["multi", 430], ["-", 435], ["purpose", 436], ["vaginal", 444], ["rings", 452], ["for", 458], ["prevention", 462], ["of", 473], ["both", 476], ["HIV", 481], ["and", 485], ["pregnancy", 489], ["have", 499], ["been", 504], ["elaborated", 509], [".", 519], ["In", 521], ["contrast", 524], ["with", 533], ["the", 538], ["CVRs", 542], [",", 546], ["multi", 548], ["-", 553], ["purpose", 554], ["vaginal", 562], ["rings", 570], ["will", 576], ["have", 581], ["to", 586], ["be", 589], ["used", 592], ["continuously", 597], [".", 609], ["Women", 611], ["who", 617], ["continuously", 621], ["use", 634], ["a", 638], ["CVR", 640], ["will", 644], ["no", 649], ["longer", 652], ["have", 659], ["menses", 664], [".", 670], ["Furthermore", 672], [",", 683], ["some", 685], ["safety", 690], ["aspects", 697], ["of", 705], ["CVR", 708], ["use", 712], ["have", 716], ["never", 721], ["been", 727], ["studied", 732], ["in", 740], ["-", 742], ["depth", 743], ["in", 749], ["the", 752], ["past", 756], [",", 760], ["such", 762], ["as", 767], ["the", 770], ["impact", 774], ["of", 781], ["the", 784], ["vaginal", 788], ["ring", 796], ["on", 801], ["the", 804], ["vaginal", 808], ["microbiota", 816], [",", 826], ["biofilm", 828], ["formation", 836], ["and", 846], ["induction", 850], ["of", 860], ["inflammation", 863], [".", 875], ["We", 877], ["studied", 880], ["acceptability", 888], ["and", 902], ["these", 906], ["novel", 912], ["aspects", 918], ["of", 926], ["safety", 929], ["in", 936], ["Rwandan", 939], ["women", 947], [".", 952], ["Although", 954], ["significant", 963], ["progress", 975], ["has", 984], ["been", 988], ["made", 993], ["over", 998], ["the", 1003], ["past", 1007], ["decade", 1012], [",", 1018], ["Rwanda", 1020], ["still", 1027], ["has", 1033], ["a", 1037], ["high", 1039], ["unmet", 1044], ["need", 1050], ["for", 1055], ["contraception", 1059], ["(", 1073], ["with", 1074], ["47", 1079], ["%", 1081], ["unplanned", 1083], ["births", 1093], [")", 1099], ["and", 1101], ["a", 1105], ["generalized", 1107], ["HIV", 1119], ["epidemic", 1123], [",", 1131], ["and", 1133], ["CVRs", 1137], ["are", 1142], ["not", 1146], ["yet", 1150], ["available", 1154], [".", 1163], ["We", 1165], ["will", 1168], ["conduct", 1173], ["an", 1181], ["open", 1184], ["label", 1189], [",", 1194], ["single", 1196], ["centre", 1203], [",", 1209], ["randomized", 1211], ["controlled", 1222], ["trial", 1233], [".", 1238], ["A", 1240], ["total", 1242], ["of", 1248], ["120", 1251], ["HIV", 1255], ["-", 1258], ["negative", 1259], ["women", 1268], ["will", 1274], ["be", 1279], ["randomized", 1282], ["to", 1293], ["intermittent", 1296], ["CVR", 1309], ["use", 1313], ["(", 1317], ["to", 1318], ["allow", 1321], ["menstruation", 1327], [")", 1339], ["or", 1341], ["continuous", 1344], ["CVR", 1355], ["use", 1359], [".", 1362], ["Women", 1364], ["will", 1370], ["be", 1375], ["followed", 1378], ["for", 1387], ["a", 1391], ["maximum", 1393], ["of", 1401], ["14", 1404], ["weeks", 1407], [".", 1412], ["In", 1414], ["parallel", 1417], [",", 1425], ["we", 1427], ["will", 1430], ["conduct", 1435], ["a", 1443], ["qualitative", 1445], ["study", 1457], ["using", 1463], ["in", 1469], ["-", 1471], ["depth", 1472], ["interview", 1478], ["and", 1488], ["focus", 1492], ["group", 1498], ["discussion", 1504], ["methodology", 1515], [".", 1526], ["In", 1528], ["addition", 1531], ["to", 1540], ["evaluating", 1543], ["the", 1554], ["safety", 1558], ["and", 1565], ["acceptability", 1569], ["of", 1583], ["intermittent", 1586], ["and", 1599], ["continuous", 1603], ["CVR", 1614], ["use", 1618], ["in", 1622], ["Rwandan", 1625], ["women", 1633], [",", 1638], ["we", 1640], ["hope", 1643], ["that", 1648], ["our", 1653], ["findings", 1657], ["will", 1666], ["inform", 1671], ["the", 1678], ["development", 1682], ["of", 1694], ["future", 1697], ["multipurpose", 1704], ["vaginal", 1717], ["rings", 1725], [",", 1730], ["will", 1732], ["prepare", 1737], ["Rwandan", 1745], ["study", 1753], ["populations", 1759], ["for", 1771], ["future", 1775], ["clinical", 1782], ["trials", 1791], ["of", 1798], ["multipurpose", 1801], ["vaginal", 1814], ["rings", 1822], [",", 1827], ["and", 1829], ["will", 1833], ["pave", 1838], ["the", 1843], ["way", 1847], ["for", 1851], ["introduction", 1855], ["of", 1868], ["CVRs", 1871], ["on", 1876], ["African", 1879], ["markets", 1887], [".", 1894], ["Clinicaltrials.gov", 1896], ["NCT01796613", 1915], [".", 1927], ["Registered", 1929], ["14", 1940], ["February", 1943], ["2013", 1952], [".", 1956]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract. We report a 58-year-old female with a history of a pigmented rash on her extremities, thick keratotic plaques on her hands, and brittle nails. Chest imaging revealed a right upper lobe mass that was proven to be small cell lung carcinoma. While Bazex syndrome has been described in the dermatology literature, it is also important for the radiologist to be aware of this entity and its common presentations.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "17fe85e739194ecda4e790b9d6224dc0", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[84, 85], [3, 4]], "char_spans": [[497, 510], [30, 43]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastic", 14], ["(", 29], ["Bazex", 30], ["syndrome", 36], [")", 44], ["is", 46], ["a", 49], ["rare", 51], [",", 55], ["but", 57], ["distinctive", 61], ["paraneoplastic", 73], ["dermatosis", 88], ["characterized", 99], ["by", 113], ["erythematosquamous", 116], ["lesions", 135], ["located", 143], ["at", 151], ["the", 154], ["acral", 158], ["sites", 164], ["and", 170], ["is", 174], ["most", 177], ["commonly", 182], ["associated", 191], ["with", 202], ["carcinomas", 207], ["of", 218], ["the", 221], ["upper", 225], ["aerodigestive", 231], ["tract", 245], [".", 250], ["We", 252], ["report", 255], ["a", 262], ["58-year", 264], ["-", 271], ["old", 272], ["female", 276], ["with", 283], ["a", 288], ["history", 290], ["of", 298], ["a", 301], ["pigmented", 303], ["rash", 313], ["on", 318], ["her", 321], ["extremities", 325], [",", 336], ["thick", 338], ["keratotic", 344], ["plaques", 354], ["on", 362], ["her", 365], ["hands", 369], [",", 374], ["and", 376], ["brittle", 380], ["nails", 388], [".", 393], ["Chest", 395], ["imaging", 401], ["revealed", 409], ["a", 418], ["right", 420], ["upper", 426], ["lobe", 432], ["mass", 437], ["that", 442], ["was", 447], ["proven", 451], ["to", 458], ["be", 461], ["small", 464], ["cell", 470], ["lung", 475], ["carcinoma", 480], [".", 489], ["While", 491], ["Bazex", 497], ["syndrome", 503], ["has", 512], ["been", 516], ["described", 521], ["in", 531], ["the", 534], ["dermatology", 538], ["literature", 550], [",", 560], ["it", 562], ["is", 565], ["also", 568], ["important", 573], ["for", 583], ["the", 587], ["radiologist", 591], ["to", 603], ["be", 606], ["aware", 609], ["of", 615], ["this", 618], ["entity", 623], ["and", 630], ["its", 634], ["common", 638], ["presentations", 645], [".", 658]]}
{"context": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 \u03bcg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4cf67c0ee39c479999455e6a1bb0566a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[40, 40], [208, 208], [111, 111], [66, 66]], "char_spans": [[215, 218], [1170, 1173], [574, 577], [358, 361]]}]}], "context_tokens": [["It", 0], ["was", 3], ["found", 7], ["in", 13], ["the", 16], ["present", 20], ["study", 28], ["that", 34], ["combined", 39], ["use", 48], ["of", 52], ["fusidic", 55], ["acid", 63], ["(", 68], ["FA", 69], [")", 71], ["and", 73], ["berberine", 77], ["chloride", 87], ["(", 96], ["BBR", 97], [")", 100], ["offered", 102], ["an", 110], ["in", 113], ["vitro", 116], ["synergistic", 122], ["action", 134], ["against", 141], ["7", 149], ["of", 151], ["the", 154], ["30", 158], ["clinical", 161], ["methicillin", 170], ["-", 181], ["resistant", 182], ["Staphylococcus", 192], ["aureus", 207], ["(", 214], ["MRSA", 215], [")", 219], ["strains", 221], [",", 228], ["with", 230], ["a", 235], ["fractional", 237], ["inhibitory", 248], ["concentration", 259], ["(", 273], ["FIC", 274], [")", 277], ["index", 279], ["ranging", 285], ["from", 293], ["0.5", 298], ["to", 302], ["0.19", 305], [".", 309], ["This", 311], ["synergistic", 316], ["effect", 328], ["was", 335], ["most", 339], ["pronounced", 344], ["on", 355], ["MRSA", 358], ["4806", 363], [",", 367], ["an", 369], ["FA", 372], ["-", 374], ["resistant", 375], ["isolate", 385], [",", 392], ["with", 394], ["a", 399], ["minimum", 401], ["inhibitory", 409], ["concentration", 420], ["(", 434], ["MIC", 435], [")", 438], ["value", 440], ["of", 446], ["1,024", 449], ["\u03bcg", 455], ["/", 457], ["ml", 458], [".", 460], ["The", 462], ["time", 466], ["-", 470], ["kill", 471], ["curve", 476], ["experiment", 482], ["showed", 493], ["that", 500], ["FA", 505], ["plus", 508], ["BBR", 513], ["yielded", 517], ["a", 525], ["4.2", 527], ["log10", 531], ["c.f.u./ml", 537], ["reduction", 547], ["in", 557], ["the", 560], ["number", 564], ["of", 571], ["MRSA", 574], ["4806", 579], ["bacteria", 584], ["after", 593], ["24-h", 599], ["incubation", 604], ["as", 615], ["compared", 618], ["with", 627], ["BBR", 632], ["alone", 636], [".", 641], ["Viable", 643], ["count", 650], ["analysis", 656], ["showed", 665], ["that", 672], ["FA", 677], ["plus", 680], ["BBR", 685], ["produced", 689], ["a", 698], ["3.0", 700], ["log10", 704], ["c.f.u./ml", 710], ["decrease", 720], ["in", 729], ["biofilm", 732], ["formation", 740], ["and", 750], ["a", 754], ["1.5", 756], ["log10", 760], ["c.f.u./ml", 766], ["decrease", 776], ["in", 785], ["mature", 788], ["biofilm", 795], ["in", 803], ["viable", 806], ["cell", 813], ["density", 818], ["as", 826], ["compared", 829], ["with", 838], ["BBR", 843], ["alone", 847], [".", 852], ["In", 854], ["addition", 857], [",", 865], ["phase", 867], ["contrast", 873], ["micrographs", 882], ["confirmed", 894], ["that", 904], ["biofilm", 909], ["formation", 917], ["was", 927], ["significantly", 931], ["inhibited", 945], ["and", 955], ["mature", 959], ["biofilm", 966], ["was", 974], ["obviously", 978], ["destructed", 988], ["when", 999], ["FA", 1004], ["was", 1007], ["used", 1011], ["in", 1016], ["combination", 1019], ["with", 1031], ["BBR", 1036], [".", 1039], ["These", 1041], ["results", 1047], ["provide", 1055], ["evidence", 1063], ["that", 1072], ["combined", 1077], ["use", 1086], ["of", 1090], ["FA", 1093], ["and", 1096], ["BBR", 1100], ["may", 1104], ["prove", 1108], ["to", 1114], ["be", 1117], ["a", 1120], ["promising", 1122], ["clinical", 1132], ["therapeutic", 1141], ["strategy", 1153], ["against", 1162], ["MRSA", 1170], [".", 1174]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "db7adf06a3c547ec93d26a22ee2e1de9", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [83, 83], [155, 155], [138, 138], [103, 103], [87, 87], [191, 191]], "char_spans": [[314, 316], [526, 528], [980, 982], [872, 874], [660, 662], [553, 555], [1198, 1200]]}]}], "context_tokens": [["Polyglutamine", 0], ["diseases", 14], [",", 22], ["including", 24], ["Huntington", 34], ["'s", 44], ["disease", 47], [",", 54], ["designate", 56], ["a", 66], ["group", 68], ["of", 74], ["nine", 77], ["neurodegenerative", 82], ["disorders", 100], ["characterized", 110], ["by", 124], ["the", 127], ["presence", 131], ["of", 140], ["a", 143], ["toxic", 145], ["polyglutamine", 151], ["expansion", 165], ["in", 175], ["specific", 178], ["target", 187], ["proteins", 194], [".", 202], ["Using", 204], ["cell", 210], ["and", 215], ["mouse", 219], ["models", 225], [",", 231], ["we", 233], ["have", 236], ["shown", 241], ["that", 247], ["expanded", 252], ["polyglutamine", 261], ["led", 275], ["to", 279], ["activation", 282], ["of", 293], ["the", 296], ["stress", 300], ["kinase", 307], ["JNK", 314], ["and", 318], ["the", 322], ["transcription", 326], ["factor", 340], ["AP-1", 347], [",", 351], ["which", 353], ["are", 359], ["implicated", 363], ["in", 374], ["neuronal", 377], ["death", 386], [".", 391], ["Polyglutamine", 393], ["expansion", 407], ["-", 416], ["induced", 417], ["stress", 425], ["shared", 432], ["common", 439], ["features", 446], ["with", 455], ["protein", 460], ["-", 467], ["damaging", 468], ["stress", 477], ["such", 484], ["as", 489], ["heat", 492], ["shock", 497], [",", 502], ["because", 504], ["activation", 512], ["of", 523], ["JNK", 526], ["involved", 530], ["inhibition", 539], ["of", 550], ["JNK", 553], ["phosphatase", 557], ["activities", 569], [".", 579], ["Indeed", 581], [",", 587], ["expanded", 589], ["polyglutamine", 598], ["impaired", 612], ["the", 621], ["solubility", 625], ["of", 636], ["the", 639], ["dual", 643], ["-", 647], ["specificity", 648], ["JNK", 660], ["phosphatase", 664], ["M3/6", 676], [".", 680], ["Aggregation", 682], ["of", 694], ["M3/6", 697], ["by", 702], ["polyglutamine", 705], ["expansion", 719], ["appeared", 729], ["to", 738], ["be", 741], ["indirect", 744], [",", 752], ["because", 754], ["M3/6", 762], ["was", 767], ["not", 771], ["recruited", 775], ["into", 785], ["polyglutamine", 790], ["inclusions", 804], [".", 814], ["The", 816], ["heat", 820], ["shock", 825], ["protein", 831], ["HSP70", 839], [",", 844], ["which", 846], ["is", 852], ["known", 855], ["to", 861], ["inhibit", 864], ["JNK", 872], ["during", 876], ["the", 883], ["heat", 887], ["shock", 892], ["response", 898], [",", 906], ["suppressed", 908], ["polyglutamine", 919], ["-", 932], ["mediated", 933], ["aggregation", 942], ["of", 954], ["M3/6", 957], ["and", 962], ["activation", 966], ["of", 977], ["JNK", 980], [".", 983], ["Interestingly", 985], [",", 998], ["levels", 1000], ["of", 1007], ["HSP70", 1010], ["were", 1016], ["down", 1021], ["-", 1025], ["regulated", 1026], ["by", 1036], ["polyglutamine", 1039], ["expansion", 1053], [".", 1062], ["We", 1064], ["suggest", 1067], ["that", 1075], ["reduction", 1080], ["of", 1090], ["HSP70", 1093], ["by", 1099], ["expanded", 1102], ["polyglutamine", 1111], ["is", 1125], ["implicated", 1128], ["in", 1139], ["aggregation", 1142], ["and", 1154], ["inhibition", 1158], ["of", 1169], ["M3/6", 1172], ["and", 1177], ["in", 1181], ["activation", 1184], ["of", 1195], ["JNK", 1198], ["and", 1202], ["AP-1", 1206], [".", 1210]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "Cyclosporine mediates its immunosuppressive effect by preventing the synthesis of lymphokine mRNA during the process of T lymphocyte activation. Although the detailed molecular mechanism by which CsA achieves this effect is unknown, two proteins have been identified as putative intracellular CsA-receptor proteins. One of these, calmodulin, is an important Ca++-binding protein and enzyme cofactor and the other, cyclophilin, is a novel protein that is reported to have protein kinase activity. In this study the CsA-binding capacity of both these proteins has been assessed using CsA-coated ELISA plates and CsA-affinity gel matrices. CsA binding was shown by cyclophilin whereas no CsA-calmodulin binding could be detected under identical conditions. However, it was not possible to demonstrate any cyclophilin-associated protein kinase activity. Jurkat cells were probed for the presence of CsA-binding proteins using the CsA-affinity gel matrix; a 17 KD protein, most probably cyclophilin, was identified as the major CsA-binding protein. In addition, a previously unidentified CsA-binding 45 KD phosphoprotein was precipitated from 32P-labeled Jurkat cells. These results would support cyclophilin as the major, if not only, intracellular receptor protein for CsA. However, the relationship between binding of CsA to cyclophilin and/or the 45 KD phosphoprotein and the immunosuppressive effects of CsA is still unknown.", "qas": [{"question": "Which is the receptor for the immunosuppressive drug cyclosporin A (CsA)?", "answers": ["cyclophilin"], "qid": "085511319724479098fd99f2b10f8fe5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["the", 26], ["immunosuppressive", 30], ["drug", 48], ["cyclosporin", 53], ["A", 65], ["(", 67], ["CsA", 68], [")", 71], ["?", 72]], "detected_answers": [{"text": "cyclophilin", "token_spans": [[170, 170], [230, 230], [65, 65], [136, 136], [113, 113], [207, 207]], "char_spans": [[982, 992], [1323, 1333], [414, 424], [802, 812], [662, 672], [1192, 1202]]}]}], "context_tokens": [["Cyclosporine", 0], ["mediates", 13], ["its", 22], ["immunosuppressive", 26], ["effect", 44], ["by", 51], ["preventing", 54], ["the", 65], ["synthesis", 69], ["of", 79], ["lymphokine", 82], ["mRNA", 93], ["during", 98], ["the", 105], ["process", 109], ["of", 117], ["T", 120], ["lymphocyte", 122], ["activation", 133], [".", 143], ["Although", 145], ["the", 154], ["detailed", 158], ["molecular", 167], ["mechanism", 177], ["by", 187], ["which", 190], ["CsA", 196], ["achieves", 200], ["this", 209], ["effect", 214], ["is", 221], ["unknown", 224], [",", 231], ["two", 233], ["proteins", 237], ["have", 246], ["been", 251], ["identified", 256], ["as", 267], ["putative", 270], ["intracellular", 279], ["CsA", 293], ["-", 296], ["receptor", 297], ["proteins", 306], [".", 314], ["One", 316], ["of", 320], ["these", 323], [",", 328], ["calmodulin", 330], [",", 340], ["is", 342], ["an", 345], ["important", 348], ["Ca++-binding", 358], ["protein", 371], ["and", 379], ["enzyme", 383], ["cofactor", 390], ["and", 399], ["the", 403], ["other", 407], [",", 412], ["cyclophilin", 414], [",", 425], ["is", 427], ["a", 430], ["novel", 432], ["protein", 438], ["that", 446], ["is", 451], ["reported", 454], ["to", 463], ["have", 466], ["protein", 471], ["kinase", 479], ["activity", 486], [".", 494], ["In", 496], ["this", 499], ["study", 504], ["the", 510], ["CsA", 514], ["-", 517], ["binding", 518], ["capacity", 526], ["of", 535], ["both", 538], ["these", 543], ["proteins", 549], ["has", 558], ["been", 562], ["assessed", 567], ["using", 576], ["CsA", 582], ["-", 585], ["coated", 586], ["ELISA", 593], ["plates", 599], ["and", 606], ["CsA", 610], ["-", 613], ["affinity", 614], ["gel", 623], ["matrices", 627], [".", 635], ["CsA", 637], ["binding", 641], ["was", 649], ["shown", 653], ["by", 659], ["cyclophilin", 662], ["whereas", 674], ["no", 682], ["CsA", 685], ["-", 688], ["calmodulin", 689], ["binding", 700], ["could", 708], ["be", 714], ["detected", 717], ["under", 726], ["identical", 732], ["conditions", 742], [".", 752], ["However", 754], [",", 761], ["it", 763], ["was", 766], ["not", 770], ["possible", 774], ["to", 783], ["demonstrate", 786], ["any", 798], ["cyclophilin", 802], ["-", 813], ["associated", 814], ["protein", 825], ["kinase", 833], ["activity", 840], [".", 848], ["Jurkat", 850], ["cells", 857], ["were", 863], ["probed", 868], ["for", 875], ["the", 879], ["presence", 883], ["of", 892], ["CsA", 895], ["-", 898], ["binding", 899], ["proteins", 907], ["using", 916], ["the", 922], ["CsA", 926], ["-", 929], ["affinity", 930], ["gel", 939], ["matrix", 943], [";", 949], ["a", 951], ["17", 953], ["KD", 956], ["protein", 959], [",", 966], ["most", 968], ["probably", 973], ["cyclophilin", 982], [",", 993], ["was", 995], ["identified", 999], ["as", 1010], ["the", 1013], ["major", 1017], ["CsA", 1023], ["-", 1026], ["binding", 1027], ["protein", 1035], [".", 1042], ["In", 1044], ["addition", 1047], [",", 1055], ["a", 1057], ["previously", 1059], ["unidentified", 1070], ["CsA", 1083], ["-", 1086], ["binding", 1087], ["45", 1095], ["KD", 1098], ["phosphoprotein", 1101], ["was", 1116], ["precipitated", 1120], ["from", 1133], ["32P", 1138], ["-", 1141], ["labeled", 1142], ["Jurkat", 1150], ["cells", 1157], [".", 1162], ["These", 1164], ["results", 1170], ["would", 1178], ["support", 1184], ["cyclophilin", 1192], ["as", 1204], ["the", 1207], ["major", 1211], [",", 1216], ["if", 1218], ["not", 1221], ["only", 1225], [",", 1229], ["intracellular", 1231], ["receptor", 1245], ["protein", 1254], ["for", 1262], ["CsA.", 1266], ["However", 1271], [",", 1278], ["the", 1280], ["relationship", 1284], ["between", 1297], ["binding", 1305], ["of", 1313], ["CsA", 1316], ["to", 1320], ["cyclophilin", 1323], ["and/or", 1335], ["the", 1342], ["45", 1346], ["KD", 1349], ["phosphoprotein", 1352], ["and", 1367], ["the", 1371], ["immunosuppressive", 1375], ["effects", 1393], ["of", 1401], ["CsA", 1404], ["is", 1408], ["still", 1411], ["unknown", 1417], [".", 1424]]}
{"context": "MicroRNAs (miRNAs) are 21 nt RNAs that regulate many biological processes in plants by mediating translational inhibition or cleavage of target transcripts. Arabidopsis mutants defective in miRNA biogenesis have overlapping and highly pleiotropic phenotypes including serrated leaves and ABA hypersensitivity. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II). Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels. Co-immunoprecipitation experiments revealed that pri-miRNAs 159, 166, 168 and 172 could be associated with CBP20 and CBP80. We found that CBP20 and CBP80 are stabilized by ABA by a post-translational mechanism, and these proteins are needed for ABA induction of miR159 during seed germination. The lack of miR159 accumulation in ABA-treated seeds of cbp20/80 mutants leads to increased MYB33 and MYB101 transcript levels, and presumably higher levels of these positive regulators result in ABA hypersensitivity. Genetic and molecular analyses show that CBP20 and 80 have overlapping function in the same developmental pathway as SE and HYL1. Our results identify new components in miRNA biogenesis.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "f8691bdd04254433a162cdef7998689e", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[53, 55]], "char_spans": [[372, 388]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["21", 23], ["nt", 26], ["RNAs", 29], ["that", 34], ["regulate", 39], ["many", 48], ["biological", 53], ["processes", 64], ["in", 74], ["plants", 77], ["by", 84], ["mediating", 87], ["translational", 97], ["inhibition", 111], ["or", 122], ["cleavage", 125], ["of", 134], ["target", 137], ["transcripts", 144], [".", 155], ["Arabidopsis", 157], ["mutants", 169], ["defective", 177], ["in", 187], ["miRNA", 190], ["biogenesis", 196], ["have", 207], ["overlapping", 212], ["and", 224], ["highly", 228], ["pleiotropic", 235], ["phenotypes", 247], ["including", 258], ["serrated", 268], ["leaves", 277], ["and", 284], ["ABA", 288], ["hypersensitivity", 292], [".", 308], ["Recent", 310], ["evidence", 317], ["indicates", 326], ["that", 336], ["miRNA", 341], ["genes", 347], ["are", 353], ["transcribed", 357], ["by", 369], ["RNA", 372], ["polymerase", 376], ["II", 387], ["(", 390], ["Pol", 391], ["II", 395], [")", 397], [".", 398], ["Since", 400], ["Pol", 406], ["II", 410], ["transcripts", 413], ["are", 425], ["capped", 429], [",", 435], ["we", 437], ["hypothesized", 440], ["that", 453], ["CBP", 458], ["(", 462], ["cap", 463], ["-", 466], ["binding", 467], ["protein", 475], [")", 482], ["20", 484], ["and", 487], ["80", 491], ["may", 494], ["bind", 498], ["to", 503], ["capped", 506], ["primary", 513], ["miRNA", 521], ["(", 527], ["pri", 528], ["-", 531], ["miRNA", 532], [")", 537], ["transcripts", 539], ["and", 551], ["play", 555], ["a", 560], ["role", 562], ["in", 567], ["their", 570], ["processing", 576], [".", 586], ["Here", 588], [",", 592], ["we", 594], ["show", 597], ["that", 602], ["cbp20", 607], ["and", 613], ["cbp80", 617], ["mutants", 623], ["have", 631], ["reduced", 636], ["miRNA", 644], ["levels", 650], ["and", 657], ["increased", 661], ["pri", 671], ["-", 674], ["miRNA", 675], ["levels", 681], [".", 687], ["Co", 689], ["-", 691], ["immunoprecipitation", 692], ["experiments", 712], ["revealed", 724], ["that", 733], ["pri", 738], ["-", 741], ["miRNAs", 742], ["159", 749], [",", 752], ["166", 754], [",", 757], ["168", 759], ["and", 763], ["172", 767], ["could", 771], ["be", 777], ["associated", 780], ["with", 791], ["CBP20", 796], ["and", 802], ["CBP80", 806], [".", 811], ["We", 813], ["found", 816], ["that", 822], ["CBP20", 827], ["and", 833], ["CBP80", 837], ["are", 843], ["stabilized", 847], ["by", 858], ["ABA", 861], ["by", 865], ["a", 868], ["post", 870], ["-", 874], ["translational", 875], ["mechanism", 889], [",", 898], ["and", 900], ["these", 904], ["proteins", 910], ["are", 919], ["needed", 923], ["for", 930], ["ABA", 934], ["induction", 938], ["of", 948], ["miR159", 951], ["during", 958], ["seed", 965], ["germination", 970], [".", 981], ["The", 983], ["lack", 987], ["of", 992], ["miR159", 995], ["accumulation", 1002], ["in", 1015], ["ABA", 1018], ["-", 1021], ["treated", 1022], ["seeds", 1030], ["of", 1036], ["cbp20/80", 1039], ["mutants", 1048], ["leads", 1056], ["to", 1062], ["increased", 1065], ["MYB33", 1075], ["and", 1081], ["MYB101", 1085], ["transcript", 1092], ["levels", 1103], [",", 1109], ["and", 1111], ["presumably", 1115], ["higher", 1126], ["levels", 1133], ["of", 1140], ["these", 1143], ["positive", 1149], ["regulators", 1158], ["result", 1169], ["in", 1176], ["ABA", 1179], ["hypersensitivity", 1183], [".", 1199], ["Genetic", 1201], ["and", 1209], ["molecular", 1213], ["analyses", 1223], ["show", 1232], ["that", 1237], ["CBP20", 1242], ["and", 1248], ["80", 1252], ["have", 1255], ["overlapping", 1260], ["function", 1272], ["in", 1281], ["the", 1284], ["same", 1288], ["developmental", 1293], ["pathway", 1307], ["as", 1315], ["SE", 1318], ["and", 1321], ["HYL1", 1325], [".", 1329], ["Our", 1331], ["results", 1335], ["identify", 1343], ["new", 1352], ["components", 1356], ["in", 1367], ["miRNA", 1370], ["biogenesis", 1376], [".", 1386]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML). Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients. Twelve chronic-phase patients initially receiving 400 mg/day and 4 patients with accelerated phase initially receiving either 400 mg/day (two patients) or 600 mg/day (two patients) had their dose increased (14 to 800 mg/day and 2 to 600 mg/day) because of progressive disease (usually clonal evolution) or inadequate cytogenetic response after at least 1 year of therapy. Six patients had major cytogenetic responses after dose increase (3 complete and 3 partial). Two others had minor cytogenetic responses. Two patients with clonal evolution transiently lost the additional clonal aberrations. Almost all of the responses occurred within 6 months, and were typically 3-6 months in duration. However, 3 patients have continuing major cytogenetic responses of >18 months duration. Dose increase was well tolerated, with thrombocytopenia, mild leukopenia, and exacerbation of prior edema being the most common adverse events. Although increasing the dose of imatinib can benefit a subgroup of patients with CML with either an inadequate cytogenetic response or disease progression, our results suggest the majority will not have a sustained meaningful response, and that other options, such as allogeneic stem cell transplant or investigational therapies, also need to be considered at the time of dose increase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "52dc16109e66480083c5d9ca84eb049e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[12, 14]], "char_spans": [[76, 82]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["tyrosine", 23], ["kinase", 32], ["inhibitor", 39], ["with", 49], ["high", 54], ["affinity", 59], ["for", 68], ["the", 72], ["BCR", 76], ["-", 79], ["ABL", 80], ["fusion", 84], ["protein", 91], ["expressed", 99], ["by", 109], ["the", 112], ["hematopoietic", 116], ["cells", 130], ["in", 136], ["chronic", 139], ["myelogenous", 147], ["leukemia", 159], ["(", 168], ["CML", 169], [")", 172], [".", 173], ["Some", 175], ["patients", 180], ["with", 189], ["chronic", 194], ["-", 201], ["phase", 202], ["or", 208], ["accelerated", 211], ["-", 222], ["phase", 223], ["CML", 229], ["either", 233], ["relapse", 240], ["after", 248], ["an", 254], ["initial", 257], ["response", 265], ["or", 274], ["are", 277], ["refractory", 281], ["to", 292], ["imatinib", 295], [",", 303], ["prompting", 305], ["us", 315], ["to", 318], ["evaluate", 321], ["the", 330], ["efficacy", 334], ["of", 343], ["dose", 346], ["increase", 351], ["in", 360], ["such", 363], ["patients", 368], [".", 376], ["Twelve", 378], ["chronic", 385], ["-", 392], ["phase", 393], ["patients", 399], ["initially", 408], ["receiving", 418], ["400", 428], ["mg", 432], ["/", 434], ["day", 435], ["and", 439], ["4", 443], ["patients", 445], ["with", 454], ["accelerated", 459], ["phase", 471], ["initially", 477], ["receiving", 487], ["either", 497], ["400", 504], ["mg", 508], ["/", 510], ["day", 511], ["(", 515], ["two", 516], ["patients", 520], [")", 528], ["or", 530], ["600", 533], ["mg", 537], ["/", 539], ["day", 540], ["(", 544], ["two", 545], ["patients", 549], [")", 557], ["had", 559], ["their", 563], ["dose", 569], ["increased", 574], ["(", 584], ["14", 585], ["to", 588], ["800", 591], ["mg", 595], ["/", 597], ["day", 598], ["and", 602], ["2", 606], ["to", 608], ["600", 611], ["mg", 615], ["/", 617], ["day", 618], [")", 621], ["because", 623], ["of", 631], ["progressive", 634], ["disease", 646], ["(", 654], ["usually", 655], ["clonal", 663], ["evolution", 670], [")", 679], ["or", 681], ["inadequate", 684], ["cytogenetic", 695], ["response", 707], ["after", 716], ["at", 722], ["least", 725], ["1", 731], ["year", 733], ["of", 738], ["therapy", 741], [".", 748], ["Six", 750], ["patients", 754], ["had", 763], ["major", 767], ["cytogenetic", 773], ["responses", 785], ["after", 795], ["dose", 801], ["increase", 806], ["(", 815], ["3", 816], ["complete", 818], ["and", 827], ["3", 831], ["partial", 833], [")", 840], [".", 841], ["Two", 843], ["others", 847], ["had", 854], ["minor", 858], ["cytogenetic", 864], ["responses", 876], [".", 885], ["Two", 887], ["patients", 891], ["with", 900], ["clonal", 905], ["evolution", 912], ["transiently", 922], ["lost", 934], ["the", 939], ["additional", 943], ["clonal", 954], ["aberrations", 961], [".", 972], ["Almost", 974], ["all", 981], ["of", 985], ["the", 988], ["responses", 992], ["occurred", 1002], ["within", 1011], ["6", 1018], ["months", 1020], [",", 1026], ["and", 1028], ["were", 1032], ["typically", 1037], ["3", 1047], ["-", 1048], ["6", 1049], ["months", 1051], ["in", 1058], ["duration", 1061], [".", 1069], ["However", 1071], [",", 1078], ["3", 1080], ["patients", 1082], ["have", 1091], ["continuing", 1096], ["major", 1107], ["cytogenetic", 1113], ["responses", 1125], ["of", 1135], [">", 1138], ["18", 1139], ["months", 1142], ["duration", 1149], [".", 1157], ["Dose", 1159], ["increase", 1164], ["was", 1173], ["well", 1177], ["tolerated", 1182], [",", 1191], ["with", 1193], ["thrombocytopenia", 1198], [",", 1214], ["mild", 1216], ["leukopenia", 1221], [",", 1231], ["and", 1233], ["exacerbation", 1237], ["of", 1250], ["prior", 1253], ["edema", 1259], ["being", 1265], ["the", 1271], ["most", 1275], ["common", 1280], ["adverse", 1287], ["events", 1295], [".", 1301], ["Although", 1303], ["increasing", 1312], ["the", 1323], ["dose", 1327], ["of", 1332], ["imatinib", 1335], ["can", 1344], ["benefit", 1348], ["a", 1356], ["subgroup", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["CML", 1384], ["with", 1388], ["either", 1393], ["an", 1400], ["inadequate", 1403], ["cytogenetic", 1414], ["response", 1426], ["or", 1435], ["disease", 1438], ["progression", 1446], [",", 1457], ["our", 1459], ["results", 1463], ["suggest", 1471], ["the", 1479], ["majority", 1483], ["will", 1492], ["not", 1497], ["have", 1501], ["a", 1506], ["sustained", 1508], ["meaningful", 1518], ["response", 1529], [",", 1537], ["and", 1539], ["that", 1543], ["other", 1548], ["options", 1554], [",", 1561], ["such", 1563], ["as", 1568], ["allogeneic", 1571], ["stem", 1582], ["cell", 1587], ["transplant", 1592], ["or", 1603], ["investigational", 1606], ["therapies", 1622], [",", 1631], ["also", 1633], ["need", 1638], ["to", 1643], ["be", 1646], ["considered", 1649], ["at", 1660], ["the", 1663], ["time", 1667], ["of", 1672], ["dose", 1675], ["increase", 1680], [".", 1688]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell aplasia characterized by normochromic macrocytic anemia, reticulocytopenia, and normocellular bone marrow with a selective deficiency of erythroid precursors. Ribosomal protein S19 (RPS19), currently the only gene associated with DBA, is mutated in 25% of DBA patients, but its role in erythropoiesis is unknown. We attempted to elucidate the importance of RPS19 in translation in relation to the pathogenesis of DBA. We measured translation and proliferation rates in unstimulated and phytohemagglutinin (PHA)-stimulated lymphocytes isolated from DBA patients, as well as in K562 cells expressing several RPS19 mutants to directly test the effect of RPS19 mutations on translation. The effect of leucine on overall translation was also studied. We found that the level of translation was on average 48-73% of controls in both unstimulated and PHA-activated DBA lymphocytes irrespective of mutations in RPS19. The addition of leucine increased the translational level in RPS19-non-mutated DBA cells, but not in cells with an RPS19 mutation. In unstimulated DBA cells, proliferation was significantly impaired in both RPS19-mutated and non-mutated cells, but in both groups could be efficiently activated by PHA. Studies on K562 cells showed that RPS19 mutations affecting RPS19 conserved arginines R56Q and R62Q could significantly inhibit the rate of protein synthesis, indicating the importance of RPS19 in translation. Our results indicate that inefficient translation may be the main cause of DBA, and administration of leucine may be beneficial for at least some DBA patients.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f06fc76bb7624c4ba8baf1c01fb0c0a8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[48, 48], [192, 192], [83, 83], [5, 5], [100, 100], [276, 276], [263, 263], [56, 56], [158, 158], [178, 178]], "char_spans": [[295, 297], [1122, 1124], [478, 480], [25, 27], [613, 615], [1633, 1635], [1562, 1564], [321, 323], [923, 925], [1054, 1056]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["pure", 51], ["red", 56], ["cell", 60], ["aplasia", 65], ["characterized", 73], ["by", 87], ["normochromic", 90], ["macrocytic", 103], ["anemia", 114], [",", 120], ["reticulocytopenia", 122], [",", 139], ["and", 141], ["normocellular", 145], ["bone", 159], ["marrow", 164], ["with", 171], ["a", 176], ["selective", 178], ["deficiency", 188], ["of", 199], ["erythroid", 202], ["precursors", 212], [".", 222], ["Ribosomal", 224], ["protein", 234], ["S19", 242], ["(", 246], ["RPS19", 247], [")", 252], [",", 253], ["currently", 255], ["the", 265], ["only", 269], ["gene", 274], ["associated", 279], ["with", 290], ["DBA", 295], [",", 298], ["is", 300], ["mutated", 303], ["in", 311], ["25", 314], ["%", 316], ["of", 318], ["DBA", 321], ["patients", 325], [",", 333], ["but", 335], ["its", 339], ["role", 343], ["in", 348], ["erythropoiesis", 351], ["is", 366], ["unknown", 369], [".", 376], ["We", 378], ["attempted", 381], ["to", 391], ["elucidate", 394], ["the", 404], ["importance", 408], ["of", 419], ["RPS19", 422], ["in", 428], ["translation", 431], ["in", 443], ["relation", 446], ["to", 455], ["the", 458], ["pathogenesis", 462], ["of", 475], ["DBA", 478], [".", 481], ["We", 483], ["measured", 486], ["translation", 495], ["and", 507], ["proliferation", 511], ["rates", 525], ["in", 531], ["unstimulated", 534], ["and", 547], ["phytohemagglutinin", 551], ["(", 570], ["PHA)-stimulated", 571], ["lymphocytes", 587], ["isolated", 599], ["from", 608], ["DBA", 613], ["patients", 617], [",", 625], ["as", 627], ["well", 630], ["as", 635], ["in", 638], ["K562", 641], ["cells", 646], ["expressing", 652], ["several", 663], ["RPS19", 671], ["mutants", 677], ["to", 685], ["directly", 688], ["test", 697], ["the", 702], ["effect", 706], ["of", 713], ["RPS19", 716], ["mutations", 722], ["on", 732], ["translation", 735], [".", 746], ["The", 748], ["effect", 752], ["of", 759], ["leucine", 762], ["on", 770], ["overall", 773], ["translation", 781], ["was", 793], ["also", 797], ["studied", 802], [".", 809], ["We", 811], ["found", 814], ["that", 820], ["the", 825], ["level", 829], ["of", 835], ["translation", 838], ["was", 850], ["on", 854], ["average", 857], ["48", 865], ["-", 867], ["73", 868], ["%", 870], ["of", 872], ["controls", 875], ["in", 884], ["both", 887], ["unstimulated", 892], ["and", 905], ["PHA", 909], ["-", 912], ["activated", 913], ["DBA", 923], ["lymphocytes", 927], ["irrespective", 939], ["of", 952], ["mutations", 955], ["in", 965], ["RPS19", 968], [".", 973], ["The", 975], ["addition", 979], ["of", 988], ["leucine", 991], ["increased", 999], ["the", 1009], ["translational", 1013], ["level", 1027], ["in", 1033], ["RPS19-non", 1036], ["-", 1045], ["mutated", 1046], ["DBA", 1054], ["cells", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["in", 1073], ["cells", 1076], ["with", 1082], ["an", 1087], ["RPS19", 1090], ["mutation", 1096], [".", 1104], ["In", 1106], ["unstimulated", 1109], ["DBA", 1122], ["cells", 1126], [",", 1131], ["proliferation", 1133], ["was", 1147], ["significantly", 1151], ["impaired", 1165], ["in", 1174], ["both", 1177], ["RPS19-mutated", 1182], ["and", 1196], ["non", 1200], ["-", 1203], ["mutated", 1204], ["cells", 1212], [",", 1217], ["but", 1219], ["in", 1223], ["both", 1226], ["groups", 1231], ["could", 1238], ["be", 1244], ["efficiently", 1247], ["activated", 1259], ["by", 1269], ["PHA", 1272], [".", 1275], ["Studies", 1277], ["on", 1285], ["K562", 1288], ["cells", 1293], ["showed", 1299], ["that", 1306], ["RPS19", 1311], ["mutations", 1317], ["affecting", 1327], ["RPS19", 1337], ["conserved", 1343], ["arginines", 1353], ["R56Q", 1363], ["and", 1368], ["R62Q", 1372], ["could", 1377], ["significantly", 1383], ["inhibit", 1397], ["the", 1405], ["rate", 1409], ["of", 1414], ["protein", 1417], ["synthesis", 1425], [",", 1434], ["indicating", 1436], ["the", 1447], ["importance", 1451], ["of", 1462], ["RPS19", 1465], ["in", 1471], ["translation", 1474], [".", 1485], ["Our", 1487], ["results", 1491], ["indicate", 1499], ["that", 1508], ["inefficient", 1513], ["translation", 1525], ["may", 1537], ["be", 1541], ["the", 1544], ["main", 1548], ["cause", 1553], ["of", 1559], ["DBA", 1562], [",", 1565], ["and", 1567], ["administration", 1571], ["of", 1586], ["leucine", 1589], ["may", 1597], ["be", 1601], ["beneficial", 1604], ["for", 1615], ["at", 1619], ["least", 1622], ["some", 1628], ["DBA", 1633], ["patients", 1637], [".", 1645]]}
{"context": "This case report is about an elderly man who presented with a long-standing history of high-grade fever and weight loss. He initially had only hepatosplenomegaly, but then developed jaundice. He also had pancytopenia and raised liver enzymes. His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus. The liver biopsy showed sinusoidal phagocytosis and the subsequent bone marrow aspiration and biopsy showed significant hemophagocytosis, hence Hemophagocytic syndrome was diagnosed. The fever was refractory to antibiotic and anti-tuberculosis therapy, but it responded only partially to steroids. Full response was only noticed following anti-viral treatment in the form of intravenous Ganciclovir. The patient's general condition, liver enzymes, bilirubin, hematological parameters and even the weight returned back to their normal range 2 weeks after Ganciclovir therapy. Cessation of this drug resulted in relapse of his symptoms and oral antivirals did not help. Splenectomy, steroid pulse therapy and immunosuppressive treatment were only partially helpful. Reintroduction of Ganciclovir did help for a short period. We conclude that our patient had virus-associated hemophagocytic syndrome most likely related to Epstein-Barr virus infection, which was then confirmed by the splenic biopsy, and that Ganciclovir can be of great help in eradicating the virus and treating the disease, provided that it is given for a long enough period.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "27f01386fc37446ab4eaa091c48db4f9", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[62, 65], [212, 215]], "char_spans": [[336, 353], [1276, 1293]]}]}], "context_tokens": [["This", 0], ["case", 5], ["report", 10], ["is", 17], ["about", 20], ["an", 26], ["elderly", 29], ["man", 37], ["who", 41], ["presented", 45], ["with", 55], ["a", 60], ["long", 62], ["-", 66], ["standing", 67], ["history", 76], ["of", 84], ["high", 87], ["-", 91], ["grade", 92], ["fever", 98], ["and", 104], ["weight", 108], ["loss", 115], [".", 119], ["He", 121], ["initially", 124], ["had", 134], ["only", 138], ["hepatosplenomegaly", 143], [",", 161], ["but", 163], ["then", 167], ["developed", 172], ["jaundice", 182], [".", 190], ["He", 192], ["also", 195], ["had", 200], ["pancytopenia", 204], ["and", 217], ["raised", 221], ["liver", 228], ["enzymes", 234], [".", 241], ["His", 243], ["septic", 247], ["screen", 254], ["was", 261], ["negative", 265], [",", 273], ["but", 275], ["he", 279], ["had", 282], ["a", 286], ["positive", 288], ["Monospot", 297], ["test", 306], ["and", 311], ["immunoglobulin", 315], ["G", 330], ["for", 332], ["Epstein", 336], ["-", 343], ["Barr", 344], ["virus", 349], [".", 354], ["The", 356], ["liver", 360], ["biopsy", 366], ["showed", 373], ["sinusoidal", 380], ["phagocytosis", 391], ["and", 404], ["the", 408], ["subsequent", 412], ["bone", 423], ["marrow", 428], ["aspiration", 435], ["and", 446], ["biopsy", 450], ["showed", 457], ["significant", 464], ["hemophagocytosis", 476], [",", 492], ["hence", 494], ["Hemophagocytic", 500], ["syndrome", 515], ["was", 524], ["diagnosed", 528], [".", 537], ["The", 539], ["fever", 543], ["was", 549], ["refractory", 553], ["to", 564], ["antibiotic", 567], ["and", 578], ["anti", 582], ["-", 586], ["tuberculosis", 587], ["therapy", 600], [",", 607], ["but", 609], ["it", 613], ["responded", 616], ["only", 626], ["partially", 631], ["to", 641], ["steroids", 644], [".", 652], ["Full", 654], ["response", 659], ["was", 668], ["only", 672], ["noticed", 677], ["following", 685], ["anti", 695], ["-", 699], ["viral", 700], ["treatment", 706], ["in", 716], ["the", 719], ["form", 723], ["of", 728], ["intravenous", 731], ["Ganciclovir", 743], [".", 754], ["The", 756], ["patient", 760], ["'s", 767], ["general", 770], ["condition", 778], [",", 787], ["liver", 789], ["enzymes", 795], [",", 802], ["bilirubin", 804], [",", 813], ["hematological", 815], ["parameters", 829], ["and", 840], ["even", 844], ["the", 849], ["weight", 853], ["returned", 860], ["back", 869], ["to", 874], ["their", 877], ["normal", 883], ["range", 890], ["2", 896], ["weeks", 898], ["after", 904], ["Ganciclovir", 910], ["therapy", 922], [".", 929], ["Cessation", 931], ["of", 941], ["this", 944], ["drug", 949], ["resulted", 954], ["in", 963], ["relapse", 966], ["of", 974], ["his", 977], ["symptoms", 981], ["and", 990], ["oral", 994], ["antivirals", 999], ["did", 1010], ["not", 1014], ["help", 1018], [".", 1022], ["Splenectomy", 1024], [",", 1035], ["steroid", 1037], ["pulse", 1045], ["therapy", 1051], ["and", 1059], ["immunosuppressive", 1063], ["treatment", 1081], ["were", 1091], ["only", 1096], ["partially", 1101], ["helpful", 1111], [".", 1118], ["Reintroduction", 1120], ["of", 1135], ["Ganciclovir", 1138], ["did", 1150], ["help", 1154], ["for", 1159], ["a", 1163], ["short", 1165], ["period", 1171], [".", 1177], ["We", 1179], ["conclude", 1182], ["that", 1191], ["our", 1196], ["patient", 1200], ["had", 1208], ["virus", 1212], ["-", 1217], ["associated", 1218], ["hemophagocytic", 1229], ["syndrome", 1244], ["most", 1253], ["likely", 1258], ["related", 1265], ["to", 1273], ["Epstein", 1276], ["-", 1283], ["Barr", 1284], ["virus", 1289], ["infection", 1295], [",", 1304], ["which", 1306], ["was", 1312], ["then", 1316], ["confirmed", 1321], ["by", 1331], ["the", 1334], ["splenic", 1338], ["biopsy", 1346], [",", 1352], ["and", 1354], ["that", 1358], ["Ganciclovir", 1363], ["can", 1375], ["be", 1379], ["of", 1382], ["great", 1385], ["help", 1391], ["in", 1396], ["eradicating", 1399], ["the", 1411], ["virus", 1415], ["and", 1421], ["treating", 1425], ["the", 1434], ["disease", 1438], [",", 1445], ["provided", 1447], ["that", 1456], ["it", 1461], ["is", 1464], ["given", 1467], ["for", 1473], ["a", 1477], ["long", 1479], ["enough", 1484], ["period", 1491], [".", 1497]]}
{"context": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome, a highly complex and dynamic macromolecular machine composed of RNA and protein. Because of its complexity, biochemical analysis of the spliceosome has been previously limited to bulk assays in largely unfractionated cell extracts. We now report development of methodologies for studying the splicing of isolated single pre-mRNA molecules in real time. In this system, a fluorescently tagged pre-mRNA is tethered to a glass surface via its 3'-end. Splicing can be observed in Saccharomyces cerevisiae whole cell extract by monitoring loss of intron-specific fluorescence with a multi-wavelength total internal reflection fluorescence (TIRF) microscope. To prolong fluorophore lifetime, two enzyme-based O2 scavenging systems compatible with splicing were also developed. This work provides a powerful new approach for elucidating the mechanisms of spliceosome function and demonstrates the feasibility of utilizing TIRF microscopy for biochemical studies of single molecules in highly complex environments.", "qas": [{"question": "What is the function of the spliceosome complex?", "answers": ["The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome."], "qid": "59b8dc15064f45a0b670dacf91a6101a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["the", 24], ["spliceosome", 28], ["complex", 40], ["?", 47]], "detected_answers": [{"text": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome.", "token_spans": [[1, 12]], "char_spans": [[4, 90]]}]}], "context_tokens": [["The", 0], ["excision", 4], ["of", 13], ["introns", 16], ["from", 24], ["nascent", 29], ["eukaryotic", 37], ["transcripts", 48], ["is", 60], ["catalyzed", 63], ["by", 73], ["the", 76], ["spliceosome", 80], [",", 91], ["a", 93], ["highly", 95], ["complex", 102], ["and", 110], ["dynamic", 114], ["macromolecular", 122], ["machine", 137], ["composed", 145], ["of", 154], ["RNA", 157], ["and", 161], ["protein", 165], [".", 172], ["Because", 174], ["of", 182], ["its", 185], ["complexity", 189], [",", 199], ["biochemical", 201], ["analysis", 213], ["of", 222], ["the", 225], ["spliceosome", 229], ["has", 241], ["been", 245], ["previously", 250], ["limited", 261], ["to", 269], ["bulk", 272], ["assays", 277], ["in", 284], ["largely", 287], ["unfractionated", 295], ["cell", 310], ["extracts", 315], [".", 323], ["We", 325], ["now", 328], ["report", 332], ["development", 339], ["of", 351], ["methodologies", 354], ["for", 368], ["studying", 372], ["the", 381], ["splicing", 385], ["of", 394], ["isolated", 397], ["single", 406], ["pre", 413], ["-", 416], ["mRNA", 417], ["molecules", 422], ["in", 432], ["real", 435], ["time", 440], [".", 444], ["In", 446], ["this", 449], ["system", 454], [",", 460], ["a", 462], ["fluorescently", 464], ["tagged", 478], ["pre", 485], ["-", 488], ["mRNA", 489], ["is", 494], ["tethered", 497], ["to", 506], ["a", 509], ["glass", 511], ["surface", 517], ["via", 525], ["its", 529], ["3'-end", 533], [".", 539], ["Splicing", 541], ["can", 550], ["be", 554], ["observed", 557], ["in", 566], ["Saccharomyces", 569], ["cerevisiae", 583], ["whole", 594], ["cell", 600], ["extract", 605], ["by", 613], ["monitoring", 616], ["loss", 627], ["of", 632], ["intron", 635], ["-", 641], ["specific", 642], ["fluorescence", 651], ["with", 664], ["a", 669], ["multi", 671], ["-", 676], ["wavelength", 677], ["total", 688], ["internal", 694], ["reflection", 703], ["fluorescence", 714], ["(", 727], ["TIRF", 728], [")", 732], ["microscope", 734], [".", 744], ["To", 746], ["prolong", 749], ["fluorophore", 757], ["lifetime", 769], [",", 777], ["two", 779], ["enzyme", 783], ["-", 789], ["based", 790], ["O2", 796], ["scavenging", 799], ["systems", 810], ["compatible", 818], ["with", 829], ["splicing", 834], ["were", 843], ["also", 848], ["developed", 853], [".", 862], ["This", 864], ["work", 869], ["provides", 874], ["a", 883], ["powerful", 885], ["new", 894], ["approach", 898], ["for", 907], ["elucidating", 911], ["the", 923], ["mechanisms", 927], ["of", 938], ["spliceosome", 941], ["function", 953], ["and", 962], ["demonstrates", 966], ["the", 979], ["feasibility", 983], ["of", 995], ["utilizing", 998], ["TIRF", 1008], ["microscopy", 1013], ["for", 1024], ["biochemical", 1028], ["studies", 1040], ["of", 1048], ["single", 1051], ["molecules", 1058], ["in", 1068], ["highly", 1071], ["complex", 1078], ["environments", 1086], [".", 1098]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus. Eleven cases were reported previously. We present 4 new patients and review one of the patients of the original report of Shprintzen and Goldberg [1982: J Craniofac Genet Dev Biol 2:65-74], 15 years later. The clinical and radiologic findings on our patients are compared with those of the previously reported patients and also with those of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224], who share many of the characteristics of Shprintzen-Goldberg syndrome. Some of the clinical data are helpful in determining if the patients of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224] have a separate syndrome or represent a variant of Shprintzen-Goldberg syndrome. However, radiologic investigations appear to be more specific, since an abnormality of the first and second cervical vertebrae, hydrocephalus, dilatation of the lateral ventricles, and a Chiari-I malformation of the brain were found only in the patients with Shprintzen-Goldberg syndrome. The apparently diagnostic findings of the 15 patients with this syndrome may be helpful in differentiating between Shprintzen-Goldberg syndrome and other syndromes with craniosynostosis and marfanoid habitus.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "3dfda990261e42298551bc5ea767d706", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[257, 257], [13, 13]], "char_spans": [[1356, 1371], [77, 92]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["is", 29], ["one", 32], ["of", 36], ["a", 39], ["group", 41], ["of", 47], ["disorders", 50], ["characterized", 60], ["by", 74], ["craniosynostosis", 77], ["and", 94], ["marfanoid", 98], ["habitus", 108], [".", 115], ["Eleven", 117], ["cases", 124], ["were", 130], ["reported", 135], ["previously", 144], [".", 154], ["We", 156], ["present", 159], ["4", 167], ["new", 169], ["patients", 173], ["and", 182], ["review", 186], ["one", 193], ["of", 197], ["the", 200], ["patients", 204], ["of", 213], ["the", 216], ["original", 220], ["report", 229], ["of", 236], ["Shprintzen", 239], ["and", 250], ["Goldberg", 254], ["[", 263], ["1982", 264], [":", 268], ["J", 270], ["Craniofac", 272], ["Genet", 282], ["Dev", 288], ["Biol", 292], ["2:65", 297], ["-", 301], ["74", 302], ["]", 304], [",", 305], ["15", 307], ["years", 310], ["later", 316], [".", 321], ["The", 323], ["clinical", 327], ["and", 336], ["radiologic", 340], ["findings", 351], ["on", 360], ["our", 363], ["patients", 367], ["are", 376], ["compared", 380], ["with", 389], ["those", 394], ["of", 400], ["the", 403], ["previously", 407], ["reported", 418], ["patients", 427], ["and", 436], ["also", 440], ["with", 445], ["those", 450], ["of", 456], ["Furlong", 459], ["et", 467], ["al", 470], [".", 472], ["[", 474], ["1987", 475], [":", 479], ["Am", 481], ["J", 484], ["Med", 486], ["Genet", 490], ["26:599", 496], ["-", 502], ["604", 503], ["]", 506], ["and", 508], ["Lacombe", 512], ["and", 520], ["Battin", 524], ["[", 531], ["1993", 532], [":", 536], ["Clin", 538], ["Dysmorphol", 543], ["2", 554], [":", 555], ["220", 557], ["-", 560], ["224", 561], ["]", 564], [",", 565], ["who", 567], ["share", 571], ["many", 577], ["of", 582], ["the", 585], ["characteristics", 589], ["of", 605], ["Shprintzen", 608], ["-", 618], ["Goldberg", 619], ["syndrome", 628], [".", 636], ["Some", 638], ["of", 643], ["the", 646], ["clinical", 650], ["data", 659], ["are", 664], ["helpful", 668], ["in", 676], ["determining", 679], ["if", 691], ["the", 694], ["patients", 698], ["of", 707], ["Furlong", 710], ["et", 718], ["al", 721], [".", 723], ["[", 725], ["1987", 726], [":", 730], ["Am", 732], ["J", 735], ["Med", 737], ["Genet", 741], ["26:599", 747], ["-", 753], ["604", 754], ["]", 757], ["and", 759], ["Lacombe", 763], ["and", 771], ["Battin", 775], ["[", 782], ["1993", 783], [":", 787], ["Clin", 789], ["Dysmorphol", 794], ["2", 805], [":", 806], ["220", 808], ["-", 811], ["224", 812], ["]", 815], ["have", 817], ["a", 822], ["separate", 824], ["syndrome", 833], ["or", 842], ["represent", 845], ["a", 855], ["variant", 857], ["of", 865], ["Shprintzen", 868], ["-", 878], ["Goldberg", 879], ["syndrome", 888], [".", 896], ["However", 898], [",", 905], ["radiologic", 907], ["investigations", 918], ["appear", 933], ["to", 940], ["be", 943], ["more", 946], ["specific", 951], [",", 959], ["since", 961], ["an", 967], ["abnormality", 970], ["of", 982], ["the", 985], ["first", 989], ["and", 995], ["second", 999], ["cervical", 1006], ["vertebrae", 1015], [",", 1024], ["hydrocephalus", 1026], [",", 1039], ["dilatation", 1041], ["of", 1052], ["the", 1055], ["lateral", 1059], ["ventricles", 1067], [",", 1077], ["and", 1079], ["a", 1083], ["Chiari", 1085], ["-", 1091], ["I", 1092], ["malformation", 1094], ["of", 1107], ["the", 1110], ["brain", 1114], ["were", 1120], ["found", 1125], ["only", 1131], ["in", 1136], ["the", 1139], ["patients", 1143], ["with", 1152], ["Shprintzen", 1157], ["-", 1167], ["Goldberg", 1168], ["syndrome", 1177], [".", 1185], ["The", 1187], ["apparently", 1191], ["diagnostic", 1202], ["findings", 1213], ["of", 1222], ["the", 1225], ["15", 1229], ["patients", 1232], ["with", 1241], ["this", 1246], ["syndrome", 1251], ["may", 1260], ["be", 1264], ["helpful", 1267], ["in", 1275], ["differentiating", 1278], ["between", 1294], ["Shprintzen", 1302], ["-", 1312], ["Goldberg", 1313], ["syndrome", 1322], ["and", 1331], ["other", 1335], ["syndromes", 1341], ["with", 1351], ["craniosynostosis", 1356], ["and", 1373], ["marfanoid", 1377], ["habitus", 1387], [".", 1394]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "N6-methyladenosine (m6A) is a common modification of mRNA with potential roles in fine-tuning the RNA life cycle. Here, we identify a dense network of proteins interacting with METTL3, a component of the methyltransferase complex, and show that three of them (WTAP, METTL14, and KIAA1429) are required for methylation. Monitoring m6A levels upon WTAP depletion allowed the definition of accurate and near single-nucleotide resolution methylation maps and their classification into WTAP-dependent and -independent sites. WTAP-dependent sites are located at internal positions in transcripts, topologically static across a variety of systems we surveyed, and inversely correlated with mRNA stability, consistent with a role in establishing \"basal\" degradation rates. WTAP-independent sites form at the first transcribed base as part of the cap structure and are present at thousands of sites, forming a previously unappreciated layer of transcriptome complexity. Our data shed light on the proteomic and transcriptional underpinnings of this RNA modification.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "c3596cdec1b2483b889a950b0ae18039", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[117, 118]], "char_spans": [[683, 696]]}]}], "context_tokens": [["N6-methyladenosine", 0], ["(", 19], ["m6A", 20], [")", 23], ["is", 25], ["a", 28], ["common", 30], ["modification", 37], ["of", 50], ["mRNA", 53], ["with", 58], ["potential", 63], ["roles", 73], ["in", 79], ["fine", 82], ["-", 86], ["tuning", 87], ["the", 94], ["RNA", 98], ["life", 102], ["cycle", 107], [".", 112], ["Here", 114], [",", 118], ["we", 120], ["identify", 123], ["a", 132], ["dense", 134], ["network", 140], ["of", 148], ["proteins", 151], ["interacting", 160], ["with", 172], ["METTL3", 177], [",", 183], ["a", 185], ["component", 187], ["of", 197], ["the", 200], ["methyltransferase", 204], ["complex", 222], [",", 229], ["and", 231], ["show", 235], ["that", 240], ["three", 245], ["of", 251], ["them", 254], ["(", 259], ["WTAP", 260], [",", 264], ["METTL14", 266], [",", 273], ["and", 275], ["KIAA1429", 279], [")", 287], ["are", 289], ["required", 293], ["for", 302], ["methylation", 306], [".", 317], ["Monitoring", 319], ["m6A", 330], ["levels", 334], ["upon", 341], ["WTAP", 346], ["depletion", 351], ["allowed", 361], ["the", 369], ["definition", 373], ["of", 384], ["accurate", 387], ["and", 396], ["near", 400], ["single", 405], ["-", 411], ["nucleotide", 412], ["resolution", 423], ["methylation", 434], ["maps", 446], ["and", 451], ["their", 455], ["classification", 461], ["into", 476], ["WTAP", 481], ["-", 485], ["dependent", 486], ["and", 496], ["-independent", 500], ["sites", 513], [".", 518], ["WTAP", 520], ["-", 524], ["dependent", 525], ["sites", 535], ["are", 541], ["located", 545], ["at", 553], ["internal", 556], ["positions", 565], ["in", 575], ["transcripts", 578], [",", 589], ["topologically", 591], ["static", 605], ["across", 612], ["a", 619], ["variety", 621], ["of", 629], ["systems", 632], ["we", 640], ["surveyed", 643], [",", 651], ["and", 653], ["inversely", 657], ["correlated", 667], ["with", 678], ["mRNA", 683], ["stability", 688], [",", 697], ["consistent", 699], ["with", 710], ["a", 715], ["role", 717], ["in", 722], ["establishing", 725], ["\"", 738], ["basal", 739], ["\"", 744], ["degradation", 746], ["rates", 758], [".", 763], ["WTAP", 765], ["-", 769], ["independent", 770], ["sites", 782], ["form", 788], ["at", 793], ["the", 796], ["first", 800], ["transcribed", 806], ["base", 818], ["as", 823], ["part", 826], ["of", 831], ["the", 834], ["cap", 838], ["structure", 842], ["and", 852], ["are", 856], ["present", 860], ["at", 868], ["thousands", 871], ["of", 881], ["sites", 884], [",", 889], ["forming", 891], ["a", 899], ["previously", 901], ["unappreciated", 912], ["layer", 926], ["of", 932], ["transcriptome", 935], ["complexity", 949], [".", 959], ["Our", 961], ["data", 965], ["shed", 970], ["light", 975], ["on", 981], ["the", 984], ["proteomic", 988], ["and", 998], ["transcriptional", 1002], ["underpinnings", 1018], ["of", 1032], ["this", 1035], ["RNA", 1040], ["modification", 1044], [".", 1056]]}
{"context": "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR (Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent M. tuberculosis infection. In silico analysis of the DosR regulon in BCG and M. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens. Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding selected latency antigens. Since immune responses to TB latency antigens have been associated with control of latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating DosR regulon antigens to complement and improve the current BCG vaccine.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "f40c5ca38b964c3fbfd353444320a3b9", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[116, 117]], "char_spans": [[695, 702]]}]}], "context_tokens": [["Mycobacterium", 0], ["bovis", 14], ["BCG", 20], ["is", 24], ["widely", 27], ["used", 34], ["as", 39], ["a", 42], ["vaccine", 44], ["against", 52], ["tuberculosis", 60], ["(", 73], ["TB", 74], [")", 76], [",", 77], ["despite", 79], ["its", 87], ["variable", 91], ["protective", 100], ["efficacy", 111], [".", 119], ["Relatively", 121], ["little", 132], ["is", 139], ["known", 142], ["about", 148], ["the", 154], ["immune", 158], ["response", 165], ["profiles", 174], ["following", 183], ["BCG", 193], ["vaccination", 197], ["in", 209], ["relation", 212], ["to", 221], ["protection", 224], ["against", 235], ["TB", 243], [".", 245], ["Here", 247], ["we", 252], ["tested", 255], ["whether", 262], ["BCG", 270], ["vaccination", 274], ["results", 286], ["in", 294], ["immune", 297], ["responses", 304], ["to", 314], ["DosR", 317], ["(", 322], ["Rv3133c", 323], [")", 330], ["regulon", 332], ["-", 339], ["encoded", 340], ["proteins", 348], [".", 356], ["These", 358], ["so", 364], ["-", 366], ["called", 367], ["TB", 374], ["latency", 377], ["antigens", 385], ["are", 394], ["targeted", 398], ["by", 407], ["the", 410], ["immune", 414], ["system", 421], ["during", 428], ["persistent", 435], ["Mycobacterium", 446], ["tuberculosis", 460], ["infection", 473], ["and", 483], ["have", 487], ["been", 492], ["associated", 497], ["with", 508], ["immunity", 513], ["against", 522], ["latent", 530], ["M.", 537], ["tuberculosis", 540], ["infection", 553], [".", 562], ["In", 564], ["silico", 567], ["analysis", 574], ["of", 583], ["the", 586], ["DosR", 590], ["regulon", 595], ["in", 603], ["BCG", 606], ["and", 610], ["M.", 614], ["tuberculosis", 617], ["showed", 630], ["at", 637], ["least", 640], ["97", 646], ["%", 648], ["amino", 650], ["acid", 656], ["sequence", 661], ["homology", 670], [",", 678], ["with", 680], ["41", 685], ["out", 688], ["of", 692], ["48", 695], ["genes", 698], ["being", 704], ["identical", 710], [".", 719], ["Transcriptional", 721], ["profiling", 737], ["of", 747], ["14", 750], ["different", 753], ["BCG", 763], ["strains", 767], [",", 774], ["under", 776], ["hypoxia", 782], ["and", 790], ["nitric", 794], ["oxide", 801], ["exposure", 807], ["in", 816], ["vitro", 819], [",", 824], ["revealed", 826], ["a", 835], ["functional", 837], ["DosR", 848], ["regulon", 853], ["similar", 861], ["to", 869], ["that", 872], ["observed", 877], ["in", 886], ["M.", 889], ["tuberculosis", 892], [".", 904], ["Next", 906], [",", 910], ["we", 912], ["assessed", 915], ["human", 924], ["immune", 930], ["responses", 937], ["to", 947], ["a", 950], ["series", 952], ["of", 959], ["immunodominant", 962], ["TB", 977], ["latency", 980], ["antigens", 988], ["and", 997], ["found", 1001], ["that", 1007], ["BCG", 1012], ["vaccination", 1016], ["fails", 1028], ["to", 1034], ["induce", 1037], ["significant", 1044], ["responses", 1056], ["to", 1066], ["latency", 1069], ["antigens", 1077], [".", 1085], ["Similar", 1087], ["results", 1095], ["were", 1103], ["obtained", 1108], ["with", 1117], ["BCG", 1122], ["-", 1125], ["vaccinated", 1126], ["BALB", 1137], ["/", 1141], ["c", 1142], ["mice", 1144], [".", 1148], ["In", 1150], ["contrast", 1153], [",", 1161], ["responses", 1163], ["to", 1173], ["latency", 1176], ["antigens", 1184], ["were", 1193], ["observed", 1198], ["in", 1207], ["individuals", 1210], ["with", 1222], ["suspected", 1227], ["exposure", 1237], ["to", 1246], ["TB", 1249], ["(", 1252], ["as", 1253], ["indicated", 1256], ["by", 1266], ["positive", 1269], ["gamma", 1278], ["interferon", 1284], ["responses", 1295], ["to", 1305], ["TB", 1308], ["-", 1310], ["specific", 1311], ["antigens", 1320], ["ESAT-6", 1329], ["and", 1336], ["CFP-10", 1340], [")", 1346], ["and", 1348], ["in", 1352], ["mice", 1355], ["vaccinated", 1360], ["with", 1371], ["plasmid", 1376], ["DNA", 1384], ["encoding", 1388], ["selected", 1397], ["latency", 1406], ["antigens", 1414], [".", 1422], ["Since", 1424], ["immune", 1430], ["responses", 1437], ["to", 1447], ["TB", 1450], ["latency", 1453], ["antigens", 1461], ["have", 1470], ["been", 1475], ["associated", 1480], ["with", 1491], ["control", 1496], ["of", 1504], ["latent", 1507], ["M.", 1514], ["tuberculosis", 1517], ["infection", 1530], [",", 1539], ["our", 1541], ["findings", 1545], ["support", 1554], ["the", 1562], ["development", 1566], ["of", 1578], ["vaccination", 1581], ["strategies", 1593], ["incorporating", 1604], ["DosR", 1618], ["regulon", 1623], ["antigens", 1631], ["to", 1640], ["complement", 1643], ["and", 1654], ["improve", 1658], ["the", 1666], ["current", 1670], ["BCG", 1678], ["vaccine", 1682], [".", 1689]]}
{"context": "Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence. Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA) show superior specificity and sensitivity but are more expensive. The present study reports the results of a three-year TB surveillance among HCW in a large teaching hospital in Rome, using TST (by standard Mantoux technique) and IGRA (by QuantiFERON-TB) as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99 (70.2%) underwent the IGRA and 16 tested positive (16.1%). The frequency of HCW tested positive for TB seems not far from other experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo X-ray diagnosis and/or chemotherapy.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "62a1183be31d4c208669a471c24c419c", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12]], "char_spans": [[64, 75]]}]}], "context_tokens": [["Health", 0], ["care", 7], ["workers", 12], ["(", 20], ["HCW", 21], [")", 24], ["are", 26], ["particularly", 30], ["at", 43], ["risk", 46], ["of", 51], ["acquiring", 54], ["tuberculosis", 64], ["(", 77], ["TB", 78], [")", 80], [",", 81], ["even", 83], ["in", 88], ["countries", 91], ["with", 101], ["low", 106], ["TB", 110], ["incidence", 113], [".", 122], ["Therefore", 124], [",", 133], ["TB", 135], ["screening", 138], ["in", 148], ["HCW", 151], ["is", 155], ["a", 158], ["useful", 160], ["prevention", 167], ["strategy", 178], ["in", 187], ["countries", 190], ["with", 200], ["both", 205], ["low", 210], ["and", 214], ["high", 218], ["TB", 223], ["incidence", 226], [".", 235], ["Tuberculin", 237], ["skin", 248], ["test", 253], ["(", 258], ["TST", 259], [")", 262], ["is", 264], ["widely", 267], ["used", 274], ["although", 279], ["it", 288], ["suffers", 291], ["of", 299], ["low", 302], ["specificity", 306], [";", 317], ["on", 319], ["the", 322], ["contrary", 326], [",", 334], ["the", 336], ["in", 340], ["vitro", 343], ["enzyme", 349], ["immunoassay", 356], ["tests", 368], ["(", 374], ["IGRA", 375], [")", 379], ["show", 381], ["superior", 386], ["specificity", 395], ["and", 407], ["sensitivity", 411], ["but", 423], ["are", 427], ["more", 431], ["expensive", 436], [".", 445], ["The", 447], ["present", 451], ["study", 459], ["reports", 465], ["the", 473], ["results", 477], ["of", 485], ["a", 488], ["three", 490], ["-", 495], ["year", 496], ["TB", 501], ["surveillance", 504], ["among", 517], ["HCW", 523], ["in", 527], ["a", 530], ["large", 532], ["teaching", 538], ["hospital", 547], ["in", 556], ["Rome", 559], [",", 563], ["using", 565], ["TST", 571], ["(", 575], ["by", 576], ["standard", 579], ["Mantoux", 588], ["technique", 596], [")", 605], ["and", 607], ["IGRA", 611], ["(", 616], ["by", 617], ["QuantiFERON", 620], ["-", 631], ["TB", 632], [")", 634], ["as", 636], ["first-", 639], ["and", 646], ["second", 650], ["-", 656], ["level", 657], ["screening", 663], ["tests", 673], [",", 678], ["respectively", 680], [".", 692], ["Out", 694], ["of", 698], ["2290", 701], ["HCW", 706], ["enrolled", 710], [",", 718], ["141", 720], ["(", 724], ["6.1", 725], ["%", 728], [")", 729], ["had", 731], ["a", 735], ["positive", 737], ["TST", 746], [";", 749], ["among", 751], ["them", 757], [",", 761], ["99", 763], ["(", 766], ["70.2", 767], ["%", 771], [")", 772], ["underwent", 774], ["the", 784], ["IGRA", 788], ["and", 793], ["16", 797], ["tested", 800], ["positive", 807], ["(", 816], ["16.1", 817], ["%", 821], [")", 822], [".", 823], ["The", 825], ["frequency", 829], ["of", 839], ["HCW", 842], ["tested", 846], ["positive", 853], ["for", 862], ["TB", 866], ["seems", 869], ["not", 875], ["far", 879], ["from", 883], ["other", 888], ["experiences", 894], ["in", 906], ["low", 909], ["incidence", 913], ["countries", 923], [".", 932], ["Our", 934], ["results", 938], ["confirm", 946], ["the", 954], ["higher", 958], ["specificity", 965], ["of", 977], ["IGRA", 980], [",", 984], ["but", 986], [",", 989], ["due", 991], ["to", 995], ["its", 998], ["higher", 1002], ["cost", 1009], [",", 1013], ["TST", 1015], ["can", 1019], ["be", 1023], ["considered", 1026], ["a", 1037], ["good", 1039], ["first", 1044], ["level", 1050], ["screening", 1056], ["test", 1066], [",", 1070], ["whose", 1072], ["positive", 1078], ["results", 1087], ["should", 1095], ["be", 1102], ["further", 1105], ["confirmed", 1113], ["by", 1123], ["IGRA", 1126], ["before", 1131], ["the", 1138], ["patients", 1142], ["undergo", 1151], ["X", 1159], ["-", 1160], ["ray", 1161], ["diagnosis", 1165], ["and/or", 1175], ["chemotherapy", 1182], [".", 1194]]}
{"context": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK. It explores the different strains of MRSA and points out the main ways to control their spread. It is intended to be a reference source for all nurses.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2227001cc02f46f4b3d6c776d15071cd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[37, 37], [10, 10]], "char_spans": [[203, 206], [72, 75]]}]}], "context_tokens": [["This", 0], ["article", 5], ["explains", 13], ["what", 22], ["methicillin", 27], ["-", 38], ["resistant", 39], ["Staphylococcus", 49], ["aureus", 64], ["(", 71], ["MRSA", 72], [")", 76], ["is", 78], [",", 80], ["how", 82], ["it", 86], ["is", 89], ["spread", 92], ["and", 99], ["what", 103], ["the", 108], ["real", 112], ["challenges", 117], ["are", 128], ["in", 132], ["healthcare", 135], ["settings", 146], ["in", 155], ["the", 158], ["UK", 162], [".", 164], ["It", 166], ["explores", 169], ["the", 178], ["different", 182], ["strains", 192], ["of", 200], ["MRSA", 203], ["and", 208], ["points", 212], ["out", 219], ["the", 223], ["main", 227], ["ways", 232], ["to", 237], ["control", 240], ["their", 248], ["spread", 254], [".", 260], ["It", 262], ["is", 265], ["intended", 268], ["to", 277], ["be", 280], ["a", 283], ["reference", 285], ["source", 295], ["for", 302], ["all", 306], ["nurses", 310], [".", 316]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "The ESC-E(Z) complex of Drosophila melanogaster Polycomb group (PcG) repressors is a histone H3 methyltransferase (HMTase). This complex silences fly Hox genes, and related HMTases control germ line development in worms, flowering in plants, and X inactivation in mammals. The fly complex contains a catalytic SET domain subunit, E(Z), plus three noncatalytic subunits, SU(Z)12, ESC, and NURF-55. The four-subunit complex is >1,000-fold more active than E(Z) alone. Here we show that ESC and SU(Z)12 play key roles in potentiating E(Z) HMTase activity. We also show that loss of ESC disrupts global methylation of histone H3-lysine 27 in fly embryos. Subunit mutations identify domains required for catalytic activity and/or binding to specific partners. We describe missense mutations in surface loops of ESC, in the CXC domain of E(Z), and in the conserved VEFS domain of SU(Z)12, which each disrupt HMTase activity but preserve complex assembly. Thus, the E(Z) SET domain requires multiple partner inputs to produce active HMTase. We also find that a recombinant worm complex containing the E(Z) homolog, MES-2, has robust HMTase activity, which depends upon both MES-6, an ESC homolog, and MES-3, a pioneer protein. Thus, although the fly and mammalian PcG complexes absolutely require SU(Z)12, the worm complex generates HMTase activity from a distinct partner set.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "455d3e2bfca04bab969414f28100925b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[57, 58], [182, 183]], "char_spans": [[310, 319], [964, 973]]}]}], "context_tokens": [["The", 0], ["ESC", 4], ["-", 7], ["E(Z", 8], [")", 11], ["complex", 13], ["of", 21], ["Drosophila", 24], ["melanogaster", 35], ["Polycomb", 48], ["group", 57], ["(", 63], ["PcG", 64], [")", 67], ["repressors", 69], ["is", 80], ["a", 83], ["histone", 85], ["H3", 93], ["methyltransferase", 96], ["(", 114], ["HMTase", 115], [")", 121], [".", 122], ["This", 124], ["complex", 129], ["silences", 137], ["fly", 146], ["Hox", 150], ["genes", 154], [",", 159], ["and", 161], ["related", 165], ["HMTases", 173], ["control", 181], ["germ", 189], ["line", 194], ["development", 199], ["in", 211], ["worms", 214], [",", 219], ["flowering", 221], ["in", 231], ["plants", 234], [",", 240], ["and", 242], ["X", 246], ["inactivation", 248], ["in", 261], ["mammals", 264], [".", 271], ["The", 273], ["fly", 277], ["complex", 281], ["contains", 289], ["a", 298], ["catalytic", 300], ["SET", 310], ["domain", 314], ["subunit", 321], [",", 328], ["E(Z", 330], [")", 333], [",", 334], ["plus", 336], ["three", 341], ["noncatalytic", 347], ["subunits", 360], [",", 368], ["SU(Z)12", 370], [",", 377], ["ESC", 379], [",", 382], ["and", 384], ["NURF-55", 388], [".", 395], ["The", 397], ["four", 401], ["-", 405], ["subunit", 406], ["complex", 414], ["is", 422], [">", 425], ["1,000-fold", 426], ["more", 437], ["active", 442], ["than", 449], ["E(Z", 454], [")", 457], ["alone", 459], [".", 464], ["Here", 466], ["we", 471], ["show", 474], ["that", 479], ["ESC", 484], ["and", 488], ["SU(Z)12", 492], ["play", 500], ["key", 505], ["roles", 509], ["in", 515], ["potentiating", 518], ["E(Z", 531], [")", 534], ["HMTase", 536], ["activity", 543], [".", 551], ["We", 553], ["also", 556], ["show", 561], ["that", 566], ["loss", 571], ["of", 576], ["ESC", 579], ["disrupts", 583], ["global", 592], ["methylation", 599], ["of", 611], ["histone", 614], ["H3-lysine", 622], ["27", 632], ["in", 635], ["fly", 638], ["embryos", 642], [".", 649], ["Subunit", 651], ["mutations", 659], ["identify", 669], ["domains", 678], ["required", 686], ["for", 695], ["catalytic", 699], ["activity", 709], ["and/or", 718], ["binding", 725], ["to", 733], ["specific", 736], ["partners", 745], [".", 753], ["We", 755], ["describe", 758], ["missense", 767], ["mutations", 776], ["in", 786], ["surface", 789], ["loops", 797], ["of", 803], ["ESC", 806], [",", 809], ["in", 811], ["the", 814], ["CXC", 818], ["domain", 822], ["of", 829], ["E(Z", 832], [")", 835], [",", 836], ["and", 838], ["in", 842], ["the", 845], ["conserved", 849], ["VEFS", 859], ["domain", 864], ["of", 871], ["SU(Z)12", 874], [",", 881], ["which", 883], ["each", 889], ["disrupt", 894], ["HMTase", 902], ["activity", 909], ["but", 918], ["preserve", 922], ["complex", 931], ["assembly", 939], [".", 947], ["Thus", 949], [",", 953], ["the", 955], ["E(Z", 959], [")", 962], ["SET", 964], ["domain", 968], ["requires", 975], ["multiple", 984], ["partner", 993], ["inputs", 1001], ["to", 1008], ["produce", 1011], ["active", 1019], ["HMTase", 1026], [".", 1032], ["We", 1034], ["also", 1037], ["find", 1042], ["that", 1047], ["a", 1052], ["recombinant", 1054], ["worm", 1066], ["complex", 1071], ["containing", 1079], ["the", 1090], ["E(Z", 1094], [")", 1097], ["homolog", 1099], [",", 1106], ["MES-2", 1108], [",", 1113], ["has", 1115], ["robust", 1119], ["HMTase", 1126], ["activity", 1133], [",", 1141], ["which", 1143], ["depends", 1149], ["upon", 1157], ["both", 1162], ["MES-6", 1167], [",", 1172], ["an", 1174], ["ESC", 1177], ["homolog", 1181], [",", 1188], ["and", 1190], ["MES-3", 1194], [",", 1199], ["a", 1201], ["pioneer", 1203], ["protein", 1211], [".", 1218], ["Thus", 1220], [",", 1224], ["although", 1226], ["the", 1235], ["fly", 1239], ["and", 1243], ["mammalian", 1247], ["PcG", 1257], ["complexes", 1261], ["absolutely", 1271], ["require", 1282], ["SU(Z)12", 1290], [",", 1297], ["the", 1299], ["worm", 1303], ["complex", 1308], ["generates", 1316], ["HMTase", 1326], ["activity", 1333], ["from", 1342], ["a", 1347], ["distinct", 1349], ["partner", 1358], ["set", 1366], [".", 1369]]}
{"context": "The classical view of the molecular clock is based on interlocked transcriptional-translational feedback loops. Because a substantial fraction of the mammalian genome is expressed in a circadian manner, chromatin remodeling has been proposed to be crucial in clock function. Here we show that Lys4 (K4) trimethylation of histone H3 is rhythmic and follows the same profile as previously described H3 acetylation on circadian promoters. MLL1, a mammalian homolog of Drosophila trithorax, is an H3K4-specific methyltransferase implicated in transcriptional control. We demonstrate that MLL1 is essential for circadian transcription and cyclic H3K4 trimethylation. MLL1 is in a complex with CLOCK-BMAL1 and contributes to its rhythmic recruitment to circadian promoters and to H3 acetylation. Yet MLL1 fails to interact with CLOCK\u039419, providing an explanation for this mutation's dominant negative phenotype. Our results favor a scenario in which H3K4 trimethylation by MLL1 is required to establish a permissive chromatin state for circadian transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "795cf9fac2ef407ba53defde51145ed3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[153, 153], [101, 101]], "char_spans": [[944, 947], [641, 644]]}]}], "context_tokens": [["The", 0], ["classical", 4], ["view", 14], ["of", 19], ["the", 22], ["molecular", 26], ["clock", 36], ["is", 42], ["based", 45], ["on", 51], ["interlocked", 54], ["transcriptional", 66], ["-", 81], ["translational", 82], ["feedback", 96], ["loops", 105], [".", 110], ["Because", 112], ["a", 120], ["substantial", 122], ["fraction", 134], ["of", 143], ["the", 146], ["mammalian", 150], ["genome", 160], ["is", 167], ["expressed", 170], ["in", 180], ["a", 183], ["circadian", 185], ["manner", 195], [",", 201], ["chromatin", 203], ["remodeling", 213], ["has", 224], ["been", 228], ["proposed", 233], ["to", 242], ["be", 245], ["crucial", 248], ["in", 256], ["clock", 259], ["function", 265], [".", 273], ["Here", 275], ["we", 280], ["show", 283], ["that", 288], ["Lys4", 293], ["(", 298], ["K4", 299], [")", 301], ["trimethylation", 303], ["of", 318], ["histone", 321], ["H3", 329], ["is", 332], ["rhythmic", 335], ["and", 344], ["follows", 348], ["the", 356], ["same", 360], ["profile", 365], ["as", 373], ["previously", 376], ["described", 387], ["H3", 397], ["acetylation", 400], ["on", 412], ["circadian", 415], ["promoters", 425], [".", 434], ["MLL1", 436], [",", 440], ["a", 442], ["mammalian", 444], ["homolog", 454], ["of", 462], ["Drosophila", 465], ["trithorax", 476], [",", 485], ["is", 487], ["an", 490], ["H3K4-specific", 493], ["methyltransferase", 507], ["implicated", 525], ["in", 536], ["transcriptional", 539], ["control", 555], [".", 562], ["We", 564], ["demonstrate", 567], ["that", 579], ["MLL1", 584], ["is", 589], ["essential", 592], ["for", 602], ["circadian", 606], ["transcription", 616], ["and", 630], ["cyclic", 634], ["H3K4", 641], ["trimethylation", 646], [".", 660], ["MLL1", 662], ["is", 667], ["in", 670], ["a", 673], ["complex", 675], ["with", 683], ["CLOCK", 688], ["-", 693], ["BMAL1", 694], ["and", 700], ["contributes", 704], ["to", 716], ["its", 719], ["rhythmic", 723], ["recruitment", 732], ["to", 744], ["circadian", 747], ["promoters", 757], ["and", 767], ["to", 771], ["H3", 774], ["acetylation", 777], [".", 788], ["Yet", 790], ["MLL1", 794], ["fails", 799], ["to", 805], ["interact", 808], ["with", 817], ["CLOCK\u039419", 822], [",", 830], ["providing", 832], ["an", 842], ["explanation", 845], ["for", 857], ["this", 861], ["mutation", 866], ["'s", 874], ["dominant", 877], ["negative", 886], ["phenotype", 895], [".", 904], ["Our", 906], ["results", 910], ["favor", 918], ["a", 924], ["scenario", 926], ["in", 935], ["which", 938], ["H3K4", 944], ["trimethylation", 949], ["by", 964], ["MLL1", 967], ["is", 972], ["required", 975], ["to", 984], ["establish", 987], ["a", 997], ["permissive", 999], ["chromatin", 1010], ["state", 1020], ["for", 1026], ["circadian", 1030], ["transcription", 1040], [".", 1053]]}
{"context": "Normal B lymphocytes receive signals from B-cell antigen receptor (BCR) that are triggered by binding of the BCR to an external antigen. Tonic signaling through the BCR provides growth and signals to chronic lymphocytic leukemia (CLL) cells, and plays an important role in the pathogenesis and progression of the disease. Antigen engagement of BCR is followed by intracellular recruitment and activation of BCR-associated kinases including spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk) and phosphatidylinositol 3-kinases (PI3K). Inhibition of signaling pathways downstream of the BCR induces disruption of chemokine-mediated CLL cell migration and cell killing. BCR signal transduction inhibitors represent a promising new strategy for targeted CLL treatment. A number of therapeutic agents have recently been developed with significant activity in CLL. The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. The clinical activity of ibrutinib, GS-1101 and fostamatinib in patients with CLL is associated with marked lymphocytosis due to release of tumor cells from the lymph nodes into the peripheral blood. Further studies are ongoing with single agents and their combinations with other targeted and conventional therapies. This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "15acdfafb8db4713a4ed63acfd61cd30", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[76, 78]], "char_spans": [[440, 461]]}]}], "context_tokens": [["Normal", 0], ["B", 7], ["lymphocytes", 9], ["receive", 21], ["signals", 29], ["from", 37], ["B", 42], ["-", 43], ["cell", 44], ["antigen", 49], ["receptor", 57], ["(", 66], ["BCR", 67], [")", 70], ["that", 72], ["are", 77], ["triggered", 81], ["by", 91], ["binding", 94], ["of", 102], ["the", 105], ["BCR", 109], ["to", 113], ["an", 116], ["external", 119], ["antigen", 128], [".", 135], ["Tonic", 137], ["signaling", 143], ["through", 153], ["the", 161], ["BCR", 165], ["provides", 169], ["growth", 178], ["and", 185], ["signals", 189], ["to", 197], ["chronic", 200], ["lymphocytic", 208], ["leukemia", 220], ["(", 229], ["CLL", 230], [")", 233], ["cells", 235], [",", 240], ["and", 242], ["plays", 246], ["an", 252], ["important", 255], ["role", 265], ["in", 270], ["the", 273], ["pathogenesis", 277], ["and", 290], ["progression", 294], ["of", 306], ["the", 309], ["disease", 313], [".", 320], ["Antigen", 322], ["engagement", 330], ["of", 341], ["BCR", 344], ["is", 348], ["followed", 351], ["by", 360], ["intracellular", 363], ["recruitment", 377], ["and", 389], ["activation", 393], ["of", 404], ["BCR", 407], ["-", 410], ["associated", 411], ["kinases", 422], ["including", 430], ["spleen", 440], ["tyrosine", 447], ["kinase", 456], ["(", 463], ["Syk", 464], [")", 467], [",", 468], ["Bruton", 470], ["'s", 476], ["tyrosine", 479], ["kinase", 488], ["(", 495], ["Btk", 496], [")", 499], ["and", 501], ["phosphatidylinositol", 505], ["3-kinases", 526], ["(", 536], ["PI3", 537], ["K", 540], [")", 541], [".", 542], ["Inhibition", 544], ["of", 555], ["signaling", 558], ["pathways", 568], ["downstream", 577], ["of", 588], ["the", 591], ["BCR", 595], ["induces", 599], ["disruption", 607], ["of", 618], ["chemokine", 621], ["-", 630], ["mediated", 631], ["CLL", 640], ["cell", 644], ["migration", 649], ["and", 659], ["cell", 663], ["killing", 668], [".", 675], ["BCR", 677], ["signal", 681], ["transduction", 688], ["inhibitors", 701], ["represent", 712], ["a", 722], ["promising", 724], ["new", 734], ["strategy", 738], ["for", 747], ["targeted", 751], ["CLL", 760], ["treatment", 764], [".", 773], ["A", 775], ["number", 777], ["of", 784], ["therapeutic", 787], ["agents", 799], ["have", 806], ["recently", 811], ["been", 820], ["developed", 825], ["with", 835], ["significant", 840], ["activity", 852], ["in", 861], ["CLL", 864], [".", 867], ["The", 869], ["compounds", 873], ["that", 883], ["are", 888], ["currently", 892], ["investigated", 902], ["in", 915], ["patients", 918], ["with", 927], ["CLL", 932], ["include", 936], ["ibrutinib", 944], ["-inhibitor", 954], ["of", 965], ["Btk", 968], [",", 971], ["fostamatinib", 973], ["-", 985], ["inhibitor", 986], ["of", 996], ["Syk", 999], ["and", 1003], ["idelalisib", 1007], ["(", 1018], ["GS-1101", 1019], [")", 1026], ["-a", 1028], ["specific", 1031], ["isoform", 1040], ["of", 1048], ["the", 1051], ["PI3", 1055], ["K", 1058], ["(", 1060], ["PI3", 1061], ["K", 1064], [")", 1065], ["inhibitor", 1067], [".", 1076], ["The", 1078], ["clinical", 1082], ["activity", 1091], ["of", 1100], ["ibrutinib", 1103], [",", 1112], ["GS-1101", 1114], ["and", 1122], ["fostamatinib", 1126], ["in", 1139], ["patients", 1142], ["with", 1151], ["CLL", 1156], ["is", 1160], ["associated", 1163], ["with", 1174], ["marked", 1179], ["lymphocytosis", 1186], ["due", 1200], ["to", 1204], ["release", 1207], ["of", 1215], ["tumor", 1218], ["cells", 1224], ["from", 1230], ["the", 1235], ["lymph", 1239], ["nodes", 1245], ["into", 1251], ["the", 1256], ["peripheral", 1260], ["blood", 1271], [".", 1276], ["Further", 1278], ["studies", 1286], ["are", 1294], ["ongoing", 1298], ["with", 1306], ["single", 1311], ["agents", 1318], ["and", 1325], ["their", 1329], ["combinations", 1335], ["with", 1348], ["other", 1353], ["targeted", 1359], ["and", 1368], ["conventional", 1372], ["therapies", 1385], [".", 1394], ["This", 1396], ["article", 1401], ["will", 1409], ["review", 1414], ["the", 1421], ["preclinical", 1425], ["rationale", 1437], ["of", 1447], ["BCR", 1450], ["signaling", 1454], ["inhibitors", 1464], ["in", 1475], ["the", 1478], ["treatment", 1482], ["of", 1492], ["CLL", 1495], [",", 1498], ["and", 1500], ["the", 1504], ["clinical", 1508], ["evidence", 1517], ["supporting", 1526], ["the", 1537], ["use", 1541], ["of", 1545], ["these", 1548], ["agents", 1554], ["in", 1561], ["CLL", 1564], ["patients", 1568], [".", 1576]]}
{"context": "Imatinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome. As a result of the translocation, a fusion gene called the Bcr-Abl gene is created from two normal cellular genes, encoding a chimeric Bcr-Abl protein with a deregulated tyrosine kinase activity. The expression of Bcr-Abl tyrosine kinase has been shown to be necessary and sufficient for the transformed phenotype of CML cells. Imatinib can block the kinase activity of Bcr-Abl, thus inhibiting the proliferation of Ph-positive progenitors, and has shown activity against all phases of CML, though responses are most substantial and durable in patients in the chronic phase. An international phase III study which compared the efficacy of imatinib with that of interferon alpha combined with low-dose cytarabine in newly diagnosed chronic-phase CML showed the rate of major cytogenetic response at 24 months was 90%, including 82% of complete cytogenetic response. These results indicated that imatinib was superior to interferon-containing treatment as a first-line therapy. More than 10,000 patients worldwide, including those in Japan, have been treated with imatinib in clinical trials, and a lot of information has been accumulated on the use of this drug. The aim of this article is to review the use of this drug and the practical management of patients with chronic myeloid leukemia.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7eb603c02b0c40579e66fe97ee76c19f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[113, 115], [84, 86], [14, 16], [141, 143], [99, 101]], "char_spans": [[606, 612], [451, 457], [81, 87], [762, 768], [527, 533]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["new", 23], ["drug", 27], ["that", 32], ["can", 37], ["inhibit", 41], ["the", 49], ["tyrosine", 53], ["kinase", 62], ["activity", 69], ["of", 78], ["Bcr", 81], ["-", 84], ["Abl", 85], [",", 88], ["the", 90], ["receptors", 94], ["for", 104], ["platelet", 108], ["-", 116], ["derived", 117], ["growth", 125], ["factor", 132], ["receptor(PDGF", 139], [")", 152], ["and", 154], ["stem", 158], ["cell", 163], ["factor", 168], [",", 174], ["or", 176], ["c", 179], ["-", 180], ["kit", 181], [".", 184], ["Chronic", 186], ["myeloid", 194], ["leukemia", 202], ["(", 211], ["CML", 212], [")", 215], ["is", 217], ["distinguished", 220], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["a", 253], ["reciprocal", 255], ["translocation", 266], ["between", 280], ["chromosomes", 288], ["9", 300], ["and", 302], ["22", 306], ["that", 309], ["results", 314], ["in", 322], ["a", 325], ["shortened", 327], ["chromosome", 337], ["22", 348], [",", 350], ["termed", 352], ["the", 359], ["Philadelphia(Ph", 363], [")", 378], ["chromosome", 380], [".", 390], ["As", 392], ["a", 395], ["result", 397], ["of", 404], ["the", 407], ["translocation", 411], [",", 424], ["a", 426], ["fusion", 428], ["gene", 435], ["called", 440], ["the", 447], ["Bcr", 451], ["-", 454], ["Abl", 455], ["gene", 459], ["is", 464], ["created", 467], ["from", 475], ["two", 480], ["normal", 484], ["cellular", 491], ["genes", 500], [",", 505], ["encoding", 507], ["a", 516], ["chimeric", 518], ["Bcr", 527], ["-", 530], ["Abl", 531], ["protein", 535], ["with", 543], ["a", 548], ["deregulated", 550], ["tyrosine", 562], ["kinase", 571], ["activity", 578], [".", 586], ["The", 588], ["expression", 592], ["of", 603], ["Bcr", 606], ["-", 609], ["Abl", 610], ["tyrosine", 614], ["kinase", 623], ["has", 630], ["been", 634], ["shown", 639], ["to", 645], ["be", 648], ["necessary", 651], ["and", 661], ["sufficient", 665], ["for", 676], ["the", 680], ["transformed", 684], ["phenotype", 696], ["of", 706], ["CML", 709], ["cells", 713], [".", 718], ["Imatinib", 720], ["can", 729], ["block", 733], ["the", 739], ["kinase", 743], ["activity", 750], ["of", 759], ["Bcr", 762], ["-", 765], ["Abl", 766], [",", 769], ["thus", 771], ["inhibiting", 776], ["the", 787], ["proliferation", 791], ["of", 805], ["Ph", 808], ["-", 810], ["positive", 811], ["progenitors", 820], [",", 831], ["and", 833], ["has", 837], ["shown", 841], ["activity", 847], ["against", 856], ["all", 864], ["phases", 868], ["of", 875], ["CML", 878], [",", 881], ["though", 883], ["responses", 890], ["are", 900], ["most", 904], ["substantial", 909], ["and", 921], ["durable", 925], ["in", 933], ["patients", 936], ["in", 945], ["the", 948], ["chronic", 952], ["phase", 960], [".", 965], ["An", 967], ["international", 970], ["phase", 984], ["III", 990], ["study", 994], ["which", 1000], ["compared", 1006], ["the", 1015], ["efficacy", 1019], ["of", 1028], ["imatinib", 1031], ["with", 1040], ["that", 1045], ["of", 1050], ["interferon", 1053], ["alpha", 1064], ["combined", 1070], ["with", 1079], ["low", 1084], ["-", 1087], ["dose", 1088], ["cytarabine", 1093], ["in", 1104], ["newly", 1107], ["diagnosed", 1113], ["chronic", 1123], ["-", 1130], ["phase", 1131], ["CML", 1137], ["showed", 1141], ["the", 1148], ["rate", 1152], ["of", 1157], ["major", 1160], ["cytogenetic", 1166], ["response", 1178], ["at", 1187], ["24", 1190], ["months", 1193], ["was", 1200], ["90", 1204], ["%", 1206], [",", 1207], ["including", 1209], ["82", 1219], ["%", 1221], ["of", 1223], ["complete", 1226], ["cytogenetic", 1235], ["response", 1247], [".", 1255], ["These", 1257], ["results", 1263], ["indicated", 1271], ["that", 1281], ["imatinib", 1286], ["was", 1295], ["superior", 1299], ["to", 1308], ["interferon", 1311], ["-", 1321], ["containing", 1322], ["treatment", 1333], ["as", 1343], ["a", 1346], ["first", 1348], ["-", 1353], ["line", 1354], ["therapy", 1359], [".", 1366], ["More", 1368], ["than", 1373], ["10,000", 1378], ["patients", 1385], ["worldwide", 1394], [",", 1403], ["including", 1405], ["those", 1415], ["in", 1421], ["Japan", 1424], [",", 1429], ["have", 1431], ["been", 1436], ["treated", 1441], ["with", 1449], ["imatinib", 1454], ["in", 1463], ["clinical", 1466], ["trials", 1475], [",", 1481], ["and", 1483], ["a", 1487], ["lot", 1489], ["of", 1493], ["information", 1496], ["has", 1508], ["been", 1512], ["accumulated", 1517], ["on", 1529], ["the", 1532], ["use", 1536], ["of", 1540], ["this", 1543], ["drug", 1548], [".", 1552], ["The", 1554], ["aim", 1558], ["of", 1562], ["this", 1565], ["article", 1570], ["is", 1578], ["to", 1581], ["review", 1584], ["the", 1591], ["use", 1595], ["of", 1599], ["this", 1602], ["drug", 1607], ["and", 1612], ["the", 1616], ["practical", 1620], ["management", 1630], ["of", 1641], ["patients", 1644], ["with", 1653], ["chronic", 1658], ["myeloid", 1666], ["leukemia", 1674], [".", 1682]]}
{"context": "The Davidson Trauma Scale (DTS) is a validated, 17-item, brief global assessment scale for posttraumatic stress disorder (PTSD). The purposes of this study were to develop a Korean version of the DTS (DTS-K) while maintaining its basic structure and to evaluate its reliability and validity for the Korean population. Participants of this study included 93 patients with PTSD (PTSD group), 73 patients with nonpsychotic mood or other anxiety disorders (psychiatric control group), and 88 healthy controls (normal control group). Subjects completed psychometric assessments, including the DTS-K and the Korean version of the Clinician-Administered PTSD Scale and the State Trait Anxiety Inventory. The DTS-K showed good internal consistency (Cronbach alpha = .97) and test-retest reliability (r = .93). The DTS-K showed a significantly positive correlation with Clinician-Administered PTSD Scale (r = .94). The highest diagnostic efficiency of DTS-K was at a total score of 47, with sensitivity and specificity of 0.87 and 0.84, respectively. Our findings suggest that the DTS-K is composed of good psychometric properties and is a valid and reliable tool for assessing the frequency and severity of PTSD symptoms regardless of ethnicity.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "2834078a6a4f4895bc36ef416995c4c9", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[69, 69], [229, 229], [166, 166], [22, 22], [119, 119], [71, 71]], "char_spans": [[371, 374], [1199, 1202], [884, 887], [122, 125], [647, 650], [377, 380]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["is", 32], ["a", 35], ["validated", 37], [",", 46], ["17-item", 48], [",", 55], ["brief", 57], ["global", 63], ["assessment", 70], ["scale", 81], ["for", 87], ["posttraumatic", 91], ["stress", 105], ["disorder", 112], ["(", 121], ["PTSD", 122], [")", 126], [".", 127], ["The", 129], ["purposes", 133], ["of", 142], ["this", 145], ["study", 150], ["were", 156], ["to", 161], ["develop", 164], ["a", 172], ["Korean", 174], ["version", 181], ["of", 189], ["the", 192], ["DTS", 196], ["(", 200], ["DTS", 201], ["-", 204], ["K", 205], [")", 206], ["while", 208], ["maintaining", 214], ["its", 226], ["basic", 230], ["structure", 236], ["and", 246], ["to", 250], ["evaluate", 253], ["its", 262], ["reliability", 266], ["and", 278], ["validity", 282], ["for", 291], ["the", 295], ["Korean", 299], ["population", 306], [".", 316], ["Participants", 318], ["of", 331], ["this", 334], ["study", 339], ["included", 345], ["93", 354], ["patients", 357], ["with", 366], ["PTSD", 371], ["(", 376], ["PTSD", 377], ["group", 382], [")", 387], [",", 388], ["73", 390], ["patients", 393], ["with", 402], ["nonpsychotic", 407], ["mood", 420], ["or", 425], ["other", 428], ["anxiety", 434], ["disorders", 442], ["(", 452], ["psychiatric", 453], ["control", 465], ["group", 473], [")", 478], [",", 479], ["and", 481], ["88", 485], ["healthy", 488], ["controls", 496], ["(", 505], ["normal", 506], ["control", 513], ["group", 521], [")", 526], [".", 527], ["Subjects", 529], ["completed", 538], ["psychometric", 548], ["assessments", 561], [",", 572], ["including", 574], ["the", 584], ["DTS", 588], ["-", 591], ["K", 592], ["and", 594], ["the", 598], ["Korean", 602], ["version", 609], ["of", 617], ["the", 620], ["Clinician", 624], ["-", 633], ["Administered", 634], ["PTSD", 647], ["Scale", 652], ["and", 658], ["the", 662], ["State", 666], ["Trait", 672], ["Anxiety", 678], ["Inventory", 686], [".", 695], ["The", 697], ["DTS", 701], ["-", 704], ["K", 705], ["showed", 707], ["good", 714], ["internal", 719], ["consistency", 728], ["(", 740], ["Cronbach", 741], ["alpha", 750], ["=", 756], [".97", 758], [")", 761], ["and", 763], ["test", 767], ["-", 771], ["retest", 772], ["reliability", 779], ["(", 791], ["r", 792], ["=", 794], [".93", 796], [")", 799], [".", 800], ["The", 802], ["DTS", 806], ["-", 809], ["K", 810], ["showed", 812], ["a", 819], ["significantly", 821], ["positive", 835], ["correlation", 844], ["with", 856], ["Clinician", 861], ["-", 870], ["Administered", 871], ["PTSD", 884], ["Scale", 889], ["(", 895], ["r", 896], ["=", 898], [".94", 900], [")", 903], [".", 904], ["The", 906], ["highest", 910], ["diagnostic", 918], ["efficiency", 929], ["of", 940], ["DTS", 943], ["-", 946], ["K", 947], ["was", 949], ["at", 953], ["a", 956], ["total", 958], ["score", 964], ["of", 970], ["47", 973], [",", 975], ["with", 977], ["sensitivity", 982], ["and", 994], ["specificity", 998], ["of", 1010], ["0.87", 1013], ["and", 1018], ["0.84", 1022], [",", 1026], ["respectively", 1028], [".", 1040], ["Our", 1042], ["findings", 1046], ["suggest", 1055], ["that", 1063], ["the", 1068], ["DTS", 1072], ["-", 1075], ["K", 1076], ["is", 1078], ["composed", 1081], ["of", 1090], ["good", 1093], ["psychometric", 1098], ["properties", 1111], ["and", 1122], ["is", 1126], ["a", 1129], ["valid", 1131], ["and", 1137], ["reliable", 1141], ["tool", 1150], ["for", 1155], ["assessing", 1159], ["the", 1169], ["frequency", 1173], ["and", 1183], ["severity", 1187], ["of", 1196], ["PTSD", 1199], ["symptoms", 1204], ["regardless", 1213], ["of", 1224], ["ethnicity", 1227], [".", 1236]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective form of autophagy whose distinctive feature is the fact that substrate proteins are translocated directly from the cytosol across the lysosomal membrane for degradation inside lysosomes. CMA substrates are cytosolic proteins bearing a pentapeptide motif in their sequence that, when recognized by the cytosolic chaperone HSPA8/HSC70, targets them to the surface of the lysosomes. Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. CMA is constitutively active in most cells but it is maximally activated under conditions of stress.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "00514408a6c643d68ffbd2cf86d20e0e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[86, 86]], "char_spans": [[528, 533]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["form", 50], ["of", 55], ["autophagy", 58], ["whose", 68], ["distinctive", 74], ["feature", 86], ["is", 94], ["the", 97], ["fact", 101], ["that", 106], ["substrate", 111], ["proteins", 121], ["are", 130], ["translocated", 134], ["directly", 147], ["from", 156], ["the", 161], ["cytosol", 165], ["across", 173], ["the", 180], ["lysosomal", 184], ["membrane", 194], ["for", 203], ["degradation", 207], ["inside", 219], ["lysosomes", 226], [".", 235], ["CMA", 237], ["substrates", 241], ["are", 252], ["cytosolic", 256], ["proteins", 266], ["bearing", 275], ["a", 283], ["pentapeptide", 285], ["motif", 298], ["in", 304], ["their", 307], ["sequence", 313], ["that", 322], [",", 326], ["when", 328], ["recognized", 333], ["by", 344], ["the", 347], ["cytosolic", 351], ["chaperone", 361], ["HSPA8/HSC70", 371], [",", 382], ["targets", 384], ["them", 392], ["to", 397], ["the", 400], ["surface", 404], ["of", 412], ["the", 415], ["lysosomes", 419], [".", 428], ["Once", 430], ["there", 435], [",", 440], ["substrate", 442], ["proteins", 452], ["bind", 461], ["to", 466], ["the", 469], ["lysosome", 473], ["-", 481], ["associated", 482], ["membrane", 493], ["protein", 502], ["type", 510], ["2", 515], ["isoform", 517], ["A", 525], ["(", 527], ["LAMP2A", 528], [")", 534], [",", 535], ["inducing", 537], ["assembly", 546], ["of", 555], ["this", 558], ["receptor", 563], ["protein", 572], ["into", 580], ["a", 585], ["higher", 587], ["molecular", 594], ["weight", 604], ["protein", 611], ["complex", 619], ["that", 627], ["is", 632], ["used", 635], ["by", 640], ["the", 643], ["substrate", 647], ["proteins", 657], ["to", 666], ["reach", 669], ["the", 675], ["lysosomal", 679], ["lumen", 689], [".", 694], ["CMA", 696], ["is", 700], ["constitutively", 703], ["active", 718], ["in", 725], ["most", 728], ["cells", 733], ["but", 739], ["it", 743], ["is", 746], ["maximally", 749], ["activated", 759], ["under", 769], ["conditions", 775], ["of", 786], ["stress", 789], [".", 795]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7d7dfb5ece1846bc8fab1c8af7bcce92", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[256, 256], [115, 115], [325, 325], [282, 282], [341, 341], [196, 196], [4, 4], [174, 174], [402, 402], [94, 94]], "char_spans": [[1517, 1520], [695, 698], [1926, 1929], [1662, 1665], [2006, 2009], [1147, 1150], [40, 43], [1011, 1014], [2397, 2400], [553, 556]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contraction", 78], ["of", 90], ["an", 93], ["array", 96], ["of", 102], ["tandem", 105], ["3.3-kb", 112], ["repeats", 119], ["(", 127], ["D4Z4", 128], [")", 132], ["at", 134], ["4q35", 137], [".", 141], ["Within", 143], ["each", 150], ["repeat", 155], ["unit", 162], ["is", 167], ["a", 170], ["gene", 172], [",", 176], ["DUX4", 178], [",", 182], ["that", 184], ["can", 189], ["encode", 193], ["a", 200], ["protein", 202], ["containing", 210], ["two", 221], ["homeodomains", 225], [".", 237], ["A", 239], ["DUX4", 241], ["transcript", 246], ["derived", 257], ["from", 265], ["the", 270], ["last", 274], ["repeat", 279], ["unit", 286], ["in", 291], ["a", 294], ["contracted", 296], ["array", 307], ["is", 313], ["associated", 316], ["with", 327], ["pathogenesis", 332], ["but", 345], ["it", 349], ["is", 352], ["unclear", 355], ["how", 363], [".", 366], ["Using", 368], ["exon", 374], ["-", 378], ["based", 379], ["microarrays", 385], [",", 396], ["the", 398], ["expression", 402], ["profiles", 413], ["of", 422], ["myogenic", 425], ["precursor", 434], ["cells", 444], ["were", 450], ["determined", 455], [".", 465], ["Both", 467], ["undifferentiated", 472], ["myoblasts", 489], ["and", 499], ["myoblasts", 503], ["differentiated", 513], ["to", 528], ["myotubes", 531], ["derived", 540], ["from", 548], ["FSHD", 553], ["patients", 558], ["and", 567], ["controls", 571], ["were", 580], ["studied", 585], ["after", 593], ["immunocytochemical", 599], ["verification", 618], ["of", 631], ["the", 634], ["quality", 638], ["of", 646], ["the", 649], ["cultures", 653], [".", 661], ["To", 663], ["further", 666], ["our", 674], ["understanding", 678], ["of", 692], ["FSHD", 695], ["and", 700], ["normal", 704], ["myogenesis", 711], [",", 721], ["the", 723], ["expression", 727], ["profiles", 738], ["obtained", 747], ["were", 756], ["compared", 761], ["to", 770], ["those", 773], ["of", 779], ["19", 782], ["non", 785], ["-", 788], ["muscle", 789], ["cell", 796], ["types", 801], ["analyzed", 807], ["by", 816], ["identical", 819], ["methods", 829], [".", 836], ["Many", 838], ["of", 843], ["the", 846], ["~17,000", 850], ["examined", 858], ["genes", 867], ["were", 873], ["differentially", 878], ["expressed", 893], ["(", 903], [">", 904], ["2-fold", 905], [",", 911], ["p<0.01", 913], [")", 919], ["in", 921], ["control", 924], ["myoblasts", 932], ["or", 942], ["myotubes", 945], ["vs.", 954], ["non", 958], ["-", 961], ["muscle", 962], ["cells", 969], ["(", 975], ["2185", 976], ["and", 981], ["3006", 985], [",", 989], ["respectively", 991], [")", 1003], ["or", 1005], ["in", 1008], ["FSHD", 1011], ["vs.", 1016], ["control", 1020], ["myoblasts", 1028], ["or", 1038], ["myotubes", 1041], ["(", 1050], ["295", 1051], ["and", 1055], ["797", 1059], [",", 1062], ["respectively", 1064], [")", 1076], [".", 1077], ["Surprisingly", 1079], [",", 1091], ["despite", 1093], ["the", 1101], ["morphologically", 1105], ["normal", 1121], ["differentiation", 1128], ["of", 1144], ["FSHD", 1147], ["myoblasts", 1152], ["to", 1162], ["myotubes", 1165], [",", 1173], ["most", 1175], ["of", 1180], ["the", 1183], ["disease", 1187], ["-", 1194], ["related", 1195], ["dysregulation", 1203], ["was", 1217], ["seen", 1221], ["as", 1226], ["dampening", 1229], ["of", 1239], ["normal", 1242], ["myogenesis", 1249], ["-", 1259], ["specific", 1260], ["expression", 1269], ["changes", 1280], [",", 1287], ["including", 1289], ["in", 1299], ["genes", 1302], ["for", 1308], ["muscle", 1312], ["structure", 1319], [",", 1328], ["mitochondrial", 1330], ["function", 1344], [",", 1352], ["stress", 1354], ["responses", 1361], [",", 1370], ["and", 1372], ["signal", 1376], ["transduction", 1383], [".", 1395], ["Other", 1397], ["classes", 1403], ["of", 1411], ["genes", 1414], [",", 1419], ["including", 1421], ["those", 1431], ["encoding", 1437], ["extracellular", 1446], ["matrix", 1460], ["or", 1467], ["pro", 1470], ["-", 1473], ["inflammatory", 1474], ["proteins", 1487], [",", 1495], ["were", 1497], ["upregulated", 1502], ["in", 1514], ["FSHD", 1517], ["myogenic", 1522], ["cells", 1531], ["independent", 1537], ["of", 1549], ["an", 1552], ["inverse", 1555], ["myogenesis", 1563], ["association", 1574], [".", 1585], ["Importantly", 1587], [",", 1598], ["the", 1600], ["disease", 1604], ["-", 1611], ["linked", 1612], ["DUX4", 1619], ["RNA", 1624], ["isoform", 1628], ["was", 1636], ["detected", 1640], ["by", 1649], ["RT", 1652], ["-", 1654], ["PCR", 1655], ["in", 1659], ["FSHD", 1662], ["myoblast", 1667], ["and", 1676], ["myotube", 1680], ["preparations", 1688], ["only", 1701], ["at", 1706], ["extremely", 1709], ["low", 1719], ["levels", 1723], [".", 1729], ["Unique", 1731], ["insights", 1738], ["into", 1747], ["myogenesis", 1752], ["-", 1762], ["specific", 1763], ["gene", 1772], ["expression", 1777], ["were", 1788], ["also", 1793], ["obtained", 1798], [".", 1806], ["For", 1808], ["example", 1812], [",", 1819], ["all", 1821], ["four", 1825], ["Argonaute", 1830], ["genes", 1840], ["involved", 1846], ["in", 1855], ["RNA", 1858], ["-", 1861], ["silencing", 1862], ["were", 1872], ["significantly", 1877], ["upregulated", 1891], ["during", 1903], ["normal", 1910], ["(", 1917], ["but", 1918], ["not", 1922], ["FSHD", 1926], [")", 1930], ["myogenesis", 1932], ["relative", 1943], ["to", 1952], ["non", 1955], ["-", 1958], ["muscle", 1959], ["cell", 1966], ["types", 1971], [".", 1976], ["DUX4", 1978], ["'s", 1982], ["pathogenic", 1985], ["effect", 1996], ["in", 2003], ["FSHD", 2006], ["may", 2011], ["occur", 2015], ["transiently", 2021], ["at", 2033], ["or", 2036], ["before", 2039], ["the", 2046], ["stage", 2050], ["of", 2056], ["myoblast", 2059], ["formation", 2068], ["to", 2078], ["establish", 2081], ["a", 2091], ["cascade", 2093], ["of", 2101], ["gene", 2104], ["dysregulation", 2109], [".", 2122], ["This", 2124], ["contrasts", 2129], ["with", 2139], ["the", 2144], ["current", 2148], ["emphasis", 2156], ["on", 2165], ["toxic", 2168], ["effects", 2174], ["of", 2182], ["experimentally", 2185], ["upregulated", 2200], ["DUX4", 2212], ["expression", 2217], ["at", 2228], ["the", 2231], ["myoblast", 2235], ["or", 2244], ["myotube", 2247], ["stages", 2255], [".", 2261], ["Our", 2263], ["model", 2267], ["could", 2273], ["explain", 2279], ["why", 2287], ["DUX4", 2291], ["'s", 2295], ["inappropriate", 2298], ["expression", 2312], ["was", 2323], ["barely", 2327], ["detectable", 2334], ["in", 2345], ["myoblasts", 2348], ["and", 2358], ["myotubes", 2362], ["but", 2371], ["nonetheless", 2375], ["linked", 2387], ["to", 2394], ["FSHD", 2397], [".", 2401]]}
{"context": "Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch receptors with ligands leads to cleavage of the Notch intracellular domain (NICD) which then translocates to the nucleus and activates the transcription factor CBF1/JBP-Jkappa, regulating downstream gene expression. To date four Notch receptors have been found in mammals. Of these, Notch3 is predominantly expressed in adult arterial smooth muscle cells in human. NOTCH3 gene mutations cause the autosomal dominant condition, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), an inherited early stroke syndrome leading to dementia due to systemic vascular degeneration. This suggests that Notch3 plays a critical role in maintaining the phenotypic stability of vascular smooth muscle cells (VSMCs). Recent publications indicate that Notch3 is involved in vascular injury and is a determinant of VSMC survival, but its exact function is unknown. The molecular mechanisms underlying CADASIL pathology are therefore intriguing. Investigation of CADASIL mutant Notch3 shows that the majority of mutations do not change CBF1/JBP-Jkappa mediated classic Notch activation, so the pathological consequences of NOTCH3 mutations in CADASIL patients can not be simply explained by loss- or gain-of-function in the classic Notch signalling pathway. This suggests that a novel Notch3-mediated signalling pathway may be present in VSMCs, or cross-regulation of Notch3 to other signalling pathway(s) may play a critical role on VSMCs survival. Alternatively, the mutant Notch3 may gain a novel or toxic function in VSMCs. This review will focus on recent findings of Notch3 in vascular development and in regulating the VSMC behaviour and phenotype, and will use findings on investigating the molecular pathology of the single gene disorder CADASIL to understand the function of Notch3 in VSMCs.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "2c9f414f7a3a499893e29b02c1e7994e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[106, 107]], "char_spans": [[680, 690]]}]}], "context_tokens": [["Proteins", 0], ["of", 9], ["the", 12], ["Notch", 16], ["family", 22], ["are", 29], ["cell", 33], ["surface", 38], ["receptors", 46], ["that", 56], ["transduce", 61], ["signals", 71], ["between", 79], ["neighbouring", 87], ["cells", 100], [".", 105], ["The", 107], ["Notch", 111], ["signalling", 117], ["pathway", 128], ["is", 136], ["highly", 139], ["evolutionarily", 146], ["conserved", 161], ["and", 171], ["critical", 175], ["for", 184], ["cell", 188], ["fate", 193], ["determination", 198], ["during", 212], ["embryonic", 219], ["development", 229], [",", 240], ["including", 242], ["many", 252], ["aspects", 257], ["of", 265], ["vascular", 268], ["development", 277], [".", 288], ["The", 290], ["interaction", 294], ["of", 306], ["Notch", 309], ["receptors", 315], ["with", 325], ["ligands", 330], ["leads", 338], ["to", 344], ["cleavage", 347], ["of", 356], ["the", 359], ["Notch", 363], ["intracellular", 369], ["domain", 383], ["(", 390], ["NICD", 391], [")", 395], ["which", 397], ["then", 403], ["translocates", 408], ["to", 421], ["the", 424], ["nucleus", 428], ["and", 436], ["activates", 440], ["the", 450], ["transcription", 454], ["factor", 468], ["CBF1/JBP", 475], ["-", 483], ["Jkappa", 484], [",", 490], ["regulating", 492], ["downstream", 503], ["gene", 514], ["expression", 519], [".", 529], ["To", 531], ["date", 534], ["four", 539], ["Notch", 544], ["receptors", 550], ["have", 560], ["been", 565], ["found", 570], ["in", 576], ["mammals", 579], [".", 586], ["Of", 588], ["these", 591], [",", 596], ["Notch3", 598], ["is", 605], ["predominantly", 608], ["expressed", 622], ["in", 632], ["adult", 635], ["arterial", 641], ["smooth", 650], ["muscle", 657], ["cells", 664], ["in", 670], ["human", 673], [".", 678], ["NOTCH3", 680], ["gene", 687], ["mutations", 692], ["cause", 702], ["the", 708], ["autosomal", 712], ["dominant", 722], ["condition", 731], [",", 740], ["cerebral", 742], ["autosomal", 751], ["dominant", 761], ["arteriopathy", 770], ["with", 783], ["subcortical", 788], ["infarcts", 800], ["and", 809], ["leukoecephelopathy", 813], ["(", 832], ["CADASIL", 833], [")", 840], [",", 841], ["an", 843], ["inherited", 846], ["early", 856], ["stroke", 862], ["syndrome", 869], ["leading", 878], ["to", 886], ["dementia", 889], ["due", 898], ["to", 902], ["systemic", 905], ["vascular", 914], ["degeneration", 923], [".", 935], ["This", 937], ["suggests", 942], ["that", 951], ["Notch3", 956], ["plays", 963], ["a", 969], ["critical", 971], ["role", 980], ["in", 985], ["maintaining", 988], ["the", 1000], ["phenotypic", 1004], ["stability", 1015], ["of", 1025], ["vascular", 1028], ["smooth", 1037], ["muscle", 1044], ["cells", 1051], ["(", 1057], ["VSMCs", 1058], [")", 1063], [".", 1064], ["Recent", 1066], ["publications", 1073], ["indicate", 1086], ["that", 1095], ["Notch3", 1100], ["is", 1107], ["involved", 1110], ["in", 1119], ["vascular", 1122], ["injury", 1131], ["and", 1138], ["is", 1142], ["a", 1145], ["determinant", 1147], ["of", 1159], ["VSMC", 1162], ["survival", 1167], [",", 1175], ["but", 1177], ["its", 1181], ["exact", 1185], ["function", 1191], ["is", 1200], ["unknown", 1203], [".", 1210], ["The", 1212], ["molecular", 1216], ["mechanisms", 1226], ["underlying", 1237], ["CADASIL", 1248], ["pathology", 1256], ["are", 1266], ["therefore", 1270], ["intriguing", 1280], [".", 1290], ["Investigation", 1292], ["of", 1306], ["CADASIL", 1309], ["mutant", 1317], ["Notch3", 1324], ["shows", 1331], ["that", 1337], ["the", 1342], ["majority", 1346], ["of", 1355], ["mutations", 1358], ["do", 1368], ["not", 1371], ["change", 1375], ["CBF1/JBP", 1382], ["-", 1390], ["Jkappa", 1391], ["mediated", 1398], ["classic", 1407], ["Notch", 1415], ["activation", 1421], [",", 1431], ["so", 1433], ["the", 1436], ["pathological", 1440], ["consequences", 1453], ["of", 1466], ["NOTCH3", 1469], ["mutations", 1476], ["in", 1486], ["CADASIL", 1489], ["patients", 1497], ["can", 1506], ["not", 1510], ["be", 1514], ["simply", 1517], ["explained", 1524], ["by", 1534], ["loss-", 1537], ["or", 1543], ["gain", 1546], ["-", 1550], ["of", 1551], ["-", 1553], ["function", 1554], ["in", 1563], ["the", 1566], ["classic", 1570], ["Notch", 1578], ["signalling", 1584], ["pathway", 1595], [".", 1602], ["This", 1604], ["suggests", 1609], ["that", 1618], ["a", 1623], ["novel", 1625], ["Notch3-mediated", 1631], ["signalling", 1647], ["pathway", 1658], ["may", 1666], ["be", 1670], ["present", 1673], ["in", 1681], ["VSMCs", 1684], [",", 1689], ["or", 1691], ["cross", 1694], ["-", 1699], ["regulation", 1700], ["of", 1711], ["Notch3", 1714], ["to", 1721], ["other", 1724], ["signalling", 1730], ["pathway(s", 1741], [")", 1750], ["may", 1752], ["play", 1756], ["a", 1761], ["critical", 1763], ["role", 1772], ["on", 1777], ["VSMCs", 1780], ["survival", 1786], [".", 1794], ["Alternatively", 1796], [",", 1809], ["the", 1811], ["mutant", 1815], ["Notch3", 1822], ["may", 1829], ["gain", 1833], ["a", 1838], ["novel", 1840], ["or", 1846], ["toxic", 1849], ["function", 1855], ["in", 1864], ["VSMCs", 1867], [".", 1872], ["This", 1874], ["review", 1879], ["will", 1886], ["focus", 1891], ["on", 1897], ["recent", 1900], ["findings", 1907], ["of", 1916], ["Notch3", 1919], ["in", 1926], ["vascular", 1929], ["development", 1938], ["and", 1950], ["in", 1954], ["regulating", 1957], ["the", 1968], ["VSMC", 1972], ["behaviour", 1977], ["and", 1987], ["phenotype", 1991], [",", 2000], ["and", 2002], ["will", 2006], ["use", 2011], ["findings", 2015], ["on", 2024], ["investigating", 2027], ["the", 2041], ["molecular", 2045], ["pathology", 2055], ["of", 2065], ["the", 2068], ["single", 2072], ["gene", 2079], ["disorder", 2084], ["CADASIL", 2093], ["to", 2101], ["understand", 2104], ["the", 2115], ["function", 2119], ["of", 2128], ["Notch3", 2131], ["in", 2138], ["VSMCs", 2141], [".", 2146]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "Polycomb gene silencing requires histone methyltransferase activity of Polycomb repressive complex 2 (PRC2), which methylates lysine 27 of histone H3. Information on how PRC2 works is limited by lack of structural data on the catalytic subunit, Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain. Here we analyze missense alleles of Drosophila E(z), selected for molecular study because of their dominant genetic effects. Four missense alleles identify key E(Z) SET domain residues, and a fifth is located in the adjacent CXC domain. Analysis of mutant PRC2 complexes in vitro, and H3-K27 methylation in vivo, shows that each SET domain mutation disrupts PRC2 histone methyltransferase. Based on known SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group. In contrast, the CXC mutant retains catalytic activity, Lys-27 specificity, and trimethylation capacity. Deletion analysis also reveals a functional requirement for a conserved E(Z) domain N-terminal to CXC and SET. These results identify critical SET domain residues needed for PRC2 enzyme function, and they also emphasize functional inputs from outside the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "94917b06092641a5af6b7e211171d69d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[134, 135], [60, 61], [123, 124], [217, 218], [91, 92], [235, 236]], "char_spans": [[742, 751], [325, 334], [666, 675], [1235, 1244], [502, 511], [1347, 1356]]}]}], "context_tokens": [["Polycomb", 0], ["gene", 9], ["silencing", 14], ["requires", 24], ["histone", 33], ["methyltransferase", 41], ["activity", 59], ["of", 68], ["Polycomb", 71], ["repressive", 80], ["complex", 91], ["2", 99], ["(", 101], ["PRC2", 102], [")", 106], [",", 107], ["which", 109], ["methylates", 115], ["lysine", 126], ["27", 133], ["of", 136], ["histone", 139], ["H3", 147], [".", 149], ["Information", 151], ["on", 163], ["how", 166], ["PRC2", 170], ["works", 175], ["is", 181], ["limited", 184], ["by", 192], ["lack", 195], ["of", 200], ["structural", 203], ["data", 214], ["on", 219], ["the", 222], ["catalytic", 226], ["subunit", 236], [",", 243], ["Enhancer", 245], ["of", 254], ["zeste", 257], ["(", 263], ["E(Z", 264], [")", 267], [")", 268], [",", 269], ["and", 271], ["the", 275], ["paucity", 279], ["of", 287], ["E(z", 290], [")", 293], ["mutant", 295], ["alleles", 302], ["that", 310], ["alter", 315], ["its", 321], ["SET", 325], ["domain", 329], [".", 335], ["Here", 337], ["we", 342], ["analyze", 345], ["missense", 353], ["alleles", 362], ["of", 370], ["Drosophila", 373], ["E(z", 384], [")", 387], [",", 388], ["selected", 390], ["for", 399], ["molecular", 403], ["study", 413], ["because", 419], ["of", 427], ["their", 430], ["dominant", 436], ["genetic", 445], ["effects", 453], [".", 460], ["Four", 462], ["missense", 467], ["alleles", 476], ["identify", 484], ["key", 493], ["E(Z", 497], [")", 500], ["SET", 502], ["domain", 506], ["residues", 513], [",", 521], ["and", 523], ["a", 527], ["fifth", 529], ["is", 535], ["located", 538], ["in", 546], ["the", 549], ["adjacent", 553], ["CXC", 562], ["domain", 566], [".", 572], ["Analysis", 574], ["of", 583], ["mutant", 586], ["PRC2", 593], ["complexes", 598], ["in", 608], ["vitro", 611], [",", 616], ["and", 618], ["H3-K27", 622], ["methylation", 629], ["in", 641], ["vivo", 644], [",", 648], ["shows", 650], ["that", 656], ["each", 661], ["SET", 666], ["domain", 670], ["mutation", 677], ["disrupts", 686], ["PRC2", 695], ["histone", 700], ["methyltransferase", 708], [".", 725], ["Based", 727], ["on", 733], ["known", 736], ["SET", 742], ["domain", 746], ["structures", 753], [",", 763], ["the", 765], ["mutations", 769], ["likely", 779], ["affect", 786], ["either", 793], ["the", 800], ["lysine", 804], ["-", 810], ["substrate", 811], ["binding", 821], ["pocket", 829], [",", 835], ["the", 837], ["binding", 841], ["site", 849], ["for", 854], ["the", 858], ["adenosylmethionine", 862], ["methyl", 881], ["donor", 888], [",", 893], ["or", 895], ["a", 898], ["critical", 900], ["tyrosine", 909], ["predicted", 918], ["to", 928], ["interact", 931], ["with", 940], ["the", 945], ["substrate", 949], ["lysine", 959], ["epsilon", 966], ["-", 973], ["amino", 974], ["group", 980], [".", 985], ["In", 987], ["contrast", 990], [",", 998], ["the", 1000], ["CXC", 1004], ["mutant", 1008], ["retains", 1015], ["catalytic", 1023], ["activity", 1033], [",", 1041], ["Lys-27", 1043], ["specificity", 1050], [",", 1061], ["and", 1063], ["trimethylation", 1067], ["capacity", 1082], [".", 1090], ["Deletion", 1092], ["analysis", 1101], ["also", 1110], ["reveals", 1115], ["a", 1123], ["functional", 1125], ["requirement", 1136], ["for", 1148], ["a", 1152], ["conserved", 1154], ["E(Z", 1164], [")", 1167], ["domain", 1169], ["N", 1176], ["-", 1177], ["terminal", 1178], ["to", 1187], ["CXC", 1190], ["and", 1194], ["SET", 1198], [".", 1201], ["These", 1203], ["results", 1209], ["identify", 1217], ["critical", 1226], ["SET", 1235], ["domain", 1239], ["residues", 1246], ["needed", 1255], ["for", 1262], ["PRC2", 1266], ["enzyme", 1271], ["function", 1278], [",", 1286], ["and", 1288], ["they", 1292], ["also", 1297], ["emphasize", 1302], ["functional", 1312], ["inputs", 1323], ["from", 1330], ["outside", 1335], ["the", 1343], ["SET", 1347], ["domain", 1351], [".", 1357]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "Ghrelin exhibits its biological effect through binding to the growth hormone secretagogue 1a receptor (GHS-R1a). Recently, it has been reported that ghrelin has an anti-apoptotic effect in several cell types. However, the molecule mechanisms underlying the anti-apoptotic effect of ghrelin remain poorly understood. In this study, we investigated the intracellular mechanisms responsible for anti-apoptotic effect of ghrelin on human umbilical vein endothelial cells (HUVEC). Treatment of HUVEC with ghrelin inhibited high glucose-induced cell apoptosis. Ghrelin stimulated the rapid phosphorylation of mammalian target of rapamycin (mTOR), P70S6K and S6. The GHS-R1a-specific antagonist [D-Lys3]-GHRP-6 abolished the anti-apoptotic effect and inhibited the activation of mTOR, P70S6K, S6 induced by ghrelin. Pretreatment of cells with specific inhibitor of mTOR blocked the anti-apoptotic effect of ghrelin. In addition, ghrelin protected HUVECs against high glucose induced apoptosis by increasing Bcl-2/Bax ratio. Taken together, our results demonstrate that ghrelin produces a protective effect on HUVECs through activating GHS-R1a and mTOR/P70S6K signaling pathway mediates the effect of ghrelin. These observations suggest that ghrelin may act as a survival factor in preventing HUVECs apoptosis caused by high glucose.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "f64f5b4347d34aeba65aabe6813b3e13", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[102, 105]], "char_spans": [[603, 631]]}]}], "context_tokens": [["Ghrelin", 0], ["exhibits", 8], ["its", 17], ["biological", 21], ["effect", 32], ["through", 39], ["binding", 47], ["to", 55], ["the", 58], ["growth", 62], ["hormone", 69], ["secretagogue", 77], ["1a", 90], ["receptor", 93], ["(", 102], ["GHS", 103], ["-", 106], ["R1a", 107], [")", 110], [".", 111], ["Recently", 113], [",", 121], ["it", 123], ["has", 126], ["been", 130], ["reported", 135], ["that", 144], ["ghrelin", 149], ["has", 157], ["an", 161], ["anti", 164], ["-", 168], ["apoptotic", 169], ["effect", 179], ["in", 186], ["several", 189], ["cell", 197], ["types", 202], [".", 207], ["However", 209], [",", 216], ["the", 218], ["molecule", 222], ["mechanisms", 231], ["underlying", 242], ["the", 253], ["anti", 257], ["-", 261], ["apoptotic", 262], ["effect", 272], ["of", 279], ["ghrelin", 282], ["remain", 290], ["poorly", 297], ["understood", 304], [".", 314], ["In", 316], ["this", 319], ["study", 324], [",", 329], ["we", 331], ["investigated", 334], ["the", 347], ["intracellular", 351], ["mechanisms", 365], ["responsible", 376], ["for", 388], ["anti", 392], ["-", 396], ["apoptotic", 397], ["effect", 407], ["of", 414], ["ghrelin", 417], ["on", 425], ["human", 428], ["umbilical", 434], ["vein", 444], ["endothelial", 449], ["cells", 461], ["(", 467], ["HUVEC", 468], [")", 473], [".", 474], ["Treatment", 476], ["of", 486], ["HUVEC", 489], ["with", 495], ["ghrelin", 500], ["inhibited", 508], ["high", 518], ["glucose", 523], ["-", 530], ["induced", 531], ["cell", 539], ["apoptosis", 544], [".", 553], ["Ghrelin", 555], ["stimulated", 563], ["the", 574], ["rapid", 578], ["phosphorylation", 584], ["of", 600], ["mammalian", 603], ["target", 613], ["of", 620], ["rapamycin", 623], ["(", 633], ["mTOR", 634], [")", 638], [",", 639], ["P70S6", 641], ["K", 646], ["and", 648], ["S6", 652], [".", 654], ["The", 656], ["GHS", 660], ["-", 663], ["R1a", 664], ["-", 667], ["specific", 668], ["antagonist", 677], ["[", 688], ["D", 689], ["-", 690], ["Lys3]-GHRP-6", 691], ["abolished", 704], ["the", 714], ["anti", 718], ["-", 722], ["apoptotic", 723], ["effect", 733], ["and", 740], ["inhibited", 744], ["the", 754], ["activation", 758], ["of", 769], ["mTOR", 772], [",", 776], ["P70S6", 778], ["K", 783], [",", 784], ["S6", 786], ["induced", 789], ["by", 797], ["ghrelin", 800], [".", 807], ["Pretreatment", 809], ["of", 822], ["cells", 825], ["with", 831], ["specific", 836], ["inhibitor", 845], ["of", 855], ["mTOR", 858], ["blocked", 863], ["the", 871], ["anti", 875], ["-", 879], ["apoptotic", 880], ["effect", 890], ["of", 897], ["ghrelin", 900], [".", 907], ["In", 909], ["addition", 912], [",", 920], ["ghrelin", 922], ["protected", 930], ["HUVECs", 940], ["against", 947], ["high", 955], ["glucose", 960], ["induced", 968], ["apoptosis", 976], ["by", 986], ["increasing", 989], ["Bcl-2/Bax", 1000], ["ratio", 1010], [".", 1015], ["Taken", 1017], ["together", 1023], [",", 1031], ["our", 1033], ["results", 1037], ["demonstrate", 1045], ["that", 1057], ["ghrelin", 1062], ["produces", 1070], ["a", 1079], ["protective", 1081], ["effect", 1092], ["on", 1099], ["HUVECs", 1102], ["through", 1109], ["activating", 1117], ["GHS", 1128], ["-", 1131], ["R1a", 1132], ["and", 1136], ["mTOR", 1140], ["/", 1144], ["P70S6", 1145], ["K", 1150], ["signaling", 1152], ["pathway", 1162], ["mediates", 1170], ["the", 1179], ["effect", 1183], ["of", 1190], ["ghrelin", 1193], [".", 1200], ["These", 1202], ["observations", 1208], ["suggest", 1221], ["that", 1229], ["ghrelin", 1234], ["may", 1242], ["act", 1246], ["as", 1250], ["a", 1253], ["survival", 1255], ["factor", 1264], ["in", 1271], ["preventing", 1274], ["HUVECs", 1285], ["apoptosis", 1292], ["caused", 1302], ["by", 1309], ["high", 1312], ["glucose", 1317], [".", 1324]]}
{"context": "The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "e7dd43f614bd4a44808e13eb2dbde1f6", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[8, 8], [75, 75]], "char_spans": [[47, 58], [414, 425]]}]}], "context_tokens": [["The", 0], ["advent", 4], ["of", 11], ["antibiotics", 14], ["for", 26], ["the", 30], ["treatment", 34], ["of", 44], ["tuberculosis", 47], ["(", 60], ["TB", 61], [")", 63], ["represented", 65], ["a", 77], ["major", 79], ["breakthrough", 85], ["in", 98], ["the", 101], ["fight", 105], ["against", 111], ["the", 119], ["disease", 123], [".", 130], ["However", 132], [",", 139], ["since", 141], ["its", 147], ["first", 151], ["use", 157], [",", 160], ["antibiotic", 162], ["therapy", 173], ["has", 181], ["been", 185], ["associated", 190], ["with", 201], ["the", 206], ["emergence", 210], ["of", 220], ["resistance", 223], ["to", 234], ["drugs", 237], [".", 242], ["The", 244], ["incorrect", 248], ["use", 258], ["of", 262], ["anti", 265], ["-", 269], ["TB", 270], ["drugs", 273], [",", 278], ["either", 280], ["due", 287], ["to", 291], ["prescription", 294], ["errors", 307], [",", 313], ["low", 315], ["patient", 319], ["compliance", 327], [",", 337], ["or", 339], ["poor", 342], ["quality", 347], ["of", 355], ["drugs", 358], [",", 363], ["led", 365], ["to", 369], ["the", 372], ["widespread", 376], ["emergence", 387], ["of", 397], ["Mycobacterium", 400], ["tuberculosis", 414], ["strains", 427], ["with", 435], ["an", 440], ["expanding", 443], ["spectrum", 453], ["of", 462], ["resistance", 465], [".", 475], ["The", 477], ["spread", 481], ["of", 488], ["multidrug", 491], ["-", 500], ["resistant", 501], ["(", 511], ["MDR", 512], [")", 515], ["strains", 517], ["(", 525], ["ie", 526], [",", 528], ["strains", 530], ["resistant", 538], ["to", 548], ["both", 551], ["isoniazid", 556], ["and", 566], ["rifampicin", 570], [")", 580], ["has", 582], ["represented", 586], ["a", 598], ["major", 600], ["threat", 606], ["to", 613], ["TB", 616], ["control", 619], ["since", 627], ["the", 633], ["1990s", 637], [".", 642], ["In", 644], ["2006", 647], [",", 651], ["the", 653], ["first", 657], ["cases", 663], ["of", 669], ["MDR", 672], ["strains", 676], ["with", 684], ["further", 689], ["resistance", 697], ["to", 708], ["fluoroquinolone", 711], ["and", 727], ["injectable", 731], ["drugs", 742], ["were", 748], ["described", 753], ["and", 763], ["named", 767], ["extensively", 773], ["drug", 785], ["-", 789], ["resistant", 790], ["TB", 800], ["(", 803], ["XDR", 804], ["-", 807], ["TB", 808], [")", 810], [".", 811], ["The", 813], ["emergence", 817], ["of", 827], ["XDR", 830], ["-", 833], ["TB", 834], ["strains", 837], ["is", 845], ["a", 848], ["result", 850], ["of", 857], ["mismanagement", 860], ["of", 874], ["MDR", 877], ["cases", 881], [",", 886], ["and", 888], ["treatment", 892], ["relies", 902], ["on", 909], ["drugs", 912], ["that", 918], ["are", 923], ["less", 927], ["potent", 932], ["and", 939], ["more", 943], ["toxic", 948], ["than", 954], ["those", 959], ["used", 965], ["to", 970], ["treat", 973], ["drug", 979], ["-", 983], ["susceptible", 984], ["or", 996], ["MDR", 999], ["strains", 1003], [".", 1010], ["Furthermore", 1012], [",", 1023], ["treatment", 1025], ["success", 1035], ["is", 1043], ["lower", 1046], ["and", 1052], ["mortality", 1056], ["higher", 1066], ["than", 1073], ["achieved", 1078], ["in", 1087], ["MDR", 1090], ["-", 1093], ["TB", 1094], ["cases", 1097], [",", 1102], ["and", 1104], ["the", 1108], ["number", 1112], ["of", 1119], ["drugs", 1122], ["necessary", 1128], ["in", 1138], ["the", 1141], ["intensive", 1145], ["phase", 1155], ["of", 1161], ["treatment", 1164], ["may", 1174], ["be", 1178], ["higher", 1181], ["than", 1188], ["the", 1193], ["four", 1197], ["drugs", 1202], ["recommended", 1208], ["for", 1220], ["MDR", 1224], ["-", 1227], ["TB", 1228], [".", 1230], ["Linezolid", 1232], ["may", 1242], ["represent", 1246], ["a", 1256], ["valuable", 1258], ["drug", 1267], ["to", 1272], ["treat", 1275], ["cases", 1281], ["of", 1287], ["XDR", 1290], ["-", 1293], ["TB", 1294], [".", 1296], ["Delamanid", 1298], [",", 1307], ["bedaquiline", 1309], [",", 1320], ["and", 1322], ["PA-824", 1326], ["are", 1333], ["new", 1337], ["anti", 1341], ["-", 1345], ["TB", 1346], ["agents", 1349], ["in", 1356], ["the", 1359], ["development", 1363], ["pipeline", 1375], ["that", 1384], ["have", 1389], ["the", 1394], ["potential", 1398], ["to", 1408], ["enhance", 1411], ["the", 1419], ["cure", 1423], ["rate", 1428], ["of", 1433], ["XDR", 1436], ["-", 1439], ["TB", 1440], [".", 1442], ["The", 1444], ["best", 1448], ["measures", 1453], ["to", 1462], ["prevent", 1465], ["new", 1473], ["cases", 1477], ["of", 1483], ["XDR", 1486], ["-", 1489], ["TB", 1490], ["are", 1493], ["the", 1497], ["correct", 1501], ["management", 1509], ["of", 1520], ["MDR", 1523], ["-", 1526], ["TB", 1527], ["patients", 1530], [",", 1538], ["early", 1540], ["detection", 1546], [",", 1555], ["and", 1557], ["proper", 1561], ["treatment", 1568], ["of", 1578], ["existing", 1581], ["patients", 1590], ["with", 1599], ["XDR", 1604], ["-", 1607], ["TB", 1608], [".", 1610]]}
{"context": "Prior studies, all using SPECT techniques, failed to find any differences for dopamine transporter (DAT) in restless legs syndrome (RLS) subjects. The distinct pharmacokinetic properties associated with SPECT-determined DAT along with rapid biodynamic changes in DAT may, however, have missed membrane-bound DAT differences. The current studies assessed real-time DAT binding potentials (BP) in striatum of RLS patients using (11)C-methylphenidate and PET techniques. RLS medications were stopped at least 11 days prior to the PET study. Clinical severity of RLS was also assessed. PET scans were performed at 2 different times of day (starting at 08:30 and 19:30) in separate groups of subjects. The primary outcome measure was total striatal DAT BP. Thirty-six patients with primary RLS and 34 age- and gender-matched controls. RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans. DAT was decreased in putamen and caudate but not the ventral striatum of RLS subjects. There were no diurnal differences in DAT for the total group or for control and RLS separately. DAT BP did not correlate with any clinical measures of RLS. The current study found a significant decrease in DAT BP in two independent studies. These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b2a12b8918344a65a2cc5f9b028e8d2b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[258, 258]], "char_spans": [[1392, 1395]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], [",", 13], ["all", 15], ["using", 19], ["SPECT", 25], ["techniques", 31], [",", 41], ["failed", 43], ["to", 50], ["find", 53], ["any", 58], ["differences", 62], ["for", 74], ["dopamine", 78], ["transporter", 87], ["(", 99], ["DAT", 100], [")", 103], ["in", 105], ["restless", 108], ["legs", 117], ["syndrome", 122], ["(", 131], ["RLS", 132], [")", 135], ["subjects", 137], [".", 145], ["The", 147], ["distinct", 151], ["pharmacokinetic", 160], ["properties", 176], ["associated", 187], ["with", 198], ["SPECT", 203], ["-", 208], ["determined", 209], ["DAT", 220], ["along", 224], ["with", 230], ["rapid", 235], ["biodynamic", 241], ["changes", 252], ["in", 260], ["DAT", 263], ["may", 267], [",", 270], ["however", 272], [",", 279], ["have", 281], ["missed", 286], ["membrane", 293], ["-", 301], ["bound", 302], ["DAT", 308], ["differences", 312], [".", 323], ["The", 325], ["current", 329], ["studies", 337], ["assessed", 345], ["real", 354], ["-", 358], ["time", 359], ["DAT", 364], ["binding", 368], ["potentials", 376], ["(", 387], ["BP", 388], [")", 390], ["in", 392], ["striatum", 395], ["of", 404], ["RLS", 407], ["patients", 411], ["using", 420], ["(", 426], ["11)C", 427], ["-", 431], ["methylphenidate", 432], ["and", 448], ["PET", 452], ["techniques", 456], [".", 466], ["RLS", 468], ["medications", 472], ["were", 484], ["stopped", 489], ["at", 497], ["least", 500], ["11", 506], ["days", 509], ["prior", 514], ["to", 520], ["the", 523], ["PET", 527], ["study", 531], [".", 536], ["Clinical", 538], ["severity", 547], ["of", 556], ["RLS", 559], ["was", 563], ["also", 567], ["assessed", 572], [".", 580], ["PET", 582], ["scans", 586], ["were", 592], ["performed", 597], ["at", 607], ["2", 610], ["different", 612], ["times", 622], ["of", 628], ["day", 631], ["(", 635], ["starting", 636], ["at", 645], ["08:30", 648], ["and", 654], ["19:30", 658], [")", 663], ["in", 665], ["separate", 668], ["groups", 677], ["of", 684], ["subjects", 687], [".", 695], ["The", 697], ["primary", 701], ["outcome", 709], ["measure", 717], ["was", 725], ["total", 729], ["striatal", 735], ["DAT", 744], ["BP", 748], [".", 750], ["Thirty", 752], ["-", 758], ["six", 759], ["patients", 763], ["with", 772], ["primary", 777], ["RLS", 785], ["and", 789], ["34", 793], ["age-", 796], ["and", 801], ["gender", 805], ["-", 811], ["matched", 812], ["controls", 820], [".", 828], ["RLS", 830], ["subjects", 834], ["had", 843], ["significantly", 847], ["lower", 861], ["DAT", 867], ["binding", 871], ["in", 879], ["the", 882], ["striatum", 886], ["compared", 895], ["to", 904], ["controls", 907], ["on", 916], ["both", 919], ["the", 924], ["Day", 928], ["and", 932], ["the", 936], ["Night", 940], ["scans", 946], [".", 951], ["DAT", 953], ["was", 957], ["decreased", 961], ["in", 971], ["putamen", 974], ["and", 982], ["caudate", 986], ["but", 994], ["not", 998], ["the", 1002], ["ventral", 1006], ["striatum", 1014], ["of", 1023], ["RLS", 1026], ["subjects", 1030], [".", 1038], ["There", 1040], ["were", 1046], ["no", 1051], ["diurnal", 1054], ["differences", 1062], ["in", 1074], ["DAT", 1077], ["for", 1081], ["the", 1085], ["total", 1089], ["group", 1095], ["or", 1101], ["for", 1104], ["control", 1108], ["and", 1116], ["RLS", 1120], ["separately", 1124], [".", 1134], ["DAT", 1136], ["BP", 1140], ["did", 1143], ["not", 1147], ["correlate", 1151], ["with", 1161], ["any", 1166], ["clinical", 1170], ["measures", 1179], ["of", 1188], ["RLS", 1191], [".", 1194], ["The", 1196], ["current", 1200], ["study", 1208], ["found", 1214], ["a", 1220], ["significant", 1222], ["decrease", 1234], ["in", 1243], ["DAT", 1246], ["BP", 1250], ["in", 1253], ["two", 1256], ["independent", 1260], ["studies", 1272], [".", 1279], ["These", 1281], ["results", 1287], ["when", 1295], ["viewed", 1300], ["along", 1307], ["with", 1313], ["prior", 1318], ["RLS", 1324], ["SPECT", 1328], ["and", 1334], ["autopsy", 1338], ["studies", 1346], ["of", 1354], ["DAT", 1357], [",", 1360], ["and", 1362], ["cell", 1366], ["culture", 1371], ["studies", 1379], ["with", 1387], ["iron", 1392], ["deficiency", 1397], ["and", 1408], ["DAT", 1412], [",", 1415], ["suggest", 1417], ["that", 1425], ["membrane", 1430], ["-", 1438], ["bound", 1439], ["striatal", 1445], ["DAT", 1454], [",", 1457], ["but", 1459], ["not", 1463], ["total", 1467], ["cellular", 1473], ["DAT", 1482], [",", 1485], ["may", 1487], ["be", 1491], ["decreased", 1494], ["in", 1504], ["RLS", 1507], [".", 1510]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. Cardiac abnormalities, such as aortic root dilation have also been noted as well as several skeletal abnormalities. Its nosological status is unclear as it is hard to delineate SGS from similar disorders, such as Furlong, Marfan type II, Camurati-Engelmann and Loeys-Dietz syndromes. It has been suggested that these conditions represent a phenotypical spectrum associated with aberrant TGF-beta signalling. In support of this notion, we found a novel TGFBR2 missense mutation in a patient with features of SGS.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "9038f03f7233434d94806443d485149a", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[22, 22]], "char_spans": [[117, 132]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["a", 38], ["rare", 40], ["disorder", 45], ["characterized", 54], ["by", 68], ["a", 71], ["Marfan", 73], ["-", 79], ["like", 80], ["habitus", 85], [",", 92], ["mental", 94], ["retardation", 101], ["and", 113], ["craniosynostosis", 117], [".", 133], ["Cardiac", 135], ["abnormalities", 143], [",", 156], ["such", 158], ["as", 163], ["aortic", 166], ["root", 173], ["dilation", 178], ["have", 187], ["also", 192], ["been", 197], ["noted", 202], ["as", 208], ["well", 211], ["as", 216], ["several", 219], ["skeletal", 227], ["abnormalities", 236], [".", 249], ["Its", 251], ["nosological", 255], ["status", 267], ["is", 274], ["unclear", 277], ["as", 285], ["it", 288], ["is", 291], ["hard", 294], ["to", 299], ["delineate", 302], ["SGS", 312], ["from", 316], ["similar", 321], ["disorders", 329], [",", 338], ["such", 340], ["as", 345], ["Furlong", 348], [",", 355], ["Marfan", 357], ["type", 364], ["II", 369], [",", 371], ["Camurati", 373], ["-", 381], ["Engelmann", 382], ["and", 392], ["Loeys", 396], ["-", 401], ["Dietz", 402], ["syndromes", 408], [".", 417], ["It", 419], ["has", 422], ["been", 426], ["suggested", 431], ["that", 441], ["these", 446], ["conditions", 452], ["represent", 463], ["a", 473], ["phenotypical", 475], ["spectrum", 488], ["associated", 497], ["with", 508], ["aberrant", 513], ["TGF", 522], ["-", 525], ["beta", 526], ["signalling", 531], [".", 541], ["In", 543], ["support", 546], ["of", 554], ["this", 557], ["notion", 562], [",", 568], ["we", 570], ["found", 573], ["a", 579], ["novel", 581], ["TGFBR2", 587], ["missense", 594], ["mutation", 603], ["in", 612], ["a", 615], ["patient", 617], ["with", 625], ["features", 630], ["of", 639], ["SGS", 642], [".", 645]]}
{"context": "Although Gaucher disease is a rare disorder, recent developments in novel means for therapeutic intervention have invigorated both academic research and pharmaceutical industry discovery programmes. The common mutations found in the lysosomal enzyme deficient in Gaucher disease, beta-glucocerebrosidase, earmark these proteins for destruction by the endoplasmic reticulum-localised protein folding machinery, resulting in enzyme insufficiency, lysosomal glycolipid storage and subsequent pathology. However, many of these mutants can be rescued from global misfolding to preserve glycolipid substrate binding and eventual catalysis in the lysosome, by the addition of subinhibitory concentrations of pharmacologically active small molecules. This novel, chaperon-mediated approach has benefited from insights into the molecular understanding of beta-glucocerebrosidase structure, drug design and development in cellular models for disease.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["beta-glucocerebrosidase", "Beta glucocerebrosidase"], "qid": "60b2647e211743f5a7666d2124d1686a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[40, 42], [123, 125]], "char_spans": [[280, 302], [846, 868]]}]}], "context_tokens": [["Although", 0], ["Gaucher", 9], ["disease", 17], ["is", 25], ["a", 28], ["rare", 30], ["disorder", 35], [",", 43], ["recent", 45], ["developments", 52], ["in", 65], ["novel", 68], ["means", 74], ["for", 80], ["therapeutic", 84], ["intervention", 96], ["have", 109], ["invigorated", 114], ["both", 126], ["academic", 131], ["research", 140], ["and", 149], ["pharmaceutical", 153], ["industry", 168], ["discovery", 177], ["programmes", 187], [".", 197], ["The", 199], ["common", 203], ["mutations", 210], ["found", 220], ["in", 226], ["the", 229], ["lysosomal", 233], ["enzyme", 243], ["deficient", 250], ["in", 260], ["Gaucher", 263], ["disease", 271], [",", 278], ["beta", 280], ["-", 284], ["glucocerebrosidase", 285], [",", 303], ["earmark", 305], ["these", 313], ["proteins", 319], ["for", 328], ["destruction", 332], ["by", 344], ["the", 347], ["endoplasmic", 351], ["reticulum", 363], ["-", 372], ["localised", 373], ["protein", 383], ["folding", 391], ["machinery", 399], [",", 408], ["resulting", 410], ["in", 420], ["enzyme", 423], ["insufficiency", 430], [",", 443], ["lysosomal", 445], ["glycolipid", 455], ["storage", 466], ["and", 474], ["subsequent", 478], ["pathology", 489], [".", 498], ["However", 500], [",", 507], ["many", 509], ["of", 514], ["these", 517], ["mutants", 523], ["can", 531], ["be", 535], ["rescued", 538], ["from", 546], ["global", 551], ["misfolding", 558], ["to", 569], ["preserve", 572], ["glycolipid", 581], ["substrate", 592], ["binding", 602], ["and", 610], ["eventual", 614], ["catalysis", 623], ["in", 633], ["the", 636], ["lysosome", 640], [",", 648], ["by", 650], ["the", 653], ["addition", 657], ["of", 666], ["subinhibitory", 669], ["concentrations", 683], ["of", 698], ["pharmacologically", 701], ["active", 719], ["small", 726], ["molecules", 732], [".", 741], ["This", 743], ["novel", 748], [",", 753], ["chaperon", 755], ["-", 763], ["mediated", 764], ["approach", 773], ["has", 782], ["benefited", 786], ["from", 796], ["insights", 801], ["into", 810], ["the", 815], ["molecular", 819], ["understanding", 829], ["of", 843], ["beta", 846], ["-", 850], ["glucocerebrosidase", 851], ["structure", 870], [",", 879], ["drug", 881], ["design", 886], ["and", 893], ["development", 897], ["in", 909], ["cellular", 912], ["models", 921], ["for", 928], ["disease", 932], [".", 939]]}
{"context": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells. The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012. SNP increased Ca(2+) influx and intracellular Ca(2+) levels. In addition, SNP increased ERK and p38 MAPK phosphorylation, and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. These effects of SNP were prevented by SEA0400. SNP-induced cytotoxicity was not affected by inhibitors of the Ca(2+), Na(+) and store-operated/capacitative channels. Moreover, SNP-induced increase in intracellular Ca(2+) levels, ROS production and decrease in cell viability were blocked by a cGMP-dependent protein kinase (PKG) inhibitor. These results suggest that Ca(2+) influx via the reverse of NCX is involved in the cascade of NO-induced neuronal apoptosis and NO activates the NCX through guanylate cyclase/PKG pathway.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "78c14f714e4744988b69ad994964895d", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[1, 4]], "char_spans": [[4, 25]]}, {"text": "NCX", "token_spans": [[291, 291], [307, 307], [6, 6], [63, 63], [88, 88], [95, 95]], "char_spans": [[1572, 1574], [1657, 1659], [28, 30], [333, 335], [471, 473], [562, 564]]}]}], "context_tokens": [["The", 0], ["Na(+)/Ca(2", 4], ["+", 14], [")", 15], ["exchanger", 17], ["(", 27], ["NCX", 28], [")", 31], ["plays", 33], ["a", 39], ["role", 41], ["in", 46], ["the", 49], ["regulation", 53], ["of", 64], ["intracellular", 67], ["Ca(2", 81], ["+", 85], [")", 86], ["levels", 88], [",", 94], ["and", 96], ["nitric", 100], ["oxide", 107], ["(", 113], ["NO", 114], [")", 116], ["is", 118], ["involved", 121], ["in", 130], ["many", 133], ["pathological", 138], ["conditions", 151], ["including", 162], ["neurodegenerative", 172], ["disorders", 190], [".", 199], ["We", 201], ["have", 204], ["previously", 209], ["found", 220], ["that", 226], ["sodium", 231], ["nitroprusside", 238], ["(", 252], ["SNP", 253], [")", 256], [",", 257], ["an", 259], ["NO", 262], ["donor", 265], [",", 270], ["causes", 272], ["apoptotic", 279], ["-", 288], ["like", 289], ["cell", 294], ["death", 299], ["in", 305], ["cultured", 308], ["glial", 317], ["cells", 323], ["via", 329], ["NCX", 333], ["-", 336], ["mediated", 337], ["pathways", 346], ["and", 355], ["the", 359], ["mechanism", 363], ["for", 373], ["NO", 377], ["-", 379], ["induced", 380], ["cytotoxicity", 388], ["is", 401], ["cell", 404], ["type", 409], ["-", 413], ["dependent", 414], [".", 423], ["The", 425], ["present", 429], ["study", 437], ["examined", 443], ["using", 452], ["the", 458], ["specific", 462], ["NCX", 471], ["inhibitor", 475], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 485], ["(", 544], ["SEA0400", 545], [")", 552], ["whether", 554], ["NCX", 562], ["is", 566], ["involved", 569], ["in", 578], ["NO", 581], ["-", 583], ["induced", 584], ["injury", 592], ["in", 599], ["cultured", 602], ["neuronal", 611], ["cells", 620], [".", 625], ["The", 627], ["treatment", 631], ["of", 641], ["neuroblastoma", 644], ["SH", 658], ["-", 660], ["SY5Y", 661], ["cells", 666], ["with", 672], ["SNP", 677], ["resulted", 681], ["in", 690], ["apoptosis", 693], ["and", 703], ["the", 707], ["cytotoxicity", 711], ["was", 724], ["blocked", 728], ["by", 736], ["the", 739], ["mitogen", 743], ["-", 750], ["activated", 751], ["protein", 761], ["(", 769], ["MAP)/extracellular", 770], ["signal", 789], ["-", 795], ["regulated", 796], ["kinase", 806], ["(", 813], ["ERK", 814], [")", 817], ["kinase", 819], ["inhibitor", 826], ["U0126", 836], ["and", 842], ["the", 846], ["p38", 850], ["MAP", 854], ["kinase", 858], ["(", 865], ["MAPK", 866], [")", 870], ["inhibitor", 872], ["SB203580", 882], [",", 890], ["but", 892], ["not", 896], ["by", 900], ["the", 903], ["c", 907], ["-", 908], ["Jun", 909], ["N", 913], ["-", 914], ["terminal", 915], ["kinase", 924], ["(", 931], ["JNK", 932], [")", 935], ["inhibitor", 937], ["SP60012", 947], [".", 954], ["SNP", 956], ["increased", 960], ["Ca(2", 970], ["+", 974], [")", 975], ["influx", 977], ["and", 984], ["intracellular", 988], ["Ca(2", 1002], ["+", 1006], [")", 1007], ["levels", 1009], [".", 1015], ["In", 1017], ["addition", 1020], [",", 1028], ["SNP", 1030], ["increased", 1034], ["ERK", 1044], ["and", 1048], ["p38", 1052], ["MAPK", 1056], ["phosphorylation", 1061], [",", 1076], ["and", 1078], ["production", 1082], ["of", 1093], ["reactive", 1096], ["oxygen", 1105], ["species", 1112], ["(", 1120], ["ROS", 1121], [")", 1124], ["in", 1126], ["an", 1129], ["extracellular", 1132], ["Ca(2+)-dependent", 1146], ["manner", 1163], [".", 1169], ["These", 1171], ["effects", 1177], ["of", 1185], ["SNP", 1188], ["were", 1192], ["prevented", 1197], ["by", 1207], ["SEA0400", 1210], [".", 1217], ["SNP", 1219], ["-", 1222], ["induced", 1223], ["cytotoxicity", 1231], ["was", 1244], ["not", 1248], ["affected", 1252], ["by", 1261], ["inhibitors", 1264], ["of", 1275], ["the", 1278], ["Ca(2", 1282], ["+", 1286], [")", 1287], [",", 1288], ["Na(+", 1290], [")", 1294], ["and", 1296], ["store", 1300], ["-", 1305], ["operated", 1306], ["/", 1314], ["capacitative", 1315], ["channels", 1328], [".", 1336], ["Moreover", 1338], [",", 1346], ["SNP", 1348], ["-", 1351], ["induced", 1352], ["increase", 1360], ["in", 1369], ["intracellular", 1372], ["Ca(2", 1386], ["+", 1390], [")", 1391], ["levels", 1393], [",", 1399], ["ROS", 1401], ["production", 1405], ["and", 1416], ["decrease", 1420], ["in", 1429], ["cell", 1432], ["viability", 1437], ["were", 1447], ["blocked", 1452], ["by", 1460], ["a", 1463], ["cGMP", 1465], ["-", 1469], ["dependent", 1470], ["protein", 1480], ["kinase", 1488], ["(", 1495], ["PKG", 1496], [")", 1499], ["inhibitor", 1501], [".", 1510], ["These", 1512], ["results", 1518], ["suggest", 1526], ["that", 1534], ["Ca(2", 1539], ["+", 1543], [")", 1544], ["influx", 1546], ["via", 1553], ["the", 1557], ["reverse", 1561], ["of", 1569], ["NCX", 1572], ["is", 1576], ["involved", 1579], ["in", 1588], ["the", 1591], ["cascade", 1595], ["of", 1603], ["NO", 1606], ["-", 1608], ["induced", 1609], ["neuronal", 1617], ["apoptosis", 1626], ["and", 1636], ["NO", 1640], ["activates", 1643], ["the", 1653], ["NCX", 1657], ["through", 1661], ["guanylate", 1669], ["cyclase", 1679], ["/", 1686], ["PKG", 1687], ["pathway", 1691], [".", 1698]]}
{"context": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues and play a major role in epigenetic regulation of gene transcription. We solved the structures of the catalytic domains of GLP, G9a, Suv39H2 and PRDM2, four of the eight known human H3K9 methyltransferases in their apo conformation or in complex with the methyl donating cofactor, and peptide substrates. We analyzed the structural determinants for methylation state specificity, and designed a G9a mutant able to tri-methylate H3K9. We show that the I-SET domain acts as a rigid docking platform, while induced-fit of the Post-SET domain is necessary to achieve a catalytically competent conformation. We also propose a model where long-range electrostatics bring enzyme and histone substrate together, while the presence of an arginine upstream of the target lysine is critical for binding and specificity. This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "2a976c6394c14d34bced70aaed51880b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [111, 112], [94, 95]], "char_spans": [[0, 9], [620, 629], [545, 554]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["methyltransferases", 11], ["deposit", 30], ["methyl", 38], ["marks", 45], ["on", 51], ["specific", 54], ["histone", 63], ["tail", 71], ["lysine", 76], ["residues", 83], ["and", 92], ["play", 96], ["a", 101], ["major", 103], ["role", 109], ["in", 114], ["epigenetic", 117], ["regulation", 128], ["of", 139], ["gene", 142], ["transcription", 147], [".", 160], ["We", 162], ["solved", 165], ["the", 172], ["structures", 176], ["of", 187], ["the", 190], ["catalytic", 194], ["domains", 204], ["of", 212], ["GLP", 215], [",", 218], ["G9a", 220], [",", 223], ["Suv39H2", 225], ["and", 233], ["PRDM2", 237], [",", 242], ["four", 244], ["of", 249], ["the", 252], ["eight", 256], ["known", 262], ["human", 268], ["H3K9", 274], ["methyltransferases", 279], ["in", 298], ["their", 301], ["apo", 307], ["conformation", 311], ["or", 324], ["in", 327], ["complex", 330], ["with", 338], ["the", 343], ["methyl", 347], ["donating", 354], ["cofactor", 363], [",", 371], ["and", 373], ["peptide", 377], ["substrates", 385], [".", 395], ["We", 397], ["analyzed", 400], ["the", 409], ["structural", 413], ["determinants", 424], ["for", 437], ["methylation", 441], ["state", 453], ["specificity", 459], [",", 470], ["and", 472], ["designed", 476], ["a", 485], ["G9a", 487], ["mutant", 491], ["able", 498], ["to", 503], ["tri", 506], ["-", 509], ["methylate", 510], ["H3K9", 520], [".", 524], ["We", 526], ["show", 529], ["that", 534], ["the", 539], ["I", 543], ["-", 544], ["SET", 545], ["domain", 549], ["acts", 556], ["as", 561], ["a", 564], ["rigid", 566], ["docking", 572], ["platform", 580], [",", 588], ["while", 590], ["induced", 596], ["-", 603], ["fit", 604], ["of", 608], ["the", 611], ["Post", 615], ["-", 619], ["SET", 620], ["domain", 624], ["is", 631], ["necessary", 634], ["to", 644], ["achieve", 647], ["a", 655], ["catalytically", 657], ["competent", 671], ["conformation", 681], [".", 693], ["We", 695], ["also", 698], ["propose", 703], ["a", 711], ["model", 713], ["where", 719], ["long", 725], ["-", 729], ["range", 730], ["electrostatics", 736], ["bring", 751], ["enzyme", 757], ["and", 764], ["histone", 768], ["substrate", 776], ["together", 786], [",", 794], ["while", 796], ["the", 802], ["presence", 806], ["of", 815], ["an", 818], ["arginine", 821], ["upstream", 830], ["of", 839], ["the", 842], ["target", 846], ["lysine", 853], ["is", 860], ["critical", 863], ["for", 872], ["binding", 876], ["and", 884], ["specificity", 888], [".", 899], ["This", 901], ["article", 906], ["can", 914], ["also", 918], ["be", 923], ["viewed", 926], ["as", 933], ["an", 936], ["enhanced", 939], ["version", 948], ["in", 956], ["which", 959], ["the", 965], ["text", 969], ["of", 974], ["the", 977], ["article", 981], ["is", 989], ["integrated", 992], ["with", 1003], ["interactive", 1008], ["3D", 1020], ["representations", 1023], ["and", 1039], ["animated", 1043], ["transitions", 1052], [".", 1063], ["Please", 1065], ["note", 1072], ["that", 1077], ["a", 1082], ["web", 1084], ["plugin", 1088], ["is", 1095], ["required", 1098], ["to", 1107], ["access", 1110], ["this", 1117], ["enhanced", 1122], ["functionality", 1131], [".", 1144], ["Instructions", 1146], ["for", 1159], ["the", 1163], ["installation", 1167], ["and", 1180], ["use", 1184], ["of", 1188], ["the", 1191], ["web", 1195], ["plugin", 1199], ["are", 1206], ["available", 1210], ["in", 1220], ["Text", 1223], ["S1", 1228], [".", 1230]]}
{"context": "Selenoproteins contain the 21st amino acid selenocysteine which is encoded by an inframe UGA codon, usually read as a stop. In eukaryotes, its co-translational recoding requires the presence of an RNA stem-loop structure, the SECIS element in the 3 untranslated region of (UTR) selenoprotein mRNAs. Despite little sequence conservation, SECIS elements share the same overall secondary structure. Until recently, the lack of a significantly high number of selenoprotein mRNA sequences hampered the identification of other potential sequence conservation. In this work, the web-based tool SECISaln provides for the first time an extensive structure-based sequence alignment of SECIS elements resulting from the well-defined secondary structure of the SECIS RNA and the increased size of the eukaryotic selenoproteome. We have used SECISaln to improve our knowledge of SECIS secondary structure and to discover novel, conserved nucleotide positions and we believe it will be a useful tool for the selenoprotein and RNA scientific communities. SECISaln is freely available as a web-based tool at http://genome.crg.es/software/secisaln/.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "8708371a1d3b41c89c378772ccbe6fb2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[128, 128], [61, 61], [42, 42], [148, 148], [116, 116]], "char_spans": [[749, 753], [337, 341], [226, 230], [866, 870], [675, 679]]}]}], "context_tokens": [["Selenoproteins", 0], ["contain", 15], ["the", 23], ["21st", 27], ["amino", 32], ["acid", 38], ["selenocysteine", 43], ["which", 58], ["is", 64], ["encoded", 67], ["by", 75], ["an", 78], ["inframe", 81], ["UGA", 89], ["codon", 93], [",", 98], ["usually", 100], ["read", 108], ["as", 113], ["a", 116], ["stop", 118], [".", 122], ["In", 124], ["eukaryotes", 127], [",", 137], ["its", 139], ["co", 143], ["-", 145], ["translational", 146], ["recoding", 160], ["requires", 169], ["the", 178], ["presence", 182], ["of", 191], ["an", 194], ["RNA", 197], ["stem", 201], ["-", 205], ["loop", 206], ["structure", 211], [",", 220], ["the", 222], ["SECIS", 226], ["element", 232], ["in", 240], ["the", 243], ["3", 247], ["untranslated", 249], ["region", 262], ["of", 269], ["(", 272], ["UTR", 273], [")", 276], ["selenoprotein", 278], ["mRNAs", 292], [".", 297], ["Despite", 299], ["little", 307], ["sequence", 314], ["conservation", 323], [",", 335], ["SECIS", 337], ["elements", 343], ["share", 352], ["the", 358], ["same", 362], ["overall", 367], ["secondary", 375], ["structure", 385], [".", 394], ["Until", 396], ["recently", 402], [",", 410], ["the", 412], ["lack", 416], ["of", 421], ["a", 424], ["significantly", 426], ["high", 440], ["number", 445], ["of", 452], ["selenoprotein", 455], ["mRNA", 469], ["sequences", 474], ["hampered", 484], ["the", 493], ["identification", 497], ["of", 512], ["other", 515], ["potential", 521], ["sequence", 531], ["conservation", 540], [".", 552], ["In", 554], ["this", 557], ["work", 562], [",", 566], ["the", 568], ["web", 572], ["-", 575], ["based", 576], ["tool", 582], ["SECISaln", 587], ["provides", 596], ["for", 605], ["the", 609], ["first", 613], ["time", 619], ["an", 624], ["extensive", 627], ["structure", 637], ["-", 646], ["based", 647], ["sequence", 653], ["alignment", 662], ["of", 672], ["SECIS", 675], ["elements", 681], ["resulting", 690], ["from", 700], ["the", 705], ["well", 709], ["-", 713], ["defined", 714], ["secondary", 722], ["structure", 732], ["of", 742], ["the", 745], ["SECIS", 749], ["RNA", 755], ["and", 759], ["the", 763], ["increased", 767], ["size", 777], ["of", 782], ["the", 785], ["eukaryotic", 789], ["selenoproteome", 800], [".", 814], ["We", 816], ["have", 819], ["used", 824], ["SECISaln", 829], ["to", 838], ["improve", 841], ["our", 849], ["knowledge", 853], ["of", 863], ["SECIS", 866], ["secondary", 872], ["structure", 882], ["and", 892], ["to", 896], ["discover", 899], ["novel", 908], [",", 913], ["conserved", 915], ["nucleotide", 925], ["positions", 936], ["and", 946], ["we", 950], ["believe", 953], ["it", 961], ["will", 964], ["be", 969], ["a", 972], ["useful", 974], ["tool", 981], ["for", 986], ["the", 990], ["selenoprotein", 994], ["and", 1008], ["RNA", 1012], ["scientific", 1016], ["communities", 1027], [".", 1038], ["SECISaln", 1040], ["is", 1049], ["freely", 1052], ["available", 1059], ["as", 1069], ["a", 1072], ["web", 1074], ["-", 1077], ["based", 1078], ["tool", 1084], ["at", 1089], ["http://genome.crg.es", 1092], ["/", 1112], ["software", 1113], ["/", 1121], ["secisaln/.", 1122]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fdeaba7b6cb142ef8d135fd8ca5d8c0a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[193, 195], [141, 143], [18, 20], [96, 98]], "char_spans": [[1032, 1038], [723, 729], [105, 111], [514, 520]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["Philadelphia", 55], ["(", 68], ["Ph", 69], [")", 71], ["chromosome", 73], ["with", 84], ["a", 89], ["chimeric", 91], ["gene", 100], ["BCR", 105], ["-", 108], ["ABL", 109], ["created", 113], ["by", 121], ["reciprocal", 124], ["t(9:22", 135], [")", 141], ["(", 143], ["q34;q11", 144], [")", 151], ["translocation", 153], [".", 166], ["Variant", 168], ["Ph", 176], ["chromosome", 179], ["translocations", 190], ["involving", 205], ["chromosomes", 215], ["other", 227], ["than", 233], ["9", 238], ["and", 240], ["22", 244], ["are", 247], ["found", 251], ["in", 257], ["5", 260], ["-", 261], ["10", 262], ["%", 264], ["of", 266], ["CML", 269], ["cases", 273], [".", 278], ["We", 280], ["here", 283], ["report", 288], ["a", 295], ["CML", 297], ["patient", 301], ["who", 309], ["carries", 313], ["a", 321], ["four", 323], ["-", 327], ["way", 328], ["Ph", 332], ["chromosome", 335], ["translocation", 346], [",", 359], ["t(9;22;15;19", 361], [")", 373], ["(", 375], ["q34;q11;q15;q13", 376], [")", 391], [".", 392], ["The", 394], ["patient", 398], ["was", 406], ["diagnosed", 410], ["in", 420], ["1997", 423], ["and", 428], ["initially", 432], ["treated", 442], ["with", 450], ["hydroxyurea", 455], [".", 466], ["In", 468], ["2002", 471], [",", 475], ["treatment", 477], ["with", 487], ["imatinib", 492], [",", 500], ["a", 502], ["selective", 504], ["BCR", 514], ["-", 517], ["ABL", 518], ["tyrosine", 522], ["kinase", 531], ["inhibitor", 538], ["(", 548], ["TKI", 549], [")", 552], [",", 553], ["was", 555], ["started", 559], ["but", 567], ["Ph", 571], ["-", 573], ["positive", 574], ["chromosomes", 583], ["remained", 595], ["at", 604], ["the", 607], ["levels", 611], ["of", 618], ["42", 621], ["-", 623], ["65", 624], ["%", 626], [",", 627], ["indicating", 629], ["imatinib", 640], ["failure", 649], [".", 656], ["In", 658], ["2006", 661], [",", 665], ["the", 667], ["point", 671], ["mutations", 677], ["of", 687], ["F359I", 690], ["and", 696], ["L387", 700], ["M", 704], ["were", 706], ["detected", 711], ["in", 720], ["BCR", 723], ["/", 726], ["ABL", 727], ["gene", 731], [",", 735], ["which", 737], ["may", 743], ["be", 747], ["related", 750], ["to", 758], ["imatinib", 761], ["failure", 770], [".", 777], ["Treatment", 779], ["with", 789], ["nilotinib", 794], [",", 803], ["a", 805], ["TKI", 807], ["with", 811], ["high", 816], ["target", 821], ["specificity", 828], [",", 839], ["was", 841], ["then", 845], ["started", 850], ["which", 858], ["resulted", 864], ["in", 873], ["durable", 876], ["major", 884], ["molecular", 890], ["response", 900], [".", 908], ["Administration", 910], ["of", 925], ["nilotinib", 928], ["offered", 938], ["an", 946], ["effective", 949], ["treatment", 959], ["in", 969], ["a", 972], ["CML", 974], ["patient", 978], ["with", 986], ["variant", 991], ["Ph", 999], ["chromosome", 1002], ["translocations", 1013], ["and", 1028], ["BCR", 1032], ["-", 1035], ["ABL", 1036], ["point", 1040], ["mutations", 1046], ["after", 1056], ["imatinib", 1062], ["failure", 1071], [".", 1078]]}
{"context": "To demonstrate the importance of preventive measures when a case of tuberculosis is detected, identify the causes that favored a tuberculosis outbreak in a school and determine the efficiency of obtaining induced sputum samples. Descriptive, study. The Santa Maria de la Providencia school, located in the municipality of Alcala de Henares in Spain. On April 11, 2005, a case of bacilliform pulmonary tuberculosis was notified in a teacher. Study of contacts in the collective was performed as a programmed intervention. Mantoux skin test and, if positive, chest radiograph were performed in contacts. Treatment of latent or active tuberculosis was recommended according to the result. School exposures were identified and underwent the Mantoux skin test (142 students in years 1, 2, 3, and 4 of compulsory secondary education and 22 teachers). The Mantoux test was positive in 68 students (48 %) and seven teachers (32 %). In seven students with results compatible with active tuberculosis disease, sputum induction was performed and treatment was started. A further two students, identified as contacts, were studied in another center and also started treatment for active tuberculosis disease. Due to the high risk of contagion, study of contacts was extended to the remaining students in compulsory secondary education. In this second phase, 134 students received the Mantoux skin test and seven were Mantoux positive (5.2 %). In all these students, active tuberculosis disease was ruled out. Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "432d404973ba41318c6fe93752543d01", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[11, 11], [21, 21], [70, 70], [210, 210], [263, 263], [270, 270], [178, 178], [110, 110]], "char_spans": [[68, 79], [129, 140], [401, 412], [1175, 1186], [1461, 1472], [1504, 1515], [978, 989], [632, 643]]}]}], "context_tokens": [["To", 0], ["demonstrate", 3], ["the", 15], ["importance", 19], ["of", 30], ["preventive", 33], ["measures", 44], ["when", 53], ["a", 58], ["case", 60], ["of", 65], ["tuberculosis", 68], ["is", 81], ["detected", 84], [",", 92], ["identify", 94], ["the", 103], ["causes", 107], ["that", 114], ["favored", 119], ["a", 127], ["tuberculosis", 129], ["outbreak", 142], ["in", 151], ["a", 154], ["school", 156], ["and", 163], ["determine", 167], ["the", 177], ["efficiency", 181], ["of", 192], ["obtaining", 195], ["induced", 205], ["sputum", 213], ["samples", 220], [".", 227], ["Descriptive", 229], [",", 240], ["study", 242], [".", 247], ["The", 249], ["Santa", 253], ["Maria", 259], ["de", 265], ["la", 268], ["Providencia", 271], ["school", 283], [",", 289], ["located", 291], ["in", 299], ["the", 302], ["municipality", 306], ["of", 319], ["Alcala", 322], ["de", 329], ["Henares", 332], ["in", 340], ["Spain", 343], [".", 348], ["On", 350], ["April", 353], ["11", 359], [",", 361], ["2005", 363], [",", 367], ["a", 369], ["case", 371], ["of", 376], ["bacilliform", 379], ["pulmonary", 391], ["tuberculosis", 401], ["was", 414], ["notified", 418], ["in", 427], ["a", 430], ["teacher", 432], [".", 439], ["Study", 441], ["of", 447], ["contacts", 450], ["in", 459], ["the", 462], ["collective", 466], ["was", 477], ["performed", 481], ["as", 491], ["a", 494], ["programmed", 496], ["intervention", 507], [".", 519], ["Mantoux", 521], ["skin", 529], ["test", 534], ["and", 539], [",", 542], ["if", 544], ["positive", 547], [",", 555], ["chest", 557], ["radiograph", 563], ["were", 574], ["performed", 579], ["in", 589], ["contacts", 592], [".", 600], ["Treatment", 602], ["of", 612], ["latent", 615], ["or", 622], ["active", 625], ["tuberculosis", 632], ["was", 645], ["recommended", 649], ["according", 661], ["to", 671], ["the", 674], ["result", 678], [".", 684], ["School", 686], ["exposures", 693], ["were", 703], ["identified", 708], ["and", 719], ["underwent", 723], ["the", 733], ["Mantoux", 737], ["skin", 745], ["test", 750], ["(", 755], ["142", 756], ["students", 760], ["in", 769], ["years", 772], ["1", 778], [",", 779], ["2", 781], [",", 782], ["3", 784], [",", 785], ["and", 787], ["4", 791], ["of", 793], ["compulsory", 796], ["secondary", 807], ["education", 817], ["and", 827], ["22", 831], ["teachers", 834], [")", 842], [".", 843], ["The", 845], ["Mantoux", 849], ["test", 857], ["was", 862], ["positive", 866], ["in", 875], ["68", 878], ["students", 881], ["(", 890], ["48", 891], ["%", 894], [")", 895], ["and", 897], ["seven", 901], ["teachers", 907], ["(", 916], ["32", 917], ["%", 920], [")", 921], [".", 922], ["In", 924], ["seven", 927], ["students", 933], ["with", 942], ["results", 947], ["compatible", 955], ["with", 966], ["active", 971], ["tuberculosis", 978], ["disease", 991], [",", 998], ["sputum", 1000], ["induction", 1007], ["was", 1017], ["performed", 1021], ["and", 1031], ["treatment", 1035], ["was", 1045], ["started", 1049], [".", 1056], ["A", 1058], ["further", 1060], ["two", 1068], ["students", 1072], [",", 1080], ["identified", 1082], ["as", 1093], ["contacts", 1096], [",", 1104], ["were", 1106], ["studied", 1111], ["in", 1119], ["another", 1122], ["center", 1130], ["and", 1137], ["also", 1141], ["started", 1146], ["treatment", 1154], ["for", 1164], ["active", 1168], ["tuberculosis", 1175], ["disease", 1188], [".", 1195], ["Due", 1197], ["to", 1201], ["the", 1204], ["high", 1208], ["risk", 1213], ["of", 1218], ["contagion", 1221], [",", 1230], ["study", 1232], ["of", 1238], ["contacts", 1241], ["was", 1250], ["extended", 1254], ["to", 1263], ["the", 1266], ["remaining", 1270], ["students", 1280], ["in", 1289], ["compulsory", 1292], ["secondary", 1303], ["education", 1313], [".", 1322], ["In", 1324], ["this", 1327], ["second", 1332], ["phase", 1339], [",", 1344], ["134", 1346], ["students", 1350], ["received", 1359], ["the", 1368], ["Mantoux", 1372], ["skin", 1380], ["test", 1385], ["and", 1390], ["seven", 1394], ["were", 1400], ["Mantoux", 1405], ["positive", 1413], ["(", 1422], ["5.2", 1423], ["%", 1427], [")", 1428], [".", 1429], ["In", 1431], ["all", 1434], ["these", 1438], ["students", 1444], [",", 1452], ["active", 1454], ["tuberculosis", 1461], ["disease", 1474], ["was", 1482], ["ruled", 1486], ["out", 1492], [".", 1495], ["Latent", 1497], ["tuberculosis", 1504], ["treatment", 1517], ["was", 1527], ["recommended", 1531], ["in", 1543], ["all", 1546], ["Mantoux", 1550], ["-", 1557], ["positive", 1558], ["contacts", 1567], [".", 1575]]}
{"context": "Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to use this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy, we interrogated CLL membrane-specific autologous immunoglobulin G reactivity. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "692ffa1dbcd344f7b86b7f0d61e5403f", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[188, 188]], "char_spans": [[1168, 1176]]}]}], "context_tokens": [["Membrane", 0], ["antigens", 9], ["are", 18], ["critical", 22], ["to", 31], ["the", 34], ["pathogenesis", 38], ["of", 51], ["chronic", 54], ["lymphocytic", 62], ["leukemia", 74], ["(", 83], ["CLL", 84], [")", 87], ["as", 89], ["they", 92], ["facilitate", 97], ["microenvironment", 108], ["homing", 125], [",", 131], ["proliferation", 133], [",", 146], ["and", 148], ["survival", 152], [".", 160], ["Targeting", 162], ["the", 172], ["CLL", 176], ["membrane", 180], ["and", 189], ["associated", 193], ["signaling", 204], ["patterns", 214], ["is", 223], ["a", 226], ["current", 228], ["focus", 236], ["of", 242], ["therapeutic", 245], ["development", 257], [".", 268], ["Many", 270], ["tumor", 275], ["membrane", 281], ["targets", 290], ["are", 298], ["simultaneously", 302], ["targeted", 317], ["by", 326], ["humoral", 329], ["immunity", 337], [",", 345], ["thus", 347], ["forming", 352], ["recognizable", 360], ["immunoglobulin", 373], ["responses", 388], [".", 397], ["We", 399], ["sought", 402], ["to", 409], ["use", 412], ["this", 416], ["immune", 421], ["response", 428], ["to", 437], ["identify", 440], ["novel", 449], ["membrane", 455], ["-", 463], ["associated", 464], ["targets", 475], ["for", 483], ["CLL", 487], [".", 490], ["Using", 492], ["a", 498], ["novel", 500], ["strategy", 506], [",", 514], ["we", 516], ["interrogated", 519], ["CLL", 532], ["membrane", 536], ["-", 544], ["specific", 545], ["autologous", 554], ["immunoglobulin", 565], ["G", 580], ["reactivity", 582], [".", 592], ["Our", 594], ["analysis", 598], ["unveiled", 607], ["lymphocyte", 616], ["cytosolic", 627], ["protein", 637], ["1", 645], ["(", 647], ["LCP1", 648], [")", 652], [",", 653], ["a", 655], ["lymphocyte", 657], ["-", 667], ["specific", 668], ["target", 677], ["that", 684], ["is", 689], ["highly", 692], ["expressed", 699], ["in", 709], ["CLL", 712], [".", 715], ["LCP1", 717], ["plays", 722], ["a", 728], ["critical", 730], ["role", 739], ["in", 744], ["B", 747], ["-", 748], ["cell", 749], ["biology", 754], ["by", 762], ["crosslinking", 765], ["F", 778], ["-", 779], ["actin", 780], ["filaments", 786], [",", 795], ["thereby", 797], ["solidifying", 805], ["cytoskeletal", 817], ["structures", 830], ["and", 841], ["providing", 845], ["a", 855], ["scaffold", 857], ["for", 866], ["critical", 870], ["signaling", 879], ["pathways", 889], [".", 897], ["Small", 899], ["interfering", 905], ["RNA", 917], ["knockdown", 921], ["of", 931], ["LCP1", 934], ["blocked", 939], ["migration", 947], ["toward", 957], ["CXCL12", 964], ["in", 971], ["transwell", 974], ["assays", 984], ["and", 991], ["to", 995], ["bone", 998], ["marrow", 1003], ["in", 1010], ["an", 1013], ["in", 1016], ["vivo", 1019], ["xenotransplant", 1024], ["model", 1039], [",", 1044], ["confirming", 1046], ["a", 1057], ["role", 1059], ["for", 1064], ["LCP1", 1068], ["in", 1073], ["leukemia", 1076], ["migration", 1085], [".", 1094], ["Furthermore", 1096], [",", 1107], ["we", 1109], ["demonstrate", 1112], ["that", 1124], ["the", 1129], ["Bruton", 1133], ["'s", 1139], ["tyrosine", 1142], ["kinase", 1151], ["inhibitor", 1158], ["ibrutinib", 1168], ["or", 1178], ["the", 1181], ["PI3", 1185], ["K", 1188], ["inhibitor", 1190], ["idelalisib", 1200], ["block", 1211], ["B", 1217], ["-", 1218], ["cell", 1219], ["receptor", 1224], ["induced", 1233], ["activation", 1241], ["of", 1252], ["LCP1", 1255], [".", 1259], ["Our", 1261], ["data", 1265], ["demonstrate", 1270], ["a", 1282], ["novel", 1284], ["strategy", 1290], ["to", 1299], ["identify", 1302], ["cancer", 1311], ["membrane", 1318], ["target", 1327], ["antigens", 1334], ["using", 1343], ["humoral", 1349], ["anti", 1357], ["-", 1361], ["tumor", 1362], ["immunity", 1368], [".", 1376], ["In", 1378], ["addition", 1381], [",", 1389], ["we", 1391], ["identify", 1394], ["LCP1", 1403], ["as", 1408], ["a", 1411], ["membrane", 1413], ["-", 1421], ["associated", 1422], ["target", 1433], ["in", 1440], ["CLL", 1443], ["with", 1447], ["confirmed", 1452], ["pathogenic", 1462], ["significance", 1473], [".", 1485], ["This", 1487], ["clinical", 1492], ["trial", 1501], ["was", 1507], ["registered", 1511], ["at", 1522], ["clinicaltrials.gov", 1525], [";", 1543], ["study", 1545], ["ID", 1551], ["number", 1554], [":", 1560], ["OSU-0025", 1562], ["OSU-0156", 1571], [".", 1579]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "Focal cortical dysplasia is a malformation of cortical development, which is the most common cause of medically refractory epilepsy in the pediatric population and the second/third most common etiology of medically intractable seizures in adults.Both genetic and acquired factors are involved in the pathogenesis of cortical dysplasia. Numerous classifications of the complex structural abnormalities of focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia are recognized.Type I focal cortical dysplasia with mild symptomatic expression and late onset, is more often seen in adults, with changes present in the temporal lobe.Clinical symptoms are more severe in type II of cortical dysplasia usually seen in children. In this type, more extensive changes occur outside the temporal lobe with predilection for the frontal lobes.New type III is one of the above dysplasias with associated another principal lesion as hippocampal sclerosis, tumor, vascular malformation or acquired pathology during early life.Brain MRI imaging shows abnormalities in the majority of type II dysplasias and in only some of type I cortical dysplasias.THE MOST COMMON FINDINGS ON MRI IMAGING INCLUDE: focal cortical thickening or thinning, areas of focal brain atrophy, blurring of the gray-white junction, increased signal on T2- and FLAIR-weighted images in the gray and subcortical white matter often tapering toward the ventricle. On the basis of the MRI findings, it is possible to differentiate between type I and type II cortical dysplasia. A complete resection of the epileptogenic zone is required for seizure-free life. MRI imaging is very helpful to identify those patients who are likely to benefit from surgical treatment in a group of patients with drug-resistant epilepsy.However, in type I cortical dysplasia, MR imaging is often normal, and also in both types the lesion seen on MRI may be smaller than the seizure-generating region seen in the EEG. The abnormalities may also involve vital for life brain parts, where curative surgery will not be an option. Therefore, other diagnostic imaging techniques such as FDG PET, MEG, DTI and intra-cranial EEG are widely used to establish the diagnosis and to decide on management.With advances in both genetics and neuroimaging, we may develop a better understanding of patients with drug-resistant epilepsy, which will help us to provide more successful pharmacological and/or surgical treatment in the future.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "6016428d0f8e493c8cbd0a4863c7c102", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[101, 103], [61, 63], [0, 2]], "char_spans": [[621, 644], [404, 427], [0, 23]]}]}], "context_tokens": [["Focal", 0], ["cortical", 6], ["dysplasia", 15], ["is", 25], ["a", 28], ["malformation", 30], ["of", 43], ["cortical", 46], ["development", 55], [",", 66], ["which", 68], ["is", 74], ["the", 77], ["most", 81], ["common", 86], ["cause", 93], ["of", 99], ["medically", 102], ["refractory", 112], ["epilepsy", 123], ["in", 132], ["the", 135], ["pediatric", 139], ["population", 149], ["and", 160], ["the", 164], ["second", 168], ["/", 174], ["third", 175], ["most", 181], ["common", 186], ["etiology", 193], ["of", 202], ["medically", 205], ["intractable", 215], ["seizures", 227], ["in", 236], ["adults", 239], [".", 245], ["Both", 246], ["genetic", 251], ["and", 259], ["acquired", 263], ["factors", 272], ["are", 280], ["involved", 284], ["in", 293], ["the", 296], ["pathogenesis", 300], ["of", 313], ["cortical", 316], ["dysplasia", 325], [".", 334], ["Numerous", 336], ["classifications", 345], ["of", 361], ["the", 364], ["complex", 368], ["structural", 376], ["abnormalities", 387], ["of", 401], ["focal", 404], ["cortical", 410], ["dysplasia", 419], ["have", 429], ["been", 434], ["proposed", 439], ["-", 448], ["from", 450], ["Taylor", 455], ["et", 462], ["al", 465], [".", 467], ["in", 469], ["1971", 472], ["to", 477], ["the", 480], ["last", 484], ["modification", 489], ["of", 502], ["Palmini", 505], ["classification", 513], ["made", 528], ["by", 533], ["Blumcke", 536], ["in", 544], ["2011", 547], [".", 551], ["In", 553], ["general", 556], [",", 563], ["three", 565], ["types", 571], ["of", 577], ["cortical", 580], ["dysplasia", 589], ["are", 599], ["recognized", 603], [".", 613], ["Type", 614], ["I", 619], ["focal", 621], ["cortical", 627], ["dysplasia", 636], ["with", 646], ["mild", 651], ["symptomatic", 656], ["expression", 668], ["and", 679], ["late", 683], ["onset", 688], [",", 693], ["is", 695], ["more", 698], ["often", 703], ["seen", 709], ["in", 714], ["adults", 717], [",", 723], ["with", 725], ["changes", 730], ["present", 738], ["in", 746], ["the", 749], ["temporal", 753], ["lobe", 762], [".", 766], ["Clinical", 767], ["symptoms", 776], ["are", 785], ["more", 789], ["severe", 794], ["in", 801], ["type", 804], ["II", 809], ["of", 812], ["cortical", 815], ["dysplasia", 824], ["usually", 834], ["seen", 842], ["in", 847], ["children", 850], [".", 858], ["In", 860], ["this", 863], ["type", 868], [",", 872], ["more", 874], ["extensive", 879], ["changes", 889], ["occur", 897], ["outside", 903], ["the", 911], ["temporal", 915], ["lobe", 924], ["with", 929], ["predilection", 934], ["for", 947], ["the", 951], ["frontal", 955], ["lobes", 963], [".", 968], ["New", 969], ["type", 973], ["III", 978], ["is", 982], ["one", 985], ["of", 989], ["the", 992], ["above", 996], ["dysplasias", 1002], ["with", 1013], ["associated", 1018], ["another", 1029], ["principal", 1037], ["lesion", 1047], ["as", 1054], ["hippocampal", 1057], ["sclerosis", 1069], [",", 1078], ["tumor", 1080], [",", 1085], ["vascular", 1087], ["malformation", 1096], ["or", 1109], ["acquired", 1112], ["pathology", 1121], ["during", 1131], ["early", 1138], ["life", 1144], [".", 1148], ["Brain", 1149], ["MRI", 1155], ["imaging", 1159], ["shows", 1167], ["abnormalities", 1173], ["in", 1187], ["the", 1190], ["majority", 1194], ["of", 1203], ["type", 1206], ["II", 1211], ["dysplasias", 1214], ["and", 1225], ["in", 1229], ["only", 1232], ["some", 1237], ["of", 1242], ["type", 1245], ["I", 1250], ["cortical", 1252], ["dysplasias", 1261], [".", 1271], ["THE", 1272], ["MOST", 1276], ["COMMON", 1281], ["FINDINGS", 1288], ["ON", 1297], ["MRI", 1300], ["IMAGING", 1304], ["INCLUDE", 1312], [":", 1319], ["focal", 1321], ["cortical", 1327], ["thickening", 1336], ["or", 1347], ["thinning", 1350], [",", 1358], ["areas", 1360], ["of", 1366], ["focal", 1369], ["brain", 1375], ["atrophy", 1381], [",", 1388], ["blurring", 1390], ["of", 1399], ["the", 1402], ["gray", 1406], ["-", 1410], ["white", 1411], ["junction", 1417], [",", 1425], ["increased", 1427], ["signal", 1437], ["on", 1444], ["T2-", 1447], ["and", 1451], ["FLAIR", 1455], ["-", 1460], ["weighted", 1461], ["images", 1470], ["in", 1477], ["the", 1480], ["gray", 1484], ["and", 1489], ["subcortical", 1493], ["white", 1505], ["matter", 1511], ["often", 1518], ["tapering", 1524], ["toward", 1533], ["the", 1540], ["ventricle", 1544], [".", 1553], ["On", 1555], ["the", 1558], ["basis", 1562], ["of", 1568], ["the", 1571], ["MRI", 1575], ["findings", 1579], [",", 1587], ["it", 1589], ["is", 1592], ["possible", 1595], ["to", 1604], ["differentiate", 1607], ["between", 1621], ["type", 1629], ["I", 1634], ["and", 1636], ["type", 1640], ["II", 1645], ["cortical", 1648], ["dysplasia", 1657], [".", 1666], ["A", 1668], ["complete", 1670], ["resection", 1679], ["of", 1689], ["the", 1692], ["epileptogenic", 1696], ["zone", 1710], ["is", 1715], ["required", 1718], ["for", 1727], ["seizure", 1731], ["-", 1738], ["free", 1739], ["life", 1744], [".", 1748], ["MRI", 1750], ["imaging", 1754], ["is", 1762], ["very", 1765], ["helpful", 1770], ["to", 1778], ["identify", 1781], ["those", 1790], ["patients", 1796], ["who", 1805], ["are", 1809], ["likely", 1813], ["to", 1820], ["benefit", 1823], ["from", 1831], ["surgical", 1836], ["treatment", 1845], ["in", 1855], ["a", 1858], ["group", 1860], ["of", 1866], ["patients", 1869], ["with", 1878], ["drug", 1883], ["-", 1887], ["resistant", 1888], ["epilepsy", 1898], [".", 1906], ["However", 1907], [",", 1914], ["in", 1916], ["type", 1919], ["I", 1924], ["cortical", 1926], ["dysplasia", 1935], [",", 1944], ["MR", 1946], ["imaging", 1949], ["is", 1957], ["often", 1960], ["normal", 1966], [",", 1972], ["and", 1974], ["also", 1978], ["in", 1983], ["both", 1986], ["types", 1991], ["the", 1997], ["lesion", 2001], ["seen", 2008], ["on", 2013], ["MRI", 2016], ["may", 2020], ["be", 2024], ["smaller", 2027], ["than", 2035], ["the", 2040], ["seizure", 2044], ["-", 2051], ["generating", 2052], ["region", 2063], ["seen", 2070], ["in", 2075], ["the", 2078], ["EEG", 2082], [".", 2085], ["The", 2087], ["abnormalities", 2091], ["may", 2105], ["also", 2109], ["involve", 2114], ["vital", 2122], ["for", 2128], ["life", 2132], ["brain", 2137], ["parts", 2143], [",", 2148], ["where", 2150], ["curative", 2156], ["surgery", 2165], ["will", 2173], ["not", 2178], ["be", 2182], ["an", 2185], ["option", 2188], [".", 2194], ["Therefore", 2196], [",", 2205], ["other", 2207], ["diagnostic", 2213], ["imaging", 2224], ["techniques", 2232], ["such", 2243], ["as", 2248], ["FDG", 2251], ["PET", 2255], [",", 2258], ["MEG", 2260], [",", 2263], ["DTI", 2265], ["and", 2269], ["intra", 2273], ["-", 2278], ["cranial", 2279], ["EEG", 2287], ["are", 2291], ["widely", 2295], ["used", 2302], ["to", 2307], ["establish", 2310], ["the", 2320], ["diagnosis", 2324], ["and", 2334], ["to", 2338], ["decide", 2341], ["on", 2348], ["management", 2351], [".", 2361], ["With", 2362], ["advances", 2367], ["in", 2376], ["both", 2379], ["genetics", 2384], ["and", 2393], ["neuroimaging", 2397], [",", 2409], ["we", 2411], ["may", 2414], ["develop", 2418], ["a", 2426], ["better", 2428], ["understanding", 2435], ["of", 2449], ["patients", 2452], ["with", 2461], ["drug", 2466], ["-", 2470], ["resistant", 2471], ["epilepsy", 2481], [",", 2489], ["which", 2491], ["will", 2497], ["help", 2502], ["us", 2507], ["to", 2510], ["provide", 2513], ["more", 2521], ["successful", 2526], ["pharmacological", 2537], ["and/or", 2553], ["surgical", 2560], ["treatment", 2569], ["in", 2579], ["the", 2582], ["future", 2586], [".", 2592]]}
{"context": "Reperfusion injury to tissue following an ischemic event occurs as a consequence of an acute inflammatory response that can cause significant morbidity and mortality. Components of both the innate (complement, immunoglobulin, monocytes, and neutrophils) and adaptive (B and T lymphocytes) immune systems have been demonstrated to mediate tissue injury. Spleen tyrosine kinase (Syk) is responsible for membrane-mediated signaling in various cell types including B lymphocytes, macrophages, and T cells. We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury. Mice were fed with chow containing a Syk inhibitor for 6 days before the performance of intestinal I/R, which resulted in silencing of the expression of the active phosphorylated Syk. Syk inhibition significantly suppressed both local and remote lung injury. The beneficial effect was associated with reduced IgM and complement 3 deposition in the tissues and significant reduction of polymorphonuclear cell infiltration. Our data place Syk upstream of events leading to the binding of natural antibodies to the ischemia-conditioned tissues and urge the consideration of the use of Syk inhibitors in the prevention or improvement of tissue injury of organs exposed to ischemia or hypoperfusion.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "c39a985f3db547f193720f8ea9d1d8ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[58, 60]], "char_spans": [[353, 374]]}]}], "context_tokens": [["Reperfusion", 0], ["injury", 12], ["to", 19], ["tissue", 22], ["following", 29], ["an", 39], ["ischemic", 42], ["event", 51], ["occurs", 57], ["as", 64], ["a", 67], ["consequence", 69], ["of", 81], ["an", 84], ["acute", 87], ["inflammatory", 93], ["response", 106], ["that", 115], ["can", 120], ["cause", 124], ["significant", 130], ["morbidity", 142], ["and", 152], ["mortality", 156], [".", 165], ["Components", 167], ["of", 178], ["both", 181], ["the", 186], ["innate", 190], ["(", 197], ["complement", 198], [",", 208], ["immunoglobulin", 210], [",", 224], ["monocytes", 226], [",", 235], ["and", 237], ["neutrophils", 241], [")", 252], ["and", 254], ["adaptive", 258], ["(", 267], ["B", 268], ["and", 270], ["T", 274], ["lymphocytes", 276], [")", 287], ["immune", 289], ["systems", 296], ["have", 304], ["been", 309], ["demonstrated", 314], ["to", 327], ["mediate", 330], ["tissue", 338], ["injury", 345], [".", 351], ["Spleen", 353], ["tyrosine", 360], ["kinase", 369], ["(", 376], ["Syk", 377], [")", 380], ["is", 382], ["responsible", 385], ["for", 397], ["membrane", 401], ["-", 409], ["mediated", 410], ["signaling", 419], ["in", 429], ["various", 432], ["cell", 440], ["types", 445], ["including", 451], ["B", 461], ["lymphocytes", 463], [",", 474], ["macrophages", 476], [",", 487], ["and", 489], ["T", 493], ["cells", 495], [".", 500], ["We", 502], ["investigated", 505], ["the", 518], ["ability", 522], ["of", 530], ["a", 533], ["small", 535], ["drug", 541], ["Syk", 546], ["inhibitor", 550], [",", 559], ["R788", 561], [",", 565], ["to", 567], ["protect", 570], ["mice", 578], ["against", 583], ["mesenteric", 591], ["ischemia", 602], ["-", 610], ["reperfusion", 611], ["(", 623], ["I", 624], ["/", 625], ["R)-induced", 626], ["local", 637], ["(", 643], ["intestine", 644], [")", 653], ["and", 655], ["remote", 659], ["lung", 666], ["injury", 671], [".", 677], ["Mice", 679], ["were", 684], ["fed", 689], ["with", 693], ["chow", 698], ["containing", 703], ["a", 714], ["Syk", 716], ["inhibitor", 720], ["for", 730], ["6", 734], ["days", 736], ["before", 741], ["the", 748], ["performance", 752], ["of", 764], ["intestinal", 767], ["I", 778], ["/", 779], ["R", 780], [",", 781], ["which", 783], ["resulted", 789], ["in", 798], ["silencing", 801], ["of", 811], ["the", 814], ["expression", 818], ["of", 829], ["the", 832], ["active", 836], ["phosphorylated", 843], ["Syk", 858], [".", 861], ["Syk", 863], ["inhibition", 867], ["significantly", 878], ["suppressed", 892], ["both", 903], ["local", 908], ["and", 914], ["remote", 918], ["lung", 925], ["injury", 930], [".", 936], ["The", 938], ["beneficial", 942], ["effect", 953], ["was", 960], ["associated", 964], ["with", 975], ["reduced", 980], ["IgM", 988], ["and", 992], ["complement", 996], ["3", 1007], ["deposition", 1009], ["in", 1020], ["the", 1023], ["tissues", 1027], ["and", 1035], ["significant", 1039], ["reduction", 1051], ["of", 1061], ["polymorphonuclear", 1064], ["cell", 1082], ["infiltration", 1087], [".", 1099], ["Our", 1101], ["data", 1105], ["place", 1110], ["Syk", 1116], ["upstream", 1120], ["of", 1129], ["events", 1132], ["leading", 1139], ["to", 1147], ["the", 1150], ["binding", 1154], ["of", 1162], ["natural", 1165], ["antibodies", 1173], ["to", 1184], ["the", 1187], ["ischemia", 1191], ["-", 1199], ["conditioned", 1200], ["tissues", 1212], ["and", 1220], ["urge", 1224], ["the", 1229], ["consideration", 1233], ["of", 1247], ["the", 1250], ["use", 1254], ["of", 1258], ["Syk", 1261], ["inhibitors", 1265], ["in", 1276], ["the", 1279], ["prevention", 1283], ["or", 1294], ["improvement", 1297], ["of", 1309], ["tissue", 1312], ["injury", 1319], ["of", 1326], ["organs", 1329], ["exposed", 1336], ["to", 1344], ["ischemia", 1347], ["or", 1356], ["hypoperfusion", 1359], [".", 1372]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described but their frequency, nature and impact are poorly known. We aimed to assess digestive features in a national cohort of EDS patients. A questionnaire has been sent to 212 EDS patients through the French patient support group, all of which had been formally diagnosed according to the Villefranche criteria. The questionnaire included questions about digestive functional symptoms, the GIQLI (Gastrointestinal Quality of Life Index), KESS scoring system and the Rome III criteria. Overall, 135 patients (64% response rate) completed the questionnaire and 134 were analyzable (123 women; 91%). Mean age and Body Mass Index were respectively 35\u00b114.7 years and 24.3\u00b16.1 kg/m(2). The most common EDS subtype was hypermobility form (n=108; 80.6%). GIQLI and KESS median values were respectively 63.5 (27-117) and 19 [13.5-22]. Eighty four percent of patients had functional bowel disorders (FBD) according to the Rome III criteria. An irritable bowel syndrome according to the same criteria was observed in 64 patients (48%) and 48 patients (36%) reported functional constipation. A gastro-esophageal reflux disease (GERD) was reported in 90 patients (68.7%), significantly associated with a poorer GIQLI (60.5\u00b116.8 versus 75.9\u00b120.3; p<0.0001). GIQLI was also negatively impacted by the presence of an irritable bowel syndrome or functional constipation (p=0.007). There was a significant correlation between FBD and GERD. Natural frequency of gastrointestinal manifestations in EDS seems higher than previously assessed. FBD and GERD are very common in our study population, the largest ever published until now. Their impact is herein shown to be important. A systematic clinical assessment of digestive features should be recommended in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "922ae9318d264f8ea1e929e98b4bbe0b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["heritable", 59], ["connective", 69], ["tissue", 80], ["disorders", 87], [".", 96], ["Gastrointestinal", 98], ["manifestations", 115], ["in", 130], ["EDS", 133], ["have", 137], ["been", 142], ["described", 147], ["but", 157], ["their", 161], ["frequency", 167], [",", 176], ["nature", 178], ["and", 185], ["impact", 189], ["are", 196], ["poorly", 200], ["known", 207], [".", 212], ["We", 214], ["aimed", 217], ["to", 223], ["assess", 226], ["digestive", 233], ["features", 243], ["in", 252], ["a", 255], ["national", 257], ["cohort", 266], ["of", 273], ["EDS", 276], ["patients", 280], [".", 288], ["A", 290], ["questionnaire", 292], ["has", 306], ["been", 310], ["sent", 315], ["to", 320], ["212", 323], ["EDS", 327], ["patients", 331], ["through", 340], ["the", 348], ["French", 352], ["patient", 359], ["support", 367], ["group", 375], [",", 380], ["all", 382], ["of", 386], ["which", 389], ["had", 395], ["been", 399], ["formally", 404], ["diagnosed", 413], ["according", 423], ["to", 433], ["the", 436], ["Villefranche", 440], ["criteria", 453], [".", 461], ["The", 463], ["questionnaire", 467], ["included", 481], ["questions", 490], ["about", 500], ["digestive", 506], ["functional", 516], ["symptoms", 527], [",", 535], ["the", 537], ["GIQLI", 541], ["(", 547], ["Gastrointestinal", 548], ["Quality", 565], ["of", 573], ["Life", 576], ["Index", 581], [")", 586], [",", 587], ["KESS", 589], ["scoring", 594], ["system", 602], ["and", 609], ["the", 613], ["Rome", 617], ["III", 622], ["criteria", 626], [".", 634], ["Overall", 636], [",", 643], ["135", 645], ["patients", 649], ["(", 658], ["64", 659], ["%", 661], ["response", 663], ["rate", 672], [")", 676], ["completed", 678], ["the", 688], ["questionnaire", 692], ["and", 706], ["134", 710], ["were", 714], ["analyzable", 719], ["(", 730], ["123", 731], ["women", 735], [";", 740], ["91", 742], ["%", 744], [")", 745], [".", 746], ["Mean", 748], ["age", 753], ["and", 757], ["Body", 761], ["Mass", 766], ["Index", 771], ["were", 777], ["respectively", 782], ["35\u00b114.7", 795], ["years", 803], ["and", 809], ["24.3\u00b16.1", 813], ["kg", 822], ["/", 824], ["m(2", 825], [")", 828], [".", 829], ["The", 831], ["most", 835], ["common", 840], ["EDS", 847], ["subtype", 851], ["was", 859], ["hypermobility", 863], ["form", 877], ["(", 882], ["n=108", 883], [";", 888], ["80.6", 890], ["%", 894], [")", 895], [".", 896], ["GIQLI", 898], ["and", 904], ["KESS", 908], ["median", 913], ["values", 920], ["were", 927], ["respectively", 932], ["63.5", 945], ["(", 950], ["27", 951], ["-", 953], ["117", 954], [")", 957], ["and", 959], ["19", 963], ["[", 966], ["13.5", 967], ["-", 971], ["22].", 972], ["Eighty", 977], ["four", 984], ["percent", 989], ["of", 997], ["patients", 1000], ["had", 1009], ["functional", 1013], ["bowel", 1024], ["disorders", 1030], ["(", 1040], ["FBD", 1041], [")", 1044], ["according", 1046], ["to", 1056], ["the", 1059], ["Rome", 1063], ["III", 1068], ["criteria", 1072], [".", 1080], ["An", 1082], ["irritable", 1085], ["bowel", 1095], ["syndrome", 1101], ["according", 1110], ["to", 1120], ["the", 1123], ["same", 1127], ["criteria", 1132], ["was", 1141], ["observed", 1145], ["in", 1154], ["64", 1157], ["patients", 1160], ["(", 1169], ["48", 1170], ["%", 1172], [")", 1173], ["and", 1175], ["48", 1179], ["patients", 1182], ["(", 1191], ["36", 1192], ["%", 1194], [")", 1195], ["reported", 1197], ["functional", 1206], ["constipation", 1217], [".", 1229], ["A", 1231], ["gastro", 1233], ["-", 1239], ["esophageal", 1240], ["reflux", 1251], ["disease", 1258], ["(", 1266], ["GERD", 1267], [")", 1271], ["was", 1273], ["reported", 1277], ["in", 1286], ["90", 1289], ["patients", 1292], ["(", 1301], ["68.7", 1302], ["%", 1306], [")", 1307], [",", 1308], ["significantly", 1310], ["associated", 1324], ["with", 1335], ["a", 1340], ["poorer", 1342], ["GIQLI", 1349], ["(", 1355], ["60.5\u00b116.8", 1356], ["versus", 1366], ["75.9\u00b120.3", 1373], [";", 1382], ["p<0.0001", 1384], [")", 1392], [".", 1393], ["GIQLI", 1395], ["was", 1401], ["also", 1405], ["negatively", 1410], ["impacted", 1421], ["by", 1430], ["the", 1433], ["presence", 1437], ["of", 1446], ["an", 1449], ["irritable", 1452], ["bowel", 1462], ["syndrome", 1468], ["or", 1477], ["functional", 1480], ["constipation", 1491], ["(", 1504], ["p=0.007", 1505], [")", 1512], [".", 1513], ["There", 1515], ["was", 1521], ["a", 1525], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["FBD", 1559], ["and", 1563], ["GERD", 1567], [".", 1571], ["Natural", 1573], ["frequency", 1581], ["of", 1591], ["gastrointestinal", 1594], ["manifestations", 1611], ["in", 1626], ["EDS", 1629], ["seems", 1633], ["higher", 1639], ["than", 1646], ["previously", 1651], ["assessed", 1662], [".", 1670], ["FBD", 1672], ["and", 1676], ["GERD", 1680], ["are", 1685], ["very", 1689], ["common", 1694], ["in", 1701], ["our", 1704], ["study", 1708], ["population", 1714], [",", 1724], ["the", 1726], ["largest", 1730], ["ever", 1738], ["published", 1743], ["until", 1753], ["now", 1759], [".", 1762], ["Their", 1764], ["impact", 1770], ["is", 1777], ["herein", 1780], ["shown", 1787], ["to", 1793], ["be", 1796], ["important", 1799], [".", 1808], ["A", 1810], ["systematic", 1812], ["clinical", 1823], ["assessment", 1832], ["of", 1843], ["digestive", 1846], ["features", 1856], ["should", 1865], ["be", 1872], ["recommended", 1875], ["in", 1887], ["EDS", 1890], [".", 1893]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common genetic disease caused by haploinsufficiency of the NF1 tumor-suppressor gene. Different pathogenetic mechanisms have been identified, with the majority (95%) causing intragenic lesions. Single or multiexon NF1 copy number changes occur in about 2% of patients, but little is known about the molecular mechanisms behind these intragenic deletions. We report here on the molecular characterization of a novel NF1 multiexonic deletion. The application of a multidisciplinary approach including multiplex ligation-dependent probe amplification, allelic segregation analysis, and fluorescent in situ hybridization allowed us to map the breakpoints in IVS27b and IVS48. Furthermore, the breakpoint junction was characterized by sequencing. Using bioinformatic analysis, we identified some recombinogenic motifs in close proximity to the centromeric and telomeric breakpoints and predicted the presence of a mutated messenger ribonucleic acid, which was deleted between exons 28 and 48 and encodes a neurofibromin that lacks some domains essential for its function. Through reverse transcriptase-polymerase chain reaction, the expression of the mutated allele was verified, showing the junction between exons 27b and 49 and, as expected, was not subjected to nonsense-mediated decay. Multiexonic deletions represent 2% of NF1 mutations, and until now, the breakpoint has been identified in only a few cases. The fine characterization of multiexonic deletions broadens the mutational repertoire of the NF1 gene, allowing for the identification of different pathogenetic mechanisms causing NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "354f714bfea84f6b8e02e7acba3f7d67", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [221, 221], [43, 43], [251, 251], [4, 4], [263, 263], [78, 78]], "char_spans": [[95, 97], [1359, 1361], [250, 252], [1538, 1540], [26, 28], [1625, 1627], [451, 453]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["genetic", 43], ["disease", 51], ["caused", 59], ["by", 66], ["haploinsufficiency", 69], ["of", 88], ["the", 91], ["NF1", 95], ["tumor", 99], ["-", 104], ["suppressor", 105], ["gene", 116], [".", 120], ["Different", 122], ["pathogenetic", 132], ["mechanisms", 145], ["have", 156], ["been", 161], ["identified", 166], [",", 176], ["with", 178], ["the", 183], ["majority", 187], ["(", 196], ["95", 197], ["%", 199], [")", 200], ["causing", 202], ["intragenic", 210], ["lesions", 221], [".", 228], ["Single", 230], ["or", 237], ["multiexon", 240], ["NF1", 250], ["copy", 254], ["number", 259], ["changes", 266], ["occur", 274], ["in", 280], ["about", 283], ["2", 289], ["%", 290], ["of", 292], ["patients", 295], [",", 303], ["but", 305], ["little", 309], ["is", 316], ["known", 319], ["about", 325], ["the", 331], ["molecular", 335], ["mechanisms", 345], ["behind", 356], ["these", 363], ["intragenic", 369], ["deletions", 380], [".", 389], ["We", 391], ["report", 394], ["here", 401], ["on", 406], ["the", 409], ["molecular", 413], ["characterization", 423], ["of", 440], ["a", 443], ["novel", 445], ["NF1", 451], ["multiexonic", 455], ["deletion", 467], [".", 475], ["The", 477], ["application", 481], ["of", 493], ["a", 496], ["multidisciplinary", 498], ["approach", 516], ["including", 525], ["multiplex", 535], ["ligation", 545], ["-", 553], ["dependent", 554], ["probe", 564], ["amplification", 570], [",", 583], ["allelic", 585], ["segregation", 593], ["analysis", 605], [",", 613], ["and", 615], ["fluorescent", 619], ["in", 631], ["situ", 634], ["hybridization", 639], ["allowed", 653], ["us", 661], ["to", 664], ["map", 667], ["the", 671], ["breakpoints", 675], ["in", 687], ["IVS27b", 690], ["and", 697], ["IVS48", 701], [".", 706], ["Furthermore", 708], [",", 719], ["the", 721], ["breakpoint", 725], ["junction", 736], ["was", 745], ["characterized", 749], ["by", 763], ["sequencing", 766], [".", 776], ["Using", 778], ["bioinformatic", 784], ["analysis", 798], [",", 806], ["we", 808], ["identified", 811], ["some", 822], ["recombinogenic", 827], ["motifs", 842], ["in", 849], ["close", 852], ["proximity", 858], ["to", 868], ["the", 871], ["centromeric", 875], ["and", 887], ["telomeric", 891], ["breakpoints", 901], ["and", 913], ["predicted", 917], ["the", 927], ["presence", 931], ["of", 940], ["a", 943], ["mutated", 945], ["messenger", 953], ["ribonucleic", 963], ["acid", 975], [",", 979], ["which", 981], ["was", 987], ["deleted", 991], ["between", 999], ["exons", 1007], ["28", 1013], ["and", 1016], ["48", 1020], ["and", 1023], ["encodes", 1027], ["a", 1035], ["neurofibromin", 1037], ["that", 1051], ["lacks", 1056], ["some", 1062], ["domains", 1067], ["essential", 1075], ["for", 1085], ["its", 1089], ["function", 1093], [".", 1101], ["Through", 1103], ["reverse", 1111], ["transcriptase", 1119], ["-", 1132], ["polymerase", 1133], ["chain", 1144], ["reaction", 1150], [",", 1158], ["the", 1160], ["expression", 1164], ["of", 1175], ["the", 1178], ["mutated", 1182], ["allele", 1190], ["was", 1197], ["verified", 1201], [",", 1209], ["showing", 1211], ["the", 1219], ["junction", 1223], ["between", 1232], ["exons", 1240], ["27b", 1246], ["and", 1250], ["49", 1254], ["and", 1257], [",", 1260], ["as", 1262], ["expected", 1265], [",", 1273], ["was", 1275], ["not", 1279], ["subjected", 1283], ["to", 1293], ["nonsense", 1296], ["-", 1304], ["mediated", 1305], ["decay", 1314], [".", 1319], ["Multiexonic", 1321], ["deletions", 1333], ["represent", 1343], ["2", 1353], ["%", 1354], ["of", 1356], ["NF1", 1359], ["mutations", 1363], [",", 1372], ["and", 1374], ["until", 1378], ["now", 1384], [",", 1387], ["the", 1389], ["breakpoint", 1393], ["has", 1404], ["been", 1408], ["identified", 1413], ["in", 1424], ["only", 1427], ["a", 1432], ["few", 1434], ["cases", 1438], [".", 1443], ["The", 1445], ["fine", 1449], ["characterization", 1454], ["of", 1471], ["multiexonic", 1474], ["deletions", 1486], ["broadens", 1496], ["the", 1505], ["mutational", 1509], ["repertoire", 1520], ["of", 1531], ["the", 1534], ["NF1", 1538], ["gene", 1542], [",", 1546], ["allowing", 1548], ["for", 1557], ["the", 1561], ["identification", 1565], ["of", 1580], ["different", 1583], ["pathogenetic", 1593], ["mechanisms", 1606], ["causing", 1617], ["NF1", 1625], [".", 1628]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) burden is increasing worldwide in hospitals [healthcare-associated (HA)-MRSA] and in communities [community-associated (CA)-MRSA]. However, the impact of CA-MRSA within hospitals remains limited, particularly in Latin America. A countrywide representative survey of S. aureus infections was performed in Argentina by analyzing 591 clinical isolates from 66 hospitals in a prospective cross-sectional, multicenter study (Nov-2009). This work involved healthcare-onset infections-(HAHO, >48 hospitalization hours) and community-onset (CO) infections [including both, infections (HACO) in patients with healthcare-associated risk-factors (HRFs) and infections (CACO) in those without HRFs]. MRSA strains were genetically typed as CA-MRSA and HA-MRSA genotypes (CA-MRSAG and HA-MRSAG) by SCCmec- and spa-typing, PFGE, MLST and virulence genes profile by PCR. Considering all isolates, 63% were from CO-infections and 55% were MRSA [39% CA-MRSAG and 16% HA-MRSAG]. A significantly higher MRSA proportion among CO- than HAHO-S. aureus infections was detected (58% vs 49%); mainly in children (62% vs 43%). The CA-MRSAG/HA-MRSAG have accounted for 16%/33% of HAHO-, 39%/13% of HACO- and 60.5%/0% of CACO-infections. Regarding the epidemiological associations identified in multivariate models for patients with healthcare-onset CA-MRSAG infections, CA-MRSAG behave like HA-MRSAG within hospitals but children were the highest risk group for healthcare-onset CA-MRSAG infections. Most CA-MRSAG belonged to two major clones: PFGE-type N-ST30-SCCmecIVc-t019-PVL(+) and PFGE-type I-ST5-IV-SCCmecIVa-t311-PVL(+) (45% each). The ST5-IV-PVL(+)/ST30-IV-PVL(+) clones have caused 31%/33% of all infections, 20%/4% of HAHO-, 43%/23% of HACO- and 35%/60% of CACO- infections, with significant differences by age groups (children/adults) and geographical regions. Importantly, an isolate belonging to USA300-0114-(ST8-SCCmecIVa-spat008-PVL(+)-ACME(+)) was detected for the first time in Argentina. Most of HA-MRSAG (66%) were related to the Cordobes/Chilean clone-(PFGE-type A-ST5-SCCmecI-t149) causing 18% of all infections (47% of HAHO- and 13% of HACO-infections). Results strongly suggest that the CA-MRSA clone ST5-IV-PVL(+) has begun to spread within hospitals, replacing the traditional Cordobes/Chilean-HA-MRSA clone ST5-I-PVL(-), mainly in children. Importantly, a growing MRSA reservoir in the community was associated with spreading of two CA-MRSA clones: ST5-IV-PVL(+), mainly in children with HRFs, and ST30-IV-PVL(+) in adults without HRFs. This is the first nationwide study in Argentina providing information about the molecular and clinical epidemiology of CA-MRSA, particularly within hospitals, which is essential for designing effective control measures in this country and worldwide.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d454454df5fe41c28b4fd7ea8089ab83", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[464, 464], [139, 139], [131, 131], [37, 37], [6, 6], [186, 186], [202, 202], [486, 486], [501, 501], [557, 557], [514, 514], [143, 143]], "char_spans": [[2237, 2240], [781, 784], [739, 742], [208, 211], [45, 48], [973, 976], [1034, 1037], [2346, 2349], [2414, 2417], [2709, 2712], [2486, 2489], [793, 796]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["burden", 51], ["is", 58], ["increasing", 61], ["worldwide", 72], ["in", 82], ["hospitals", 85], ["[", 95], ["healthcare", 96], ["-", 106], ["associated", 107], ["(", 118], ["HA)-MRSA", 119], ["]", 127], ["and", 129], ["in", 133], ["communities", 136], ["[", 148], ["community", 149], ["-", 158], ["associated", 159], ["(", 170], ["CA)-MRSA].", 171], ["However", 182], [",", 189], ["the", 191], ["impact", 195], ["of", 202], ["CA", 205], ["-", 207], ["MRSA", 208], ["within", 213], ["hospitals", 220], ["remains", 230], ["limited", 238], [",", 245], ["particularly", 247], ["in", 260], ["Latin", 263], ["America", 269], [".", 276], ["A", 278], ["countrywide", 280], ["representative", 292], ["survey", 307], ["of", 314], ["S.", 317], ["aureus", 320], ["infections", 327], ["was", 338], ["performed", 342], ["in", 352], ["Argentina", 355], ["by", 365], ["analyzing", 368], ["591", 378], ["clinical", 382], ["isolates", 391], ["from", 400], ["66", 405], ["hospitals", 408], ["in", 418], ["a", 421], ["prospective", 423], ["cross", 435], ["-", 440], ["sectional", 441], [",", 450], ["multicenter", 452], ["study", 464], ["(", 470], ["Nov-2009", 471], [")", 479], [".", 480], ["This", 482], ["work", 487], ["involved", 492], ["healthcare", 501], ["-", 511], ["onset", 512], ["infections-(HAHO", 518], [",", 534], [">", 536], ["48", 537], ["hospitalization", 540], ["hours", 556], [")", 561], ["and", 563], ["community", 567], ["-", 576], ["onset", 577], ["(", 583], ["CO", 584], [")", 586], ["infections", 588], ["[", 599], ["including", 600], ["both", 610], [",", 614], ["infections", 616], ["(", 627], ["HACO", 628], [")", 632], ["in", 634], ["patients", 637], ["with", 646], ["healthcare", 651], ["-", 661], ["associated", 662], ["risk", 673], ["-", 677], ["factors", 678], ["(", 686], ["HRFs", 687], [")", 691], ["and", 693], ["infections", 697], ["(", 708], ["CACO", 709], [")", 713], ["in", 715], ["those", 718], ["without", 724], ["HRFs].", 732], ["MRSA", 739], ["strains", 744], ["were", 752], ["genetically", 757], ["typed", 769], ["as", 775], ["CA", 778], ["-", 780], ["MRSA", 781], ["and", 786], ["HA", 790], ["-", 792], ["MRSA", 793], ["genotypes", 798], ["(", 808], ["CA", 809], ["-", 811], ["MRSAG", 812], ["and", 818], ["HA", 822], ["-", 824], ["MRSAG", 825], [")", 830], ["by", 832], ["SCCmec-", 835], ["and", 843], ["spa", 847], ["-", 850], ["typing", 851], [",", 857], ["PFGE", 859], [",", 863], ["MLST", 865], ["and", 870], ["virulence", 874], ["genes", 884], ["profile", 890], ["by", 898], ["PCR", 901], [".", 904], ["Considering", 906], ["all", 918], ["isolates", 922], [",", 930], ["63", 932], ["%", 934], ["were", 936], ["from", 941], ["CO", 946], ["-", 948], ["infections", 949], ["and", 960], ["55", 964], ["%", 966], ["were", 968], ["MRSA", 973], ["[", 978], ["39", 979], ["%", 981], ["CA", 983], ["-", 985], ["MRSAG", 986], ["and", 992], ["16", 996], ["%", 998], ["HA", 1000], ["-", 1002], ["MRSAG].", 1003], ["A", 1011], ["significantly", 1013], ["higher", 1027], ["MRSA", 1034], ["proportion", 1039], ["among", 1050], ["CO-", 1056], ["than", 1060], ["HAHO", 1065], ["-", 1069], ["S.", 1070], ["aureus", 1073], ["infections", 1080], ["was", 1091], ["detected", 1095], ["(", 1104], ["58", 1105], ["%", 1107], ["vs", 1109], ["49", 1112], ["%", 1114], [")", 1115], [";", 1116], ["mainly", 1118], ["in", 1125], ["children", 1128], ["(", 1137], ["62", 1138], ["%", 1140], ["vs", 1142], ["43", 1145], ["%", 1147], [")", 1148], [".", 1149], ["The", 1151], ["CA", 1155], ["-", 1157], ["MRSAG", 1158], ["/", 1163], ["HA", 1164], ["-", 1166], ["MRSAG", 1167], ["have", 1173], ["accounted", 1178], ["for", 1188], ["16%/33", 1192], ["%", 1198], ["of", 1200], ["HAHO-", 1203], [",", 1208], ["39%/13", 1210], ["%", 1216], ["of", 1218], ["HACO-", 1221], ["and", 1227], ["60.5%/0", 1231], ["%", 1238], ["of", 1240], ["CACO", 1243], ["-", 1247], ["infections", 1248], [".", 1258], ["Regarding", 1260], ["the", 1270], ["epidemiological", 1274], ["associations", 1290], ["identified", 1303], ["in", 1314], ["multivariate", 1317], ["models", 1330], ["for", 1337], ["patients", 1341], ["with", 1350], ["healthcare", 1355], ["-", 1365], ["onset", 1366], ["CA", 1372], ["-", 1374], ["MRSAG", 1375], ["infections", 1381], [",", 1391], ["CA", 1393], ["-", 1395], ["MRSAG", 1396], ["behave", 1402], ["like", 1409], ["HA", 1414], ["-", 1416], ["MRSAG", 1417], ["within", 1423], ["hospitals", 1430], ["but", 1440], ["children", 1444], ["were", 1453], ["the", 1458], ["highest", 1462], ["risk", 1470], ["group", 1475], ["for", 1481], ["healthcare", 1485], ["-", 1495], ["onset", 1496], ["CA", 1502], ["-", 1504], ["MRSAG", 1505], ["infections", 1511], [".", 1521], ["Most", 1523], ["CA", 1528], ["-", 1530], ["MRSAG", 1531], ["belonged", 1537], ["to", 1546], ["two", 1549], ["major", 1553], ["clones", 1559], [":", 1565], ["PFGE", 1567], ["-", 1571], ["type", 1572], ["N", 1577], ["-", 1578], ["ST30-SCCmecIVc", 1579], ["-", 1593], ["t019-PVL(+", 1594], [")", 1604], ["and", 1606], ["PFGE", 1610], ["-", 1614], ["type", 1615], ["I", 1620], ["-", 1621], ["ST5-IV", 1622], ["-", 1628], ["SCCmecIVa", 1629], ["-", 1638], ["t311-PVL(+", 1639], [")", 1649], ["(", 1651], ["45", 1652], ["%", 1654], ["each", 1656], [")", 1660], [".", 1661], ["The", 1663], ["ST5-IV", 1667], ["-", 1673], ["PVL(+)/ST30-IV", 1674], ["-", 1688], ["PVL(+", 1689], [")", 1694], ["clones", 1696], ["have", 1703], ["caused", 1708], ["31%/33", 1715], ["%", 1721], ["of", 1723], ["all", 1726], ["infections", 1730], [",", 1740], ["20%/4", 1742], ["%", 1747], ["of", 1749], ["HAHO-", 1752], [",", 1757], ["43%/23", 1759], ["%", 1765], ["of", 1767], ["HACO-", 1770], ["and", 1776], ["35%/60", 1780], ["%", 1786], ["of", 1788], ["CACO-", 1791], ["infections", 1797], [",", 1807], ["with", 1809], ["significant", 1814], ["differences", 1826], ["by", 1838], ["age", 1841], ["groups", 1845], ["(", 1852], ["children", 1853], ["/", 1861], ["adults", 1862], [")", 1868], ["and", 1870], ["geographical", 1874], ["regions", 1887], [".", 1894], ["Importantly", 1896], [",", 1907], ["an", 1909], ["isolate", 1912], ["belonging", 1920], ["to", 1930], ["USA300", 1933], ["-", 1939], ["0114-(ST8-SCCmecIVa", 1940], ["-", 1959], ["spat008-PVL(+)-ACME(+", 1960], [")", 1981], [")", 1982], ["was", 1984], ["detected", 1988], ["for", 1997], ["the", 2001], ["first", 2005], ["time", 2011], ["in", 2016], ["Argentina", 2019], [".", 2028], ["Most", 2030], ["of", 2035], ["HA", 2038], ["-", 2040], ["MRSAG", 2041], ["(", 2047], ["66", 2048], ["%", 2050], [")", 2051], ["were", 2053], ["related", 2058], ["to", 2066], ["the", 2069], ["Cordobes", 2073], ["/", 2081], ["Chilean", 2082], ["clone-(PFGE", 2090], ["-", 2101], ["type", 2102], ["A", 2107], ["-", 2108], ["ST5-SCCmecI", 2109], ["-", 2120], ["t149", 2121], [")", 2125], ["causing", 2127], ["18", 2135], ["%", 2137], ["of", 2139], ["all", 2142], ["infections", 2146], ["(", 2157], ["47", 2158], ["%", 2160], ["of", 2162], ["HAHO-", 2165], ["and", 2171], ["13", 2175], ["%", 2177], ["of", 2179], ["HACO", 2182], ["-", 2186], ["infections", 2187], [")", 2197], [".", 2198], ["Results", 2200], ["strongly", 2208], ["suggest", 2217], ["that", 2225], ["the", 2230], ["CA", 2234], ["-", 2236], ["MRSA", 2237], ["clone", 2242], ["ST5-IV", 2248], ["-", 2254], ["PVL(+", 2255], [")", 2260], ["has", 2262], ["begun", 2266], ["to", 2272], ["spread", 2275], ["within", 2282], ["hospitals", 2289], [",", 2298], ["replacing", 2300], ["the", 2310], ["traditional", 2314], ["Cordobes", 2326], ["/", 2334], ["Chilean", 2335], ["-", 2342], ["HA", 2343], ["-", 2345], ["MRSA", 2346], ["clone", 2351], ["ST5-I", 2357], ["-", 2362], ["PVL(-", 2363], [")", 2368], [",", 2369], ["mainly", 2371], ["in", 2378], ["children", 2381], [".", 2389], ["Importantly", 2391], [",", 2402], ["a", 2404], ["growing", 2406], ["MRSA", 2414], ["reservoir", 2419], ["in", 2429], ["the", 2432], ["community", 2436], ["was", 2446], ["associated", 2450], ["with", 2461], ["spreading", 2466], ["of", 2476], ["two", 2479], ["CA", 2483], ["-", 2485], ["MRSA", 2486], ["clones", 2491], [":", 2497], ["ST5-IV", 2499], ["-", 2505], ["PVL(+", 2506], [")", 2511], [",", 2512], ["mainly", 2514], ["in", 2521], ["children", 2524], ["with", 2533], ["HRFs", 2538], [",", 2542], ["and", 2544], ["ST30-IV", 2548], ["-", 2555], ["PVL(+", 2556], [")", 2561], ["in", 2563], ["adults", 2566], ["without", 2573], ["HRFs", 2581], [".", 2585], ["This", 2587], ["is", 2592], ["the", 2595], ["first", 2599], ["nationwide", 2605], ["study", 2616], ["in", 2622], ["Argentina", 2625], ["providing", 2635], ["information", 2645], ["about", 2657], ["the", 2663], ["molecular", 2667], ["and", 2677], ["clinical", 2681], ["epidemiology", 2690], ["of", 2703], ["CA", 2706], ["-", 2708], ["MRSA", 2709], [",", 2713], ["particularly", 2715], ["within", 2728], ["hospitals", 2735], [",", 2744], ["which", 2746], ["is", 2752], ["essential", 2755], ["for", 2765], ["designing", 2769], ["effective", 2779], ["control", 2789], ["measures", 2797], ["in", 2806], ["this", 2809], ["country", 2814], ["and", 2822], ["worldwide", 2826], [".", 2835]]}
{"context": "Theories for restless legs syndrome (RLS) pathogenesis include iron deficiency, dopamine dysregulation and peripheral neuropathy. Increased prevalence of small intestinal bacterial overgrowth (SIBO) in controlled studies in RLS and case reports of post-infectious RLS suggest potential roles for inflammation and immunological alterations. A literature search for all conditions associated with RLS was performed. These included secondary RLS disorders and factors that may exacerbate RLS. All of these conditions were reviewed with respect to potential pathogenesis including reports of iron deficiency, neuropathy, SIBO, inflammation and immune changes. A condition was defined as highly-associated if there was a prevalence study that utilized an appropriate control group. Small case reports were recorded but not included as definite RLS-associated conditions. Fifty four diseases, syndromes and conditions have been reported to cause and/or exacerbate RLS. Of these, 38 have been reported to have a higher prevalence than age-matched controls, 9 have adequate sized reports and have general acceptance as RLS-associated conditions and 7 have been reported in case report form. Overall, 42 of the 47 RLS-associated conditions (89%) have also been associated with inflammatory and/or immune changes. In addition, 43% have been associated with peripheral iron deficiency, 40% with peripheral neuropathy and 32% with SIBO. Most of the remaining conditions have yet to be studied for these factors. The fact that 95% of the 38 highly-associated RLS conditions are also associated with inflammatory/immune changes suggests the possibility that RLS may be mediated or affected through these mechanisms. Inflammation can be responsible for iron deficiency and hypothetically could cause central nervous system iron deficiency-induced RLS. Alternatively, an immune reaction to gastrointestinal bacteria or other antigens may hypothetically cause RLS by a direct immunological attack on the central or peripheral nervous system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cf13cc1b9e0a4705a20d0630e0acbe2a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[229, 229], [10, 10], [297, 297], [89, 89], [306, 306]], "char_spans": [[1358, 1361], [63, 66], [1738, 1741], [588, 591], [1808, 1811]]}]}], "context_tokens": [["Theories", 0], ["for", 9], ["restless", 13], ["legs", 22], ["syndrome", 27], ["(", 36], ["RLS", 37], [")", 40], ["pathogenesis", 42], ["include", 55], ["iron", 63], ["deficiency", 68], [",", 78], ["dopamine", 80], ["dysregulation", 89], ["and", 103], ["peripheral", 107], ["neuropathy", 118], [".", 128], ["Increased", 130], ["prevalence", 140], ["of", 151], ["small", 154], ["intestinal", 160], ["bacterial", 171], ["overgrowth", 181], ["(", 192], ["SIBO", 193], [")", 197], ["in", 199], ["controlled", 202], ["studies", 213], ["in", 221], ["RLS", 224], ["and", 228], ["case", 232], ["reports", 237], ["of", 245], ["post", 248], ["-", 252], ["infectious", 253], ["RLS", 264], ["suggest", 268], ["potential", 276], ["roles", 286], ["for", 292], ["inflammation", 296], ["and", 309], ["immunological", 313], ["alterations", 327], [".", 338], ["A", 340], ["literature", 342], ["search", 353], ["for", 360], ["all", 364], ["conditions", 368], ["associated", 379], ["with", 390], ["RLS", 395], ["was", 399], ["performed", 403], [".", 412], ["These", 414], ["included", 420], ["secondary", 429], ["RLS", 439], ["disorders", 443], ["and", 453], ["factors", 457], ["that", 465], ["may", 470], ["exacerbate", 474], ["RLS", 485], [".", 488], ["All", 490], ["of", 494], ["these", 497], ["conditions", 503], ["were", 514], ["reviewed", 519], ["with", 528], ["respect", 533], ["to", 541], ["potential", 544], ["pathogenesis", 554], ["including", 567], ["reports", 577], ["of", 585], ["iron", 588], ["deficiency", 593], [",", 603], ["neuropathy", 605], [",", 615], ["SIBO", 617], [",", 621], ["inflammation", 623], ["and", 636], ["immune", 640], ["changes", 647], [".", 654], ["A", 656], ["condition", 658], ["was", 668], ["defined", 672], ["as", 680], ["highly", 683], ["-", 689], ["associated", 690], ["if", 701], ["there", 704], ["was", 710], ["a", 714], ["prevalence", 716], ["study", 727], ["that", 733], ["utilized", 738], ["an", 747], ["appropriate", 750], ["control", 762], ["group", 770], [".", 775], ["Small", 777], ["case", 783], ["reports", 788], ["were", 796], ["recorded", 801], ["but", 810], ["not", 814], ["included", 818], ["as", 827], ["definite", 830], ["RLS", 839], ["-", 842], ["associated", 843], ["conditions", 854], [".", 864], ["Fifty", 866], ["four", 872], ["diseases", 877], [",", 885], ["syndromes", 887], ["and", 897], ["conditions", 901], ["have", 912], ["been", 917], ["reported", 922], ["to", 931], ["cause", 934], ["and/or", 940], ["exacerbate", 947], ["RLS", 958], [".", 961], ["Of", 963], ["these", 966], [",", 971], ["38", 973], ["have", 976], ["been", 981], ["reported", 986], ["to", 995], ["have", 998], ["a", 1003], ["higher", 1005], ["prevalence", 1012], ["than", 1023], ["age", 1028], ["-", 1031], ["matched", 1032], ["controls", 1040], [",", 1048], ["9", 1050], ["have", 1052], ["adequate", 1057], ["sized", 1066], ["reports", 1072], ["and", 1080], ["have", 1084], ["general", 1089], ["acceptance", 1097], ["as", 1108], ["RLS", 1111], ["-", 1114], ["associated", 1115], ["conditions", 1126], ["and", 1137], ["7", 1141], ["have", 1143], ["been", 1148], ["reported", 1153], ["in", 1162], ["case", 1165], ["report", 1170], ["form", 1177], [".", 1181], ["Overall", 1183], [",", 1190], ["42", 1192], ["of", 1195], ["the", 1198], ["47", 1202], ["RLS", 1205], ["-", 1208], ["associated", 1209], ["conditions", 1220], ["(", 1231], ["89", 1232], ["%", 1234], [")", 1235], ["have", 1237], ["also", 1242], ["been", 1247], ["associated", 1252], ["with", 1263], ["inflammatory", 1268], ["and/or", 1281], ["immune", 1288], ["changes", 1295], [".", 1302], ["In", 1304], ["addition", 1307], [",", 1315], ["43", 1317], ["%", 1319], ["have", 1321], ["been", 1326], ["associated", 1331], ["with", 1342], ["peripheral", 1347], ["iron", 1358], ["deficiency", 1363], [",", 1373], ["40", 1375], ["%", 1377], ["with", 1379], ["peripheral", 1384], ["neuropathy", 1395], ["and", 1406], ["32", 1410], ["%", 1412], ["with", 1414], ["SIBO", 1419], [".", 1423], ["Most", 1425], ["of", 1430], ["the", 1433], ["remaining", 1437], ["conditions", 1447], ["have", 1458], ["yet", 1463], ["to", 1467], ["be", 1470], ["studied", 1473], ["for", 1481], ["these", 1485], ["factors", 1491], [".", 1498], ["The", 1500], ["fact", 1504], ["that", 1509], ["95", 1514], ["%", 1516], ["of", 1518], ["the", 1521], ["38", 1525], ["highly", 1528], ["-", 1534], ["associated", 1535], ["RLS", 1546], ["conditions", 1550], ["are", 1561], ["also", 1565], ["associated", 1570], ["with", 1581], ["inflammatory", 1586], ["/", 1598], ["immune", 1599], ["changes", 1606], ["suggests", 1614], ["the", 1623], ["possibility", 1627], ["that", 1639], ["RLS", 1644], ["may", 1648], ["be", 1652], ["mediated", 1655], ["or", 1664], ["affected", 1667], ["through", 1676], ["these", 1684], ["mechanisms", 1690], [".", 1700], ["Inflammation", 1702], ["can", 1715], ["be", 1719], ["responsible", 1722], ["for", 1734], ["iron", 1738], ["deficiency", 1743], ["and", 1754], ["hypothetically", 1758], ["could", 1773], ["cause", 1779], ["central", 1785], ["nervous", 1793], ["system", 1801], ["iron", 1808], ["deficiency", 1813], ["-", 1823], ["induced", 1824], ["RLS", 1832], [".", 1835], ["Alternatively", 1837], [",", 1850], ["an", 1852], ["immune", 1855], ["reaction", 1862], ["to", 1871], ["gastrointestinal", 1874], ["bacteria", 1891], ["or", 1900], ["other", 1903], ["antigens", 1909], ["may", 1918], ["hypothetically", 1922], ["cause", 1937], ["RLS", 1943], ["by", 1947], ["a", 1950], ["direct", 1952], ["immunological", 1959], ["attack", 1973], ["on", 1980], ["the", 1983], ["central", 1987], ["or", 1995], ["peripheral", 1998], ["nervous", 2009], ["system", 2017], [".", 2023]]}
{"context": "Alterations in GABAergic mRNA expression play a key role for prefrontal dysfunction in schizophrenia and other neurodevelopmental disease. Here, we show that histone H3-lysine 4 methylation, a chromatin mark associated with the transcriptional process, progressively increased at GAD1 and other GABAergic gene promoters (GAD2, NPY, SST) in human prefrontal cortex (PFC) from prenatal to peripubertal ages and throughout adulthood. Alterations in schizophrenia included decreased GAD1 expression and H3K4-trimethylation, predominantly in females and in conjunction with a risk haplotype at the 5' end of GAD1. Heterozygosity for a truncated, lacZ knock-in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4 methylation at GABAergic gene promoters. In contrast, Gad1 H3K4 (tri)methylation and Mll1 occupancy was increased in cerebral cortex of mice after treatment with the atypical antipsychotic, clozapine. These effects were not mimicked by haloperidol or genetic ablation of dopamine D2 and D3 receptors, suggesting that blockade of D2-like signaling is not sufficient for clozapine-induced histone methylation. Therefore, chromatin remodeling mechanisms at GABAergic gene promoters, including MLL1-mediated histone methylation, operate throughout an extended period of normal human PFC development and play a role in the neurobiology of schizophrenia.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "e6d3491bc82b418c870a7d4356305e46", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[132, 132], [143, 143]], "char_spans": [[799, 802], [863, 866]]}]}], "context_tokens": [["Alterations", 0], ["in", 12], ["GABAergic", 15], ["mRNA", 25], ["expression", 30], ["play", 41], ["a", 46], ["key", 48], ["role", 52], ["for", 57], ["prefrontal", 61], ["dysfunction", 72], ["in", 84], ["schizophrenia", 87], ["and", 101], ["other", 105], ["neurodevelopmental", 111], ["disease", 130], [".", 137], ["Here", 139], [",", 143], ["we", 145], ["show", 148], ["that", 153], ["histone", 158], ["H3-lysine", 166], ["4", 176], ["methylation", 178], [",", 189], ["a", 191], ["chromatin", 193], ["mark", 203], ["associated", 208], ["with", 219], ["the", 224], ["transcriptional", 228], ["process", 244], [",", 251], ["progressively", 253], ["increased", 267], ["at", 277], ["GAD1", 280], ["and", 285], ["other", 289], ["GABAergic", 295], ["gene", 305], ["promoters", 310], ["(", 320], ["GAD2", 321], [",", 325], ["NPY", 327], [",", 330], ["SST", 332], [")", 335], ["in", 337], ["human", 340], ["prefrontal", 346], ["cortex", 357], ["(", 364], ["PFC", 365], [")", 368], ["from", 370], ["prenatal", 375], ["to", 384], ["peripubertal", 387], ["ages", 400], ["and", 405], ["throughout", 409], ["adulthood", 420], [".", 429], ["Alterations", 431], ["in", 443], ["schizophrenia", 446], ["included", 460], ["decreased", 469], ["GAD1", 479], ["expression", 484], ["and", 495], ["H3K4-trimethylation", 499], [",", 518], ["predominantly", 520], ["in", 534], ["females", 537], ["and", 545], ["in", 549], ["conjunction", 552], ["with", 564], ["a", 569], ["risk", 571], ["haplotype", 576], ["at", 586], ["the", 589], ["5", 593], ["'", 594], ["end", 596], ["of", 600], ["GAD1", 603], [".", 607], ["Heterozygosity", 609], ["for", 624], ["a", 628], ["truncated", 630], [",", 639], ["lacZ", 641], ["knock", 646], ["-", 651], ["in", 652], ["allele", 655], ["of", 662], ["mixed", 665], ["-", 670], ["lineage", 671], ["leukemia", 679], ["1", 688], ["(", 690], ["Mll1", 691], [")", 695], [",", 696], ["a", 698], ["histone", 700], ["methyltransferase", 708], ["expressed", 726], ["in", 736], ["GABAergic", 739], ["and", 749], ["other", 753], ["cortical", 759], ["neurons", 768], [",", 775], ["resulted", 777], ["in", 786], ["decreased", 789], ["H3K4", 799], ["methylation", 804], ["at", 816], ["GABAergic", 819], ["gene", 829], ["promoters", 834], [".", 843], ["In", 845], ["contrast", 848], [",", 856], ["Gad1", 858], ["H3K4", 863], ["(", 868], ["tri)methylation", 869], ["and", 885], ["Mll1", 889], ["occupancy", 894], ["was", 904], ["increased", 908], ["in", 918], ["cerebral", 921], ["cortex", 930], ["of", 937], ["mice", 940], ["after", 945], ["treatment", 951], ["with", 961], ["the", 966], ["atypical", 970], ["antipsychotic", 979], [",", 992], ["clozapine", 994], [".", 1003], ["These", 1005], ["effects", 1011], ["were", 1019], ["not", 1024], ["mimicked", 1028], ["by", 1037], ["haloperidol", 1040], ["or", 1052], ["genetic", 1055], ["ablation", 1063], ["of", 1072], ["dopamine", 1075], ["D2", 1084], ["and", 1087], ["D3", 1091], ["receptors", 1094], [",", 1103], ["suggesting", 1105], ["that", 1116], ["blockade", 1121], ["of", 1130], ["D2-like", 1133], ["signaling", 1141], ["is", 1151], ["not", 1154], ["sufficient", 1158], ["for", 1169], ["clozapine", 1173], ["-", 1182], ["induced", 1183], ["histone", 1191], ["methylation", 1199], [".", 1210], ["Therefore", 1212], [",", 1221], ["chromatin", 1223], ["remodeling", 1233], ["mechanisms", 1244], ["at", 1255], ["GABAergic", 1258], ["gene", 1268], ["promoters", 1273], [",", 1282], ["including", 1284], ["MLL1-mediated", 1294], ["histone", 1308], ["methylation", 1316], [",", 1327], ["operate", 1329], ["throughout", 1337], ["an", 1348], ["extended", 1351], ["period", 1360], ["of", 1367], ["normal", 1370], ["human", 1377], ["PFC", 1383], ["development", 1387], ["and", 1399], ["play", 1403], ["a", 1408], ["role", 1410], ["in", 1415], ["the", 1418], ["neurobiology", 1422], ["of", 1435], ["schizophrenia", 1438], [".", 1451]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "To investigate the effect of global cerebral ischemia on brain cell proliferation in young adult macaques, we infused 5-bromo-2'-deoxyuridine (BrdU), a DNA replication indicator, into monkeys subjected to ischemia or sham-operated. Subsequent quantification by BrdU immunohistochemistry revealed a significant postischemic increase in the number of BrdU-labeled cells in the hippocampal dentate gyrus, subventricular zone of the temporal horn of the lateral ventricle, and temporal neocortex. In all animals, 20-40% of the newly generated cells in the dentate gyrus and subventricular zone expressed the neural progenitor cell markers Musashi1 or Nestin. A few BrdU-positive cells in postischemic monkeys were double-stained for markers of neuronal progenitors (class III beta-tubulin, TUC4, doublecortin, or Hu), neurons (NeuN), or glia (S100beta or GFAP). Our results suggest that ischemia activates endogenous neuronal and glial precursors residing in diverse locations of the adult primate central nervous system.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "e071020dd038420e9fd5fc750ec99bbe", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106]], "char_spans": [[647, 652]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["effect", 19], ["of", 26], ["global", 29], ["cerebral", 36], ["ischemia", 45], ["on", 54], ["brain", 57], ["cell", 63], ["proliferation", 68], ["in", 82], ["young", 85], ["adult", 91], ["macaques", 97], [",", 105], ["we", 107], ["infused", 110], ["5-bromo-2'-deoxyuridine", 118], ["(", 142], ["BrdU", 143], [")", 147], [",", 148], ["a", 150], ["DNA", 152], ["replication", 156], ["indicator", 168], [",", 177], ["into", 179], ["monkeys", 184], ["subjected", 192], ["to", 202], ["ischemia", 205], ["or", 214], ["sham", 217], ["-", 221], ["operated", 222], [".", 230], ["Subsequent", 232], ["quantification", 243], ["by", 258], ["BrdU", 261], ["immunohistochemistry", 266], ["revealed", 287], ["a", 296], ["significant", 298], ["postischemic", 310], ["increase", 323], ["in", 332], ["the", 335], ["number", 339], ["of", 346], ["BrdU", 349], ["-", 353], ["labeled", 354], ["cells", 362], ["in", 368], ["the", 371], ["hippocampal", 375], ["dentate", 387], ["gyrus", 395], [",", 400], ["subventricular", 402], ["zone", 417], ["of", 422], ["the", 425], ["temporal", 429], ["horn", 438], ["of", 443], ["the", 446], ["lateral", 450], ["ventricle", 458], [",", 467], ["and", 469], ["temporal", 473], ["neocortex", 482], [".", 491], ["In", 493], ["all", 496], ["animals", 500], [",", 507], ["20", 509], ["-", 511], ["40", 512], ["%", 514], ["of", 516], ["the", 519], ["newly", 523], ["generated", 529], ["cells", 539], ["in", 545], ["the", 548], ["dentate", 552], ["gyrus", 560], ["and", 566], ["subventricular", 570], ["zone", 585], ["expressed", 590], ["the", 600], ["neural", 604], ["progenitor", 611], ["cell", 622], ["markers", 627], ["Musashi1", 635], ["or", 644], ["Nestin", 647], [".", 653], ["A", 655], ["few", 657], ["BrdU", 661], ["-", 665], ["positive", 666], ["cells", 675], ["in", 681], ["postischemic", 684], ["monkeys", 697], ["were", 705], ["double", 710], ["-", 716], ["stained", 717], ["for", 725], ["markers", 729], ["of", 737], ["neuronal", 740], ["progenitors", 749], ["(", 761], ["class", 762], ["III", 768], ["beta", 772], ["-", 776], ["tubulin", 777], [",", 784], ["TUC4", 786], [",", 790], ["doublecortin", 792], [",", 804], ["or", 806], ["Hu", 809], [")", 811], [",", 812], ["neurons", 814], ["(", 822], ["NeuN", 823], [")", 827], [",", 828], ["or", 830], ["glia", 833], ["(", 838], ["S100beta", 839], ["or", 848], ["GFAP", 851], [")", 855], [".", 856], ["Our", 858], ["results", 862], ["suggest", 870], ["that", 878], ["ischemia", 883], ["activates", 892], ["endogenous", 902], ["neuronal", 913], ["and", 922], ["glial", 926], ["precursors", 932], ["residing", 943], ["in", 952], ["diverse", 955], ["locations", 963], ["of", 973], ["the", 976], ["adult", 980], ["primate", 986], ["central", 994], ["nervous", 1002], ["system", 1010], [".", 1016]]}
{"context": "Malaria is one of the most devastating infectious diseases in the developing world. Until now, only one candidate malaria vaccine RTS,S/AS01 has shown modest protection in phase 3 trial in African infants. Hence the treatment of malaria still depends on the current chemotherapeutic drugs. Considering the resistance of malaria parasites to almost all used antimalarial drugs, aiming at multi-targets rather than a single target will be a more promising strategy. Previous studies have shown that myricetin and fisetin exhibited in vitro antimalarial activity against Plasmodium falciparum, but very little research focused on the molecular mechanism for their parasiticidal activity. The cysteine protease falcipain-2 and aspartic protease plasmepsin II have long been considered as important antimalarial drug targets, especially combined inhibition of these two proteases. In this study, we determined that myricetin and fisetin are dual inhibitors of falcipain-2 and plasmepsin II, which might account for their antimalarial properties. Overall, the dual inhibition of falcipain-2 and plasmepsin II by myricetin and fisetin has shed light on a possible mechanism for their antimalarial activity and provided a rationale for further development as antimalarial drugs.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "7d74ba9e281e40f4942cf692644eec7b", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[20, 20], [56, 56], [0, 0], [43, 43]], "char_spans": [[114, 120], [320, 326], [0, 6], [229, 235]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["one", 11], ["of", 15], ["the", 18], ["most", 22], ["devastating", 27], ["infectious", 39], ["diseases", 50], ["in", 59], ["the", 62], ["developing", 66], ["world", 77], [".", 82], ["Until", 84], ["now", 90], [",", 93], ["only", 95], ["one", 100], ["candidate", 104], ["malaria", 114], ["vaccine", 122], ["RTS", 130], [",", 133], ["S", 134], ["/", 135], ["AS01", 136], ["has", 141], ["shown", 145], ["modest", 151], ["protection", 158], ["in", 169], ["phase", 172], ["3", 178], ["trial", 180], ["in", 186], ["African", 189], ["infants", 197], [".", 204], ["Hence", 206], ["the", 212], ["treatment", 216], ["of", 226], ["malaria", 229], ["still", 237], ["depends", 243], ["on", 251], ["the", 254], ["current", 258], ["chemotherapeutic", 266], ["drugs", 283], [".", 288], ["Considering", 290], ["the", 302], ["resistance", 306], ["of", 317], ["malaria", 320], ["parasites", 328], ["to", 338], ["almost", 341], ["all", 348], ["used", 352], ["antimalarial", 357], ["drugs", 370], [",", 375], ["aiming", 377], ["at", 384], ["multi", 387], ["-", 392], ["targets", 393], ["rather", 401], ["than", 408], ["a", 413], ["single", 415], ["target", 422], ["will", 429], ["be", 434], ["a", 437], ["more", 439], ["promising", 444], ["strategy", 454], [".", 462], ["Previous", 464], ["studies", 473], ["have", 481], ["shown", 486], ["that", 492], ["myricetin", 497], ["and", 507], ["fisetin", 511], ["exhibited", 519], ["in", 529], ["vitro", 532], ["antimalarial", 538], ["activity", 551], ["against", 560], ["Plasmodium", 568], ["falciparum", 579], [",", 589], ["but", 591], ["very", 595], ["little", 600], ["research", 607], ["focused", 616], ["on", 624], ["the", 627], ["molecular", 631], ["mechanism", 641], ["for", 651], ["their", 655], ["parasiticidal", 661], ["activity", 675], [".", 683], ["The", 685], ["cysteine", 689], ["protease", 698], ["falcipain-2", 707], ["and", 719], ["aspartic", 723], ["protease", 732], ["plasmepsin", 741], ["II", 752], ["have", 755], ["long", 760], ["been", 765], ["considered", 770], ["as", 781], ["important", 784], ["antimalarial", 794], ["drug", 807], ["targets", 812], [",", 819], ["especially", 821], ["combined", 832], ["inhibition", 841], ["of", 852], ["these", 855], ["two", 861], ["proteases", 865], [".", 874], ["In", 876], ["this", 879], ["study", 884], [",", 889], ["we", 891], ["determined", 894], ["that", 905], ["myricetin", 910], ["and", 920], ["fisetin", 924], ["are", 932], ["dual", 936], ["inhibitors", 941], ["of", 952], ["falcipain-2", 955], ["and", 967], ["plasmepsin", 971], ["II", 982], [",", 984], ["which", 986], ["might", 992], ["account", 998], ["for", 1006], ["their", 1010], ["antimalarial", 1016], ["properties", 1029], [".", 1039], ["Overall", 1041], [",", 1048], ["the", 1050], ["dual", 1054], ["inhibition", 1059], ["of", 1070], ["falcipain-2", 1073], ["and", 1085], ["plasmepsin", 1089], ["II", 1100], ["by", 1103], ["myricetin", 1106], ["and", 1116], ["fisetin", 1120], ["has", 1128], ["shed", 1132], ["light", 1137], ["on", 1143], ["a", 1146], ["possible", 1148], ["mechanism", 1157], ["for", 1167], ["their", 1171], ["antimalarial", 1177], ["activity", 1190], ["and", 1199], ["provided", 1203], ["a", 1212], ["rationale", 1214], ["for", 1224], ["further", 1228], ["development", 1236], ["as", 1248], ["antimalarial", 1251], ["drugs", 1264], [".", 1269]]}
{"context": "Forces deployed to the first Gulf War report more ill health than veterans who did not serve there. Many studies of post-Gulf morbidity are based on relatively small sample sizes and selection bias is often a concern. In a setting where selection bias relating to the ill health of veterans may be reduced, we: i) examined self-reported adult ill health in a large sample of male UK Gulf War veterans and a demographically similar non-deployed comparison group; and ii) explored self-reported ill health among veterans who believed that they had Gulf War syndrome. This study uses data from a retrospective cohort study of reproduction and child health in which a validated postal questionnaire was sent to all UK Gulf War veterans (GWV) and a comparison cohort of Armed Service personnel who were not deployed to the Gulf (NGWV). The cohort for analysis comprises 42,818 males who responded to the questionnaire. We confirmed that GWV report higher rates of general ill health. GWV were significantly more likely to have reported at least one new medical symptom or disease since 1990 than NGWV (61% versus 37%, OR 2.7, 95% CI 2.5-2.8). They were also more likely to report higher numbers of symptoms. The strongest associations were for mood swings (OR 20.9, 95%CI 16.2-27.0), memory loss/lack of concentration (OR 19.6, 95% CI 15.5-24.8), night sweats (OR 9.9, 95% CI 6.5-15.2), general fatigue (OR 9.6, 95% CI 8.3-11.1) and sexual dysfunction (OR 4.6, 95%CI 3.2-6.6). 6% of GWV believed they had Gulf War syndrome (GWS), and this was associated with the highest symptom reporting. Increased levels of reported ill health among GWV were confirmed. This study was the first to use a questionnaire which did not focus specifically on the veterans' symptoms themselves. Nevertheless, the results are consistent with those of other studies of post-Gulf war illness and thus strengthen overall findings in this area of research. Further examination of the mechanisms underlying the reporting of ill health is required.", "qas": [{"question": "What memory problems are reported in the \" Gulf war syndrome\"", "answers": ["memory loss"], "qid": "b59f8200d7c241df95bf00fcbea3ba21", "question_tokens": [["What", 0], ["memory", 5], ["problems", 12], ["are", 21], ["reported", 25], ["in", 34], ["the", 37], ["\"", 41], ["Gulf", 43], ["war", 48], ["syndrome", 52], ["\"", 60]], "detected_answers": [{"text": "memory loss", "token_spans": [[251, 252]], "char_spans": [[1279, 1289]]}]}], "context_tokens": [["Forces", 0], ["deployed", 7], ["to", 16], ["the", 19], ["first", 23], ["Gulf", 29], ["War", 34], ["report", 38], ["more", 45], ["ill", 50], ["health", 54], ["than", 61], ["veterans", 66], ["who", 75], ["did", 79], ["not", 83], ["serve", 87], ["there", 93], [".", 98], ["Many", 100], ["studies", 105], ["of", 113], ["post", 116], ["-", 120], ["Gulf", 121], ["morbidity", 126], ["are", 136], ["based", 140], ["on", 146], ["relatively", 149], ["small", 160], ["sample", 166], ["sizes", 173], ["and", 179], ["selection", 183], ["bias", 193], ["is", 198], ["often", 201], ["a", 207], ["concern", 209], [".", 216], ["In", 218], ["a", 221], ["setting", 223], ["where", 231], ["selection", 237], ["bias", 247], ["relating", 252], ["to", 261], ["the", 264], ["ill", 268], ["health", 272], ["of", 279], ["veterans", 282], ["may", 291], ["be", 295], ["reduced", 298], [",", 305], ["we", 307], [":", 309], ["i", 311], [")", 312], ["examined", 314], ["self", 323], ["-", 327], ["reported", 328], ["adult", 337], ["ill", 343], ["health", 347], ["in", 354], ["a", 357], ["large", 359], ["sample", 365], ["of", 372], ["male", 375], ["UK", 380], ["Gulf", 383], ["War", 388], ["veterans", 392], ["and", 401], ["a", 405], ["demographically", 407], ["similar", 423], ["non", 431], ["-", 434], ["deployed", 435], ["comparison", 444], ["group", 455], [";", 460], ["and", 462], ["ii", 466], [")", 468], ["explored", 470], ["self", 479], ["-", 483], ["reported", 484], ["ill", 493], ["health", 497], ["among", 504], ["veterans", 510], ["who", 519], ["believed", 523], ["that", 532], ["they", 537], ["had", 542], ["Gulf", 546], ["War", 551], ["syndrome", 555], [".", 563], ["This", 565], ["study", 570], ["uses", 576], ["data", 581], ["from", 586], ["a", 591], ["retrospective", 593], ["cohort", 607], ["study", 614], ["of", 620], ["reproduction", 623], ["and", 636], ["child", 640], ["health", 646], ["in", 653], ["which", 656], ["a", 662], ["validated", 664], ["postal", 674], ["questionnaire", 681], ["was", 695], ["sent", 699], ["to", 704], ["all", 707], ["UK", 711], ["Gulf", 714], ["War", 719], ["veterans", 723], ["(", 732], ["GWV", 733], [")", 736], ["and", 738], ["a", 742], ["comparison", 744], ["cohort", 755], ["of", 762], ["Armed", 765], ["Service", 771], ["personnel", 779], ["who", 789], ["were", 793], ["not", 798], ["deployed", 802], ["to", 811], ["the", 814], ["Gulf", 818], ["(", 823], ["NGWV", 824], [")", 828], [".", 829], ["The", 831], ["cohort", 835], ["for", 842], ["analysis", 846], ["comprises", 855], ["42,818", 865], ["males", 872], ["who", 878], ["responded", 882], ["to", 892], ["the", 895], ["questionnaire", 899], [".", 912], ["We", 914], ["confirmed", 917], ["that", 927], ["GWV", 932], ["report", 936], ["higher", 943], ["rates", 950], ["of", 956], ["general", 959], ["ill", 967], ["health", 971], [".", 977], ["GWV", 979], ["were", 983], ["significantly", 988], ["more", 1002], ["likely", 1007], ["to", 1014], ["have", 1017], ["reported", 1022], ["at", 1031], ["least", 1034], ["one", 1040], ["new", 1044], ["medical", 1048], ["symptom", 1056], ["or", 1064], ["disease", 1067], ["since", 1075], ["1990", 1081], ["than", 1086], ["NGWV", 1091], ["(", 1096], ["61", 1097], ["%", 1099], ["versus", 1101], ["37", 1108], ["%", 1110], [",", 1111], ["OR", 1113], ["2.7", 1116], [",", 1119], ["95", 1121], ["%", 1123], ["CI", 1125], ["2.5", 1128], ["-", 1131], ["2.8", 1132], [")", 1135], [".", 1136], ["They", 1138], ["were", 1143], ["also", 1148], ["more", 1153], ["likely", 1158], ["to", 1165], ["report", 1168], ["higher", 1175], ["numbers", 1182], ["of", 1190], ["symptoms", 1193], [".", 1201], ["The", 1203], ["strongest", 1207], ["associations", 1217], ["were", 1230], ["for", 1235], ["mood", 1239], ["swings", 1244], ["(", 1251], ["OR", 1252], ["20.9", 1255], [",", 1259], ["95%CI", 1261], ["16.2", 1267], ["-", 1271], ["27.0", 1272], [")", 1276], [",", 1277], ["memory", 1279], ["loss", 1286], ["/", 1290], ["lack", 1291], ["of", 1296], ["concentration", 1299], ["(", 1313], ["OR", 1314], ["19.6", 1317], [",", 1321], ["95", 1323], ["%", 1325], ["CI", 1327], ["15.5", 1330], ["-", 1334], ["24.8", 1335], [")", 1339], [",", 1340], ["night", 1342], ["sweats", 1348], ["(", 1355], ["OR", 1356], ["9.9", 1359], [",", 1362], ["95", 1364], ["%", 1366], ["CI", 1368], ["6.5", 1371], ["-", 1374], ["15.2", 1375], [")", 1379], [",", 1380], ["general", 1382], ["fatigue", 1390], ["(", 1398], ["OR", 1399], ["9.6", 1402], [",", 1405], ["95", 1407], ["%", 1409], ["CI", 1411], ["8.3", 1414], ["-", 1417], ["11.1", 1418], [")", 1422], ["and", 1424], ["sexual", 1428], ["dysfunction", 1435], ["(", 1447], ["OR", 1448], ["4.6", 1451], [",", 1454], ["95%CI", 1456], ["3.2", 1462], ["-", 1465], ["6.6", 1466], [")", 1469], [".", 1470], ["6", 1472], ["%", 1473], ["of", 1475], ["GWV", 1478], ["believed", 1482], ["they", 1491], ["had", 1496], ["Gulf", 1500], ["War", 1505], ["syndrome", 1509], ["(", 1518], ["GWS", 1519], [")", 1522], [",", 1523], ["and", 1525], ["this", 1529], ["was", 1534], ["associated", 1538], ["with", 1549], ["the", 1554], ["highest", 1558], ["symptom", 1566], ["reporting", 1574], [".", 1583], ["Increased", 1585], ["levels", 1595], ["of", 1602], ["reported", 1605], ["ill", 1614], ["health", 1618], ["among", 1625], ["GWV", 1631], ["were", 1635], ["confirmed", 1640], [".", 1649], ["This", 1651], ["study", 1656], ["was", 1662], ["the", 1666], ["first", 1670], ["to", 1676], ["use", 1679], ["a", 1683], ["questionnaire", 1685], ["which", 1699], ["did", 1705], ["not", 1709], ["focus", 1713], ["specifically", 1719], ["on", 1732], ["the", 1735], ["veterans", 1739], ["'", 1747], ["symptoms", 1749], ["themselves", 1758], [".", 1768], ["Nevertheless", 1770], [",", 1782], ["the", 1784], ["results", 1788], ["are", 1796], ["consistent", 1800], ["with", 1811], ["those", 1816], ["of", 1822], ["other", 1825], ["studies", 1831], ["of", 1839], ["post", 1842], ["-", 1846], ["Gulf", 1847], ["war", 1852], ["illness", 1856], ["and", 1864], ["thus", 1868], ["strengthen", 1873], ["overall", 1884], ["findings", 1892], ["in", 1901], ["this", 1904], ["area", 1909], ["of", 1914], ["research", 1917], [".", 1925], ["Further", 1927], ["examination", 1935], ["of", 1947], ["the", 1950], ["mechanisms", 1954], ["underlying", 1965], ["the", 1976], ["reporting", 1980], ["of", 1990], ["ill", 1993], ["health", 1997], ["is", 2004], ["required", 2007], [".", 2015]]}
{"context": "Treatment of CLL patients with conventional cytotoxic agents is often combined with significant toxicity that prevents broad application especially in elderly patients. In addition, relapse frequently occurs after application of conventional chemotherapy in CLL. Recently several new chemo-free treatment options have been introduced within clinical trials. Among them are monoclonal antibodies, most of them targeting the CD20 molecule: besides the licensed drugs rituximab and ofatumumab obinutuzumab, although in combination with chemotherapy, has recently shown high clinical efficacy in front-line treatment of elderly patients with CLL. Lenalidomide as monotherapy has demonstrated clinical efficacy in patients with relapsed disease and first data within clinical trials have been generated in the front-line setting. A promising class of novel agents has been designed to block aberrant signaling from the B-cell receptor. Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. Another class of drugs with potential impact for chemo-free treatment strategies in CLL are the BH3-mimetic inhibitors of the Bcl-2 family of pro-survival proteins. Other interesting candidate drugs that are currently explored for CLL patients include small modular immunopharmaceutical (SMIP) proteins (e. g. TRU-016), CDK inhibitors (e. g. dinaciclib), HDAC inhibitors and others. Given all these novel agents and targets, chemo-free or at least chemo-reduced concepts may become reality in the near future for our patients suffering from CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f2a99dbd8b2344b8b93f9e08e0029f24", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[146, 146]], "char_spans": [[931, 939]]}]}], "context_tokens": [["Treatment", 0], ["of", 10], ["CLL", 13], ["patients", 17], ["with", 26], ["conventional", 31], ["cytotoxic", 44], ["agents", 54], ["is", 61], ["often", 64], ["combined", 70], ["with", 79], ["significant", 84], ["toxicity", 96], ["that", 105], ["prevents", 110], ["broad", 119], ["application", 125], ["especially", 137], ["in", 148], ["elderly", 151], ["patients", 159], [".", 167], ["In", 169], ["addition", 172], [",", 180], ["relapse", 182], ["frequently", 190], ["occurs", 201], ["after", 208], ["application", 214], ["of", 226], ["conventional", 229], ["chemotherapy", 242], ["in", 255], ["CLL", 258], [".", 261], ["Recently", 263], ["several", 272], ["new", 280], ["chemo", 284], ["-", 289], ["free", 290], ["treatment", 295], ["options", 305], ["have", 313], ["been", 318], ["introduced", 323], ["within", 334], ["clinical", 341], ["trials", 350], [".", 356], ["Among", 358], ["them", 364], ["are", 369], ["monoclonal", 373], ["antibodies", 384], [",", 394], ["most", 396], ["of", 401], ["them", 404], ["targeting", 409], ["the", 419], ["CD20", 423], ["molecule", 428], [":", 436], ["besides", 438], ["the", 446], ["licensed", 450], ["drugs", 459], ["rituximab", 465], ["and", 475], ["ofatumumab", 479], ["obinutuzumab", 490], [",", 502], ["although", 504], ["in", 513], ["combination", 516], ["with", 528], ["chemotherapy", 533], [",", 545], ["has", 547], ["recently", 551], ["shown", 560], ["high", 566], ["clinical", 571], ["efficacy", 580], ["in", 589], ["front", 592], ["-", 597], ["line", 598], ["treatment", 603], ["of", 613], ["elderly", 616], ["patients", 624], ["with", 633], ["CLL", 638], [".", 641], ["Lenalidomide", 643], ["as", 656], ["monotherapy", 659], ["has", 671], ["demonstrated", 675], ["clinical", 688], ["efficacy", 697], ["in", 706], ["patients", 709], ["with", 718], ["relapsed", 723], ["disease", 732], ["and", 740], ["first", 744], ["data", 750], ["within", 755], ["clinical", 762], ["trials", 771], ["have", 778], ["been", 783], ["generated", 788], ["in", 798], ["the", 801], ["front", 805], ["-", 810], ["line", 811], ["setting", 816], [".", 823], ["A", 825], ["promising", 827], ["class", 837], ["of", 843], ["novel", 846], ["agents", 852], ["has", 859], ["been", 863], ["designed", 868], ["to", 877], ["block", 880], ["aberrant", 886], ["signaling", 895], ["from", 905], ["the", 910], ["B", 914], ["-", 915], ["cell", 916], ["receptor", 921], [".", 929], ["Ibrutinib", 931], ["acts", 941], ["by", 946], ["inhibiting", 949], ["the", 960], ["Bruton", 964], ["'s", 970], ["tyrosine", 973], ["kinase", 982], ["(", 989], ["BTK", 990], [")", 993], ["while", 995], ["idelalisib", 1001], ["represents", 1012], ["a", 1023], ["first", 1025], ["-", 1030], ["in", 1031], ["-", 1033], ["class", 1034], ["specific", 1040], ["inhibitor", 1049], ["of", 1059], ["the", 1062], ["phosphoinositol-3", 1066], ["kinase", 1084], ["(", 1091], ["PI3", 1092], ["K", 1095], [")", 1096], ["delta", 1098], ["isoform", 1104], [".", 1111], ["Another", 1113], ["class", 1121], ["of", 1127], ["drugs", 1130], ["with", 1136], ["potential", 1141], ["impact", 1151], ["for", 1158], ["chemo", 1162], ["-", 1167], ["free", 1168], ["treatment", 1173], ["strategies", 1183], ["in", 1194], ["CLL", 1197], ["are", 1201], ["the", 1205], ["BH3-mimetic", 1209], ["inhibitors", 1221], ["of", 1232], ["the", 1235], ["Bcl-2", 1239], ["family", 1245], ["of", 1252], ["pro", 1255], ["-", 1258], ["survival", 1259], ["proteins", 1268], [".", 1276], ["Other", 1278], ["interesting", 1284], ["candidate", 1296], ["drugs", 1306], ["that", 1312], ["are", 1317], ["currently", 1321], ["explored", 1331], ["for", 1340], ["CLL", 1344], ["patients", 1348], ["include", 1357], ["small", 1365], ["modular", 1371], ["immunopharmaceutical", 1379], ["(", 1400], ["SMIP", 1401], [")", 1405], ["proteins", 1407], ["(", 1416], ["e.", 1417], ["g.", 1420], ["TRU-016", 1423], [")", 1430], [",", 1431], ["CDK", 1433], ["inhibitors", 1437], ["(", 1448], ["e.", 1449], ["g.", 1452], ["dinaciclib", 1455], [")", 1465], [",", 1466], ["HDAC", 1468], ["inhibitors", 1473], ["and", 1484], ["others", 1488], [".", 1494], ["Given", 1496], ["all", 1502], ["these", 1506], ["novel", 1512], ["agents", 1518], ["and", 1525], ["targets", 1529], [",", 1536], ["chemo", 1538], ["-", 1543], ["free", 1544], ["or", 1549], ["at", 1552], ["least", 1555], ["chemo", 1561], ["-", 1566], ["reduced", 1567], ["concepts", 1575], ["may", 1584], ["become", 1588], ["reality", 1595], ["in", 1603], ["the", 1606], ["near", 1610], ["future", 1615], ["for", 1622], ["our", 1626], ["patients", 1630], ["suffering", 1639], ["from", 1649], ["CLL", 1654], [".", 1657]]}
{"context": "Double homeobox 4 (DUX4) is a candidate disease gene for facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophies characterized by progressive skeletal muscle degeneration. Despite great strides in understanding precise genetics of FSHD, the molecular pathophysiology of the disease remains unclear. One of the major limitations has been the availability of appropriate molecular tools to study DUX4 protein. In the present study, we report the development of five new monoclonal antibodies targeted against the N- and C-termini of human DUX4, and characterize their reactivity using Western blot and immunofluorescence staining. Additionally, we show that expression of the canonical full coding DUX4 induces cell death in human primary muscle cells, whereas the expression of a shorter splice form of DUX4 results in no such toxicity. Immunostaining with these new antibodies reveals a differential effect of two DUX4 isoforms on human muscle cells. These antibodies will provide an excellent tool for investigating the role of DUX4 in FSHD pathogenesis.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7247ffe169f140339020744b6f54923c", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[12, 13]], "char_spans": [[57, 85]]}, {"text": "FSHD", "token_spans": [[175, 175], [40, 40], [15, 15]], "char_spans": [[1063, 1066], [257, 260], [88, 91]]}]}], "context_tokens": [["Double", 0], ["homeobox", 7], ["4", 16], ["(", 18], ["DUX4", 19], [")", 23], ["is", 25], ["a", 28], ["candidate", 30], ["disease", 40], ["gene", 48], ["for", 53], ["facioscapulohumeral", 57], ["dystrophy", 77], ["(", 87], ["FSHD", 88], [")", 92], [",", 93], ["one", 95], ["of", 99], ["the", 102], ["most", 106], ["common", 111], ["muscular", 118], ["dystrophies", 127], ["characterized", 139], ["by", 153], ["progressive", 156], ["skeletal", 168], ["muscle", 177], ["degeneration", 184], [".", 196], ["Despite", 198], ["great", 206], ["strides", 212], ["in", 220], ["understanding", 223], ["precise", 237], ["genetics", 245], ["of", 254], ["FSHD", 257], [",", 261], ["the", 263], ["molecular", 267], ["pathophysiology", 277], ["of", 293], ["the", 296], ["disease", 300], ["remains", 308], ["unclear", 316], [".", 323], ["One", 325], ["of", 329], ["the", 332], ["major", 336], ["limitations", 342], ["has", 354], ["been", 358], ["the", 363], ["availability", 367], ["of", 380], ["appropriate", 383], ["molecular", 395], ["tools", 405], ["to", 411], ["study", 414], ["DUX4", 420], ["protein", 425], [".", 432], ["In", 434], ["the", 437], ["present", 441], ["study", 449], [",", 454], ["we", 456], ["report", 459], ["the", 466], ["development", 470], ["of", 482], ["five", 485], ["new", 490], ["monoclonal", 494], ["antibodies", 505], ["targeted", 516], ["against", 525], ["the", 533], ["N-", 537], ["and", 540], ["C", 544], ["-", 545], ["termini", 546], ["of", 554], ["human", 557], ["DUX4", 563], [",", 567], ["and", 569], ["characterize", 573], ["their", 586], ["reactivity", 592], ["using", 603], ["Western", 609], ["blot", 617], ["and", 622], ["immunofluorescence", 626], ["staining", 645], [".", 653], ["Additionally", 655], [",", 667], ["we", 669], ["show", 672], ["that", 677], ["expression", 682], ["of", 693], ["the", 696], ["canonical", 700], ["full", 710], ["coding", 715], ["DUX4", 722], ["induces", 727], ["cell", 735], ["death", 740], ["in", 746], ["human", 749], ["primary", 755], ["muscle", 763], ["cells", 770], [",", 775], ["whereas", 777], ["the", 785], ["expression", 789], ["of", 800], ["a", 803], ["shorter", 805], ["splice", 813], ["form", 820], ["of", 825], ["DUX4", 828], ["results", 833], ["in", 841], ["no", 844], ["such", 847], ["toxicity", 852], [".", 860], ["Immunostaining", 862], ["with", 877], ["these", 882], ["new", 888], ["antibodies", 892], ["reveals", 903], ["a", 911], ["differential", 913], ["effect", 926], ["of", 933], ["two", 936], ["DUX4", 940], ["isoforms", 945], ["on", 954], ["human", 957], ["muscle", 963], ["cells", 970], [".", 975], ["These", 977], ["antibodies", 983], ["will", 994], ["provide", 999], ["an", 1007], ["excellent", 1010], ["tool", 1020], ["for", 1025], ["investigating", 1029], ["the", 1043], ["role", 1047], ["of", 1052], ["DUX4", 1055], ["in", 1060], ["FSHD", 1063], ["pathogenesis", 1068], [".", 1080]]}
{"context": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. Although MS is a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. The severity of the cephalo-facial anomalies was variable among these family members.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "d053f9773d0649b8b2acea49e06af19f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[32, 38]], "char_spans": [[202, 243]]}]}], "context_tokens": [["The", 0], ["Muenke", 4], ["syndrome", 11], ["(", 20], ["MS", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["unicoronal", 45], ["or", 56], ["bicoronal", 59], ["craniosynostosis", 69], [",", 85], ["midfacial", 87], ["hypoplasia", 97], [",", 107], ["ocular", 109], ["hypertelorism", 116], [",", 129], ["and", 131], ["a", 135], ["variety", 137], ["of", 145], ["minor", 148], ["abnormalities", 154], ["associated", 168], ["with", 179], ["a", 184], ["mutation", 186], ["in", 195], ["the", 198], ["fibroblast", 202], ["growth", 213], ["factor", 220], ["receptor", 227], ["3", 236], ["(", 238], ["FGFR3", 239], [")", 244], ["gene", 246], [".", 250], ["The", 252], ["birth", 256], ["prevalence", 262], ["is", 273], ["approximately", 276], ["one", 290], ["in", 294], ["10,000", 297], ["live", 304], ["births", 309], [",", 315], ["accounting", 317], ["for", 328], ["8", 332], ["-", 333], ["10", 334], ["%", 336], ["of", 338], ["patients", 341], ["with", 350], ["coronal", 355], ["synostosis", 363], [".", 373], ["Although", 375], ["MS", 384], ["is", 387], ["a", 390], ["relatively", 392], ["common", 403], ["diagnosis", 410], ["in", 420], ["patients", 423], ["with", 432], ["craniosynostosis", 437], ["syndromes", 454], [",", 463], ["with", 465], ["autosomal", 470], ["dominant", 480], ["inheritance", 489], [",", 500], ["there", 502], ["has", 508], ["been", 512], ["no", 517], ["report", 520], ["of", 527], ["MS", 530], [",", 532], ["in", 534], ["an", 537], ["affected", 540], ["Korean", 549], ["family", 556], ["with", 563], ["typical", 568], ["cephalo", 576], ["-", 583], ["facial", 584], ["morphology", 591], ["that", 602], ["has", 607], ["been", 611], ["confirmed", 616], ["by", 626], ["molecular", 629], ["studies", 639], [".", 646], ["Here", 648], [",", 652], ["we", 654], ["report", 657], ["a", 664], ["familial", 666], ["case", 675], ["of", 680], ["MS", 683], ["in", 686], ["a", 689], ["female", 691], ["patient", 698], ["with", 706], ["a", 711], ["Pro250Arg", 713], ["mutation", 723], ["in", 732], ["exon", 735], ["7", 740], ["(", 742], ["IgII", 743], ["-", 747], ["IGIII", 748], ["linker", 754], ["domain", 761], [")", 767], ["of", 769], ["the", 772], ["FGFR3", 776], ["gene", 782], [".", 786], ["This", 788], ["patient", 793], ["had", 801], ["mild", 805], ["midfacial", 810], ["hypoplasia", 820], [",", 830], ["hypertelorism", 832], [",", 845], ["downslanting", 847], ["palpebral", 860], ["fissures", 870], [",", 878], ["a", 880], ["beak", 882], ["shaped", 887], ["nose", 894], [",", 898], ["plagio", 900], ["-", 906], ["brachycephaly", 907], [",", 920], ["and", 922], ["mild", 926], ["neurodevelopmental", 931], ["delay", 950], [".", 955], ["The", 957], ["same", 961], ["mutation", 966], ["was", 975], ["confirmed", 979], ["in", 989], ["the", 992], ["patient", 996], ["'s", 1003], ["mother", 1006], [",", 1012], ["two", 1014], ["of", 1018], ["the", 1021], ["mother", 1025], ["'s", 1031], ["sisters", 1034], ["and", 1042], ["the", 1046], ["maternal", 1050], ["grandfather", 1059], [".", 1070], ["The", 1072], ["severity", 1076], ["of", 1085], ["the", 1088], ["cephalo", 1092], ["-", 1099], ["facial", 1100], ["anomalies", 1107], ["was", 1117], ["variable", 1121], ["among", 1130], ["these", 1136], ["family", 1142], ["members", 1149], [".", 1156]]}
{"context": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1. However, the role of the small GTPase Rac remained to be clarified. Here we show that Rac directly participates in Nox1 activation via interacting with Noxa1. Electropermeabilized HeLa cells, ectopically expressing Nox1, Noxo1, and Noxa1, produce superoxide in a GTP-dependent manner, which is abrogated by expression of a mutant Noxa1(R103E), defective in Rac binding. Superoxide production in Nox1-expressing HeLa and Caco-2 cells is decreased by depletion or sequestration of Rac; on the other hand, it is enhanced by expression of the constitutively active Rac1(Q61L), but not by that of a mutant Rac1 with the A27K substitution, deficient in binding to Noxa1. We also demonstrate that Nox1 activation requires membrane recruitment of Noxa1, which is normally mediated via Noxa1 binding to Noxo1, a protein tethered to the Nox1 partner p22(phox): the Noxa1-Noxo1 and Noxo1-p22(phox) interactions are both essential for Nox1 activity. Rac likely facilitates the membrane localization of Noxa1: although Noxa1(W436R), defective in Noxo1 binding, neither associates with the membrane nor activates Nox1, the effects of the W436R substitution are restored by expression of Rac1(Q61L). The Rac-Noxa1 interaction also serves at a step different from the Noxa1 localization, because the binding-defective Noxa1(R103E), albeit targeted to the membrane, does not support superoxide production by Nox1. Furthermore, a mutant Noxa1 carrying the substitution of Ala for Val-205 in the activation domain, which is expected to undergo a conformational change upon Rac binding, fully localizes to the membrane but fails to activate Nox1.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "7b72b7fbe25641d2afc299fbcc7284d8", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[11, 11], [155, 155], [221, 221], [52, 52], [313, 313], [178, 178], [273, 273], [193, 193], [65, 65]], "char_spans": [[68, 71], [864, 867], [1273, 1276], [289, 292], [1795, 1798], [1001, 1004], [1565, 1568], [1097, 1100], [389, 392]]}]}], "context_tokens": [["Activation", 0], ["of", 11], ["the", 14], ["non", 18], ["-", 21], ["phagocytic", 22], ["superoxide", 33], ["-", 43], ["producing", 44], ["NADPH", 54], ["oxidase", 60], ["Nox1", 68], [",", 72], ["complexed", 74], ["with", 84], ["p22(phox", 89], [")", 97], ["at", 99], ["the", 102], ["membrane", 106], [",", 114], ["requires", 116], ["its", 125], ["regulatory", 129], ["soluble", 140], ["proteins", 148], ["Noxo1", 157], ["and", 163], ["Noxa1", 167], [".", 172], ["However", 174], [",", 181], ["the", 183], ["role", 187], ["of", 192], ["the", 195], ["small", 199], ["GTPase", 205], ["Rac", 212], ["remained", 216], ["to", 225], ["be", 228], ["clarified", 231], [".", 240], ["Here", 242], ["we", 247], ["show", 250], ["that", 255], ["Rac", 260], ["directly", 264], ["participates", 273], ["in", 286], ["Nox1", 289], ["activation", 294], ["via", 305], ["interacting", 309], ["with", 321], ["Noxa1", 326], [".", 331], ["Electropermeabilized", 333], ["HeLa", 354], ["cells", 359], [",", 364], ["ectopically", 366], ["expressing", 378], ["Nox1", 389], [",", 393], ["Noxo1", 395], [",", 400], ["and", 402], ["Noxa1", 406], [",", 411], ["produce", 413], ["superoxide", 421], ["in", 432], ["a", 435], ["GTP", 437], ["-", 440], ["dependent", 441], ["manner", 451], [",", 457], ["which", 459], ["is", 465], ["abrogated", 468], ["by", 478], ["expression", 481], ["of", 492], ["a", 495], ["mutant", 497], ["Noxa1(R103E", 504], [")", 515], [",", 516], ["defective", 518], ["in", 528], ["Rac", 531], ["binding", 535], [".", 542], ["Superoxide", 544], ["production", 555], ["in", 566], ["Nox1-expressing", 569], ["HeLa", 585], ["and", 590], ["Caco-2", 594], ["cells", 601], ["is", 607], ["decreased", 610], ["by", 620], ["depletion", 623], ["or", 633], ["sequestration", 636], ["of", 650], ["Rac", 653], [";", 656], ["on", 658], ["the", 661], ["other", 665], ["hand", 671], [",", 675], ["it", 677], ["is", 680], ["enhanced", 683], ["by", 692], ["expression", 695], ["of", 706], ["the", 709], ["constitutively", 713], ["active", 728], ["Rac1(Q61L", 735], [")", 744], [",", 745], ["but", 747], ["not", 751], ["by", 755], ["that", 758], ["of", 763], ["a", 766], ["mutant", 768], ["Rac1", 775], ["with", 780], ["the", 785], ["A27", 789], ["K", 792], ["substitution", 794], [",", 806], ["deficient", 808], ["in", 818], ["binding", 821], ["to", 829], ["Noxa1", 832], [".", 837], ["We", 839], ["also", 842], ["demonstrate", 847], ["that", 859], ["Nox1", 864], ["activation", 869], ["requires", 880], ["membrane", 889], ["recruitment", 898], ["of", 910], ["Noxa1", 913], [",", 918], ["which", 920], ["is", 926], ["normally", 929], ["mediated", 938], ["via", 947], ["Noxa1", 951], ["binding", 957], ["to", 965], ["Noxo1", 968], [",", 973], ["a", 975], ["protein", 977], ["tethered", 985], ["to", 994], ["the", 997], ["Nox1", 1001], ["partner", 1006], ["p22(phox", 1014], [")", 1022], [":", 1023], ["the", 1025], ["Noxa1-Noxo1", 1029], ["and", 1041], ["Noxo1-p22(phox", 1045], [")", 1059], ["interactions", 1061], ["are", 1074], ["both", 1078], ["essential", 1083], ["for", 1093], ["Nox1", 1097], ["activity", 1102], [".", 1110], ["Rac", 1112], ["likely", 1116], ["facilitates", 1123], ["the", 1135], ["membrane", 1139], ["localization", 1148], ["of", 1161], ["Noxa1", 1164], [":", 1169], ["although", 1171], ["Noxa1(W436R", 1180], [")", 1191], [",", 1192], ["defective", 1194], ["in", 1204], ["Noxo1", 1207], ["binding", 1213], [",", 1220], ["neither", 1222], ["associates", 1230], ["with", 1241], ["the", 1246], ["membrane", 1250], ["nor", 1259], ["activates", 1263], ["Nox1", 1273], [",", 1277], ["the", 1279], ["effects", 1283], ["of", 1291], ["the", 1294], ["W436R", 1298], ["substitution", 1304], ["are", 1317], ["restored", 1321], ["by", 1330], ["expression", 1333], ["of", 1344], ["Rac1(Q61L", 1347], [")", 1356], [".", 1357], ["The", 1359], ["Rac", 1363], ["-", 1366], ["Noxa1", 1367], ["interaction", 1373], ["also", 1385], ["serves", 1390], ["at", 1397], ["a", 1400], ["step", 1402], ["different", 1407], ["from", 1417], ["the", 1422], ["Noxa1", 1426], ["localization", 1432], [",", 1444], ["because", 1446], ["the", 1454], ["binding", 1458], ["-", 1465], ["defective", 1466], ["Noxa1(R103E", 1476], [")", 1487], [",", 1488], ["albeit", 1490], ["targeted", 1497], ["to", 1506], ["the", 1509], ["membrane", 1513], [",", 1521], ["does", 1523], ["not", 1528], ["support", 1532], ["superoxide", 1540], ["production", 1551], ["by", 1562], ["Nox1", 1565], [".", 1569], ["Furthermore", 1571], [",", 1582], ["a", 1584], ["mutant", 1586], ["Noxa1", 1593], ["carrying", 1599], ["the", 1608], ["substitution", 1612], ["of", 1625], ["Ala", 1628], ["for", 1632], ["Val-205", 1636], ["in", 1644], ["the", 1647], ["activation", 1651], ["domain", 1662], [",", 1668], ["which", 1670], ["is", 1676], ["expected", 1679], ["to", 1688], ["undergo", 1691], ["a", 1699], ["conformational", 1701], ["change", 1716], ["upon", 1723], ["Rac", 1728], ["binding", 1732], [",", 1739], ["fully", 1741], ["localizes", 1747], ["to", 1757], ["the", 1760], ["membrane", 1764], ["but", 1773], ["fails", 1777], ["to", 1783], ["activate", 1786], ["Nox1", 1795], [".", 1799]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse. This painless syndrome appears during or after a long period of drug addiction. It involves the hands and sometimes the forearms, and may cause functional, aesthetic and social disturbances when the hand volume is important. Physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies, infectious complications and direct toxicity of injected drugs and their adulterants. Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "da08626bddab419dbddfc38db2657996", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[8, 10]], "char_spans": [[55, 76]]}]}], "context_tokens": [["Puffy", 0], ["hand", 6], ["syndrome", 11], ["is", 20], ["an", 23], ["unrecognized", 26], ["complication", 39], ["of", 52], ["intravenous", 55], ["drug", 67], ["abuse", 72], [".", 77], ["This", 79], ["painless", 84], ["syndrome", 93], ["appears", 102], ["during", 110], ["or", 117], ["after", 120], ["a", 126], ["long", 128], ["period", 133], ["of", 140], ["drug", 143], ["addiction", 148], [".", 157], ["It", 159], ["involves", 162], ["the", 171], ["hands", 175], ["and", 181], ["sometimes", 185], ["the", 195], ["forearms", 199], [",", 207], ["and", 209], ["may", 213], ["cause", 217], ["functional", 223], [",", 233], ["aesthetic", 235], ["and", 245], ["social", 249], ["disturbances", 256], ["when", 269], ["the", 274], ["hand", 278], ["volume", 283], ["is", 290], ["important", 293], [".", 302], ["Physiopathological", 304], ["mechanisms", 323], ["of", 334], ["the", 337], ["puffy", 341], ["hand", 347], ["syndrome", 352], ["are", 361], ["unclear", 365], ["and", 373], ["include", 377], ["venous", 385], ["and", 392], ["lymphatic", 396], ["insufficiencies", 406], [",", 421], ["infectious", 423], ["complications", 434], ["and", 448], ["direct", 452], ["toxicity", 459], ["of", 468], ["injected", 471], ["drugs", 480], ["and", 486], ["their", 490], ["adulterants", 496], [".", 507], ["Low", 509], ["-", 512], ["stretch", 513], ["bandage", 521], ["and", 529], ["elastic", 533], ["garment", 541], [",", 548], ["usually", 550], ["used", 558], ["in", 563], ["lymphedema", 566], ["treatment", 577], [",", 586], ["are", 588], ["proposed", 592], ["to", 601], ["treat", 604], ["the", 610], ["puffy", 614], ["hand", 620], ["syndrome", 625], [".", 633]]}
{"context": "The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions. This dynamic alteration in nucleosome structure provides a molecular mechanism to regulate transcription, gene silencing, chromosome segregation and DNA repair. Here we show that genetic instability, sensitivity to drugs impairing different cellular processes and genome-wide transcriptional misregulation in htz1Delta can be partially or totally suppressed if SWR1 is not formed (swr1Delta), if it forms but cannot bind to chromatin (swc2Delta) or if it binds to chromatin but lacks histone replacement activity (swc5Delta and the ATPase-dead swr1-K727G). These results suggest that in htz1Delta the nucleosome remodelling activity of SWR1 affects chromatin integrity because of an attempt to replace H2A with Htz1 in the absence of the latter. This would impair transcription and, either directly or indirectly, other cellular processes. Specifically, we show that in htz1Delta, the SWR1 complex causes an accumulation of recombinogenic DNA damage by a mechanism dependent on phosphorylation of H2A at Ser129, a modification that occurs in response to DNA damage, suggesting that the SWR1 complex impairs the repair of spontaneous DNA damage in htz1Delta. In addition, SWR1 causes DSBs sensitivity in htz1Delta; consistently, in the absence of Htz1 the SWR1 complex bound near an endonuclease HO-induced DSB at the mating-type (MAT) locus impairs DSB-induced checkpoint activation. Our results support a stepwise mechanism for the replacement of H2A with Htz1 and demonstrate that a tight control of this mechanism is essential to regulate chromatin dynamics but also to prevent the deleterious consequences of an incomplete nucleosome remodelling.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "d2627627aba84f99995af53314a00a58", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[171, 171], [219, 219], [74, 74], [234, 234], [204, 204], [1, 1], [127, 127]], "char_spans": [[1007, 1010], [1293, 1296], [483, 486], [1377, 1380], [1208, 1211], [4, 7], [758, 761]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["replaces", 17], ["the", 26], ["canonical", 30], ["histone", 40], ["H2A", 48], ["with", 52], ["the", 57], ["variant", 61], ["H2A.Z", 69], ["(", 75], ["Htz1", 76], ["in", 81], ["yeast", 84], [")", 89], ["at", 91], ["specific", 94], ["chromatin", 103], ["regions", 113], [".", 120], ["This", 122], ["dynamic", 127], ["alteration", 135], ["in", 146], ["nucleosome", 149], ["structure", 160], ["provides", 170], ["a", 179], ["molecular", 181], ["mechanism", 191], ["to", 201], ["regulate", 204], ["transcription", 213], [",", 226], ["gene", 228], ["silencing", 233], [",", 242], ["chromosome", 244], ["segregation", 255], ["and", 267], ["DNA", 271], ["repair", 275], [".", 281], ["Here", 283], ["we", 288], ["show", 291], ["that", 296], ["genetic", 301], ["instability", 309], [",", 320], ["sensitivity", 322], ["to", 334], ["drugs", 337], ["impairing", 343], ["different", 353], ["cellular", 363], ["processes", 372], ["and", 382], ["genome", 386], ["-", 392], ["wide", 393], ["transcriptional", 398], ["misregulation", 414], ["in", 428], ["htz1Delta", 431], ["can", 441], ["be", 445], ["partially", 448], ["or", 458], ["totally", 461], ["suppressed", 469], ["if", 480], ["SWR1", 483], ["is", 488], ["not", 491], ["formed", 495], ["(", 502], ["swr1Delta", 503], [")", 512], [",", 513], ["if", 515], ["it", 518], ["forms", 521], ["but", 527], ["can", 531], ["not", 534], ["bind", 538], ["to", 543], ["chromatin", 546], ["(", 556], ["swc2Delta", 557], [")", 566], ["or", 568], ["if", 571], ["it", 574], ["binds", 577], ["to", 583], ["chromatin", 586], ["but", 596], ["lacks", 600], ["histone", 606], ["replacement", 614], ["activity", 626], ["(", 635], ["swc5Delta", 636], ["and", 646], ["the", 650], ["ATPase", 654], ["-", 660], ["dead", 661], ["swr1-K727", 666], ["G", 675], [")", 676], [".", 677], ["These", 679], ["results", 685], ["suggest", 693], ["that", 701], ["in", 706], ["htz1Delta", 709], ["the", 719], ["nucleosome", 723], ["remodelling", 734], ["activity", 746], ["of", 755], ["SWR1", 758], ["affects", 763], ["chromatin", 771], ["integrity", 781], ["because", 791], ["of", 799], ["an", 802], ["attempt", 805], ["to", 813], ["replace", 816], ["H2A", 824], ["with", 828], ["Htz1", 833], ["in", 838], ["the", 841], ["absence", 845], ["of", 853], ["the", 856], ["latter", 860], [".", 866], ["This", 868], ["would", 873], ["impair", 879], ["transcription", 886], ["and", 900], [",", 903], ["either", 905], ["directly", 912], ["or", 921], ["indirectly", 924], [",", 934], ["other", 936], ["cellular", 942], ["processes", 951], [".", 960], ["Specifically", 962], [",", 974], ["we", 976], ["show", 979], ["that", 984], ["in", 989], ["htz1Delta", 992], [",", 1001], ["the", 1003], ["SWR1", 1007], ["complex", 1012], ["causes", 1020], ["an", 1027], ["accumulation", 1030], ["of", 1043], ["recombinogenic", 1046], ["DNA", 1061], ["damage", 1065], ["by", 1072], ["a", 1075], ["mechanism", 1077], ["dependent", 1087], ["on", 1097], ["phosphorylation", 1100], ["of", 1116], ["H2A", 1119], ["at", 1123], ["Ser129", 1126], [",", 1132], ["a", 1134], ["modification", 1136], ["that", 1149], ["occurs", 1154], ["in", 1161], ["response", 1164], ["to", 1173], ["DNA", 1176], ["damage", 1180], [",", 1186], ["suggesting", 1188], ["that", 1199], ["the", 1204], ["SWR1", 1208], ["complex", 1213], ["impairs", 1221], ["the", 1229], ["repair", 1233], ["of", 1240], ["spontaneous", 1243], ["DNA", 1255], ["damage", 1259], ["in", 1266], ["htz1Delta", 1269], [".", 1278], ["In", 1280], ["addition", 1283], [",", 1291], ["SWR1", 1293], ["causes", 1298], ["DSBs", 1305], ["sensitivity", 1310], ["in", 1322], ["htz1Delta", 1325], [";", 1334], ["consistently", 1336], [",", 1348], ["in", 1350], ["the", 1353], ["absence", 1357], ["of", 1365], ["Htz1", 1368], ["the", 1373], ["SWR1", 1377], ["complex", 1382], ["bound", 1390], ["near", 1396], ["an", 1401], ["endonuclease", 1404], ["HO", 1417], ["-", 1419], ["induced", 1420], ["DSB", 1428], ["at", 1432], ["the", 1435], ["mating", 1439], ["-", 1445], ["type", 1446], ["(", 1451], ["MAT", 1452], [")", 1455], ["locus", 1457], ["impairs", 1463], ["DSB", 1471], ["-", 1474], ["induced", 1475], ["checkpoint", 1483], ["activation", 1494], [".", 1504], ["Our", 1506], ["results", 1510], ["support", 1518], ["a", 1526], ["stepwise", 1528], ["mechanism", 1537], ["for", 1547], ["the", 1551], ["replacement", 1555], ["of", 1567], ["H2A", 1570], ["with", 1574], ["Htz1", 1579], ["and", 1584], ["demonstrate", 1588], ["that", 1600], ["a", 1605], ["tight", 1607], ["control", 1613], ["of", 1621], ["this", 1624], ["mechanism", 1629], ["is", 1639], ["essential", 1642], ["to", 1652], ["regulate", 1655], ["chromatin", 1664], ["dynamics", 1674], ["but", 1683], ["also", 1687], ["to", 1692], ["prevent", 1695], ["the", 1703], ["deleterious", 1707], ["consequences", 1719], ["of", 1732], ["an", 1735], ["incomplete", 1738], ["nucleosome", 1749], ["remodelling", 1760], [".", 1771]]}
{"context": "The product of the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene, menin, is an integral component of MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4). We show that menin is a transcriptional coactivator of the nuclear receptors for estrogen and vitamin D. Activation of the endogenous estrogen-responsive TFF1 (pS2) gene results in promoter recruitment of menin and in elevated trimethylation of H3K4. Knockdown of menin reduces both activated TFF1 (pS2) transcription and H3K4 trimethylation. In addition, menin can directly interact with the estrogen receptor-alpha (ERalpha) in a hormone-dependent manner. The majority of disease-related MEN1 mutations prevent menin-ERalpha interaction. Importantly, ERalpha-interacting mutants are also defective in coactivator function. Our results indicate that menin is a critical link between recruitment of histone methyltransferase complexes and nuclear receptor-mediated transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "70cf419b833d4e9abc7eac1c6be3673c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[91, 91], [77, 77], [34, 34]], "char_spans": [[528, 531], [451, 454], [199, 202]]}]}], "context_tokens": [["The", 0], ["product", 4], ["of", 12], ["the", 15], ["multiple", 19], ["endocrine", 28], ["neoplasia", 38], ["type", 48], ["1", 53], ["(", 55], ["MEN1", 56], [")", 60], ["tumor", 62], ["suppressor", 68], ["gene", 79], [",", 83], ["menin", 85], [",", 90], ["is", 92], ["an", 95], ["integral", 98], ["component", 107], ["of", 117], ["MLL1/MLL2", 120], ["histone", 130], ["methyltransferase", 138], ["complexes", 156], ["specific", 166], ["for", 175], ["Lys4", 179], ["of", 184], ["histone", 187], ["H3", 195], ["(", 198], ["H3K4", 199], [")", 203], [".", 204], ["We", 206], ["show", 209], ["that", 214], ["menin", 219], ["is", 225], ["a", 228], ["transcriptional", 230], ["coactivator", 246], ["of", 258], ["the", 261], ["nuclear", 265], ["receptors", 273], ["for", 283], ["estrogen", 287], ["and", 296], ["vitamin", 300], ["D.", 308], ["Activation", 311], ["of", 322], ["the", 325], ["endogenous", 329], ["estrogen", 340], ["-", 348], ["responsive", 349], ["TFF1", 360], ["(", 365], ["pS2", 366], [")", 369], ["gene", 371], ["results", 376], ["in", 384], ["promoter", 387], ["recruitment", 396], ["of", 408], ["menin", 411], ["and", 417], ["in", 421], ["elevated", 424], ["trimethylation", 433], ["of", 448], ["H3K4", 451], [".", 455], ["Knockdown", 457], ["of", 467], ["menin", 470], ["reduces", 476], ["both", 484], ["activated", 489], ["TFF1", 499], ["(", 504], ["pS2", 505], [")", 508], ["transcription", 510], ["and", 524], ["H3K4", 528], ["trimethylation", 533], [".", 547], ["In", 549], ["addition", 552], [",", 560], ["menin", 562], ["can", 568], ["directly", 572], ["interact", 581], ["with", 590], ["the", 595], ["estrogen", 599], ["receptor", 608], ["-", 616], ["alpha", 617], ["(", 623], ["ERalpha", 624], [")", 631], ["in", 633], ["a", 636], ["hormone", 638], ["-", 645], ["dependent", 646], ["manner", 656], [".", 662], ["The", 664], ["majority", 668], ["of", 677], ["disease", 680], ["-", 687], ["related", 688], ["MEN1", 696], ["mutations", 701], ["prevent", 711], ["menin", 719], ["-", 724], ["ERalpha", 725], ["interaction", 733], [".", 744], ["Importantly", 746], [",", 757], ["ERalpha", 759], ["-", 766], ["interacting", 767], ["mutants", 779], ["are", 787], ["also", 791], ["defective", 796], ["in", 806], ["coactivator", 809], ["function", 821], [".", 829], ["Our", 831], ["results", 835], ["indicate", 843], ["that", 852], ["menin", 857], ["is", 863], ["a", 866], ["critical", 868], ["link", 877], ["between", 882], ["recruitment", 890], ["of", 902], ["histone", 905], ["methyltransferase", 913], ["complexes", 931], ["and", 941], ["nuclear", 945], ["receptor", 953], ["-", 961], ["mediated", 962], ["transcription", 971], [".", 984]]}
{"context": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1), also known as HARP, is an ATP-dependent annealing helicase that stabilizes replication forks during DNA damage. Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions. In this review, we summarize the main roles of SMARCAL1 in DNA repair, telomere maintenance and replication fork stability in response to DNA replication stress.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "HARP"], "qid": "94ca9bf4ee72459085a2b6464d531562", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[0, 20]], "char_spans": [[0, 103]]}, {"text": "HARP", "token_spans": [[26, 26]], "char_spans": [[121, 124]]}]}], "context_tokens": [["SMARCAL1", 0], ["(", 9], ["SWI", 10], ["/", 13], ["SNF", 14], ["Related", 18], [",", 25], ["Matrix", 27], ["Associated", 34], [",", 44], ["Actin", 46], ["Dependent", 52], ["Regulator", 62], ["Of", 72], ["Chromatin", 75], [",", 84], ["Subfamily", 86], ["A", 96], ["-", 97], ["Like", 98], ["1", 103], [")", 104], [",", 105], ["also", 107], ["known", 112], ["as", 118], ["HARP", 121], [",", 125], ["is", 127], ["an", 130], ["ATP", 133], ["-", 136], ["dependent", 137], ["annealing", 147], ["helicase", 157], ["that", 166], ["stabilizes", 171], ["replication", 182], ["forks", 194], ["during", 200], ["DNA", 207], ["damage", 211], [".", 217], ["Mutations", 219], ["in", 229], ["this", 232], ["gene", 237], ["are", 242], ["the", 246], ["cause", 250], ["of", 256], ["Schimke", 259], ["immune", 267], ["-", 273], ["osseous", 274], ["dysplasia", 282], ["(", 292], ["SIOD", 293], [")", 297], [",", 298], ["an", 300], ["autosomal", 303], ["recessive", 313], ["disorder", 323], ["characterized", 332], ["by", 346], ["T", 349], ["-", 350], ["cell", 351], ["immunodeficiency", 356], ["and", 373], ["growth", 377], ["dysfunctions", 384], [".", 396], ["In", 398], ["this", 401], ["review", 406], [",", 412], ["we", 414], ["summarize", 417], ["the", 427], ["main", 431], ["roles", 436], ["of", 442], ["SMARCAL1", 445], ["in", 454], ["DNA", 457], ["repair", 461], [",", 467], ["telomere", 469], ["maintenance", 478], ["and", 490], ["replication", 494], ["fork", 506], ["stability", 511], ["in", 521], ["response", 524], ["to", 533], ["DNA", 536], ["replication", 540], ["stress", 552], [".", 558]]}
{"context": "Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis. This hormone decreases export of cellular iron by binding to ferroportin, an iron exporter present at the basolateral surface of enterocytes and macrophages (the sites of dietary iron absorption and iron recycling, respectively), inducing its internalization and degradation. Hepcidin contains eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets. We noticed in the sequence of hepcidin a Cys*-X-Cys* motif which can act as a metal binding site able to trap iron and/or copper. We have tested this hypothesis using a pseudopeptidic synthetic bis-disulfide analogue and we have shown that direct metalation of such ligand leads to the formation of a copper(III) complex with the typical N(2)S(2)\u00a0donor set. This compound crystallizes in the orthorhombic system, space group Imma. The Cu(III) configuration is square planar, built up from two carboximado-N and two thiolato-S donors. This complex is converted back to the bis-disulfide, with release of the copper salt, upon oxidation with iodine.", "qas": [{"question": "How many disulfide bridges has the protein hepcidin got?", "answers": ["Hepcidin contains eight cysteine residues that form four disulfide bridges"], "qid": "1f9ba193c3004e76bc6c7b235f7af430", "question_tokens": [["How", 0], ["many", 4], ["disulfide", 9], ["bridges", 19], ["has", 27], ["the", 31], ["protein", 35], ["hepcidin", 43], ["got", 52], ["?", 55]], "detected_answers": [{"text": "Hepcidin contains eight cysteine residues that form four disulfide bridges", "token_spans": [[75, 84]], "char_spans": [[435, 508]]}]}], "context_tokens": [["Hepcidin", 0], [",", 8], ["a", 10], ["25-amino", 12], ["-", 20], ["acid", 21], ["peptide", 26], ["secreted", 34], ["by", 43], ["the", 46], ["liver", 50], [",", 55], ["distributed", 57], ["in", 69], ["the", 72], ["plasma", 76], ["and", 83], ["excreted", 87], ["in", 96], ["urine", 99], [",", 104], ["is", 106], ["a", 109], ["key", 111], ["central", 115], ["regulator", 123], ["of", 133], ["body", 136], ["iron", 141], ["homeostasis", 146], [".", 157], ["This", 159], ["hormone", 164], ["decreases", 172], ["export", 182], ["of", 189], ["cellular", 192], ["iron", 201], ["by", 206], ["binding", 209], ["to", 217], ["ferroportin", 220], [",", 231], ["an", 233], ["iron", 236], ["exporter", 241], ["present", 250], ["at", 258], ["the", 261], ["basolateral", 265], ["surface", 277], ["of", 285], ["enterocytes", 288], ["and", 300], ["macrophages", 304], ["(", 316], ["the", 317], ["sites", 321], ["of", 327], ["dietary", 330], ["iron", 338], ["absorption", 343], ["and", 354], ["iron", 358], ["recycling", 363], [",", 372], ["respectively", 374], [")", 386], [",", 387], ["inducing", 389], ["its", 398], ["internalization", 402], ["and", 418], ["degradation", 422], [".", 433], ["Hepcidin", 435], ["contains", 444], ["eight", 453], ["cysteine", 459], ["residues", 468], ["that", 477], ["form", 482], ["four", 487], ["disulfide", 492], ["bridges", 502], [",", 509], ["which", 511], ["stabilize", 517], ["a", 527], ["hairpin", 529], ["-", 536], ["shaped", 537], ["structure", 544], ["with", 554], ["two", 559], ["beta", 563], ["sheets", 568], [".", 574], ["We", 576], ["noticed", 579], ["in", 587], ["the", 590], ["sequence", 594], ["of", 603], ["hepcidin", 606], ["a", 615], ["Cys*-X", 617], ["-", 623], ["Cys", 624], ["*", 627], ["motif", 629], ["which", 635], ["can", 641], ["act", 645], ["as", 649], ["a", 652], ["metal", 654], ["binding", 660], ["site", 668], ["able", 673], ["to", 678], ["trap", 681], ["iron", 686], ["and/or", 691], ["copper", 698], [".", 704], ["We", 706], ["have", 709], ["tested", 714], ["this", 721], ["hypothesis", 726], ["using", 737], ["a", 743], ["pseudopeptidic", 745], ["synthetic", 760], ["bis", 770], ["-", 773], ["disulfide", 774], ["analogue", 784], ["and", 793], ["we", 797], ["have", 800], ["shown", 805], ["that", 811], ["direct", 816], ["metalation", 823], ["of", 834], ["such", 837], ["ligand", 842], ["leads", 849], ["to", 855], ["the", 858], ["formation", 862], ["of", 872], ["a", 875], ["copper(III", 877], [")", 887], ["complex", 889], ["with", 897], ["the", 902], ["typical", 906], ["N(2)S(2", 914], [")", 921], ["donor", 923], ["set", 929], [".", 932], ["This", 934], ["compound", 939], ["crystallizes", 948], ["in", 961], ["the", 964], ["orthorhombic", 968], ["system", 981], [",", 987], ["space", 989], ["group", 995], ["Imma", 1001], [".", 1005], ["The", 1007], ["Cu(III", 1011], [")", 1017], ["configuration", 1019], ["is", 1033], ["square", 1036], ["planar", 1043], [",", 1049], ["built", 1051], ["up", 1057], ["from", 1060], ["two", 1065], ["carboximado", 1069], ["-", 1080], ["N", 1081], ["and", 1083], ["two", 1087], ["thiolato", 1091], ["-", 1099], ["S", 1100], ["donors", 1102], [".", 1108], ["This", 1110], ["complex", 1115], ["is", 1123], ["converted", 1126], ["back", 1136], ["to", 1141], ["the", 1144], ["bis", 1148], ["-", 1151], ["disulfide", 1152], [",", 1161], ["with", 1163], ["release", 1168], ["of", 1176], ["the", 1179], ["copper", 1183], ["salt", 1190], [",", 1194], ["upon", 1196], ["oxidation", 1201], ["with", 1211], ["iodine", 1216], [".", 1222]]}
{"context": "The FOXP2 gene is important for the development of proper speech motor control in humans. However, the role of the gene in general vocal behavior in other mammals, including mice, is unclear. Here, we track the vocal development of Foxp2 heterozygous knockout (Foxp2+/-) mice and their wildtype (WT) littermates from juvenile to adult ages, and observe severe abnormalities in the courtship song of Foxp2+/- mice. In comparison to their WT littermates, Foxp2+/- mice vocalized less, produced shorter syllable sequences, and possessed an abnormal syllable inventory. In addition, Foxp2+/- song also exhibited irregular rhythmic structure, and its development did not follow the consistent trajectories observed in WT vocalizations. These results demonstrate that the Foxp2 gene is critical for normal vocal behavior in juvenile and adult mice, and that Foxp2 mutant mice may provide a tractable model system for the study of the gene's role in general vocal motor control.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "9d3f3ba44ee44d29bc6fd1b262200ffb", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[45, 45], [131, 131], [74, 74], [147, 147], [84, 84], [104, 104], [1, 1], [49, 49]], "char_spans": [[232, 236], [766, 770], [399, 406], [852, 856], [453, 460], [579, 586], [4, 8], [261, 268]]}]}], "context_tokens": [["The", 0], ["FOXP2", 4], ["gene", 10], ["is", 15], ["important", 18], ["for", 28], ["the", 32], ["development", 36], ["of", 48], ["proper", 51], ["speech", 58], ["motor", 65], ["control", 71], ["in", 79], ["humans", 82], [".", 88], ["However", 90], [",", 97], ["the", 99], ["role", 103], ["of", 108], ["the", 111], ["gene", 115], ["in", 120], ["general", 123], ["vocal", 131], ["behavior", 137], ["in", 146], ["other", 149], ["mammals", 155], [",", 162], ["including", 164], ["mice", 174], [",", 178], ["is", 180], ["unclear", 183], [".", 190], ["Here", 192], [",", 196], ["we", 198], ["track", 201], ["the", 207], ["vocal", 211], ["development", 217], ["of", 229], ["Foxp2", 232], ["heterozygous", 238], ["knockout", 251], ["(", 260], ["Foxp2+/-", 261], [")", 269], ["mice", 271], ["and", 276], ["their", 280], ["wildtype", 286], ["(", 295], ["WT", 296], [")", 298], ["littermates", 300], ["from", 312], ["juvenile", 317], ["to", 326], ["adult", 329], ["ages", 335], [",", 339], ["and", 341], ["observe", 345], ["severe", 353], ["abnormalities", 360], ["in", 374], ["the", 377], ["courtship", 381], ["song", 391], ["of", 396], ["Foxp2+/-", 399], ["mice", 408], [".", 412], ["In", 414], ["comparison", 417], ["to", 428], ["their", 431], ["WT", 437], ["littermates", 440], [",", 451], ["Foxp2+/-", 453], ["mice", 462], ["vocalized", 467], ["less", 477], [",", 481], ["produced", 483], ["shorter", 492], ["syllable", 500], ["sequences", 509], [",", 518], ["and", 520], ["possessed", 524], ["an", 534], ["abnormal", 537], ["syllable", 546], ["inventory", 555], [".", 564], ["In", 566], ["addition", 569], [",", 577], ["Foxp2+/-", 579], ["song", 588], ["also", 593], ["exhibited", 598], ["irregular", 608], ["rhythmic", 618], ["structure", 627], [",", 636], ["and", 638], ["its", 642], ["development", 646], ["did", 658], ["not", 662], ["follow", 666], ["the", 673], ["consistent", 677], ["trajectories", 688], ["observed", 701], ["in", 710], ["WT", 713], ["vocalizations", 716], [".", 729], ["These", 731], ["results", 737], ["demonstrate", 745], ["that", 757], ["the", 762], ["Foxp2", 766], ["gene", 772], ["is", 777], ["critical", 780], ["for", 789], ["normal", 793], ["vocal", 800], ["behavior", 806], ["in", 815], ["juvenile", 818], ["and", 827], ["adult", 831], ["mice", 837], [",", 841], ["and", 843], ["that", 847], ["Foxp2", 852], ["mutant", 858], ["mice", 865], ["may", 870], ["provide", 874], ["a", 882], ["tractable", 884], ["model", 894], ["system", 900], ["for", 907], ["the", 911], ["study", 915], ["of", 921], ["the", 924], ["gene", 928], ["'s", 932], ["role", 935], ["in", 940], ["general", 943], ["vocal", 951], ["motor", 957], ["control", 963], [".", 970]]}
{"context": "Nuclear receptor co-repressor (N-CoR) plays important role in transcriptional control mediated by several tumor suppressor proteins. Recently, we reported a role of misfolded-conformation dependent loss (MCDL) of N-CoR in the activation of oncogenic survival pathway in acute promyelocytic leukemia (APL). Since N-CoR plays important role in cellular homeostasis in various tissues, therefore, we hypothesized that an APL like MCDL of N-CoR might also be involved in other malignancy. Indeed, our initial screening of N-CoR status in various leukemia and solid tumor cells revealed an APL like MCDL of N-CoR in primary and secondary tumor cells derived from non-small cell lung cancer (NSCLC). The NSCLC cell specific N-CoR loss could be blocked by Kaletra, a clinical grade protease inhibitor and by genistein, an inhibitor of N-CoR misfolding previously characterized by us. The misfolded N-CoR presented in NSCLC cells was linked to the amplification of ER stress and was subjected to degradation by NSCLC cell specific aberrant protease activity. In NSCLC cells, misfolded N-CoR was found to be associated with Hsc70, a molecular chaperone involved in chaperone mediated autophagy (CMA). Genetic and chemical inhibition of Lamp2A, a rate limiting factor of CMA, significantly blocked the loss of N-CoR in NSCLC cells, suggesting a crucial role of CMA in N-CoR degradation. These findings identify an important role of CMA-induced degradation of misfolded N-CoR in the neutralization of ER stress and suggest a possible role of misfolded N-CoR protein in the activation of oncogenic survival pathway in NSCLC cells.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "af4403448ae94c1aa52153c83756e095", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[234, 234]], "char_spans": [[1227, 1232]]}]}], "context_tokens": [["Nuclear", 0], ["receptor", 8], ["co", 17], ["-", 19], ["repressor", 20], ["(", 30], ["N", 31], ["-", 32], ["CoR", 33], [")", 36], ["plays", 38], ["important", 44], ["role", 54], ["in", 59], ["transcriptional", 62], ["control", 78], ["mediated", 86], ["by", 95], ["several", 98], ["tumor", 106], ["suppressor", 112], ["proteins", 123], [".", 131], ["Recently", 133], [",", 141], ["we", 143], ["reported", 146], ["a", 155], ["role", 157], ["of", 162], ["misfolded", 165], ["-", 174], ["conformation", 175], ["dependent", 188], ["loss", 198], ["(", 203], ["MCDL", 204], [")", 208], ["of", 210], ["N", 213], ["-", 214], ["CoR", 215], ["in", 219], ["the", 222], ["activation", 226], ["of", 237], ["oncogenic", 240], ["survival", 250], ["pathway", 259], ["in", 267], ["acute", 270], ["promyelocytic", 276], ["leukemia", 290], ["(", 299], ["APL", 300], [")", 303], [".", 304], ["Since", 306], ["N", 312], ["-", 313], ["CoR", 314], ["plays", 318], ["important", 324], ["role", 334], ["in", 339], ["cellular", 342], ["homeostasis", 351], ["in", 363], ["various", 366], ["tissues", 374], [",", 381], ["therefore", 383], [",", 392], ["we", 394], ["hypothesized", 397], ["that", 410], ["an", 415], ["APL", 418], ["like", 422], ["MCDL", 427], ["of", 432], ["N", 435], ["-", 436], ["CoR", 437], ["might", 441], ["also", 447], ["be", 452], ["involved", 455], ["in", 464], ["other", 467], ["malignancy", 473], [".", 483], ["Indeed", 485], [",", 491], ["our", 493], ["initial", 497], ["screening", 505], ["of", 515], ["N", 518], ["-", 519], ["CoR", 520], ["status", 524], ["in", 531], ["various", 534], ["leukemia", 542], ["and", 551], ["solid", 555], ["tumor", 561], ["cells", 567], ["revealed", 573], ["an", 582], ["APL", 585], ["like", 589], ["MCDL", 594], ["of", 599], ["N", 602], ["-", 603], ["CoR", 604], ["in", 608], ["primary", 611], ["and", 619], ["secondary", 623], ["tumor", 633], ["cells", 639], ["derived", 645], ["from", 653], ["non", 658], ["-", 661], ["small", 662], ["cell", 668], ["lung", 673], ["cancer", 678], ["(", 685], ["NSCLC", 686], [")", 691], [".", 692], ["The", 694], ["NSCLC", 698], ["cell", 704], ["specific", 709], ["N", 718], ["-", 719], ["CoR", 720], ["loss", 724], ["could", 729], ["be", 735], ["blocked", 738], ["by", 746], ["Kaletra", 749], [",", 756], ["a", 758], ["clinical", 760], ["grade", 769], ["protease", 775], ["inhibitor", 784], ["and", 794], ["by", 798], ["genistein", 801], [",", 810], ["an", 812], ["inhibitor", 815], ["of", 825], ["N", 828], ["-", 829], ["CoR", 830], ["misfolding", 834], ["previously", 845], ["characterized", 856], ["by", 870], ["us", 873], [".", 875], ["The", 877], ["misfolded", 881], ["N", 891], ["-", 892], ["CoR", 893], ["presented", 897], ["in", 907], ["NSCLC", 910], ["cells", 916], ["was", 922], ["linked", 926], ["to", 933], ["the", 936], ["amplification", 940], ["of", 954], ["ER", 957], ["stress", 960], ["and", 967], ["was", 971], ["subjected", 975], ["to", 985], ["degradation", 988], ["by", 1000], ["NSCLC", 1003], ["cell", 1009], ["specific", 1014], ["aberrant", 1023], ["protease", 1032], ["activity", 1041], [".", 1049], ["In", 1051], ["NSCLC", 1054], ["cells", 1060], [",", 1065], ["misfolded", 1067], ["N", 1077], ["-", 1078], ["CoR", 1079], ["was", 1083], ["found", 1087], ["to", 1093], ["be", 1096], ["associated", 1099], ["with", 1110], ["Hsc70", 1115], [",", 1120], ["a", 1122], ["molecular", 1124], ["chaperone", 1134], ["involved", 1144], ["in", 1153], ["chaperone", 1156], ["mediated", 1166], ["autophagy", 1175], ["(", 1185], ["CMA", 1186], [")", 1189], [".", 1190], ["Genetic", 1192], ["and", 1200], ["chemical", 1204], ["inhibition", 1213], ["of", 1224], ["Lamp2A", 1227], [",", 1233], ["a", 1235], ["rate", 1237], ["limiting", 1242], ["factor", 1251], ["of", 1258], ["CMA", 1261], [",", 1264], ["significantly", 1266], ["blocked", 1280], ["the", 1288], ["loss", 1292], ["of", 1297], ["N", 1300], ["-", 1301], ["CoR", 1302], ["in", 1306], ["NSCLC", 1309], ["cells", 1315], [",", 1320], ["suggesting", 1322], ["a", 1333], ["crucial", 1335], ["role", 1343], ["of", 1348], ["CMA", 1351], ["in", 1355], ["N", 1358], ["-", 1359], ["CoR", 1360], ["degradation", 1364], [".", 1375], ["These", 1377], ["findings", 1383], ["identify", 1392], ["an", 1401], ["important", 1404], ["role", 1414], ["of", 1419], ["CMA", 1422], ["-", 1425], ["induced", 1426], ["degradation", 1434], ["of", 1446], ["misfolded", 1449], ["N", 1459], ["-", 1460], ["CoR", 1461], ["in", 1465], ["the", 1468], ["neutralization", 1472], ["of", 1487], ["ER", 1490], ["stress", 1493], ["and", 1500], ["suggest", 1504], ["a", 1512], ["possible", 1514], ["role", 1523], ["of", 1528], ["misfolded", 1531], ["N", 1541], ["-", 1542], ["CoR", 1543], ["protein", 1547], ["in", 1555], ["the", 1558], ["activation", 1562], ["of", 1573], ["oncogenic", 1576], ["survival", 1586], ["pathway", 1595], ["in", 1603], ["NSCLC", 1606], ["cells", 1612], [".", 1617]]}
{"context": "The discovery of the Hippo pathway can be traced back to two areas of research. Genetic screens in fruit flies led to the identification of the Hippo pathway kinases and scaffolding proteins that function together to suppress cell proliferation and tumor growth. Independent research, often in the context of muscle biology, described Tead (TEA domain) transcription factors, which bind CATTCC DNA motifs to regulate gene expression. These two research areas were joined by the finding that the Hippo pathway regulates the activity of Tead transcription factors mainly through phosphorylation of the transcriptional coactivators Yap and Taz, which bind to and activate Teads. Additionally, many other signal transduction proteins crosstalk to members of the Hippo pathway forming a Hippo signal transduction network. We discuss evidence that the Hippo signal transduction network plays important roles in myogenesis, regeneration, muscular dystrophy, and rhabdomyosarcoma in skeletal muscle, as well as in myogenesis, organ size control, and regeneration of the heart. Understanding the role of Hippo kinases in skeletal and heart muscle physiology could have important implications for translational research.", "qas": [{"question": "Which are the coactivators of the Yes-associated protein (yap)?", "answers": ["Tead (TEA domain) transcription factors."], "qid": "42652e9339554e27af6c273cfd698386", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["coactivators", 14], ["of", 27], ["the", 30], ["Yes", 34], ["-", 37], ["associated", 38], ["protein", 49], ["(", 57], ["yap", 58], [")", 61], ["?", 62]], "detected_answers": [{"text": "Tead (TEA domain) transcription factors.", "token_spans": [[56, 62]], "char_spans": [[335, 373]]}]}], "context_tokens": [["The", 0], ["discovery", 4], ["of", 14], ["the", 17], ["Hippo", 21], ["pathway", 27], ["can", 35], ["be", 39], ["traced", 42], ["back", 49], ["to", 54], ["two", 57], ["areas", 61], ["of", 67], ["research", 70], [".", 78], ["Genetic", 80], ["screens", 88], ["in", 96], ["fruit", 99], ["flies", 105], ["led", 111], ["to", 115], ["the", 118], ["identification", 122], ["of", 137], ["the", 140], ["Hippo", 144], ["pathway", 150], ["kinases", 158], ["and", 166], ["scaffolding", 170], ["proteins", 182], ["that", 191], ["function", 196], ["together", 205], ["to", 214], ["suppress", 217], ["cell", 226], ["proliferation", 231], ["and", 245], ["tumor", 249], ["growth", 255], [".", 261], ["Independent", 263], ["research", 275], [",", 283], ["often", 285], ["in", 291], ["the", 294], ["context", 298], ["of", 306], ["muscle", 309], ["biology", 316], [",", 323], ["described", 325], ["Tead", 335], ["(", 340], ["TEA", 341], ["domain", 345], [")", 351], ["transcription", 353], ["factors", 367], [",", 374], ["which", 376], ["bind", 382], ["CATTCC", 387], ["DNA", 394], ["motifs", 398], ["to", 405], ["regulate", 408], ["gene", 417], ["expression", 422], [".", 432], ["These", 434], ["two", 440], ["research", 444], ["areas", 453], ["were", 459], ["joined", 464], ["by", 471], ["the", 474], ["finding", 478], ["that", 486], ["the", 491], ["Hippo", 495], ["pathway", 501], ["regulates", 509], ["the", 519], ["activity", 523], ["of", 532], ["Tead", 535], ["transcription", 540], ["factors", 554], ["mainly", 562], ["through", 569], ["phosphorylation", 577], ["of", 593], ["the", 596], ["transcriptional", 600], ["coactivators", 616], ["Yap", 629], ["and", 633], ["Taz", 637], [",", 640], ["which", 642], ["bind", 648], ["to", 653], ["and", 656], ["activate", 660], ["Teads", 669], [".", 674], ["Additionally", 676], [",", 688], ["many", 690], ["other", 695], ["signal", 701], ["transduction", 708], ["proteins", 721], ["crosstalk", 730], ["to", 740], ["members", 743], ["of", 751], ["the", 754], ["Hippo", 758], ["pathway", 764], ["forming", 772], ["a", 780], ["Hippo", 782], ["signal", 788], ["transduction", 795], ["network", 808], [".", 815], ["We", 817], ["discuss", 820], ["evidence", 828], ["that", 837], ["the", 842], ["Hippo", 846], ["signal", 852], ["transduction", 859], ["network", 872], ["plays", 880], ["important", 886], ["roles", 896], ["in", 902], ["myogenesis", 905], [",", 915], ["regeneration", 917], [",", 929], ["muscular", 931], ["dystrophy", 940], [",", 949], ["and", 951], ["rhabdomyosarcoma", 955], ["in", 972], ["skeletal", 975], ["muscle", 984], [",", 990], ["as", 992], ["well", 995], ["as", 1000], ["in", 1003], ["myogenesis", 1006], [",", 1016], ["organ", 1018], ["size", 1024], ["control", 1029], [",", 1036], ["and", 1038], ["regeneration", 1042], ["of", 1055], ["the", 1058], ["heart", 1062], [".", 1067], ["Understanding", 1069], ["the", 1083], ["role", 1087], ["of", 1092], ["Hippo", 1095], ["kinases", 1101], ["in", 1109], ["skeletal", 1112], ["and", 1121], ["heart", 1125], ["muscle", 1131], ["physiology", 1138], ["could", 1149], ["have", 1155], ["important", 1160], ["implications", 1170], ["for", 1183], ["translational", 1187], ["research", 1201], [".", 1209]]}
{"context": "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "db97a187c75442e883f177344a687937", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[243, 243]], "char_spans": [[1399, 1408]]}]}], "context_tokens": [["Venous", 0], ["thromboembolism", 7], ["(", 23], ["VTE", 24], [")", 27], ["is", 29], ["associated", 32], ["with", 43], ["significant", 48], ["morbidity", 60], ["and", 70], ["mortality", 74], [".", 83], ["Factors", 85], ["such", 93], ["as", 98], ["the", 101], ["presence", 105], ["of", 114], ["transient", 117], ["risk", 127], ["factors", 132], ["for", 140], ["VTE", 144], [",", 147], ["risk", 149], ["of", 154], ["bleeding", 157], [",", 165], ["and", 167], ["location", 171], ["of", 180], ["deep", 183], ["vein", 188], ["thrombosis", 193], ["(", 204], ["DVT", 205], [")", 208], ["determine", 210], ["the", 220], ["duration", 224], ["of", 233], ["anticoagulation", 236], [".", 251], ["Extended", 253], ["anticoagulation", 262], ["is", 278], ["offered", 281], ["to", 289], ["patients", 292], ["with", 301], ["unprovoked", 306], ["pulmonary", 317], ["embolism", 327], ["(", 336], ["PE", 337], [")", 339], ["or", 341], ["proximal", 344], ["DVT", 353], ["and", 357], ["a", 361], ["low", 363], ["risk", 367], ["of", 372], ["bleeding", 375], [".", 383], ["Anticoagulation", 385], ["for", 401], ["3", 405], ["months", 407], ["is", 414], ["advised", 417], ["in", 425], ["patients", 428], ["with", 437], ["provoked", 442], ["DVT", 451], ["or", 455], ["PE", 458], [",", 460], ["high", 462], ["risk", 467], ["of", 472], ["bleeding", 475], [",", 483], ["and", 485], ["isolated", 489], ["distal", 498], ["or", 505], ["upper", 508], ["extremity", 514], ["DVT", 524], [".", 527], ["In", 529], ["patients", 532], ["with", 541], ["unprovoked", 546], ["PE", 557], ["or", 560], ["proximal", 563], ["DVT", 572], ["and", 576], ["a", 580], ["low", 582], ["risk", 586], ["of", 591], ["bleeding", 594], [",", 602], ["who", 604], ["want", 608], ["to", 613], ["stop", 616], ["anticoagulation", 621], ["after", 637], ["3", 643], ["months", 645], [",", 651], ["further", 653], ["risk", 661], ["stratification", 666], ["is", 681], ["necessary", 684], [".", 693], ["Clinical", 695], ["scoring", 704], ["system", 712], [",", 718], ["and", 720], ["thrombophilia", 724], ["testing", 738], ["otherwise", 746], ["not", 756], ["routinely", 760], ["performed", 770], [",", 779], ["may", 781], ["be", 785], ["considered", 788], ["to", 799], ["measure", 802], ["risk", 810], ["of", 815], ["annual", 818], ["recurrence", 825], ["in", 836], ["such", 839], ["cases", 844], [".", 849], ["Short", 851], ["-", 856], ["term", 857], ["anticoagulation", 862], ["may", 878], ["be", 882], ["considered", 885], ["in", 896], ["subsegmental", 899], ["PE", 912], ["and", 915], ["superficial", 919], ["vein", 931], ["thrombosis", 936], [",", 946], ["particularly", 948], ["if", 961], ["patients", 964], ["are", 973], ["at", 977], ["low", 980], ["risk", 984], ["of", 989], ["bleeding", 992], ["and", 1001], ["have", 1005], ["persistent", 1010], ["risk", 1021], ["factors", 1026], ["for", 1034], ["recurrent", 1038], ["VTE", 1048], [".", 1051], ["In", 1053], ["cases", 1056], ["of", 1062], ["catheter", 1065], ["-", 1073], ["associated", 1074], ["thrombosis", 1085], [",", 1095], ["the", 1097], ["catheter", 1101], ["need", 1110], ["not", 1115], ["be", 1119], ["removed", 1122], ["routinely", 1130], [",", 1139], ["and", 1141], ["the", 1145], ["patient", 1149], ["may", 1157], ["be", 1161], ["anticoagulated", 1164], ["for", 1179], ["3", 1183], ["months", 1185], ["or", 1192], ["longer", 1195], ["if", 1202], ["the", 1205], ["catheter", 1209], ["is", 1218], ["maintained", 1221], ["in", 1232], ["patients", 1235], ["with", 1244], ["cancer", 1249], [".", 1255], ["Extensive", 1257], ["screening", 1267], ["for", 1277], ["occult", 1281], ["cancer", 1288], ["in", 1295], ["cases", 1298], ["of", 1304], ["unprovoked", 1307], ["VTE", 1318], ["is", 1322], ["not", 1325], ["beneficial", 1329], [".", 1339], ["New", 1341], ["oral", 1345], ["anticoagulants", 1350], ["such", 1365], ["as", 1370], ["apixaban", 1373], [",", 1381], ["rivaroxaban", 1383], [",", 1394], ["or", 1396], ["dabigatran", 1399], ["may", 1410], ["be", 1414], ["preferred", 1417], ["to", 1427], ["vitamin", 1430], ["K", 1438], ["antagonists", 1440], ["in", 1452], ["patients", 1455], ["without", 1464], ["cancer", 1472], ["or", 1479], ["renal", 1482], ["failure", 1488], [",", 1495], ["more", 1497], ["so", 1502], ["after", 1505], ["the", 1511], ["development", 1515], ["of", 1527], ["reversal", 1530], ["agents", 1539], ["such", 1546], ["as", 1551], ["idarucizumab", 1554], ["and", 1567], ["andexanet", 1571], ["alfa", 1581], [".", 1585]]}
{"context": "Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for posttraumatic stress disorder (PTSD). Serotonergic (5HT) attenuation of stress sensitivity is postulated from SSRIs' effects in other anxiety disorders, and we studied this in PTSD. Ten patients with PTSD fully recovered on SSRIs (Clinical Global Impression Scale-I 1 and 2) were enrolled in the study. Patients were tested on two occasions 1 week apart; in each session, they received a drink containing large neutral amino acids (LNAAs) either with (sham tryptophan depletion [STD], control) or without (acute tryptophan depletion [ATD]) tryptophan. At 5.5 hours after the drink, subjects were exposed to a trauma-related exposure challenge. Self-reports of PTSD (visual analogue scales [VAS] and the Davidson Trauma Scale [DTS]), anxiety (Spielberger State Inventory [STAI] Form Y-1), and mood (Profile of Mood States [POMS]) were obtained. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were also measured. The trauma-related exposure challenge induced anxiety on both days, with more marked responses on the ATD day according to VAS, DTS, POMS, and DBP (p < .05). A trend of significance (.1 > p > .05) was observed for STAI Form Y-1, HR, and SBP. These data demonstrate that ATD accentuates responses to trauma-related stimuli in SSRI-recovered PTSD. They also suggest that SSRI-induced increases in serotonin function restrain PTSD symptoms, especially under provocation, supporting a role for serotonin in mediating stress resilience.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "a197452996814e96bc9331b41b870709", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[283, 283], [44, 44], [297, 297], [17, 17], [143, 143], [49, 49]], "char_spans": [[1349, 1352], [254, 257], [1432, 1435], [109, 112], [738, 741], [278, 281]]}]}], "context_tokens": [["Selective", 0], ["serotonin", 10], ["reuptake", 20], ["inhibitors", 29], ["(", 40], ["SSRIs", 41], [")", 46], ["are", 48], ["first", 52], ["-", 57], ["line", 58], ["treatments", 63], ["for", 74], ["posttraumatic", 78], ["stress", 92], ["disorder", 99], ["(", 108], ["PTSD", 109], [")", 113], [".", 114], ["Serotonergic", 116], ["(", 129], ["5HT", 130], [")", 133], ["attenuation", 135], ["of", 147], ["stress", 150], ["sensitivity", 157], ["is", 169], ["postulated", 172], ["from", 183], ["SSRIs", 188], ["'", 193], ["effects", 195], ["in", 203], ["other", 206], ["anxiety", 212], ["disorders", 220], [",", 229], ["and", 231], ["we", 235], ["studied", 238], ["this", 246], ["in", 251], ["PTSD", 254], [".", 258], ["Ten", 260], ["patients", 264], ["with", 273], ["PTSD", 278], ["fully", 283], ["recovered", 289], ["on", 299], ["SSRIs", 302], ["(", 308], ["Clinical", 309], ["Global", 318], ["Impression", 325], ["Scale", 336], ["-", 341], ["I", 342], ["1", 344], ["and", 346], ["2", 350], [")", 351], ["were", 353], ["enrolled", 358], ["in", 367], ["the", 370], ["study", 374], [".", 379], ["Patients", 381], ["were", 390], ["tested", 395], ["on", 402], ["two", 405], ["occasions", 409], ["1", 419], ["week", 421], ["apart", 426], [";", 431], ["in", 433], ["each", 436], ["session", 441], [",", 448], ["they", 450], ["received", 455], ["a", 464], ["drink", 466], ["containing", 472], ["large", 483], ["neutral", 489], ["amino", 497], ["acids", 503], ["(", 509], ["LNAAs", 510], [")", 515], ["either", 517], ["with", 524], ["(", 529], ["sham", 530], ["tryptophan", 535], ["depletion", 546], ["[", 556], ["STD", 557], ["]", 560], [",", 561], ["control", 563], [")", 570], ["or", 572], ["without", 575], ["(", 583], ["acute", 584], ["tryptophan", 590], ["depletion", 601], ["[", 611], ["ATD", 612], ["]", 615], [")", 616], ["tryptophan", 618], [".", 628], ["At", 630], ["5.5", 633], ["hours", 637], ["after", 643], ["the", 649], ["drink", 653], [",", 658], ["subjects", 660], ["were", 669], ["exposed", 674], ["to", 682], ["a", 685], ["trauma", 687], ["-", 693], ["related", 694], ["exposure", 702], ["challenge", 711], [".", 720], ["Self", 722], ["-", 726], ["reports", 727], ["of", 735], ["PTSD", 738], ["(", 743], ["visual", 744], ["analogue", 751], ["scales", 760], ["[", 767], ["VAS", 768], ["]", 771], ["and", 773], ["the", 777], ["Davidson", 781], ["Trauma", 790], ["Scale", 797], ["[", 803], ["DTS", 804], ["]", 807], [")", 808], [",", 809], ["anxiety", 811], ["(", 819], ["Spielberger", 820], ["State", 832], ["Inventory", 838], ["[", 848], ["STAI", 849], ["]", 853], ["Form", 855], ["Y-1", 860], [")", 863], [",", 864], ["and", 866], ["mood", 870], ["(", 875], ["Profile", 876], ["of", 884], ["Mood", 887], ["States", 892], ["[", 899], ["POMS", 900], ["]", 904], [")", 905], ["were", 907], ["obtained", 912], [".", 920], ["Heart", 922], ["rate", 928], ["(", 933], ["HR", 934], [")", 936], [",", 937], ["systolic", 939], ["(", 948], ["SBP", 949], [")", 952], ["and", 954], ["diastolic", 958], ["(", 968], ["DBP", 969], [")", 972], ["blood", 974], ["pressure", 980], ["were", 989], ["also", 994], ["measured", 999], [".", 1007], ["The", 1009], ["trauma", 1013], ["-", 1019], ["related", 1020], ["exposure", 1028], ["challenge", 1037], ["induced", 1047], ["anxiety", 1055], ["on", 1063], ["both", 1066], ["days", 1071], [",", 1075], ["with", 1077], ["more", 1082], ["marked", 1087], ["responses", 1094], ["on", 1104], ["the", 1107], ["ATD", 1111], ["day", 1115], ["according", 1119], ["to", 1129], ["VAS", 1132], [",", 1135], ["DTS", 1137], [",", 1140], ["POMS", 1142], [",", 1146], ["and", 1148], ["DBP", 1152], ["(", 1156], ["p", 1157], ["<", 1159], [".05", 1161], [")", 1164], [".", 1165], ["A", 1167], ["trend", 1169], ["of", 1175], ["significance", 1178], ["(", 1191], [".1", 1192], [">", 1195], ["p", 1197], [">", 1199], [".05", 1201], [")", 1204], ["was", 1206], ["observed", 1210], ["for", 1219], ["STAI", 1223], ["Form", 1228], ["Y-1", 1233], [",", 1236], ["HR", 1238], [",", 1240], ["and", 1242], ["SBP", 1246], [".", 1249], ["These", 1251], ["data", 1257], ["demonstrate", 1262], ["that", 1274], ["ATD", 1279], ["accentuates", 1283], ["responses", 1295], ["to", 1305], ["trauma", 1308], ["-", 1314], ["related", 1315], ["stimuli", 1323], ["in", 1331], ["SSRI", 1334], ["-", 1338], ["recovered", 1339], ["PTSD", 1349], [".", 1353], ["They", 1355], ["also", 1360], ["suggest", 1365], ["that", 1373], ["SSRI", 1378], ["-", 1382], ["induced", 1383], ["increases", 1391], ["in", 1401], ["serotonin", 1404], ["function", 1414], ["restrain", 1423], ["PTSD", 1432], ["symptoms", 1437], [",", 1445], ["especially", 1447], ["under", 1458], ["provocation", 1464], [",", 1475], ["supporting", 1477], ["a", 1488], ["role", 1490], ["for", 1495], ["serotonin", 1499], ["in", 1509], ["mediating", 1512], ["stress", 1522], ["resilience", 1529], [".", 1539]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0c2e363266584674a6c79cd1c7d3e1eb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[34, 36]], "char_spans": [[203, 209]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["chromosome", 84], [",", 94], ["which", 96], ["is", 102], ["associated", 105], ["with", 116], ["a", 121], ["balanced", 123], ["translocation", 132], ["involving", 146], ["chromosomes", 156], ["9", 168], ["and", 170], ["22", 174], ["to", 177], ["produce", 180], ["a", 188], ["fusion", 190], ["gene", 197], ["(", 202], ["bcr", 203], ["-", 206], ["abl", 207], [")", 210], ["that", 212], ["gives", 217], ["rise", 223], ["to", 228], ["a", 231], ["constitutively", 233], ["activated", 248], ["Abl", 258], ["tyrosine", 262], ["kinase", 271], [".", 277], ["This", 279], ["kinase", 284], ["led", 291], ["to", 295], ["the", 298], ["discovery", 302], ["of", 312], ["several", 315], ["small", 323], ["-", 328], ["molecule", 329], ["inhibitors", 338], [",", 348], ["imatinib", 350], ["being", 359], ["the", 365], ["first", 369], ["and", 375], ["most", 379], ["successful", 384], ["of", 395], ["these", 398], [".", 403], ["Resistance", 405], ["to", 416], ["imatinib", 419], ["results", 428], ["in", 436], ["some", 439], ["patients", 444], ["from", 453], ["Abl", 458], ["kinase", 462], ["point", 469], ["mutations", 475], [".", 484], ["Overcoming", 486], ["imatinib", 497], ["resistance", 506], ["represents", 517], ["one", 528], ["of", 532], ["the", 535], ["biggest", 539], ["challenges", 547], ["facing", 558], ["clinicians", 565], ["in", 576], ["the", 579], ["modern", 583], ["management", 590], ["of", 601], ["CML", 604], [".", 607], ["In", 609], ["this", 612], ["review", 617], [",", 623], ["we", 625], ["discuss", 628], ["the", 636], ["current", 640], ["understanding", 648], ["of", 662], ["CML", 665], ["pathophysiology", 669], ["and", 685], ["mechanisms", 689], ["of", 700], ["imatinib", 703], ["resistance", 712], ["and", 723], ["how", 727], ["advancing", 731], ["this", 741], ["knowledge", 746], ["has", 756], ["led", 760], ["to", 764], ["the", 767], ["design", 771], ["of", 778], ["novel", 781], ["therapies", 787], ["in", 797], ["the", 800], ["area", 804], ["of", 809], ["blastic", 812], ["phase", 820], ["CML", 826], ["and", 830], ["Philadelphia", 834], ["chromosome", 847], ["-", 857], ["positive", 858], ["acute", 867], ["lymphoblastic", 873], ["leukemia", 887], ["with", 896], ["previous", 901], ["imatinib", 910], ["failure", 919], [".", 926]]}
{"context": "CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein. The disease starts in CP (chronic phase), but as a result of genomic instability, it progresses over time to accelerated phase and then to BC (blast crisis), becoming increasingly resistant to therapy. bcr-abl is a constitutively active tyrosine kinase that has been targeted by TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate), nilotinib and dasatinib. We have developed various flow cytometry techniques to enable us to isolate candidate CML stem cells from CP patients at diagnosis that efflux Hoechst dye, express CD34, lack CD38 and are cytokine-non-responsive in culture over periods of up to 12 days in growth factors. These stem cells have been shown to regenerate bcr-abl-positive haemopoiesis in immunocompromised mice upon transplantation. We previously demonstrated that IM was antiproliferative for CML stem cells but did not induce apoptosis. Clinical experience now confirms that IM may not target CML stem cells in vivo with few patients achieving complete molecular remission and relapse occurring rapidly upon drug withdrawal. Our recent efforts have focused on understanding why CML stem cells are resistant to IM and on trying to find novel ways to induce apoptosis of this population. We have shown that CML stem cells express very high levels of functional wild-type bcr-abl; no kinase domain mutations have been detected in the stem cell population. Dasatinib, a more potent multitargeted TKI than IM, inhibits bcr-abl activity more efficiently than IM but still does not induce apoptosis of the stem cell population. Most recently, we have tested a number of novel drug combinations and found that FTIs (farnesyl transferase inhibitors) have activity against CML. BMS-214662 is the most effective of these and induces apoptosis of phenotypically and functionally defined CML stem cells in vitro, as a single agent and in combination with IM or dasatinib. The effect against CML stem cells is selective with little effect on normal stem cells. The drug is also effective against BC CML stem cells and equally effective against wild-type and mutant bcr-abl, including the most resistant mutant T315I. In association with apoptosis, there is activation of caspase 8 and caspase 3, inhibition of the MAPK pathway, IAP-1 (inhibitor of apoptosis protein-1), NF-kappaB (nuclear factor kappaB) and iNOS (inducible nitric oxide synthase). Furthermore, BMS-214662 synergizes with MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors, suggesting a second mechanism other that RAS inhibition for induction of apoptosis. Our intentions are now to explore the activity of BMS-214662 in other cancer stem cell disorders and to move this preclinical work to a clinical trial combining dasatinib with BMS-214662 in CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "88390fb06cb44b229884042b868e9663", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[84, 86], [278, 280], [420, 422], [39, 41], [306, 308], [175, 177]], "char_spans": [[432, 438], [1538, 1544], [2320, 2326], [209, 215], [1683, 1689], [922, 928]]}]}], "context_tokens": [["CML", 0], ["(", 4], ["chronic", 5], ["myeloid", 13], ["leukaemia", 21], [")", 30], ["is", 32], ["a", 35], ["myeloproliferative", 37], ["disease", 56], ["that", 64], ["originates", 69], ["in", 80], ["an", 83], ["HSC", 86], ["(", 90], ["haemopoietic", 91], ["stem", 104], ["cell", 109], [")", 113], ["as", 115], ["a", 118], ["result", 120], ["of", 127], ["the", 130], ["t(9;22", 134], [")", 140], ["translocation", 142], [",", 155], ["giving", 157], ["rise", 164], ["to", 169], ["the", 172], ["Ph", 176], ["(", 179], ["Philadelphia", 180], ["chromosome", 193], [")", 203], ["and", 205], ["bcr", 209], ["-", 212], ["abl", 213], ["oncoprotein", 217], [".", 228], ["The", 230], ["disease", 234], ["starts", 242], ["in", 249], ["CP", 252], ["(", 255], ["chronic", 256], ["phase", 264], [")", 269], [",", 270], ["but", 272], ["as", 276], ["a", 279], ["result", 281], ["of", 288], ["genomic", 291], ["instability", 299], [",", 310], ["it", 312], ["progresses", 315], ["over", 326], ["time", 331], ["to", 336], ["accelerated", 339], ["phase", 351], ["and", 357], ["then", 361], ["to", 366], ["BC", 369], ["(", 372], ["blast", 373], ["crisis", 379], [")", 385], [",", 386], ["becoming", 388], ["increasingly", 397], ["resistant", 410], ["to", 420], ["therapy", 423], [".", 430], ["bcr", 432], ["-", 435], ["abl", 436], ["is", 440], ["a", 443], ["constitutively", 445], ["active", 460], ["tyrosine", 467], ["kinase", 476], ["that", 483], ["has", 488], ["been", 492], ["targeted", 497], ["by", 506], ["TKIs", 509], ["(", 514], ["tyrosine", 515], ["kinase", 524], ["inhibitors", 531], [")", 541], [",", 542], ["including", 544], ["IM", 554], ["(", 557], ["imatinib", 558], ["mesylate", 567], [")", 575], [",", 576], ["nilotinib", 578], ["and", 588], ["dasatinib", 592], [".", 601], ["We", 603], ["have", 606], ["developed", 611], ["various", 621], ["flow", 629], ["cytometry", 634], ["techniques", 644], ["to", 655], ["enable", 658], ["us", 665], ["to", 668], ["isolate", 671], ["candidate", 679], ["CML", 689], ["stem", 693], ["cells", 698], ["from", 704], ["CP", 709], ["patients", 712], ["at", 721], ["diagnosis", 724], ["that", 734], ["efflux", 739], ["Hoechst", 746], ["dye", 754], [",", 757], ["express", 759], ["CD34", 767], [",", 771], ["lack", 773], ["CD38", 778], ["and", 783], ["are", 787], ["cytokine", 791], ["-", 799], ["non", 800], ["-", 803], ["responsive", 804], ["in", 815], ["culture", 818], ["over", 826], ["periods", 831], ["of", 839], ["up", 842], ["to", 845], ["12", 848], ["days", 851], ["in", 856], ["growth", 859], ["factors", 866], [".", 873], ["These", 875], ["stem", 881], ["cells", 886], ["have", 892], ["been", 897], ["shown", 902], ["to", 908], ["regenerate", 911], ["bcr", 922], ["-", 925], ["abl", 926], ["-", 929], ["positive", 930], ["haemopoiesis", 939], ["in", 952], ["immunocompromised", 955], ["mice", 973], ["upon", 978], ["transplantation", 983], [".", 998], ["We", 1000], ["previously", 1003], ["demonstrated", 1014], ["that", 1027], ["IM", 1032], ["was", 1035], ["antiproliferative", 1039], ["for", 1057], ["CML", 1061], ["stem", 1065], ["cells", 1070], ["but", 1076], ["did", 1080], ["not", 1084], ["induce", 1088], ["apoptosis", 1095], [".", 1104], ["Clinical", 1106], ["experience", 1115], ["now", 1126], ["confirms", 1130], ["that", 1139], ["IM", 1144], ["may", 1147], ["not", 1151], ["target", 1155], ["CML", 1162], ["stem", 1166], ["cells", 1171], ["in", 1177], ["vivo", 1180], ["with", 1185], ["few", 1190], ["patients", 1194], ["achieving", 1203], ["complete", 1213], ["molecular", 1222], ["remission", 1232], ["and", 1242], ["relapse", 1246], ["occurring", 1254], ["rapidly", 1264], ["upon", 1272], ["drug", 1277], ["withdrawal", 1282], [".", 1292], ["Our", 1294], ["recent", 1298], ["efforts", 1305], ["have", 1313], ["focused", 1318], ["on", 1326], ["understanding", 1329], ["why", 1343], ["CML", 1347], ["stem", 1351], ["cells", 1356], ["are", 1362], ["resistant", 1366], ["to", 1376], ["IM", 1379], ["and", 1382], ["on", 1386], ["trying", 1389], ["to", 1396], ["find", 1399], ["novel", 1404], ["ways", 1410], ["to", 1415], ["induce", 1418], ["apoptosis", 1425], ["of", 1435], ["this", 1438], ["population", 1443], [".", 1453], ["We", 1455], ["have", 1458], ["shown", 1463], ["that", 1469], ["CML", 1474], ["stem", 1478], ["cells", 1483], ["express", 1489], ["very", 1497], ["high", 1502], ["levels", 1507], ["of", 1514], ["functional", 1517], ["wild", 1528], ["-", 1532], ["type", 1533], ["bcr", 1538], ["-", 1541], ["abl", 1542], [";", 1545], ["no", 1547], ["kinase", 1550], ["domain", 1557], ["mutations", 1564], ["have", 1574], ["been", 1579], ["detected", 1584], ["in", 1593], ["the", 1596], ["stem", 1600], ["cell", 1605], ["population", 1610], [".", 1620], ["Dasatinib", 1622], [",", 1631], ["a", 1633], ["more", 1635], ["potent", 1640], ["multitargeted", 1647], ["TKI", 1661], ["than", 1665], ["IM", 1670], [",", 1672], ["inhibits", 1674], ["bcr", 1683], ["-", 1686], ["abl", 1687], ["activity", 1691], ["more", 1700], ["efficiently", 1705], ["than", 1717], ["IM", 1722], ["but", 1725], ["still", 1729], ["does", 1735], ["not", 1740], ["induce", 1744], ["apoptosis", 1751], ["of", 1761], ["the", 1764], ["stem", 1768], ["cell", 1773], ["population", 1778], [".", 1788], ["Most", 1790], ["recently", 1795], [",", 1803], ["we", 1805], ["have", 1808], ["tested", 1813], ["a", 1820], ["number", 1822], ["of", 1829], ["novel", 1832], ["drug", 1838], ["combinations", 1843], ["and", 1856], ["found", 1860], ["that", 1866], ["FTIs", 1871], ["(", 1876], ["farnesyl", 1877], ["transferase", 1886], ["inhibitors", 1898], [")", 1908], ["have", 1910], ["activity", 1915], ["against", 1924], ["CML", 1932], [".", 1935], ["BMS-214662", 1937], ["is", 1948], ["the", 1951], ["most", 1955], ["effective", 1960], ["of", 1970], ["these", 1973], ["and", 1979], ["induces", 1983], ["apoptosis", 1991], ["of", 2001], ["phenotypically", 2004], ["and", 2019], ["functionally", 2023], ["defined", 2036], ["CML", 2044], ["stem", 2048], ["cells", 2053], ["in", 2059], ["vitro", 2062], [",", 2067], ["as", 2069], ["a", 2072], ["single", 2074], ["agent", 2081], ["and", 2087], ["in", 2091], ["combination", 2094], ["with", 2106], ["IM", 2111], ["or", 2114], ["dasatinib", 2117], [".", 2126], ["The", 2128], ["effect", 2132], ["against", 2139], ["CML", 2147], ["stem", 2151], ["cells", 2156], ["is", 2162], ["selective", 2165], ["with", 2175], ["little", 2180], ["effect", 2187], ["on", 2194], ["normal", 2197], ["stem", 2204], ["cells", 2209], [".", 2214], ["The", 2216], ["drug", 2220], ["is", 2225], ["also", 2228], ["effective", 2233], ["against", 2243], ["BC", 2251], ["CML", 2254], ["stem", 2258], ["cells", 2263], ["and", 2269], ["equally", 2273], ["effective", 2281], ["against", 2291], ["wild", 2299], ["-", 2303], ["type", 2304], ["and", 2309], ["mutant", 2313], ["bcr", 2320], ["-", 2323], ["abl", 2324], [",", 2327], ["including", 2329], ["the", 2339], ["most", 2343], ["resistant", 2348], ["mutant", 2358], ["T315I.", 2365], ["In", 2372], ["association", 2375], ["with", 2387], ["apoptosis", 2392], [",", 2401], ["there", 2403], ["is", 2409], ["activation", 2412], ["of", 2423], ["caspase", 2426], ["8", 2434], ["and", 2436], ["caspase", 2440], ["3", 2448], [",", 2449], ["inhibition", 2451], ["of", 2462], ["the", 2465], ["MAPK", 2469], ["pathway", 2474], [",", 2481], ["IAP-1", 2483], ["(", 2489], ["inhibitor", 2490], ["of", 2500], ["apoptosis", 2503], ["protein-1", 2513], [")", 2522], [",", 2523], ["NF", 2525], ["-", 2527], ["kappaB", 2528], ["(", 2535], ["nuclear", 2536], ["factor", 2544], ["kappaB", 2551], [")", 2557], ["and", 2559], ["iNOS", 2563], ["(", 2568], ["inducible", 2569], ["nitric", 2579], ["oxide", 2586], ["synthase", 2592], [")", 2600], [".", 2601], ["Furthermore", 2603], [",", 2614], ["BMS-214662", 2616], ["synergizes", 2627], ["with", 2638], ["MEK1/2", 2643], ["[", 2650], ["MAPK", 2651], ["(", 2656], ["mitogen", 2657], ["-", 2664], ["activated", 2665], ["protein", 2675], ["kinase)/ERK", 2683], ["(", 2695], ["extracellular", 2696], ["-", 2709], ["signal", 2710], ["-", 2716], ["regulated", 2717], ["kinase", 2727], [")", 2733], ["kinase", 2735], ["1/2", 2742], ["]", 2745], ["inhibitors", 2747], [",", 2757], ["suggesting", 2759], ["a", 2770], ["second", 2772], ["mechanism", 2779], ["other", 2789], ["that", 2795], ["RAS", 2800], ["inhibition", 2804], ["for", 2815], ["induction", 2819], ["of", 2829], ["apoptosis", 2832], [".", 2841], ["Our", 2843], ["intentions", 2847], ["are", 2858], ["now", 2862], ["to", 2866], ["explore", 2869], ["the", 2877], ["activity", 2881], ["of", 2890], ["BMS-214662", 2893], ["in", 2904], ["other", 2907], ["cancer", 2913], ["stem", 2920], ["cell", 2925], ["disorders", 2930], ["and", 2940], ["to", 2944], ["move", 2947], ["this", 2952], ["preclinical", 2957], ["work", 2969], ["to", 2974], ["a", 2977], ["clinical", 2979], ["trial", 2988], ["combining", 2994], ["dasatinib", 3004], ["with", 3014], ["BMS-214662", 3019], ["in", 3030], ["CML", 3033], [".", 3036]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "1d0edfd264d5465fadb7c6268c608128", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[229, 232]], "char_spans": [[1388, 1401]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["formation", 51], ["of", 61], ["a", 64], ["BCR", 66], ["-", 69], ["ABL", 70], ["fusion", 74], ["gene", 81], [",", 85], ["usually", 87], ["as", 95], ["a", 98], ["consequence", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["(", 132], ["Ph", 133], [")", 135], ["translocation", 137], ["between", 151], ["chromosomes", 159], ["9", 171], ["and", 173], ["22", 177], [".", 179], ["Recently", 181], ["the", 190], ["development", 194], ["of", 206], ["new", 209], ["fluorescence", 213], ["in", 226], ["-", 228], ["situ", 229], ["hybridization", 234], ["(", 248], ["FISH", 249], [")", 253], ["techniques", 255], ["has", 266], ["allowed", 270], ["identification", 278], ["of", 293], ["unexpected", 296], ["deletions", 307], ["of", 317], ["the", 320], ["reciprocal", 324], ["translocation", 335], ["product", 349], [",", 356], ["the", 358], ["derivative", 362], ["chromosome", 373], ["9", 384], [",", 385], ["in", 387], ["10", 390], ["%", 392], ["to", 394], ["15", 397], ["%", 399], ["of", 401], ["patients", 404], ["with", 413], ["CML", 418], [".", 421], ["These", 423], ["deletions", 429], ["are", 439], ["large", 443], [",", 448], ["span", 450], ["the", 455], ["translocation", 459], ["breakpoint", 473], [",", 483], ["and", 485], ["occur", 489], ["at", 495], ["the", 498], ["same", 502], ["time", 507], ["as", 512], ["the", 515], ["Ph", 519], ["translocation", 522], [".", 535], ["Such", 537], ["deletions", 542], ["therefore", 552], ["give", 562], ["rise", 567], ["to", 572], ["previously", 575], ["unsuspected", 586], ["molecular", 598], ["heterogeneity", 608], ["from", 622], ["the", 627], ["very", 631], ["beginning", 636], ["of", 646], ["this", 649], ["disease", 654], [",", 661], ["and", 663], ["there", 667], ["is", 673], ["mounting", 676], ["evidence", 685], ["for", 694], ["similar", 698], ["deletions", 706], ["associated", 716], ["with", 727], ["other", 732], ["translocations", 738], [".", 752], ["Several", 754], ["studies", 762], ["have", 770], ["demonstrated", 775], ["that", 788], ["CML", 793], ["patients", 797], ["who", 806], ["carry", 810], ["derivative", 816], ["chromosome", 827], ["9", 838], ["deletions", 840], ["exhibit", 850], ["a", 858], ["more", 860], ["rapid", 865], ["progression", 871], ["to", 883], ["blast", 886], ["crisis", 892], ["and", 899], ["a", 903], ["shorter", 905], ["survival", 913], [".", 921], ["Deletion", 923], ["status", 932], ["is", 939], ["independent", 942], ["of", 954], [",", 956], ["and", 958], ["more", 962], ["powerful", 967], ["than", 976], [",", 980], ["the", 982], ["Sokal", 986], ["and", 992], ["Hasford", 996], ["/", 1003], ["European", 1004], ["prognostic", 1013], ["scoring", 1024], ["systems", 1032], [".", 1039], ["The", 1041], ["poor", 1045], ["prognosis", 1050], ["associated", 1060], ["with", 1071], ["deletions", 1076], ["is", 1086], ["seen", 1089], ["in", 1094], ["patients", 1097], ["treated", 1106], ["with", 1114], ["hydroxyurea", 1119], ["or", 1131], ["interferon", 1134], [",", 1144], ["and", 1146], ["preliminary", 1150], ["evidence", 1162], ["suggests", 1171], ["that", 1180], ["patients", 1185], ["with", 1194], ["deletions", 1199], ["may", 1209], ["also", 1213], ["have", 1218], ["a", 1223], ["worse", 1225], ["outcome", 1231], ["than", 1239], ["nondeleted", 1244], ["patients", 1255], ["following", 1264], ["stem", 1274], ["cell", 1279], ["transplantation", 1284], ["or", 1300], ["treatment", 1303], ["with", 1313], ["imatinib", 1318], [".", 1326], ["Poor", 1328], ["outcome", 1333], ["can", 1341], ["not", 1344], ["be", 1348], ["attributed", 1351], ["to", 1362], ["loss", 1365], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["fusion", 1396], ["gene", 1403], ["expression", 1408], ["alone", 1419], [",", 1424], ["and", 1426], ["is", 1430], ["likely", 1433], ["to", 1440], ["reflect", 1443], ["loss", 1451], ["of", 1456], ["one", 1459], ["or", 1463], ["more", 1466], ["critical", 1471], ["genes", 1480], ["within", 1486], ["the", 1493], ["deleted", 1497], ["region", 1505], [".", 1511], ["The", 1513], ["molecular", 1517], ["heterogeneity", 1527], ["associated", 1541], ["with", 1552], ["the", 1557], ["Philadelphia", 1561], ["translocation", 1574], ["provides", 1588], ["a", 1597], ["new", 1599], ["paradigm", 1603], ["with", 1612], ["potential", 1617], ["relevance", 1627], ["to", 1637], ["all", 1640], ["malignancies", 1644], ["associated", 1657], ["with", 1668], ["reciprocal", 1673], ["chromosomal", 1684], ["translocations", 1696], ["and/or", 1711], ["fusion", 1718], ["gene", 1725], ["formation", 1730], [".", 1739]]}
{"context": "Sedation is an important aspect of care for critically ill newborns. Proper sedation reduces stress during procedures such as mechanical ventilation. Midazolam, a short-acting benzodiazepine, is widely administered as a sedative in newborn intensive care units but is not without side effects. Three term newborns developed myoclonic-like abnormal movements after receiving midazolam. In one, flumazenil controlled the abnormal movements. Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose. Flumazenil may be considered in cases of abnormal movements associated with midazolam. However, further studies are needed to provide guidelines for the administration of this drug in newborns.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "53789d187e204d27ba5d871adbcd3fd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[105, 105], [65, 65], [71, 71]], "char_spans": [[696, 705], [393, 402], [439, 448]]}]}], "context_tokens": [["Sedation", 0], ["is", 9], ["an", 12], ["important", 15], ["aspect", 25], ["of", 32], ["care", 35], ["for", 40], ["critically", 44], ["ill", 55], ["newborns", 59], [".", 67], ["Proper", 69], ["sedation", 76], ["reduces", 85], ["stress", 93], ["during", 100], ["procedures", 107], ["such", 118], ["as", 123], ["mechanical", 126], ["ventilation", 137], [".", 148], ["Midazolam", 150], [",", 159], ["a", 161], ["short", 163], ["-", 168], ["acting", 169], ["benzodiazepine", 176], [",", 190], ["is", 192], ["widely", 195], ["administered", 202], ["as", 215], ["a", 218], ["sedative", 220], ["in", 229], ["newborn", 232], ["intensive", 240], ["care", 250], ["units", 255], ["but", 261], ["is", 265], ["not", 268], ["without", 272], ["side", 280], ["effects", 285], [".", 292], ["Three", 294], ["term", 300], ["newborns", 305], ["developed", 314], ["myoclonic", 324], ["-", 333], ["like", 334], ["abnormal", 339], ["movements", 348], ["after", 358], ["receiving", 364], ["midazolam", 374], [".", 383], ["In", 385], ["one", 388], [",", 391], ["flumazenil", 393], ["controlled", 404], ["the", 415], ["abnormal", 419], ["movements", 428], [".", 437], ["Flumazenil", 439], ["is", 450], ["a", 453], ["potent", 455], ["benzodiazepine", 462], ["antagonist", 477], ["that", 488], ["competitively", 493], ["blocks", 507], ["the", 514], ["central", 518], ["effects", 526], ["of", 534], ["benzodiazepines", 537], [".", 552], ["It", 554], ["can", 557], ["reverse", 561], ["the", 569], ["sedative", 573], ["effects", 582], ["of", 590], ["benzodiazepines", 593], ["occurring", 609], ["after", 619], ["diagnostic", 625], ["or", 636], ["therapeutic", 639], ["procedures", 651], ["or", 662], ["after", 665], ["benzodiazepine", 671], ["overdose", 686], [".", 694], ["Flumazenil", 696], ["may", 707], ["be", 711], ["considered", 714], ["in", 725], ["cases", 728], ["of", 734], ["abnormal", 737], ["movements", 746], ["associated", 756], ["with", 767], ["midazolam", 772], [".", 781], ["However", 783], [",", 790], ["further", 792], ["studies", 800], ["are", 808], ["needed", 812], ["to", 819], ["provide", 822], ["guidelines", 830], ["for", 841], ["the", 845], ["administration", 849], ["of", 864], ["this", 867], ["drug", 872], ["in", 877], ["newborns", 880], [".", 888]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital red-cell aplasia characterized by anemia, bone-marrow erythroblastopenia, and congenital anomalies and is associated with heterozygous mutations in the ribosomal protein (RP) S19 gene (RPS19) in approximately 25% of probands. We report identification of de novo nonsense and splice-site mutations in another RP, RPS24 (encoded by RPS24 [10q22-q23]) in approximately 2% of RPS19 mutation-negative probands. This finding strongly suggests that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted ribosomal biogenesis and/or function may also cause DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f987a6c739454ffa9a27e24c4e5235c2", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[93, 93], [120, 120], [5, 5]], "char_spans": [[493, 495], [659, 661], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["red", 51], ["-", 54], ["cell", 55], ["aplasia", 60], ["characterized", 68], ["by", 82], ["anemia", 85], [",", 91], ["bone", 93], ["-", 97], ["marrow", 98], ["erythroblastopenia", 105], [",", 123], ["and", 125], ["congenital", 129], ["anomalies", 140], ["and", 150], ["is", 154], ["associated", 157], ["with", 168], ["heterozygous", 173], ["mutations", 186], ["in", 196], ["the", 199], ["ribosomal", 203], ["protein", 213], ["(", 221], ["RP", 222], [")", 224], ["S19", 226], ["gene", 230], ["(", 235], ["RPS19", 236], [")", 241], ["in", 243], ["approximately", 246], ["25", 260], ["%", 262], ["of", 264], ["probands", 267], [".", 275], ["We", 277], ["report", 280], ["identification", 287], ["of", 302], ["de", 305], ["novo", 308], ["nonsense", 313], ["and", 322], ["splice", 326], ["-", 332], ["site", 333], ["mutations", 338], ["in", 348], ["another", 351], ["RP", 359], [",", 361], ["RPS24", 363], ["(", 369], ["encoded", 370], ["by", 378], ["RPS24", 381], ["[", 387], ["10q22-q23", 388], ["]", 397], [")", 398], ["in", 400], ["approximately", 403], ["2", 417], ["%", 418], ["of", 420], ["RPS19", 423], ["mutation", 429], ["-", 437], ["negative", 438], ["probands", 447], [".", 455], ["This", 457], ["finding", 462], ["strongly", 470], ["suggests", 479], ["that", 488], ["DBA", 493], ["is", 497], ["a", 500], ["disorder", 502], ["of", 511], ["ribosome", 514], ["synthesis", 523], ["and", 533], ["that", 537], ["mutations", 542], ["in", 552], ["other", 555], ["RP", 561], ["or", 564], ["associated", 567], ["genes", 578], ["that", 584], ["lead", 589], ["to", 594], ["disrupted", 597], ["ribosomal", 607], ["biogenesis", 617], ["and/or", 628], ["function", 635], ["may", 644], ["also", 648], ["cause", 653], ["DBA", 659], [".", 662]]}
{"context": "Fibrillar \u03b1-synuclein (\u03b1-Syn) is the principal component of Lewy bodies, which are evident in individuals affected by Parkinson disease (PD). This neuropathologic form of \u03b1-Syn plays a central role in PD progression as it has been shown to propagate between neurons. Tools that interfere with \u03b1-Syn assembly or change the physicochemical properties of the fibrils have potential therapeutic properties as they may be sufficient to interfere with and/or halt cell-to-cell transmission and the systematic spread of \u03b1-Syn assemblies within the central nervous system. Vertebrate molecular chaperones from the constitutive/heat-inducible heat shock protein 70 (Hsc/p70) family have been shown to hinder the assembly of soluble \u03b1-Syn into fibrils and to bind to the fibrils and very significantly reduce their toxicity. To understand how Hsc70 family members sequester soluble \u03b1-Syn, we set up experiments to identify the molecular chaperone-\u03b1-Syn surface interfaces. We cross-linked human Hsc70 and its yeast homologue Ssa1p and \u03b1-Syn using a chemical cross-linker and mapped the Hsc70- and Ssa1p-\u03b1-Syn interface. We show that the client binding domain of Hsc70 and Ssa1p binds two regions within \u03b1-Syn similar to a tweezer, with the first spanning residues 10-45 and the second spanning residues 97-102. Our findings define what is necessary and sufficient for engineering Hsc70- and Ssa1p-derived polypeptide with minichaperone properties with a potential as therapeutic agents in Parkinson disease through their ability to affect \u03b1-Syn assembly and/or toxicity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "344f79431db040ea8cbbb6cb3a1b171a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["\u03b1", 23], ["-", 24], ["Syn", 25], [")", 28], ["is", 30], ["the", 33], ["principal", 37], ["component", 47], ["of", 57], ["Lewy", 60], ["bodies", 65], [",", 71], ["which", 73], ["are", 79], ["evident", 83], ["in", 91], ["individuals", 94], ["affected", 106], ["by", 115], ["Parkinson", 118], ["disease", 128], ["(", 136], ["PD", 137], [")", 139], [".", 140], ["This", 142], ["neuropathologic", 147], ["form", 163], ["of", 168], ["\u03b1", 171], ["-", 172], ["Syn", 173], ["plays", 177], ["a", 183], ["central", 185], ["role", 193], ["in", 198], ["PD", 201], ["progression", 204], ["as", 216], ["it", 219], ["has", 222], ["been", 226], ["shown", 231], ["to", 237], ["propagate", 240], ["between", 250], ["neurons", 258], [".", 265], ["Tools", 267], ["that", 273], ["interfere", 278], ["with", 288], ["\u03b1", 293], ["-", 294], ["Syn", 295], ["assembly", 299], ["or", 308], ["change", 311], ["the", 318], ["physicochemical", 322], ["properties", 338], ["of", 349], ["the", 352], ["fibrils", 356], ["have", 364], ["potential", 369], ["therapeutic", 379], ["properties", 391], ["as", 402], ["they", 405], ["may", 410], ["be", 414], ["sufficient", 417], ["to", 428], ["interfere", 431], ["with", 441], ["and/or", 446], ["halt", 453], ["cell", 458], ["-", 462], ["to", 463], ["-", 465], ["cell", 466], ["transmission", 471], ["and", 484], ["the", 488], ["systematic", 492], ["spread", 503], ["of", 510], ["\u03b1", 513], ["-", 514], ["Syn", 515], ["assemblies", 519], ["within", 530], ["the", 537], ["central", 541], ["nervous", 549], ["system", 557], [".", 563], ["Vertebrate", 565], ["molecular", 576], ["chaperones", 586], ["from", 597], ["the", 602], ["constitutive", 606], ["/", 618], ["heat", 619], ["-", 623], ["inducible", 624], ["heat", 634], ["shock", 639], ["protein", 645], ["70", 653], ["(", 656], ["Hsc", 657], ["/", 660], ["p70", 661], [")", 664], ["family", 666], ["have", 673], ["been", 678], ["shown", 683], ["to", 689], ["hinder", 692], ["the", 699], ["assembly", 703], ["of", 712], ["soluble", 715], ["\u03b1", 723], ["-", 724], ["Syn", 725], ["into", 729], ["fibrils", 734], ["and", 742], ["to", 746], ["bind", 749], ["to", 754], ["the", 757], ["fibrils", 761], ["and", 769], ["very", 773], ["significantly", 778], ["reduce", 792], ["their", 799], ["toxicity", 805], [".", 813], ["To", 815], ["understand", 818], ["how", 829], ["Hsc70", 833], ["family", 839], ["members", 846], ["sequester", 854], ["soluble", 864], ["\u03b1", 872], ["-", 873], ["Syn", 874], [",", 877], ["we", 879], ["set", 882], ["up", 886], ["experiments", 889], ["to", 901], ["identify", 904], ["the", 913], ["molecular", 917], ["chaperone", 927], ["-", 936], ["\u03b1", 937], ["-", 938], ["Syn", 939], ["surface", 943], ["interfaces", 951], [".", 961], ["We", 963], ["cross", 966], ["-", 971], ["linked", 972], ["human", 979], ["Hsc70", 985], ["and", 991], ["its", 995], ["yeast", 999], ["homologue", 1005], ["Ssa1p", 1015], ["and", 1021], ["\u03b1", 1025], ["-", 1026], ["Syn", 1027], ["using", 1031], ["a", 1037], ["chemical", 1039], ["cross", 1048], ["-", 1053], ["linker", 1054], ["and", 1061], ["mapped", 1065], ["the", 1072], ["Hsc70-", 1076], ["and", 1083], ["Ssa1p", 1087], ["-", 1092], ["\u03b1", 1093], ["-", 1094], ["Syn", 1095], ["interface", 1099], [".", 1108], ["We", 1110], ["show", 1113], ["that", 1118], ["the", 1123], ["client", 1127], ["binding", 1134], ["domain", 1142], ["of", 1149], ["Hsc70", 1152], ["and", 1158], ["Ssa1p", 1162], ["binds", 1168], ["two", 1174], ["regions", 1178], ["within", 1186], ["\u03b1", 1193], ["-", 1194], ["Syn", 1195], ["similar", 1199], ["to", 1207], ["a", 1210], ["tweezer", 1212], [",", 1219], ["with", 1221], ["the", 1226], ["first", 1230], ["spanning", 1236], ["residues", 1245], ["10", 1254], ["-", 1256], ["45", 1257], ["and", 1260], ["the", 1264], ["second", 1268], ["spanning", 1275], ["residues", 1284], ["97", 1293], ["-", 1295], ["102", 1296], [".", 1299], ["Our", 1301], ["findings", 1305], ["define", 1314], ["what", 1321], ["is", 1326], ["necessary", 1329], ["and", 1339], ["sufficient", 1343], ["for", 1354], ["engineering", 1358], ["Hsc70-", 1370], ["and", 1377], ["Ssa1p", 1381], ["-", 1386], ["derived", 1387], ["polypeptide", 1395], ["with", 1407], ["minichaperone", 1412], ["properties", 1426], ["with", 1437], ["a", 1442], ["potential", 1444], ["as", 1454], ["therapeutic", 1457], ["agents", 1469], ["in", 1476], ["Parkinson", 1479], ["disease", 1489], ["through", 1497], ["their", 1505], ["ability", 1511], ["to", 1519], ["affect", 1522], ["\u03b1", 1529], ["-", 1530], ["Syn", 1531], ["assembly", 1535], ["and/or", 1544], ["toxicity", 1551], [".", 1559]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Anticoagulation therapy is indicated for management of various clinical conditions to prevent adverse events and introduction of direct oral anticoagulants (DOACs) has ushered in a new era in anticoagulation therapy. Major advantages of DOACS include fewer drug interactions and that they do not need periodic monitoring. Several patients who were not on anticoagulation before due to older age, polypharmacy/drug interaction concerns, and logistics of periodic monitoring are now on anticoagulation with DOACs. Despite their many advantages, a challenge while prescribing DOACs is very limited availability of specific reversal agents and lack of understanding or guidance about the treatment strategy in case of major life threatening bleeding or need for urgent surgery. So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran. Several other reversal agents are under final phases of development such as andexanet alfa and PER977 (ciraparantag) and will help in developing specific strategies for reversal of these agents. In this article, we review current strategies to manage bleeding with DOACs and provide guidance to clinicians of inhibiting LF activity in vitro and in cells, as well as in animal models of anthrax infection.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "92d38fcd3d864c5aa90a01fe0e5787f2", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[149, 149]], "char_spans": [[906, 915]]}]}], "context_tokens": [["Anticoagulation", 0], ["therapy", 16], ["is", 24], ["indicated", 27], ["for", 37], ["management", 41], ["of", 52], ["various", 55], ["clinical", 63], ["conditions", 72], ["to", 83], ["prevent", 86], ["adverse", 94], ["events", 102], ["and", 109], ["introduction", 113], ["of", 126], ["direct", 129], ["oral", 136], ["anticoagulants", 141], ["(", 156], ["DOACs", 157], [")", 162], ["has", 164], ["ushered", 168], ["in", 176], ["a", 179], ["new", 181], ["era", 185], ["in", 189], ["anticoagulation", 192], ["therapy", 208], [".", 215], ["Major", 217], ["advantages", 223], ["of", 234], ["DOACS", 237], ["include", 243], ["fewer", 251], ["drug", 257], ["interactions", 262], ["and", 275], ["that", 279], ["they", 284], ["do", 289], ["not", 292], ["need", 296], ["periodic", 301], ["monitoring", 310], [".", 320], ["Several", 322], ["patients", 330], ["who", 339], ["were", 343], ["not", 348], ["on", 352], ["anticoagulation", 355], ["before", 371], ["due", 378], ["to", 382], ["older", 385], ["age", 391], [",", 394], ["polypharmacy", 396], ["/", 408], ["drug", 409], ["interaction", 414], ["concerns", 426], [",", 434], ["and", 436], ["logistics", 440], ["of", 450], ["periodic", 453], ["monitoring", 462], ["are", 473], ["now", 477], ["on", 481], ["anticoagulation", 484], ["with", 500], ["DOACs", 505], [".", 510], ["Despite", 512], ["their", 520], ["many", 526], ["advantages", 531], [",", 541], ["a", 543], ["challenge", 545], ["while", 555], ["prescribing", 561], ["DOACs", 573], ["is", 579], ["very", 582], ["limited", 587], ["availability", 595], ["of", 608], ["specific", 611], ["reversal", 620], ["agents", 629], ["and", 636], ["lack", 640], ["of", 645], ["understanding", 648], ["or", 662], ["guidance", 665], ["about", 674], ["the", 680], ["treatment", 684], ["strategy", 694], ["in", 703], ["case", 706], ["of", 711], ["major", 714], ["life", 720], ["threatening", 725], ["bleeding", 737], ["or", 746], ["need", 749], ["for", 754], ["urgent", 758], ["surgery", 765], [".", 772], ["So", 774], ["far", 777], ["only", 781], ["one", 786], ["reversal", 790], ["agent", 799], ["has", 805], ["been", 809], ["approved", 814], ["by", 823], ["the", 826], ["Food", 830], ["and", 835], ["Drug", 839], ["Administration", 844], ["(", 859], ["FDA", 860], [")", 863], [",", 864], ["idarucizumab", 866], ["for", 879], ["one", 883], ["of", 887], ["the", 890], ["DOACs", 894], ["i.e.", 900], [",", 904], ["dabigatran", 906], [".", 916], ["Several", 918], ["other", 926], ["reversal", 932], ["agents", 941], ["are", 948], ["under", 952], ["final", 958], ["phases", 964], ["of", 971], ["development", 974], ["such", 986], ["as", 991], ["andexanet", 994], ["alfa", 1004], ["and", 1009], ["PER977", 1013], ["(", 1020], ["ciraparantag", 1021], [")", 1033], ["and", 1035], ["will", 1039], ["help", 1044], ["in", 1049], ["developing", 1052], ["specific", 1063], ["strategies", 1072], ["for", 1083], ["reversal", 1087], ["of", 1096], ["these", 1099], ["agents", 1105], [".", 1111], ["In", 1113], ["this", 1116], ["article", 1121], [",", 1128], ["we", 1130], ["review", 1133], ["current", 1140], ["strategies", 1148], ["to", 1159], ["manage", 1162], ["bleeding", 1169], ["with", 1178], ["DOACs", 1183], ["and", 1189], ["provide", 1193], ["guidance", 1201], ["to", 1210], ["clinicians", 1213], ["of", 1224], ["inhibiting", 1227], ["LF", 1238], ["activity", 1241], ["in", 1250], ["vitro", 1253], ["and", 1259], ["in", 1263], ["cells", 1266], [",", 1271], ["as", 1273], ["well", 1276], ["as", 1281], ["in", 1284], ["animal", 1287], ["models", 1294], ["of", 1301], ["anthrax", 1304], ["infection", 1312], [".", 1321]]}
{"context": "Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30\u2009mg/kg weekly, beginning gestation day (GD) 20 through parturition (\u223cGD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4\u2009mg/kg (n\u2009=\u20099) and 30\u2009mg/kg (n\u2009=\u20091). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "341ad31d93c34ba196d196dbeca4aa12", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[5, 7]], "char_spans": [[26, 44]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["an", 11], ["antibody", 14], ["to", 23], ["nerve", 26], ["growth", 32], ["factor", 39], [",", 45], ["was", 47], ["administered", 51], ["to", 64], ["pregnant", 67], ["cynomolgus", 76], ["monkeys", 87], ["at", 95], ["0", 98], [",", 99], ["0.5", 101], [",", 104], ["4", 106], [",", 107], ["and", 109], ["30", 113], ["mg", 116], ["/", 118], ["kg", 119], ["weekly", 122], [",", 128], ["beginning", 130], ["gestation", 140], ["day", 150], ["(", 154], ["GD", 155], [")", 157], ["20", 159], ["through", 162], ["parturition", 170], ["(", 182], ["\u223cGD165", 183], [")", 189], [".", 190], ["Maternal", 192], ["tanezumab", 201], ["administration", 211], ["appeared", 226], ["to", 235], ["increase", 238], ["stillbirths", 247], ["and", 259], ["infant", 263], ["mortality", 270], [",", 279], ["but", 281], ["no", 285], ["consistent", 288], ["pattern", 299], ["of", 307], ["gross", 310], ["and/or", 316], ["microscopic", 323], ["change", 335], ["was", 342], ["detected", 346], ["to", 355], ["explain", 358], ["the", 366], ["mortality", 370], [".", 379], ["Offspring", 381], ["exposed", 391], ["in", 399], ["utero", 402], ["were", 408], ["evaluated", 413], ["at", 423], ["12", 426], ["months", 429], ["of", 436], ["age", 439], ["using", 443], ["light", 449], ["microscopy", 455], ["(", 466], ["all", 467], ["tissues", 471], [")", 478], [",", 479], ["stereology", 481], ["(", 492], ["basal", 493], ["forebrain", 499], ["cholinergic", 509], ["and", 521], ["dorsal", 525], ["root", 532], ["ganglia", 537], ["neurons", 545], [")", 552], [",", 553], ["and", 555], ["morphometry", 559], ["(", 571], ["sural", 572], ["nerve", 578], [")", 583], [".", 584], ["Light", 586], ["microscopy", 592], ["revealed", 603], ["decreased", 612], ["number", 622], ["of", 629], ["neurons", 632], ["in", 640], ["sympathetic", 643], ["ganglia", 655], ["(", 663], ["superior", 664], ["mesenteric", 673], [",", 683], ["cervicothoracic", 685], [",", 700], ["and", 702], ["ganglia", 706], ["in", 714], ["the", 717], ["thoracic", 721], ["sympathetic", 730], ["trunk", 742], [")", 747], [".", 748], ["Stereologic", 750], ["assessment", 762], ["indicated", 773], ["an", 783], ["overall", 786], ["decrease", 794], ["in", 803], ["dorsal", 806], ["root", 813], ["ganglion", 818], ["(", 827], ["thoracic", 828], [")", 836], ["volume", 838], ["and", 845], ["number", 849], ["of", 856], ["neurons", 859], ["in", 867], ["animals", 870], ["exposed", 878], ["to", 886], ["tanezumab", 889], ["4", 899], ["mg", 901], ["/", 903], ["kg", 904], ["(", 907], ["n", 908], ["=", 910], ["9", 912], [")", 913], ["and", 915], ["30", 919], ["mg", 922], ["/", 924], ["kg", 925], ["(", 928], ["n", 929], ["=", 931], ["1", 933], [")", 934], [".", 935], ["At", 937], ["all", 940], ["tanezumab", 944], ["doses", 954], [",", 959], ["the", 961], ["sural", 965], ["nerve", 971], ["was", 977], ["small", 981], ["due", 987], ["to", 991], ["decreases", 994], ["in", 1004], ["myelinated", 1007], ["and", 1018], ["unmyelinated", 1022], ["axons", 1035], [".", 1040], ["Existing", 1042], ["axons", 1051], ["/", 1056], ["myelin", 1057], ["sheaths", 1064], ["appeared", 1072], ["normal", 1081], ["when", 1088], ["viewed", 1093], ["with", 1100], ["light", 1105], ["and", 1111], ["transmission", 1115], ["electron", 1128], ["microscopy", 1137], [".", 1147], ["There", 1149], ["was", 1155], ["no", 1159], ["indication", 1162], ["of", 1173], ["tanezumab", 1176], ["-", 1185], ["related", 1186], [",", 1193], ["active", 1195], ["neuron", 1202], ["/", 1208], ["nerve", 1209], ["fiber", 1215], ["degeneration", 1221], ["/", 1233], ["necrosis", 1234], ["in", 1243], ["any", 1246], ["tissue", 1250], [",", 1256], ["indicating", 1258], ["decreased", 1269], ["sensory", 1279], ["/", 1286], ["sympathetic", 1287], ["neurons", 1299], ["and", 1307], ["axonal", 1311], ["changes", 1318], ["were", 1326], ["due", 1331], ["to", 1335], ["hypoplasia", 1338], ["or", 1349], ["atrophy", 1352], [".", 1359], ["These", 1361], ["changes", 1367], ["in", 1375], ["the", 1378], ["sensory", 1382], ["and", 1390], ["sympathetic", 1394], ["portions", 1406], ["of", 1415], ["the", 1418], ["peripheral", 1422], ["nervous", 1433], ["system", 1441], ["suggest", 1448], ["some", 1456], ["degree", 1461], ["of", 1468], ["developmental", 1471], ["neurotoxicity", 1485], [",", 1498], ["although", 1500], ["what", 1509], ["effect", 1514], [",", 1520], ["if", 1522], ["any", 1525], [",", 1528], ["the", 1530], ["changes", 1534], ["had", 1542], ["on", 1546], ["normal", 1549], ["function", 1556], ["and", 1565], ["survival", 1569], ["was", 1578], ["not", 1582], ["apparent", 1586], [".", 1594], ["Overall", 1596], [",", 1603], ["these", 1605], ["changes", 1611], ["were", 1619], ["consistent", 1624], ["with", 1635], ["published", 1640], ["data", 1650], ["from", 1655], ["rodent", 1660], ["studies", 1667], [".", 1674]]}
{"context": "MicroRNAs (miRNAs) are non-coding, short (21-23nt) regulators of protein-coding genes that are generally transcribed first into primary miRNA (pri-miR), followed by the generation of precursor miRNA (pre-miR). This finally leads to the production of the mature miRNA. A large amount of information is available on the pre- and mature miRNAs. However, very little is known about the pri-miRs, due to a lack of knowledge about their transcription start sites (TSSs). Based on the genomic loci, miRNAs can be categorized into two types --intragenic (intra-miR) and intergenic (inter-miR). While it is already an established fact that intra-miRs are commonly transcribed in conjunction with their host genes, the transcription machinery of inter-miRs is poorly understood. Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs. In this paper, we concentrate on the problem of TSS prediction for miRNAs. The present study begins with the identification of positive and negative promoter samples from recently published data stemming from RNA-sequencing studies. From these samples of experimentally validated miRNA TSSs, a number of standard sequence features are extracted. Furthermore, to account for potential footprints related to promoter regulation by CpG dinucleotide targeted DNA methylation, a number of novel features are defined. We develop a support vector machine (SVM) with RBF kernel for the prediction of miRNA TSSs trained on human miRNA promoters. A novel feature reduction technique based on archived multi-objective simulated annealing (AMOSA) identifies the final set of features. The resulting model trained on miRNA promoters shows improved performance over the one trained on protein-coding gene promoters in terms of classification accuracy, sensitivity and specificity. Results are also reported for a completely independent biologically validated test set. In a part of the investigation, the proposed approach is used to predict protein-coding gene TSSs. It shows a significantly improved performance when compared to previously published gene TSS prediction methods.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cdd96acd2fc94e268b146391bc401383", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[179, 181]], "char_spans": [[887, 903]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["short", 35], ["(", 41], ["21", 42], ["-", 44], ["23nt", 45], [")", 49], ["regulators", 51], ["of", 62], ["protein", 65], ["-", 72], ["coding", 73], ["genes", 80], ["that", 86], ["are", 91], ["generally", 95], ["transcribed", 105], ["first", 117], ["into", 123], ["primary", 128], ["miRNA", 136], ["(", 142], ["pri", 143], ["-", 146], ["miR", 147], [")", 150], [",", 151], ["followed", 153], ["by", 162], ["the", 165], ["generation", 169], ["of", 180], ["precursor", 183], ["miRNA", 193], ["(", 199], ["pre", 200], ["-", 203], ["miR", 204], [")", 207], [".", 208], ["This", 210], ["finally", 215], ["leads", 223], ["to", 229], ["the", 232], ["production", 236], ["of", 247], ["the", 250], ["mature", 254], ["miRNA", 261], [".", 266], ["A", 268], ["large", 270], ["amount", 276], ["of", 283], ["information", 286], ["is", 298], ["available", 301], ["on", 311], ["the", 314], ["pre-", 318], ["and", 323], ["mature", 327], ["miRNAs", 334], [".", 340], ["However", 342], [",", 349], ["very", 351], ["little", 356], ["is", 363], ["known", 366], ["about", 372], ["the", 378], ["pri", 382], ["-", 385], ["miRs", 386], [",", 390], ["due", 392], ["to", 396], ["a", 399], ["lack", 401], ["of", 406], ["knowledge", 409], ["about", 419], ["their", 425], ["transcription", 431], ["start", 445], ["sites", 451], ["(", 457], ["TSSs", 458], [")", 462], [".", 463], ["Based", 465], ["on", 471], ["the", 474], ["genomic", 478], ["loci", 486], [",", 490], ["miRNAs", 492], ["can", 499], ["be", 503], ["categorized", 506], ["into", 518], ["two", 523], ["types", 527], ["--intragenic", 533], ["(", 546], ["intra", 547], ["-", 552], ["miR", 553], [")", 556], ["and", 558], ["intergenic", 562], ["(", 573], ["inter", 574], ["-", 579], ["miR", 580], [")", 583], [".", 584], ["While", 586], ["it", 592], ["is", 595], ["already", 598], ["an", 606], ["established", 609], ["fact", 621], ["that", 626], ["intra", 631], ["-", 636], ["miRs", 637], ["are", 642], ["commonly", 646], ["transcribed", 655], ["in", 667], ["conjunction", 670], ["with", 682], ["their", 687], ["host", 693], ["genes", 698], [",", 703], ["the", 705], ["transcription", 709], ["machinery", 723], ["of", 733], ["inter", 736], ["-", 741], ["miRs", 742], ["is", 747], ["poorly", 750], ["understood", 757], [".", 767], ["Although", 769], ["it", 778], ["is", 781], ["assumed", 784], ["that", 792], ["miRNA", 797], ["promoters", 803], ["are", 813], ["similar", 817], ["in", 825], ["structure", 828], ["to", 838], ["gene", 841], ["promoters", 846], [",", 855], ["since", 857], ["both", 863], ["are", 868], ["transcribed", 872], ["by", 884], ["RNA", 887], ["polymerase", 891], ["II", 902], ["(", 905], ["Pol", 906], ["II", 910], [")", 912], [",", 913], ["computational", 915], ["validations", 929], ["exhibit", 941], ["poor", 949], ["performance", 954], ["of", 966], ["gene", 969], ["promoter", 974], ["prediction", 983], ["methods", 994], ["on", 1002], ["miRNAs", 1005], [".", 1011], ["In", 1013], ["this", 1016], ["paper", 1021], [",", 1026], ["we", 1028], ["concentrate", 1031], ["on", 1043], ["the", 1046], ["problem", 1050], ["of", 1058], ["TSS", 1061], ["prediction", 1065], ["for", 1076], ["miRNAs", 1080], [".", 1086], ["The", 1088], ["present", 1092], ["study", 1100], ["begins", 1106], ["with", 1113], ["the", 1118], ["identification", 1122], ["of", 1137], ["positive", 1140], ["and", 1149], ["negative", 1153], ["promoter", 1162], ["samples", 1171], ["from", 1179], ["recently", 1184], ["published", 1193], ["data", 1203], ["stemming", 1208], ["from", 1217], ["RNA", 1222], ["-", 1225], ["sequencing", 1226], ["studies", 1237], [".", 1244], ["From", 1246], ["these", 1251], ["samples", 1257], ["of", 1265], ["experimentally", 1268], ["validated", 1283], ["miRNA", 1293], ["TSSs", 1299], [",", 1303], ["a", 1305], ["number", 1307], ["of", 1314], ["standard", 1317], ["sequence", 1326], ["features", 1335], ["are", 1344], ["extracted", 1348], [".", 1357], ["Furthermore", 1359], [",", 1370], ["to", 1372], ["account", 1375], ["for", 1383], ["potential", 1387], ["footprints", 1397], ["related", 1408], ["to", 1416], ["promoter", 1419], ["regulation", 1428], ["by", 1439], ["CpG", 1442], ["dinucleotide", 1446], ["targeted", 1459], ["DNA", 1468], ["methylation", 1472], [",", 1483], ["a", 1485], ["number", 1487], ["of", 1494], ["novel", 1497], ["features", 1503], ["are", 1512], ["defined", 1516], [".", 1523], ["We", 1525], ["develop", 1528], ["a", 1536], ["support", 1538], ["vector", 1546], ["machine", 1553], ["(", 1561], ["SVM", 1562], [")", 1565], ["with", 1567], ["RBF", 1572], ["kernel", 1576], ["for", 1583], ["the", 1587], ["prediction", 1591], ["of", 1602], ["miRNA", 1605], ["TSSs", 1611], ["trained", 1616], ["on", 1624], ["human", 1627], ["miRNA", 1633], ["promoters", 1639], [".", 1648], ["A", 1650], ["novel", 1652], ["feature", 1658], ["reduction", 1666], ["technique", 1676], ["based", 1686], ["on", 1692], ["archived", 1695], ["multi", 1704], ["-", 1709], ["objective", 1710], ["simulated", 1720], ["annealing", 1730], ["(", 1740], ["AMOSA", 1741], [")", 1746], ["identifies", 1748], ["the", 1759], ["final", 1763], ["set", 1769], ["of", 1773], ["features", 1776], [".", 1784], ["The", 1786], ["resulting", 1790], ["model", 1800], ["trained", 1806], ["on", 1814], ["miRNA", 1817], ["promoters", 1823], ["shows", 1833], ["improved", 1839], ["performance", 1848], ["over", 1860], ["the", 1865], ["one", 1869], ["trained", 1873], ["on", 1881], ["protein", 1884], ["-", 1891], ["coding", 1892], ["gene", 1899], ["promoters", 1904], ["in", 1914], ["terms", 1917], ["of", 1923], ["classification", 1926], ["accuracy", 1941], [",", 1949], ["sensitivity", 1951], ["and", 1963], ["specificity", 1967], [".", 1978], ["Results", 1980], ["are", 1988], ["also", 1992], ["reported", 1997], ["for", 2006], ["a", 2010], ["completely", 2012], ["independent", 2023], ["biologically", 2035], ["validated", 2048], ["test", 2058], ["set", 2063], [".", 2066], ["In", 2068], ["a", 2071], ["part", 2073], ["of", 2078], ["the", 2081], ["investigation", 2085], [",", 2098], ["the", 2100], ["proposed", 2104], ["approach", 2113], ["is", 2122], ["used", 2125], ["to", 2130], ["predict", 2133], ["protein", 2141], ["-", 2148], ["coding", 2149], ["gene", 2156], ["TSSs", 2161], [".", 2165], ["It", 2167], ["shows", 2170], ["a", 2176], ["significantly", 2178], ["improved", 2192], ["performance", 2201], ["when", 2213], ["compared", 2218], ["to", 2227], ["previously", 2230], ["published", 2241], ["gene", 2251], ["TSS", 2256], ["prediction", 2260], ["methods", 2271], [".", 2278]]}
{"context": "The theory of positive deviance holds that in any group, some people are more effective than others even when they have the same resources at hand. The object is to identify those people, see what they're doing differently and share it with the larger group. The Plexus Institute and the Robert Wood Johnson Foundation recently collaborated on a six-hospital positive-deviance study that reduced methicillin-resistant Staphylococcus aureus (MRSA) infection rates by 70 percent. What these hospitals learned may help others cut their MRSA rates.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "54d034854e514d05b8be8c343c9d0484", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[95, 95], [78, 78]], "char_spans": [[533, 536], [441, 444]]}]}], "context_tokens": [["The", 0], ["theory", 4], ["of", 11], ["positive", 14], ["deviance", 23], ["holds", 32], ["that", 38], ["in", 43], ["any", 46], ["group", 50], [",", 55], ["some", 57], ["people", 62], ["are", 69], ["more", 73], ["effective", 78], ["than", 88], ["others", 93], ["even", 100], ["when", 105], ["they", 110], ["have", 115], ["the", 120], ["same", 124], ["resources", 129], ["at", 139], ["hand", 142], [".", 146], ["The", 148], ["object", 152], ["is", 159], ["to", 162], ["identify", 165], ["those", 174], ["people", 180], [",", 186], ["see", 188], ["what", 192], ["they", 197], ["'re", 201], ["doing", 205], ["differently", 211], ["and", 223], ["share", 227], ["it", 233], ["with", 236], ["the", 241], ["larger", 245], ["group", 252], [".", 257], ["The", 259], ["Plexus", 263], ["Institute", 270], ["and", 280], ["the", 284], ["Robert", 288], ["Wood", 295], ["Johnson", 300], ["Foundation", 308], ["recently", 319], ["collaborated", 328], ["on", 341], ["a", 344], ["six", 346], ["-", 349], ["hospital", 350], ["positive", 359], ["-", 367], ["deviance", 368], ["study", 377], ["that", 383], ["reduced", 388], ["methicillin", 396], ["-", 407], ["resistant", 408], ["Staphylococcus", 418], ["aureus", 433], ["(", 440], ["MRSA", 441], [")", 445], ["infection", 447], ["rates", 457], ["by", 463], ["70", 466], ["percent", 469], [".", 476], ["What", 478], ["these", 483], ["hospitals", 489], ["learned", 499], ["may", 507], ["help", 511], ["others", 516], ["cut", 523], ["their", 527], ["MRSA", 533], ["rates", 538], [".", 543]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "daeaeaba2d634317b4b23a5d6051f0e1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[37, 39], [71, 73]], "char_spans": [[238, 244], [418, 424]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["progressive", 40], ["and", 52], ["often", 56], ["fatal", 62], ["hematopoietic", 68], ["neoplasm", 82], ["characterized", 91], ["by", 105], ["the", 108], ["presence", 112], ["of", 121], ["the", 124], ["Philadelphia", 128], ["chromosome", 141], [".", 151], ["This", 153], ["arises", 158], ["from", 165], ["a", 170], ["balanced", 172], ["translocation", 181], ["between", 195], ["chromosomes", 203], ["9", 215], ["and", 217], ["22", 221], [",", 223], ["creating", 225], ["the", 234], ["bcr", 238], ["-", 241], ["abl", 242], ["fusion", 246], ["gene", 253], [".", 257], ["It", 259], ["is", 262], ["often", 265], ["stated", 271], ["that", 278], ["the", 283], ["only", 287], ["proven", 292], ["curative", 299], ["option", 308], ["is", 315], ["allogeneic", 318], ["stem", 329], ["cell", 334], ["transplantation", 339], [",", 354], ["which", 356], ["is", 362], ["indicated", 365], ["for", 375], ["only", 379], ["a", 384], ["limited", 386], ["subset", 394], ["of", 401], ["patients", 404], [".", 412], ["The", 414], ["Bcr", 418], ["-", 421], ["Abl", 422], ["tyrosine", 426], ["kinase", 435], ["inhibitor", 442], ["imatinib", 452], ["represented", 461], ["a", 473], ["major", 475], ["advance", 481], ["over", 489], ["conventional", 494], ["CML", 507], ["therapy", 511], [".", 518], ["After", 520], ["imatinib", 526], ["treatment", 535], [",", 544], [">", 546], ["90", 548], ["%", 550], ["of", 552], ["patients", 555], ["had", 564], ["a", 568], ["complete", 570], ["hematologic", 579], ["response", 591], [",", 599], ["and", 601], ["70%-80", 605], ["%", 611], ["had", 613], ["a", 617], ["complete", 619], ["cytogenetic", 628], ["response", 640], [".", 648], ["With", 650], ["5", 655], ["years", 657], ["of", 663], ["follow", 666], ["-", 672], ["up", 673], [",", 675], ["the", 677], ["data", 681], ["are", 686], ["very", 690], ["encouraging", 695], ["and", 707], ["exhibit", 711], ["a", 719], ["major", 721], ["change", 727], ["in", 734], ["the", 737], ["natural", 741], ["history", 749], ["of", 757], ["the", 760], ["disease", 764], [".", 771], ["The", 773], ["understanding", 777], ["of", 791], ["some", 794], ["of", 799], ["the", 802], ["mechanisms", 806], ["of", 817], ["resistance", 820], ["to", 831], ["imatinib", 834], ["has", 843], ["led", 847], ["to", 851], ["a", 854], ["rapid", 856], ["development", 862], ["of", 874], ["new", 877], ["agents", 881], ["that", 888], ["might", 893], ["overcome", 899], ["this", 908], ["resistance", 913], [".", 923], ["The", 925], ["outlook", 929], ["today", 937], ["for", 943], ["patients", 947], ["with", 956], ["CML", 961], ["is", 965], ["much", 968], ["brighter", 973], ["than", 982], ["that", 987], ["of", 992], ["a", 995], ["few", 997], ["years", 1001], ["ago", 1007], [".", 1010]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "Neurofibromatosis type 1 (NF1) is a hereditary disorder caused by mutations in the NF1 gene. Detecting mutation in NF1 is hindered by the gene's large size, the lack of mutation hotspots, the presence of pseudogenes, and the wide variety of possible lesions. We developed a method for detecting germline mutations by combining an original RNA-based cDNA-PCR mutation detection method and denaturing high-performance liquid chromatography (DHPLC) with multiplex ligation-dependent probe amplification (MLPA). The protocol was validated in a cohort of 56 blood samples from NF1 patients who fulfilled NIH diagnostic criteria, identifying the germline mutation in 53 cases (95% sensitivity). The efficiency and reliability of this approach facilitated detection of different types of mutations, including single-base substitutions, deletions or insertions of one to several nucleotides, microdeletions, and changes in intragenic copy number. Because mutational screening for minor lesions was performed using cDNA and the characterization of mutated alleles was performed at both the RNA and genomic DNA level, the analysis provided insight into the nature of the different mutations and their effect on NF1 mRNA splicing. After validation, we implemented the protocol as a routine test. Here we present the overall unbiased spectrum of NF1 mutations identified in 93 patients in a cohort of 105. The results indicate that this protocol is a powerful new tool for the molecular diagnosis of NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "c9db9e67e67b4c408b9e053169e05a70", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[21, 21], [230, 230], [258, 258], [4, 4], [104, 104], [206, 206], [15, 15]], "char_spans": [[115, 117], [1334, 1336], [1488, 1490], [26, 28], [572, 574], [1201, 1203], [83, 85]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["hereditary", 36], ["disorder", 47], ["caused", 56], ["by", 63], ["mutations", 66], ["in", 76], ["the", 79], ["NF1", 83], ["gene", 87], [".", 91], ["Detecting", 93], ["mutation", 103], ["in", 112], ["NF1", 115], ["is", 119], ["hindered", 122], ["by", 131], ["the", 134], ["gene", 138], ["'s", 142], ["large", 145], ["size", 151], [",", 155], ["the", 157], ["lack", 161], ["of", 166], ["mutation", 169], ["hotspots", 178], [",", 186], ["the", 188], ["presence", 192], ["of", 201], ["pseudogenes", 204], [",", 215], ["and", 217], ["the", 221], ["wide", 225], ["variety", 230], ["of", 238], ["possible", 241], ["lesions", 250], [".", 257], ["We", 259], ["developed", 262], ["a", 272], ["method", 274], ["for", 281], ["detecting", 285], ["germline", 295], ["mutations", 304], ["by", 314], ["combining", 317], ["an", 327], ["original", 330], ["RNA", 339], ["-", 342], ["based", 343], ["cDNA", 349], ["-", 353], ["PCR", 354], ["mutation", 358], ["detection", 367], ["method", 377], ["and", 384], ["denaturing", 388], ["high", 399], ["-", 403], ["performance", 404], ["liquid", 416], ["chromatography", 423], ["(", 438], ["DHPLC", 439], [")", 444], ["with", 446], ["multiplex", 451], ["ligation", 461], ["-", 469], ["dependent", 470], ["probe", 480], ["amplification", 486], ["(", 500], ["MLPA", 501], [")", 505], [".", 506], ["The", 508], ["protocol", 512], ["was", 521], ["validated", 525], ["in", 535], ["a", 538], ["cohort", 540], ["of", 547], ["56", 550], ["blood", 553], ["samples", 559], ["from", 567], ["NF1", 572], ["patients", 576], ["who", 585], ["fulfilled", 589], ["NIH", 599], ["diagnostic", 603], ["criteria", 614], [",", 622], ["identifying", 624], ["the", 636], ["germline", 640], ["mutation", 649], ["in", 658], ["53", 661], ["cases", 664], ["(", 670], ["95", 671], ["%", 673], ["sensitivity", 675], [")", 686], [".", 687], ["The", 689], ["efficiency", 693], ["and", 704], ["reliability", 708], ["of", 720], ["this", 723], ["approach", 728], ["facilitated", 737], ["detection", 749], ["of", 759], ["different", 762], ["types", 772], ["of", 778], ["mutations", 781], [",", 790], ["including", 792], ["single", 802], ["-", 808], ["base", 809], ["substitutions", 814], [",", 827], ["deletions", 829], ["or", 839], ["insertions", 842], ["of", 853], ["one", 856], ["to", 860], ["several", 863], ["nucleotides", 871], [",", 882], ["microdeletions", 884], [",", 898], ["and", 900], ["changes", 904], ["in", 912], ["intragenic", 915], ["copy", 926], ["number", 931], [".", 937], ["Because", 939], ["mutational", 947], ["screening", 958], ["for", 968], ["minor", 972], ["lesions", 978], ["was", 986], ["performed", 990], ["using", 1000], ["cDNA", 1006], ["and", 1011], ["the", 1015], ["characterization", 1019], ["of", 1036], ["mutated", 1039], ["alleles", 1047], ["was", 1055], ["performed", 1059], ["at", 1069], ["both", 1072], ["the", 1077], ["RNA", 1081], ["and", 1085], ["genomic", 1089], ["DNA", 1097], ["level", 1101], [",", 1106], ["the", 1108], ["analysis", 1112], ["provided", 1121], ["insight", 1130], ["into", 1138], ["the", 1143], ["nature", 1147], ["of", 1154], ["the", 1157], ["different", 1161], ["mutations", 1171], ["and", 1181], ["their", 1185], ["effect", 1191], ["on", 1198], ["NF1", 1201], ["mRNA", 1205], ["splicing", 1210], [".", 1218], ["After", 1220], ["validation", 1226], [",", 1236], ["we", 1238], ["implemented", 1241], ["the", 1253], ["protocol", 1257], ["as", 1266], ["a", 1269], ["routine", 1271], ["test", 1279], [".", 1283], ["Here", 1285], ["we", 1290], ["present", 1293], ["the", 1301], ["overall", 1305], ["unbiased", 1313], ["spectrum", 1322], ["of", 1331], ["NF1", 1334], ["mutations", 1338], ["identified", 1348], ["in", 1359], ["93", 1362], ["patients", 1365], ["in", 1374], ["a", 1377], ["cohort", 1379], ["of", 1386], ["105", 1389], [".", 1392], ["The", 1394], ["results", 1398], ["indicate", 1406], ["that", 1415], ["this", 1420], ["protocol", 1425], ["is", 1434], ["a", 1437], ["powerful", 1439], ["new", 1448], ["tool", 1452], ["for", 1457], ["the", 1461], ["molecular", 1465], ["diagnosis", 1475], ["of", 1485], ["NF1", 1488], [".", 1491]]}
{"context": "Several gene products are involved in co-translational insertion of selenocysteine by the tRNA(Sec). In addition, a stem-loop structure in the mRNAs coding for selenoproteins is essential to mediate the selection of the proper selenocysteine UGA codon. Interestingly, in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region, far downstream of the UGA codon. In view of unravelling the underlying complex mechanism, we have attempted to detect RNA-binding proteins with specificity for the SECIS element. Using mobility shift assays, we could show that a protein, present in different types of mammalian cell extracts, possesses the capacity of binding the SECIS element of the selenoprotein glutathione peroxidase (GPx) mRNA. We have termed this protein SBP, for Secis Binding Protein. Competition experiments attested that the binding is highly specific and UV cross-linking indicated that the protein has an apparent molecular weight in the range of 60-65 kDa. Finally, some data suggest that the SECIS elements in the mRNAs of GPx and another selenoprotein, type I iodothyronine 5' deiodinase, recognize the same SBP protein. This constitutes the first report of the existence of a 3' UTR binding protein possibly involved in the eukaryotic selenocysteine insertion mechanism.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22db25e825ff4bcfb783e89d2d7a8162", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[131, 131], [101, 101], [151, 151], [62, 62], [194, 194]], "char_spans": [[754, 758], [587, 591], [861, 865], [368, 372], [1097, 1101]]}]}], "context_tokens": [["Several", 0], ["gene", 8], ["products", 13], ["are", 22], ["involved", 26], ["in", 35], ["co", 38], ["-", 40], ["translational", 41], ["insertion", 55], ["of", 65], ["selenocysteine", 68], ["by", 83], ["the", 86], ["tRNA(Sec", 90], [")", 98], [".", 99], ["In", 101], ["addition", 104], [",", 112], ["a", 114], ["stem", 116], ["-", 120], ["loop", 121], ["structure", 126], ["in", 136], ["the", 139], ["mRNAs", 143], ["coding", 149], ["for", 156], ["selenoproteins", 160], ["is", 175], ["essential", 178], ["to", 188], ["mediate", 191], ["the", 199], ["selection", 203], ["of", 213], ["the", 216], ["proper", 220], ["selenocysteine", 227], ["UGA", 242], ["codon", 246], [".", 251], ["Interestingly", 253], [",", 266], ["in", 268], ["eukaryotic", 271], ["selenoprotein", 282], ["mRNAs", 296], [",", 301], ["this", 303], ["stem", 308], ["-", 312], ["loop", 313], ["structure", 318], [",", 327], ["the", 329], ["selenocysteine", 333], ["insertion", 348], ["sequence", 358], ["(", 367], ["SECIS", 368], [")", 373], ["element", 375], [",", 382], ["resides", 384], ["in", 392], ["the", 395], ["3'-untranslated", 399], ["region", 415], [",", 421], ["far", 423], ["downstream", 427], ["of", 438], ["the", 441], ["UGA", 445], ["codon", 449], [".", 454], ["In", 456], ["view", 459], ["of", 464], ["unravelling", 467], ["the", 479], ["underlying", 483], ["complex", 494], ["mechanism", 502], [",", 511], ["we", 513], ["have", 516], ["attempted", 521], ["to", 531], ["detect", 534], ["RNA", 541], ["-", 544], ["binding", 545], ["proteins", 553], ["with", 562], ["specificity", 567], ["for", 579], ["the", 583], ["SECIS", 587], ["element", 593], [".", 600], ["Using", 602], ["mobility", 608], ["shift", 617], ["assays", 623], [",", 629], ["we", 631], ["could", 634], ["show", 640], ["that", 645], ["a", 650], ["protein", 652], [",", 659], ["present", 661], ["in", 669], ["different", 672], ["types", 682], ["of", 688], ["mammalian", 691], ["cell", 701], ["extracts", 706], [",", 714], ["possesses", 716], ["the", 726], ["capacity", 730], ["of", 739], ["binding", 742], ["the", 750], ["SECIS", 754], ["element", 760], ["of", 768], ["the", 771], ["selenoprotein", 775], ["glutathione", 789], ["peroxidase", 801], ["(", 812], ["GPx", 813], [")", 816], ["mRNA", 818], [".", 822], ["We", 824], ["have", 827], ["termed", 832], ["this", 839], ["protein", 844], ["SBP", 852], [",", 855], ["for", 857], ["Secis", 861], ["Binding", 867], ["Protein", 875], [".", 882], ["Competition", 884], ["experiments", 896], ["attested", 908], ["that", 917], ["the", 922], ["binding", 926], ["is", 934], ["highly", 937], ["specific", 944], ["and", 953], ["UV", 957], ["cross", 960], ["-", 965], ["linking", 966], ["indicated", 974], ["that", 984], ["the", 989], ["protein", 993], ["has", 1001], ["an", 1005], ["apparent", 1008], ["molecular", 1017], ["weight", 1027], ["in", 1034], ["the", 1037], ["range", 1041], ["of", 1047], ["60", 1050], ["-", 1052], ["65", 1053], ["kDa", 1056], [".", 1059], ["Finally", 1061], [",", 1068], ["some", 1070], ["data", 1075], ["suggest", 1080], ["that", 1088], ["the", 1093], ["SECIS", 1097], ["elements", 1103], ["in", 1112], ["the", 1115], ["mRNAs", 1119], ["of", 1125], ["GPx", 1128], ["and", 1132], ["another", 1136], ["selenoprotein", 1144], [",", 1157], ["type", 1159], ["I", 1164], ["iodothyronine", 1166], ["5", 1180], ["'", 1181], ["deiodinase", 1183], [",", 1193], ["recognize", 1195], ["the", 1205], ["same", 1209], ["SBP", 1214], ["protein", 1218], [".", 1225], ["This", 1227], ["constitutes", 1232], ["the", 1244], ["first", 1248], ["report", 1254], ["of", 1261], ["the", 1264], ["existence", 1268], ["of", 1278], ["a", 1281], ["3", 1283], ["'", 1284], ["UTR", 1286], ["binding", 1290], ["protein", 1298], ["possibly", 1306], ["involved", 1315], ["in", 1324], ["the", 1327], ["eukaryotic", 1331], ["selenocysteine", 1342], ["insertion", 1357], ["mechanism", 1367], [".", 1376]]}
{"context": "The classic form of Ehlers-Danlos syndrome (cEDS) is an inherited connective tissue disorder, where mutations in type V collagen-encoding genes result in abnormal collagen fibrils. Thus the cEDS patients have pathological connective tissue morphology and low stiffness, but the rate of connective tissue protein turnover is unknown. We investigated whether cEDS affected the protein synthesis rate in skin and tendon, and whether this could be stimulated in tendon tissue with insulin-like growth factor-I (IGF-I). Five patients with cEDS and 10 healthy, matched controls (CTRL) were included. One patellar tendon of each participant was injected with 0.1 ml IGF-I (Increlex, Ipsen, 10 mg/ml) and the contralateral tendon with 0.1 ml isotonic saline as control. The injections were performed at both 24 and 6 h prior to tissue sampling. The fractional synthesis rate (FSR) of proteins in skin and tendon was measured with the stable isotope technique using a flood-primed continuous infusion over 6 h. After the infusion one skin biopsy and two tendon biopsies (one from each patellar tendon) were obtained. We found similar baseline FSR values in skin and tendon in the cEDS patients and controls [skin: 0.005 \u00b1 0.002 (cEDS) and 0.007 \u00b1 0.002 (CTRL); tendon: 0.008 \u00b1 0.001 (cEDS) and 0.009 \u00b1 0.002 (CTRL) %/h, mean \u00b1 SE]. IGF-I injections significantly increased FSR values in cEDS patients but not in controls (delta values: cEDS 0.007 \u00b1 0.002, CTRL 0.001 \u00b1 0.001%/h). In conclusion, baseline protein synthesis rates in connective tissue appeared normal in cEDS patients, and the patients responded with an increased tendon protein synthesis rate to IGF-I injections.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ddecd10050b24b4abea3af198ad1f3d2", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[303, 304], [50, 51], [14, 15], [39, 40]], "char_spans": [[1522, 1538], [286, 302], [66, 82], [222, 238]]}]}], "context_tokens": [["The", 0], ["classic", 4], ["form", 12], ["of", 17], ["Ehlers", 20], ["-", 26], ["Danlos", 27], ["syndrome", 34], ["(", 43], ["cEDS", 44], [")", 48], ["is", 50], ["an", 53], ["inherited", 56], ["connective", 66], ["tissue", 77], ["disorder", 84], [",", 92], ["where", 94], ["mutations", 100], ["in", 110], ["type", 113], ["V", 118], ["collagen", 120], ["-", 128], ["encoding", 129], ["genes", 138], ["result", 144], ["in", 151], ["abnormal", 154], ["collagen", 163], ["fibrils", 172], [".", 179], ["Thus", 181], ["the", 186], ["cEDS", 190], ["patients", 195], ["have", 204], ["pathological", 209], ["connective", 222], ["tissue", 233], ["morphology", 240], ["and", 251], ["low", 255], ["stiffness", 259], [",", 268], ["but", 270], ["the", 274], ["rate", 278], ["of", 283], ["connective", 286], ["tissue", 297], ["protein", 304], ["turnover", 312], ["is", 321], ["unknown", 324], [".", 331], ["We", 333], ["investigated", 336], ["whether", 349], ["cEDS", 357], ["affected", 362], ["the", 371], ["protein", 375], ["synthesis", 383], ["rate", 393], ["in", 398], ["skin", 401], ["and", 406], ["tendon", 410], [",", 416], ["and", 418], ["whether", 422], ["this", 430], ["could", 435], ["be", 441], ["stimulated", 444], ["in", 455], ["tendon", 458], ["tissue", 465], ["with", 472], ["insulin", 477], ["-", 484], ["like", 485], ["growth", 490], ["factor", 497], ["-", 503], ["I", 504], ["(", 506], ["IGF", 507], ["-", 510], ["I", 511], [")", 512], [".", 513], ["Five", 515], ["patients", 520], ["with", 529], ["cEDS", 534], ["and", 539], ["10", 543], ["healthy", 546], [",", 553], ["matched", 555], ["controls", 563], ["(", 572], ["CTRL", 573], [")", 577], ["were", 579], ["included", 584], [".", 592], ["One", 594], ["patellar", 598], ["tendon", 607], ["of", 614], ["each", 617], ["participant", 622], ["was", 634], ["injected", 638], ["with", 647], ["0.1", 652], ["ml", 656], ["IGF", 659], ["-", 662], ["I", 663], ["(", 665], ["Increlex", 666], [",", 674], ["Ipsen", 676], [",", 681], ["10", 683], ["mg", 686], ["/", 688], ["ml", 689], [")", 691], ["and", 693], ["the", 697], ["contralateral", 701], ["tendon", 715], ["with", 722], ["0.1", 727], ["ml", 731], ["isotonic", 734], ["saline", 743], ["as", 750], ["control", 753], [".", 760], ["The", 762], ["injections", 766], ["were", 777], ["performed", 782], ["at", 792], ["both", 795], ["24", 800], ["and", 803], ["6", 807], ["h", 809], ["prior", 811], ["to", 817], ["tissue", 820], ["sampling", 827], [".", 835], ["The", 837], ["fractional", 841], ["synthesis", 852], ["rate", 862], ["(", 867], ["FSR", 868], [")", 871], ["of", 873], ["proteins", 876], ["in", 885], ["skin", 888], ["and", 893], ["tendon", 897], ["was", 904], ["measured", 908], ["with", 917], ["the", 922], ["stable", 926], ["isotope", 933], ["technique", 941], ["using", 951], ["a", 957], ["flood", 959], ["-", 964], ["primed", 965], ["continuous", 972], ["infusion", 983], ["over", 992], ["6", 997], ["h.", 999], ["After", 1002], ["the", 1008], ["infusion", 1012], ["one", 1021], ["skin", 1025], ["biopsy", 1030], ["and", 1037], ["two", 1041], ["tendon", 1045], ["biopsies", 1052], ["(", 1061], ["one", 1062], ["from", 1066], ["each", 1071], ["patellar", 1076], ["tendon", 1085], [")", 1091], ["were", 1093], ["obtained", 1098], [".", 1106], ["We", 1108], ["found", 1111], ["similar", 1117], ["baseline", 1125], ["FSR", 1134], ["values", 1138], ["in", 1145], ["skin", 1148], ["and", 1153], ["tendon", 1157], ["in", 1164], ["the", 1167], ["cEDS", 1171], ["patients", 1176], ["and", 1185], ["controls", 1189], ["[", 1198], ["skin", 1199], [":", 1203], ["0.005", 1205], ["\u00b1", 1211], ["0.002", 1213], ["(", 1219], ["cEDS", 1220], [")", 1224], ["and", 1226], ["0.007", 1230], ["\u00b1", 1236], ["0.002", 1238], ["(", 1244], ["CTRL", 1245], [")", 1249], [";", 1250], ["tendon", 1252], [":", 1258], ["0.008", 1260], ["\u00b1", 1266], ["0.001", 1268], ["(", 1274], ["cEDS", 1275], [")", 1279], ["and", 1281], ["0.009", 1285], ["\u00b1", 1291], ["0.002", 1293], ["(", 1299], ["CTRL", 1300], [")", 1304], ["%", 1306], ["/h", 1307], [",", 1309], ["mean", 1311], ["\u00b1", 1316], ["SE].", 1318], ["IGF", 1323], ["-", 1326], ["I", 1327], ["injections", 1329], ["significantly", 1340], ["increased", 1354], ["FSR", 1364], ["values", 1368], ["in", 1375], ["cEDS", 1378], ["patients", 1383], ["but", 1392], ["not", 1396], ["in", 1400], ["controls", 1403], ["(", 1412], ["delta", 1413], ["values", 1419], [":", 1425], ["cEDS", 1427], ["0.007", 1432], ["\u00b1", 1438], ["0.002", 1440], [",", 1445], ["CTRL", 1447], ["0.001", 1452], ["\u00b1", 1458], ["0.001%/h", 1460], [")", 1468], [".", 1469], ["In", 1471], ["conclusion", 1474], [",", 1484], ["baseline", 1486], ["protein", 1495], ["synthesis", 1503], ["rates", 1513], ["in", 1519], ["connective", 1522], ["tissue", 1533], ["appeared", 1540], ["normal", 1549], ["in", 1556], ["cEDS", 1559], ["patients", 1564], [",", 1572], ["and", 1574], ["the", 1578], ["patients", 1582], ["responded", 1591], ["with", 1601], ["an", 1606], ["increased", 1609], ["tendon", 1619], ["protein", 1626], ["synthesis", 1634], ["rate", 1644], ["to", 1649], ["IGF", 1652], ["-", 1655], ["I", 1656], ["injections", 1658], [".", 1668]]}
{"context": "Dementia with Lewy bodies is an \u03b1-synucleinopathy characterized by neocortical Lewy-related pathology (LRP). We carried out a genome-wide association study (GWAS) on neocortical LRP in a population-based sample of subjects aged 85 or over. LRP was analyzed in 304 subjects in the Vantaa 85+ sample from Southern Finland. The GWAS included 41 cases with midbrain, hippocampal, and neocortical LRP and 177 controls without midbrain and hippocampal LRP. The Medical Research Council Cognitive Function and Ageing Study (CFAS) material was used for replication (51 cases and 131 controls). By analyzing 327,010 markers the top signal was obtained at the HLA-DPA1/DPB1 locus (P\u00a0=\u00a01.29\u00a0\u00d7\u00a010(-7)); five other loci on chromosomes 15q14, 2p21, 2q31, 18p11, and 5q23 were associated with neocortical LRP at P\u00a0<\u00a010(-5). Two loci were marked by multiple markers, 2p21 (P\u00a0=\u00a03.9\u00a0\u00d7\u00a010(-6), upstream of the SPTBN1 gene), and HLA-DPA1/DPB1; these were tested in the CFAS material. Single marker (P\u00a0=\u00a00.0035) and haplotype (P\u00a0=\u00a00.04) associations on 2p21 were replicated in CFAS, whereas HLA-DPA1/DPB1 association was not. Bioinformatic analyses suggest functional effects for the HLA-DPA1/DPB1 markers as well as the 15q14 marker rs8037309. We identified suggestive novel risk factors for neocortical LRP. SPTBN1 is the candidate on 2p21, it encodes beta-spectrin, an \u03b1-synuclein binding protein and a component of Lewy bodies. The HLA-DPA1/DPB1 association suggests a role for antigen presentation or alternatively, cis-regulatory effects, one of the regulated neighboring genes identified here (vacuolar protein sorting 52) plays a role in vesicular trafficking and has been shown to interact with \u03b1-synuclein in a yeast model.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a9b0e00be51344dca4d96c64bd53c6e7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[329, 331], [271, 273]], "char_spans": [[1683, 1693], [1351, 1361]]}]}], "context_tokens": [["Dementia", 0], ["with", 9], ["Lewy", 14], ["bodies", 19], ["is", 26], ["an", 29], ["\u03b1", 32], ["-", 33], ["synucleinopathy", 34], ["characterized", 50], ["by", 64], ["neocortical", 67], ["Lewy", 79], ["-", 83], ["related", 84], ["pathology", 92], ["(", 102], ["LRP", 103], [")", 106], [".", 107], ["We", 109], ["carried", 112], ["out", 120], ["a", 124], ["genome", 126], ["-", 132], ["wide", 133], ["association", 138], ["study", 150], ["(", 156], ["GWAS", 157], [")", 161], ["on", 163], ["neocortical", 166], ["LRP", 178], ["in", 182], ["a", 185], ["population", 187], ["-", 197], ["based", 198], ["sample", 204], ["of", 211], ["subjects", 214], ["aged", 223], ["85", 228], ["or", 231], ["over", 234], [".", 238], ["LRP", 240], ["was", 244], ["analyzed", 248], ["in", 257], ["304", 260], ["subjects", 264], ["in", 273], ["the", 276], ["Vantaa", 280], ["85", 287], ["+", 289], ["sample", 291], ["from", 298], ["Southern", 303], ["Finland", 312], [".", 319], ["The", 321], ["GWAS", 325], ["included", 330], ["41", 339], ["cases", 342], ["with", 348], ["midbrain", 353], [",", 361], ["hippocampal", 363], [",", 374], ["and", 376], ["neocortical", 380], ["LRP", 392], ["and", 396], ["177", 400], ["controls", 404], ["without", 413], ["midbrain", 421], ["and", 430], ["hippocampal", 434], ["LRP", 446], [".", 449], ["The", 451], ["Medical", 455], ["Research", 463], ["Council", 472], ["Cognitive", 480], ["Function", 490], ["and", 499], ["Ageing", 503], ["Study", 510], ["(", 516], ["CFAS", 517], [")", 521], ["material", 523], ["was", 532], ["used", 536], ["for", 541], ["replication", 545], ["(", 557], ["51", 558], ["cases", 561], ["and", 567], ["131", 571], ["controls", 575], [")", 583], [".", 584], ["By", 586], ["analyzing", 589], ["327,010", 599], ["markers", 607], ["the", 615], ["top", 619], ["signal", 623], ["was", 630], ["obtained", 634], ["at", 643], ["the", 646], ["HLA", 650], ["-", 653], ["DPA1/DPB1", 654], ["locus", 664], ["(", 670], ["P", 671], ["=", 673], ["1.29", 675], ["\u00d7", 680], ["10(-7", 682], [")", 687], [")", 688], [";", 689], ["five", 691], ["other", 696], ["loci", 702], ["on", 707], ["chromosomes", 710], ["15q14", 722], [",", 727], ["2p21", 729], [",", 733], ["2q31", 735], [",", 739], ["18p11", 741], [",", 746], ["and", 748], ["5q23", 752], ["were", 757], ["associated", 762], ["with", 773], ["neocortical", 778], ["LRP", 790], ["at", 794], ["P", 797], ["<", 799], ["10(-5", 801], [")", 806], [".", 807], ["Two", 809], ["loci", 813], ["were", 818], ["marked", 823], ["by", 830], ["multiple", 833], ["markers", 842], [",", 849], ["2p21", 851], ["(", 856], ["P", 857], ["=", 859], ["3.9", 861], ["\u00d7", 865], ["10(-6", 867], [")", 872], [",", 873], ["upstream", 875], ["of", 884], ["the", 887], ["SPTBN1", 891], ["gene", 898], [")", 902], [",", 903], ["and", 905], ["HLA", 909], ["-", 912], ["DPA1/DPB1", 913], [";", 922], ["these", 924], ["were", 930], ["tested", 935], ["in", 942], ["the", 945], ["CFAS", 949], ["material", 954], [".", 962], ["Single", 964], ["marker", 971], ["(", 978], ["P", 979], ["=", 981], ["0.0035", 983], [")", 989], ["and", 991], ["haplotype", 995], ["(", 1005], ["P", 1006], ["=", 1008], ["0.04", 1010], [")", 1014], ["associations", 1016], ["on", 1029], ["2p21", 1032], ["were", 1037], ["replicated", 1042], ["in", 1053], ["CFAS", 1056], [",", 1060], ["whereas", 1062], ["HLA", 1070], ["-", 1073], ["DPA1/DPB1", 1074], ["association", 1084], ["was", 1096], ["not", 1100], [".", 1103], ["Bioinformatic", 1105], ["analyses", 1119], ["suggest", 1128], ["functional", 1136], ["effects", 1147], ["for", 1155], ["the", 1159], ["HLA", 1163], ["-", 1166], ["DPA1/DPB1", 1167], ["markers", 1177], ["as", 1185], ["well", 1188], ["as", 1193], ["the", 1196], ["15q14", 1200], ["marker", 1206], ["rs8037309", 1213], [".", 1222], ["We", 1224], ["identified", 1227], ["suggestive", 1238], ["novel", 1249], ["risk", 1255], ["factors", 1260], ["for", 1268], ["neocortical", 1272], ["LRP", 1284], [".", 1287], ["SPTBN1", 1289], ["is", 1296], ["the", 1299], ["candidate", 1303], ["on", 1313], ["2p21", 1316], [",", 1320], ["it", 1322], ["encodes", 1325], ["beta", 1333], ["-", 1337], ["spectrin", 1338], [",", 1346], ["an", 1348], ["\u03b1", 1351], ["-", 1352], ["synuclein", 1353], ["binding", 1363], ["protein", 1371], ["and", 1379], ["a", 1383], ["component", 1385], ["of", 1395], ["Lewy", 1398], ["bodies", 1403], [".", 1409], ["The", 1411], ["HLA", 1415], ["-", 1418], ["DPA1/DPB1", 1419], ["association", 1429], ["suggests", 1441], ["a", 1450], ["role", 1452], ["for", 1457], ["antigen", 1461], ["presentation", 1469], ["or", 1482], ["alternatively", 1485], [",", 1498], ["cis", 1500], ["-", 1503], ["regulatory", 1504], ["effects", 1515], [",", 1522], ["one", 1524], ["of", 1528], ["the", 1531], ["regulated", 1535], ["neighboring", 1545], ["genes", 1557], ["identified", 1563], ["here", 1574], ["(", 1579], ["vacuolar", 1580], ["protein", 1589], ["sorting", 1597], ["52", 1605], [")", 1607], ["plays", 1609], ["a", 1615], ["role", 1617], ["in", 1622], ["vesicular", 1625], ["trafficking", 1635], ["and", 1647], ["has", 1651], ["been", 1655], ["shown", 1660], ["to", 1666], ["interact", 1669], ["with", 1678], ["\u03b1", 1683], ["-", 1684], ["synuclein", 1685], ["in", 1695], ["a", 1698], ["yeast", 1700], ["model", 1706], [".", 1711]]}
{"context": "Questions of if and when protein structures change within cells pervade biology and include questions of how the cytoskeleton sustains stresses on cells--particularly in mutant versus normal cells. Cysteine shotgun labeling with fluorophores is analyzed here with mass spectrometry of the spectrin-actin membrane skeleton in sheared red blood cell ghosts from normal and diseased mice. Sheared samples are compared to static samples at 37\u2009\u00b0C in terms of cell membrane intensity in fluorescence microscopy, separated protein fluorescence, and tryptic peptide modification in liquid chromatography-tandem mass spectrometry (LC-MS/MS). Spectrin labeling proves to be the most sensitive to shear, whereas binding partners ankyrin and actin exhibit shear thresholds in labeling and both the ankyrin-binding membrane protein band 3 and the spectrin-actin stabilizer 4.1R show minimal differential labeling. Cells from 4.1R-null mice differ significantly from normal in the shear-dependent labeling of spectrin, ankyrin, and band 3: Decreased labeling of spectrin reveals less stress on the mutant network as spectrin dissociates from actin. Mapping the stress-dependent labeling kinetics of \u03b1- and \u03b2-spectrin by LC-MS/MS identifies Cys in these antiparallel chains that are either force-enhanced or force-independent in labeling, with structural analyses indicating the force-enhanced sites are sequestered either in spectrin's triple-helical domains or in interactions with actin or ankyrin. Shear-sensitive sites identified comprehensively here in both spectrin and ankyrin appear consistent with stress relief through forced unfolding followed by cytoskeletal disruption.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "13e06194c39f4c6793d4a21daead187f", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[214, 214]], "char_spans": [[1239, 1250]]}]}], "context_tokens": [["Questions", 0], ["of", 10], ["if", 13], ["and", 16], ["when", 20], ["protein", 25], ["structures", 33], ["change", 44], ["within", 51], ["cells", 58], ["pervade", 64], ["biology", 72], ["and", 80], ["include", 84], ["questions", 92], ["of", 102], ["how", 105], ["the", 109], ["cytoskeleton", 113], ["sustains", 126], ["stresses", 135], ["on", 144], ["cells", 147], ["--", 152], ["particularly", 154], ["in", 167], ["mutant", 170], ["versus", 177], ["normal", 184], ["cells", 191], [".", 196], ["Cysteine", 198], ["shotgun", 207], ["labeling", 215], ["with", 224], ["fluorophores", 229], ["is", 242], ["analyzed", 245], ["here", 254], ["with", 259], ["mass", 264], ["spectrometry", 269], ["of", 282], ["the", 285], ["spectrin", 289], ["-", 297], ["actin", 298], ["membrane", 304], ["skeleton", 313], ["in", 322], ["sheared", 325], ["red", 333], ["blood", 337], ["cell", 343], ["ghosts", 348], ["from", 355], ["normal", 360], ["and", 367], ["diseased", 371], ["mice", 380], [".", 384], ["Sheared", 386], ["samples", 394], ["are", 402], ["compared", 406], ["to", 415], ["static", 418], ["samples", 425], ["at", 433], ["37", 436], ["\u00b0", 439], ["C", 440], ["in", 442], ["terms", 445], ["of", 451], ["cell", 454], ["membrane", 459], ["intensity", 468], ["in", 478], ["fluorescence", 481], ["microscopy", 494], [",", 504], ["separated", 506], ["protein", 516], ["fluorescence", 524], [",", 536], ["and", 538], ["tryptic", 542], ["peptide", 550], ["modification", 558], ["in", 571], ["liquid", 574], ["chromatography", 581], ["-", 595], ["tandem", 596], ["mass", 603], ["spectrometry", 608], ["(", 621], ["LC", 622], ["-", 624], ["MS", 625], ["/", 627], ["MS", 628], [")", 630], [".", 631], ["Spectrin", 633], ["labeling", 642], ["proves", 651], ["to", 658], ["be", 661], ["the", 664], ["most", 668], ["sensitive", 673], ["to", 683], ["shear", 686], [",", 691], ["whereas", 693], ["binding", 701], ["partners", 709], ["ankyrin", 718], ["and", 726], ["actin", 730], ["exhibit", 736], ["shear", 744], ["thresholds", 750], ["in", 761], ["labeling", 764], ["and", 773], ["both", 777], ["the", 782], ["ankyrin", 786], ["-", 793], ["binding", 794], ["membrane", 802], ["protein", 811], ["band", 819], ["3", 824], ["and", 826], ["the", 830], ["spectrin", 834], ["-", 842], ["actin", 843], ["stabilizer", 849], ["4.1R", 860], ["show", 865], ["minimal", 870], ["differential", 878], ["labeling", 891], [".", 899], ["Cells", 901], ["from", 907], ["4.1R", 912], ["-", 916], ["null", 917], ["mice", 922], ["differ", 927], ["significantly", 934], ["from", 948], ["normal", 953], ["in", 960], ["the", 963], ["shear", 967], ["-", 972], ["dependent", 973], ["labeling", 983], ["of", 992], ["spectrin", 995], [",", 1003], ["ankyrin", 1005], [",", 1012], ["and", 1014], ["band", 1018], ["3", 1023], [":", 1024], ["Decreased", 1026], ["labeling", 1036], ["of", 1045], ["spectrin", 1048], ["reveals", 1057], ["less", 1065], ["stress", 1070], ["on", 1077], ["the", 1080], ["mutant", 1084], ["network", 1091], ["as", 1099], ["spectrin", 1102], ["dissociates", 1111], ["from", 1123], ["actin", 1128], [".", 1133], ["Mapping", 1135], ["the", 1143], ["stress", 1147], ["-", 1153], ["dependent", 1154], ["labeling", 1164], ["kinetics", 1173], ["of", 1182], ["\u03b1-", 1185], ["and", 1188], ["\u03b2", 1192], ["-", 1193], ["spectrin", 1194], ["by", 1203], ["LC", 1206], ["-", 1208], ["MS", 1209], ["/", 1211], ["MS", 1212], ["identifies", 1215], ["Cys", 1226], ["in", 1230], ["these", 1233], ["antiparallel", 1239], ["chains", 1252], ["that", 1259], ["are", 1264], ["either", 1268], ["force", 1275], ["-", 1280], ["enhanced", 1281], ["or", 1290], ["force", 1293], ["-", 1298], ["independent", 1299], ["in", 1311], ["labeling", 1314], [",", 1322], ["with", 1324], ["structural", 1329], ["analyses", 1340], ["indicating", 1349], ["the", 1360], ["force", 1364], ["-", 1369], ["enhanced", 1370], ["sites", 1379], ["are", 1385], ["sequestered", 1389], ["either", 1401], ["in", 1408], ["spectrin", 1411], ["'s", 1419], ["triple", 1422], ["-", 1428], ["helical", 1429], ["domains", 1437], ["or", 1445], ["in", 1448], ["interactions", 1451], ["with", 1464], ["actin", 1469], ["or", 1475], ["ankyrin", 1478], [".", 1485], ["Shear", 1487], ["-", 1492], ["sensitive", 1493], ["sites", 1503], ["identified", 1509], ["comprehensively", 1520], ["here", 1536], ["in", 1541], ["both", 1544], ["spectrin", 1549], ["and", 1558], ["ankyrin", 1562], ["appear", 1570], ["consistent", 1577], ["with", 1588], ["stress", 1593], ["relief", 1600], ["through", 1607], ["forced", 1615], ["unfolding", 1622], ["followed", 1632], ["by", 1641], ["cytoskeletal", 1644], ["disruption", 1657], [".", 1667]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Chronic myeloid leukaemia (CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation. STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase. In the chronic phase of the disease, normal peripheral blood values are achieved within the first month of treatment in the large majority of patients and in many patients also a cytogenic response within the following months. The results in the advanced phase are far less favourable, which is explained by the development of resistance owing to reactivation of the BCR-ABL signal transduction. Side effects are primarily nausea, vomiting, various rashes, oedema, most often in the periorbital region, and musculoskeletal symptoms, including muscle cramps. Perspectives for treatment with STI571 are described, as are combinations with alpha-interferon and other cytostatics with a synergistic profile.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ed0d438eec964bbe89eb0e88bcc31b14", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[149, 151], [40, 42], [80, 82], [31, 33]], "char_spans": [[866, 872], [222, 228], [474, 480], [167, 173]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterised", 35], ["by", 49], ["the", 52], ["occurrence", 56], ["of", 67], ["the", 70], ["Philadelphia", 74], ["(", 87], ["Ph", 88], [")", 90], ["chromosome", 92], ["(", 103], ["9/22", 104], ["translocation", 109], [")", 122], ["and", 124], ["the", 128], ["formation", 132], ["of", 142], ["a", 145], ["fusion", 147], ["protein", 154], ["--", 161], ["the", 163], ["BCR", 167], ["-", 170], ["ABL", 171], ["transcript", 175], ["with", 186], ["constitutive", 191], ["activation", 204], ["of", 215], ["the", 218], ["BCR", 222], ["-", 225], ["ABL", 226], ["tyrosine", 230], ["kinase", 239], ["and", 246], ["consequent", 250], ["changes", 261], ["in", 269], ["the", 272], ["intracellular", 276], ["signal", 290], ["transduction", 297], [",", 309], ["which", 311], ["is", 317], ["responsible", 320], ["for", 332], ["the", 336], ["deregulated", 340], ["myeloid", 352], ["cell", 360], ["proliferation", 365], [".", 378], ["STI571", 380], ["(", 387], ["signal", 388], ["transduction", 395], ["inhibition", 408], ["number", 419], ["571", 426], [")", 429], ["is", 431], ["a", 434], ["potent", 436], ["and", 443], ["selective", 447], ["inhibitor", 457], ["of", 467], ["the", 470], ["BCR", 474], ["-", 477], ["ABL", 478], ["tyrosine", 482], ["kinase", 491], [".", 497], ["In", 499], ["the", 502], ["chronic", 506], ["phase", 514], ["of", 520], ["the", 523], ["disease", 527], [",", 534], ["normal", 536], ["peripheral", 543], ["blood", 554], ["values", 560], ["are", 567], ["achieved", 571], ["within", 580], ["the", 587], ["first", 591], ["month", 597], ["of", 603], ["treatment", 606], ["in", 616], ["the", 619], ["large", 623], ["majority", 629], ["of", 638], ["patients", 641], ["and", 650], ["in", 654], ["many", 657], ["patients", 662], ["also", 671], ["a", 676], ["cytogenic", 678], ["response", 688], ["within", 697], ["the", 704], ["following", 708], ["months", 718], [".", 724], ["The", 726], ["results", 730], ["in", 738], ["the", 741], ["advanced", 745], ["phase", 754], ["are", 760], ["far", 764], ["less", 768], ["favourable", 773], [",", 783], ["which", 785], ["is", 791], ["explained", 794], ["by", 804], ["the", 807], ["development", 811], ["of", 823], ["resistance", 826], ["owing", 837], ["to", 843], ["reactivation", 846], ["of", 859], ["the", 862], ["BCR", 866], ["-", 869], ["ABL", 870], ["signal", 874], ["transduction", 881], [".", 893], ["Side", 895], ["effects", 900], ["are", 908], ["primarily", 912], ["nausea", 922], [",", 928], ["vomiting", 930], [",", 938], ["various", 940], ["rashes", 948], [",", 954], ["oedema", 956], [",", 962], ["most", 964], ["often", 969], ["in", 975], ["the", 978], ["periorbital", 982], ["region", 994], [",", 1000], ["and", 1002], ["musculoskeletal", 1006], ["symptoms", 1022], [",", 1030], ["including", 1032], ["muscle", 1042], ["cramps", 1049], [".", 1055], ["Perspectives", 1057], ["for", 1070], ["treatment", 1074], ["with", 1084], ["STI571", 1089], ["are", 1096], ["described", 1100], [",", 1109], ["as", 1111], ["are", 1114], ["combinations", 1118], ["with", 1131], ["alpha", 1136], ["-", 1141], ["interferon", 1142], ["and", 1153], ["other", 1157], ["cytostatics", 1163], ["with", 1175], ["a", 1180], ["synergistic", 1182], ["profile", 1194], [".", 1201]]}
{"context": "Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "b7441dc6481f4a8c8ea767fe70d618bb", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[79, 79], [61, 61], [18, 18]], "char_spans": [[474, 476], [361, 363], [109, 111]]}]}], "context_tokens": [["Stress", 0], ["signals", 7], ["elicit", 15], ["a", 22], ["wide", 24], ["variety", 29], ["of", 37], ["cellular", 40], ["responses", 49], [",", 58], ["many", 60], ["of", 65], ["which", 68], ["converge", 74], ["on", 83], ["the", 86], ["phosphorylation", 90], ["of", 106], ["JNK", 109], ["and", 113], ["p38", 117], ["kinases", 121], [",", 128], ["the", 130], ["activation", 134], ["of", 145], ["which", 148], ["has", 154], ["been", 158], ["well", 163], ["-", 167], ["characterized", 168], [".", 181], ["How", 183], ["these", 187], ["kinases", 193], ["are", 201], ["switched", 205], ["off", 214], ["by", 218], ["dephosphorylation", 221], ["is", 239], ["not", 242], ["well", 246], ["understood", 251], [".", 261], ["Here", 263], ["we", 268], ["describe", 271], ["how", 280], ["diverse", 284], ["cellular", 292], ["stresses", 301], ["affect", 310], ["differently", 317], ["the", 329], ["stability", 333], ["and", 343], ["activity", 347], ["of", 356], ["a", 359], ["JNK", 361], ["-", 364], ["inactivating", 365], ["dual", 378], ["-", 382], ["specificity", 383], ["threonine", 395], ["-", 404], ["tyrosine", 405], ["phosphatase", 414], ["M3/6", 426], [".", 430], ["Both", 432], ["anisomycin", 437], ["and", 448], ["arsenite", 452], ["activate", 461], ["the", 470], ["JNK", 474], ["pathway", 478], ["and", 486], [",", 489], ["in", 491], ["addition", 494], [",", 502], ["inactivate", 504], ["the", 515], ["M3/6", 519], ["phosphatase", 524], [".", 535], ["However", 537], [",", 544], ["while", 546], ["anisomycin", 552], ["treatment", 563], ["of", 573], ["cells", 576], ["leads", 582], ["to", 588], ["M3/6", 591], ["protein", 596], ["degradation", 604], [",", 615], ["arsenite", 617], ["appears", 626], ["to", 634], ["inactivate", 637], ["M3/6", 648], ["directly", 653], [".", 661], ["These", 663], ["results", 669], ["might", 677], ["have", 683], ["implications", 688], ["for", 701], ["the", 705], ["mechanism", 709], ["of", 719], ["tumour", 722], ["promotion", 729], ["by", 739], ["arsenic", 742], [".", 749]]}
{"context": "Eukaryotic centromeres are maintained at specific chromosomal sites over many generations. In the budding yeast Saccharomyces cerevisiae, centromeres are genetic elements defined by a DNA sequence that is both necessary and sufficient for function; whereas, in most other eukaryotes, centromeres are maintained by poorly characterized epigenetic mechanisms in which DNA has a less definitive role. Here we use the pathogenic yeast Candida albicans as a model organism to study the DNA replication properties of centromeric DNA. By determining the genome-wide replication timing program of the C. albicans genome, we discovered that each centromere is associated with a replication origin that is the first to fire on its respective chromosome. Importantly, epigenetic formation of new ectopic centromeres (neocentromeres) was accompanied by shifts in replication timing, such that a neocentromere became the first to replicate and became associated with origin recognition complex (ORC) components. Furthermore, changing the level of the centromere-specific histone H3 isoform led to a concomitant change in levels of ORC association with centromere regions, further supporting the idea that centromere proteins determine origin activity. Finally, analysis of centromere-associated DNA revealed a replication-dependent sequence pattern characteristic of constitutively active replication origins. This strand-biased pattern is conserved, together with centromere position, among related strains and species, in a manner independent of primary DNA sequence. Thus, inheritance of centromere position is correlated with a constitutively active origin of replication that fires at a distinct early time. We suggest a model in which the distinct timing of DNA replication serves as an epigenetic mechanism for the inheritance of centromere position.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "f86ba8d933b746bc9dcc170bdad24a09", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[268, 268]], "char_spans": [[1688, 1692]]}]}], "context_tokens": [["Eukaryotic", 0], ["centromeres", 11], ["are", 23], ["maintained", 27], ["at", 38], ["specific", 41], ["chromosomal", 50], ["sites", 62], ["over", 68], ["many", 73], ["generations", 78], [".", 89], ["In", 91], ["the", 94], ["budding", 98], ["yeast", 106], ["Saccharomyces", 112], ["cerevisiae", 126], [",", 136], ["centromeres", 138], ["are", 150], ["genetic", 154], ["elements", 162], ["defined", 171], ["by", 179], ["a", 182], ["DNA", 184], ["sequence", 188], ["that", 197], ["is", 202], ["both", 205], ["necessary", 210], ["and", 220], ["sufficient", 224], ["for", 235], ["function", 239], [";", 247], ["whereas", 249], [",", 256], ["in", 258], ["most", 261], ["other", 266], ["eukaryotes", 272], [",", 282], ["centromeres", 284], ["are", 296], ["maintained", 300], ["by", 311], ["poorly", 314], ["characterized", 321], ["epigenetic", 335], ["mechanisms", 346], ["in", 357], ["which", 360], ["DNA", 366], ["has", 370], ["a", 374], ["less", 376], ["definitive", 381], ["role", 392], [".", 396], ["Here", 398], ["we", 403], ["use", 406], ["the", 410], ["pathogenic", 414], ["yeast", 425], ["Candida", 431], ["albicans", 439], ["as", 448], ["a", 451], ["model", 453], ["organism", 459], ["to", 468], ["study", 471], ["the", 477], ["DNA", 481], ["replication", 485], ["properties", 497], ["of", 508], ["centromeric", 511], ["DNA", 523], [".", 526], ["By", 528], ["determining", 531], ["the", 543], ["genome", 547], ["-", 553], ["wide", 554], ["replication", 559], ["timing", 571], ["program", 578], ["of", 586], ["the", 589], ["C.", 593], ["albicans", 596], ["genome", 605], [",", 611], ["we", 613], ["discovered", 616], ["that", 627], ["each", 632], ["centromere", 637], ["is", 648], ["associated", 651], ["with", 662], ["a", 667], ["replication", 669], ["origin", 681], ["that", 688], ["is", 693], ["the", 696], ["first", 700], ["to", 706], ["fire", 709], ["on", 714], ["its", 717], ["respective", 721], ["chromosome", 732], [".", 742], ["Importantly", 744], [",", 755], ["epigenetic", 757], ["formation", 768], ["of", 778], ["new", 781], ["ectopic", 785], ["centromeres", 793], ["(", 805], ["neocentromeres", 806], [")", 820], ["was", 822], ["accompanied", 826], ["by", 838], ["shifts", 841], ["in", 848], ["replication", 851], ["timing", 863], [",", 869], ["such", 871], ["that", 876], ["a", 881], ["neocentromere", 883], ["became", 897], ["the", 904], ["first", 908], ["to", 914], ["replicate", 917], ["and", 927], ["became", 931], ["associated", 938], ["with", 949], ["origin", 954], ["recognition", 961], ["complex", 973], ["(", 981], ["ORC", 982], [")", 985], ["components", 987], [".", 997], ["Furthermore", 999], [",", 1010], ["changing", 1012], ["the", 1021], ["level", 1025], ["of", 1031], ["the", 1034], ["centromere", 1038], ["-", 1048], ["specific", 1049], ["histone", 1058], ["H3", 1066], ["isoform", 1069], ["led", 1077], ["to", 1081], ["a", 1084], ["concomitant", 1086], ["change", 1098], ["in", 1105], ["levels", 1108], ["of", 1115], ["ORC", 1118], ["association", 1122], ["with", 1134], ["centromere", 1139], ["regions", 1150], [",", 1157], ["further", 1159], ["supporting", 1167], ["the", 1178], ["idea", 1182], ["that", 1187], ["centromere", 1192], ["proteins", 1203], ["determine", 1212], ["origin", 1222], ["activity", 1229], [".", 1237], ["Finally", 1239], [",", 1246], ["analysis", 1248], ["of", 1257], ["centromere", 1260], ["-", 1270], ["associated", 1271], ["DNA", 1282], ["revealed", 1286], ["a", 1295], ["replication", 1297], ["-", 1308], ["dependent", 1309], ["sequence", 1319], ["pattern", 1328], ["characteristic", 1336], ["of", 1351], ["constitutively", 1354], ["active", 1369], ["replication", 1376], ["origins", 1388], [".", 1395], ["This", 1397], ["strand", 1402], ["-", 1408], ["biased", 1409], ["pattern", 1416], ["is", 1424], ["conserved", 1427], [",", 1436], ["together", 1438], ["with", 1447], ["centromere", 1452], ["position", 1463], [",", 1471], ["among", 1473], ["related", 1479], ["strains", 1487], ["and", 1495], ["species", 1499], [",", 1506], ["in", 1508], ["a", 1511], ["manner", 1513], ["independent", 1520], ["of", 1532], ["primary", 1535], ["DNA", 1543], ["sequence", 1547], [".", 1555], ["Thus", 1557], [",", 1561], ["inheritance", 1563], ["of", 1575], ["centromere", 1578], ["position", 1589], ["is", 1598], ["correlated", 1601], ["with", 1612], ["a", 1617], ["constitutively", 1619], ["active", 1634], ["origin", 1641], ["of", 1648], ["replication", 1651], ["that", 1663], ["fires", 1668], ["at", 1674], ["a", 1677], ["distinct", 1679], ["early", 1688], ["time", 1694], [".", 1698], ["We", 1700], ["suggest", 1703], ["a", 1711], ["model", 1713], ["in", 1719], ["which", 1722], ["the", 1728], ["distinct", 1732], ["timing", 1741], ["of", 1748], ["DNA", 1751], ["replication", 1755], ["serves", 1767], ["as", 1774], ["an", 1777], ["epigenetic", 1780], ["mechanism", 1791], ["for", 1801], ["the", 1805], ["inheritance", 1809], ["of", 1821], ["centromere", 1824], ["position", 1835], [".", 1843]]}
{"context": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.", "qas": [{"question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answers": ["Intravenous"], "qid": "b281754e18ae429e9ea7345319018381", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["administration", 12], ["route", 27], ["of", 33], ["IVIG", 36], ["in", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Intravenous", "token_spans": [[0, 0]], "char_spans": [[0, 10]]}]}], "context_tokens": [["Intravenous", 0], ["immunoglobulin", 12], ["(", 27], ["IVIG", 28], [")", 32], ["has", 34], ["shown", 38], ["limited", 44], ["promise", 52], ["so", 60], ["far", 63], ["in", 67], ["human", 70], ["clinical", 76], ["studies", 85], ["on", 93], ["Alzheimer", 96], ["'s", 105], ["disease", 108], ["(", 116], ["AD", 117], [")", 119], [",", 120], ["yet", 122], ["overwhelmingly", 126], ["positive", 141], ["preclinical", 150], ["work", 162], ["in", 167], ["animals", 170], ["and", 178], ["human", 182], ["brain", 188], ["cultures", 194], ["support", 203], ["the", 211], ["notion", 215], ["that", 222], ["the", 227], ["therapy", 231], ["remains", 239], ["potentially", 247], ["efficacious", 259], [".", 270], ["Here", 272], [",", 276], ["we", 278], ["elaborate", 281], ["on", 291], ["IVIG", 294], ["neuropreservation", 299], ["by", 317], ["demonstrating", 320], ["that", 334], ["IVIG", 339], ["protects", 344], ["human", 353], ["primary", 359], ["neurons", 367], ["against", 375], ["oxidative", 383], ["stress", 393], ["in", 400], ["vitro", 403], ["and", 409], ["that", 413], ["IVIG", 418], ["preserves", 423], ["antioxidant", 433], ["defense", 445], ["mechanisms", 453], ["in", 464], ["vivo", 467], [".", 471], ["Based", 473], ["on", 479], ["these", 482], ["results", 488], [",", 495], ["we", 497], ["propose", 500], ["the", 508], ["following", 512], ["translational", 522], ["impact", 536], [":", 542], ["If", 544], ["the", 547], ["dosage", 551], ["and", 558], ["treatment", 562], ["conditions", 572], ["are", 583], ["adequately", 587], ["optimized", 598], [",", 607], ["then", 609], ["IVIG", 614], ["treatment", 619], ["could", 629], ["play", 635], ["a", 640], ["significant", 642], ["role", 654], ["in", 659], ["preventing", 662], ["and/or", 673], ["delaying", 680], ["the", 689], ["progression", 693], ["of", 705], ["neurodegenerative", 708], ["diseases", 726], [",", 734], ["such", 736], ["as", 741], ["AD", 744], [".", 746], ["We", 748], ["suggest", 751], ["that", 759], ["IVIG", 764], ["warrants", 769], ["further", 778], ["investigation", 786], ["to", 800], ["fully", 803], ["exploit", 809], ["its", 817], ["potential", 821], ["as", 831], ["an", 834], ["anti", 837], ["-", 841], ["oxidant", 842], [",", 849], ["neuroprotective", 851], ["and", 867], ["synapto", 871], ["-", 878], ["protecting", 879], ["agent", 890], [".", 895]]}
{"context": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimer's disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE \u03b54 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and A\u03b21-42 of which the latter association was weaker and only present in APOE \u03b54 carriers indicating a differential involvement of ApoE in tau versus A\u03b2-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE \u025b4 carriers and whether this decrease in plasma ApoE predisposes APOE \u025b4 carriers to AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "19f812e350824082b6b21522a0ba9fa9", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[210, 211]], "char_spans": [[1133, 1145]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["ApoE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["is", 38], ["the", 41], ["strongest", 45], ["risk", 55], ["factor", 60], ["of", 67], ["sporadic", 70], ["Alzheimer", 79], ["'s", 88], ["disease", 91], ["(", 99], ["AD", 100], [")", 102], [",", 103], ["however", 105], [",", 112], ["the", 114], ["fluid", 118], ["concentrations", 124], ["of", 139], ["ApoE", 142], ["and", 147], ["its", 151], ["different", 155], ["isoforms", 165], ["(", 174], ["ApoE2", 175], [",", 180], ["ApoE3", 182], ["and", 188], ["ApoE4", 192], [")", 197], ["in", 199], ["AD", 202], ["patients", 205], ["and", 214], ["among", 218], ["APOE", 224], ["genotypes", 229], ["(", 239], ["APOE", 240], ["\u03b52", 245], [",", 247], ["\u03b53", 249], [",", 251], ["\u03b54", 253], [")", 255], ["remain", 257], ["controversial", 264], [".", 277], ["Using", 279], ["a", 285], ["novel", 287], ["mass", 293], ["spectrometry", 298], ["-", 310], ["based", 311], ["method", 317], [",", 323], ["we", 325], ["quantified", 328], ["total", 339], ["ApoE", 345], ["and", 350], ["specific", 354], ["ApoE", 363], ["isoform", 368], ["concentrations", 376], ["and", 391], ["potential", 395], ["associations", 405], ["with", 418], ["age", 423], [",", 426], ["cognitive", 428], ["status", 438], [",", 444], ["cholesterol", 446], ["levels", 458], ["and", 465], ["established", 469], ["AD", 481], ["biomarkers", 484], ["in", 495], ["cerebrospinal", 498], ["fluid", 512], ["(", 518], ["CSF", 519], [")", 522], ["from", 524], ["AD", 529], ["patients", 532], ["versus", 541], ["non", 548], ["-", 551], ["AD", 552], ["individuals", 555], ["with", 567], ["different", 572], ["APOE", 582], ["genotypes", 587], [".", 596], ["We", 598], ["also", 601], ["investigated", 606], ["plasma", 619], ["total", 626], ["ApoE", 632], ["and", 637], ["ApoE", 641], ["isoform", 646], ["composition", 654], ["in", 666], ["a", 669], ["subset", 671], ["of", 678], ["these", 681], ["individuals", 687], [".", 698], ["In", 700], ["total", 703], ["n", 709], ["=", 711], ["43", 713], ["AD", 716], ["and", 719], ["n", 723], ["=", 725], ["43", 727], ["non", 730], ["-", 733], ["AD", 734], ["subjects", 737], ["were", 746], ["included", 751], [".", 759], ["We", 761], ["found", 764], ["that", 770], ["CSF", 775], ["and", 779], ["plasma", 783], ["total", 790], ["ApoE", 796], ["levels", 801], ["did", 808], ["not", 812], ["correlate", 816], ["with", 826], ["age", 831], ["or", 835], ["cognitive", 838], ["status", 848], ["and", 855], ["did", 859], ["not", 863], ["differ", 867], ["between", 874], ["AD", 882], ["and", 885], ["non", 889], ["-", 892], ["AD", 893], ["subjects", 896], ["deeming", 905], ["ApoE", 913], ["as", 918], ["an", 921], ["unfit", 924], ["diagnostic", 930], ["marker", 941], ["for", 948], ["AD", 952], [".", 954], ["Also", 956], [",", 960], ["whereas", 962], ["CSF", 970], ["ApoE", 974], ["levels", 979], ["did", 986], ["not", 990], ["vary", 994], ["between", 999], ["APOE", 1007], ["genotypes", 1012], ["APOE", 1022], ["\u03b54", 1027], ["carriers", 1030], ["exhibited", 1039], ["significantly", 1049], ["decreased", 1063], ["plasma", 1073], ["ApoE", 1080], ["levels", 1085], ["attributed", 1092], ["to", 1103], ["a", 1106], ["specific", 1108], ["decrease", 1117], ["in", 1126], ["the", 1129], ["ApoE4", 1133], ["isoform", 1139], ["concentrations", 1147], [".", 1161], ["CSF", 1163], ["total", 1167], ["ApoE", 1173], ["concentrations", 1178], ["were", 1193], ["positively", 1198], ["associated", 1209], ["with", 1220], ["CSF", 1225], [",", 1228], ["total", 1230], ["tau", 1236], [",", 1239], ["tau", 1241], ["phosphorylated", 1245], ["at", 1260], ["Thr181", 1263], ["and", 1270], ["A\u03b21", 1274], ["-", 1277], ["42", 1278], ["of", 1281], ["which", 1284], ["the", 1290], ["latter", 1294], ["association", 1301], ["was", 1313], ["weaker", 1317], ["and", 1324], ["only", 1328], ["present", 1333], ["in", 1341], ["APOE", 1344], ["\u03b54", 1349], ["carriers", 1352], ["indicating", 1361], ["a", 1372], ["differential", 1374], ["involvement", 1387], ["of", 1399], ["ApoE", 1402], ["in", 1407], ["tau", 1410], ["versus", 1414], ["A\u03b2", 1421], ["-", 1423], ["linked", 1424], ["neuropathological", 1431], ["processes", 1449], [".", 1458], ["Future", 1460], ["studies", 1467], ["need", 1475], ["to", 1480], ["elucidate", 1483], ["whether", 1493], ["the", 1501], ["observed", 1505], ["plasma", 1514], ["ApoE4", 1521], ["deficiency", 1527], ["is", 1538], ["a", 1541], ["life", 1543], ["-", 1547], ["long", 1548], ["condition", 1553], ["in", 1563], ["APOE", 1566], ["\u025b4", 1571], ["carriers", 1574], ["and", 1583], ["whether", 1587], ["this", 1595], ["decrease", 1600], ["in", 1609], ["plasma", 1612], ["ApoE", 1619], ["predisposes", 1624], ["APOE", 1636], ["\u025b4", 1641], ["carriers", 1644], ["to", 1653], ["AD", 1656], [".", 1658]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "A study was performed to determine the utility of the 8-point recognition of stroke in the emergency room (ROSIER) instrument as a diagnostic tool in a large Irish emergency department. Fifty patients had ROSIER scores completed by doctors. Diagnoses achieved using the score were compared with discharge diagnoses. Relations between ROSIER score, impairment and length of stay were assessed. Forty-seven patients (94%) had a ROSIER Score > or =1 indicating a stroke, 44 (94%) of these had stroke confirmed on investigation. Two patients with stroke were missed and three were wrongly identified. Positive predictive value for the ROSIER was 94%. ROSIER correlated with Scandinavian neurological stroke score. (r = -0.414, p = 0.003) and was associated with increasing length of stay in survivors (p = 0.16, one-way ANOVA. F = 3.116, df = 6). The ROSIER is a suitable and useful adjunct in the assessment of stroke patients in Ireland.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "84e440c52ada4da9ab59b02ebf6421e1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[13, 13], [179, 179], [102, 102], [84, 84], [126, 126], [94, 94]], "char_spans": [[77, 82], [908, 913], [543, 548], [460, 465], [696, 701], [490, 495]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["performed", 12], ["to", 22], ["determine", 25], ["the", 35], ["utility", 39], ["of", 47], ["the", 50], ["8-point", 54], ["recognition", 62], ["of", 74], ["stroke", 77], ["in", 84], ["the", 87], ["emergency", 91], ["room", 101], ["(", 106], ["ROSIER", 107], [")", 113], ["instrument", 115], ["as", 126], ["a", 129], ["diagnostic", 131], ["tool", 142], ["in", 147], ["a", 150], ["large", 152], ["Irish", 158], ["emergency", 164], ["department", 174], [".", 184], ["Fifty", 186], ["patients", 192], ["had", 201], ["ROSIER", 205], ["scores", 212], ["completed", 219], ["by", 229], ["doctors", 232], [".", 239], ["Diagnoses", 241], ["achieved", 251], ["using", 260], ["the", 266], ["score", 270], ["were", 276], ["compared", 281], ["with", 290], ["discharge", 295], ["diagnoses", 305], [".", 314], ["Relations", 316], ["between", 326], ["ROSIER", 334], ["score", 341], [",", 346], ["impairment", 348], ["and", 359], ["length", 363], ["of", 370], ["stay", 373], ["were", 378], ["assessed", 383], [".", 391], ["Forty", 393], ["-", 398], ["seven", 399], ["patients", 405], ["(", 414], ["94", 415], ["%", 417], [")", 418], ["had", 420], ["a", 424], ["ROSIER", 426], ["Score", 433], [">", 439], ["or", 441], ["=", 444], ["1", 445], ["indicating", 447], ["a", 458], ["stroke", 460], [",", 466], ["44", 468], ["(", 471], ["94", 472], ["%", 474], [")", 475], ["of", 477], ["these", 480], ["had", 486], ["stroke", 490], ["confirmed", 497], ["on", 507], ["investigation", 510], [".", 523], ["Two", 525], ["patients", 529], ["with", 538], ["stroke", 543], ["were", 550], ["missed", 555], ["and", 562], ["three", 566], ["were", 572], ["wrongly", 577], ["identified", 585], [".", 595], ["Positive", 597], ["predictive", 606], ["value", 617], ["for", 623], ["the", 627], ["ROSIER", 631], ["was", 638], ["94", 642], ["%", 644], [".", 645], ["ROSIER", 647], ["correlated", 654], ["with", 665], ["Scandinavian", 670], ["neurological", 683], ["stroke", 696], ["score", 703], [".", 708], ["(", 710], ["r", 711], ["=", 713], ["-0.414", 715], [",", 721], ["p", 723], ["=", 725], ["0.003", 727], [")", 732], ["and", 734], ["was", 738], ["associated", 742], ["with", 753], ["increasing", 758], ["length", 769], ["of", 776], ["stay", 779], ["in", 784], ["survivors", 787], ["(", 797], ["p", 798], ["=", 800], ["0.16", 802], [",", 806], ["one", 808], ["-", 811], ["way", 812], ["ANOVA", 816], [".", 821], ["F", 823], ["=", 825], ["3.116", 827], [",", 832], ["df", 834], ["=", 837], ["6", 839], [")", 840], [".", 841], ["The", 843], ["ROSIER", 847], ["is", 854], ["a", 857], ["suitable", 859], ["and", 868], ["useful", 872], ["adjunct", 879], ["in", 887], ["the", 890], ["assessment", 894], ["of", 905], ["stroke", 908], ["patients", 915], ["in", 924], ["Ireland", 927], [".", 934]]}
{"context": "One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular \u03b2-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exendin-4 and liraglutide, have been shown to promote plaque-lowering and mnemonic effects of in a number of experimental models of AD. Transgenic mouse models carrying genetic mutations of amyloid protein precursor (APP) and presenilin-1 (PS1) are commonly used to assess the pharmacodynamics of potential amyloidosis-lowering and pro-cognitive compounds. In this study, effects of long-term liraglutide treatment were therefore determined in two double APP/PS1 transgenic mouse models of Alzheimer's disease carrying different clinical APP/PS1 mutations, i.e. the 'London' (hAPPLon/PS1A246E) and 'Swedish' mutation variant (hAPPSwe/PS1\u0394E9) of APP, with co-expression of distinct PS1 variants. Liraglutide was administered in 5 month-old hAPPLon/PS1A246E mice for 3 months (100 or 500 ng/kg/day, s.c.), or 7 month-old hAPPSwe/PS1\u0394E9 mice for 5 months (500 ng/kg/day, s.c.). In both models, regional plaque load was quantified throughout the brain using stereological methods. Vehicle-dosed hAPPSwe/PS1\u0394E9 mice exhibited considerably higher cerebral plaque load than hAPPLon/PS1A246E control mice. Compared to vehicle-dosed transgenic controls, liraglutide treatment had no effect on the plaque levels in hAPPLon/PS1A246E and hAPPSwe/PS1\u0394E9 mice. In conclusion, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two transgenic mouse models of low- and high-grade amyloidosis, which suggests differential sensitivity to long-term liraglutide treatment in various transgenic mouse models mimicking distinct pathological hallmarks of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "9e28aa040a2f43c3ab63eeba84b5f4de", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[138, 140], [7, 9]], "char_spans": [[786, 804], [48, 66]]}, {"text": "AD", "token_spans": [[76, 76], [11, 11], [346, 346], [46, 46]], "char_spans": [[428, 429], [69, 70], [1856, 1857], [257, 258]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["major", 11], ["histopathological", 17], ["hallmarks", 35], ["of", 45], ["Alzheimer", 48], ["'s", 57], ["disease", 60], ["(", 68], ["AD", 69], [")", 71], ["is", 73], ["cerebral", 76], ["deposits", 85], ["of", 94], ["extracellular", 97], ["\u03b2", 111], ["-", 112], ["amyloid", 113], ["peptides", 121], [".", 129], ["Preclinical", 131], ["studies", 143], ["have", 151], ["pointed", 156], ["to", 164], ["glucagon", 167], ["-", 175], ["like", 176], ["peptide", 181], ["1", 189], ["(", 191], ["GLP-1", 192], [")", 197], ["receptors", 199], ["as", 209], ["a", 212], ["potential", 214], ["novel", 224], ["target", 230], ["in", 237], ["the", 240], ["treatment", 244], ["of", 254], ["AD", 257], [".", 259], ["GLP-1", 261], ["receptor", 267], ["agonists", 276], [",", 284], ["including", 286], ["exendin-4", 296], ["and", 306], ["liraglutide", 310], [",", 321], ["have", 323], ["been", 328], ["shown", 333], ["to", 339], ["promote", 342], ["plaque", 350], ["-", 356], ["lowering", 357], ["and", 366], ["mnemonic", 370], ["effects", 379], ["of", 387], ["in", 390], ["a", 393], ["number", 395], ["of", 402], ["experimental", 405], ["models", 418], ["of", 425], ["AD", 428], [".", 430], ["Transgenic", 432], ["mouse", 443], ["models", 449], ["carrying", 456], ["genetic", 465], ["mutations", 473], ["of", 483], ["amyloid", 486], ["protein", 494], ["precursor", 502], ["(", 512], ["APP", 513], [")", 516], ["and", 518], ["presenilin-1", 522], ["(", 535], ["PS1", 536], [")", 539], ["are", 541], ["commonly", 545], ["used", 554], ["to", 559], ["assess", 562], ["the", 569], ["pharmacodynamics", 573], ["of", 590], ["potential", 593], ["amyloidosis", 603], ["-", 614], ["lowering", 615], ["and", 624], ["pro", 628], ["-", 631], ["cognitive", 632], ["compounds", 642], [".", 651], ["In", 653], ["this", 656], ["study", 661], [",", 666], ["effects", 668], ["of", 676], ["long", 679], ["-", 683], ["term", 684], ["liraglutide", 689], ["treatment", 701], ["were", 711], ["therefore", 716], ["determined", 726], ["in", 737], ["two", 740], ["double", 744], ["APP", 751], ["/", 754], ["PS1", 755], ["transgenic", 759], ["mouse", 770], ["models", 776], ["of", 783], ["Alzheimer", 786], ["'s", 795], ["disease", 798], ["carrying", 806], ["different", 815], ["clinical", 825], ["APP", 834], ["/", 837], ["PS1", 838], ["mutations", 842], [",", 851], ["i.e.", 853], ["the", 858], ["'", 862], ["London", 863], ["'", 869], ["(", 871], ["hAPPLon", 872], ["/", 879], ["PS1A246E", 880], [")", 888], ["and", 890], ["'", 894], ["Swedish", 895], ["'", 902], ["mutation", 904], ["variant", 913], ["(", 921], ["hAPPSwe", 922], ["/", 929], ["PS1\u0394E9", 930], [")", 936], ["of", 938], ["APP", 941], [",", 944], ["with", 946], ["co", 951], ["-", 953], ["expression", 954], ["of", 965], ["distinct", 968], ["PS1", 977], ["variants", 981], [".", 989], ["Liraglutide", 991], ["was", 1003], ["administered", 1007], ["in", 1020], ["5", 1023], ["month", 1025], ["-", 1030], ["old", 1031], ["hAPPLon", 1035], ["/", 1042], ["PS1A246E", 1043], ["mice", 1052], ["for", 1057], ["3", 1061], ["months", 1063], ["(", 1070], ["100", 1071], ["or", 1075], ["500", 1078], ["ng", 1082], ["/", 1084], ["kg", 1085], ["/", 1087], ["day", 1088], [",", 1091], ["s.c", 1093], [".", 1096], [")", 1097], [",", 1098], ["or", 1100], ["7", 1103], ["month", 1105], ["-", 1110], ["old", 1111], ["hAPPSwe", 1115], ["/", 1122], ["PS1\u0394E9", 1123], ["mice", 1130], ["for", 1135], ["5", 1139], ["months", 1141], ["(", 1148], ["500", 1149], ["ng", 1153], ["/", 1155], ["kg", 1156], ["/", 1158], ["day", 1159], [",", 1162], ["s.c", 1164], [".", 1167], [")", 1168], [".", 1169], ["In", 1171], ["both", 1174], ["models", 1179], [",", 1185], ["regional", 1187], ["plaque", 1196], ["load", 1203], ["was", 1208], ["quantified", 1212], ["throughout", 1223], ["the", 1234], ["brain", 1238], ["using", 1244], ["stereological", 1250], ["methods", 1264], [".", 1271], ["Vehicle", 1273], ["-", 1280], ["dosed", 1281], ["hAPPSwe", 1287], ["/", 1294], ["PS1\u0394E9", 1295], ["mice", 1302], ["exhibited", 1307], ["considerably", 1317], ["higher", 1330], ["cerebral", 1337], ["plaque", 1346], ["load", 1353], ["than", 1358], ["hAPPLon", 1363], ["/", 1370], ["PS1A246E", 1371], ["control", 1380], ["mice", 1388], [".", 1392], ["Compared", 1394], ["to", 1403], ["vehicle", 1406], ["-", 1413], ["dosed", 1414], ["transgenic", 1420], ["controls", 1431], [",", 1439], ["liraglutide", 1441], ["treatment", 1453], ["had", 1463], ["no", 1467], ["effect", 1470], ["on", 1477], ["the", 1480], ["plaque", 1484], ["levels", 1491], ["in", 1498], ["hAPPLon", 1501], ["/", 1508], ["PS1A246E", 1509], ["and", 1518], ["hAPPSwe", 1522], ["/", 1529], ["PS1\u0394E9", 1530], ["mice", 1537], [".", 1541], ["In", 1543], ["conclusion", 1546], [",", 1556], ["long", 1558], ["-", 1562], ["term", 1563], ["liraglutide", 1568], ["treatment", 1580], ["exhibited", 1590], ["no", 1600], ["effect", 1603], ["on", 1610], ["cerebral", 1613], ["plaque", 1622], ["load", 1629], ["in", 1634], ["two", 1637], ["transgenic", 1641], ["mouse", 1652], ["models", 1658], ["of", 1665], ["low-", 1668], ["and", 1673], ["high", 1677], ["-", 1681], ["grade", 1682], ["amyloidosis", 1688], [",", 1699], ["which", 1701], ["suggests", 1707], ["differential", 1716], ["sensitivity", 1729], ["to", 1741], ["long", 1744], ["-", 1748], ["term", 1749], ["liraglutide", 1754], ["treatment", 1766], ["in", 1776], ["various", 1779], ["transgenic", 1787], ["mouse", 1798], ["models", 1804], ["mimicking", 1811], ["distinct", 1821], ["pathological", 1830], ["hallmarks", 1843], ["of", 1853], ["AD", 1856], [".", 1858]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "Apical membrane antigen 1 (AMA1) is an asexual blood-stage protein expressed in the invasive merozoite form of Plasmodia species, which are the causative agent of malaria. We have complemented the function of Plasmodium falciparum AMA1 (PfAMA1) with a divergent AMA1 transgene from Plasmodium chabaudi (PcAMA1). It was not possible to disrupt the PfAMA1 gene using 'knock-out' plasmids, although we demonstrate that the PfAMA1 gene can be targeted by homologous recombination. These experiments suggest that PfAMA1 is critical, perhaps essential, for blood-stage growth. Importantly, we showed that PcAMA1 expression in P. falciparum provides trans-species complementation to at least 35% of the function of endogenous PfAMA1 in human red cells. Furthermore, expression of this transgene in P. falciparum leads to more efficient invasion of murine erythrocytes. These results indicate an important role for AMA1 in the invasion of red blood cells (RBCs) across divergent Plasmodium species.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "e3479299b8474eb5a5963d6564d7faa9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[173, 174]], "char_spans": [[971, 988]]}]}], "context_tokens": [["Apical", 0], ["membrane", 7], ["antigen", 16], ["1", 24], ["(", 26], ["AMA1", 27], [")", 31], ["is", 33], ["an", 36], ["asexual", 39], ["blood", 47], ["-", 52], ["stage", 53], ["protein", 59], ["expressed", 67], ["in", 77], ["the", 80], ["invasive", 84], ["merozoite", 93], ["form", 103], ["of", 108], ["Plasmodia", 111], ["species", 121], [",", 128], ["which", 130], ["are", 136], ["the", 140], ["causative", 144], ["agent", 154], ["of", 160], ["malaria", 163], [".", 170], ["We", 172], ["have", 175], ["complemented", 180], ["the", 193], ["function", 197], ["of", 206], ["Plasmodium", 209], ["falciparum", 220], ["AMA1", 231], ["(", 236], ["PfAMA1", 237], [")", 243], ["with", 245], ["a", 250], ["divergent", 252], ["AMA1", 262], ["transgene", 267], ["from", 277], ["Plasmodium", 282], ["chabaudi", 293], ["(", 302], ["PcAMA1", 303], [")", 309], [".", 310], ["It", 312], ["was", 315], ["not", 319], ["possible", 323], ["to", 332], ["disrupt", 335], ["the", 343], ["PfAMA1", 347], ["gene", 354], ["using", 359], ["'", 365], ["knock", 366], ["-", 371], ["out", 372], ["'", 375], ["plasmids", 377], [",", 385], ["although", 387], ["we", 396], ["demonstrate", 399], ["that", 411], ["the", 416], ["PfAMA1", 420], ["gene", 427], ["can", 432], ["be", 436], ["targeted", 439], ["by", 448], ["homologous", 451], ["recombination", 462], [".", 475], ["These", 477], ["experiments", 483], ["suggest", 495], ["that", 503], ["PfAMA1", 508], ["is", 515], ["critical", 518], [",", 526], ["perhaps", 528], ["essential", 536], [",", 545], ["for", 547], ["blood", 551], ["-", 556], ["stage", 557], ["growth", 563], [".", 569], ["Importantly", 571], [",", 582], ["we", 584], ["showed", 587], ["that", 594], ["PcAMA1", 599], ["expression", 606], ["in", 617], ["P.", 620], ["falciparum", 623], ["provides", 634], ["trans", 643], ["-", 648], ["species", 649], ["complementation", 657], ["to", 673], ["at", 676], ["least", 679], ["35", 685], ["%", 687], ["of", 689], ["the", 692], ["function", 696], ["of", 705], ["endogenous", 708], ["PfAMA1", 719], ["in", 726], ["human", 729], ["red", 735], ["cells", 739], [".", 744], ["Furthermore", 746], [",", 757], ["expression", 759], ["of", 770], ["this", 773], ["transgene", 778], ["in", 788], ["P.", 791], ["falciparum", 794], ["leads", 805], ["to", 811], ["more", 814], ["efficient", 819], ["invasion", 829], ["of", 838], ["murine", 841], ["erythrocytes", 848], [".", 860], ["These", 862], ["results", 868], ["indicate", 876], ["an", 885], ["important", 888], ["role", 898], ["for", 903], ["AMA1", 907], ["in", 912], ["the", 915], ["invasion", 919], ["of", 928], ["red", 931], ["blood", 935], ["cells", 941], ["(", 947], ["RBCs", 948], [")", 952], ["across", 954], ["divergent", 961], ["Plasmodium", 971], ["species", 982], [".", 989]]}
{"context": "Canonical primary microRNA (pri-miRNA) precursors are transcribed by RNA polymerase II and then processed by the Drosha endonuclease to generate approximately 60 nt pre-miRNA hairpins. Pre-miRNAs in turn are cleaved by Dicer to generate mature miRNAs. Previously, some short introns, called miRtrons, were reported to fold into pre-miRNA hairpins after splicing and debranching, and miRNAs can also be excised by Dicer cleavage of rare endogenous short hairpin RNAs. Here we report that the miRNAs encoded by murine gamma-herpesvirus 68 (MHV68) are also generated via atypical mechanisms. Specifically, MHV68 miRNAs are transcribed from RNA polymerase III promoters located within adjacent viral tRNA-like sequences. The resultant pri-miRNAs, which bear a 5' tRNA moiety, are not processed by Drosha but instead by cellular tRNase Z, which cleaves 3' to the tRNA to liberate pre-miRNA hairpins that are then processed by Dicer to yield the mature viral miRNAs.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "354a06365eb5430db7d04eb6bea5af55", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[12, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Canonical", 0], ["primary", 10], ["microRNA", 18], ["(", 27], ["pri", 28], ["-", 31], ["miRNA", 32], [")", 37], ["precursors", 39], ["are", 50], ["transcribed", 54], ["by", 66], ["RNA", 69], ["polymerase", 73], ["II", 84], ["and", 87], ["then", 91], ["processed", 96], ["by", 106], ["the", 109], ["Drosha", 113], ["endonuclease", 120], ["to", 133], ["generate", 136], ["approximately", 145], ["60", 159], ["nt", 162], ["pre", 165], ["-", 168], ["miRNA", 169], ["hairpins", 175], [".", 183], ["Pre", 185], ["-", 188], ["miRNAs", 189], ["in", 196], ["turn", 199], ["are", 204], ["cleaved", 208], ["by", 216], ["Dicer", 219], ["to", 225], ["generate", 228], ["mature", 237], ["miRNAs", 244], [".", 250], ["Previously", 252], [",", 262], ["some", 264], ["short", 269], ["introns", 275], [",", 282], ["called", 284], ["miRtrons", 291], [",", 299], ["were", 301], ["reported", 306], ["to", 315], ["fold", 318], ["into", 323], ["pre", 328], ["-", 331], ["miRNA", 332], ["hairpins", 338], ["after", 347], ["splicing", 353], ["and", 362], ["debranching", 366], [",", 377], ["and", 379], ["miRNAs", 383], ["can", 390], ["also", 394], ["be", 399], ["excised", 402], ["by", 410], ["Dicer", 413], ["cleavage", 419], ["of", 428], ["rare", 431], ["endogenous", 436], ["short", 447], ["hairpin", 453], ["RNAs", 461], [".", 465], ["Here", 467], ["we", 472], ["report", 475], ["that", 482], ["the", 487], ["miRNAs", 491], ["encoded", 498], ["by", 506], ["murine", 509], ["gamma", 516], ["-", 521], ["herpesvirus", 522], ["68", 534], ["(", 537], ["MHV68", 538], [")", 543], ["are", 545], ["also", 549], ["generated", 554], ["via", 564], ["atypical", 568], ["mechanisms", 577], [".", 587], ["Specifically", 589], [",", 601], ["MHV68", 603], ["miRNAs", 609], ["are", 616], ["transcribed", 620], ["from", 632], ["RNA", 637], ["polymerase", 641], ["III", 652], ["promoters", 656], ["located", 666], ["within", 674], ["adjacent", 681], ["viral", 690], ["tRNA", 696], ["-", 700], ["like", 701], ["sequences", 706], [".", 715], ["The", 717], ["resultant", 721], ["pri", 731], ["-", 734], ["miRNAs", 735], [",", 741], ["which", 743], ["bear", 749], ["a", 754], ["5", 756], ["'", 757], ["tRNA", 759], ["moiety", 764], [",", 770], ["are", 772], ["not", 776], ["processed", 780], ["by", 790], ["Drosha", 793], ["but", 800], ["instead", 804], ["by", 812], ["cellular", 815], ["tRNase", 824], ["Z", 831], [",", 832], ["which", 834], ["cleaves", 840], ["3", 848], ["'", 849], ["to", 851], ["the", 854], ["tRNA", 858], ["to", 863], ["liberate", 866], ["pre", 875], ["-", 878], ["miRNA", 879], ["hairpins", 885], ["that", 894], ["are", 899], ["then", 903], ["processed", 908], ["by", 918], ["Dicer", 921], ["to", 927], ["yield", 930], ["the", 936], ["mature", 940], ["viral", 947], ["miRNAs", 953], [".", 959]]}
{"context": "It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation. On other hand, EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib. We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases. 192 adenocarcinoma cases were included. The presence or absence of EGFR polymorphism of exon 13 was analyzed by PCR-RFLP method. EGFR mutations at kinase domain were found from 95 of 225 lung cancer patients. In 86.2% of patients, homo- or heterozygous Lys497 allele was present. No correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes. EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. In node-negative patients, R497KEGFR genotype was not correlated with disease outcome. In node-positive patients, however, R497K EGFR was significantly associated with better overall survival. This association was attributable to neo-adjuvant or adjuvant chemotherapy. In 46 total gefitinib treated NSCLC patients, the prognosis was not different between the EGFR wild type (GG) patients and AG+AA patients. R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "98bf14cf3f54411fb46b808b1029b76d", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[56, 99]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["reported", 12], ["that", 21], ["the", 26], ["R497", 30], ["K", 34], ["polymorphism", 36], ["of", 49], ["the", 52], ["epidermal", 56], ["growth", 66], ["factor", 73], ["receptor", 80], ["(", 89], ["EGFR", 90], [")", 94], ["gene", 96], ["has", 101], ["attenuated", 105], ["functions", 116], ["in", 126], ["ligand", 129], ["binding", 136], [",", 143], ["tyrosine", 145], ["kinase", 154], ["activation", 161], [",", 171], ["and", 173], ["growth", 177], ["stimulation", 184], [".", 195], ["On", 197], ["other", 200], ["hand", 206], [",", 210], ["EGFR", 212], ["gene", 217], ["mutations", 222], ["at", 232], ["kinase", 235], ["domain", 242], ["in", 249], ["non", 252], ["-", 255], ["small", 256], ["cell", 262], ["lung", 267], ["cancer", 272], ["(", 279], ["NSCLC", 280], [")", 285], ["have", 287], ["been", 292], ["examined", 297], ["for", 306], ["their", 310], ["ability", 316], ["to", 324], ["predict", 327], ["sensitivity", 335], ["to", 347], ["gefitinib", 350], ["or", 360], ["erlotinib", 363], [".", 372], ["We", 374], ["investigated", 377], ["the", 390], ["EGFR", 394], ["mutations", 399], ["and/or", 409], ["R497", 416], ["K", 420], ["polymorphism", 422], ["statuses", 435], ["in", 444], ["225", 447], ["surgically", 451], ["treated", 462], ["NSCLC", 470], ["cases", 476], [".", 481], ["192", 483], ["adenocarcinoma", 487], ["cases", 502], ["were", 508], ["included", 513], [".", 521], ["The", 523], ["presence", 527], ["or", 536], ["absence", 539], ["of", 547], ["EGFR", 550], ["polymorphism", 555], ["of", 568], ["exon", 571], ["13", 576], ["was", 579], ["analyzed", 583], ["by", 592], ["PCR", 595], ["-", 598], ["RFLP", 599], ["method", 604], [".", 610], ["EGFR", 612], ["mutations", 617], ["at", 627], ["kinase", 630], ["domain", 637], ["were", 644], ["found", 649], ["from", 655], ["95", 660], ["of", 663], ["225", 666], ["lung", 670], ["cancer", 675], ["patients", 682], [".", 690], ["In", 692], ["86.2", 695], ["%", 699], ["of", 701], ["patients", 704], [",", 712], ["homo-", 714], ["or", 720], ["heterozygous", 723], ["Lys497", 736], ["allele", 743], ["was", 750], ["present", 754], [".", 761], ["No", 763], ["correlation", 766], ["existed", 778], ["between", 786], ["R497", 794], ["K", 798], ["EGFR", 800], ["genotype", 805], ["and", 814], ["clinico", 818], ["-", 825], ["pathological", 826], ["features", 839], [",", 847], ["such", 849], ["as", 854], ["gender", 857], [",", 863], ["smoking", 865], ["status", 873], [",", 879], ["and", 881], ["pathological", 885], ["subtypes", 898], [".", 906], ["EGFR", 908], ["mutation", 913], ["status", 922], ["was", 929], ["not", 933], ["correlated", 937], ["with", 948], ["R497KEGFR", 953], ["genotype", 963], ["of", 972], ["lung", 975], ["cancers", 980], [".", 987], ["In", 989], ["node", 992], ["-", 996], ["negative", 997], ["patients", 1006], [",", 1014], ["R497KEGFR", 1016], ["genotype", 1026], ["was", 1035], ["not", 1039], ["correlated", 1043], ["with", 1054], ["disease", 1059], ["outcome", 1067], [".", 1074], ["In", 1076], ["node", 1079], ["-", 1083], ["positive", 1084], ["patients", 1093], [",", 1101], ["however", 1103], [",", 1110], ["R497", 1112], ["K", 1116], ["EGFR", 1118], ["was", 1123], ["significantly", 1127], ["associated", 1141], ["with", 1152], ["better", 1157], ["overall", 1164], ["survival", 1172], [".", 1180], ["This", 1182], ["association", 1187], ["was", 1199], ["attributable", 1203], ["to", 1216], ["neo", 1219], ["-", 1222], ["adjuvant", 1223], ["or", 1232], ["adjuvant", 1235], ["chemotherapy", 1244], [".", 1256], ["In", 1258], ["46", 1261], ["total", 1264], ["gefitinib", 1270], ["treated", 1280], ["NSCLC", 1288], ["patients", 1294], [",", 1302], ["the", 1304], ["prognosis", 1308], ["was", 1318], ["not", 1322], ["different", 1326], ["between", 1336], ["the", 1344], ["EGFR", 1348], ["wild", 1353], ["type", 1358], ["(", 1363], ["GG", 1364], [")", 1366], ["patients", 1368], ["and", 1377], ["AG+AA", 1381], ["patients", 1387], [".", 1395], ["R497KEGFR", 1397], ["polymorphism", 1407], ["might", 1420], ["be", 1426], ["associated", 1429], ["with", 1440], ["favorable", 1445], ["prognosis", 1455], ["of", 1465], ["advanced", 1468], ["lung", 1477], ["cancers", 1482], ["and", 1490], ["correlated", 1494], ["with", 1505], ["chemosensitivity", 1510], [".", 1526]]}
{"context": "The effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a newly synthesized Na(+)-Ca(2+) exchanger (NCX) inhibitor, on the NCX current and other membrane currents were examined in isolated guinea-pig ventricular myocytes and compared with those of 2-[2-[4-(4-nitrobenzyloxy) phenyl]ethyl]isothiourea (KB-R7943). SEA0400 concentration-dependently inhibited the NCX current with a 10 fold higher potency than that of KB-R7943; 1 microM SEA0400 and 10 microM KB-R7943 inhibited the NCX current by more than 80%. KB-R7943, at 10 microM, inhibited the sodium current, L-type calcium current, delayed rectifier potassium current and inwardly rectifying potassium current by more than 50%, but SEA0400 (1 microM) had no significant effect on these currents. These results indicate that SEA0400 is a potent and highly selective inhibitor of NCX, and would be a powerful tool for further studies on the role of NCX in the heart and the therapeutic potential of its inhibition.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "3c5acbfea860401088f0e789580bf84b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[59, 59], [85, 85], [154, 154], [169, 169], [24, 24], [18, 18]], "char_spans": [[390, 392], [509, 511], [863, 865], [932, 934], [153, 155], [130, 132]]}]}], "context_tokens": [["The", 0], ["effects", 4], ["of", 12], ["2-[4-[(2,5-difluorophenyl", 15], [")", 40], ["methoxy]phenoxy]-5-ethoxyaniline", 42], ["(", 75], ["SEA0400", 76], [")", 83], [",", 84], ["a", 86], ["newly", 88], ["synthesized", 94], ["Na(+)-Ca(2", 106], ["+", 116], [")", 117], ["exchanger", 119], ["(", 129], ["NCX", 130], [")", 133], ["inhibitor", 135], [",", 144], ["on", 146], ["the", 149], ["NCX", 153], ["current", 157], ["and", 165], ["other", 169], ["membrane", 175], ["currents", 184], ["were", 193], ["examined", 198], ["in", 207], ["isolated", 210], ["guinea", 219], ["-", 225], ["pig", 226], ["ventricular", 230], ["myocytes", 242], ["and", 251], ["compared", 255], ["with", 264], ["those", 269], ["of", 275], ["2-[2-[4-(4-nitrobenzyloxy", 278], [")", 303], ["phenyl]ethyl]isothiourea", 305], ["(", 330], ["KB", 331], ["-", 333], ["R7943", 334], [")", 339], [".", 340], ["SEA0400", 342], ["concentration", 350], ["-", 363], ["dependently", 364], ["inhibited", 376], ["the", 386], ["NCX", 390], ["current", 394], ["with", 402], ["a", 407], ["10", 409], ["fold", 412], ["higher", 417], ["potency", 424], ["than", 432], ["that", 437], ["of", 442], ["KB", 445], ["-", 447], ["R7943", 448], [";", 453], ["1", 455], ["microM", 457], ["SEA0400", 464], ["and", 472], ["10", 476], ["microM", 479], ["KB", 486], ["-", 488], ["R7943", 489], ["inhibited", 495], ["the", 505], ["NCX", 509], ["current", 513], ["by", 521], ["more", 524], ["than", 529], ["80", 534], ["%", 536], [".", 537], ["KB", 539], ["-", 541], ["R7943", 542], [",", 547], ["at", 549], ["10", 552], ["microM", 555], [",", 561], ["inhibited", 563], ["the", 573], ["sodium", 577], ["current", 584], [",", 591], ["L", 593], ["-", 594], ["type", 595], ["calcium", 600], ["current", 608], [",", 615], ["delayed", 617], ["rectifier", 625], ["potassium", 635], ["current", 645], ["and", 653], ["inwardly", 657], ["rectifying", 666], ["potassium", 677], ["current", 687], ["by", 695], ["more", 698], ["than", 703], ["50", 708], ["%", 710], [",", 711], ["but", 713], ["SEA0400", 717], ["(", 725], ["1", 726], ["microM", 728], [")", 734], ["had", 736], ["no", 740], ["significant", 743], ["effect", 755], ["on", 762], ["these", 765], ["currents", 771], [".", 779], ["These", 781], ["results", 787], ["indicate", 795], ["that", 804], ["SEA0400", 809], ["is", 817], ["a", 820], ["potent", 822], ["and", 829], ["highly", 833], ["selective", 840], ["inhibitor", 850], ["of", 860], ["NCX", 863], [",", 866], ["and", 868], ["would", 872], ["be", 878], ["a", 881], ["powerful", 883], ["tool", 892], ["for", 897], ["further", 901], ["studies", 909], ["on", 917], ["the", 920], ["role", 924], ["of", 929], ["NCX", 932], ["in", 936], ["the", 939], ["heart", 943], ["and", 949], ["the", 953], ["therapeutic", 957], ["potential", 969], ["of", 979], ["its", 982], ["inhibition", 986], [".", 996]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "The aim of this study was to elucidate the role of lysyl oxidase (LOX) and lysyl oxidase like (LOXL) 2 in pathologic wound healing after glaucoma surgery. We therefore investigated the expression of LOX and LOXL2 and evaluated the therapeutic potential of anti-LOX (GS-639556, formerly M64) and anti-LOXL2 (GS-607601, formerly AB0023) antibodies in a rabbit model of glaucoma trabeculectomy. Ocular expression of LOX and LOXL2 was investigated by immunohistologic staining at different time points after trabeculectomy. Treatment with GS-639556 or GS-607601 was initiated in rabbits immediately after trabeculectomy by giving both intracameral and subconjunctival injections. Thereafter, the antibodies were given twice a week subconjunctivally until day 30 after surgery (day of euthanization). Treatment outcome was studied by clinical investigation of the bleb and by immunohistochemical analysis of angiogenesis, inflammation, and collagen deposition. LOX and LOXL2 were both upregulated in Tenon's capsule and the conjunctiva after glaucoma surgery. Repeated administration of LOX- or LOXL2-targeting monoclonal antibodies increased bleb area and bleb survival. Analyses of immunohistologic stainings showed that both antibodies significantly decreased fibrosis, whereas the anti-LOXL2 antibody also significantly reduced blood vessel density and inflammation. Targeting LOXL2 with an inhibitory monoclonal antibody (GS-607601) reduced pathologic angiogenesis, inflammation, and fibrosis. These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", "qas": [{"question": "What is the drug target for Simtuzumab?", "answers": ["LOXL2"], "qid": "09d197c3c5924d1ca53e19a939eede2e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["drug", 12], ["target", 17], ["for", 24], ["Simtuzumab", 28], ["?", 38]], "detected_answers": [{"text": "LOXL2", "token_spans": [[80, 80], [205, 205], [59, 59], [217, 217], [40, 40], [239, 239], [159, 159]], "char_spans": [[421, 425], [1285, 1289], [300, 304], [1376, 1380], [207, 211], [1521, 1525], [964, 968]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["elucidate", 29], ["the", 39], ["role", 43], ["of", 48], ["lysyl", 51], ["oxidase", 57], ["(", 65], ["LOX", 66], [")", 69], ["and", 71], ["lysyl", 75], ["oxidase", 81], ["like", 89], ["(", 94], ["LOXL", 95], [")", 99], ["2", 101], ["in", 103], ["pathologic", 106], ["wound", 117], ["healing", 123], ["after", 131], ["glaucoma", 137], ["surgery", 146], [".", 153], ["We", 155], ["therefore", 158], ["investigated", 168], ["the", 181], ["expression", 185], ["of", 196], ["LOX", 199], ["and", 203], ["LOXL2", 207], ["and", 213], ["evaluated", 217], ["the", 227], ["therapeutic", 231], ["potential", 243], ["of", 253], ["anti", 256], ["-", 260], ["LOX", 261], ["(", 265], ["GS-639556", 266], [",", 275], ["formerly", 277], ["M64", 286], [")", 289], ["and", 291], ["anti", 295], ["-", 299], ["LOXL2", 300], ["(", 306], ["GS-607601", 307], [",", 316], ["formerly", 318], ["AB0023", 327], [")", 333], ["antibodies", 335], ["in", 346], ["a", 349], ["rabbit", 351], ["model", 358], ["of", 364], ["glaucoma", 367], ["trabeculectomy", 376], [".", 390], ["Ocular", 392], ["expression", 399], ["of", 410], ["LOX", 413], ["and", 417], ["LOXL2", 421], ["was", 427], ["investigated", 431], ["by", 444], ["immunohistologic", 447], ["staining", 464], ["at", 473], ["different", 476], ["time", 486], ["points", 491], ["after", 498], ["trabeculectomy", 504], [".", 518], ["Treatment", 520], ["with", 530], ["GS-639556", 535], ["or", 545], ["GS-607601", 548], ["was", 558], ["initiated", 562], ["in", 572], ["rabbits", 575], ["immediately", 583], ["after", 595], ["trabeculectomy", 601], ["by", 616], ["giving", 619], ["both", 626], ["intracameral", 631], ["and", 644], ["subconjunctival", 648], ["injections", 664], [".", 674], ["Thereafter", 676], [",", 686], ["the", 688], ["antibodies", 692], ["were", 703], ["given", 708], ["twice", 714], ["a", 720], ["week", 722], ["subconjunctivally", 727], ["until", 745], ["day", 751], ["30", 755], ["after", 758], ["surgery", 764], ["(", 772], ["day", 773], ["of", 777], ["euthanization", 780], [")", 793], [".", 794], ["Treatment", 796], ["outcome", 806], ["was", 814], ["studied", 818], ["by", 826], ["clinical", 829], ["investigation", 838], ["of", 852], ["the", 855], ["bleb", 859], ["and", 864], ["by", 868], ["immunohistochemical", 871], ["analysis", 891], ["of", 900], ["angiogenesis", 903], [",", 915], ["inflammation", 917], [",", 929], ["and", 931], ["collagen", 935], ["deposition", 944], [".", 954], ["LOX", 956], ["and", 960], ["LOXL2", 964], ["were", 970], ["both", 975], ["upregulated", 980], ["in", 992], ["Tenon", 995], ["'s", 1000], ["capsule", 1003], ["and", 1011], ["the", 1015], ["conjunctiva", 1019], ["after", 1031], ["glaucoma", 1037], ["surgery", 1046], [".", 1053], ["Repeated", 1055], ["administration", 1064], ["of", 1079], ["LOX-", 1082], ["or", 1087], ["LOXL2-targeting", 1090], ["monoclonal", 1106], ["antibodies", 1117], ["increased", 1128], ["bleb", 1138], ["area", 1143], ["and", 1148], ["bleb", 1152], ["survival", 1157], [".", 1165], ["Analyses", 1167], ["of", 1176], ["immunohistologic", 1179], ["stainings", 1196], ["showed", 1206], ["that", 1213], ["both", 1218], ["antibodies", 1223], ["significantly", 1234], ["decreased", 1248], ["fibrosis", 1258], [",", 1266], ["whereas", 1268], ["the", 1276], ["anti", 1280], ["-", 1284], ["LOXL2", 1285], ["antibody", 1291], ["also", 1300], ["significantly", 1305], ["reduced", 1319], ["blood", 1327], ["vessel", 1333], ["density", 1340], ["and", 1348], ["inflammation", 1352], [".", 1364], ["Targeting", 1366], ["LOXL2", 1376], ["with", 1382], ["an", 1387], ["inhibitory", 1390], ["monoclonal", 1401], ["antibody", 1412], ["(", 1421], ["GS-607601", 1422], [")", 1431], ["reduced", 1433], ["pathologic", 1441], ["angiogenesis", 1452], [",", 1464], ["inflammation", 1466], [",", 1478], ["and", 1480], ["fibrosis", 1484], [".", 1492], ["These", 1494], ["results", 1500], ["suggest", 1508], ["that", 1516], ["LOXL2", 1521], ["could", 1527], ["be", 1533], ["an", 1536], ["appealing", 1539], ["target", 1549], ["for", 1556], ["treatment", 1560], ["of", 1570], ["scar", 1573], ["formation", 1578], ["after", 1588], ["glaucoma", 1594], ["surgery", 1603], [",", 1610], ["and", 1612], ["point", 1616], ["to", 1622], ["the", 1625], ["potential", 1629], ["therapeutic", 1639], ["benefits", 1651], ["of", 1660], ["simtuzumab", 1663], [",", 1673], ["a", 1675], ["humanized", 1677], ["monoclonal", 1687], ["antibody", 1698], ["derived", 1707], ["from", 1715], ["GS-607601", 1720], [".", 1729]]}
{"context": "Selenocysteine, a selenium-containing analog of cysteine, is found in the prokaryotic and eukaryotic kingdoms in active sites of enzymes involved in oxidation-reduction reactions. Its biosynthesis and cotranslational insertion into selenoproteins is performed by an outstanding mechanism, implying the participation of several gene products. The tRNA(Sec) is one of these. In eukaryotes, its transcription mode by RNA polymerase III differs from that of classical tRNA genes, both at the level of the promoter elements and transcription factors involved. In addition, enhanced transcription is afforded by a newly characterized zinc finger activator. Not only transcription of the gene, but also the tRNA(Sec) itself is atypical since its 2D and 3D structures exhibit features which set it apart from classical tRNAs. Decoding of eukaryotic selenocysteine UGA codons requires a stem-loop structure in the 3'UTR of mRNAs, the selenocysteine insertion sequence (SECIS) element. Structure probing and sequence comparisons led us to propose a 2D structure model for the SECIS element, containing a novel RNA motif composed of four consecutive non-Watson-Crick base-pairs. A 3D model, rationalizing the accessibility data, was elaborated by computer modeling. It yields indicative or suggestive evidence for the role that could play some conserved residues and/or structural features in SECIS function. These might act as signals for interaction with SBP, the SECIS binding protein that we have characterized.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "8588c6a6d2b34d4ba7cbf44f2320db4d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[160, 160], [248, 248], [179, 179], [234, 234]], "char_spans": [[960, 964], [1455, 1459], [1066, 1070], [1382, 1386]]}]}], "context_tokens": [["Selenocysteine", 0], [",", 14], ["a", 16], ["selenium", 18], ["-", 26], ["containing", 27], ["analog", 38], ["of", 45], ["cysteine", 48], [",", 56], ["is", 58], ["found", 61], ["in", 67], ["the", 70], ["prokaryotic", 74], ["and", 86], ["eukaryotic", 90], ["kingdoms", 101], ["in", 110], ["active", 113], ["sites", 120], ["of", 126], ["enzymes", 129], ["involved", 137], ["in", 146], ["oxidation", 149], ["-", 158], ["reduction", 159], ["reactions", 169], [".", 178], ["Its", 180], ["biosynthesis", 184], ["and", 197], ["cotranslational", 201], ["insertion", 217], ["into", 227], ["selenoproteins", 232], ["is", 247], ["performed", 250], ["by", 260], ["an", 263], ["outstanding", 266], ["mechanism", 278], [",", 287], ["implying", 289], ["the", 298], ["participation", 302], ["of", 316], ["several", 319], ["gene", 327], ["products", 332], [".", 340], ["The", 342], ["tRNA(Sec", 346], [")", 354], ["is", 356], ["one", 359], ["of", 363], ["these", 366], [".", 371], ["In", 373], ["eukaryotes", 376], [",", 386], ["its", 388], ["transcription", 392], ["mode", 406], ["by", 411], ["RNA", 414], ["polymerase", 418], ["III", 429], ["differs", 433], ["from", 441], ["that", 446], ["of", 451], ["classical", 454], ["tRNA", 464], ["genes", 469], [",", 474], ["both", 476], ["at", 481], ["the", 484], ["level", 488], ["of", 494], ["the", 497], ["promoter", 501], ["elements", 510], ["and", 519], ["transcription", 523], ["factors", 537], ["involved", 545], [".", 553], ["In", 555], ["addition", 558], [",", 566], ["enhanced", 568], ["transcription", 577], ["is", 591], ["afforded", 594], ["by", 603], ["a", 606], ["newly", 608], ["characterized", 614], ["zinc", 628], ["finger", 633], ["activator", 640], [".", 649], ["Not", 651], ["only", 655], ["transcription", 660], ["of", 674], ["the", 677], ["gene", 681], [",", 685], ["but", 687], ["also", 691], ["the", 696], ["tRNA(Sec", 700], [")", 708], ["itself", 710], ["is", 717], ["atypical", 720], ["since", 729], ["its", 735], ["2D", 739], ["and", 742], ["3D", 746], ["structures", 749], ["exhibit", 760], ["features", 768], ["which", 777], ["set", 783], ["it", 787], ["apart", 790], ["from", 796], ["classical", 801], ["tRNAs", 811], [".", 816], ["Decoding", 818], ["of", 827], ["eukaryotic", 830], ["selenocysteine", 841], ["UGA", 856], ["codons", 860], ["requires", 867], ["a", 876], ["stem", 878], ["-", 882], ["loop", 883], ["structure", 888], ["in", 898], ["the", 901], ["3'UTR", 905], ["of", 911], ["mRNAs", 914], [",", 919], ["the", 921], ["selenocysteine", 925], ["insertion", 940], ["sequence", 950], ["(", 959], ["SECIS", 960], [")", 965], ["element", 967], [".", 974], ["Structure", 976], ["probing", 986], ["and", 994], ["sequence", 998], ["comparisons", 1007], ["led", 1019], ["us", 1023], ["to", 1026], ["propose", 1029], ["a", 1037], ["2D", 1039], ["structure", 1042], ["model", 1052], ["for", 1058], ["the", 1062], ["SECIS", 1066], ["element", 1072], [",", 1079], ["containing", 1081], ["a", 1092], ["novel", 1094], ["RNA", 1100], ["motif", 1104], ["composed", 1110], ["of", 1119], ["four", 1122], ["consecutive", 1127], ["non", 1139], ["-", 1142], ["Watson", 1143], ["-", 1149], ["Crick", 1150], ["base", 1156], ["-", 1160], ["pairs", 1161], [".", 1166], ["A", 1168], ["3D", 1170], ["model", 1173], [",", 1178], ["rationalizing", 1180], ["the", 1194], ["accessibility", 1198], ["data", 1212], [",", 1216], ["was", 1218], ["elaborated", 1222], ["by", 1233], ["computer", 1236], ["modeling", 1245], [".", 1253], ["It", 1255], ["yields", 1258], ["indicative", 1265], ["or", 1276], ["suggestive", 1279], ["evidence", 1290], ["for", 1299], ["the", 1303], ["role", 1307], ["that", 1312], ["could", 1317], ["play", 1323], ["some", 1328], ["conserved", 1333], ["residues", 1343], ["and/or", 1352], ["structural", 1359], ["features", 1370], ["in", 1379], ["SECIS", 1382], ["function", 1388], [".", 1396], ["These", 1398], ["might", 1404], ["act", 1410], ["as", 1414], ["signals", 1417], ["for", 1425], ["interaction", 1429], ["with", 1441], ["SBP", 1446], [",", 1449], ["the", 1451], ["SECIS", 1455], ["binding", 1461], ["protein", 1469], ["that", 1477], ["we", 1482], ["have", 1485], ["characterized", 1490], [".", 1503]]}
{"context": "Osteoporosis and several other bone disorders occur when there is an imbalance between the resorption and formation components of bone remodeling activity. Therapies available for some of these conditions modulate the activity of osteoclasts and/or osteoblasts. The recent discoveries of receptor activator of NF-kappaB ligand (RANKL), an endogenous activator of osteoclastogenenesis and osteoclast activity and its inhibitor, osteoprotegerin (OPG) as pivotal regulatory factors in the pathogenesis of bone diseases like osteoporosis provide unique targets for therapeutic agents. In laboratory animals and now in humans, administering forms of OPG markedly inhibits osteoclast activity and improves bone strength, documenting that the strategy of inhibiting RANKL activity has therapeutic promise. A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density. Attributes of denosumab in these clinical studies include a very rapid onset of action, sustained effects for several months after a single injection, and good tolerability. These results provide the basis for studies evaluating the effectiveness of denosumab in several clinical conditions characterized by increased osteoclastic activity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "93cde7c0b055488588b25d93e9cddb8a", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[129, 129], [115, 115], [50, 50]], "char_spans": [[847, 851], [759, 763], [328, 332]]}]}], "context_tokens": [["Osteoporosis", 0], ["and", 13], ["several", 17], ["other", 25], ["bone", 31], ["disorders", 36], ["occur", 46], ["when", 52], ["there", 57], ["is", 63], ["an", 66], ["imbalance", 69], ["between", 79], ["the", 87], ["resorption", 91], ["and", 102], ["formation", 106], ["components", 116], ["of", 127], ["bone", 130], ["remodeling", 135], ["activity", 146], [".", 154], ["Therapies", 156], ["available", 166], ["for", 176], ["some", 180], ["of", 185], ["these", 188], ["conditions", 194], ["modulate", 205], ["the", 214], ["activity", 218], ["of", 227], ["osteoclasts", 230], ["and/or", 242], ["osteoblasts", 249], [".", 260], ["The", 262], ["recent", 266], ["discoveries", 273], ["of", 285], ["receptor", 288], ["activator", 297], ["of", 307], ["NF", 310], ["-", 312], ["kappaB", 313], ["ligand", 320], ["(", 327], ["RANKL", 328], [")", 333], [",", 334], ["an", 336], ["endogenous", 339], ["activator", 350], ["of", 360], ["osteoclastogenenesis", 363], ["and", 384], ["osteoclast", 388], ["activity", 399], ["and", 408], ["its", 412], ["inhibitor", 416], [",", 425], ["osteoprotegerin", 427], ["(", 443], ["OPG", 444], [")", 447], ["as", 449], ["pivotal", 452], ["regulatory", 460], ["factors", 471], ["in", 479], ["the", 482], ["pathogenesis", 486], ["of", 499], ["bone", 502], ["diseases", 507], ["like", 516], ["osteoporosis", 521], ["provide", 534], ["unique", 542], ["targets", 549], ["for", 557], ["therapeutic", 561], ["agents", 573], [".", 579], ["In", 581], ["laboratory", 584], ["animals", 595], ["and", 603], ["now", 607], ["in", 611], ["humans", 614], [",", 620], ["administering", 622], ["forms", 636], ["of", 642], ["OPG", 645], ["markedly", 649], ["inhibits", 658], ["osteoclast", 667], ["activity", 678], ["and", 687], ["improves", 691], ["bone", 700], ["strength", 705], [",", 713], ["documenting", 715], ["that", 727], ["the", 732], ["strategy", 736], ["of", 745], ["inhibiting", 748], ["RANKL", 759], ["activity", 765], ["has", 774], ["therapeutic", 778], ["promise", 790], [".", 797], ["A", 799], ["highly", 801], ["specific", 808], [",", 816], ["fully", 818], ["human", 824], ["antibody", 830], ["against", 839], ["RANKL", 847], ["has", 853], ["been", 857], ["produced", 862], ["(", 871], ["denosumab", 872], [")", 881], ["that", 883], ["in", 888], ["early", 891], ["studies", 897], ["in", 905], ["humans", 908], ["reduces", 915], ["bone", 923], ["turnover", 928], ["and", 937], ["improves", 941], ["bone", 950], ["density", 955], [".", 962], ["Attributes", 964], ["of", 975], ["denosumab", 978], ["in", 988], ["these", 991], ["clinical", 997], ["studies", 1006], ["include", 1014], ["a", 1022], ["very", 1024], ["rapid", 1029], ["onset", 1035], ["of", 1041], ["action", 1044], [",", 1050], ["sustained", 1052], ["effects", 1062], ["for", 1070], ["several", 1074], ["months", 1082], ["after", 1089], ["a", 1095], ["single", 1097], ["injection", 1104], [",", 1113], ["and", 1115], ["good", 1119], ["tolerability", 1124], [".", 1136], ["These", 1138], ["results", 1144], ["provide", 1152], ["the", 1160], ["basis", 1164], ["for", 1170], ["studies", 1174], ["evaluating", 1182], ["the", 1193], ["effectiveness", 1197], ["of", 1211], ["denosumab", 1214], ["in", 1224], ["several", 1227], ["clinical", 1235], ["conditions", 1244], ["characterized", 1255], ["by", 1269], ["increased", 1272], ["osteoclastic", 1282], ["activity", 1295], [".", 1303]]}
{"context": "When cDNA containing proteins enriched in the bovine cerebellar cortex were cloned, a clone which seemed to encode a selenoprotein P-like protein was isolated. The coding nucleotide sequence of its cDNA insert displayed high homology to rat and human selenoprotein P cDNA but contained 12 rather than 10 TGAs (12 rather than 10 selenocysteines in deduced amino acids), a tandem repeat of one CACTCC (His-Ser) and seven CATCCCs (His-Pro), and a 3' untranslated region approximately 890 bases shorter than that of rat liver selenoprotein P. RT-PCR using a set of primers flanking to the repeat displayed the existence of mRNA without the repeat. The tandem repeat and its adjacent region consisted of a similar motif of CAC/TCC/AC/T. Thus, these proteins included a (His-Pro) rich domain with a slightly negative free energy change irrespective of having the tandem repeat or not. Such His-Pro repeats reportedly exist in the segmentation gene paired or homeobox protein Om(1D) of Drosophila. Moreover, both this selenoprotein P-like protein mRNA and selenoprotein P mRNA were expressed in all the areas of the brain but most prominently in the cerebellar cortex, hippocampus, and olfactory bulb. These findings suggest the possibility that these selenoproteins are major selenium carriers in the brain and play a role in the morphological response of nerve or glial cells.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "ac71a6d1dc574af19a94520c1b63208d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[20, 21], [100, 101], [196, 197], [43, 44], [203, 204]], "char_spans": [[117, 131], [522, 537], [1011, 1025], [251, 265], [1049, 1063]]}]}], "context_tokens": [["When", 0], ["cDNA", 5], ["containing", 10], ["proteins", 21], ["enriched", 30], ["in", 39], ["the", 42], ["bovine", 46], ["cerebellar", 53], ["cortex", 64], ["were", 71], ["cloned", 76], [",", 82], ["a", 84], ["clone", 86], ["which", 92], ["seemed", 98], ["to", 105], ["encode", 108], ["a", 115], ["selenoprotein", 117], ["P", 131], ["-", 132], ["like", 133], ["protein", 138], ["was", 146], ["isolated", 150], [".", 158], ["The", 160], ["coding", 164], ["nucleotide", 171], ["sequence", 182], ["of", 191], ["its", 194], ["cDNA", 198], ["insert", 203], ["displayed", 210], ["high", 220], ["homology", 225], ["to", 234], ["rat", 237], ["and", 241], ["human", 245], ["selenoprotein", 251], ["P", 265], ["cDNA", 267], ["but", 272], ["contained", 276], ["12", 286], ["rather", 289], ["than", 296], ["10", 301], ["TGAs", 304], ["(", 309], ["12", 310], ["rather", 313], ["than", 320], ["10", 325], ["selenocysteines", 328], ["in", 344], ["deduced", 347], ["amino", 355], ["acids", 361], [")", 366], [",", 367], ["a", 369], ["tandem", 371], ["repeat", 378], ["of", 385], ["one", 388], ["CACTCC", 392], ["(", 399], ["His", 400], ["-", 403], ["Ser", 404], [")", 407], ["and", 409], ["seven", 413], ["CATCCCs", 419], ["(", 427], ["His", 428], ["-", 431], ["Pro", 432], [")", 435], [",", 436], ["and", 438], ["a", 442], ["3", 444], ["'", 445], ["untranslated", 447], ["region", 460], ["approximately", 467], ["890", 481], ["bases", 485], ["shorter", 491], ["than", 499], ["that", 504], ["of", 509], ["rat", 512], ["liver", 516], ["selenoprotein", 522], ["P.", 536], ["RT", 539], ["-", 541], ["PCR", 542], ["using", 546], ["a", 552], ["set", 554], ["of", 558], ["primers", 561], ["flanking", 569], ["to", 578], ["the", 581], ["repeat", 585], ["displayed", 592], ["the", 602], ["existence", 606], ["of", 616], ["mRNA", 619], ["without", 624], ["the", 632], ["repeat", 636], [".", 642], ["The", 644], ["tandem", 648], ["repeat", 655], ["and", 662], ["its", 666], ["adjacent", 670], ["region", 679], ["consisted", 686], ["of", 696], ["a", 699], ["similar", 701], ["motif", 709], ["of", 715], ["CAC", 718], ["/", 721], ["TCC", 722], ["/", 725], ["AC", 726], ["/", 728], ["T.", 729], ["Thus", 732], [",", 736], ["these", 738], ["proteins", 744], ["included", 753], ["a", 762], ["(", 764], ["His", 765], ["-", 768], ["Pro", 769], [")", 772], ["rich", 774], ["domain", 779], ["with", 786], ["a", 791], ["slightly", 793], ["negative", 802], ["free", 811], ["energy", 816], ["change", 823], ["irrespective", 830], ["of", 843], ["having", 846], ["the", 853], ["tandem", 857], ["repeat", 864], ["or", 871], ["not", 874], [".", 877], ["Such", 879], ["His", 884], ["-", 887], ["Pro", 888], ["repeats", 892], ["reportedly", 900], ["exist", 911], ["in", 917], ["the", 920], ["segmentation", 924], ["gene", 937], ["paired", 942], ["or", 949], ["homeobox", 952], ["protein", 961], ["Om(1D", 969], [")", 974], ["of", 976], ["Drosophila", 979], [".", 989], ["Moreover", 991], [",", 999], ["both", 1001], ["this", 1006], ["selenoprotein", 1011], ["P", 1025], ["-", 1026], ["like", 1027], ["protein", 1032], ["mRNA", 1040], ["and", 1045], ["selenoprotein", 1049], ["P", 1063], ["mRNA", 1065], ["were", 1070], ["expressed", 1075], ["in", 1085], ["all", 1088], ["the", 1092], ["areas", 1096], ["of", 1102], ["the", 1105], ["brain", 1109], ["but", 1115], ["most", 1119], ["prominently", 1124], ["in", 1136], ["the", 1139], ["cerebellar", 1143], ["cortex", 1154], [",", 1160], ["hippocampus", 1162], [",", 1173], ["and", 1175], ["olfactory", 1179], ["bulb", 1189], [".", 1193], ["These", 1195], ["findings", 1201], ["suggest", 1210], ["the", 1218], ["possibility", 1222], ["that", 1234], ["these", 1239], ["selenoproteins", 1245], ["are", 1260], ["major", 1264], ["selenium", 1270], ["carriers", 1279], ["in", 1288], ["the", 1291], ["brain", 1295], ["and", 1301], ["play", 1305], ["a", 1310], ["role", 1312], ["in", 1317], ["the", 1320], ["morphological", 1324], ["response", 1338], ["of", 1347], ["nerve", 1350], ["or", 1356], ["glial", 1359], ["cells", 1365], [".", 1370]]}
{"context": "To elucidate the phenotype, genotype, and MRI findings of Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mutation carriers. The authors studied 40 members of nine unrelated Korean CADASIL families. After genetic analysis of Notch3, clinical and MRI findings were correlated in 27 mutation carriers. Notch3 mutation sites were C174R (one family, n = 3), R133C (one family, n = 3), R587C (one family, n = 1), R544C (two families, n = 5), and R75P (four families, n = 15). The clinical features were typical of CADASIL, but the frequency of migraine in the Korean population appears low. MRI abnormalities were found in 54% of the mutant carriers, the most common being white matter hyperintensities. The prevalence of lacunes and microbleeds increased with patient age. Anterior temporal areas were less often involved in subjects with R75P mutations than in those where mutations occurred in other sites (p = 0.02). Gradient echo imaging identified microbleedings in 33% of mutation carriers (64% of those with abnormal MRI), whereas diffusion-weighted MRI showed abnormal findings in only one patient. Neurologic disability was related to the number of lacunar infarcts and the lesion volume of white matter hyperintensities (p < 0.001) whereas MMSE score was related to the number of lacunar infarcts (p < 0.005). Although Korean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutation carriers show similar clinical and MRI findings, these abnormalities appear less frequently than in other populations. Relatively frequent microbleedings on gradient echo imaging suggest that treatment should be individualized according to MRI findings. The novel mutation of R75P, not involving a cysteine residue, is related to less frequent involvement of the anterior temporal area, thus broadening the spectrum of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "ea472668bef643f08d9793d914e6370d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[326, 326]], "char_spans": [[1818, 1825]]}]}], "context_tokens": [["To", 0], ["elucidate", 3], ["the", 13], ["phenotype", 17], [",", 26], ["genotype", 28], [",", 36], ["and", 38], ["MRI", 42], ["findings", 46], ["of", 55], ["Korean", 58], ["patients", 65], ["with", 74], ["cerebral", 79], ["autosomal", 88], ["dominant", 98], ["arteriopathy", 107], ["with", 120], ["subcortical", 125], ["infarcts", 137], ["and", 146], ["leukoencephalopathy", 150], ["(", 170], ["CADASIL", 171], [")", 178], ["and", 180], ["mutation", 184], ["carriers", 193], [".", 201], ["The", 203], ["authors", 207], ["studied", 215], ["40", 223], ["members", 226], ["of", 234], ["nine", 237], ["unrelated", 242], ["Korean", 252], ["CADASIL", 259], ["families", 267], [".", 275], ["After", 277], ["genetic", 283], ["analysis", 291], ["of", 300], ["Notch3", 303], [",", 309], ["clinical", 311], ["and", 320], ["MRI", 324], ["findings", 328], ["were", 337], ["correlated", 342], ["in", 353], ["27", 356], ["mutation", 359], ["carriers", 368], [".", 376], ["Notch3", 378], ["mutation", 385], ["sites", 394], ["were", 400], ["C174R", 405], ["(", 411], ["one", 412], ["family", 416], [",", 422], ["n", 424], ["=", 426], ["3", 428], [")", 429], [",", 430], ["R133C", 432], ["(", 438], ["one", 439], ["family", 443], [",", 449], ["n", 451], ["=", 453], ["3", 455], [")", 456], [",", 457], ["R587C", 459], ["(", 465], ["one", 466], ["family", 470], [",", 476], ["n", 478], ["=", 480], ["1", 482], [")", 483], [",", 484], ["R544C", 486], ["(", 492], ["two", 493], ["families", 497], [",", 505], ["n", 507], ["=", 509], ["5", 511], [")", 512], [",", 513], ["and", 515], ["R75P", 519], ["(", 524], ["four", 525], ["families", 530], [",", 538], ["n", 540], ["=", 542], ["15", 544], [")", 546], [".", 547], ["The", 549], ["clinical", 553], ["features", 562], ["were", 571], ["typical", 576], ["of", 584], ["CADASIL", 587], [",", 594], ["but", 596], ["the", 600], ["frequency", 604], ["of", 614], ["migraine", 617], ["in", 626], ["the", 629], ["Korean", 633], ["population", 640], ["appears", 651], ["low", 659], [".", 662], ["MRI", 664], ["abnormalities", 668], ["were", 682], ["found", 687], ["in", 693], ["54", 696], ["%", 698], ["of", 700], ["the", 703], ["mutant", 707], ["carriers", 714], [",", 722], ["the", 724], ["most", 728], ["common", 733], ["being", 740], ["white", 746], ["matter", 752], ["hyperintensities", 759], [".", 775], ["The", 777], ["prevalence", 781], ["of", 792], ["lacunes", 795], ["and", 803], ["microbleeds", 807], ["increased", 819], ["with", 829], ["patient", 834], ["age", 842], [".", 845], ["Anterior", 847], ["temporal", 856], ["areas", 865], ["were", 871], ["less", 876], ["often", 881], ["involved", 887], ["in", 896], ["subjects", 899], ["with", 908], ["R75P", 913], ["mutations", 918], ["than", 928], ["in", 933], ["those", 936], ["where", 942], ["mutations", 948], ["occurred", 958], ["in", 967], ["other", 970], ["sites", 976], ["(", 982], ["p", 983], ["=", 985], ["0.02", 987], [")", 991], [".", 992], ["Gradient", 994], ["echo", 1003], ["imaging", 1008], ["identified", 1016], ["microbleedings", 1027], ["in", 1042], ["33", 1045], ["%", 1047], ["of", 1049], ["mutation", 1052], ["carriers", 1061], ["(", 1070], ["64", 1071], ["%", 1073], ["of", 1075], ["those", 1078], ["with", 1084], ["abnormal", 1089], ["MRI", 1098], [")", 1101], [",", 1102], ["whereas", 1104], ["diffusion", 1112], ["-", 1121], ["weighted", 1122], ["MRI", 1131], ["showed", 1135], ["abnormal", 1142], ["findings", 1151], ["in", 1160], ["only", 1163], ["one", 1168], ["patient", 1172], [".", 1179], ["Neurologic", 1181], ["disability", 1192], ["was", 1203], ["related", 1207], ["to", 1215], ["the", 1218], ["number", 1222], ["of", 1229], ["lacunar", 1232], ["infarcts", 1240], ["and", 1249], ["the", 1253], ["lesion", 1257], ["volume", 1264], ["of", 1271], ["white", 1274], ["matter", 1280], ["hyperintensities", 1287], ["(", 1304], ["p", 1305], ["<", 1307], ["0.001", 1309], [")", 1314], ["whereas", 1316], ["MMSE", 1324], ["score", 1329], ["was", 1335], ["related", 1339], ["to", 1347], ["the", 1350], ["number", 1354], ["of", 1361], ["lacunar", 1364], ["infarcts", 1372], ["(", 1381], ["p", 1382], ["<", 1384], ["0.005", 1386], [")", 1391], [".", 1392], ["Although", 1394], ["Korean", 1403], ["cerebral", 1410], ["autosomal", 1419], ["dominant", 1429], ["arteriopathy", 1438], ["with", 1451], ["subcortical", 1456], ["infarcts", 1468], ["and", 1477], ["leukoencephalopathy", 1481], ["(", 1501], ["CADASIL", 1502], [")", 1509], ["mutation", 1511], ["carriers", 1520], ["show", 1529], ["similar", 1534], ["clinical", 1542], ["and", 1551], ["MRI", 1555], ["findings", 1559], [",", 1567], ["these", 1569], ["abnormalities", 1575], ["appear", 1589], ["less", 1596], ["frequently", 1601], ["than", 1612], ["in", 1617], ["other", 1620], ["populations", 1626], [".", 1637], ["Relatively", 1639], ["frequent", 1650], ["microbleedings", 1659], ["on", 1674], ["gradient", 1677], ["echo", 1686], ["imaging", 1691], ["suggest", 1699], ["that", 1707], ["treatment", 1712], ["should", 1722], ["be", 1729], ["individualized", 1732], ["according", 1747], ["to", 1757], ["MRI", 1760], ["findings", 1764], [".", 1772], ["The", 1774], ["novel", 1778], ["mutation", 1784], ["of", 1793], ["R75P", 1796], [",", 1800], ["not", 1802], ["involving", 1806], ["a", 1816], ["cysteine", 1818], ["residue", 1827], [",", 1834], ["is", 1836], ["related", 1839], ["to", 1847], ["less", 1850], ["frequent", 1855], ["involvement", 1864], ["of", 1876], ["the", 1879], ["anterior", 1883], ["temporal", 1892], ["area", 1901], [",", 1905], ["thus", 1907], ["broadening", 1912], ["the", 1923], ["spectrum", 1927], ["of", 1936], ["CADASIL", 1939], [".", 1946]]}
{"context": "Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "7084fb7065f745f3870b1046a517cc3a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[231, 233], [199, 201], [93, 95], [186, 188], [153, 155], [112, 114], [75, 77]], "char_spans": [[1279, 1284], [1087, 1092], [628, 633], [1028, 1033], [869, 874], [704, 709], [550, 555]]}]}], "context_tokens": [["Clozapine", 0], ["reduces", 10], ["L-3,4-dihydroxyphenylalanine", 18], ["(", 47], ["L", 48], ["-", 49], ["Dopa)-induced", 50], ["dyskinesias", 64], ["in", 76], ["parkinsonian", 79], ["patients", 92], [".", 100], ["To", 102], ["test", 105], ["if", 110], ["the", 113], ["antidyskinetic", 117], ["effect", 132], ["of", 139], ["clozapine", 142], ["is", 152], ["related", 155], ["to", 163], ["antagonism", 166], ["at", 177], ["the", 180], ["dopamine", 184], ["D(4", 193], [")", 196], ["receptor", 198], [",", 206], ["we", 208], ["investigated", 211], ["the", 224], ["effect", 228], ["of", 235], ["8-methyl-6-(4-methyl-1-piperazinyl)-11H", 238], ["-", 277], ["pyrido[2,3-b][1", 278], [",", 293], ["4]benzodiazepine", 295], ["(", 312], ["JL-18", 313], [")", 318], [",", 319], ["a", 321], ["structural", 323], ["analog", 334], ["of", 341], ["clozapine", 344], ["which", 354], ["is", 360], ["more", 363], ["selective", 368], ["for", 378], ["this", 382], ["receptor", 387], [".", 395], ["Four", 397], ["1-methyl-4-phenyl-1,2,3", 402], [",", 425], ["6-tetrahydropyridine", 427], ["(", 448], ["MPTP)-treated", 449], ["cynomolgus", 463], ["monkeys", 474], ["with", 482], ["a", 487], ["stable", 489], ["parkinsonian", 496], ["syndrome", 509], ["and", 518], ["reproducible", 522], ["dyskinesias", 535], ["to", 547], ["L", 550], ["-", 551], ["Dopa", 552], ["were", 557], ["used", 562], ["in", 567], ["this", 570], ["study", 575], [".", 580], ["They", 582], ["were", 587], ["injected", 592], ["subcutaneously", 601], ["(", 616], ["s.c", 617], [".", 620], [")", 621], ["with", 623], ["L", 628], ["-", 629], ["Dopa", 630], ["methyl", 635], ["ester", 642], ["(", 648], ["125", 649], ["mg", 653], ["per", 656], ["animal", 660], [")", 666], ["plus", 668], ["benserazide", 673], ["(", 685], ["50", 686], ["mg", 689], ["per", 692], ["animal", 696], [";", 702], ["L", 704], ["-", 705], ["Dopa", 706], ["/", 710], ["benserazide", 711], [")", 722], ["alone", 724], ["or", 730], ["in", 733], ["combination", 736], ["with", 748], ["JL-18", 753], ["(", 759], ["at", 760], ["the", 763], ["doses", 767], ["of", 773], ["0.1", 776], [",", 779], ["0.3", 781], [",", 784], ["or", 786], ["0.9", 789], ["mg", 793], ["/", 795], ["kg", 796], [",", 798], ["s.c", 800], [".", 803], [")", 804], [".", 805], ["Subcutaneous", 807], ["injection", 820], ["of", 830], ["sterile", 833], ["saline", 841], ["was", 848], ["used", 852], ["as", 857], ["control", 860], [".", 867], ["L", 869], ["-", 870], ["Dopa", 871], ["/", 875], ["benserazide", 876], ["increased", 888], ["locomotion", 898], ["and", 909], ["improved", 913], ["parkinsonism", 922], ["but", 935], ["also", 939], ["induced", 944], ["dyskinesias", 952], [".", 963], ["Co", 965], ["-", 967], ["administration", 968], ["of", 983], ["JL-18", 986], [",", 991], ["at", 993], ["low", 996], ["doses", 1000], ["(", 1006], ["0.1", 1007], [",", 1010], ["0.3", 1012], ["mg", 1016], ["/", 1018], ["kg", 1019], [")", 1021], ["with", 1023], ["L", 1028], ["-", 1029], ["Dopa", 1030], ["/", 1034], ["benserazide", 1035], [",", 1046], ["produced", 1048], ["a", 1057], ["dose", 1059], ["-", 1063], ["dependent", 1064], ["reduction", 1074], ["in", 1084], ["L", 1087], ["-", 1088], ["Dopa", 1089], ["-", 1093], ["induced", 1094], ["dyskinesias", 1102], ["without", 1114], ["a", 1122], ["parallel", 1124], ["return", 1133], ["to", 1140], ["parkinsonism", 1143], [".", 1155], ["The", 1157], ["present", 1161], ["results", 1169], ["suggest", 1177], ["that", 1185], ["novel", 1190], ["selective", 1196], ["dopamine", 1206], ["D(4", 1215], [")", 1218], ["receptor", 1220], ["antagonists", 1229], ["may", 1241], ["represent", 1245], ["a", 1255], ["useful", 1257], ["tool", 1264], ["to", 1269], ["reduce", 1272], ["L", 1279], ["-", 1280], ["Dopa", 1281], ["-", 1285], ["induced", 1286], ["dyskinesias", 1294], [".", 1305]]}
{"context": "Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with over 1400 mutations identified in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Mutations in the CFTR gene may be also causative for CBAVD (Congenital Bilateral Absence of the Vas Deferens). The type and distribution of mutations varies widely between different countries and/or ethnic groups, and is relatively unknown in Iran. We therefore performed a comprehensive analysis of the CFTR gene in Iranian CF patients. 69 Iranian CF patients, and 1 CBAVD patient, were analysed for mutations in the complete coding region, and its exon/intron junctions, of their CFTR genes, using different methods, such as ARMS (amplification refractory mutation system)-PCR, SSCP (single stranded conformation polymorphism) analysis, restriction enzyme digestion analysis, direct sequencing, and MLPA (Multiplex Ligation-mediated Probe Amplification). CFTR mutation analysis revealed the identification of 37 mutations in 69 Iranian CF patients. Overall, 81.9% (113/138) CFTR genes derived from Iranian CF patients could be characterized for a disease-causing mutation. The CBAVD patient was found to be homozygous for the p.W1145R mutation. The most common mutations were p.F508del (DeltaF508) (18.1%), c.2183_2184delAAinsG (2183AA>G) (6.5%), p.S466X (5.8%), p.N1303K (4.3%), c.2789+5G>A (4.3%), p.G542X (3.6%), c.3120+1G>A (3.6%), p.R334W (2.9%) and c.3130delA (2.9%). These 9 types of mutant CFTR genes totaled for 52% of all CFTR genes derived from the 69 Iranian CF patients. Eight mutations, c.406-8T>C, p.A566D, c.2576delA, c.2752-1_2756delGGTGGCinsTTG, p.T1036I, p.W1145R, c.3850-24G>A, c.1342-?_1524+?del, were found for the first time in this study. We identified 37 CFTR mutations in 69 well characterized Iranian CF patients, obtaining a CFTR mutation detection rate of 81.9%, the highest detection rate obtained in the Iranian population so far. These findings will assist in genetic counseling, prenatal diagnosis and future screening of CF in Iran.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "721f570c564a469791dc784b8d46492b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[226, 226]], "char_spans": [[1282, 1290]]}]}], "context_tokens": [["Cystic", 0], ["fibrosis", 7], ["(", 16], ["CF", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["inherited", 40], ["disorder", 50], ["in", 59], ["Caucasian", 62], ["populations", 72], [",", 83], ["with", 85], ["over", 90], ["1400", 95], ["mutations", 100], ["identified", 110], ["in", 121], ["the", 124], ["Cystic", 128], ["Fibrosis", 135], ["Transmembrane", 144], ["conductance", 158], ["Regulator", 170], ["(", 180], ["CFTR", 181], [")", 185], ["gene", 187], [".", 191], ["Mutations", 193], ["in", 203], ["the", 206], ["CFTR", 210], ["gene", 215], ["may", 220], ["be", 224], ["also", 227], ["causative", 232], ["for", 242], ["CBAVD", 246], ["(", 252], ["Congenital", 253], ["Bilateral", 264], ["Absence", 274], ["of", 282], ["the", 285], ["Vas", 289], ["Deferens", 293], [")", 301], [".", 302], ["The", 304], ["type", 308], ["and", 313], ["distribution", 317], ["of", 330], ["mutations", 333], ["varies", 343], ["widely", 350], ["between", 357], ["different", 365], ["countries", 375], ["and/or", 385], ["ethnic", 392], ["groups", 399], [",", 405], ["and", 407], ["is", 411], ["relatively", 414], ["unknown", 425], ["in", 433], ["Iran", 436], [".", 440], ["We", 442], ["therefore", 445], ["performed", 455], ["a", 465], ["comprehensive", 467], ["analysis", 481], ["of", 490], ["the", 493], ["CFTR", 497], ["gene", 502], ["in", 507], ["Iranian", 510], ["CF", 518], ["patients", 521], [".", 529], ["69", 531], ["Iranian", 534], ["CF", 542], ["patients", 545], [",", 553], ["and", 555], ["1", 559], ["CBAVD", 561], ["patient", 567], [",", 574], ["were", 576], ["analysed", 581], ["for", 590], ["mutations", 594], ["in", 604], ["the", 607], ["complete", 611], ["coding", 620], ["region", 627], [",", 633], ["and", 635], ["its", 639], ["exon", 643], ["/", 647], ["intron", 648], ["junctions", 655], [",", 664], ["of", 666], ["their", 669], ["CFTR", 675], ["genes", 680], [",", 685], ["using", 687], ["different", 693], ["methods", 703], [",", 710], ["such", 712], ["as", 717], ["ARMS", 720], ["(", 725], ["amplification", 726], ["refractory", 740], ["mutation", 751], ["system)-PCR", 760], [",", 771], ["SSCP", 773], ["(", 778], ["single", 779], ["stranded", 786], ["conformation", 795], ["polymorphism", 808], [")", 820], ["analysis", 822], [",", 830], ["restriction", 832], ["enzyme", 844], ["digestion", 851], ["analysis", 861], [",", 869], ["direct", 871], ["sequencing", 878], [",", 888], ["and", 890], ["MLPA", 894], ["(", 899], ["Multiplex", 900], ["Ligation", 910], ["-", 918], ["mediated", 919], ["Probe", 928], ["Amplification", 934], [")", 947], [".", 948], ["CFTR", 950], ["mutation", 955], ["analysis", 964], ["revealed", 973], ["the", 982], ["identification", 986], ["of", 1001], ["37", 1004], ["mutations", 1007], ["in", 1017], ["69", 1020], ["Iranian", 1023], ["CF", 1031], ["patients", 1034], [".", 1042], ["Overall", 1044], [",", 1051], ["81.9", 1053], ["%", 1057], ["(", 1059], ["113/138", 1060], [")", 1067], ["CFTR", 1069], ["genes", 1074], ["derived", 1080], ["from", 1088], ["Iranian", 1093], ["CF", 1101], ["patients", 1104], ["could", 1113], ["be", 1119], ["characterized", 1122], ["for", 1136], ["a", 1140], ["disease", 1142], ["-", 1149], ["causing", 1150], ["mutation", 1158], [".", 1166], ["The", 1168], ["CBAVD", 1172], ["patient", 1178], ["was", 1186], ["found", 1190], ["to", 1196], ["be", 1199], ["homozygous", 1202], ["for", 1213], ["the", 1217], ["p", 1221], [".", 1222], ["W1145R", 1223], ["mutation", 1230], [".", 1238], ["The", 1240], ["most", 1244], ["common", 1249], ["mutations", 1256], ["were", 1266], ["p", 1271], [".", 1272], ["F508del", 1273], ["(", 1281], ["DeltaF508", 1282], [")", 1291], ["(", 1293], ["18.1", 1294], ["%", 1298], [")", 1299], [",", 1300], ["c.2183_2184delAAinsG", 1302], ["(", 1323], ["2183AA", 1324], [">", 1330], ["G", 1331], [")", 1332], ["(", 1334], ["6.5", 1335], ["%", 1338], [")", 1339], [",", 1340], ["p", 1342], [".", 1343], ["S466X", 1344], ["(", 1350], ["5.8", 1351], ["%", 1354], [")", 1355], [",", 1356], ["p", 1358], [".", 1359], ["N1303", 1360], ["K", 1365], ["(", 1367], ["4.3", 1368], ["%", 1371], [")", 1372], [",", 1373], ["c.2789", 1375], ["+", 1381], ["5G", 1382], [">", 1384], ["A", 1385], ["(", 1387], ["4.3", 1388], ["%", 1391], [")", 1392], [",", 1393], ["p", 1395], [".", 1396], ["G542X", 1397], ["(", 1403], ["3.6", 1404], ["%", 1407], [")", 1408], [",", 1409], ["c.3120", 1411], ["+", 1417], ["1G", 1418], [">", 1420], ["A", 1421], ["(", 1423], ["3.6", 1424], ["%", 1427], [")", 1428], [",", 1429], ["p", 1431], [".", 1432], ["R334W", 1433], ["(", 1439], ["2.9", 1440], ["%", 1443], [")", 1444], ["and", 1446], ["c.3130delA", 1450], ["(", 1461], ["2.9", 1462], ["%", 1465], [")", 1466], [".", 1467], ["These", 1469], ["9", 1475], ["types", 1477], ["of", 1483], ["mutant", 1486], ["CFTR", 1493], ["genes", 1498], ["totaled", 1504], ["for", 1512], ["52", 1516], ["%", 1518], ["of", 1520], ["all", 1523], ["CFTR", 1527], ["genes", 1532], ["derived", 1538], ["from", 1546], ["the", 1551], ["69", 1555], ["Iranian", 1558], ["CF", 1566], ["patients", 1569], [".", 1577], ["Eight", 1579], ["mutations", 1585], [",", 1594], ["c.406", 1596], ["-", 1601], ["8T", 1602], [">", 1604], ["C", 1605], [",", 1606], ["p", 1608], [".", 1609], ["A566D", 1610], [",", 1615], ["c.2576delA", 1617], [",", 1627], ["c.2752", 1629], ["-", 1635], ["1_2756delGGTGGCinsTTG", 1636], [",", 1657], ["p", 1659], [".", 1660], ["T1036I", 1661], [",", 1667], ["p", 1669], [".", 1670], ["W1145R", 1671], [",", 1677], ["c.3850", 1679], ["-", 1685], ["24G", 1686], [">", 1689], ["A", 1690], [",", 1691], ["c.1342-?_1524+?del", 1693], [",", 1711], ["were", 1713], ["found", 1718], ["for", 1724], ["the", 1728], ["first", 1732], ["time", 1738], ["in", 1743], ["this", 1746], ["study", 1751], [".", 1756], ["We", 1758], ["identified", 1761], ["37", 1772], ["CFTR", 1775], ["mutations", 1780], ["in", 1790], ["69", 1793], ["well", 1796], ["characterized", 1801], ["Iranian", 1815], ["CF", 1823], ["patients", 1826], [",", 1834], ["obtaining", 1836], ["a", 1846], ["CFTR", 1848], ["mutation", 1853], ["detection", 1862], ["rate", 1872], ["of", 1877], ["81.9", 1880], ["%", 1884], [",", 1885], ["the", 1887], ["highest", 1891], ["detection", 1899], ["rate", 1909], ["obtained", 1914], ["in", 1923], ["the", 1926], ["Iranian", 1930], ["population", 1938], ["so", 1949], ["far", 1952], [".", 1955], ["These", 1957], ["findings", 1963], ["will", 1972], ["assist", 1977], ["in", 1984], ["genetic", 1987], ["counseling", 1995], [",", 2005], ["prenatal", 2007], ["diagnosis", 2016], ["and", 2026], ["future", 2030], ["screening", 2037], ["of", 2047], ["CF", 2050], ["in", 2053], ["Iran", 2056], [".", 2060]]}
{"context": "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10\u00a0days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p\u00a0\u2264\u00a00.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p\u00a0=\u00a00.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "38addabed56946b49d470b639537d475", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[11, 12]], "char_spans": [[63, 74]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["infection", 37], ["(", 47], ["CDI", 48], [")", 51], ["caused", 53], ["by", 60], ["ribotype", 63], ["027", 72], ["(", 76], ["B1/NAP1", 77], [")", 84], ["began", 86], ["in", 92], ["our", 95], ["hospital", 99], ["in", 108], ["November", 111], ["2014", 120], [",", 124], ["and", 126], ["produced", 130], ["141", 139], ["episodes", 143], ["in", 152], ["the", 155], ["following", 159], ["months", 169], [".", 175], ["The", 177], ["aim", 181], ["of", 185], ["this", 188], ["study", 193], ["is", 199], ["to", 202], ["describe", 205], ["this", 214], ["outbreak", 219], [",", 227], ["assess", 229], ["risk", 236], ["factors", 241], ["for", 249], ["recurrence", 253], ["of", 264], ["CDI-027", 267], ["and", 275], ["to", 279], ["analyze", 282], ["the", 290], ["implementation", 294], ["of", 309], ["a", 312], ["novel", 314], ["treatment", 320], ["strategy", 330], [".", 338], ["This", 340], ["is", 345], ["a", 348], ["prospective", 350], ["study", 362], ["of", 368], ["all", 371], ["patients", 375], ["with", 384], ["CDI-027", 389], [",", 396], ["from", 398], ["November", 403], ["2014", 412], ["to", 417], ["November", 420], ["2015", 429], [".", 433], ["The", 435], ["epidemiological", 439], ["data", 455], ["were", 460], ["collected", 465], ["daily", 475], ["for", 481], ["each", 485], ["patient", 490], [".", 497], ["We", 499], ["compared", 502], ["clinical", 511], ["characteristics", 520], ["and", 536], ["treatment", 540], ["between", 550], ["patients", 558], ["with", 567], ["and", 572], ["without", 576], ["recurrence", 584], ["of", 595], ["CDI-027", 598], [".", 605], ["Interestingly", 607], [",", 620], ["liver", 622], ["cirrhosis", 628], ["was", 638], ["present", 642], ["in", 650], ["22", 653], ["%", 655], ["of", 657], ["the", 660], ["patients", 664], [",", 672], ["and", 674], ["most", 678], ["of", 683], ["them", 686], ["received", 691], ["prophylaxis", 700], ["for", 712], ["hepatic", 716], ["encephalopathy", 724], ["with", 739], ["rifaximin", 744], [".", 753], ["Patients", 755], ["were", 764], ["also", 769], ["taking", 774], ["antimicrobial", 781], ["drugs", 795], ["(", 801], ["93.6", 802], ["%", 806], [")", 807], ["and", 809], ["proton", 813], ["pump", 820], ["inhibitors", 825], ["(", 836], ["80.1", 837], ["%", 841], [")", 842], [".", 843], ["Overall", 845], [",", 852], ["27", 854], ["(", 857], ["23.5", 858], ["%", 862], [")", 863], ["patients", 865], ["had", 874], ["a", 878], ["first", 880], ["recurrence", 886], ["of", 897], ["CDI-027", 900], [".", 907], ["Liver", 909], ["cirrhosis", 915], ["increased", 925], ["the", 935], ["risk", 939], ["of", 944], ["recurrence", 947], ["(", 958], ["44.4", 959], ["%", 963], ["vs", 965], ["14.8", 968], ["%", 972], [")", 973], [".", 974], ["Patients", 976], ["treated", 985], ["with", 993], ["a", 998], ["prolonged", 1000], ["oral", 1010], ["vancomycin", 1015], ["regimen", 1026], ["vs", 1034], ["the", 1037], ["conventional", 1041], ["regimen", 1054], ["(", 1062], ["oral", 1063], ["metronidazole", 1068], ["or", 1082], ["10", 1085], ["days", 1088], ["of", 1093], ["vancomycin", 1096], [")", 1106], ["had", 1108], ["fewer", 1112], ["recurrences", 1118], ["(", 1130], ["8.6", 1131], ["versus", 1135], ["44.7", 1142], ["%", 1146], ["[", 1148], ["p", 1149], ["\u2264", 1151], ["0.01", 1153], ["]", 1157], [";", 1158], ["OR", 1160], [",", 1162], ["0.91", 1164], [";", 1168], ["95", 1170], ["%", 1172], ["CI", 1174], [",", 1176], ["0.028", 1178], ["-", 1183], ["0.294", 1184], [")", 1189], ["and", 1191], ["less", 1195], ["attributable", 1200], ["mortality", 1213], ["(", 1223], ["0", 1224], ["%", 1225], ["versus", 1227], ["7.1", 1234], ["%", 1237], [";", 1238], ["p", 1240], ["=", 1242], ["0.058", 1244], [")", 1249], [".", 1250], ["We", 1252], ["report", 1255], ["an", 1262], ["outbreak", 1265], ["of", 1274], ["CDI-027", 1277], [",", 1284], ["mainly", 1286], ["in", 1293], ["patients", 1296], ["with", 1305], ["liver", 1310], ["cirrhosis", 1316], [".", 1325], ["Recurrence", 1327], ["of", 1338], ["CDI-027", 1341], ["was", 1349], ["more", 1353], ["common", 1358], ["in", 1365], ["those", 1368], ["patients", 1374], [".", 1382], ["A", 1384], ["novel", 1386], ["approach", 1392], ["involving", 1401], ["high", 1411], ["-", 1415], ["dose", 1416], ["prolonged", 1421], ["vancomycin", 1431], ["taper", 1442], ["as", 1448], ["a", 1451], ["first", 1453], ["-", 1458], ["line", 1459], ["treatment", 1464], [",", 1473], ["together", 1475], ["with", 1484], ["a", 1489], ["bundle", 1491], ["of", 1498], ["outbreak", 1501], ["measures", 1510], [",", 1518], ["seemed", 1520], ["to", 1527], ["reduce", 1530], ["the", 1537], ["number", 1541], ["of", 1548], ["cases", 1551], ["of", 1557], ["CDI-027", 1560], [",", 1567], ["recurrences", 1569], [",", 1580], ["and", 1582], ["attributable", 1586], ["mortality", 1599], [".", 1608], ["Nevertheless", 1610], [",", 1622], ["this", 1624], ["approach", 1629], ["warrants", 1638], ["further", 1647], ["investigation", 1655], [".", 1668]]}
{"context": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running race. Blood was collected immediately before (Pre), upon completion/retirement (Post), and following the race at Day 1, Day 7 and Day 28. Lymphocyte lysates were examined for PRDX-2 by reducing and non-reducing SDS-PAGE with western blotting. In a sub-group of men who completed the race (n = 4), PRDX-2 oligomeric state (indicative of redox status) was investigated. Ultra-endurance exercise caused significant changes in lymphocyte PRDX-2 (F(4,32) 3.409, p = 0.020, \u03b7(2) = 0.299): 7 days after the race, PRDX-2 levels in lymphocytes had fallen to 30% of pre-race values (p = 0.013) and returned to near-normal levels at Day 28. Non-reducing gels demonstrated that dimeric PRDX-2 (intracellular reduced PRDX-2 monomers) was increased in three of four race completers immediately post-race, indicative of an 'antioxidant response'. Moreover, monomeric PRDX-2 was also increased immediately post-race in two of four race-completing subjects, indicative of oxidative damage, which was not detectable by Day 7. Lymphocyte PRDX-2 was decreased below normal levels 7 days after ultra-endurance exercise. Excessive accumulation of reactive oxygen species induced by ultra-endurance exercise may underlie depletion of lymphocyte PRDX-2 by triggering its turnover after oxidation. Low levels of lymphocyte PRDX-2 could influence cell function and might, in part, explain reports of dysregulated immunity following ultra-endurance exercise.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "5972815d8210470eb84c3da30f0aa090", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[234, 234], [6, 6]], "char_spans": [[1127, 1137], [31, 41]]}]}], "context_tokens": [["Peroxiredoxin-2", 0], ["(", 16], ["PRDX-2", 17], [")", 23], ["is", 25], ["an", 28], ["antioxidant", 31], ["and", 43], ["chaperone", 47], ["-", 56], ["like", 57], ["protein", 62], ["critical", 70], ["for", 79], ["cell", 83], ["function", 88], [".", 96], ["This", 98], ["study", 103], ["examined", 109], ["whether", 118], ["the", 126], ["levels", 130], ["of", 137], ["lymphocyte", 140], ["PRDX-2", 151], ["are", 158], ["altered", 162], ["over", 170], ["1", 175], ["month", 177], ["following", 183], ["ultra", 193], ["-", 198], ["endurance", 199], ["exercise", 209], [".", 217], ["Nine", 219], ["middle", 224], ["-", 230], ["aged", 231], ["men", 236], ["undertook", 240], ["a", 250], ["single", 252], ["-", 258], ["stage", 259], [",", 264], ["multi", 266], ["-", 271], ["day", 272], ["233", 276], ["km", 280], ["(", 283], ["145", 284], ["mile", 288], [")", 292], ["ultra", 294], ["-", 299], ["endurance", 300], ["running", 310], ["race", 318], [".", 322], ["Blood", 324], ["was", 330], ["collected", 334], ["immediately", 344], ["before", 356], ["(", 363], ["Pre", 364], [")", 367], [",", 368], ["upon", 370], ["completion", 375], ["/", 385], ["retirement", 386], ["(", 397], ["Post", 398], [")", 402], [",", 403], ["and", 405], ["following", 409], ["the", 419], ["race", 423], ["at", 428], ["Day", 431], ["1", 435], [",", 436], ["Day", 438], ["7", 442], ["and", 444], ["Day", 448], ["28", 452], [".", 454], ["Lymphocyte", 456], ["lysates", 467], ["were", 475], ["examined", 480], ["for", 489], ["PRDX-2", 493], ["by", 500], ["reducing", 503], ["and", 512], ["non", 516], ["-", 519], ["reducing", 520], ["SDS", 529], ["-", 532], ["PAGE", 533], ["with", 538], ["western", 543], ["blotting", 551], [".", 559], ["In", 561], ["a", 564], ["sub", 566], ["-", 569], ["group", 570], ["of", 576], ["men", 579], ["who", 583], ["completed", 587], ["the", 597], ["race", 601], ["(", 606], ["n", 607], ["=", 609], ["4", 611], [")", 612], [",", 613], ["PRDX-2", 615], ["oligomeric", 622], ["state", 633], ["(", 639], ["indicative", 640], ["of", 651], ["redox", 654], ["status", 660], [")", 666], ["was", 668], ["investigated", 672], [".", 684], ["Ultra", 686], ["-", 691], ["endurance", 692], ["exercise", 702], ["caused", 711], ["significant", 718], ["changes", 730], ["in", 738], ["lymphocyte", 741], ["PRDX-2", 752], ["(", 759], ["F(4,32", 760], [")", 766], ["3.409", 768], [",", 773], ["p", 775], ["=", 777], ["0.020", 779], [",", 784], ["\u03b7(2", 786], [")", 789], ["=", 791], ["0.299", 793], [")", 798], [":", 799], ["7", 801], ["days", 803], ["after", 808], ["the", 814], ["race", 818], [",", 822], ["PRDX-2", 824], ["levels", 831], ["in", 838], ["lymphocytes", 841], ["had", 853], ["fallen", 857], ["to", 864], ["30", 867], ["%", 869], ["of", 871], ["pre", 874], ["-", 877], ["race", 878], ["values", 883], ["(", 890], ["p", 891], ["=", 893], ["0.013", 895], [")", 900], ["and", 902], ["returned", 906], ["to", 915], ["near", 918], ["-", 922], ["normal", 923], ["levels", 930], ["at", 937], ["Day", 940], ["28", 944], [".", 946], ["Non", 948], ["-", 951], ["reducing", 952], ["gels", 961], ["demonstrated", 966], ["that", 979], ["dimeric", 984], ["PRDX-2", 992], ["(", 999], ["intracellular", 1000], ["reduced", 1014], ["PRDX-2", 1022], ["monomers", 1029], [")", 1037], ["was", 1039], ["increased", 1043], ["in", 1053], ["three", 1056], ["of", 1062], ["four", 1065], ["race", 1070], ["completers", 1075], ["immediately", 1086], ["post", 1098], ["-", 1102], ["race", 1103], [",", 1107], ["indicative", 1109], ["of", 1120], ["an", 1123], ["'", 1126], ["antioxidant", 1127], ["response", 1139], ["'", 1147], [".", 1148], ["Moreover", 1150], [",", 1158], ["monomeric", 1160], ["PRDX-2", 1170], ["was", 1177], ["also", 1181], ["increased", 1186], ["immediately", 1196], ["post", 1208], ["-", 1212], ["race", 1213], ["in", 1218], ["two", 1221], ["of", 1225], ["four", 1228], ["race", 1233], ["-", 1237], ["completing", 1238], ["subjects", 1249], [",", 1257], ["indicative", 1259], ["of", 1270], ["oxidative", 1273], ["damage", 1283], [",", 1289], ["which", 1291], ["was", 1297], ["not", 1301], ["detectable", 1305], ["by", 1316], ["Day", 1319], ["7", 1323], [".", 1324], ["Lymphocyte", 1326], ["PRDX-2", 1337], ["was", 1344], ["decreased", 1348], ["below", 1358], ["normal", 1364], ["levels", 1371], ["7", 1378], ["days", 1380], ["after", 1385], ["ultra", 1391], ["-", 1396], ["endurance", 1397], ["exercise", 1407], [".", 1415], ["Excessive", 1417], ["accumulation", 1427], ["of", 1440], ["reactive", 1443], ["oxygen", 1452], ["species", 1459], ["induced", 1467], ["by", 1475], ["ultra", 1478], ["-", 1483], ["endurance", 1484], ["exercise", 1494], ["may", 1503], ["underlie", 1507], ["depletion", 1516], ["of", 1526], ["lymphocyte", 1529], ["PRDX-2", 1540], ["by", 1547], ["triggering", 1550], ["its", 1561], ["turnover", 1565], ["after", 1574], ["oxidation", 1580], [".", 1589], ["Low", 1591], ["levels", 1595], ["of", 1602], ["lymphocyte", 1605], ["PRDX-2", 1616], ["could", 1623], ["influence", 1629], ["cell", 1639], ["function", 1644], ["and", 1653], ["might", 1657], [",", 1662], ["in", 1664], ["part", 1667], [",", 1671], ["explain", 1673], ["reports", 1681], ["of", 1689], ["dysregulated", 1692], ["immunity", 1705], ["following", 1714], ["ultra", 1724], ["-", 1729], ["endurance", 1730], ["exercise", 1740], [".", 1748]]}
{"context": "Tuberculosis is responsible for more then 2 million deaths worldwide each year and vies with HIV as the world's most fatal infectious disease. In many developing countries, attempts to control the spread of infection rely solely on identification and treatment of those with active disease, ignoring subclinical infection. However, in developed countries, large efforts are also expended to identify and give prophylactic drugs to people with latent tuberculosis infection. Until recently, the 100-year-old tuberculin skin test (Mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations. Advances in scientific knowledge have led to the development of tests for tuberculosis that measure the production of interferon-gamma by T-cells stimulated in vitro with Mycobacterium tuberculosis-specific antigens. These interferon-gamma tests are highly specific and unaffected by prior Bacille Calmette-Gu\u00e9rin vaccination or immune reactivity to most atypical mycobacteria. They are more sensitive than the tuberculin skin test in detecting people with active tuberculosis, and their results correlate more closely with M. tuberculosis exposure risk factors than the tuberculin skin test in people likely to have latent tuberculosis infection. Science has caught up with one of the oldest diagnostic tests still in use worldwide, and the adoption of new, tuberculosis-specific interferon-gamma-based tests should move us one step closer to better control of this insidious pathogen.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "fc2548420f034a03b63b99f76249f358", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [99, 99], [122, 122], [74, 74], [234, 234], [140, 140], [184, 184], [194, 194], [209, 209]], "char_spans": [[0, 11], [593, 604], [732, 743], [450, 461], [1417, 1428], [843, 854], [1122, 1133], [1185, 1196], [1282, 1293]]}]}], "context_tokens": [["Tuberculosis", 0], ["is", 13], ["responsible", 16], ["for", 28], ["more", 32], ["then", 37], ["2", 42], ["million", 44], ["deaths", 52], ["worldwide", 59], ["each", 69], ["year", 74], ["and", 79], ["vies", 83], ["with", 88], ["HIV", 93], ["as", 97], ["the", 100], ["world", 104], ["'s", 109], ["most", 112], ["fatal", 117], ["infectious", 123], ["disease", 134], [".", 141], ["In", 143], ["many", 146], ["developing", 151], ["countries", 162], [",", 171], ["attempts", 173], ["to", 182], ["control", 185], ["the", 193], ["spread", 197], ["of", 204], ["infection", 207], ["rely", 217], ["solely", 222], ["on", 229], ["identification", 232], ["and", 247], ["treatment", 251], ["of", 261], ["those", 264], ["with", 270], ["active", 275], ["disease", 282], [",", 289], ["ignoring", 291], ["subclinical", 300], ["infection", 312], [".", 321], ["However", 323], [",", 330], ["in", 332], ["developed", 335], ["countries", 345], [",", 354], ["large", 356], ["efforts", 362], ["are", 370], ["also", 374], ["expended", 379], ["to", 388], ["identify", 391], ["and", 400], ["give", 404], ["prophylactic", 409], ["drugs", 422], ["to", 428], ["people", 431], ["with", 438], ["latent", 443], ["tuberculosis", 450], ["infection", 463], [".", 472], ["Until", 474], ["recently", 480], [",", 488], ["the", 490], ["100-year", 494], ["-", 502], ["old", 503], ["tuberculin", 507], ["skin", 518], ["test", 523], ["(", 528], ["Mantoux", 529], [")", 536], ["has", 538], ["been", 542], ["the", 547], ["only", 551], ["available", 556], ["diagnostic", 566], ["test", 577], ["for", 582], ["latent", 586], ["tuberculosis", 593], ["infection", 606], [",", 615], ["despite", 617], ["its", 625], ["many", 629], ["well", 634], ["-", 638], ["known", 639], ["limitations", 645], [".", 656], ["Advances", 658], ["in", 667], ["scientific", 670], ["knowledge", 681], ["have", 691], ["led", 696], ["to", 700], ["the", 703], ["development", 707], ["of", 719], ["tests", 722], ["for", 728], ["tuberculosis", 732], ["that", 745], ["measure", 750], ["the", 758], ["production", 762], ["of", 773], ["interferon", 776], ["-", 786], ["gamma", 787], ["by", 793], ["T", 796], ["-", 797], ["cells", 798], ["stimulated", 804], ["in", 815], ["vitro", 818], ["with", 824], ["Mycobacterium", 829], ["tuberculosis", 843], ["-", 855], ["specific", 856], ["antigens", 865], [".", 873], ["These", 875], ["interferon", 881], ["-", 891], ["gamma", 892], ["tests", 898], ["are", 904], ["highly", 908], ["specific", 915], ["and", 924], ["unaffected", 928], ["by", 939], ["prior", 942], ["Bacille", 948], ["Calmette", 956], ["-", 964], ["Gu\u00e9rin", 965], ["vaccination", 972], ["or", 984], ["immune", 987], ["reactivity", 994], ["to", 1005], ["most", 1008], ["atypical", 1013], ["mycobacteria", 1022], [".", 1034], ["They", 1036], ["are", 1041], ["more", 1045], ["sensitive", 1050], ["than", 1060], ["the", 1065], ["tuberculin", 1069], ["skin", 1080], ["test", 1085], ["in", 1090], ["detecting", 1093], ["people", 1103], ["with", 1110], ["active", 1115], ["tuberculosis", 1122], [",", 1134], ["and", 1136], ["their", 1140], ["results", 1146], ["correlate", 1154], ["more", 1164], ["closely", 1169], ["with", 1177], ["M.", 1182], ["tuberculosis", 1185], ["exposure", 1198], ["risk", 1207], ["factors", 1212], ["than", 1220], ["the", 1225], ["tuberculin", 1229], ["skin", 1240], ["test", 1245], ["in", 1250], ["people", 1253], ["likely", 1260], ["to", 1267], ["have", 1270], ["latent", 1275], ["tuberculosis", 1282], ["infection", 1295], [".", 1304], ["Science", 1306], ["has", 1314], ["caught", 1318], ["up", 1325], ["with", 1328], ["one", 1333], ["of", 1337], ["the", 1340], ["oldest", 1344], ["diagnostic", 1351], ["tests", 1362], ["still", 1368], ["in", 1374], ["use", 1377], ["worldwide", 1381], [",", 1390], ["and", 1392], ["the", 1396], ["adoption", 1400], ["of", 1409], ["new", 1412], [",", 1415], ["tuberculosis", 1417], ["-", 1429], ["specific", 1430], ["interferon", 1439], ["-", 1449], ["gamma", 1450], ["-", 1455], ["based", 1456], ["tests", 1462], ["should", 1468], ["move", 1475], ["us", 1480], ["one", 1483], ["step", 1487], ["closer", 1492], ["to", 1499], ["better", 1502], ["control", 1509], ["of", 1517], ["this", 1520], ["insidious", 1525], ["pathogen", 1535], [".", 1543]]}
{"context": "Neurofibromatosis type 1 (NF1) gene is a tumor suppressor gene, and the NF1 gene product, neurofibromin, can downregulate the N-ras gene. Because the N-ras gene is often mutated in acute myelogenous leukemia (AML), we wondered if the NF1 gene might be mutated in those AML samples not having N-ras mutations. We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML. Of 48 AML patients, 10 (21%) had point (missense) mutations of the N-ras gene involving codons 12, 13 and 61. However, mutations in the FLR exon of the NF1 gene were not detected in any of the AML samples. We also examined the difference of clinical response to induction therapy between AML patients with and without N-ras mutation. A significantly lower rate of complete remission was noted in individuals with N-ras gene mutations. These results suggest that mutation of the NF1 gene, at least in the FLR exon, is very rare in AML and the NF1 gene probably is not a functional complement of the N-ras gene mutation. The presence of N-ras gene mutation may be associated with a lower clinical response to antileukemic therapy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fb9d60b81eed4b7e93174fdf341800eb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [189, 189], [4, 4], [265, 265], [248, 248], [50, 50], [15, 15]], "char_spans": [[447, 449], [871, 873], [26, 28], [1261, 1263], [1197, 1199], [234, 236], [72, 74]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["gene", 31], ["is", 36], ["a", 39], ["tumor", 41], ["suppressor", 47], ["gene", 58], [",", 62], ["and", 64], ["the", 68], ["NF1", 72], ["gene", 76], ["product", 81], [",", 88], ["neurofibromin", 90], [",", 103], ["can", 105], ["downregulate", 109], ["the", 122], ["N", 126], ["-", 127], ["ras", 128], ["gene", 132], [".", 136], ["Because", 138], ["the", 146], ["N", 150], ["-", 151], ["ras", 152], ["gene", 156], ["is", 161], ["often", 164], ["mutated", 170], ["in", 178], ["acute", 181], ["myelogenous", 187], ["leukemia", 199], ["(", 208], ["AML", 209], [")", 212], [",", 213], ["we", 215], ["wondered", 218], ["if", 227], ["the", 230], ["NF1", 234], ["gene", 238], ["might", 243], ["be", 249], ["mutated", 252], ["in", 260], ["those", 263], ["AML", 269], ["samples", 273], ["not", 281], ["having", 285], ["N", 292], ["-", 293], ["ras", 294], ["mutations", 298], [".", 307], ["We", 309], ["investigated", 312], ["the", 325], ["mutational", 329], ["status", 340], ["of", 347], ["the", 350], ["N", 354], ["-", 355], ["ras", 356], ["gene", 360], ["and", 365], ["the", 369], ["FLR", 373], ["exon", 377], ["of", 382], ["codons", 385], ["1371", 392], ["-", 396], ["1423", 397], ["of", 402], ["the", 405], ["open", 409], ["reading", 414], ["frame", 422], ["of", 428], ["the", 431], ["full", 435], ["-", 439], ["length", 440], ["NF1", 447], ["cDNA", 451], [",", 455], ["which", 457], ["has", 463], ["a", 467], ["strong", 469], ["homology", 476], ["with", 485], ["the", 490], ["mammalian", 494], ["ras", 504], ["GTPase", 508], ["-", 514], ["activating", 515], ["protein", 526], ["(", 534], ["GAP", 535], [")", 538], [",", 539], ["especially", 541], ["for", 552], ["a", 556], ["stretch", 558], ["of", 566], ["three", 569], ["consecutive", 575], ["amino", 587], ["acids", 593], ["(", 599], ["F", 600], [",", 601], ["L", 603], [",", 604], ["R", 606], [")", 607], [",", 608], ["by", 610], ["single", 613], ["-", 619], ["strand", 620], ["conformation", 627], ["polymorphism", 640], ["analysis", 653], ["and", 662], ["direct", 666], ["sequencing", 673], ["in", 684], ["samples", 687], ["from", 695], ["patients", 700], ["with", 709], ["AML", 714], [".", 717], ["Of", 719], ["48", 722], ["AML", 725], ["patients", 729], [",", 737], ["10", 739], ["(", 742], ["21", 743], ["%", 745], [")", 746], ["had", 748], ["point", 752], ["(", 758], ["missense", 759], [")", 767], ["mutations", 769], ["of", 779], ["the", 782], ["N", 786], ["-", 787], ["ras", 788], ["gene", 792], ["involving", 797], ["codons", 807], ["12", 814], [",", 816], ["13", 818], ["and", 821], ["61", 825], [".", 827], ["However", 829], [",", 836], ["mutations", 838], ["in", 848], ["the", 851], ["FLR", 855], ["exon", 859], ["of", 864], ["the", 867], ["NF1", 871], ["gene", 875], ["were", 880], ["not", 885], ["detected", 889], ["in", 898], ["any", 901], ["of", 905], ["the", 908], ["AML", 912], ["samples", 916], [".", 923], ["We", 925], ["also", 928], ["examined", 933], ["the", 942], ["difference", 946], ["of", 957], ["clinical", 960], ["response", 969], ["to", 978], ["induction", 981], ["therapy", 991], ["between", 999], ["AML", 1007], ["patients", 1011], ["with", 1020], ["and", 1025], ["without", 1029], ["N", 1037], ["-", 1038], ["ras", 1039], ["mutation", 1043], [".", 1051], ["A", 1053], ["significantly", 1055], ["lower", 1069], ["rate", 1075], ["of", 1080], ["complete", 1083], ["remission", 1092], ["was", 1102], ["noted", 1106], ["in", 1112], ["individuals", 1115], ["with", 1127], ["N", 1132], ["-", 1133], ["ras", 1134], ["gene", 1138], ["mutations", 1143], [".", 1152], ["These", 1154], ["results", 1160], ["suggest", 1168], ["that", 1176], ["mutation", 1181], ["of", 1190], ["the", 1193], ["NF1", 1197], ["gene", 1201], [",", 1205], ["at", 1207], ["least", 1210], ["in", 1216], ["the", 1219], ["FLR", 1223], ["exon", 1227], [",", 1231], ["is", 1233], ["very", 1236], ["rare", 1241], ["in", 1246], ["AML", 1249], ["and", 1253], ["the", 1257], ["NF1", 1261], ["gene", 1265], ["probably", 1270], ["is", 1279], ["not", 1282], ["a", 1286], ["functional", 1288], ["complement", 1299], ["of", 1310], ["the", 1313], ["N", 1317], ["-", 1318], ["ras", 1319], ["gene", 1323], ["mutation", 1328], [".", 1336], ["The", 1338], ["presence", 1342], ["of", 1351], ["N", 1354], ["-", 1355], ["ras", 1356], ["gene", 1360], ["mutation", 1365], ["may", 1374], ["be", 1378], ["associated", 1381], ["with", 1392], ["a", 1397], ["lower", 1399], ["clinical", 1405], ["response", 1414], ["to", 1423], ["antileukemic", 1426], ["therapy", 1439], [".", 1446]]}
{"context": "The ubiquitously expressed iron storage protein ferritin plays a central role in maintaining cellular iron homeostasis. Cytosolic ferritins are composed of heavy (H) and light (L) subunits that co-assemble into a hollow spherical shell with an internal cavity where iron is stored. The ferroxidase activity of the ferritin H chain is critical to store iron in its Fe3+ oxidation state, while the L chain shows iron nucleation properties. We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). We show that L chain ferritin is undetectable in primary fibroblasts from the patient, and thus ferritin consists only of H chains. Increased iron incorporation into the FtH homopolymer leads to reduced cellular iron availability, diminished levels of cytosolic catalase, SOD1 protein levels, enhanced ROS production and higher levels of oxidized proteins. Importantly, key phenotypic features observed in fibroblasts are also mirrored in reprogrammed neurons from the patient's fibroblasts. Our results demonstrate for the first time the pathophysiological consequences of L-ferritin deficiency in a human and help to define the concept for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f7f92b936c074e0eb3a943162c19c19b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[14, 14], [144, 144], [75, 75], [3, 3], [46, 46], [154, 154], [62, 62]], "char_spans": [[102, 105], [786, 789], [410, 413], [27, 30], [266, 269], [856, 859], [352, 355]]}]}], "context_tokens": [["The", 0], ["ubiquitously", 4], ["expressed", 17], ["iron", 27], ["storage", 32], ["protein", 40], ["ferritin", 48], ["plays", 57], ["a", 63], ["central", 65], ["role", 73], ["in", 78], ["maintaining", 81], ["cellular", 93], ["iron", 102], ["homeostasis", 107], [".", 118], ["Cytosolic", 120], ["ferritins", 130], ["are", 140], ["composed", 144], ["of", 153], ["heavy", 156], ["(", 162], ["H", 163], [")", 164], ["and", 166], ["light", 170], ["(", 176], ["L", 177], [")", 178], ["subunits", 180], ["that", 189], ["co", 194], ["-", 196], ["assemble", 197], ["into", 206], ["a", 211], ["hollow", 213], ["spherical", 220], ["shell", 230], ["with", 236], ["an", 241], ["internal", 244], ["cavity", 253], ["where", 260], ["iron", 266], ["is", 271], ["stored", 274], [".", 280], ["The", 282], ["ferroxidase", 286], ["activity", 298], ["of", 307], ["the", 310], ["ferritin", 314], ["H", 323], ["chain", 325], ["is", 331], ["critical", 334], ["to", 343], ["store", 346], ["iron", 352], ["in", 357], ["its", 360], ["Fe3", 364], ["+", 367], ["oxidation", 369], ["state", 379], [",", 384], ["while", 386], ["the", 392], ["L", 396], ["chain", 398], ["shows", 404], ["iron", 410], ["nucleation", 415], ["properties", 426], [".", 436], ["We", 438], ["describe", 441], ["a", 450], ["unique", 452], ["case", 459], ["of", 464], ["a", 467], ["23-yr", 469], ["-", 474], ["old", 475], ["female", 479], ["patient", 486], ["affected", 494], ["by", 503], ["a", 506], ["homozygous", 508], ["loss", 519], ["of", 524], ["function", 527], ["mutation", 536], ["in", 545], ["the", 548], ["L", 552], ["-", 553], ["ferritin", 554], ["gene", 563], [",", 567], ["idiopathic", 569], ["generalized", 580], ["seizures", 592], [",", 600], ["and", 602], ["atypical", 606], ["restless", 615], ["leg", 624], ["syndrome", 628], ["(", 637], ["RLS", 638], [")", 641], [".", 642], ["We", 644], ["show", 647], ["that", 652], ["L", 657], ["chain", 659], ["ferritin", 665], ["is", 674], ["undetectable", 677], ["in", 690], ["primary", 693], ["fibroblasts", 701], ["from", 713], ["the", 718], ["patient", 722], [",", 729], ["and", 731], ["thus", 735], ["ferritin", 740], ["consists", 749], ["only", 758], ["of", 763], ["H", 766], ["chains", 768], [".", 774], ["Increased", 776], ["iron", 786], ["incorporation", 791], ["into", 805], ["the", 810], ["FtH", 814], ["homopolymer", 818], ["leads", 830], ["to", 836], ["reduced", 839], ["cellular", 847], ["iron", 856], ["availability", 861], [",", 873], ["diminished", 875], ["levels", 886], ["of", 893], ["cytosolic", 896], ["catalase", 906], [",", 914], ["SOD1", 916], ["protein", 921], ["levels", 929], [",", 935], ["enhanced", 937], ["ROS", 946], ["production", 950], ["and", 961], ["higher", 965], ["levels", 972], ["of", 979], ["oxidized", 982], ["proteins", 991], [".", 999], ["Importantly", 1001], [",", 1012], ["key", 1014], ["phenotypic", 1018], ["features", 1029], ["observed", 1038], ["in", 1047], ["fibroblasts", 1050], ["are", 1062], ["also", 1066], ["mirrored", 1071], ["in", 1080], ["reprogrammed", 1083], ["neurons", 1096], ["from", 1104], ["the", 1109], ["patient", 1113], ["'s", 1120], ["fibroblasts", 1123], [".", 1134], ["Our", 1136], ["results", 1140], ["demonstrate", 1148], ["for", 1160], ["the", 1164], ["first", 1168], ["time", 1174], ["the", 1179], ["pathophysiological", 1183], ["consequences", 1202], ["of", 1215], ["L", 1218], ["-", 1219], ["ferritin", 1220], ["deficiency", 1229], ["in", 1240], ["a", 1243], ["human", 1245], ["and", 1251], ["help", 1255], ["to", 1260], ["define", 1263], ["the", 1270], ["concept", 1274], ["for", 1282], ["a", 1286], ["new", 1288], ["disease", 1292], ["entity", 1300], ["hallmarked", 1307], ["by", 1318], ["idiopathic", 1321], ["generalized", 1332], ["seizure", 1344], ["and", 1352], ["atypical", 1356], ["RLS", 1365], [".", 1368]]}
{"context": "Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease. Although the pathogenic mechanisms of RLS are not entirely understood, it is becoming increasingly evident that many diseases such as RLS can be attributed to an epistasis. The study objectives were to evaluate whether the associations of RLS with all loci determined in previous GWAS for Caucasians can be replicated significantly for the Korean population and to elucidate whether an epistasis plays a role in the pathogenesis of RLS. DNA from 320 patients with RLS and 320 age- and sex-matched controls were genotyped for variants in the RLS loci. A significant association was found for rs3923809 and rs9296249 in BTBD9 (P < 0.0001 and P = 0.001, respectively); the odds ratio (OR) for rs3923809 was 1.61 (P < 0.0001) to 1.88 (P < 0.0001) and the OR for rs9296249 was 1.44 (P = 0.001) to 1.73 (P = 0.002), according to the model of inheritance. The OR for the interaction between rs3923809 in BTBD9 and rs4626664 in PTPRD was 2.05 (P < 0.0001) in the additive model, 1.80 (P = 0.002) in the dominant model and 2.47 (P = 0.004) in the recessive model. There was no significant association between genotypes of all tested single nucleotide polymorphisms and the mean value of serum iron parameters. Our results suggest that the role of BTBD9 in the pathogenesis of restless legs syndrome is more universal across populations than previously reported and more efforts should be focused on the role of epistasis in the genetic architecture of restless legs syndrome.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "82ca01123a974473aaa47dcd81f47ba5", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23], [284, 286], [311, 313]], "char_spans": [[142, 163], [1475, 1496], [1651, 1672]]}]}], "context_tokens": [["Recent", 0], ["genome", 7], ["-", 13], ["wide", 14], ["association", 19], ["studies", 31], ["(", 39], ["GWAS", 40], [")", 44], ["for", 46], ["Caucasians", 50], ["identified", 61], ["several", 72], ["allelic", 80], ["variants", 88], ["associated", 97], ["with", 108], ["increased", 113], ["risk", 123], ["of", 128], ["developing", 131], ["restless", 142], ["legs", 151], ["syndrome", 156], ["(", 165], ["RLS", 166], [")", 169], [",", 170], ["also", 172], ["known", 177], ["as", 183], ["Willis", 186], ["-", 192], ["Ekbom", 193], ["disease", 199], [".", 206], ["Although", 208], ["the", 217], ["pathogenic", 221], ["mechanisms", 232], ["of", 243], ["RLS", 246], ["are", 250], ["not", 254], ["entirely", 258], ["understood", 267], [",", 277], ["it", 279], ["is", 282], ["becoming", 285], ["increasingly", 294], ["evident", 307], ["that", 315], ["many", 320], ["diseases", 325], ["such", 334], ["as", 339], ["RLS", 342], ["can", 346], ["be", 350], ["attributed", 353], ["to", 364], ["an", 367], ["epistasis", 370], [".", 379], ["The", 381], ["study", 385], ["objectives", 391], ["were", 402], ["to", 407], ["evaluate", 410], ["whether", 419], ["the", 427], ["associations", 431], ["of", 444], ["RLS", 447], ["with", 451], ["all", 456], ["loci", 460], ["determined", 465], ["in", 476], ["previous", 479], ["GWAS", 488], ["for", 493], ["Caucasians", 497], ["can", 508], ["be", 512], ["replicated", 515], ["significantly", 526], ["for", 540], ["the", 544], ["Korean", 548], ["population", 555], ["and", 566], ["to", 570], ["elucidate", 573], ["whether", 583], ["an", 591], ["epistasis", 594], ["plays", 604], ["a", 610], ["role", 612], ["in", 617], ["the", 620], ["pathogenesis", 624], ["of", 637], ["RLS", 640], [".", 643], ["DNA", 645], ["from", 649], ["320", 654], ["patients", 658], ["with", 667], ["RLS", 672], ["and", 676], ["320", 680], ["age-", 684], ["and", 689], ["sex", 693], ["-", 696], ["matched", 697], ["controls", 705], ["were", 714], ["genotyped", 719], ["for", 729], ["variants", 733], ["in", 742], ["the", 745], ["RLS", 749], ["loci", 753], [".", 757], ["A", 759], ["significant", 761], ["association", 773], ["was", 785], ["found", 789], ["for", 795], ["rs3923809", 799], ["and", 809], ["rs9296249", 813], ["in", 823], ["BTBD9", 826], ["(", 832], ["P", 833], ["<", 835], ["0.0001", 837], ["and", 844], ["P", 848], ["=", 850], ["0.001", 852], [",", 857], ["respectively", 859], [")", 871], [";", 872], ["the", 874], ["odds", 878], ["ratio", 883], ["(", 889], ["OR", 890], [")", 892], ["for", 894], ["rs3923809", 898], ["was", 908], ["1.61", 912], ["(", 917], ["P", 918], ["<", 920], ["0.0001", 922], [")", 928], ["to", 930], ["1.88", 933], ["(", 938], ["P", 939], ["<", 941], ["0.0001", 943], [")", 949], ["and", 951], ["the", 955], ["OR", 959], ["for", 962], ["rs9296249", 966], ["was", 976], ["1.44", 980], ["(", 985], ["P", 986], ["=", 988], ["0.001", 990], [")", 995], ["to", 997], ["1.73", 1000], ["(", 1005], ["P", 1006], ["=", 1008], ["0.002", 1010], [")", 1015], [",", 1016], ["according", 1018], ["to", 1028], ["the", 1031], ["model", 1035], ["of", 1041], ["inheritance", 1044], [".", 1055], ["The", 1057], ["OR", 1061], ["for", 1064], ["the", 1068], ["interaction", 1072], ["between", 1084], ["rs3923809", 1092], ["in", 1102], ["BTBD9", 1105], ["and", 1111], ["rs4626664", 1115], ["in", 1125], ["PTPRD", 1128], ["was", 1134], ["2.05", 1138], ["(", 1143], ["P", 1144], ["<", 1146], ["0.0001", 1148], [")", 1154], ["in", 1156], ["the", 1159], ["additive", 1163], ["model", 1172], [",", 1177], ["1.80", 1179], ["(", 1184], ["P", 1185], ["=", 1187], ["0.002", 1189], [")", 1194], ["in", 1196], ["the", 1199], ["dominant", 1203], ["model", 1212], ["and", 1218], ["2.47", 1222], ["(", 1227], ["P", 1228], ["=", 1230], ["0.004", 1232], [")", 1237], ["in", 1239], ["the", 1242], ["recessive", 1246], ["model", 1256], [".", 1261], ["There", 1263], ["was", 1269], ["no", 1273], ["significant", 1276], ["association", 1288], ["between", 1300], ["genotypes", 1308], ["of", 1318], ["all", 1321], ["tested", 1325], ["single", 1332], ["nucleotide", 1339], ["polymorphisms", 1350], ["and", 1364], ["the", 1368], ["mean", 1372], ["value", 1377], ["of", 1383], ["serum", 1386], ["iron", 1392], ["parameters", 1397], [".", 1407], ["Our", 1409], ["results", 1413], ["suggest", 1421], ["that", 1429], ["the", 1434], ["role", 1438], ["of", 1443], ["BTBD9", 1446], ["in", 1452], ["the", 1455], ["pathogenesis", 1459], ["of", 1472], ["restless", 1475], ["legs", 1484], ["syndrome", 1489], ["is", 1498], ["more", 1501], ["universal", 1506], ["across", 1516], ["populations", 1523], ["than", 1535], ["previously", 1540], ["reported", 1551], ["and", 1560], ["more", 1564], ["efforts", 1569], ["should", 1577], ["be", 1584], ["focused", 1587], ["on", 1595], ["the", 1598], ["role", 1602], ["of", 1607], ["epistasis", 1610], ["in", 1620], ["the", 1623], ["genetic", 1627], ["architecture", 1635], ["of", 1648], ["restless", 1651], ["legs", 1660], ["syndrome", 1665], [".", 1673]]}
{"context": "Nucleotide excision repair (NER), which is arguably the most versatile DNA repair system, is strongly attenuated in human cells of the monocytic lineage when they differentiate into macrophages. Within active genes, however, both DNA strands continue to be proficiently repaired. The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes. We now report that the previously termed differentiation-associated repair (DAR) depends upon transcription, but not simply upon RNA polymerase II (RNAPII) encountering a lesion: proficient repair of both DNA strands can occur in a part of a gene that the polymerase never reaches, and even if the translocation of RNAPII is blocked with transcription inhibitors. This suggests that DAR may be a subset of global NER, restricted to the subnuclear compartments or chromatin domains within which transcription occurs. Downregulation of selected NER genes with small interfering RNA has confirmed that DAR relies upon the same genes as global genome repair, rather than upon TCR-specific genes. Our findings support the general view that the genomic domains within which transcription is active are more accessible than the bulk of the genome to the recognition and repair of lesions through the global pathway and that TCR is superimposed upon that pathway of NER.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "84dfe31ea9704f369ff876aaf7937ab8", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[77, 78]], "char_spans": [[443, 460]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], [",", 32], ["which", 34], ["is", 40], ["arguably", 43], ["the", 52], ["most", 56], ["versatile", 61], ["DNA", 71], ["repair", 75], ["system", 82], [",", 88], ["is", 90], ["strongly", 93], ["attenuated", 102], ["in", 113], ["human", 116], ["cells", 122], ["of", 128], ["the", 131], ["monocytic", 135], ["lineage", 145], ["when", 153], ["they", 158], ["differentiate", 163], ["into", 177], ["macrophages", 182], [".", 193], ["Within", 195], ["active", 202], ["genes", 209], [",", 214], ["however", 216], [",", 223], ["both", 225], ["DNA", 230], ["strands", 234], ["continue", 242], ["to", 251], ["be", 254], ["proficiently", 257], ["repaired", 270], [".", 278], ["The", 280], ["proficient", 284], ["repair", 295], ["of", 302], ["the", 305], ["nontranscribed", 309], ["strand", 324], ["can", 331], ["not", 334], ["be", 338], ["explained", 341], ["by", 351], ["the", 354], ["dedicated", 358], ["subpathway", 368], ["of", 379], ["transcription", 382], ["-", 395], ["coupled", 396], ["repair", 404], ["(", 411], ["TCR", 412], [")", 415], [",", 416], ["which", 418], ["is", 424], ["targeted", 427], ["to", 436], ["the", 439], ["transcribed", 443], ["strand", 455], ["in", 462], ["expressed", 465], ["genes", 475], [".", 480], ["We", 482], ["now", 485], ["report", 489], ["that", 496], ["the", 501], ["previously", 505], ["termed", 516], ["differentiation", 523], ["-", 538], ["associated", 539], ["repair", 550], ["(", 557], ["DAR", 558], [")", 561], ["depends", 563], ["upon", 571], ["transcription", 576], [",", 589], ["but", 591], ["not", 595], ["simply", 599], ["upon", 606], ["RNA", 611], ["polymerase", 615], ["II", 626], ["(", 629], ["RNAPII", 630], [")", 636], ["encountering", 638], ["a", 651], ["lesion", 653], [":", 659], ["proficient", 661], ["repair", 672], ["of", 679], ["both", 682], ["DNA", 687], ["strands", 691], ["can", 699], ["occur", 703], ["in", 709], ["a", 712], ["part", 714], ["of", 719], ["a", 722], ["gene", 724], ["that", 729], ["the", 734], ["polymerase", 738], ["never", 749], ["reaches", 755], [",", 762], ["and", 764], ["even", 768], ["if", 773], ["the", 776], ["translocation", 780], ["of", 794], ["RNAPII", 797], ["is", 804], ["blocked", 807], ["with", 815], ["transcription", 820], ["inhibitors", 834], [".", 844], ["This", 846], ["suggests", 851], ["that", 860], ["DAR", 865], ["may", 869], ["be", 873], ["a", 876], ["subset", 878], ["of", 885], ["global", 888], ["NER", 895], [",", 898], ["restricted", 900], ["to", 911], ["the", 914], ["subnuclear", 918], ["compartments", 929], ["or", 942], ["chromatin", 945], ["domains", 955], ["within", 963], ["which", 970], ["transcription", 976], ["occurs", 990], [".", 996], ["Downregulation", 998], ["of", 1013], ["selected", 1016], ["NER", 1025], ["genes", 1029], ["with", 1035], ["small", 1040], ["interfering", 1046], ["RNA", 1058], ["has", 1062], ["confirmed", 1066], ["that", 1076], ["DAR", 1081], ["relies", 1085], ["upon", 1092], ["the", 1097], ["same", 1101], ["genes", 1106], ["as", 1112], ["global", 1115], ["genome", 1122], ["repair", 1129], [",", 1135], ["rather", 1137], ["than", 1144], ["upon", 1149], ["TCR", 1154], ["-", 1157], ["specific", 1158], ["genes", 1167], [".", 1172], ["Our", 1174], ["findings", 1178], ["support", 1187], ["the", 1195], ["general", 1199], ["view", 1207], ["that", 1212], ["the", 1217], ["genomic", 1221], ["domains", 1229], ["within", 1237], ["which", 1244], ["transcription", 1250], ["is", 1264], ["active", 1267], ["are", 1274], ["more", 1278], ["accessible", 1283], ["than", 1294], ["the", 1299], ["bulk", 1303], ["of", 1308], ["the", 1311], ["genome", 1315], ["to", 1322], ["the", 1325], ["recognition", 1329], ["and", 1341], ["repair", 1345], ["of", 1352], ["lesions", 1355], ["through", 1363], ["the", 1371], ["global", 1375], ["pathway", 1382], ["and", 1390], ["that", 1394], ["TCR", 1399], ["is", 1403], ["superimposed", 1406], ["upon", 1419], ["that", 1424], ["pathway", 1429], ["of", 1437], ["NER", 1440], [".", 1443]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type. Clinical picture is characterized by the myotonic, myopathic, and endocrine-autonomic syndrome. A clinical, genetic, and electromyographic study was carried out to elucidate the problem of this condition inheritance, its intra- and interfamilial clinical polymorphism, and effects of environmental factors on its course and outcomes.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "52cd8f90006a41c999627c367f252ff3", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[11, 12]], "char_spans": [[75, 92]]}]}], "context_tokens": [["Dystrophic", 0], ["myotonia", 11], ["is", 20], ["a", 23], ["sufficiently", 25], ["rare", 38], ["disease", 43], ["inherited", 51], ["mainly", 61], ["by", 68], ["the", 71], ["autosomal", 75], ["dominant", 85], ["type", 94], [".", 98], ["Clinical", 100], ["picture", 109], ["is", 117], ["characterized", 120], ["by", 134], ["the", 137], ["myotonic", 141], [",", 149], ["myopathic", 151], [",", 160], ["and", 162], ["endocrine", 166], ["-", 175], ["autonomic", 176], ["syndrome", 186], [".", 194], ["A", 196], ["clinical", 198], [",", 206], ["genetic", 208], [",", 215], ["and", 217], ["electromyographic", 221], ["study", 239], ["was", 245], ["carried", 249], ["out", 257], ["to", 261], ["elucidate", 264], ["the", 274], ["problem", 278], ["of", 286], ["this", 289], ["condition", 294], ["inheritance", 304], [",", 315], ["its", 317], ["intra-", 321], ["and", 328], ["interfamilial", 332], ["clinical", 346], ["polymorphism", 355], [",", 367], ["and", 369], ["effects", 373], ["of", 381], ["environmental", 384], ["factors", 398], ["on", 406], ["its", 409], ["course", 413], ["and", 420], ["outcomes", 424], [".", 432]]}
{"context": "Recent reports have described a distinct and recurrent pattern of systemic malformation that associates craniosynostosis and neurodevelopmental abnormalities with many clinical features of the Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular microfibril caused by defects in the gene encoding fibrillin-1, FBN1 (ref. 8). Additional common findings include other craniofacial anomalies, hypotonia, obstructive apnea, foot deformity, and congenital weakness of the abdominal wall. So far, only 11 cases have been reported precluding the assignment of definitive diagnostic criteria. While it remains unclear whether these cases represent a discrete clinical entity with a single aetiology, they have been pragmatically grouped under the rubric Marfanoid-craniosynostosis or Shprintzen-Goldberg syndrome (SGS). Because of the significant clinical overlap between MFS and SGS, we proposed that they may be caused by allelic mutations. We now report two SGS patients who harbour mutations in FBN1. While it remains unclear whether these mutations are sufficient for the clinical expression of the entire SGS phenotype, these data suggest a role for fibrillin-1 in early craniofacial and central nervous system development. Our recent observation that FBN1 transcript is expressed as early as the 8-cell stage of human embryogenesis is consistent with this hypothesis.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0d848258b8d84a2a99aa7452c73c0752", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[121, 121], [14, 14]], "char_spans": [[778, 793], [104, 119]]}]}], "context_tokens": [["Recent", 0], ["reports", 7], ["have", 15], ["described", 20], ["a", 30], ["distinct", 32], ["and", 41], ["recurrent", 45], ["pattern", 55], ["of", 63], ["systemic", 66], ["malformation", 75], ["that", 88], ["associates", 93], ["craniosynostosis", 104], ["and", 121], ["neurodevelopmental", 125], ["abnormalities", 144], ["with", 158], ["many", 163], ["clinical", 168], ["features", 177], ["of", 186], ["the", 189], ["Marfan", 193], ["syndrome", 200], ["(", 209], ["MFS", 210], [")", 213], [",", 214], ["an", 216], ["autosomal", 219], ["dominant", 229], ["disorder", 238], ["of", 247], ["the", 250], ["extracellular", 254], ["microfibril", 268], ["caused", 280], ["by", 287], ["defects", 290], ["in", 298], ["the", 301], ["gene", 305], ["encoding", 310], ["fibrillin-1", 319], [",", 330], ["FBN1", 332], ["(", 337], ["ref", 338], [".", 341], ["8)", 343], [".", 345], ["Additional", 347], ["common", 358], ["findings", 365], ["include", 374], ["other", 382], ["craniofacial", 388], ["anomalies", 401], [",", 410], ["hypotonia", 412], [",", 421], ["obstructive", 423], ["apnea", 435], [",", 440], ["foot", 442], ["deformity", 447], [",", 456], ["and", 458], ["congenital", 462], ["weakness", 473], ["of", 482], ["the", 485], ["abdominal", 489], ["wall", 499], [".", 503], ["So", 505], ["far", 508], [",", 511], ["only", 513], ["11", 518], ["cases", 521], ["have", 527], ["been", 532], ["reported", 537], ["precluding", 546], ["the", 557], ["assignment", 561], ["of", 572], ["definitive", 575], ["diagnostic", 586], ["criteria", 597], [".", 605], ["While", 607], ["it", 613], ["remains", 616], ["unclear", 624], ["whether", 632], ["these", 640], ["cases", 646], ["represent", 652], ["a", 662], ["discrete", 664], ["clinical", 673], ["entity", 682], ["with", 689], ["a", 694], ["single", 696], ["aetiology", 703], [",", 712], ["they", 714], ["have", 719], ["been", 724], ["pragmatically", 729], ["grouped", 743], ["under", 751], ["the", 757], ["rubric", 761], ["Marfanoid", 768], ["-", 777], ["craniosynostosis", 778], ["or", 795], ["Shprintzen", 798], ["-", 808], ["Goldberg", 809], ["syndrome", 818], ["(", 827], ["SGS", 828], [")", 831], [".", 832], ["Because", 834], ["of", 842], ["the", 845], ["significant", 849], ["clinical", 861], ["overlap", 870], ["between", 878], ["MFS", 886], ["and", 890], ["SGS", 894], [",", 897], ["we", 899], ["proposed", 902], ["that", 911], ["they", 916], ["may", 921], ["be", 925], ["caused", 928], ["by", 935], ["allelic", 938], ["mutations", 946], [".", 955], ["We", 957], ["now", 960], ["report", 964], ["two", 971], ["SGS", 975], ["patients", 979], ["who", 988], ["harbour", 992], ["mutations", 1000], ["in", 1010], ["FBN1", 1013], [".", 1017], ["While", 1019], ["it", 1025], ["remains", 1028], ["unclear", 1036], ["whether", 1044], ["these", 1052], ["mutations", 1058], ["are", 1068], ["sufficient", 1072], ["for", 1083], ["the", 1087], ["clinical", 1091], ["expression", 1100], ["of", 1111], ["the", 1114], ["entire", 1118], ["SGS", 1125], ["phenotype", 1129], [",", 1138], ["these", 1140], ["data", 1146], ["suggest", 1151], ["a", 1159], ["role", 1161], ["for", 1166], ["fibrillin-1", 1170], ["in", 1182], ["early", 1185], ["craniofacial", 1191], ["and", 1204], ["central", 1208], ["nervous", 1216], ["system", 1224], ["development", 1231], [".", 1242], ["Our", 1244], ["recent", 1248], ["observation", 1255], ["that", 1267], ["FBN1", 1272], ["transcript", 1277], ["is", 1288], ["expressed", 1291], ["as", 1301], ["early", 1304], ["as", 1310], ["the", 1313], ["8-cell", 1317], ["stage", 1324], ["of", 1330], ["human", 1333], ["embryogenesis", 1339], ["is", 1353], ["consistent", 1356], ["with", 1367], ["this", 1372], ["hypothesis", 1377], [".", 1387]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective autophagy-lysosome protein degradation pathway. The role of CMA in normal neuronal functions and in neural disease pathogenesis remains unclear, in part because there is no available method to monitor CMA activity at the single-cell level. We sought to establish a single-cell monitoring method by visualizing translocation of CMA substrates from the cytosol to lysosomes using the HaloTag (HT) system. GAPDH, a CMA substrate, was fused to HT (GAPDH-HT); this protein accumulated in the lysosomes of HeLa cells and cultured cerebellar Purkinje cells (PCs) after labeling with fluorescent dye-conjugated HT ligand. Lysosomal accumulation was enhanced by treatments that activate CMA and prevented by siRNA-mediated knockdown of LAMP2A, a lysosomal receptor for CMA, and by treatments that inactivate CMA. These results suggest that lysosomal accumulation of GAPDH-HT reflects CMA activity. Using this method, we revealed that mutant \u03b3PKC, which causes spinocerebellar ataxia type 14, decreased CMA activity in cultured PCs. In the present study, we established a novel fluorescent-based method to evaluate CMA activity in a single neuron. This novel method should be useful and valuable for evaluating the role of CMA in various neuronal functions and neural disease pathogenesis.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "86bd299403624adfa79bf2ac1de79528", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[141, 141]], "char_spans": [[777, 782]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["autophagy", 50], ["-", 59], ["lysosome", 60], ["protein", 69], ["degradation", 77], ["pathway", 89], [".", 96], ["The", 98], ["role", 102], ["of", 107], ["CMA", 110], ["in", 114], ["normal", 117], ["neuronal", 124], ["functions", 133], ["and", 143], ["in", 147], ["neural", 150], ["disease", 157], ["pathogenesis", 165], ["remains", 178], ["unclear", 186], [",", 193], ["in", 195], ["part", 198], ["because", 203], ["there", 211], ["is", 217], ["no", 220], ["available", 223], ["method", 233], ["to", 240], ["monitor", 243], ["CMA", 251], ["activity", 255], ["at", 264], ["the", 267], ["single", 271], ["-", 277], ["cell", 278], ["level", 283], [".", 288], ["We", 290], ["sought", 293], ["to", 300], ["establish", 303], ["a", 313], ["single", 315], ["-", 321], ["cell", 322], ["monitoring", 327], ["method", 338], ["by", 345], ["visualizing", 348], ["translocation", 360], ["of", 374], ["CMA", 377], ["substrates", 381], ["from", 392], ["the", 397], ["cytosol", 401], ["to", 409], ["lysosomes", 412], ["using", 422], ["the", 428], ["HaloTag", 432], ["(", 440], ["HT", 441], [")", 443], ["system", 445], [".", 451], ["GAPDH", 453], [",", 458], ["a", 460], ["CMA", 462], ["substrate", 466], [",", 475], ["was", 477], ["fused", 481], ["to", 487], ["HT", 490], ["(", 493], ["GAPDH", 494], ["-", 499], ["HT", 500], [")", 502], [";", 503], ["this", 505], ["protein", 510], ["accumulated", 518], ["in", 530], ["the", 533], ["lysosomes", 537], ["of", 547], ["HeLa", 550], ["cells", 555], ["and", 561], ["cultured", 565], ["cerebellar", 574], ["Purkinje", 585], ["cells", 594], ["(", 600], ["PCs", 601], [")", 604], ["after", 606], ["labeling", 612], ["with", 621], ["fluorescent", 626], ["dye", 638], ["-", 641], ["conjugated", 642], ["HT", 653], ["ligand", 656], [".", 662], ["Lysosomal", 664], ["accumulation", 674], ["was", 687], ["enhanced", 691], ["by", 700], ["treatments", 703], ["that", 714], ["activate", 719], ["CMA", 728], ["and", 732], ["prevented", 736], ["by", 746], ["siRNA", 749], ["-", 754], ["mediated", 755], ["knockdown", 764], ["of", 774], ["LAMP2A", 777], [",", 783], ["a", 785], ["lysosomal", 787], ["receptor", 797], ["for", 806], ["CMA", 810], [",", 813], ["and", 815], ["by", 819], ["treatments", 822], ["that", 833], ["inactivate", 838], ["CMA", 849], [".", 852], ["These", 854], ["results", 860], ["suggest", 868], ["that", 876], ["lysosomal", 881], ["accumulation", 891], ["of", 904], ["GAPDH", 907], ["-", 912], ["HT", 913], ["reflects", 916], ["CMA", 925], ["activity", 929], [".", 937], ["Using", 939], ["this", 945], ["method", 950], [",", 956], ["we", 958], ["revealed", 961], ["that", 970], ["mutant", 975], ["\u03b3PKC", 982], [",", 986], ["which", 988], ["causes", 994], ["spinocerebellar", 1001], ["ataxia", 1017], ["type", 1024], ["14", 1029], [",", 1031], ["decreased", 1033], ["CMA", 1043], ["activity", 1047], ["in", 1056], ["cultured", 1059], ["PCs", 1068], [".", 1071], ["In", 1073], ["the", 1076], ["present", 1080], ["study", 1088], [",", 1093], ["we", 1095], ["established", 1098], ["a", 1110], ["novel", 1112], ["fluorescent", 1118], ["-", 1129], ["based", 1130], ["method", 1136], ["to", 1143], ["evaluate", 1146], ["CMA", 1155], ["activity", 1159], ["in", 1168], ["a", 1171], ["single", 1173], ["neuron", 1180], [".", 1186], ["This", 1188], ["novel", 1193], ["method", 1199], ["should", 1206], ["be", 1213], ["useful", 1216], ["and", 1223], ["valuable", 1227], ["for", 1236], ["evaluating", 1240], ["the", 1251], ["role", 1255], ["of", 1260], ["CMA", 1263], ["in", 1267], ["various", 1270], ["neuronal", 1278], ["functions", 1287], ["and", 1297], ["neural", 1301], ["disease", 1308], ["pathogenesis", 1316], [".", 1328]]}
{"context": "Emotion regulation has been associated with perceived health in rheumatoid arthritis, which is diagnosed three times more often in women than men. Our aim was to examine gender differences in styles of emotion regulation (ambiguity, control, orientation, and expression) and gender-specificity of the associations between emotion regulation and perceived health (psychological well-being, social functioning, physical functioning, and disease activity) in 244 female and 91 male patients with rheumatoid arthritis. Women reported more emotional orientation than men, but did not differ from men with regard to ambiguity, control, and expression. Structural equation modelling showed that relationships between emotion regulation and perceived health were more frequent and stronger for women than men. This held especially for the affective dimension of health, while associations were similar for both women and men with regard to social and physical functioning. Only for women, the association between ambiguity and disease activity was significant, which appeared to be mediated by affective functioning. The observations that women are more emotionally oriented than men and that emotion regulation is more interwoven with psychological health in women than men, support the usefulness of a gender-sensitive approach in research and health care of patients with rheumatoid arthritis.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "33ce31f2b31e434a8646df96cc8b9daa", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[128, 128], [203, 203], [86, 86], [148, 148], [20, 20], [185, 185], [161, 161]], "char_spans": [[786, 790], [1252, 1256], [515, 519], [903, 907], [131, 135], [1131, 1135], [974, 978]]}]}], "context_tokens": [["Emotion", 0], ["regulation", 8], ["has", 19], ["been", 23], ["associated", 28], ["with", 39], ["perceived", 44], ["health", 54], ["in", 61], ["rheumatoid", 64], ["arthritis", 75], [",", 84], ["which", 86], ["is", 92], ["diagnosed", 95], ["three", 105], ["times", 111], ["more", 117], ["often", 122], ["in", 128], ["women", 131], ["than", 137], ["men", 142], [".", 145], ["Our", 147], ["aim", 151], ["was", 155], ["to", 159], ["examine", 162], ["gender", 170], ["differences", 177], ["in", 189], ["styles", 192], ["of", 199], ["emotion", 202], ["regulation", 210], ["(", 221], ["ambiguity", 222], [",", 231], ["control", 233], [",", 240], ["orientation", 242], [",", 253], ["and", 255], ["expression", 259], [")", 269], ["and", 271], ["gender", 275], ["-", 281], ["specificity", 282], ["of", 294], ["the", 297], ["associations", 301], ["between", 314], ["emotion", 322], ["regulation", 330], ["and", 341], ["perceived", 345], ["health", 355], ["(", 362], ["psychological", 363], ["well", 377], ["-", 381], ["being", 382], [",", 387], ["social", 389], ["functioning", 396], [",", 407], ["physical", 409], ["functioning", 418], [",", 429], ["and", 431], ["disease", 435], ["activity", 443], [")", 451], ["in", 453], ["244", 456], ["female", 460], ["and", 467], ["91", 471], ["male", 474], ["patients", 479], ["with", 488], ["rheumatoid", 493], ["arthritis", 504], [".", 513], ["Women", 515], ["reported", 521], ["more", 530], ["emotional", 535], ["orientation", 545], ["than", 557], ["men", 562], [",", 565], ["but", 567], ["did", 571], ["not", 575], ["differ", 579], ["from", 586], ["men", 591], ["with", 595], ["regard", 600], ["to", 607], ["ambiguity", 610], [",", 619], ["control", 621], [",", 628], ["and", 630], ["expression", 634], [".", 644], ["Structural", 646], ["equation", 657], ["modelling", 666], ["showed", 676], ["that", 683], ["relationships", 688], ["between", 702], ["emotion", 710], ["regulation", 718], ["and", 729], ["perceived", 733], ["health", 743], ["were", 750], ["more", 755], ["frequent", 760], ["and", 769], ["stronger", 773], ["for", 782], ["women", 786], ["than", 792], ["men", 797], [".", 800], ["This", 802], ["held", 807], ["especially", 812], ["for", 823], ["the", 827], ["affective", 831], ["dimension", 841], ["of", 851], ["health", 854], [",", 860], ["while", 862], ["associations", 868], ["were", 881], ["similar", 886], ["for", 894], ["both", 898], ["women", 903], ["and", 909], ["men", 913], ["with", 917], ["regard", 922], ["to", 929], ["social", 932], ["and", 939], ["physical", 943], ["functioning", 952], [".", 963], ["Only", 965], ["for", 970], ["women", 974], [",", 979], ["the", 981], ["association", 985], ["between", 997], ["ambiguity", 1005], ["and", 1015], ["disease", 1019], ["activity", 1027], ["was", 1036], ["significant", 1040], [",", 1051], ["which", 1053], ["appeared", 1059], ["to", 1068], ["be", 1071], ["mediated", 1074], ["by", 1083], ["affective", 1086], ["functioning", 1096], [".", 1107], ["The", 1109], ["observations", 1113], ["that", 1126], ["women", 1131], ["are", 1137], ["more", 1141], ["emotionally", 1146], ["oriented", 1158], ["than", 1167], ["men", 1172], ["and", 1176], ["that", 1180], ["emotion", 1185], ["regulation", 1193], ["is", 1204], ["more", 1207], ["interwoven", 1212], ["with", 1223], ["psychological", 1228], ["health", 1242], ["in", 1249], ["women", 1252], ["than", 1258], ["men", 1263], [",", 1266], ["support", 1268], ["the", 1276], ["usefulness", 1280], ["of", 1291], ["a", 1294], ["gender", 1296], ["-", 1302], ["sensitive", 1303], ["approach", 1313], ["in", 1322], ["research", 1325], ["and", 1334], ["health", 1338], ["care", 1345], ["of", 1350], ["patients", 1353], ["with", 1362], ["rheumatoid", 1367], ["arthritis", 1378], [".", 1387]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "Detection of latent tuberculosis infection is an important step in the control of tuberculosis. The tuberculin skin test is the only proven method for identifying tuberculosis infection in patients who do not have tuberculosis disease. The prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (Mantoux technique). Interpretation of the Mantoux test was based on the size of induration in millimeters and the individual risk profile of the patients, according to the guidelines of the American Thoracic Society and the Centers for Disease Control, revised in 1989. Of 697 tested patients, 252 showed test results consistent with tuberculosis infection (36.2%). 55 of these 697 patients had active tuberculosis disease or a prior history of tuberculosis (7.9%). A positive tuberculin skin test was found in 197 of 642 patients (30.7%) with a diagnosis different from tuberculosis (COPD, pneumonia, cancer and others). In our study, the sensitivity of the tuberculin skin test for active tuberculosis infection was 95%. The present study revealed a high prevalence of tuberculosis infection among hospitalized patients in a pneumological department. Further studies are needed to assess the usefulness of routine tuberculin skin testing in hospitalized populations.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a2d8fa1d4aec4b51af662fbe80cc7535", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[144, 144], [3, 3], [13, 13], [26, 26], [123, 123], [171, 171], [195, 195], [137, 137], [40, 40], [34, 34], [209, 209]], "char_spans": [[865, 876], [20, 31], [82, 93], [163, 174], [754, 765], [991, 1002], [1111, 1122], [822, 833], [254, 265], [214, 225], [1191, 1202]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["latent", 13], ["tuberculosis", 20], ["infection", 33], ["is", 43], ["an", 46], ["important", 49], ["step", 59], ["in", 64], ["the", 67], ["control", 71], ["of", 79], ["tuberculosis", 82], [".", 94], ["The", 96], ["tuberculin", 100], ["skin", 111], ["test", 116], ["is", 121], ["the", 124], ["only", 128], ["proven", 133], ["method", 140], ["for", 147], ["identifying", 151], ["tuberculosis", 163], ["infection", 176], ["in", 186], ["patients", 189], ["who", 198], ["do", 202], ["not", 205], ["have", 209], ["tuberculosis", 214], ["disease", 227], [".", 234], ["The", 236], ["prevalence", 240], ["of", 251], ["tuberculosis", 254], ["infection", 267], ["among", 277], ["hospitalized", 283], ["patients", 296], ["in", 305], ["a", 308], ["pneumological", 310], ["department", 324], ["of", 335], ["an", 338], ["inner", 341], ["-", 346], ["city", 347], ["hospital", 352], ["was", 361], ["evaluated", 365], [",", 374], ["using", 376], ["the", 382], ["intradermal", 386], ["tuberculin", 398], ["skin", 409], ["test", 414], ["(", 419], ["Mantoux", 420], ["technique", 428], [")", 437], [".", 438], ["Interpretation", 440], ["of", 455], ["the", 458], ["Mantoux", 462], ["test", 470], ["was", 475], ["based", 479], ["on", 485], ["the", 488], ["size", 492], ["of", 497], ["induration", 500], ["in", 511], ["millimeters", 514], ["and", 526], ["the", 530], ["individual", 534], ["risk", 545], ["profile", 550], ["of", 558], ["the", 561], ["patients", 565], [",", 573], ["according", 575], ["to", 585], ["the", 588], ["guidelines", 592], ["of", 603], ["the", 606], ["American", 610], ["Thoracic", 619], ["Society", 628], ["and", 636], ["the", 640], ["Centers", 644], ["for", 652], ["Disease", 656], ["Control", 664], [",", 671], ["revised", 673], ["in", 681], ["1989", 684], [".", 688], ["Of", 690], ["697", 693], ["tested", 697], ["patients", 704], [",", 712], ["252", 714], ["showed", 718], ["test", 725], ["results", 730], ["consistent", 738], ["with", 749], ["tuberculosis", 754], ["infection", 767], ["(", 777], ["36.2", 778], ["%", 782], [")", 783], [".", 784], ["55", 786], ["of", 789], ["these", 792], ["697", 798], ["patients", 802], ["had", 811], ["active", 815], ["tuberculosis", 822], ["disease", 835], ["or", 843], ["a", 846], ["prior", 848], ["history", 854], ["of", 862], ["tuberculosis", 865], ["(", 878], ["7.9", 879], ["%", 882], [")", 883], [".", 884], ["A", 886], ["positive", 888], ["tuberculin", 897], ["skin", 908], ["test", 913], ["was", 918], ["found", 922], ["in", 928], ["197", 931], ["of", 935], ["642", 938], ["patients", 942], ["(", 951], ["30.7", 952], ["%", 956], [")", 957], ["with", 959], ["a", 964], ["diagnosis", 966], ["different", 976], ["from", 986], ["tuberculosis", 991], ["(", 1004], ["COPD", 1005], [",", 1009], ["pneumonia", 1011], [",", 1020], ["cancer", 1022], ["and", 1029], ["others", 1033], [")", 1039], [".", 1040], ["In", 1042], ["our", 1045], ["study", 1049], [",", 1054], ["the", 1056], ["sensitivity", 1060], ["of", 1072], ["the", 1075], ["tuberculin", 1079], ["skin", 1090], ["test", 1095], ["for", 1100], ["active", 1104], ["tuberculosis", 1111], ["infection", 1124], ["was", 1134], ["95", 1138], ["%", 1140], [".", 1141], ["The", 1143], ["present", 1147], ["study", 1155], ["revealed", 1161], ["a", 1170], ["high", 1172], ["prevalence", 1177], ["of", 1188], ["tuberculosis", 1191], ["infection", 1204], ["among", 1214], ["hospitalized", 1220], ["patients", 1233], ["in", 1242], ["a", 1245], ["pneumological", 1247], ["department", 1261], [".", 1271], ["Further", 1273], ["studies", 1281], ["are", 1289], ["needed", 1293], ["to", 1300], ["assess", 1303], ["the", 1310], ["usefulness", 1314], ["of", 1325], ["routine", 1328], ["tuberculin", 1336], ["skin", 1347], ["testing", 1352], ["in", 1360], ["hospitalized", 1363], ["populations", 1376], [".", 1387]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Selenoproteins are an elite group of proteins containing a rare amino acid, selenocysteine (Sec), encoded by the codon, UGA. In eukaryotes, incorporation of Sec requires a Sec insertion sequence (SECIS) element, a stem-loop structure located in the 3'-untranslated regions of selenoprotein mRNAs. Here we report identification of a noncanonical form of SECIS element in Toxoplasma gondii and Neospora canine, single-celled apicomplexan parasites of humans and domestic animals. This SECIS has a GGGA sequence in the SBP2-binding site in place of AUGA previously considered invariant. Using a combination of computational and molecular techniques, we show that Toxoplasma and Neospora possess both canonical and noncanonical SECIS elements. The GGGA-type SECIS element supported Sec insertion in mammalian HEK 293 and NIH 3T3 cells and did so more efficiently than the natural mammalian SECIS elements tested. In addition, mammalian type I and type II SECIS elements mutated into the GGGA forms were functional but manifested decreased Sec insertion efficiency. We carried out computational searches for both AUGA and GGGA forms of SECIS elements in Toxoplasma and detected five selenoprotein genes, including one coding for a previously undescribed selenoprotein, designated SelQ, and two containing the GGGA form of the SECIS element. In contrast, the GGGA-type SECIS elements were not detected in mammals and nematodes. As a practical outcome of the study, we developed pSelExpress1, a vector for convenient expression of selenoproteins in mammalian cells. It contains an SBP2 gene and the most efficient tested SECIS element: an AUGA mutant of the GGGA-type Toxoplasma SelT structure.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "60845a786b424b11bfedd9ec58170947", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[64, 64], [192, 192], [37, 37], [85, 85], [122, 122], [275, 275], [164, 164], [151, 151], [232, 232], [222, 222], [129, 129]], "char_spans": [[353, 357], [1131, 1135], [196, 200], [483, 487], [724, 728], [1614, 1618], [951, 955], [886, 890], [1363, 1367], [1321, 1325], [754, 758]]}]}], "context_tokens": [["Selenoproteins", 0], ["are", 15], ["an", 19], ["elite", 22], ["group", 28], ["of", 34], ["proteins", 37], ["containing", 46], ["a", 57], ["rare", 59], ["amino", 64], ["acid", 70], [",", 74], ["selenocysteine", 76], ["(", 91], ["Sec", 92], [")", 95], [",", 96], ["encoded", 98], ["by", 106], ["the", 109], ["codon", 113], [",", 118], ["UGA", 120], [".", 123], ["In", 125], ["eukaryotes", 128], [",", 138], ["incorporation", 140], ["of", 154], ["Sec", 157], ["requires", 161], ["a", 170], ["Sec", 172], ["insertion", 176], ["sequence", 186], ["(", 195], ["SECIS", 196], [")", 201], ["element", 203], [",", 210], ["a", 212], ["stem", 214], ["-", 218], ["loop", 219], ["structure", 224], ["located", 234], ["in", 242], ["the", 245], ["3'-untranslated", 249], ["regions", 265], ["of", 273], ["selenoprotein", 276], ["mRNAs", 290], [".", 295], ["Here", 297], ["we", 302], ["report", 305], ["identification", 312], ["of", 327], ["a", 330], ["noncanonical", 332], ["form", 345], ["of", 350], ["SECIS", 353], ["element", 359], ["in", 367], ["Toxoplasma", 370], ["gondii", 381], ["and", 388], ["Neospora", 392], ["canine", 401], [",", 407], ["single", 409], ["-", 415], ["celled", 416], ["apicomplexan", 423], ["parasites", 436], ["of", 446], ["humans", 449], ["and", 456], ["domestic", 460], ["animals", 469], [".", 476], ["This", 478], ["SECIS", 483], ["has", 489], ["a", 493], ["GGGA", 495], ["sequence", 500], ["in", 509], ["the", 512], ["SBP2-binding", 516], ["site", 529], ["in", 534], ["place", 537], ["of", 543], ["AUGA", 546], ["previously", 551], ["considered", 562], ["invariant", 573], [".", 582], ["Using", 584], ["a", 590], ["combination", 592], ["of", 604], ["computational", 607], ["and", 621], ["molecular", 625], ["techniques", 635], [",", 645], ["we", 647], ["show", 650], ["that", 655], ["Toxoplasma", 660], ["and", 671], ["Neospora", 675], ["possess", 684], ["both", 692], ["canonical", 697], ["and", 707], ["noncanonical", 711], ["SECIS", 724], ["elements", 730], [".", 738], ["The", 740], ["GGGA", 744], ["-", 748], ["type", 749], ["SECIS", 754], ["element", 760], ["supported", 768], ["Sec", 778], ["insertion", 782], ["in", 792], ["mammalian", 795], ["HEK", 805], ["293", 809], ["and", 813], ["NIH", 817], ["3T3", 821], ["cells", 825], ["and", 831], ["did", 835], ["so", 839], ["more", 842], ["efficiently", 847], ["than", 859], ["the", 864], ["natural", 868], ["mammalian", 876], ["SECIS", 886], ["elements", 892], ["tested", 901], [".", 907], ["In", 909], ["addition", 912], [",", 920], ["mammalian", 922], ["type", 932], ["I", 937], ["and", 939], ["type", 943], ["II", 948], ["SECIS", 951], ["elements", 957], ["mutated", 966], ["into", 974], ["the", 979], ["GGGA", 983], ["forms", 988], ["were", 994], ["functional", 999], ["but", 1010], ["manifested", 1014], ["decreased", 1025], ["Sec", 1035], ["insertion", 1039], ["efficiency", 1049], [".", 1059], ["We", 1061], ["carried", 1064], ["out", 1072], ["computational", 1076], ["searches", 1090], ["for", 1099], ["both", 1103], ["AUGA", 1108], ["and", 1113], ["GGGA", 1117], ["forms", 1122], ["of", 1128], ["SECIS", 1131], ["elements", 1137], ["in", 1146], ["Toxoplasma", 1149], ["and", 1160], ["detected", 1164], ["five", 1173], ["selenoprotein", 1178], ["genes", 1192], [",", 1197], ["including", 1199], ["one", 1209], ["coding", 1213], ["for", 1220], ["a", 1224], ["previously", 1226], ["undescribed", 1237], ["selenoprotein", 1249], [",", 1262], ["designated", 1264], ["SelQ", 1275], [",", 1279], ["and", 1281], ["two", 1285], ["containing", 1289], ["the", 1300], ["GGGA", 1304], ["form", 1309], ["of", 1314], ["the", 1317], ["SECIS", 1321], ["element", 1327], [".", 1334], ["In", 1336], ["contrast", 1339], [",", 1347], ["the", 1349], ["GGGA", 1353], ["-", 1357], ["type", 1358], ["SECIS", 1363], ["elements", 1369], ["were", 1378], ["not", 1383], ["detected", 1387], ["in", 1396], ["mammals", 1399], ["and", 1407], ["nematodes", 1411], [".", 1420], ["As", 1422], ["a", 1425], ["practical", 1427], ["outcome", 1437], ["of", 1445], ["the", 1448], ["study", 1452], [",", 1457], ["we", 1459], ["developed", 1462], ["pSelExpress1", 1472], [",", 1484], ["a", 1486], ["vector", 1488], ["for", 1495], ["convenient", 1499], ["expression", 1510], ["of", 1521], ["selenoproteins", 1524], ["in", 1539], ["mammalian", 1542], ["cells", 1552], [".", 1557], ["It", 1559], ["contains", 1562], ["an", 1571], ["SBP2", 1574], ["gene", 1579], ["and", 1584], ["the", 1588], ["most", 1592], ["efficient", 1597], ["tested", 1607], ["SECIS", 1614], ["element", 1620], [":", 1627], ["an", 1629], ["AUGA", 1632], ["mutant", 1637], ["of", 1644], ["the", 1647], ["GGGA", 1651], ["-", 1655], ["type", 1656], ["Toxoplasma", 1661], ["SelT", 1672], ["structure", 1677], [".", 1686]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "The skeletal and immune systems have a complex relationship. Both systems are intimately coupled, with osteoclastogenesis and hematopoiesis occurring in the bone marrow. Bone and immune cells also share common hematopoietic precursors. Furthermore, the skeletal and immune systems share various cytokines, receptors, and transcription factors that regulate signal transduction pathways involved in osteoclastogenesis and immune system activation, including the receptor activator of nuclear factor-\u03ba\u0392 ligand/receptor activator of nuclear factor-\u03ba\u0392/osteoprotegerin (RANKL-RANK-OPG) pathway. Cancer cells can disrupt both the skeletal and immune systems. Interaction between cancer and bone cells results in a vicious cycle of bone destruction and cancer growth. Bone remodeling generates a growth-factor-rich environment that attracts cancer cells and promotes their proliferation. In turn, cancer cells stimulate osteoclast formation and activity, resulting in additional bone resorption that further stimulates cancer cell growth. Currently available bone-targeted therapies may also modulate the immune system. Bisphosphonates such as zoledronic acid exert stimulating effects on the immune system, resulting in possible anticancer activity against malignant cells. Denosumab, an anti-RANKL monoclonal antibody with proven antiosteoclast activity, may suppress immune responses. This may result in the reported association with an increased risk of neoplasms, as well as serious skin and other infections as reported in some studies, mainly in the postmenopausal setting. When assessing bone-targeted therapies, it is important to consider the shared signaling pathways between bone and the immune system, as well as the clinical risk:benefit ratio.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "0fbe0e984dcb489284a2e09de385fb16", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[205, 205], [86, 86]], "char_spans": [[1287, 1291], [565, 569]]}]}], "context_tokens": [["The", 0], ["skeletal", 4], ["and", 13], ["immune", 17], ["systems", 24], ["have", 32], ["a", 37], ["complex", 39], ["relationship", 47], [".", 59], ["Both", 61], ["systems", 66], ["are", 74], ["intimately", 78], ["coupled", 89], [",", 96], ["with", 98], ["osteoclastogenesis", 103], ["and", 122], ["hematopoiesis", 126], ["occurring", 140], ["in", 150], ["the", 153], ["bone", 157], ["marrow", 162], [".", 168], ["Bone", 170], ["and", 175], ["immune", 179], ["cells", 186], ["also", 192], ["share", 197], ["common", 203], ["hematopoietic", 210], ["precursors", 224], [".", 234], ["Furthermore", 236], [",", 247], ["the", 249], ["skeletal", 253], ["and", 262], ["immune", 266], ["systems", 273], ["share", 281], ["various", 287], ["cytokines", 295], [",", 304], ["receptors", 306], [",", 315], ["and", 317], ["transcription", 321], ["factors", 335], ["that", 343], ["regulate", 348], ["signal", 357], ["transduction", 364], ["pathways", 377], ["involved", 386], ["in", 395], ["osteoclastogenesis", 398], ["and", 417], ["immune", 421], ["system", 428], ["activation", 435], [",", 445], ["including", 447], ["the", 457], ["receptor", 461], ["activator", 470], ["of", 480], ["nuclear", 483], ["factor", 491], ["-", 497], ["\u03ba\u0392", 498], ["ligand", 501], ["/", 507], ["receptor", 508], ["activator", 517], ["of", 527], ["nuclear", 530], ["factor", 538], ["-", 544], ["\u03ba\u0392", 545], ["/", 547], ["osteoprotegerin", 548], ["(", 564], ["RANKL", 565], ["-", 570], ["RANK", 571], ["-", 575], ["OPG", 576], [")", 579], ["pathway", 581], [".", 588], ["Cancer", 590], ["cells", 597], ["can", 603], ["disrupt", 607], ["both", 615], ["the", 620], ["skeletal", 624], ["and", 633], ["immune", 637], ["systems", 644], [".", 651], ["Interaction", 653], ["between", 665], ["cancer", 673], ["and", 680], ["bone", 684], ["cells", 689], ["results", 695], ["in", 703], ["a", 706], ["vicious", 708], ["cycle", 716], ["of", 722], ["bone", 725], ["destruction", 730], ["and", 742], ["cancer", 746], ["growth", 753], [".", 759], ["Bone", 761], ["remodeling", 766], ["generates", 777], ["a", 787], ["growth", 789], ["-", 795], ["factor", 796], ["-", 802], ["rich", 803], ["environment", 808], ["that", 820], ["attracts", 825], ["cancer", 834], ["cells", 841], ["and", 847], ["promotes", 851], ["their", 860], ["proliferation", 866], [".", 879], ["In", 881], ["turn", 884], [",", 888], ["cancer", 890], ["cells", 897], ["stimulate", 903], ["osteoclast", 913], ["formation", 924], ["and", 934], ["activity", 938], [",", 946], ["resulting", 948], ["in", 958], ["additional", 961], ["bone", 972], ["resorption", 977], ["that", 988], ["further", 993], ["stimulates", 1001], ["cancer", 1012], ["cell", 1019], ["growth", 1024], [".", 1030], ["Currently", 1032], ["available", 1042], ["bone", 1052], ["-", 1056], ["targeted", 1057], ["therapies", 1066], ["may", 1076], ["also", 1080], ["modulate", 1085], ["the", 1094], ["immune", 1098], ["system", 1105], [".", 1111], ["Bisphosphonates", 1113], ["such", 1129], ["as", 1134], ["zoledronic", 1137], ["acid", 1148], ["exert", 1153], ["stimulating", 1159], ["effects", 1171], ["on", 1179], ["the", 1182], ["immune", 1186], ["system", 1193], [",", 1199], ["resulting", 1201], ["in", 1211], ["possible", 1214], ["anticancer", 1223], ["activity", 1234], ["against", 1243], ["malignant", 1251], ["cells", 1261], [".", 1266], ["Denosumab", 1268], [",", 1277], ["an", 1279], ["anti", 1282], ["-", 1286], ["RANKL", 1287], ["monoclonal", 1293], ["antibody", 1304], ["with", 1313], ["proven", 1318], ["antiosteoclast", 1325], ["activity", 1340], [",", 1348], ["may", 1350], ["suppress", 1354], ["immune", 1363], ["responses", 1370], [".", 1379], ["This", 1381], ["may", 1386], ["result", 1390], ["in", 1397], ["the", 1400], ["reported", 1404], ["association", 1413], ["with", 1425], ["an", 1430], ["increased", 1433], ["risk", 1443], ["of", 1448], ["neoplasms", 1451], [",", 1460], ["as", 1462], ["well", 1465], ["as", 1470], ["serious", 1473], ["skin", 1481], ["and", 1486], ["other", 1490], ["infections", 1496], ["as", 1507], ["reported", 1510], ["in", 1519], ["some", 1522], ["studies", 1527], [",", 1534], ["mainly", 1536], ["in", 1543], ["the", 1546], ["postmenopausal", 1550], ["setting", 1565], [".", 1572], ["When", 1574], ["assessing", 1579], ["bone", 1589], ["-", 1593], ["targeted", 1594], ["therapies", 1603], [",", 1612], ["it", 1614], ["is", 1617], ["important", 1620], ["to", 1630], ["consider", 1633], ["the", 1642], ["shared", 1646], ["signaling", 1653], ["pathways", 1663], ["between", 1672], ["bone", 1680], ["and", 1685], ["the", 1689], ["immune", 1693], ["system", 1700], [",", 1706], ["as", 1708], ["well", 1711], ["as", 1716], ["the", 1719], ["clinical", 1723], ["risk", 1732], [":", 1736], ["benefit", 1737], ["ratio", 1745], [".", 1750]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels. Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec. Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0641e4745b234652b621a99faaec9192", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[145, 147], [161, 163], [20, 22], [270, 272], [53, 55], [26, 28], [104, 106], [328, 330], [346, 348], [194, 196], [128, 130], [115, 117]], "char_spans": [[794, 800], [899, 905], [127, 133], [1479, 1485], [290, 296], [147, 153], [585, 591], [1812, 1818], [1917, 1923], [1065, 1071], [699, 705], [638, 644]]}]}], "context_tokens": [["The", 0], ["cytogenetic", 4], ["characteristic", 16], ["of", 31], ["Chronic", 34], ["Myeloid", 42], ["Leukemia", 50], ["(", 59], ["CML", 60], [")", 63], ["is", 65], ["the", 68], ["formation", 72], ["of", 82], ["the", 85], ["Philadelphia", 89], ["chromosome", 102], ["gene", 113], ["product", 118], [",", 125], ["BCR", 127], ["-", 130], ["ABL", 131], [".", 134], ["Given", 136], ["that", 142], ["BCR", 147], ["-", 150], ["ABL", 151], ["is", 155], ["the", 158], ["specific", 162], ["target", 171], ["of", 178], ["Gleevec", 181], ["in", 189], ["CML", 192], ["treatment", 196], [",", 205], ["we", 207], ["investigated", 210], ["the", 223], ["regulation", 227], ["of", 238], ["the", 241], ["catalytic", 245], ["component", 255], ["of", 265], ["telomerase", 268], [",", 278], ["hTERT", 280], [",", 285], ["by", 287], ["BCR", 290], ["-", 293], ["ABL", 294], ["at", 298], ["multiple", 301], ["levels", 310], ["in", 317], ["K562", 320], ["cells", 325], [".", 330], ["Molecular", 332], ["techniques", 342], ["such", 353], ["as", 358], ["over", 361], ["expression", 366], [",", 376], ["knockdown", 378], [",", 387], ["real", 389], ["-", 393], ["time", 394], ["PCR", 399], [",", 402], ["immunoprecipitation", 404], [",", 423], ["western", 425], ["blotting", 433], [",", 441], ["reporter", 443], ["assay", 452], [",", 457], ["confocal", 459], ["microscopy", 468], [",", 478], ["telomerase", 480], ["assays", 491], ["and", 498], ["microarray", 502], ["were", 513], ["used", 518], ["to", 523], ["suggest", 526], ["that", 534], ["hTERT", 539], ["expression", 545], ["and", 556], ["activity", 560], ["is", 569], ["modulated", 572], ["by", 582], ["BCR", 585], ["-", 588], ["ABL", 589], ["at", 593], ["multiple", 596], ["levels", 605], [".", 611], ["Our", 613], ["results", 617], ["suggest", 625], ["that", 633], ["BCR", 638], ["-", 641], ["ABL", 642], ["plays", 646], ["an", 652], ["important", 655], ["role", 665], ["in", 670], ["regulating", 673], ["hTERT", 684], ["in", 690], ["K562", 693], ["(", 698], ["BCR", 699], ["-", 702], ["ABL", 703], ["positive", 707], ["human", 716], ["leukemia", 722], [")", 730], ["cells", 732], [".", 737], ["When", 739], ["Gleevec", 744], ["inhibited", 752], ["the", 762], ["tyrosine", 766], ["kinase", 775], ["activity", 782], ["of", 791], ["BCR", 794], ["-", 797], ["ABL", 798], [",", 801], ["phosphorylation", 803], ["of", 819], ["hTERT", 822], ["was", 828], ["downregulated", 832], [",", 845], ["therefore", 847], ["suggesting", 857], ["a", 868], ["positive", 870], ["correlation", 879], ["between", 891], ["BCR", 899], ["-", 902], ["ABL", 903], ["and", 907], ["hTERT", 911], [".", 916], ["Gleevec", 918], ["treatment", 926], ["inhibited", 936], ["hTERT", 946], ["at", 952], ["mRNA", 955], ["level", 960], ["and", 966], ["significantly", 970], ["reduced", 984], ["telomerase", 992], ["activity", 1003], ["(", 1012], ["TA", 1013], [")", 1015], ["in", 1017], ["K562", 1020], ["cells", 1025], [",", 1030], ["but", 1032], ["not", 1036], ["in", 1040], ["HL60", 1043], ["or", 1048], ["Jurkat", 1051], ["cells", 1058], ["(", 1064], ["BCR", 1065], ["-", 1068], ["ABL", 1069], ["negative", 1073], ["cells", 1082], [")", 1087], [".", 1088], ["We", 1090], ["also", 1093], ["demonstrated", 1098], ["that", 1111], ["the", 1116], ["transcription", 1120], ["factor", 1134], ["STAT5a", 1141], ["plays", 1148], ["a", 1154], ["critical", 1156], ["role", 1165], ["in", 1170], ["hTERT", 1173], ["gene", 1179], ["regulation", 1184], ["in", 1195], ["K562", 1198], ["cells", 1203], [".", 1208], ["Knockdown", 1210], ["of", 1220], ["STAT5a", 1223], [",", 1229], ["but", 1231], ["not", 1235], ["STAT5b", 1239], [",", 1245], ["resulted", 1247], ["in", 1256], ["a", 1259], ["marked", 1261], ["downregulation", 1268], ["of", 1283], ["hTERT", 1286], ["mRNA", 1292], ["level", 1297], [",", 1302], ["TA", 1304], ["and", 1307], ["hTERT", 1311], ["protein", 1317], ["level", 1325], ["in", 1331], ["K562", 1334], ["cells", 1339], [".", 1344], ["Furthermore", 1346], [",", 1357], ["translocation", 1359], ["of", 1373], ["hTERT", 1376], ["from", 1382], ["nucleoli", 1387], ["to", 1396], ["nucleoplasm", 1399], ["was", 1411], ["observed", 1415], ["in", 1424], ["K562", 1427], ["cells", 1432], ["induced", 1438], ["by", 1446], ["Gleevec", 1449], [".", 1456], ["Our", 1458], ["data", 1462], ["reveal", 1467], ["that", 1474], ["BCR", 1479], ["-", 1482], ["ABL", 1483], ["can", 1487], ["regulate", 1491], ["TA", 1500], ["at", 1503], ["multiple", 1506], ["levels", 1515], [",", 1521], ["including", 1523], ["transcription", 1533], [",", 1546], ["post", 1548], ["-", 1552], ["translational", 1553], ["level", 1567], [",", 1572], ["and", 1574], ["proper", 1578], ["localization", 1585], [".", 1597], ["Thus", 1599], [",", 1603], ["suppression", 1605], ["of", 1617], ["cell", 1620], ["growth", 1625], ["and", 1632], ["induction", 1636], ["of", 1646], ["apoptosis", 1649], ["by", 1659], ["Gleevec", 1662], ["treatment", 1670], ["may", 1680], ["be", 1684], ["partially", 1687], ["due", 1697], ["to", 1701], ["TA", 1704], ["inhibition", 1707], [".", 1717], ["Additionally", 1719], [",", 1731], ["we", 1733], ["have", 1736], ["identified", 1741], ["STAT5a", 1752], ["as", 1759], ["critical", 1762], ["mediator", 1771], ["of", 1780], ["the", 1783], ["hTERT", 1787], ["gene", 1793], ["expression", 1798], ["in", 1809], ["BCR", 1812], ["-", 1815], ["ABL", 1816], ["positive", 1820], ["CML", 1829], ["cells", 1833], [",", 1838], ["suggesting", 1840], ["that", 1851], ["targeting", 1856], ["STAT5a", 1866], ["may", 1873], ["be", 1877], ["a", 1880], ["promising", 1882], ["therapeutic", 1892], ["strategy", 1904], ["for", 1913], ["BCR", 1917], ["-", 1920], ["ABL", 1921], ["positive", 1925], ["CML", 1934], ["patients", 1938], [".", 1946]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "To determine the validity of the rapid antigen test (RAT) OSOM StrepA Genzyme for the diagnosis of acute pharyngitis caused by group A beta-haemolytic strep (GABHS). Diagnostic techniques survey. Urban primary care centre, Spain. All patients over 14 years old seen in 6 surgeries with sore throat and 2 or more Centor criteria: pharyngotonsillar exudate, tender laterocervical nodes, absence of coughing, and/or history or presence of fever. Pharyngeal swabs were taken from all the patients, one for RAT and another to send for culture in the microbiology department. A total of 182 patients were evaluable, with a mean age of 30.6 (12.1) years of which 116 were women (63.7%); 63 patients had 2 Centor criteria; 83 had 3 and 36, the 4 criteria. The culture was positive in 102 patients (56%), with GABHS showing infection in forty (22%; 95% confidence interval [CI], 21.2-22.8). Group C Streptococcus was isolated in 26 patients (14.3%). GABHS was higher among patients with four Centor criteria (38.9% vs 25.3% observed among those with 3 criteria and 7.9% with 2 criteria; P<.001). Sensitivity of RAT was 95%, with a specificity of 93%, a positive predictive value of 79.2% and a negative predictive value of 98.5%. These results show the usefulness of RAT for diagnosing streptococcal pharyngitis. Its use should be spread to all primary care practices.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "e8f16ae3e5874a4181985bd826ce59f8", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[268, 269]], "char_spans": [[1277, 1301]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["validity", 17], ["of", 26], ["the", 29], ["rapid", 33], ["antigen", 39], ["test", 47], ["(", 52], ["RAT", 53], [")", 56], ["OSOM", 58], ["StrepA", 63], ["Genzyme", 70], ["for", 78], ["the", 82], ["diagnosis", 86], ["of", 96], ["acute", 99], ["pharyngitis", 105], ["caused", 117], ["by", 124], ["group", 127], ["A", 133], ["beta", 135], ["-", 139], ["haemolytic", 140], ["strep", 151], ["(", 157], ["GABHS", 158], [")", 163], [".", 164], ["Diagnostic", 166], ["techniques", 177], ["survey", 188], [".", 194], ["Urban", 196], ["primary", 202], ["care", 210], ["centre", 215], [",", 221], ["Spain", 223], [".", 228], ["All", 230], ["patients", 234], ["over", 243], ["14", 248], ["years", 251], ["old", 257], ["seen", 261], ["in", 266], ["6", 269], ["surgeries", 271], ["with", 281], ["sore", 286], ["throat", 291], ["and", 298], ["2", 302], ["or", 304], ["more", 307], ["Centor", 312], ["criteria", 319], [":", 327], ["pharyngotonsillar", 329], ["exudate", 347], [",", 354], ["tender", 356], ["laterocervical", 363], ["nodes", 378], [",", 383], ["absence", 385], ["of", 393], ["coughing", 396], [",", 404], ["and/or", 406], ["history", 413], ["or", 421], ["presence", 424], ["of", 433], ["fever", 436], [".", 441], ["Pharyngeal", 443], ["swabs", 454], ["were", 460], ["taken", 465], ["from", 471], ["all", 476], ["the", 480], ["patients", 484], [",", 492], ["one", 494], ["for", 498], ["RAT", 502], ["and", 506], ["another", 510], ["to", 518], ["send", 521], ["for", 526], ["culture", 530], ["in", 538], ["the", 541], ["microbiology", 545], ["department", 558], [".", 568], ["A", 570], ["total", 572], ["of", 578], ["182", 581], ["patients", 585], ["were", 594], ["evaluable", 599], [",", 608], ["with", 610], ["a", 615], ["mean", 617], ["age", 622], ["of", 626], ["30.6", 629], ["(", 634], ["12.1", 635], [")", 639], ["years", 641], ["of", 647], ["which", 650], ["116", 656], ["were", 660], ["women", 665], ["(", 671], ["63.7", 672], ["%", 676], [")", 677], [";", 678], ["63", 680], ["patients", 683], ["had", 692], ["2", 696], ["Centor", 698], ["criteria", 705], [";", 713], ["83", 715], ["had", 718], ["3", 722], ["and", 724], ["36", 728], [",", 730], ["the", 732], ["4", 736], ["criteria", 738], [".", 746], ["The", 748], ["culture", 752], ["was", 760], ["positive", 764], ["in", 773], ["102", 776], ["patients", 780], ["(", 789], ["56", 790], ["%", 792], [")", 793], [",", 794], ["with", 796], ["GABHS", 801], ["showing", 807], ["infection", 815], ["in", 825], ["forty", 828], ["(", 834], ["22", 835], ["%", 837], [";", 838], ["95", 840], ["%", 842], ["confidence", 844], ["interval", 855], ["[", 864], ["CI", 865], ["]", 867], [",", 868], ["21.2", 870], ["-", 874], ["22.8", 875], [")", 879], [".", 880], ["Group", 882], ["C", 888], ["Streptococcus", 890], ["was", 904], ["isolated", 908], ["in", 917], ["26", 920], ["patients", 923], ["(", 932], ["14.3", 933], ["%", 937], [")", 938], [".", 939], ["GABHS", 941], ["was", 947], ["higher", 951], ["among", 958], ["patients", 964], ["with", 973], ["four", 978], ["Centor", 983], ["criteria", 990], ["(", 999], ["38.9", 1000], ["%", 1004], ["vs", 1006], ["25.3", 1009], ["%", 1013], ["observed", 1015], ["among", 1024], ["those", 1030], ["with", 1036], ["3", 1041], ["criteria", 1043], ["and", 1052], ["7.9", 1056], ["%", 1059], ["with", 1061], ["2", 1066], ["criteria", 1068], [";", 1076], ["P<.001", 1078], [")", 1084], [".", 1085], ["Sensitivity", 1087], ["of", 1099], ["RAT", 1102], ["was", 1106], ["95", 1110], ["%", 1112], [",", 1113], ["with", 1115], ["a", 1120], ["specificity", 1122], ["of", 1134], ["93", 1137], ["%", 1139], [",", 1140], ["a", 1142], ["positive", 1144], ["predictive", 1153], ["value", 1164], ["of", 1170], ["79.2", 1173], ["%", 1177], ["and", 1179], ["a", 1183], ["negative", 1185], ["predictive", 1194], ["value", 1205], ["of", 1211], ["98.5", 1214], ["%", 1218], [".", 1219], ["These", 1221], ["results", 1227], ["show", 1235], ["the", 1240], ["usefulness", 1244], ["of", 1255], ["RAT", 1258], ["for", 1262], ["diagnosing", 1266], ["streptococcal", 1277], ["pharyngitis", 1291], [".", 1302], ["Its", 1304], ["use", 1308], ["should", 1312], ["be", 1319], ["spread", 1322], ["to", 1329], ["all", 1332], ["primary", 1336], ["care", 1344], ["practices", 1349], [".", 1358]]}
{"context": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable presentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have the DM2 (CCTG)(n) expansion. To study the evolution of this mutation, we constructed a comprehensive physical map of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception of the (CCTG)(n) expansion, the available markers indicate that the DM2 haplotype is identical to the most common haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and of the DM2 (CCTG) expansion mutation to be approximately 200-540 generations.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "3dff550077ca471a8137430b2d11722c", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[29, 30]], "char_spans": [[172, 189]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["(", 19], ["DM", 20], [")", 22], [",", 23], ["the", 25], ["most", 29], ["common", 34], ["form", 41], ["of", 46], ["muscular", 49], ["dystrophy", 58], ["in", 68], ["adults", 71], [",", 77], ["is", 79], ["a", 82], ["clinically", 84], ["and", 95], ["genetically", 99], ["heterogeneous", 111], ["neuromuscular", 125], ["disorder", 139], [".", 147], ["DM", 149], ["is", 152], ["characterized", 155], ["by", 169], ["autosomal", 172], ["dominant", 182], ["inheritance", 191], [",", 202], ["muscular", 204], ["dystrophy", 213], [",", 222], ["myotonia", 224], [",", 232], ["and", 234], ["multisystem", 238], ["involvement", 250], [".", 261], ["Type", 263], ["1", 268], ["DM", 270], ["(", 273], ["DM1", 274], [")", 277], ["is", 279], ["caused", 282], ["by", 289], ["a", 292], ["(", 294], ["CTG)(n", 295], [")", 301], ["expansion", 303], ["in", 313], ["the", 316], ["3", 320], ["'", 321], ["untranslated", 323], ["region", 336], ["of", 343], ["DMPK", 346], ["in", 351], ["19q13.3", 354], [".", 361], ["Multiple", 363], ["families", 372], [",", 380], ["predominantly", 382], ["of", 396], ["German", 399], ["descent", 406], ["and", 414], ["with", 418], ["clinically", 423], ["variable", 434], ["presentation", 443], ["that", 456], ["included", 461], ["proximal", 470], ["myotonic", 479], ["myopathy", 488], ["(", 497], ["PROMM", 498], [")", 503], ["and", 505], ["type", 509], ["2", 514], ["DM", 516], ["(", 519], ["DM2", 520], [")", 523], ["but", 525], ["without", 529], ["the", 537], ["DM1", 541], ["mutation", 545], [",", 553], ["showed", 555], ["linkage", 562], ["to", 570], ["the", 573], ["3q21", 577], ["region", 582], ["and", 589], ["were", 593], ["recently", 598], ["shown", 607], ["to", 613], ["segregate", 616], ["a", 626], ["(", 628], ["CCTG)(n", 629], [")", 636], ["expansion", 638], ["mutation", 648], ["in", 657], ["intron", 660], ["1", 667], ["of", 669], ["ZNF9", 672], [".", 676], ["Here", 678], [",", 682], ["we", 684], ["present", 687], ["linkage", 695], ["to", 703], ["3q21", 706], ["and", 711], ["mutational", 715], ["confirmation", 726], ["in", 739], ["17", 742], ["kindreds", 745], ["of", 754], ["European", 757], ["origin", 766], ["with", 773], ["PROMM", 778], ["and", 784], ["proximal", 788], ["myotonic", 797], ["dystrophy", 806], [",", 815], ["from", 817], ["geographically", 822], ["distinct", 837], ["populations", 846], [".", 857], ["All", 859], ["patients", 863], ["have", 872], ["the", 877], ["DM2", 881], ["(", 885], ["CCTG)(n", 886], [")", 893], ["expansion", 895], [".", 904], ["To", 906], ["study", 909], ["the", 915], ["evolution", 919], ["of", 929], ["this", 932], ["mutation", 937], [",", 945], ["we", 947], ["constructed", 950], ["a", 962], ["comprehensive", 964], ["physical", 978], ["map", 987], ["of", 991], ["the", 994], ["DM2", 998], ["region", 1002], ["around", 1009], ["ZNF9", 1016], [".", 1020], ["High", 1022], ["-", 1026], ["resolution", 1027], ["haplotype", 1038], ["analysis", 1048], ["of", 1057], ["disease", 1060], ["chromosomes", 1068], ["with", 1080], ["five", 1085], ["microsatellite", 1090], ["and", 1105], ["22", 1109], ["single", 1112], ["-", 1118], ["nucleotide", 1119], ["polymorphism", 1130], ["markers", 1143], ["around", 1151], ["the", 1158], ["DM2", 1162], ["mutation", 1166], ["identified", 1175], ["extensive", 1186], ["linkage", 1196], ["disequilibrium", 1204], ["and", 1219], ["a", 1223], ["single", 1225], ["shared", 1232], ["haplotype", 1239], ["of", 1249], ["at", 1252], ["least", 1255], ["132", 1261], ["kb", 1265], ["among", 1268], ["patients", 1274], ["from", 1283], ["the", 1288], ["different", 1292], ["populations", 1302], [".", 1313], ["With", 1315], ["the", 1320], ["exception", 1324], ["of", 1334], ["the", 1337], ["(", 1341], ["CCTG)(n", 1342], [")", 1349], ["expansion", 1351], [",", 1360], ["the", 1362], ["available", 1366], ["markers", 1376], ["indicate", 1384], ["that", 1393], ["the", 1398], ["DM2", 1402], ["haplotype", 1406], ["is", 1416], ["identical", 1419], ["to", 1429], ["the", 1432], ["most", 1436], ["common", 1441], ["haplotype", 1448], ["in", 1458], ["normal", 1461], ["individuals", 1468], [".", 1479], ["This", 1481], ["situation", 1486], ["is", 1496], ["reminiscent", 1499], ["of", 1511], ["that", 1514], ["seen", 1519], ["in", 1524], ["DM1", 1527], [".", 1530], ["Taken", 1532], ["together", 1538], [",", 1546], ["these", 1548], ["data", 1554], ["suggest", 1559], ["a", 1567], ["single", 1569], ["founding", 1576], ["mutation", 1585], ["in", 1594], ["DM2", 1597], ["patients", 1601], ["of", 1610], ["European", 1613], ["origin", 1622], [".", 1628], ["We", 1630], ["estimate", 1633], ["the", 1642], ["age", 1646], ["of", 1650], ["the", 1653], ["founding", 1657], ["haplotype", 1666], ["and", 1676], ["of", 1680], ["the", 1683], ["DM2", 1687], ["(", 1691], ["CCTG", 1692], [")", 1696], ["expansion", 1698], ["mutation", 1708], ["to", 1717], ["be", 1720], ["approximately", 1723], ["200", 1737], ["-", 1740], ["540", 1741], ["generations", 1745], [".", 1756]]}
